Clustering O 0 0.001208735047839582
of O 0 3.360553819220513e-05
missense O 0 0.0007960761431604624
mutations O 0 8.113342482829466e-05
in O 0 1.1406918929424137e-05
the O 0 7.232789357658476e-05
ataxia B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999837875366211
telangiectasia I-Disease 1 0.9999942779541016
gene O 0 4.653076030081138e-05
in O 0 3.459685558482306e-06
a O 0 7.397383342322428e-06
sporadic B-Disease 0 0.000651889480650425
T I-Disease 1 0.995323121547699
- I-Disease 0 0.22219285368919373
cell I-Disease 0 0.03216050937771797
leukaemia I-Disease 1 0.995360791683197
. O 0 8.539843838661909e-05

Ataxia B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999934434890747
telangiectasia I-Disease 1 0.9999994039535522
( O 0 0.0017821750370785594
A B-Disease 1 0.9909404516220093
- I-Disease 1 0.9999762773513794
T I-Disease 1 0.9999958276748657
) O 0 3.974817445850931e-06
is O 0 6.537285912600055e-07
a O 0 4.159267973591341e-06
recessive B-Disease 0 0.0011078501120209694
multi I-Disease 0 0.009931212291121483
- I-Disease 1 0.9896609783172607
system I-Disease 0 0.006944705732166767
disorder I-Disease 1 0.8796215653419495
caused O 0 9.607419997337274e-06
by O 0 9.247886509911041e-07
mutations O 0 2.579559122750652e-06
in O 0 3.836682935798308e-07
the O 0 6.109987680247286e-07
ATM O 0 1.9898290702258237e-05
gene O 0 5.706830052076839e-06
at O 0 2.2994929622655036e-06
11q22 O 0 5.005930142942816e-05
- O 0 9.914913243846968e-05
q23 O 0 6.936046702321619e-05
( O 0 3.0922417408874026e-06
ref O 0 0.0001302293676417321
. O 0 7.575150675620534e-07
3 O 0 1.5662734540455858e-06
) O 0 1.6866497389855795e-06
. O 0 4.126266503590159e-06

The O 0 4.5698794565396383e-05
risk O 0 2.3210837753140368e-05
of O 0 2.189808128605364e-06
cancer B-Disease 0 0.006698806304484606
, O 0 1.0898905884459964e-06
especially O 0 3.998068223154405e-06
lymphoid B-Disease 0 0.008525696583092213
neoplasias I-Disease 0 0.007836579345166683
, O 0 1.3998165968587273e-06
is O 0 3.5268848819214327e-07
substantially O 0 9.074173249246087e-06
elevated O 0 6.67185213387711e-06
in O 0 4.452541361388285e-06
A B-Disease 1 0.9998749494552612
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
patients O 0 0.06738247722387314
and O 0 2.0917007077514427e-06
has O 0 1.2115456229366828e-06
long O 0 1.7955559314941638e-06
been O 0 2.048680926236557e-06
associated O 0 4.550794074020814e-06
with O 0 7.7015720307827e-06
chromosomal O 1 0.9996849298477173
instability O 1 0.5120453238487244
. O 0 6.77323987474665e-05

By O 0 0.00022627637372352183
analysing O 0 0.0029738489538431168
tumour B-Disease 1 0.999983549118042
DNA O 0 0.00027928658528253436
from O 0 1.3279171980684623e-05
patients O 0 5.956373206572607e-05
with O 0 1.69571069363883e-06
sporadic B-Disease 0 0.00033574760891497135
T I-Disease 1 0.976382851600647
- I-Disease 0 0.03469585254788399
cell I-Disease 0 0.0020237716380506754
prolymphocytic I-Disease 0 0.4638907015323639
leukaemia I-Disease 1 0.9999151229858398
( O 0 3.2696403650334105e-05
T B-Disease 0 0.021041786298155785
- I-Disease 0 0.00023826461983844638
PLL I-Disease 0 0.0008361476357094944
) O 0 1.570859922139789e-06
, O 0 3.5371280660001503e-07
a O 0 7.255996479216265e-07
rare O 0 7.806420398992486e-06
clonal B-Disease 0 0.0003589382686186582
malignancy I-Disease 0 0.0007888493710197508
with O 0 8.935732580539479e-07
similarities O 0 4.136846200708533e-06
to O 0 6.5080683953056e-07
a O 0 3.3073497434088495e-06
mature B-Disease 0 4.784023985848762e-05
T I-Disease 0 0.034451499581336975
- I-Disease 0 0.0021602807100862265
cell I-Disease 0 0.002120767254382372
leukaemia I-Disease 1 0.9866679906845093
seen O 0 8.73745830176631e-06
in O 0 2.3680493086430943e-06
A B-Disease 1 0.9004687070846558
- I-Disease 1 0.9981802701950073
T I-Disease 1 0.9998993873596191
, O 0 3.9090278391995525e-07
we O 0 2.115218080689374e-07
demonstrate O 0 6.726551760039001e-07
a O 0 2.859519270259625e-07
high O 0 5.255047312857641e-07
frequency O 0 1.0129731435881695e-06
of O 0 2.063265611695897e-07
ATM O 0 9.599946497473866e-05
mutations O 0 1.1870026355609298e-05
in O 0 6.398885943781352e-06
T B-Disease 0 0.24510814249515533
- I-Disease 0 0.004237850662320852
PLL I-Disease 0 0.005179437808692455
. O 0 6.35532705928199e-05

In O 0 4.7068991989362985e-05
marked O 0 1.3100969226798043e-05
contrast O 0 6.109729838499334e-06
to O 0 9.867145536190947e-07
the O 0 1.2067819170624716e-06
ATM O 0 4.1776067519094795e-05
mutation O 0 4.730203272629296e-06
pattern O 0 3.113523462161538e-06
in O 0 1.3771606290902128e-06
A B-Disease 1 0.9736077189445496
- I-Disease 1 0.9999485015869141
T I-Disease 1 0.9999881982803345
, O 0 4.4477866367742536e-07
the O 0 1.1130515531476703e-07
most O 0 1.4382062829554343e-07
frequent O 0 6.152238825052336e-07
nucleotide O 0 1.4576653484255075e-06
changes O 0 1.2033480061290902e-06
in O 0 9.560109219819424e-07
this O 0 3.3555011214048136e-06
leukaemia B-Disease 1 0.9242607355117798
were O 0 4.194624489173293e-05
missense O 0 0.0011642837198451161
mutations O 0 0.0002148862840840593
. O 0 3.544652645359747e-05

These O 0 1.8745919078355655e-05
clustered O 0 2.8822189051425084e-05
in O 0 2.5738975182321155e-06
the O 0 4.816712930733047e-07
region O 0 9.030377441376913e-07
corresponding O 0 3.032305926353729e-07
to O 0 1.6574315964135167e-07
the O 0 1.6442496075796953e-07
kinase O 0 5.842062819283456e-06
domain O 0 3.6622384413931286e-07
, O 0 6.987653478063294e-08
which O 0 4.8647144978986034e-08
is O 0 3.815475579926897e-08
highly O 0 1.0092897895219721e-07
conserved O 0 1.8242232613374654e-07
in O 0 4.5579287188957096e-07
ATM O 0 5.6982633395818993e-05
- O 0 4.8669819079805166e-05
related O 0 1.5028971347419429e-06
proteins O 0 3.41716827279015e-07
in O 0 7.598962952215516e-07
mouse O 0 2.3188449631561525e-05
, O 0 1.2815705758839613e-06
yeast O 0 1.8711552911554463e-05
and O 0 4.033754976262571e-06
Drosophila O 0 4.445712693268433e-05
. O 0 1.1859357982757501e-05

The O 0 4.366131906863302e-05
resulting O 0 3.763019776670262e-05
amino O 0 1.0852661034732591e-05
- O 0 2.127806692442391e-05
acid O 0 3.90438844988239e-06
substitutions O 0 3.0970611533120973e-06
are O 0 1.9361802117145999e-07
predicted O 0 1.3861442766938126e-06
to O 0 2.0435126657503133e-07
interfere O 0 2.1386367734521627e-06
with O 0 5.8788992873815e-07
ATP O 0 0.00018477522826287895
binding O 0 5.276251158647938e-06
or O 0 1.6795967212601681e-06
substrate O 0 1.6161635358002968e-05
recognition O 0 1.2886403055745177e-05
. O 0 2.2410526071325876e-05

Two O 0 1.3752780432696454e-05
of O 0 2.4677931378391804e-06
seventeen O 0 5.486268855747767e-05
mutated O 0 0.00026151875499635935
T B-Disease 0 0.011789853684604168
- I-Disease 0 0.0005875114002265036
PLL I-Disease 0 0.0011056571966037154
samples O 0 1.0828572158061434e-05
had O 0 3.6911555980623234e-06
a O 0 1.229711983796733e-06
previously O 0 8.256149158114567e-06
reported O 0 0.00015081297897268087
A B-Disease 1 0.9515535831451416
- I-Disease 1 0.9999338388442993
T I-Disease 1 0.9999927282333374
allele O 0 0.0006371648050844669
. O 0 4.325600093579851e-05

In O 0 8.705423533683643e-05
contrast O 0 9.713096369523555e-05
, O 0 4.696195901487954e-06
no O 0 2.990727807627991e-06
mutations O 0 6.703639883198775e-06
were O 0 1.449600063097023e-06
detected O 0 4.721333880297607e-06
in O 0 3.687162291043933e-07
the O 0 4.071853823006677e-07
p53 O 0 3.2843734061316354e-06
gene O 0 1.8321262587051024e-06
, O 0 3.57282061713704e-07
suggesting O 0 2.2280246412265114e-06
that O 0 3.406674409234256e-07
this O 0 2.164207444366184e-06
tumour B-Disease 1 0.9999649524688721
suppressor O 0 6.355751975206658e-05
is O 0 7.392633278868743e-07
not O 0 5.529718691832386e-07
frequently O 0 2.205367081842269e-06
altered O 0 1.0088439012179151e-05
in O 0 2.8076410671928898e-06
this O 0 1.1116911082353909e-05
leukaemia B-Disease 1 0.9934154748916626
. O 0 9.111525287153199e-05

Occasional O 0 0.0015614086296409369
missense O 0 0.00235973228700459
mutations O 0 0.00020460851374082267
in O 0 5.250406047707656e-06
ATM O 0 5.545417297980748e-05
were O 0 3.312482476758305e-06
also O 0 8.927989938456449e-07
found O 0 1.1307978411423392e-06
in O 0 5.6669464356673416e-06
tumour B-Disease 1 0.9999946355819702
DNA O 0 2.5031053155544214e-05
from O 0 2.0774846234417055e-06
patients O 0 8.700008947926108e-06
with O 0 5.176270292395202e-07
B B-Disease 0 0.00016774532559793442
- I-Disease 0 0.00350078078918159
cell I-Disease 0 0.0003054147236980498
non I-Disease 0 0.0002694226277526468
- I-Disease 1 0.9972409009933472
Hodgkins I-Disease 1 0.9999983310699463
lymphomas I-Disease 1 0.9942519664764404
( O 0 5.324895028024912e-06
B B-Disease 0 3.7768255424452946e-05
- I-Disease 0 3.574095171643421e-05
NHL I-Disease 0 5.900282303628046e-06
) O 0 4.335896051088639e-07
and O 0 1.9338145307301602e-07
a O 0 9.356611485600297e-07
B B-Disease 0 5.6054974265862256e-05
- I-Disease 0 0.00011769644333980978
NHL I-Disease 0 4.269035343895666e-05
cell O 0 6.417250551749021e-05
line O 0 7.566258864244446e-05
. O 0 2.2044876459403895e-05

The O 0 2.4952567400760017e-05
evidence O 0 5.892831268283771e-06
of O 0 4.1180288690156885e-07
a O 0 8.796819201961625e-07
significant O 0 6.07198614943627e-07
proportion O 0 9.427469649381237e-07
of O 0 1.639323841118312e-07
loss O 0 9.678073183749802e-06
- O 0 2.5036184524651617e-05
of O 0 2.386692017353198e-07
- O 0 3.147221650579013e-05
function O 0 5.050627009950404e-07
mutations O 0 8.866269922691572e-07
and O 0 8.39502618532606e-08
a O 0 1.8409977542432898e-07
complete O 0 3.7832501220691483e-07
absence O 0 5.586525162470934e-07
of O 0 4.705152178985372e-08
the O 0 1.6721715212497656e-07
normal O 0 7.79830827468686e-07
copy O 0 8.020816153475607e-07
of O 0 6.872107150002194e-08
ATM O 0 8.601439731137361e-06
in O 0 5.880570483896008e-07
the O 0 2.8214057579134533e-07
majority O 0 5.950354307060479e-07
of O 0 9.470923032495193e-07
mutated O 0 0.00022233302297536284
tumours B-Disease 1 0.9834006428718567
establishes O 0 3.3853924833238125e-05
somatic O 0 4.8100620915647596e-05
inactivation O 0 3.8177600799826905e-05
of O 0 2.9278837132551416e-07
this O 0 4.2066244532179553e-07
gene O 0 1.5132851558519178e-06
in O 0 2.8087609393878665e-07
the O 0 4.089241087967821e-07
pathogenesis O 0 1.3414241948339622e-05
of O 0 4.729905356271047e-07
sporadic B-Disease 0 0.00019568980496842414
T I-Disease 1 0.9776601791381836
- I-Disease 0 0.003478995757177472
PLL I-Disease 0 0.0003714916529133916
and O 0 1.1234080830035964e-06
suggests O 0 1.2061710776833934e-06
that O 0 2.474589564371854e-07
ATM O 0 8.996647920866963e-06
acts O 0 1.5584064385620877e-06
as O 0 1.5097679124664865e-06
a O 0 1.4434430340770632e-05
tumour B-Disease 1 0.9999439716339111
suppressor O 0 0.0006055880803614855
. O 0 4.1776391299208626e-05

As O 0 2.655820753716398e-05
constitutional O 0 1.8810062101692893e-05
DNA O 0 1.9956083633587696e-05
was O 0 4.866612471232656e-06
not O 0 4.821695256396197e-07
available O 0 7.631163612131786e-07
, O 0 3.3835434010143217e-07
a O 0 1.6288123561025714e-06
putative O 0 0.00023077390505932271
hereditary O 0 0.36942484974861145
predisposition O 0 0.0005008263979107141
to O 0 1.5994784916983917e-05
T B-Disease 1 0.8278310894966125
- I-Disease 0 0.0016153758624568582
PLL I-Disease 0 0.0006471080123446882
will O 0 1.1053892876589089e-06
require O 0 1.4152719813864678e-06
further O 0 1.2951337566846632e-06
investigation O 0 6.704522093059495e-06
. O 0 2.249653562103049e-06
. O 0 1.3219168067735154e-05

Myotonic B-Disease 1 0.9999988079071045
dystrophy I-Disease 1 0.9999992847442627
protein O 0 0.0005386744742281735
kinase O 0 0.000194074324099347
is O 0 1.544277552056883e-06
involved O 0 6.211516847542953e-07
in O 0 2.965395538012672e-07
the O 0 3.1066701922100037e-07
modulation O 0 2.427109166092123e-06
of O 0 2.0175527026822238e-07
the O 0 2.5119918518612394e-06
Ca2 O 0 0.0002762236981652677
+ O 0 0.00013554094766732305
homeostasis O 0 0.0003814122173935175
in O 0 2.4788349037407897e-05
skeletal O 1 0.6965185403823853
muscle O 0 0.024692576378583908
cells O 0 0.00016099773347377777
. O 0 4.0525377698941156e-05

Myotonic B-Disease 1 0.9999998807907104
dystrophy I-Disease 1 1.0
( O 1 0.862296998500824
DM B-Disease 1 1.0
) O 0 1.8189808542956598e-05
, O 0 1.3482963368005585e-06
the O 0 6.233871658878343e-07
most O 0 2.434320776956156e-06
prevalent O 0 0.12882427871227264
muscular B-Disease 1 0.9999985694885254
disorder I-Disease 1 0.999239444732666
in O 0 9.160233457805589e-05
adults O 0 8.041861292440444e-05
, O 0 6.715104632348812e-07
is O 0 2.4089808903227095e-07
caused O 0 1.4771619589737384e-06
by O 0 4.3209033151470067e-07
( O 0 1.4538004506903235e-06
CTG O 0 6.75676274113357e-05
) O 0 8.841259955261194e-07
n O 0 2.975612687805551e-06
- O 0 2.6282950784661807e-06
repeat O 0 1.4341687801788794e-06
expansion O 0 1.3084610372970928e-06
in O 0 4.618619300345017e-07
a O 0 5.998464871481701e-07
gene O 0 3.0658668492833385e-06
encoding O 0 2.3362215415545506e-06
a O 0 2.0455688627407653e-06
protein O 0 8.275927939394023e-06
kinase O 0 9.224749373970553e-05
( O 0 8.118357982311863e-06
DM B-Disease 1 0.9999805688858032
protein O 0 1.354656615148997e-05
kinase O 0 4.666166933020577e-05
; O 0 2.9103996439516777e-06
DMPK O 0 6.072473115636967e-05
) O 0 6.218492671905551e-07
and O 0 2.631904294503329e-07
involves O 0 6.918347139617254e-07
changes O 0 1.141528969128558e-06
in O 0 1.7379358041580417e-06
cytoarchitecture O 0 0.00013296480756253004
and O 0 6.490988198493142e-06
ion O 0 0.00018562318291515112
homeostasis O 0 0.000736155197955668
. O 0 3.3682124922052026e-05

To O 0 3.177314647473395e-05
obtain O 0 1.7995871530729346e-05
clues O 0 1.5255950529535767e-05
to O 0 7.526716103711806e-07
the O 0 7.772699746055878e-07
normal O 0 1.827233631956915e-06
biological O 0 1.2482638567234972e-06
role O 0 3.524023668433074e-07
of O 0 1.0820708240544263e-07
DMPK O 0 5.671325561706908e-05
in O 0 1.820814645725477e-06
cellular O 0 1.4677908438898157e-05
ion O 0 1.5065324078022968e-05
homeostasis O 0 4.496104156714864e-05
, O 0 3.493306337531976e-07
we O 0 8.736375178841627e-08
have O 0 8.605508838854803e-08
compared O 0 3.819517075953627e-07
the O 0 1.7529438878227666e-07
resting O 0 4.626634563464904e-06
[ O 0 3.7667755350412335e-06
Ca2 O 0 2.2205042114364915e-05
+ O 0 9.673321073933039e-06
] O 0 2.592828195702168e-06
i O 0 4.74885297307992e-07
, O 0 5.48316663184778e-08
the O 0 5.1007546630899014e-08
amplitude O 0 4.1087358226832293e-07
and O 0 2.375415419919591e-07
shape O 0 1.1419656402722467e-06
of O 0 2.434640578030667e-07
depolarization O 0 2.2127143893158063e-05
- O 0 0.00020459310326259583
induced O 0 9.180381312035024e-05
Ca2 O 0 8.616021659690887e-05
+ O 0 2.8763870432158e-05
transients O 0 1.8294573237653822e-05
, O 0 2.1145079642792552e-07
and O 0 7.114119426887555e-08
the O 0 6.941280616956647e-08
content O 0 1.7002791707909637e-07
of O 0 8.355186764674727e-08
ATP O 0 2.042207051999867e-05
- O 0 4.398976670927368e-06
driven O 0 4.705691480921814e-06
ion O 0 7.1047338678909e-06
pumps O 0 1.5746600183774717e-05
in O 0 3.2664377158653224e-06
cultured O 0 0.00217708433046937
skeletal O 0 0.06139116734266281
muscle O 0 0.0002085909218294546
cells O 0 4.984249244444072e-06
of O 0 3.0414636853492993e-07
wild O 0 2.707066869334085e-06
- O 0 3.1086405215319246e-05
type O 0 5.759823125117691e-06
and O 0 1.7569785768500878e-06
DMPK O 0 0.0034807934425771236
[ O 0 6.196439790073782e-05
- O 0 0.019130617380142212
/ O 0 0.031590674072504044
- O 0 0.0017127792816609144
] O 0 0.00014252858818508685
knockout O 0 0.002627419773489237
mice O 0 0.0013963989913463593
. O 0 4.213937427266501e-05

In O 0 0.00021580859902314842
vitro O 0 0.0017306603258475661
- O 0 0.0010758654680103064
differentiated O 0 0.0003919358423445374
DMPK O 0 0.00173389189876616
[ O 0 0.00013751661754213274
- O 0 0.002774112392216921
/ O 0 0.0025458422023802996
- O 0 0.00029637585976161063
] O 0 2.031777512456756e-05
myotubes O 0 4.255459498381242e-05
exhibit O 0 3.1165302516455995e-06
a O 0 1.165726757790253e-06
higher O 0 2.6467271254659863e-06
resting O 0 1.4911323887645267e-05
[ O 0 1.077336219168501e-05
Ca2 O 0 4.400840407470241e-05
+ O 0 3.422606459935196e-05
] O 0 6.731655048497487e-06
i O 0 9.890509318211116e-07
than O 0 1.908219502411157e-07
do O 0 2.2426094403726893e-07
wild O 0 5.946779992882512e-07
- O 0 8.585540854255669e-06
type O 0 2.1621156065521063e-06
myotubes O 0 2.0748371753143147e-05
because O 0 2.653915487371705e-07
of O 0 6.014182929447998e-08
an O 0 1.8616545105487603e-07
altered O 0 2.261095914946054e-06
open O 0 1.0231166243102052e-06
probability O 0 2.476374163506989e-07
of O 0 1.5113367624053353e-07
voltage O 0 8.320743290823884e-06
- O 0 8.095829252852127e-05
dependent O 0 3.297751391073689e-05
l O 0 0.000980554148554802
- O 0 8.02990616648458e-05
type O 0 1.3162873074179515e-05
Ca2 O 0 3.949588426621631e-05
+ O 0 1.766262539604213e-05
and O 0 2.308138618900557e-06
Na O 0 5.5059070291463286e-05
+ O 0 2.9443406674545258e-05
channels O 0 2.5900633772835135e-05
. O 0 1.5626297681592405e-05

The O 0 0.00015542027540504932
mutant O 0 0.000820071145426482
myotubes O 0 0.0004807900986634195
exhibit O 0 2.0252520698704757e-05
smaller O 0 7.5655439104593825e-06
and O 0 2.3122320271795616e-06
slower O 0 6.241934170247987e-05
Ca2 O 0 6.001421934342943e-05
+ O 0 1.1022260878235102e-05
responses O 0 2.3444883936463157e-06
upon O 0 4.831670139537891e-07
triggering O 0 3.397564569240785e-06
by O 0 8.340154522556986e-07
acetylcholine O 0 8.172592970367987e-06
or O 0 8.741873216422391e-07
high O 0 1.829155053201248e-06
external O 0 1.3942041732661892e-05
K O 0 0.0001287327177124098
+ O 0 0.00010068307165056467
. O 0 1.5502373571507633e-05

In O 0 3.741835826076567e-05
addition O 0 5.2498248805932235e-06
, O 0 8.497611929669802e-07
we O 0 2.5533313419146e-07
observed O 0 2.6385589535493637e-07
that O 0 1.0029685881818295e-07
these O 0 1.6021553506107011e-07
Ca2 O 0 1.259507280337857e-05
+ O 0 1.311917367274873e-05
transients O 0 2.674996358109638e-05
partially O 0 6.093623142078286e-06
result O 0 7.037784826025018e-07
from O 0 1.9051773847422737e-07
an O 0 1.1359812646105638e-07
influx O 0 7.598317779411445e-07
of O 0 2.229279800758377e-07
extracellular O 0 4.268513293936849e-06
Ca2 O 0 1.4396762708202004e-05
+ O 0 6.055723588360706e-06
through O 0 1.0872101938730339e-06
the O 0 1.3442418094200548e-06
l O 0 0.00040943259955383837
- O 0 6.648857379332185e-05
type O 0 3.175609526806511e-05
Ca2 O 0 8.908551535569131e-05
+ O 0 4.225192606099881e-05
channel O 0 5.376011540647596e-05
. O 0 1.598292146809399e-05

Neither O 0 0.00011312774586258456
the O 0 5.303396847011754e-06
content O 0 5.421330115495948e-06
nor O 0 2.7461462650535395e-06
the O 0 3.7438837807712844e-07
activity O 0 1.4093994877839577e-06
of O 0 5.62640138923598e-07
Na O 0 0.00017445364210288972
+ O 0 7.30263491277583e-05
/ O 0 6.252448656596243e-05
K O 0 4.1233313822885975e-05
+ O 0 4.8525042075198144e-05
ATPase O 0 0.00016781315207481384
and O 0 9.20875754673034e-06
sarcoplasmic O 0 0.0009399859118275344
reticulum O 0 0.0014765207888558507
Ca2 O 0 0.0004853521822951734
+ O 0 0.00016329488425981253
- O 0 5.087871613795869e-05
ATPase O 0 7.321537850657478e-05
are O 0 4.6014116605874733e-07
affected O 0 4.178686140221544e-06
by O 0 3.1517572551820194e-06
DMPK O 0 0.0008285139920189977
absence O 0 6.0088030295446515e-05
. O 0 2.8595606636372395e-05

In O 0 3.153551369905472e-05
conclusion O 0 1.1739506589947268e-05
, O 0 6.41703991277609e-07
our O 0 2.7220431775276666e-07
data O 0 5.024032248002186e-07
suggest O 0 8.179886776815692e-07
that O 0 2.02341041699583e-07
DMPK O 0 2.8387670681695454e-05
is O 0 1.582653368359388e-07
involved O 0 2.3575412910759042e-07
in O 0 4.994146820536116e-07
modulating O 0 8.04733281256631e-06
the O 0 4.061072615968442e-07
initial O 0 1.1927123750865576e-06
events O 0 7.113997071428457e-07
of O 0 2.8058778411832463e-07
excitation O 0 1.2821530617657118e-05
- O 0 0.0001612792257219553
contraction O 0 0.00010928231495199725
coupling O 0 3.927458601538092e-05
in O 0 1.3262631000543479e-05
skeletal O 0 0.0460602343082428
muscle O 0 0.0007480307831428945
. O 0 9.318559023085982e-06
. O 0 1.4725044820806943e-05

Constitutional O 0 0.002968790242448449
RB1 O 1 0.9748611450195312
- O 0 0.06390645354986191
gene O 0 0.00030369925661943853
mutations O 0 0.0001058978887158446
in O 0 2.1195373847149312e-05
patients O 0 0.0005303755751810968
with O 0 7.4690078690764494e-06
isolated O 0 0.0005491747288033366
unilateral B-Disease 0 0.001153466640971601
retinoblastoma I-Disease 0 0.25503095984458923
. O 0 7.680397538933903e-05

In O 0 0.0001109200093196705
most O 0 2.524842602724675e-05
patients O 0 0.0003343674761708826
with O 0 2.5317851850559236e-06
isolated O 0 0.00010739235585788265
unilateral B-Disease 0 0.0004962226958014071
retinoblastoma I-Disease 0 0.3996637761592865
, O 0 1.5679495845688507e-05
tumor B-Disease 0 0.0001494656753493473
development O 0 1.8180628558184253e-06
is O 0 2.6615015258357744e-07
initiated O 0 2.417118821540498e-06
by O 0 1.0831523695742362e-06
somatic O 0 1.4538902178173885e-05
inactivation O 0 2.1695990653824992e-05
of O 0 1.578240187427582e-07
both O 0 4.0693032588023925e-07
alleles O 0 2.716905555644189e-06
of O 0 2.815122002175485e-07
the O 0 1.025040455715498e-05
RB1 O 0 0.09783610701560974
gene O 0 9.199028136208653e-05
. O 0 3.3953994716284797e-05

However O 0 6.329253665171564e-05
, O 0 2.401306801402825e-06
some O 0 1.9613287349784514e-07
of O 0 9.81468559757559e-08
these O 0 6.113624522186001e-07
patients O 0 9.943687473423779e-05
can O 0 1.513931920271716e-06
transmit O 0 8.27483381726779e-05
retinoblastoma B-Disease 1 0.5294075012207031
predisposition O 0 0.0003349366597831249
to O 0 3.7448050989041803e-06
their O 0 8.400058504776098e-06
offspring O 0 9.622272773412988e-05
. O 0 2.7980184313491918e-05

To O 0 2.565761678852141e-05
determine O 0 6.825654963904526e-06
the O 0 9.358503803014173e-07
frequency O 0 1.498697656643344e-06
and O 0 2.9387626909738174e-07
nature O 0 4.175982439846848e-07
of O 0 1.844794041971909e-07
constitutional O 0 1.3959203897684347e-05
RB1 O 0 0.15818065404891968
- O 0 0.0004911054274998605
gene O 0 1.949852958205156e-05
mutations O 0 1.0820024726854172e-05
in O 0 4.16337161368574e-06
patients O 0 0.00011067879677284509
with O 0 1.6431300764452317e-06
isolated O 0 0.00012594468716997653
unilateral B-Disease 0 0.00014818664931226522
retinoblastoma I-Disease 0 0.005201607011258602
, O 0 9.486217891208071e-07
we O 0 4.4044409719390387e-07
analyzed O 0 2.7090943603980122e-06
DNA O 0 3.405580400794861e-06
from O 0 1.0266783192491857e-06
peripheral O 0 0.00024335927446372807
blood O 0 1.7388561900588684e-05
and O 0 2.2793124117015395e-06
from O 0 1.8315693523618393e-05
tumor B-Disease 0 0.08965248614549637
tissue O 0 0.0007920951466076076
. O 0 3.165440648444928e-05

The O 0 4.304778121877462e-05
analysis O 0 1.7242766261915676e-05
of O 0 3.1103718356462196e-06
tumors B-Disease 1 0.9984643459320068
from O 0 2.8317535907262936e-06
54 O 0 1.1256493053224403e-05
( O 0 1.615357177797705e-06
71 O 0 6.696738637401722e-06
% O 0 7.517605808970984e-07
) O 0 1.40880658250353e-07
of O 0 1.3785599151105998e-07
76 O 0 2.5309684133389965e-05
informative O 0 0.00011140421702293679
patients O 0 0.025470174849033356
showed O 0 7.300170545931906e-05
loss O 0 8.321219866047613e-06
of O 0 5.089525529911043e-07
constitutional O 0 3.298081719549373e-05
heterozygosity O 0 0.004098277073353529
( O 0 0.00010339818254578859
LOH O 1 0.9999397993087769
) O 0 8.885282113624271e-06
at O 0 1.3089903404761571e-05
intragenic O 0 0.000327587389620021
loci O 0 0.0001837681047618389
. O 0 3.792200004681945e-05

Three O 0 2.699235665204469e-05
of O 0 7.974200343596749e-06
13 O 0 8.042712579481304e-05
uninformative O 1 0.6895403265953064
patients O 0 0.3813806176185608
had O 0 6.171718996483833e-05
constitutional O 0 5.335494643077254e-05
deletions O 0 0.00048692748532630503
. O 0 6.416999531211331e-05

For O 0 4.295833787182346e-05
39 O 0 6.013549864292145e-05
randomly O 0 2.4121718524838798e-05
selected O 0 2.3443195459549315e-05
tumors B-Disease 1 0.9850854277610779
, O 0 3.2584819109615637e-06
SSCP O 0 0.0002564595779404044
, O 0 3.622701569838682e-06
hetero O 0 0.0008212488610297441
- O 0 0.00012034170504193753
duplex O 0 0.0001465958630433306
analysis O 0 2.0526354091998655e-06
, O 0 3.098140268775751e-07
sequencing O 0 1.793026740415371e-06
, O 0 1.9455848132565734e-07
and O 0 1.877856163901015e-07
Southern O 0 1.307097818425973e-06
blot O 0 8.641538443043828e-05
analysis O 0 1.0279362641085754e-06
were O 0 4.941082920595363e-07
used O 0 7.099967547219421e-07
to O 0 1.1759390190491104e-06
identify O 0 1.2978097402083222e-05
mutations O 0 2.8792737793992274e-05
. O 0 1.2840080671594478e-05

Mutations O 0 0.0013655071379616857
were O 0 2.809714169416111e-05
detected O 0 2.3876535124145448e-05
in O 0 1.9218728084524628e-06
21 O 0 3.5127234241372207e-06
( O 0 1.011677568385494e-06
91 O 0 4.364248525234871e-06
% O 0 1.039973881233891e-06
) O 0 3.876012044656818e-07
of O 0 3.2899993129831273e-07
23 O 0 0.001048013917170465
tumors B-Disease 1 0.999984860420227
with O 0 9.611341374693438e-05
LOH O 1 0.9999977350234985
. O 0 0.0001575335772940889

In O 0 4.022306529805064e-05
6 O 0 1.0908380318142008e-05
( O 0 2.0093470993742812e-06
38 O 0 2.5661083782324567e-06
% O 0 5.106254548081779e-07
) O 0 1.964619684713398e-07
of O 0 1.7179375788600737e-07
16 O 0 5.04339077451732e-05
tumors B-Disease 1 0.9999085664749146
without O 0 1.087755026674131e-05
LOH O 1 0.9998939037322998
, O 0 8.886984801392828e-07
one O 0 3.1410883138960344e-07
mutation O 0 1.9327758309373166e-06
was O 0 1.8903057252828148e-06
detected O 0 1.8660055047803326e-06
, O 0 1.0873444722392378e-07
and O 0 9.530953803960074e-08
in O 0 2.2163615653880697e-07
9 O 0 1.0138891184396925e-06
( O 0 2.868125079658057e-07
56 O 0 5.99581085225509e-07
% O 0 2.672027790140419e-07
) O 0 1.294765468173864e-07
of O 0 9.29111720893161e-08
the O 0 6.054198820493184e-06
tumors B-Disease 1 0.9999935626983643
without O 0 2.1634421500493772e-05
LOH O 1 0.9999966621398926
, O 0 1.8913480062110466e-06
both O 0 1.2522114047897048e-06
mutations O 0 5.319240244716639e-06
were O 0 2.1988987555232598e-06
found O 0 8.72876353241736e-06
. O 0 1.0439334801048972e-05

Thus O 0 3.442600791458972e-05
, O 0 1.9670035271701636e-06
a O 0 7.226515776892484e-07
total O 0 3.0437530540439184e-07
of O 0 1.3957372857476003e-07
45 O 0 1.686958626123669e-06
mutations O 0 3.536214308041963e-06
were O 0 1.483763981013908e-06
identified O 0 7.570999969175318e-06
in O 0 3.569568070815876e-05
tumors B-Disease 1 0.9992915391921997
of O 0 1.9356386928848224e-06
36 O 0 0.00014229529188014567
patients O 0 0.001135336933657527
. O 0 5.549056731979363e-05

Thirty O 0 0.0003129963588435203
- O 0 8.831395098241046e-05
nine O 0 3.8106647934910143e-06
of O 0 2.431392260859866e-07
the O 0 3.8979308669695456e-07
mutations O 0 3.153880243189633e-06
- O 0 4.837364031118341e-06
including O 0 5.779289153906575e-07
34 O 0 2.6925224574370077e-06
small O 0 1.3100755040795775e-06
mutations O 0 3.907387053914135e-06
, O 0 4.527615544702712e-07
2 O 0 4.5390248715193593e-07
large O 0 9.315530746789591e-07
structural O 0 5.664072523359209e-05
alterations O 0 0.00035313176340423524
, O 0 1.4870333870931063e-06
and O 0 1.4241634289646754e-06
hypermethylation O 0 0.0002609483490232378
in O 0 7.536063549196115e-06
3 O 0 5.955924643785693e-05
tumors O 1 0.9999904632568359
- O 0 9.394626249559224e-05
were O 0 9.811660675040912e-07
not O 0 3.7517327200475847e-07
detected O 0 1.552125013404293e-06
in O 0 2.7186499096387706e-07
the O 0 6.04833701345342e-07
corresponding O 0 4.308088136895094e-06
peripheral O 0 0.0002860124222934246
blood O 0 4.625540168490261e-05
DNA O 0 9.091415267903358e-05
. O 0 1.9764336684602313e-05

In O 0 3.735197606147267e-05
6 O 0 1.6159816368599422e-05
( O 0 2.0401801066327607e-06
17 O 0 8.317580295624794e-07
% O 0 3.134134090032603e-07
) O 0 5.3796259891214504e-08
of O 0 2.195540282912134e-08
the O 0 2.1736073563261016e-07
36 O 0 1.0971115443680901e-05
patients O 0 3.760531035368331e-05
, O 0 2.58346375403562e-07
a O 0 1.1932777397305472e-06
mutation O 0 3.640089744294528e-06
was O 0 5.64316860618419e-06
detected O 0 3.7113388771103928e-06
in O 0 4.520526886153675e-07
constitutional O 0 1.181602556243888e-06
DNA O 0 1.6163527334356331e-06
, O 0 7.869343221500458e-08
and O 0 7.97053729684194e-08
1 O 0 9.152255131539277e-08
of O 0 2.936036125333885e-08
these O 0 1.1384225473420884e-07
mutations O 0 7.619433972649858e-07
is O 0 7.443470906309813e-08
known O 0 2.6013407250502496e-07
to O 0 1.40134034154471e-07
be O 0 2.235372846826067e-07
associated O 0 9.461768968321849e-07
with O 0 7.763965186313726e-07
reduced O 0 3.1892450351733714e-05
expressivity O 0 0.0016055454034358263
. O 0 4.788551450474188e-05

The O 0 9.162748938251752e-06
presence O 0 3.1752831546327798e-06
of O 0 2.765194153653283e-07
a O 0 4.788417982126703e-07
constitutional O 0 2.0532852431642823e-06
mutation O 0 2.7975170269201044e-06
was O 0 2.224950094387168e-06
not O 0 2.266021255081796e-07
associated O 0 3.172744982293807e-07
with O 0 1.1462608995316259e-07
an O 0 3.95542713249597e-07
early O 0 1.5055442418088205e-05
age O 0 8.810161489236634e-06
at O 0 6.02862928644754e-06
treatment O 0 0.00030386666185222566
. O 0 2.169259823858738e-05

In O 0 6.207203841768205e-05
1 O 0 2.3576121748192236e-05
patient O 0 7.113537139957771e-05
, O 0 3.263800181230181e-06
somatic O 0 4.636001540347934e-05
mosaicism O 0 0.0005040725809521973
was O 0 1.2155684999015648e-05
demonstrated O 0 3.7863501347601414e-06
by O 0 4.5770556766910886e-07
molecular O 0 1.4609665868192678e-06
analysis O 0 6.643139727202652e-07
of O 0 1.6238477940078155e-07
DNA O 0 2.8609042601601686e-06
and O 0 1.092455818252347e-06
RNA O 0 6.049345302017173e-06
from O 0 2.747807002378977e-06
peripheral O 0 0.0005213310359977186
blood O 0 9.113566920859739e-05
. O 0 2.403565486019943e-05

In O 0 0.00010793524415930733
2 O 0 5.2017854613950476e-05
patients O 0 0.0002219674497609958
without O 0 2.589595851532067e-06
a O 0 9.785880138224456e-06
detectable O 0 6.97561918059364e-05
mutation O 0 1.573393092257902e-05
in O 0 5.071858140581753e-06
peripheral O 0 0.0010496384929865599
blood O 0 4.424211147124879e-05
, O 0 2.712912873903406e-06
mosaicism O 0 0.00023894984042271972
was O 0 1.1198738320672419e-05
suggested O 0 2.071059725494706e-06
because O 0 2.6093189831044583e-07
1 O 0 2.2575486013920454e-07
of O 0 1.2299848606289743e-07
the O 0 3.07867958326824e-06
patients O 0 0.02449393831193447
showed O 1 0.53029865026474
multifocal O 1 0.9999892711639404
tumors B-Disease 1 0.9999945163726807
and O 0 1.754376739881991e-06
the O 0 6.656165965068794e-07
other O 0 4.974131115886848e-07
later O 0 4.486636498768348e-06
developed O 0 1.8024058590526693e-05
bilateral B-Disease 0 6.894863327033818e-05
retinoblastoma I-Disease 0 0.018931498751044273
. O 0 7.845711661502719e-05

In O 0 6.413922528736293e-05
conclusion O 0 3.2118161470862105e-05
, O 0 1.2463165148801636e-06
our O 0 7.540201636402344e-07
results O 0 1.7673037291388027e-06
emphasize O 0 1.2936486655235058e-06
that O 0 1.373833811157965e-07
the O 0 2.8956554842807236e-07
manifestation O 0 4.302910838305252e-06
and O 0 5.02755483466899e-07
transmissibility O 0 7.371263563982211e-06
of O 0 2.8882612923553097e-07
retinoblastoma B-Disease 0 9.254432370653376e-05
depend O 0 1.6505022131241276e-06
on O 0 4.44387779907629e-07
the O 0 1.2433730489647132e-07
nature O 0 9.839746439865849e-08
of O 0 1.7643882799234234e-08
the O 0 7.445103022973854e-08
first O 0 3.1302090519602643e-07
mutation O 0 5.271148779684154e-07
, O 0 4.4575276803016095e-08
its O 0 5.0956984409822326e-08
time O 0 1.0167402564320582e-07
in O 0 8.596535394644889e-08
development O 0 1.8263017409481108e-07
, O 0 5.9188867140846924e-08
and O 0 5.889607024300858e-08
the O 0 3.786339064504318e-08
number O 0 3.975200613126617e-08
and O 0 5.572606198711583e-08
types O 0 1.209409532521022e-07
of O 0 4.062513170310922e-08
cells O 0 1.565001298331481e-06
that O 0 1.9401207396185782e-07
are O 0 1.9902003600691387e-07
affected O 0 3.1677188871981343e-06
. O 0 2.0960137590009253e-06
. O 0 9.154835424851626e-06

Hereditary B-Disease 1 0.9999974966049194
deficiency I-Disease 1 0.9952722191810608
of I-Disease 0 2.484095148247434e-06
the I-Disease 0 1.9603223790909396e-06
fifth I-Disease 0 6.053431206964888e-06
component I-Disease 0 1.9889055238309084e-06
of I-Disease 0 1.7660354956205992e-07
complement I-Disease 0 3.015233914993587e-06
in O 0 4.641390660253819e-06
man O 0 8.960984268924221e-05
. O 0 1.3125405530445278e-05

I O 0 0.006148642860352993
. O 0 0.0007184370188042521

Clinical O 0 0.019912855699658394
, O 0 3.376165477675386e-05
immunochemical O 0 0.00041591719491407275
, O 0 2.4894407033571042e-06
and O 0 1.3815923693982768e-06
family O 0 9.479367690801155e-06
studies O 0 2.320205203432124e-05
. O 0 3.072401523240842e-05

The O 0 3.5387554817134514e-05
first O 0 1.2772496120305732e-05
recognized O 0 6.00868406763766e-06
human O 0 3.945103799196659e-06
kindred O 0 0.0007127386634238064
with O 0 0.00014764447405468673
hereditary B-Disease 1 0.9999990463256836
deficiency I-Disease 1 0.8384976387023926
of I-Disease 0 1.6602047026026412e-07
the I-Disease 0 4.5621473532264645e-07
fifth I-Disease 0 2.275348833791213e-06
component I-Disease 0 6.897503226355184e-07
of I-Disease 0 1.2997324461139215e-07
complement I-Disease 0 3.645217020675773e-06
( O 0 4.53332449978916e-06
C5 O 0 0.00045245018554851413
) O 0 1.7984401665671612e-06
is O 0 6.667385150649352e-07
described O 0 2.1450347048812546e-05
. O 0 1.4711796211486217e-05

The O 0 5.529506233870052e-05
proband O 0 0.00042695915908552706
, O 0 2.98695954370487e-06
a O 0 1.2918808351969346e-06
20 O 0 1.8592998003441608e-06
- O 0 3.054167245863937e-05
year O 0 4.517304660112131e-06
- O 0 5.561367652262561e-05
old O 0 7.569045556010678e-05
black O 0 5.716109080822207e-05
female O 0 5.391115337260999e-05
with O 0 0.0004890502896159887
systemic B-Disease 1 1.0
lupus I-Disease 1 1.0
erythematosus I-Disease 1 1.0
since O 0 0.0004589131276588887
age O 0 3.775075310841203e-05
11 O 0 4.306071332393913e-06
, O 0 1.0992279158017482e-06
lacked O 0 0.00024377474619541317
serum O 0 0.001441272790543735
hemolytic O 0 0.007225384935736656
complement O 0 1.1616069059527945e-05
activity O 0 4.655581051338231e-06
, O 0 4.981783945368079e-07
even O 0 6.289695306804788e-07
during O 0 1.23000154417241e-05
remission O 0 0.0006094269338063896
. O 0 2.3409394998452626e-05

C5 O 0 0.0768796056509018
was O 0 0.0001988766307476908
undetectable O 0 0.00016998531646095216
in O 0 5.170421445654938e-06
her O 0 1.0797738468681928e-05
serum O 0 2.8378493880154565e-05
by O 0 1.3230441027189954e-06
both O 0 2.6371126295998693e-06
immunodiffusion O 0 0.00027649724506773055
and O 0 1.9305161913507618e-05
hemolytic O 1 0.5554535984992981
assays O 0 0.0007319841533899307
. O 0 5.7043038395931944e-05

Other O 0 1.5010125025582965e-05
complement O 0 1.286965016333852e-05
components O 0 6.562585895153461e-06
were O 0 1.4767056200071238e-06
normal O 0 3.4986385344382143e-06
during O 0 8.511574378644582e-06
remission O 0 0.0002986116742249578
of O 0 5.04486797581194e-06
lupus O 1 0.9998629093170166
, O 0 2.682772219486651e-06
but O 0 3.459497293079039e-06
C1 O 0 0.0009135215077549219
, O 0 1.6917097127588931e-06
C4 O 0 0.0003441252338234335
, O 0 1.4849191529719974e-06
C2 O 0 0.00012593531573656946
, O 0 3.6217267052052193e-07
and O 0 8.738647920836229e-07
C3 O 0 0.0006093966658227146
levels O 0 4.944990450894693e-06
fell O 0 3.32315539708361e-05
during O 0 3.560725235729478e-05
exacerbations O 0 0.005364898592233658
. O 0 8.953484211815521e-05

A O 0 0.00010785870108520612
younger O 0 0.00015009437629487365
half O 0 2.4560991732869297e-05
- O 0 0.0001586357393534854
sister O 0 5.4863055993337184e-05
, O 0 9.709871164886863e-07
who O 0 7.930984793347307e-07
had O 0 2.670850790309487e-06
no O 0 4.160704520472791e-06
underlying O 0 0.0027923404704779387
disease O 0 0.0032880641520023346
, O 0 1.968970536836423e-06
was O 0 2.2971998987486586e-05
also O 0 7.148859140215791e-07
found O 0 5.030082093071542e-07
to O 0 5.251259835858946e-07
lack O 0 2.0879579096799716e-05
immunochemically O 0 0.00394432945176959
detectable O 0 0.0002132686786353588
C5 O 0 0.0010871192207559943
. O 0 3.866925180773251e-05

By O 0 0.0005347423139028251
hemolytic O 1 0.9513176679611206
assay O 0 0.0006995883886702359
, O 0 7.826493856555317e-06
she O 0 5.535318905458553e-06
exhibited O 0 8.667643669468816e-06
1 O 0 9.136102221418696e-07
- O 0 3.913682121492457e-06
2 O 0 2.0294631042361289e-07
% O 0 8.878287616198577e-08
of O 0 1.914637337563363e-08
the O 0 2.0207878037581395e-07
normal O 0 3.5952671169070527e-06
serum O 0 2.468139791744761e-05
C5 O 0 6.835987005615607e-05
level O 0 6.072212386243336e-07
and O 0 3.190218365034525e-07
normal O 0 1.0502208169782534e-06
concentrations O 0 5.616708449451835e-07
of O 0 1.0344312784127396e-07
other O 0 3.030172592843883e-07
complement O 0 4.673526746046264e-06
components O 0 2.6467814677744173e-05
. O 0 1.469363814976532e-05

C5 O 0 0.0037784564774483442
levels O 0 1.7990139895118773e-05
of O 0 5.472383577398432e-07
other O 0 3.184017884905188e-07
family O 0 1.0859345138669596e-06
members O 0 1.31692587501675e-07
were O 0 2.6781532369568595e-07
either O 0 2.183571723435307e-07
normal O 0 3.949377287426614e-07
or O 0 1.326702943060809e-07
approximately O 0 1.5962349664278008e-07
half O 0 4.4511304508887406e-07
- O 0 9.38587800192181e-06
normal O 0 1.289031843043631e-06
, O 0 3.045161349746195e-07
consistent O 0 3.1802107969269855e-06
with O 0 3.980590918217786e-06
autosomal O 0 0.013284296728670597
codominant O 0 0.0004223371506668627
inheritance O 0 5.981418325973209e-06
of O 0 5.755895813308598e-07
the O 0 2.8655297228397103e-06
gene O 0 5.4724168876418844e-05
determining O 0 0.00020918683730997145
C5 B-Disease 1 0.9999995231628418
deficiency I-Disease 1 0.9999938011169434
. O 0 0.00010156308417208493

Normal O 0 0.04439196735620499
hemolytic O 1 0.9994235038757324
titers O 0 0.010280180722475052
were O 0 4.255711246514693e-05
restored O 0 7.471343997167423e-05
to O 0 5.745855105487863e-06
both O 0 6.902826953592012e-06
homozygous O 0 0.006309259217232466
C5 B-Disease 1 0.9999974966049194
- I-Disease 1 0.9999574422836304
deficient I-Disease 1 0.9999992847442627
( O 0 6.426803884096444e-05
C5D B-Disease 1 0.9996553659439087
) O 0 3.944426680391189e-06
sera O 0 1.9636152501334436e-05
by O 0 4.750669120312523e-07
addition O 0 3.932138668005791e-07
of O 0 3.169506044287118e-07
highly O 0 6.310655408015009e-06
purified O 0 5.26758267369587e-05
human O 0 1.4197753444022965e-05
C5 O 0 0.0010450338013470173
. O 0 4.826926306122914e-05

In O 0 8.430964226135984e-05
specific O 0 4.9091486289398745e-05
C5 O 0 0.0015557329170405865
titrations O 0 0.0006606582901440561
, O 0 2.9960949632368283e-06
however O 0 1.5285060044334386e-06
, O 0 3.224928377676406e-07
it O 0 1.2006687200027955e-07
was O 0 7.730718039056228e-07
noted O 0 2.336733331276264e-07
that O 0 3.9636542936705155e-08
when O 0 8.227236492075463e-08
limited O 0 2.077723308957502e-07
amounts O 0 1.5430600797117222e-07
of O 0 7.41727959052696e-08
C5 O 0 4.679655467043631e-05
were O 0 6.984574270063604e-07
assayed O 0 4.357569650892401e-06
in O 0 3.306847133899282e-07
the O 0 1.3127427678227832e-07
presence O 0 3.2396658866673533e-07
of O 0 7.789955702719453e-08
low O 0 2.1202702100708848e-06
dilutions O 0 2.1010047930758446e-05
of O 0 4.4868284021504223e-07
either O 0 4.187661943433341e-06
C5D B-Disease 1 0.9999374151229858
serum O 0 7.238800026243553e-05
, O 0 7.178646228567231e-07
curving O 0 2.7464288905321155e-06
rather O 0 7.45544753044669e-07
than O 0 2.7943576696998207e-07
linear O 0 1.9457106645859312e-06
dose O 0 2.5178265786962584e-05
- O 0 2.9345717848627828e-05
response O 0 1.910739456434385e-06
plots O 0 1.4016600289323833e-06
were O 0 4.6250985974438663e-07
consistently O 0 1.935195768965059e-06
obtained O 0 7.38605137939885e-07
, O 0 2.4062990178208565e-07
suggesting O 0 1.943494453371386e-06
some O 0 6.025837251399935e-07
inhibitory O 0 1.4770444067835342e-05
effect O 0 8.321076165884733e-06
. O 0 1.1178719432791695e-05

Further O 0 0.00010520219802856445
studies O 0 3.821416248683818e-05
suggested O 0 1.4606094737246167e-05
that O 0 1.067808739207976e-06
low O 0 7.694141459069215e-06
dilutions O 0 0.0001697414118098095
of O 0 3.4063762086589122e-06
C5D B-Disease 1 0.9999879598617554
serum O 0 0.0002827995631378144
contain O 0 2.1177118014747975e-06
a O 0 1.0827133110069553e-06
factor O 0 1.3264400422485778e-06
( O 0 4.9814036628959e-07
or O 0 3.0991034805083473e-07
factors O 0 2.976215398575732e-07
) O 0 1.8320933747872914e-07
interfering O 0 8.534515814062615e-07
at O 0 4.147735523929441e-07
some O 0 1.1727488669066588e-07
step O 0 1.0904218470386695e-06
in O 0 8.644527156320692e-07
the O 0 2.9646282655448886e-06
hemolytic O 0 0.007389822509139776
assay O 0 3.413242302485742e-05
of O 0 5.390039063968288e-07
C5 O 0 0.0007327968487516046
, O 0 9.861294074653415e-07
rather O 0 4.6436881007139164e-07
than O 0 4.4322425196696713e-07
a O 0 1.0624474953147e-06
true O 0 7.456033927155659e-06
C5 O 0 0.0009559049503877759
inhibitor O 0 9.42543993005529e-05
or O 0 5.29156523043639e-06
inactivator O 0 0.0002550056960899383
. O 0 2.149886313418392e-05

Of O 0 2.220197166025173e-05
clinical O 0 0.0002110103814629838
interest O 0 2.2997585347184213e-06
are O 0 3.936040400276397e-07
( O 0 6.08144432590052e-07
a O 0 4.170514671386627e-07
) O 0 3.439515126046899e-07
the O 0 2.8823203024330724e-07
documentation O 0 3.3447727219027e-06
of O 0 1.4692002423544182e-06
membranous O 1 0.8224636912345886
glomerulonephritis B-Disease 1 0.9999995231628418
, O 0 0.0008016392821446061
vasculitis B-Disease 1 0.9999957084655762
, O 0 5.3642324928659946e-05
and O 0 0.08834633231163025
arthritis B-Disease 1 1.0
in O 0 3.0379062536667334e-06
an O 0 2.6843540013032907e-07
individual O 0 3.87307096616496e-07
lacking O 0 1.8769747839542106e-05
C5 O 0 0.0009886504849418998
( O 0 6.398035452548356e-07
and O 0 1.9634471470908466e-07
its O 0 2.650197643561114e-07
biologic O 0 8.001258720469195e-06
functions O 0 2.039237472217792e-07
) O 0 1.6382500689360313e-07
, O 0 7.220322828516146e-08
and O 0 1.8429265935537842e-07
( O 0 3.22477148984035e-07
b O 0 1.6283075865430874e-06
) O 0 1.741257449339173e-07
a O 0 4.4798633780374075e-07
remarkable O 0 3.42741032000049e-06
propensity O 0 5.606598642771132e-05
to O 0 4.9200400098925456e-05
bacterial B-Disease 1 0.9999793767929077
infections I-Disease 1 0.9999736547470093
in O 0 5.244971362117212e-06
the O 0 1.99922783394868e-06
proband O 0 0.00016338148270733654
, O 0 6.326010861812392e-07
even O 0 2.811652564105316e-07
during O 0 6.206489615578903e-07
periods O 0 7.284173761945567e-07
of O 0 1.4280992388648883e-07
low O 0 3.5159175695298472e-06
- O 0 2.609505463624373e-05
dose O 0 1.2473672541091219e-05
or O 0 1.2728858109767316e-06
alternate O 0 6.337378636089852e-06
- O 0 0.0001121486202464439
day O 0 3.6337089113658294e-05
corticosteroid O 0 0.00459809135645628
therapy O 0 0.002189860912039876
. O 0 8.183296449715272e-05

Other O 0 2.3210130166262388e-05
observations O 0 4.055054523632862e-05
indicate O 0 7.345573067141231e-06
that O 0 7.472581273759715e-07
the O 0 9.874751185634523e-07
C5D B-Disease 1 0.913812518119812
state O 0 4.861134925704391e-07
is O 0 2.5845037043836783e-07
compatible O 0 2.2671374608762562e-06
with O 0 4.035537699564884e-07
normal O 0 4.987078227713937e-06
coagulation O 0 1.5023071682662703e-05
function O 0 4.644449802526651e-07
and O 0 2.5127366143351537e-07
the O 0 2.787891730804404e-07
capacity O 0 9.322587288806972e-07
to O 0 4.503452828430454e-07
mount O 0 1.602629890840035e-05
a O 0 1.3813059013045859e-05
neutrophilic O 0 0.14223285019397736
leukocytosis O 0 0.006197426468133926
during O 0 0.0003463401226326823
pyogenic B-Disease 1 0.7528806924819946
infection I-Disease 0 0.008592462167143822
. O 0 1.936418266268447e-05
. O 0 2.928097455878742e-05

Susceptibility O 0 0.2304476797580719
to O 0 0.02780107408761978
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
in O 0 0.000646988395601511
twins O 0 0.0006313141202554107
: O 0 2.4624282559670974e-06
the O 0 4.2564138880152314e-07
role O 0 5.352217726795061e-07
of O 0 1.2495222279085283e-07
genes O 0 9.976147339330055e-07
, O 0 7.061692031129496e-07
HLA O 0 0.005931959953159094
, O 0 5.614314204649418e-07
and O 0 4.839301936954143e-07
the O 0 1.5055464928082074e-06
environment O 0 2.4686150936759077e-05
. O 0 9.302781108999625e-06

OBJECTIVE O 0 0.00011007151624653488
To O 0 5.085259545012377e-06
determine O 0 2.7773248802986927e-06
the O 0 5.42345219400886e-07
relative O 0 1.8112079942511627e-06
effects O 0 2.3066136236593593e-06
of O 0 2.545837389789085e-07
genetic O 0 3.7056092878628988e-06
and O 0 9.820515742831049e-07
environmental O 0 3.2906689284573076e-06
factors O 0 1.3807047025693464e-06
in O 0 1.0941105756501202e-05
susceptibility O 0 0.0046934690326452255
to O 0 0.14004062116146088
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
( O 0 0.0007877143798395991
AS B-Disease 0 0.009085887111723423
) O 0 1.37030438054353e-05
. O 0 1.4279959941632114e-05

METHODS O 0 0.0007158900843933225
Twins O 0 0.0005504526197910309
with O 0 5.835948741150787e-06
AS B-Disease 0 0.00018398022803012282
were O 0 1.5918431017780676e-06
identified O 0 9.361199317936553e-07
from O 0 2.3336488652603293e-07
the O 0 3.735050313480315e-07
Royal O 0 0.00012647168477997184
National O 0 9.582449820300099e-06
Hospital O 0 0.4610077142715454
for O 0 0.0007650629268027842
Rheumatic B-Disease 1 0.9999998807907104
Diseases I-Disease 1 0.9963054656982422
database O 0 0.0001558803633088246
. O 0 6.930294330231845e-05

Clinical O 0 0.007079500705003738
and O 0 3.3981854357989505e-05
radiographic O 0 0.04353195056319237
examinations O 0 0.0007038979674689472
were O 0 9.195452548738103e-06
performed O 0 5.625077847071225e-06
to O 0 5.681956736225402e-07
establish O 0 6.835517524450552e-06
diagnoses O 0 0.32470929622650146
, O 0 1.0857950655918103e-05
and O 0 0.0024263726081699133
disease O 1 0.9529646039009094
severity O 1 0.5382519364356995
was O 0 0.0002055049844784662
assessed O 0 1.3578175639850087e-05
using O 0 9.256391990675183e-07
a O 0 8.667790893923666e-07
combination O 0 2.858812422346091e-06
of O 0 4.681617440382979e-07
validated O 0 1.704219357634429e-05
scoring O 0 5.800149210699601e-06
systems O 0 2.856535320461262e-05
. O 0 1.9176406567567028e-05

HLA O 0 0.31996938586235046
typing O 0 0.0014866952551528811
for O 0 6.134412251412868e-05
HLA O 0 0.05873425304889679
- O 0 0.00021640575141645968
B27 O 0 0.0001631380000617355
, O 0 7.1224671955860686e-06
HLA O 0 0.001328804763033986
- O 0 5.402689930633642e-05
B60 O 0 3.4627617424121127e-05
, O 0 1.0037213087343844e-06
and O 0 1.984924438147573e-06
HLA O 0 0.42225173115730286
- O 0 0.0038416788447648287
DR1 O 1 0.853444516658783
was O 0 1.1136966350022703e-05
performed O 0 2.3456939288735157e-06
by O 0 6.136019692348782e-07
polymerase O 0 7.128535798983648e-06
chain O 0 2.834066435752902e-06
reaction O 0 9.084528187486285e-07
with O 0 1.294241940286156e-07
sequence O 0 2.600807533781335e-07
- O 0 1.1060429869758082e-06
specific O 0 3.4611269938977784e-07
primers O 0 5.841795427841134e-06
, O 0 3.7807001262990525e-07
and O 0 7.068888407957274e-07
zygosity O 0 0.00011056813673349097
was O 0 1.3539448445953894e-05
assessed O 0 1.1815387551905587e-05
using O 0 8.949249604484066e-06
microsatellite O 0 0.00020705444330815226
markers O 0 6.91991881467402e-05
. O 0 2.639315789565444e-05

Genetic O 0 0.0008939182152971625
and O 0 2.077831231872551e-05
environmental O 0 1.652530590945389e-05
variance O 0 3.837645181192784e-06
components O 0 3.951776307076216e-06
were O 0 1.9331298517499818e-06
assessed O 0 2.603515213195351e-06
with O 0 2.0098690356462612e-07
the O 0 4.053767383993545e-07
program O 0 2.0957259039278142e-06
Mx O 0 9.832663636188954e-06
, O 0 1.1295848167947042e-07
using O 0 1.4700326289585064e-07
data O 0 1.982675570388892e-07
from O 0 5.511918033107577e-08
this O 0 3.4652611446972514e-08
and O 0 7.424484493867567e-08
previous O 0 4.935247943649301e-07
studies O 0 3.3035689739335794e-07
of O 0 1.310047537117498e-07
twins O 0 1.3326707630767487e-05
with O 0 1.3194630810176022e-06
AS B-Disease 0 0.007308532018214464
. O 0 2.577833402028773e-05

RESULTS O 0 0.00037688229349441826
Six O 0 8.74506076797843e-06
of O 0 1.8474577245797263e-06
8 O 0 1.1997215551673435e-05
monozygotic O 0 0.000601224775891751
( O 0 2.0572193534462713e-05
MZ O 1 0.9846212863922119
) O 0 3.612878799685859e-06
twin O 0 3.651396764325909e-05
pairs O 0 6.350416697387118e-06
were O 0 3.3253305446123704e-05
disease O 0 0.00020246389613021165
concordant O 0 3.5707322240341455e-05
, O 0 1.1552041314644157e-06
compared O 0 1.5977656175891752e-06
with O 0 1.032810672541018e-07
4 O 0 4.4685688749268593e-07
of O 0 2.074585125910744e-07
15 O 0 1.449658043384261e-06
B27 O 0 5.815905751660466e-05
- O 0 6.107830267865211e-05
positive O 0 4.796228495251853e-06
dizygotic O 0 9.25490094232373e-05
( O 0 5.406187028711429e-06
DZ O 0 0.0019474438158795238
) O 0 2.141596269211732e-06
twin O 0 1.1637257557595149e-05
pairs O 0 2.4785531422821805e-06
( O 0 7.019686449893925e-07
27 O 0 7.734781775070587e-07
% O 0 2.7054178985963517e-07
) O 0 1.0884276235856305e-07
and O 0 9.739569861721975e-08
4 O 0 2.2514490183311864e-07
of O 0 1.4935055503428885e-07
32 O 0 4.4316143430478405e-06
DZ O 0 0.13386142253875732
twin O 0 0.00017320904589723796
pairs O 0 6.5539366005396005e-06
overall O 0 1.0462107638886664e-05
( O 0 1.192094714497216e-06
12 O 0 8.443834644822346e-07
. O 0 2.5157362415484386e-07
5 O 0 1.0069704785564682e-06
% O 0 1.9475410226732492e-06
) O 0 2.165396608688752e-06
. O 0 5.482473170559388e-06

Nonsignificant O 0 0.004627138841897249
increases O 0 0.00010438379104016349
in O 0 5.1669026106537785e-06
similarity O 0 2.9548223210440483e-06
with O 0 2.6136325459447107e-07
regard O 0 1.3403081311480491e-06
to O 0 5.861980980625958e-07
age O 0 1.0695795026549604e-05
at O 0 0.00011790761345764622
disease O 0 0.10702670365571976
onset O 0 0.007694306783378124
and O 0 4.136031463986001e-07
all O 0 6.917068162692885e-08
of O 0 8.731711176324097e-08
the O 0 3.255614501540549e-05
disease O 0 0.144076406955719
severity O 0 0.006904112175107002
scores O 0 2.337751539016608e-05
assessed O 0 1.5784518836881034e-05
were O 0 3.870400632877136e-06
noted O 0 1.0745104191300925e-05
in O 0 4.900869316770695e-05
disease O 0 0.016744161024689674
- O 0 0.046861592680215836
concordant O 0 0.04149895906448364
MZ O 1 0.999950647354126
twins O 0 0.0020645984914153814
compared O 0 7.31305917724967e-05
with O 0 1.1751199963327963e-05
concordant O 0 0.003024701727554202
DZ O 1 0.9940280914306641
twins O 0 0.0031855725683271885
. O 0 0.00011097481183242053

HLA O 1 0.9936217665672302
- O 0 0.005103441420942545
B27 O 0 0.0006746972794644535
and O 0 7.010192348388955e-06
B60 O 0 4.172764965915121e-05
were O 0 2.2112258193374146e-06
associated O 0 2.004286898227292e-06
with O 0 5.506033176061464e-07
the O 0 7.910176464065444e-06
disease O 0 0.00011627714411588386
in O 0 2.366617991356179e-06
probands O 0 0.0003070060920435935
, O 0 3.079432246977376e-07
and O 0 1.1981133241079078e-07
the O 0 1.4954696325730765e-07
rate O 0 6.326397397060646e-07
of O 0 4.389165439988574e-07
disease O 0 2.9096423531882465e-05
concordance O 0 3.500572347547859e-05
was O 0 3.8071288145147264e-05
significantly O 0 1.7962762285606004e-05
increased O 0 2.513501385692507e-06
among O 0 8.666402209200896e-07
DZ O 0 0.005371291656047106
twin O 0 2.028834387601819e-05
pairs O 0 1.3492854122887366e-06
in O 0 3.812995146290632e-07
which O 0 1.4410456117275317e-07
the O 0 2.597211050670012e-07
co O 0 1.0311782716598827e-05
- O 0 3.3882319257827476e-05
twin O 0 2.986214531119913e-05
was O 0 1.9082265225733863e-06
positive O 0 5.581955520028714e-07
for O 0 2.4224905814662634e-07
both O 0 8.50893286497012e-07
B27 O 0 5.866277206223458e-05
and O 0 1.1016123607987538e-05
DR1 O 1 0.6808615922927856
. O 0 4.9810867494670674e-05

Additive O 0 0.0013678845716640353
genetic O 0 0.00027658187900669873
effects O 0 4.9443762691225857e-05
were O 0 2.927622972492827e-06
estimated O 0 6.960098630770517e-07
to O 0 2.0602315942142013e-07
contribute O 0 6.990932206463185e-07
97 O 0 2.496144816177548e-06
% O 0 3.5200335446461395e-07
of O 0 8.566288300926317e-08
the O 0 7.968239401634492e-07
population O 0 2.6540317321632756e-06
variance O 0 9.701091585156973e-06
. O 0 1.5263824025169015e-05

CONCLUSION O 0 0.0006636226316913962
Susceptibility O 0 0.0004570141318254173
to O 0 8.238302143581677e-06
AS B-Disease 0 7.217267557280138e-05
is O 0 5.334199499884562e-07
largely O 0 1.3735864285990829e-06
genetically O 0 6.115576525189681e-06
determined O 0 1.6531865867364104e-06
, O 0 2.1735222333063575e-07
and O 0 1.960410429546755e-07
the O 0 2.3498488133100182e-07
environmental O 0 1.0252048241454759e-06
trigger O 0 2.429487494737259e-06
for O 0 3.0092908787082706e-07
the O 0 2.0773301002918743e-05
disease O 0 0.003372790524736047
is O 0 1.2319892448431347e-06
probably O 0 1.5086946405062918e-05
ubiquitous O 0 8.194299880415201e-05
. O 0 2.3984226572792977e-05

HLA O 1 0.9745129942893982
- O 0 0.001255341456271708
B27 O 0 0.00024497119011357427
accounts O 0 3.916000423487276e-06
for O 0 4.6686164978382294e-07
a O 0 5.445893975775107e-07
minority O 0 1.1092192835349124e-06
of O 0 1.4930427028048143e-07
the O 0 8.921452945287456e-07
overall O 0 5.9017784224124625e-05
genetic O 0 4.381694088806398e-05
susceptibility O 0 4.7794776037335396e-05
to O 0 7.441379239025991e-06
AS B-Disease 0 0.0031236012000590563
. O 0 2.198936272179708e-05

Cell O 0 0.0027710197027772665
cycle O 0 0.0005085135926492512
- O 0 0.00021566892974078655
dependent O 0 5.646389035973698e-05
colocalization O 0 7.596391515107825e-05
of O 0 1.4855068002361804e-06
BARD1 O 0 0.0005431972676888108
and O 0 6.896720606164308e-06
BRCA1 O 0 0.00013791254605166614
proteins O 0 2.2229628484637942e-06
in O 0 1.378427327836107e-06
discrete O 0 1.597822665644344e-05
nuclear O 0 7.417194865411147e-05
domains O 0 5.081888230051845e-05
. O 0 2.4911956643336453e-05

Germ O 0 0.3391152620315552
- O 0 0.0010322241578251123
line O 0 5.357413465389982e-05
mutations O 0 1.3781584129901603e-05
of O 0 4.197191287858004e-07
the O 0 2.0053823845955776e-06
BRCA1 O 0 0.0005484831053763628
gene O 0 1.7595457393326797e-05
predispose O 0 1.7071539332391694e-05
women O 0 2.8255221877770964e-06
to O 0 8.70668770858174e-07
early O 0 6.965841021155939e-05
- O 1 0.9389854669570923
onset O 1 0.9968984127044678
breast B-Disease 1 0.9988013505935669
and I-Disease 1 0.8875890970230103
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999942779541016
by O 0 5.214672000874998e-06
compromising O 0 5.3148971346672624e-05
the O 0 2.5075898975046584e-06
genes O 0 6.3544634940626565e-06
presumptive O 0 9.902544843498617e-05
function O 0 2.5652468593762023e-06
as O 0 2.9276677651068894e-06
a O 0 2.183501965191681e-05
tumor B-Disease 0 0.0029005336109548807
suppressor O 0 0.0006783646531403065
. O 0 7.194391218945384e-05

Although O 0 7.037242176011205e-05
the O 0 9.110156497627031e-06
biochemical O 0 4.823222116101533e-05
properties O 0 4.1764474190131295e-06
of O 0 7.295053023881337e-07
BRCA1 O 0 0.0002749609702732414
polypeptides O 0 1.1620434634096455e-05
are O 0 3.766072040889412e-07
not O 0 4.4855448777525453e-07
understood O 0 1.497591824772826e-06
, O 0 1.463547505409224e-07
their O 0 2.3049965136578976e-07
expression O 0 7.076712904563465e-07
pattern O 0 1.8809977291311952e-06
and O 0 3.464429312316497e-07
subcellular O 0 1.3091651453578379e-05
localization O 0 1.116817020374583e-05
suggest O 0 1.449428509658901e-06
a O 0 3.869234888043138e-07
role O 0 9.248785772797419e-07
in O 0 1.2637752888622344e-06
cell O 0 4.9514452257426456e-05
- O 0 0.0002673818089533597
cycle O 0 4.000726039521396e-05
regulation O 0 3.284409467596561e-05
. O 0 2.3244421754498035e-05

When O 0 0.000153614382725209
resting O 0 0.0001832581911003217
cells O 0 3.3707379770930856e-05
are O 0 8.086261118478433e-07
induced O 0 1.0270318853145e-05
to O 0 7.876030281295243e-07
proliferate O 0 1.0439016477903351e-05
, O 0 2.1799286287205177e-07
the O 0 2.265049090510729e-07
steady O 0 1.785525569175661e-06
- O 0 1.8754502661977313e-06
state O 0 1.1622860540683178e-07
levels O 0 1.1776612751646098e-07
of O 0 5.8736208785603594e-08
BRCA1 O 0 8.285687727038749e-06
increase O 0 4.040593921672553e-07
in O 0 5.501739792634908e-07
late O 0 1.5972893379512243e-05
G1 O 0 0.000271143508143723
and O 0 3.41628805244909e-07
reach O 0 5.29753606315353e-07
a O 0 3.7479063053069694e-07
maximum O 0 1.3025099860897171e-06
during O 0 4.673147486755624e-06
S O 0 0.00015773710038047284
phase O 0 4.8439142119605094e-05
. O 0 1.7000444131554104e-05

Moreover O 0 0.00015998589515220374
, O 0 1.0370333257014863e-05
in O 0 4.611612894223072e-06
S O 0 0.00012822479766327888
phase O 0 2.4325698177563027e-05
cells O 0 1.2426123248587828e-05
, O 0 1.7314029037152068e-06
BRCA1 O 0 4.384289786685258e-05
polypeptides O 0 8.309894838021137e-06
are O 0 5.422510866992525e-07
hyperphosphorylated O 0 2.206576209573541e-05
and O 0 1.2953252053193864e-06
accumulate O 0 4.353025360614993e-06
into O 0 2.589376208561589e-06
discrete O 0 2.5345358153572306e-05
subnuclear O 0 0.0003420223365537822
foci O 0 0.0003459094441495836
termed O 0 0.00021105684572830796
" O 0 2.932719507953152e-05
BRCA1 O 0 0.00041950985905714333
nuclear O 0 0.00011356060713296756
dots O 0 0.0003056967107113451
. O 0 4.8693826101953164e-05

" O 0 0.0008356155594810843
BRCA1 O 0 0.014400862157344818
associates O 0 0.00035944252158515155
in O 0 6.25337042947649e-06
vivo O 0 6.54421019135043e-05
with O 0 1.0618355190672446e-06
a O 0 5.626923666568473e-06
structurally O 0 0.00026958397938869894
related O 0 1.0848190868273377e-05
protein O 0 2.4702756491024047e-05
termed O 0 0.00013776584819424897
BARD1 O 0 0.028841407969594002
. O 0 5.1405728299869224e-05

Here O 0 3.675257175927982e-05
we O 0 1.0799012670759112e-06
show O 0 1.0571453685770393e-06
that O 0 6.598059343332352e-08
the O 0 8.309447707688378e-08
steady O 0 1.6124481589940842e-06
- O 0 1.8746545720205177e-06
state O 0 1.0340958311871873e-07
levels O 0 1.0218065682465749e-07
of O 0 5.392097079948144e-08
BARD1 O 0 7.632953202119097e-05
, O 0 1.8132129753212212e-07
unlike O 0 3.77599036482934e-07
those O 0 1.1486212514455474e-07
of O 0 1.2625824297174404e-07
BRCA1 O 0 7.776936399750412e-05
, O 0 7.722347277194785e-07
remain O 0 9.392766742166714e-07
relatively O 0 1.1780414297390962e-06
constant O 0 2.9295752028701827e-06
during O 0 1.1496099432406481e-05
cell O 0 7.026940875221044e-05
cycle O 0 6.544865755131468e-05
progression O 0 9.891682566376403e-05
. O 0 1.9133549358230084e-05

However O 0 0.00010772250971058384
, O 0 1.8346392607782036e-05
immunostaining O 0 0.00030071724904701114
revealed O 0 3.607206599554047e-05
that O 0 1.5895190017545247e-06
BARD1 O 0 0.00017362524522468448
resides O 0 5.757845883636037e-06
within O 0 1.3109016663293005e-06
BRCA1 O 0 9.63409838732332e-05
nuclear O 0 1.2983333363081329e-05
dots O 0 1.1883346815011464e-05
during O 0 3.1500567274633795e-06
S O 0 2.194038825109601e-05
phase O 0 1.139755795520614e-06
of O 0 7.944809965465538e-08
the O 0 2.5817053028731607e-07
cell O 0 7.56214649300091e-06
cycle O 0 2.8652809760387754e-06
, O 0 2.8736005219798244e-07
but O 0 3.914564103979501e-07
not O 0 2.768291835764103e-07
during O 0 2.43745216721436e-06
the O 0 3.3199303288711235e-06
G1 O 0 0.0012248206185176969
phase O 0 6.266978016356006e-05
. O 0 3.158159233862534e-05

Nevertheless O 0 0.0009829632472246885
, O 0 3.1218252843245864e-05
BARD1 O 0 0.0006247995770536363
polypeptides O 0 3.9866728911874816e-05
are O 0 7.815953608769632e-07
found O 0 5.600672352557012e-07
exclusively O 0 3.427733474836714e-07
in O 0 2.1210296097251558e-07
the O 0 1.6268737113023235e-07
nuclear O 0 1.2814105048164492e-06
fractions O 0 7.667068757655215e-07
of O 0 1.0020143292877037e-07
both O 0 6.064844910724787e-07
G1 O 0 0.0003667552082333714
- O 0 1.4895519598212559e-05
and O 0 1.306687750002311e-06
S O 0 0.00014577234105672687
- O 0 4.893621371593326e-05
phase O 0 2.5893594283843413e-05
cells O 0 3.620039933593944e-05
. O 0 1.256088671652833e-05

Therefore O 0 0.00014948078023735434
, O 0 1.700299071671907e-05
progression O 0 3.3572898246347904e-05
to O 0 2.4244902760983678e-06
S O 0 8.461563265882432e-05
phase O 0 5.901733857172076e-06
is O 0 1.8216364594536572e-07
accompanied O 0 4.5387866975943325e-07
by O 0 1.979794319595385e-07
the O 0 2.3611077892837784e-07
aggregation O 0 1.2918708307552151e-06
of O 0 3.1632976060791407e-07
nuclear O 0 3.0621609766967595e-05
BARD1 O 0 0.0006917305872775614
polypeptides O 0 5.39558932359796e-05
into O 0 9.251642040908337e-06
BRCA1 O 0 0.00035972133628092706
nuclear O 0 0.00016185693675652146
dots O 0 0.0002580334839876741
. O 0 4.0418777643935755e-05

This O 0 7.566641579614952e-05
cell O 0 0.00026040556258521974
cycle O 0 9.696383494883776e-05
- O 0 7.57241650717333e-05
dependent O 0 1.7967369785765186e-05
colocalization O 0 3.661166920210235e-05
of O 0 8.190627340809442e-07
BARD1 O 0 0.0004222904099151492
and O 0 3.609524355852045e-06
BRCA1 O 0 0.00012157515448052436
indicates O 0 4.533255378191825e-06
a O 0 1.1632457699306542e-06
role O 0 2.6048537620226853e-06
for O 0 1.3991092373544234e-06
BARD1 O 0 0.0016343629686161876
in O 0 3.6532292142510414e-05
BRCA1 O 0 0.027890987694263458
- O 0 0.019432974979281425
mediated O 0 0.00928782019764185
tumor B-Disease 0 0.0029060123488307
suppression O 0 0.00021010253112763166
. O 0 5.033694833400659e-05

Ethnic O 0 0.00011250433453824371
differences O 0 0.00011742391507141292
in O 0 2.5849083613138646e-05
the O 0 1.8925184122053906e-05
HFE O 0 0.00479079270735383
codon O 0 0.000559582666028291
282 O 0 0.0005922674899920821
( O 0 0.00011863922554766759
Cys O 1 0.8470509648323059
/ O 0 0.05080849677324295
Tyr O 0 0.006719255819916725
) O 0 3.385485979379155e-05
polymorphism O 0 0.00023438417701981962
. O 0 4.796330176759511e-05

Recent O 0 0.00010499624477233738
studies O 0 1.9498251276672818e-05
have O 0 3.1212712201522663e-06
shown O 0 9.830957424128428e-06
that O 0 4.5447337470250204e-05
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
( O 0 0.06640980392694473
HH B-Disease 1 0.9999517202377319
) O 0 1.8650393940333743e-06
is O 0 1.4684688665056456e-07
likely O 0 4.5259321268531494e-07
to O 0 1.4658034785952623e-07
be O 0 2.843678146291495e-07
caused O 0 9.031488730215642e-07
by O 0 3.8471029029096826e-07
homozygosity O 0 1.3105593097861856e-05
for O 0 2.3596962250849174e-07
a O 0 2.183175183745334e-06
Cys282Tyr O 0 0.0001921093207783997
mutation O 0 4.212544354231795e-06
in O 0 1.1049834256482427e-06
the O 0 2.7535993467608932e-06
HFE O 0 0.0007096162880770862
gene O 0 2.0476947611314245e-05
located O 0 8.00933594291564e-06
4 O 0 1.6011326806619763e-05
. O 0 1.8702954548643902e-05

5 O 0 0.0010337396524846554
Mb O 0 0.018897294998168945
telomeric O 0 0.0050008343532681465
to O 0 8.901723776943982e-05
HLA O 1 0.8223044276237488
- O 0 0.00031554847373627126
A O 0 3.238366844016127e-05
. O 0 2.7660229534376413e-05

Population O 0 3.1506508094025776e-05
studies O 0 8.138884368236177e-06
of O 0 5.213615281718376e-07
this O 0 6.925615707586985e-07
polymorphism O 0 8.214288754970767e-06
are O 0 1.7338554414436658e-07
facilitated O 0 2.2424646886065602e-06
by O 0 3.223142073238705e-07
the O 0 2.3393711501284997e-07
fact O 0 4.044862293994811e-07
that O 0 1.5156885524447716e-07
the O 0 6.988612994973664e-07
Cys282Tyr O 0 0.0001178891834570095
mutation O 0 9.428662451682612e-06
creates O 0 4.304683443479007e-06
a O 0 4.843734132009558e-06
Rsal O 0 0.00015887552581261843
restriction O 0 6.057037171558477e-05
site O 0 2.4460294298478402e-05
. O 0 1.9984954633400775e-05

We O 0 2.9414024538709782e-05
have O 0 3.5221996768086683e-06
studied O 0 4.467160124477232e-06
the O 0 2.6138020530197537e-06
codon O 0 4.107992572244257e-05
282 O 0 6.83746620779857e-05
( O 0 1.55030229507247e-05
Cys O 0 0.29954561591148376
/ O 0 0.00489142257720232
Tyr O 0 0.0008547669858671725
) O 0 2.310684521944495e-06
polymorphism O 0 6.944272627151804e-06
in O 0 4.763903120874602e-07
different O 0 3.9862254652689444e-07
ethnic O 0 1.3028713965468341e-06
groups O 0 3.935337645089021e-06
. O 0 1.3713410226046108e-05

In O 0 7.094710599631071e-05
agreement O 0 2.0689176380983554e-05
with O 0 2.595468004074064e-06
previous O 0 8.965898814494722e-06
observations O 0 9.69173288467573e-06
the O 0 2.5488916435278952e-06
Tyr O 0 0.0006746011786162853
allele O 0 3.0113402317510918e-05
appeared O 0 7.608979558426654e-06
to O 0 3.669426291708078e-07
be O 0 2.1418073004042526e-07
rare O 0 7.099201866367366e-07
or O 0 6.93715037414222e-07
absent O 0 1.0722859769884963e-05
in O 0 3.411116040297202e-06
Asiatic O 0 0.0008279129979200661
( O 0 1.574618636368541e-06
Indian O 0 1.1519542795213056e-06
, O 0 3.0648095616925275e-07
Chinese O 0 4.4319594394437445e-07
) O 0 1.0867800028790953e-06
populations O 0 3.2359778288082452e-06
. O 0 4.000795343017671e-06

The O 0 2.1084753825562075e-05
highest O 0 1.4214470866136253e-05
allele O 0 3.646577170002274e-05
frequency O 0 6.5673252720444e-06
( O 0 1.190126340588904e-06
7 O 0 9.450658353671315e-07
. O 0 1.6591189933023998e-07
5 O 0 2.118874249390501e-07
% O 0 2.2960431067531317e-07
) O 0 2.5465658382017864e-07
was O 0 1.5430998701049248e-06
found O 0 8.407763516515843e-07
in O 0 3.1851523090153933e-06
Swedes O 0 0.005420034751296043
. O 0 2.5958961487049237e-05

Saamis O 0 0.004540585912764072
( O 0 3.6051846109330654e-05
2 O 0 6.0682277762680314e-06
% O 0 2.0459358438529307e-06
) O 0 3.3640134233792196e-07
and O 0 2.2575721914108726e-07
Mordvinians O 0 1.8761871615424752e-05
( O 0 3.219344932858803e-07
1 O 0 1.671250089430032e-07
. O 0 1.2005817495719384e-07
8 O 0 3.9103329640965967e-07
% O 0 4.154441626269545e-07
) O 0 3.119022835562646e-07
had O 0 9.59669364419824e-07
significantly O 0 3.685629508254351e-06
lower O 0 1.1700236655087792e-06
frequencies O 0 1.4062632089917315e-06
of O 0 2.6148066467612807e-07
the O 0 3.95962706534192e-06
Tyr O 0 0.0012873600935563445
allele O 0 0.00014267898222897202
. O 0 1.9065282685915008e-05

Comparisons O 0 0.00014831090811640024
with O 0 1.3803524780087173e-05
allele O 0 7.810015813447535e-05
frequencies O 0 9.814676559471991e-06
based O 0 4.6800605559838004e-06
on O 0 4.307599283492891e-06
prevalence O 0 6.971615948714316e-05
estimates O 0 4.413335318531608e-06
of O 0 5.935968943049375e-07
HH B-Disease 1 0.9995274543762207
showed O 0 2.1658344849129207e-05
some O 0 5.165125571693352e-07
disagreements O 0 3.594526560846134e-06
with O 0 3.1469980399378983e-07
the O 0 1.1163421049786848e-06
RFLP O 0 0.0005210915696807206
data O 0 1.5829627955099568e-06
, O 0 3.2015168471843936e-07
particularly O 0 1.618049168428115e-06
in O 0 2.8259182727197185e-06
Finns O 0 0.000298495520837605
. O 0 2.94296805805061e-05

The O 0 5.747094837715849e-05
newly O 0 0.00011851642921101302
described O 0 0.00010249436309095472
HFE O 0 0.0010606605792418122
marker O 0 1.4526317499985453e-05
provides O 0 1.8156404166802531e-06
a O 0 9.820628292800393e-07
new O 0 1.0064214848171105e-06
approach O 0 1.6018361748137977e-06
to O 0 1.918831316061187e-07
the O 0 2.769464231278107e-07
screening O 0 1.743593429637258e-06
of O 0 2.38160581034208e-07
HH B-Disease 0 0.4172404110431671
as O 0 4.5388429725790047e-07
well O 0 2.515932919777697e-07
as O 0 8.407525342590816e-08
studies O 0 1.2113579828110232e-07
of O 0 3.432292317029351e-08
the O 0 2.150653699573013e-07
relationship O 0 1.1963314818785875e-06
between O 0 7.972937510203337e-07
the O 0 3.195798853994347e-06
HFE O 0 0.004050890915095806
Tyr O 0 0.0011858122888952494
allele O 0 6.488341750809923e-05
and O 0 4.143609658058267e-06
different O 0 1.3738099369220436e-05
disorders O 1 0.7224041819572449
including O 0 0.00016593970940448344
cancer B-Disease 1 0.9610371589660645

Autosomal B-Disease 1 0.9995682835578918
dominant I-Disease 1 0.9935914874076843
neurohypophyseal I-Disease 1 0.9999884366989136
diabetes I-Disease 1 0.9999996423721313
insipidus I-Disease 1 0.9998117089271545
associated O 0 0.00017156974354293197
with O 0 1.000623706204351e-05
a O 0 1.8633967556525022e-05
missense O 0 0.0002345610409975052
mutation O 0 2.7728579880204052e-05
encoding O 0 2.507071076252032e-05
Gly23 O 0 0.0006053809192962945
- O 0 0.0086273904889822
- O 0 0.014624063856899738
> O 0 0.00031266766018234193
Val O 0 0.0006722274702042341
in O 0 1.0642794222803786e-05
neurophysin O 0 0.0013237999519333243
II O 0 0.0046556913293898106
. O 0 4.5048287574900314e-05

Autosomal B-Disease 1 0.9993902444839478
dominant I-Disease 1 0.9889693260192871
neurohypophyseal I-Disease 1 0.9999935626983643
diabetes I-Disease 1 0.9999998807907104
insipidus I-Disease 1 0.999966025352478
( O 0 0.000294188444968313
ADNDI B-Disease 0 0.07667292654514313
) O 0 4.989480203221319e-06
is O 0 1.5121541991902632e-06
an O 0 2.9234017347334884e-05
inherited B-Disease 1 1.0
disease I-Disease 1 0.9999994039535522
caused O 0 0.0005874824710190296
by O 0 1.2183842045487836e-05
progressive O 0 0.021002059802412987
degeneration O 0 0.0030689965933561325
of O 0 1.8608807295095176e-07
the O 0 9.038994335242023e-07
magnocellular O 0 0.00011081682168878615
neurons O 0 3.1502399906457867e-06
of O 0 8.142203711258844e-08
the O 0 3.067271450163389e-07
hypothalamus O 0 4.321103006077465e-06
leading O 0 9.437158610126062e-07
to O 0 4.233540948916925e-07
decreased O 0 3.0983817396190716e-06
ability O 0 7.258681762323249e-07
to O 0 1.72902559825161e-07
produce O 0 6.262611123020179e-07
the O 0 1.2331788639130536e-06
hormone O 0 2.3126702217268758e-05
arginine O 0 3.585298691177741e-05
vasopressin O 0 0.00010274996020598337
( O 0 1.0588298209768254e-05
AVP O 0 0.0005548843764699996
) O 0 8.736733434488997e-06
. O 0 1.0467007996339817e-05

Affected O 0 0.0005292108398862183
individuals O 0 1.179813716589706e-05
are O 0 9.25810468288546e-07
not O 0 1.3816938917443622e-06
symptomatic O 0 0.0001708201743895188
at O 0 2.8428910354705295e-06
birth O 0 1.9619397789938375e-05
, O 0 8.08431025234313e-07
but O 0 1.1588399502215907e-06
usually O 0 2.9315315259736963e-06
develop O 0 0.0007733377860859036
diabetes B-Disease 1 0.9966548681259155
insipidus I-Disease 0 0.04060908406972885
at O 0 4.653894393413793e-06
1 O 0 3.7837514810235007e-06
- O 0 0.00011128572805318981
6 O 0 8.828715181152802e-06
yr O 0 0.0001222681748913601
of O 0 7.237820227601333e-07
age O 0 1.5420628187712282e-05
. O 0 1.3456666238198522e-05

The O 0 4.7929650463629514e-05
genetic O 0 6.928390939719975e-05
locus O 0 2.4579714590799995e-05
of O 0 1.2117512824261212e-06
the O 0 1.4521941011480521e-05
disease O 0 0.000509384204633534
is O 0 7.281457783392398e-07
the O 0 2.4005146315175807e-06
AVP O 0 0.14787976443767548
- O 0 0.00033576099667698145
neurophysin O 0 0.0004730642831418663
II O 0 0.00033059302950277925
( O 0 2.1555397324846126e-06
NPII O 0 4.9893536925083026e-05
) O 0 5.601692123491375e-07
gene O 0 1.291586272600398e-06
, O 0 1.078273754728798e-07
and O 0 2.023769383185936e-07
mutations O 0 1.1591870361371548e-06
that O 0 1.5458142854640755e-07
cause O 0 1.60054719344771e-06
ADNDI B-Disease 0 0.000615343393292278
have O 0 4.4158892364976055e-07
been O 0 3.560891173037817e-07
found O 0 1.8827138603683125e-07
in O 0 7.70519363868516e-08
both O 0 6.077710423824101e-08
the O 0 1.1113078102198415e-07
signal O 0 9.96957396637299e-07
peptide O 0 3.1232821129378863e-07
of O 0 5.7638285255734445e-08
the O 0 7.926145713099686e-07
prepro O 0 0.000331733375787735
- O 0 0.002212299033999443
AVP O 0 0.03493480756878853
- O 0 5.856891948496923e-05
NPII O 0 0.00010223880235571414
precursor O 0 1.4452034520218149e-05
and O 0 1.0297318340235506e-06
within O 0 1.6181571709239506e-06
NPII O 0 0.00016564724501222372
itself O 0 2.0897585272905417e-05
. O 0 1.4392259799933527e-05

An O 0 3.7923156924080104e-05
affected O 0 6.480950833065435e-05
girl O 0 7.82205315772444e-05
who O 0 1.3368792224355275e-06
presented O 0 9.572544286129414e-07
at O 0 5.621263312605151e-07
9 O 0 6.389456075339695e-07
months O 0 4.911995574730099e-07
of O 0 5.562422344951301e-08
age O 0 9.320347089669667e-07
and O 0 2.6167376176999824e-07
her O 0 2.599270146674826e-06
similarly O 0 1.1445308700785972e-05
affected O 0 2.8159267912997166e-06
younger O 0 6.599672815355007e-06
brother O 0 3.6865542369923787e-06
and O 0 5.316312581271632e-07
father O 0 2.5212800665030954e-06
were O 0 5.044450404056988e-07
all O 0 5.70586671244655e-08
found O 0 1.7587376532901544e-07
to O 0 1.1495890106516526e-07
have O 0 1.8668852419523319e-07
a O 0 4.650698883779114e-07
novel O 0 3.3572489428479457e-06
missense O 0 5.084820440970361e-05
mutation O 0 6.14451391811599e-06
( O 0 1.5884628510320908e-06
G1758 O 0 4.4657128455583006e-05
- O 0 0.000594580196775496
- O 0 0.002112236339598894
> O 0 5.934222281211987e-05
T O 0 7.22505574231036e-05
) O 0 5.625848302770464e-07
encoding O 0 2.1840371573489392e-06
the O 0 6.18395631590829e-07
amino O 0 2.388746679571341e-06
acid O 0 4.2531696635705885e-06
substitution O 0 1.0531040061323438e-05
Gly23 O 0 0.0004305256879888475
- O 0 0.001812892616726458
- O 0 0.0011609852081164718
> O 0 0.00013237580424174666
Val O 0 0.00040946187800727785
within O 0 1.7343218132737093e-05
NPII O 0 0.0014412063173949718
. O 0 4.105247717234306e-05

The O 0 5.689852696377784e-05
mutation O 0 0.00010375552665209398
was O 0 2.1717065465054475e-05
confirmed O 0 2.6634246751200408e-05
by O 0 7.65990171203157e-06
restriction O 0 5.038824019720778e-05
endonuclease O 0 0.0005623201141133904
analysis O 0 5.207090362091549e-05
. O 0 3.725488932104781e-05

A O 0 0.0008616256527602673
T1 O 1 0.6719934940338135
- O 0 0.0003648221318144351
weighted O 0 3.9403410482918844e-05
magnetic O 0 3.256800846429542e-05
resonance O 0 6.771954213036224e-05
imaging O 0 8.781194628681988e-05
of O 0 9.477329285800806e-07
the O 0 3.7584650272037834e-06
fathers O 0 0.00028784252936020494
pituitary O 0 0.001115223509259522
gland O 0 0.00030161827453412116
demonstrates O 0 3.7633570173056796e-05
an O 0 6.721243607898941e-06
attenuated O 0 0.0006016260012984276
posterior O 0 0.0008564936579205096
pituitary O 0 0.0015026022447273135
bright O 0 0.0002680326870176941
spot O 0 0.00010795768321258947
. O 0 4.677782271755859e-05

This O 0 4.759492367156781e-05
mutation O 0 9.740356472320855e-05
may O 0 6.129029316070955e-06
be O 0 1.819520036860922e-07
valuable O 0 3.62160591294014e-07
for O 0 1.0672085437590795e-07
developing O 0 9.685971917861025e-07
models O 0 4.949849426338915e-06
of O 0 5.889359613320266e-07
dominantly B-Disease 0 0.049846094101667404
inherited I-Disease 1 0.9983304142951965
neurodegeneration I-Disease 1 0.9999996423721313
, O 0 3.3698875085974578e-06
as O 0 2.5905345069077157e-07
the O 0 1.5285803556253086e-07
early O 0 1.945159510796657e-06
age O 0 5.882141067559132e-07
of O 0 1.3371135310080717e-07
onset O 0 0.006954657845199108
of O 0 2.4783048502285965e-06
symptoms O 1 0.7433280944824219
suggests O 0 4.747036655317061e-06
that O 0 3.1177884807220835e-07
this O 0 6.034883881511632e-07
mutation O 0 5.658252575813094e-06
may O 0 1.7844922695076093e-06
be O 0 4.088016680725559e-07
particularly O 0 2.017594397329958e-06
deleterious O 0 1.4494350580207538e-05
to O 0 8.610990107627003e-07
the O 0 2.6623415578796994e-06
magnocellular O 0 0.0003551197296474129
neuron O 0 0.0001303910103160888
. O 0 4.48789933216176e-06
. O 0 1.0382910659245681e-05

Frequent O 0 0.0011864218395203352
inactivation O 0 0.0036170114763081074
of O 0 2.676346048247069e-05
PTEN O 1 0.7570371627807617
/ O 0 0.05973780155181885
MMAC1 O 0 0.06646103411912918
in O 0 0.00024543431936763227
primary O 1 0.960568368434906
prostate B-Disease 1 1.0
cancer I-Disease 1 0.9999988079071045
. O 0 0.0003058384172618389

Sporadic B-Disease 1 0.9999518394470215
prostate I-Disease 1 1.0
carcinoma I-Disease 1 1.0
is O 0 1.869703373813536e-05
the O 0 2.872326149372384e-06
most O 0 2.0703628251794726e-06
common O 0 1.0503125849936623e-05
male B-Disease 0 0.00034056190634146333
cancer I-Disease 0 0.0005968826590105891
in O 0 5.888016971766774e-07
the O 0 2.830539358456008e-07
Western O 0 1.8653526012712973e-06
world O 0 1.5143175460252678e-06
, O 0 1.4785121038585203e-07
yet O 0 1.488286045514542e-07
many O 0 1.9222337499513742e-08
of O 0 1.5539846742740338e-08
the O 0 1.5997858326954884e-07
major O 0 6.074592988625227e-07
genetic O 0 2.0361915176181355e-06
events O 0 4.030153206713294e-07
involved O 0 3.8900429899513256e-07
in O 0 4.097040289252618e-07
the O 0 3.336949419008306e-07
progression O 0 2.591495785964071e-06
of O 0 1.5410981291097414e-07
this O 0 1.0145042779186042e-06
often O 0 3.356249362695962e-05
fatal O 1 0.9952300786972046
cancer B-Disease 0 0.49604275822639465
remain O 0 7.172382993303472e-06
to O 0 2.078957095363876e-06
be O 0 4.560799879982369e-06
elucidated O 0 0.00019465920922812074
. O 0 1.876453825389035e-05

Numerous O 0 0.00033181815524585545
cytogenetic O 0 0.0036200066097080708
and O 0 3.723556801560335e-05
allelotype O 0 0.0014132189098745584
studies O 0 1.5395809896290302e-05
have O 0 2.8380125058902195e-06
reported O 0 4.576816536427941e-06
frequent O 0 2.5705660391395213e-06
loss O 0 7.194668796728365e-06
of O 0 5.992741307636607e-07
heterozygosity O 0 0.00015668939158786088
on O 0 2.179220609832555e-05
chromosomal O 0 0.0006686908309347928
arm O 0 0.0035684178583323956
10q O 0 0.0008570999489165843
in O 0 9.98062314465642e-05
sporadic B-Disease 1 0.9992265701293945
prostate I-Disease 1 1.0
cancer I-Disease 1 0.999998927116394
. O 0 0.0002686367370188236

Deletion O 0 0.002059581223875284
mapping O 0 0.0001777178404154256
studies O 0 2.7362608307157643e-05
have O 0 7.264455234690104e-06
unambiguously O 0 4.699126657214947e-05
identified O 0 2.3874599719420075e-06
a O 0 7.396138244075701e-07
region O 0 1.1378324416000396e-06
of O 0 4.045355979087617e-07
chromosome O 0 1.2213682566653006e-05
10q23 O 0 1.9666173102450557e-05
to O 0 4.27925527901607e-07
be O 0 2.015441111780092e-07
the O 0 2.3499900692058873e-07
minimal O 0 1.6654616956657264e-06
area O 0 1.0049827778857434e-06
of O 0 5.375896421355719e-07
loss O 0 6.930029485374689e-05
. O 0 1.8424783775117248e-05

A O 0 0.000302214699331671
new O 0 0.00014456748613156378
tumor B-Disease 0 0.002613359596580267
suppressor O 0 0.00025605526752769947
gene O 0 5.61698034289293e-05
, O 0 7.554628609796055e-06
PTEN O 0 0.004142803605645895
/ O 0 0.002583986846730113
MMAC1 O 0 0.0026760203763842583
, O 0 1.1398874448786955e-06
was O 0 3.459685558482306e-06
isolated O 0 3.23535437019018e-06
recently O 0 1.6283262311844737e-06
at O 0 2.8929034101565776e-07
this O 0 5.973038952333809e-08
region O 0 2.1569987040948035e-07
of O 0 1.0229044278275978e-07
chromosome O 0 2.9796392482239753e-06
10q23 O 0 1.3604695595859084e-05
and O 0 5.111970153848233e-07
found O 0 4.900214207737008e-07
to O 0 1.0309684483900128e-07
be O 0 1.637487940797655e-07
inactivated O 0 3.7516936117754085e-06
by O 0 6.21346600837569e-07
mutation O 0 3.0452677037828835e-06
in O 0 3.2243824534816667e-06
three O 0 0.0014601736329495907
prostate B-Disease 1 1.0
cancer I-Disease 1 0.9999978542327881
cell O 0 0.002291962504386902
lines O 0 9.774718637345359e-05
. O 0 5.2515875722747296e-05

We O 0 0.00010826242942130193
screened O 0 0.001551736262626946
80 O 0 0.004252952989190817
prostate B-Disease 1 0.9999985694885254
tumors I-Disease 1 0.9999562501907349
by O 0 5.181444521440426e-06
microsatellite O 0 6.973691051825881e-05
analysis O 0 5.2162886277073994e-06
and O 0 1.324033746641362e-06
found O 0 4.644379714591196e-06
chromosome O 0 9.103138836508151e-06
10q23 O 0 1.0817682777997106e-05
to O 0 4.7374356881846325e-07
be O 0 4.371894988253189e-07
deleted O 0 4.3477029976202175e-06
in O 0 1.5813000118214404e-06
23 O 0 1.0495546121092048e-05
cases O 0 5.097972007206408e-06
. O 0 1.2600695299624931e-05

We O 0 2.260300789203029e-05
then O 0 4.020109827251872e-06
proceeded O 0 4.677619926951593e-06
with O 0 1.7591133882888244e-07
sequence O 0 2.709923876409448e-07
analysis O 0 2.179978508820568e-07
of O 0 7.521565237311734e-08
the O 0 7.888125423960446e-07
entire O 0 1.2645948118006345e-05
PTEN O 0 0.19852988421916962
/ O 0 0.00886998325586319
MMAC1 O 0 0.002275171224027872
coding O 0 4.165462087257765e-05
region O 0 2.93565540232521e-06
and O 0 1.0270132406731136e-06
tested O 0 6.029394171491731e-06
for O 0 4.227061651818076e-07
homozygous O 0 1.4772810573049355e-05
deletion O 0 8.544699085177854e-06
with O 0 5.96170309563604e-07
new O 0 3.152851832055603e-06
intragenic O 0 0.0001462497457396239
markers O 0 2.5014062430273043e-06
in O 0 4.3127357685079915e-07
these O 0 2.3956039285621955e-07
23 O 0 1.925879814734799e-06
cases O 0 5.698111635865644e-07
with O 0 6.425349852179352e-07
10q23 O 0 0.0003383037110324949
loss O 0 3.0115441404632293e-05
of O 0 4.001062279712642e-06
heterozygosity O 0 0.0006953557603992522
. O 0 5.5159343901323155e-05

The O 0 1.5689309293520637e-05
identification O 0 5.980511559755541e-06
of O 0 5.318056537362281e-07
the O 0 6.476071234828851e-07
second O 0 4.20051719629555e-06
mutational O 0 7.444511720677838e-05
event O 0 3.1357506031781668e-06
in O 0 7.790993663547852e-07
10 O 0 5.470744781632675e-07
( O 0 6.381107482411608e-07
43 O 0 3.2719688078941545e-06
% O 0 6.5901003836188465e-06
) O 0 2.1995085262460634e-05
tumors B-Disease 1 0.999763548374176
establishes O 0 0.0001735348632792011
PTEN O 0 0.21112331748008728
/ O 0 0.005234427284449339
MMAC1 O 0 0.000564743357244879
as O 0 9.088271895052458e-07
a O 0 7.58418593704846e-07
main O 0 2.7658768431138014e-06
inactivation O 0 1.6880378097994253e-05
target O 0 2.3387515284412075e-06
of O 0 5.994930916131125e-07
10q O 0 8.688172965776175e-05
loss O 0 3.435307371546514e-05
in O 0 6.350934563670307e-05
sporadic B-Disease 1 0.9998981952667236
prostate I-Disease 1 1.0
cancer I-Disease 1 0.999998927116394
. O 0 3.413841113797389e-05
. O 0 3.3148127840831876e-05

Risk O 0 0.002362913452088833
reversals O 0 0.0010565861593931913
in O 0 7.732036465313286e-05
predictive O 0 0.000519930908922106
testing O 0 0.0005926116718910635
for O 0 0.0004262171860318631
Huntington B-Disease 1 0.9999995231628418
disease I-Disease 1 0.9999794960021973
. O 0 0.00021164912323001772

The O 0 5.288929969538003e-05
first O 0 2.0970972400391474e-05
predictive O 0 0.00010692650539567694
testing O 0 6.859423592686653e-05
for O 0 0.00011273576819803566
Huntington B-Disease 1 1.0
disease I-Disease 1 0.9999920129776001
( O 0 5.696781499864301e-06
HD B-Disease 0 0.0004328286449890584
) O 0 6.226967457223509e-07
was O 0 4.929236183670582e-07
based O 0 4.6559267730117426e-07
on O 0 2.869172703867662e-07
analysis O 0 3.286744174602063e-07
of O 0 1.373673796933872e-07
linked O 0 9.77922809397569e-06
polymorphic O 0 2.8963235308765434e-05
DNA O 0 9.017357115226332e-06
markers O 0 2.0189954739180394e-06
to O 0 2.584974367891846e-07
estimate O 0 8.249036227425677e-07
the O 0 1.386396490943298e-07
likelihood O 0 6.742820346516964e-07
of O 0 1.5740374692541081e-07
inheriting O 0 7.80969548941357e-06
the O 0 2.0942895844200393e-06
mutation O 0 1.0767343155748677e-05
for O 0 3.496606950648129e-06
HD B-Disease 0 0.0011996312532573938
. O 0 2.9587776225525886e-05

Limits O 0 6.861634028609842e-05
to O 0 4.839666416955879e-06
accuracy O 0 6.423765626095701e-06
included O 0 9.039623023454624e-07
recombination O 0 3.5443174510874087e-06
between O 0 4.3510317482287064e-07
the O 0 4.206183064070501e-07
DNA O 0 2.35161610362411e-06
markers O 0 8.661709216539748e-07
and O 0 1.3479488814027718e-07
the O 0 2.163382930575608e-07
mutation O 0 1.8568490531833959e-06
, O 0 3.0853527732688235e-07
pedigree O 0 6.382960691553308e-06
structure O 0 4.1922709215214127e-07
, O 0 1.0058997190753871e-07
and O 0 1.3694189249235933e-07
whether O 0 3.274623452398373e-07
DNA O 0 1.7510437828605063e-06
samples O 0 5.913069571761298e-07
were O 0 4.2335003058724396e-07
available O 0 3.87349160746453e-07
from O 0 4.873654120274296e-07
family O 0 2.403749249424436e-06
members O 0 4.223920768708922e-06
. O 0 1.438535673514707e-05

With O 0 1.4239721167541575e-05
direct O 0 7.542836101492867e-06
tests O 0 6.142111942608608e-06
for O 0 3.271090065481985e-07
the O 0 5.356425276659138e-07
HD B-Disease 0 0.00037169994902797043
mutation O 0 3.536369376888615e-06
, O 0 2.2148761047446897e-07
we O 0 1.0176520959248592e-07
have O 0 1.8094749520969344e-07
assessed O 0 4.5627214717569586e-07
the O 0 8.187880240484446e-08
accuracy O 0 5.773675297859882e-07
of O 0 7.620205622060894e-08
results O 0 2.174661631215713e-06
obtained O 0 5.975586532258603e-07
by O 0 4.418753860591096e-07
linkage O 0 4.041602551296819e-06
approaches O 0 1.1842627145597362e-06
when O 0 3.6047387652615726e-07
requested O 0 6.582949936273508e-07
to O 0 1.2531786808267498e-07
do O 0 1.2886921751942282e-07
so O 0 1.2379317126942624e-07
by O 0 1.3556375222378847e-07
the O 0 5.395192488322209e-07
test O 0 8.562106813769788e-06
individuals O 0 2.1582404770015273e-06
. O 0 5.710248842660803e-06

For O 0 9.569418580213096e-06
six O 0 3.0183468879840802e-06
such O 0 4.418189405441808e-07
individuals O 0 2.6424973498251347e-07
, O 0 1.9254228789122863e-07
there O 0 1.3102375362450402e-07
was O 0 1.8066674556393991e-06
significant O 0 8.778908977546962e-07
disparity O 0 5.828622761328006e-06
between O 0 9.487909551353368e-07
the O 0 2.1904600089328596e-06
tests O 0 3.61672427970916e-05
. O 0 1.0772273526526988e-05

Three O 0 1.537335992907174e-05
went O 0 7.355449724855134e-06
from O 0 8.130980404530419e-07
a O 0 1.4491700994767598e-06
decreased O 0 2.7604259230429307e-05
risk O 0 9.322516234533396e-07
to O 0 1.460219749560565e-07
an O 0 1.8143823865557351e-07
increased O 0 7.201425091807323e-07
risk O 0 7.90396882166533e-07
, O 0 8.309796584171636e-08
while O 0 1.3942485566076357e-07
in O 0 1.5540015851911448e-07
another O 0 2.55572842888796e-07
three O 0 2.0702863423593953e-07
the O 0 6.285197855504521e-07
risk O 0 5.145252089278074e-06
was O 0 1.1409855687816162e-05
decreased O 0 5.709250763175078e-05
. O 0 9.41932466957951e-06

Knowledge O 0 2.7310628865961917e-05
of O 0 1.4892586932546692e-06
the O 0 1.0035261084340164e-06
potential O 0 7.944785238578334e-07
reasons O 0 5.20271782988857e-07
for O 0 8.484204983005839e-08
these O 0 8.945087159872855e-08
changes O 0 4.1991370380856097e-07
in O 0 5.711827384402568e-07
results O 0 3.750895757548278e-06
and O 0 1.506929834249604e-07
impact O 0 1.7231883475687937e-07
of O 0 3.9862172229732096e-08
these O 0 1.9202883549951366e-07
risk O 0 1.198983682115795e-06
reversals O 0 7.094502961990656e-06
on O 0 6.555503659910755e-07
both O 0 9.249861818716454e-07
patients O 0 8.23339451017091e-06
and O 0 1.5243776374518347e-07
the O 0 2.749340808350098e-07
counseling O 0 4.040546627948061e-06
team O 0 7.051981469885504e-07
can O 0 4.380191853670112e-08
assist O 0 1.461628329479936e-07
in O 0 1.06805778443686e-07
the O 0 6.52131433298564e-08
development O 0 2.0405194334216503e-07
of O 0 5.0535462037260004e-08
strategies O 0 7.726059720880585e-07
for O 0 1.2537046245597594e-07
the O 0 3.566389921161317e-07
prevention O 0 2.3658190002606716e-06
and O 0 1.9049703325890732e-07
, O 0 1.2424284534517938e-07
where O 0 1.5266776642874902e-07
necessary O 0 4.347249102920614e-07
, O 0 2.616754954942735e-07
management O 0 6.87034344082349e-07
of O 0 9.304541492838325e-08
a O 0 3.0265416626207298e-06
risk O 0 7.66205630498007e-06
reversal O 0 1.6459485777886584e-05
in O 0 9.650998435972724e-07
any O 0 1.0816854683071142e-06
predictive O 0 2.0716026483569294e-05
testing O 0 1.210729078593431e-05
program O 0 5.313815563567914e-06
. O 0 4.252439339325065e-06
. O 0 1.4699636267323513e-05

A O 0 0.00022567802807316184
novel O 0 8.822935342323035e-05
common O 0 3.689233199111186e-05
missense O 0 0.0004556332714855671
mutation O 0 6.196646427270025e-05
G301C O 0 0.00010460639896336943
in O 0 2.975357119794353e-06
the O 0 1.9011766880794312e-06
N O 0 4.3789081246359274e-05
- O 0 8.501784759573638e-05
acetylgalactosamine O 0 0.00022961394279263914
- O 0 0.00012672724551521242
6 O 0 2.641939681780059e-05
- O 0 0.0004022427892778069
sulfate O 0 0.0003481498861219734
sulfatase O 0 0.0009020963334478438
gene O 0 7.327712955884635e-05
in O 0 2.1619160179398023e-05
mucopolysaccharidosis B-Disease 0 0.0018157268641516566
IVA I-Disease 0 0.00612746924161911
. O 0 5.874651833437383e-05

Mucopolysaccharidosis B-Disease 0 0.39478299021720886
IVA I-Disease 1 0.9894620776176453
( O 0 0.001388618373312056
MPS B-Disease 1 0.9999204874038696
IVA I-Disease 1 0.9999668598175049
) O 0 2.3026945200399496e-05
is O 0 3.857989213429391e-06
an O 0 8.314222213812172e-06
autosomal B-Disease 1 0.9282588362693787
recessive I-Disease 1 0.998184859752655
lysosomal I-Disease 1 0.999860405921936
storage I-Disease 1 0.9999750852584839
disorder I-Disease 1 0.9999927282333374
caused O 0 0.00016014583525247872
by O 0 4.403434104460757e-06
a O 0 0.00010852092964341864
genetic B-Disease 1 0.9867780208587646
defect I-Disease 1 0.9846699237823486
in O 0 6.8824365371256135e-06
N O 0 9.896475239656866e-05
- O 0 0.00011500967957545072
acetylgalactosamine O 0 0.00035483931424096227
- O 0 0.00016363064059987664
6 O 0 2.693971327971667e-05
- O 0 0.000507980992551893
sulfate O 0 0.00048804853577166796
sulfatase O 0 0.0013850325485691428
( O 0 1.5665495084249415e-05
GALNS O 0 0.00029985010041855276
) O 0 7.737165105936583e-06
. O 0 1.0524121535127051e-05

In O 0 2.9772714697173797e-05
previous O 0 2.1155776266823523e-05
studies O 0 8.469719432468992e-06
, O 0 5.798506776955037e-07
we O 0 1.2578831842802174e-07
have O 0 9.118277688457965e-08
found O 0 1.3063871051599563e-07
two O 0 1.1981887837464456e-07
common O 0 1.5476020962523762e-06
mutations O 0 3.763116637856001e-06
in O 0 1.1017949645975023e-06
Caucasians O 0 1.941233131219633e-05
and O 0 1.0240381698167766e-06
Japanese O 0 4.524487849266734e-06
, O 0 1.0404442036815453e-06
respectively O 0 6.440830929932417e-06
. O 0 7.78296816861257e-06

To O 0 8.83836328284815e-05
characterize O 0 0.000234675346291624
the O 0 1.2557977242977358e-05
mutational O 0 0.00023473193868994713
spectrum O 0 2.549492819525767e-05
in O 0 1.7258837488043355e-06
various O 0 4.4996062342761434e-07
ethnic O 0 5.426546181297454e-07
groups O 0 3.8499473475894774e-07
, O 0 2.9191542694206873e-07
mutations O 0 1.3759843113803072e-06
in O 0 4.0239777376882557e-07
the O 0 8.279450298687152e-07
GALNS O 0 0.000166633864864707
gene O 0 3.4671336379688e-06
in O 0 1.2828006674681092e-06
Colombian O 0 1.7901711544254795e-05
MPS B-Disease 1 0.9999716281890869
IVA I-Disease 1 0.9999990463256836
patients O 0 0.019734108820557594
were O 0 3.6039211863680976e-06
investigated O 0 1.1756007552321535e-05
, O 0 5.034622176935954e-07
and O 0 6.423983336389938e-07
genetic O 0 4.4325274757284205e-06
backgrounds O 0 3.76796128875867e-06
were O 0 1.4802319583395729e-06
extensively O 0 8.537824214727152e-06
analyzed O 0 1.7862885215436108e-06
to O 0 2.0959710411716514e-07
identify O 0 6.521998443531629e-07
racial O 0 3.686146214931796e-07
origin O 0 3.766783152059361e-07
, O 0 1.320410660810012e-07
based O 0 6.249347848097386e-07
on O 0 1.1363587191226543e-06
mitochondrial O 0 3.351173654664308e-05
DNA O 0 3.183113585691899e-05
( O 0 3.4043141567963175e-06
mtDNA O 0 3.8938647776376456e-05
) O 0 4.7917847041389905e-06
lineages O 0 5.114608211442828e-05
. O 0 1.874988629424479e-05

Three O 0 9.421702998224646e-05
novel O 0 0.00016087958647403866
missense O 0 0.00060322938952595
mutations O 0 6.86719868099317e-05
never O 0 9.629334272176493e-06
identified O 0 3.608213091865764e-06
previously O 0 9.478612810198683e-07
in O 0 2.8403496799001005e-07
other O 0 1.0456091814603496e-07
populations O 0 2.0730898597776104e-07
and O 0 1.0367383396214791e-07
found O 0 2.884547711801133e-07
in O 0 1.4841755557881697e-07
16 O 0 1.945646062040396e-07
out O 0 7.01065516750532e-08
of O 0 6.833652577142857e-08
19 O 0 3.349298822286073e-06
Colombian O 0 1.4429296243179124e-05
MPS B-Disease 1 0.9990605711936951
IVA I-Disease 1 0.9995688796043396
unrelated O 0 0.00012458705168683082
alleles O 0 1.4530460248352028e-05
account O 0 3.1459826459467877e-06
for O 0 2.07380890060449e-06
84 O 0 4.291035293135792e-05
. O 0 2.5530989660182968e-05

2 O 0 5.0832353736041114e-05
% O 0 5.038699782744516e-06
of O 0 3.7936229091428686e-07
the O 0 8.22274728307093e-07
alleles O 0 7.451583769579884e-06
in O 0 1.4298260566647514e-06
this O 0 2.495878106856253e-06
study O 0 8.4631064964924e-06
. O 0 1.0009158359025605e-05

The O 0 9.580622281646356e-05
G301C O 0 0.0005123892915435135
and O 0 1.8953396647702903e-05
S162F O 0 0.00019411744142416865
mutations O 0 2.2156538761919364e-05
account O 0 3.272858066338813e-06
for O 0 1.8365137748332927e-06
68 O 0 5.392626553657465e-05
. O 0 2.304370718775317e-05

4 O 0 0.00021681201178580523
% O 0 4.025452653877437e-05
and O 0 9.063534889719449e-06
10 O 0 9.608656910131685e-06
. O 0 1.5535555576207116e-05

5 O 0 4.605434514814988e-05
% O 0 5.804952706967015e-06
of O 0 4.6629077132820385e-07
mutations O 0 4.038127372041345e-06
, O 0 2.726371803873917e-07
respectively O 0 8.296302098642627e-07
, O 0 1.7312497391230863e-07
whereas O 0 3.121766383173963e-07
the O 0 1.6868622765287e-07
remaining O 0 1.0118377531398437e-06
F69V O 0 0.0002538500411901623
is O 0 1.6818940196117182e-07
limited O 0 8.952509347182058e-07
to O 0 3.932719891963643e-07
a O 0 1.5468126548512373e-06
single O 0 1.0903879228862934e-05
allele O 0 0.00011007591820089146
. O 0 1.7503709386801347e-05

The O 0 7.711035868851468e-05
skewed O 0 0.0003834661329165101
prevalence O 0 0.00012426456669345498
of O 0 1.9142687506246148e-06
G301C O 0 5.952251376584172e-05
in O 0 1.426978997187689e-06
only O 0 6.673836310255865e-07
Colombian O 0 6.847587883385131e-06
patients O 0 4.918473132420331e-05
and O 0 2.459752749928157e-06
haplotype O 0 5.631945168715902e-05
analysis O 0 1.5891188240857446e-06
by O 0 7.2074988111126e-07
restriction O 0 3.816593107330846e-06
fragment O 0 7.5105785981577355e-06
length O 0 3.0790113214607118e-06
polymorphisms O 0 6.748128271283349e-06
in O 0 5.470139967655996e-07
the O 0 7.836119948478881e-07
GALNS O 0 0.0003906059137079865
gene O 0 3.7908087051619077e-06
suggest O 0 1.4263926004787209e-06
that O 0 2.602509425742028e-07
G301C O 0 1.1233855730097275e-05
originated O 0 1.9913632058887742e-06
from O 0 5.618127829620789e-07
a O 0 2.3946201963553904e-06
common O 0 8.94976983545348e-06
ancestor O 0 5.3335366828832775e-05
. O 0 2.5600667868275195e-05

Investigation O 0 0.00016256254457402974
of O 0 2.9334780720091658e-06
the O 0 2.548680186009733e-06
genetic O 0 5.775388672191184e-06
background O 0 2.508051466065808e-06
by O 0 3.158823744797701e-07
means O 0 3.6498886402114294e-07
of O 0 1.4734446551756264e-07
mtDNA O 0 9.887237865768839e-06
lineages O 0 4.210162387607852e-06
indicate O 0 9.710093991088797e-07
that O 0 9.15131295187166e-08
all O 0 5.830703031506346e-08
our O 0 4.910384632239584e-07
patients O 0 1.4522522178594954e-05
are O 0 1.1815546940852073e-07
probably O 0 8.608592452219455e-07
of O 0 2.102012217619631e-07
native O 0 4.761282525578281e-06
American O 0 1.1405634722905234e-05
descent O 0 0.000215379215660505

Low O 0 0.0003807120374403894
frequency O 0 0.00015795757644809783
of O 0 1.6241237972280942e-05
BRCA1 O 0 0.002217331435531378
germline O 0 0.0007687162724323571
mutations O 0 5.7046137953875586e-05
in O 0 6.650875548075419e-06
45 O 0 6.567184755112976e-05
German O 1 0.9999181032180786
breast B-Disease 1 0.9999998807907104
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999994039535522
families O 0 0.00041315596899949014
. O 0 0.00017222239694092423

In O 0 4.765795893035829e-05
this O 0 4.548403467197204e-06
study O 0 2.2684091618430102e-06
we O 0 9.817874797590775e-07
investigated O 0 1.2060308108630124e-05
45 O 0 1.1580033060454298e-05
German O 1 0.9997705817222595
breast B-Disease 1 0.9999998807907104
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999983310699463
families O 0 2.1585990907624364e-05
for O 0 9.273442628909834e-06
germline O 0 0.001988174393773079
mutations O 0 4.053202428622171e-05
in O 0 3.331281504870276e-06
the O 0 8.358608283742797e-06
BRCA1 O 0 0.0009280572412535548
gene O 0 9.109952952712774e-05
. O 0 3.094027124461718e-05

We O 0 4.5765602408209816e-05
identified O 0 3.328395541757345e-05
four O 0 5.513618816621602e-06
germline O 0 0.00028616408235393465
mutations O 0 1.5254960999300238e-05
in O 0 1.5656104324079934e-06
three O 0 1.3972323358757421e-05
breast B-Disease 1 0.9994256496429443
cancer I-Disease 0 0.03685478866100311
families O 0 2.2471790543932e-06
and O 0 8.06485900284315e-07
in O 0 2.132705731128226e-06
one O 0 4.926139081362635e-05
breast B-Disease 1 0.9999986886978149
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
family O 0 4.304642789065838e-05
. O 0 1.1518015980982454e-06
among O 0 2.8985840572204324e-07
these O 0 1.15553099533372e-07
were O 0 5.784157792732003e-07
one O 0 7.834819371055346e-07
frameshift O 0 9.669532300904393e-05
mutation O 0 4.670104772230843e-06
, O 0 3.072717333907349e-07
one O 0 4.351264237811847e-07
nonsense O 0 1.4695388927066233e-05
mutation O 0 3.1588349429512164e-06
, O 0 2.9087220809742576e-07
one O 0 4.5296928874449804e-07
novel O 0 3.063613576159696e-06
splice O 0 6.479252624558285e-05
site O 0 6.558875611517578e-06
mutation O 0 4.514350166573422e-06
, O 0 5.858661324964487e-07
and O 0 6.883703349558346e-07
one O 0 2.600507514216588e-06
missense O 0 0.00025556699256412685
mutation O 0 9.462940943194553e-05
. O 0 2.6719268134911545e-05

The O 0 0.0002065171574940905
missense O 0 0.001468509784899652
mutation O 0 0.00012099619925720617
was O 0 1.630561200727243e-05
also O 0 2.202214773205924e-06
found O 0 2.194524540755083e-06
in O 0 1.6112031744341948e-06
2 O 0 5.627427981380606e-06
. O 0 1.0455335541337263e-05

8 O 0 6.211384607013315e-05
% O 0 5.37027335667517e-06
of O 0 3.116786615464662e-07
the O 0 3.6157149452265003e-07
general O 0 6.797396849833603e-07
population O 0 3.0713988508068724e-07
, O 0 1.7297166721164103e-07
suggesting O 0 1.9073276007475215e-06
that O 0 1.3060919457075215e-07
it O 0 1.3928425346421136e-07
is O 0 2.2014323519670143e-07
not O 0 4.327750957600074e-06
disease O 0 0.00013366603525355458
associated O 0 1.1345503480697516e-05
. O 0 2.172622043872252e-05

The O 0 2.7383230190025643e-05
average O 0 4.024911322630942e-05
age O 0 1.7604505046620034e-05
of O 0 5.639644768962171e-06
disease O 1 0.5558360815048218
onset O 0 0.4057353734970093
in O 0 9.723014045448508e-06
those O 0 2.7323217182129156e-06
families O 0 1.1660307791316882e-05
harbouring O 0 0.004587118048220873
causative O 0 0.0003473673132248223
mutations O 0 4.366165376268327e-05
was O 0 6.892282726767007e-06
between O 0 2.606903990454157e-06
32 O 0 1.719580359349493e-05
. O 0 1.386619533150224e-05

3 O 0 0.00025189234293065965
and O 0 5.0708025810308754e-05
37 O 0 0.00015104164776857942
. O 0 7.909654232207686e-05

4 O 0 9.965843491954729e-05
years O 0 1.4617548004025593e-05
, O 0 1.1038628144888207e-06
whereas O 0 1.8226841120849713e-06
the O 0 4.6991658564365935e-07
family O 0 3.0540013540303335e-06
harbouring O 0 4.943735257256776e-05
the O 0 1.4453468111241818e-06
missense O 0 5.816188786411658e-05
mutation O 0 5.704169325326802e-06
had O 0 1.624047513359983e-06
an O 0 2.825972842401825e-07
average O 0 1.4459961903412477e-06
age O 0 1.4957362282075337e-06
of O 0 4.731024603188416e-07
onset O 0 0.000353976443875581
of O 0 2.4938367459981237e-06
51 O 0 7.01864410075359e-05
. O 0 2.6833766241907142e-05

2 O 0 0.0005668876110576093
years O 0 0.0002061799168586731
. O 0 0.00011856174387503415

These O 0 3.0215784136089496e-05
findings O 0 4.1136656363960356e-05
show O 0 6.946551366127096e-06
that O 0 1.3542706938096671e-06
BRCA1 O 0 8.752685971558094e-05
is O 0 4.564323035083362e-07
implicated O 0 4.09508220400312e-06
in O 0 3.9604054791197996e-07
a O 0 4.998883014195599e-07
small O 0 6.56361635265057e-07
fraction O 0 2.6171819627052173e-06
of O 0 5.623383003694471e-06
breast B-Disease 1 0.9999992847442627
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999995231628418
families O 0 1.4679645573778544e-05
suggesting O 0 1.3962691809865646e-05
the O 0 1.0462210866535315e-06
involvement O 0 4.053390966873849e-06
of O 0 4.773931436830026e-07
another O 0 3.5882076190318912e-06
susceptibility O 0 9.55685245571658e-05
gene O 0 3.113978891633451e-05
( O 0 8.155278919730335e-06
s O 0 0.00019921503553632647
) O 0 3.95868337363936e-05

Paternal O 0 0.3231971263885498
transmission O 1 0.5584772825241089
of O 0 0.009453554637730122
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 0.003333033062517643

We O 0 7.698060653638095e-05
report O 0 4.316765262046829e-05
a O 0 6.8690669650095515e-06
rare O 0 9.48430533753708e-06
case O 0 9.049266736838035e-06
of O 0 8.714848263480235e-06
paternally O 1 0.9979641437530518
transmitted O 1 0.9999960660934448
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9586949944496155
DM B-Disease 1 1.0
) O 0 0.00015077315038070083
. O 0 6.034350735717453e-05

The O 0 5.262075501377694e-05
proband O 0 0.0004063510859850794
is O 0 1.1675803079924663e-06
a O 0 1.2827689488403848e-06
23 O 0 3.0560759114450775e-06
year O 0 1.6620440419501392e-06
old O 0 0.00012139375030528754
, O 0 5.3855241276323795e-05
mentally B-Disease 1 0.9999997615814209
retarded I-Disease 1 0.9999982118606567
male O 0 0.001143559580668807
who O 0 0.0006173494621179998
suffers O 1 0.9998947381973267
severe O 1 0.9999470710754395
muscular B-Disease 1 0.9999837875366211
weakness I-Disease 1 0.9939119815826416
. O 0 0.00016495278396178037

He O 0 0.00010696903336793184
presented O 0 5.4280309996102005e-05
with O 0 2.2437387087848037e-05
respiratory O 1 0.9788903594017029
and O 0 9.620558557799086e-06
feeding O 0 5.84914450882934e-05
difficulties O 0 0.00014508218737319112
at O 0 1.7545577065902762e-05
birth O 0 0.00013927664258517325
. O 0 2.7186961233383045e-05

His O 0 0.0002924013533629477
two O 0 8.852076280163601e-05
sibs O 1 0.9825803637504578
suffer O 0 0.10095668584108353
from O 0 7.436494342982769e-05
childhood O 0 0.4657929241657257
onset O 1 0.9999904632568359
DM B-Disease 1 1.0
. O 0 0.0011105261510238051

Their O 0 4.397467273520306e-05
late O 0 0.00016412613331340253
father O 0 3.648890560725704e-05
had O 0 3.794465555984061e-06
the O 0 7.793319127813447e-07
adult O 0 2.6138645807805005e-06
type O 0 2.726384536799742e-06
of O 0 1.6624434238110553e-06
DM B-Disease 1 1.0
, O 0 4.317461844038917e-06
with O 0 2.2591927972825943e-06
onset O 0 0.0057995617389678955
around O 0 2.463541704855743e-06
30 O 0 4.753859684569761e-06
years O 0 6.979646968829911e-06
. O 0 1.2987914487894159e-05

Only O 0 2.104042323480826e-05
six O 0 6.323897650872823e-06
other O 0 9.206966637975711e-07
cases O 0 8.631874379716464e-07
of O 0 3.710584906002623e-07
paternal O 0 0.0005879115196876228
transmission O 0 0.03143816813826561
of O 0 0.0008762851357460022
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
have O 0 0.0004983479739166796
been O 0 3.620326242526062e-05
reported O 0 7.85802913014777e-05
recently O 0 6.579050386790186e-05
. O 0 2.121402030752506e-05

We O 0 3.680939335026778e-05
review O 0 1.845207589212805e-05
the O 0 3.4940203477162868e-06
sex O 0 1.4083881069382187e-05
related O 0 1.024538232741179e-05
effects O 0 2.3598528059665114e-05
on O 0 1.4579974049411248e-05
transmission O 0 0.0011536974925547838
of O 0 0.00011487781739560887
congenital B-Disease 1 0.9999998807907104
DM I-Disease 1 1.0
. O 0 0.0012929547810927033

Decreased O 0 0.0029788706451654434
fertility O 0 0.0003584779624361545
of O 0 3.6637511584558524e-06
males O 0 1.1257074220338836e-05
with O 0 2.7264647997071734e-06
adult O 0 0.0003418601700104773
onset O 1 0.999840259552002
DM B-Disease 1 1.0
and O 0 2.376520205871202e-05
contraction O 0 3.319146344438195e-05
of O 0 1.9312490451284248e-07
the O 0 4.4714846580973244e-07
repeat O 0 4.7831053961999714e-06
upon O 0 8.949641028266342e-07
male O 0 4.110450845473679e-06
transmission O 0 7.385230674117338e-06
contribute O 0 8.200475463127077e-07
to O 0 2.1099896230225568e-07
the O 0 3.231288587812742e-07
almost O 0 5.424776077234128e-07
absent O 0 5.559066266869195e-06
occurrence O 0 4.471144166018348e-06
of O 0 7.561898200947326e-07
paternal O 0 0.0018775674980133772
transmission O 0 0.08567828685045242
of O 0 0.0002859568048734218
congenital B-Disease 1 0.9999998807907104
DM I-Disease 1 1.0
. O 0 0.0017991644563153386

Also O 0 1.6943149603321217e-05
the O 0 1.6362420183213544e-06
fathers O 0 3.985042894782964e-06
of O 0 1.6930269453041547e-07
the O 0 8.31477223073307e-07
reported O 0 8.451321627944708e-05
congenitally O 0 0.02600351721048355
affected O 0 1.0096822734340094e-05
children O 0 5.6881385717133526e-06
showed O 0 6.6037146098096855e-06
, O 0 1.900118462572209e-07
on O 0 2.952322404325969e-07
average O 0 1.0596788797556655e-06
, O 0 4.7508277134511445e-07
shorter O 0 3.616289541241713e-05
CTG O 0 0.00020678296277765185
repeat O 0 7.979380825418048e-06
lengths O 0 1.6439735190942883e-05
and O 0 1.3431937304630992e-06
hence O 0 3.691500523927971e-06
less O 0 1.805693500500638e-05
severe O 1 0.9950411915779114
clinical O 1 0.9979884624481201
symptoms O 1 0.9103026390075684
than O 0 1.069418999577465e-06
the O 0 1.3005140999666764e-06
mothers O 0 6.679988928226521e-06
of O 0 6.330567998702463e-07
children O 0 5.8467914641369134e-05
with O 0 0.010741767473518848
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 0.0012788840103894472

We O 0 5.538874029298313e-05
conclude O 0 0.00011769711272791028
that O 0 4.0908739720180165e-06
paternal O 0 0.0001475257013225928
transmission O 0 0.0014013067120686173
of O 0 0.00030235128360800445
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
is O 0 4.9832058721221983e-05
rare O 0 1.7293059499934316e-05
and O 0 2.271129915243364e-06
preferentially O 0 1.1756803360185586e-05
occurs O 0 1.682370111666387e-06
with O 0 7.068072704896622e-07
onset O 0 0.00037046143552288413
of O 0 3.360637947480427e-06
DM B-Disease 1 0.9999998807907104
past O 0 5.628346116282046e-06
30 O 0 1.42811711612012e-06
years O 0 6.281674131969339e-07
in O 0 3.691046401854692e-07
the O 0 6.689651854685508e-07
father O 0 1.229095141752623e-05
. O 0 2.41631687458721e-06
. O 0 7.768158866383601e-06

The O 0 0.00044590054312720895
RB1 O 0 0.0757305920124054
gene O 0 0.0002857611107174307
mutation O 0 9.4448565505445e-05
in O 0 1.1239192645007279e-05
a O 0 1.6022049749153666e-05
child O 0 0.00022432245896197855
with O 0 6.512603431474417e-05
ectopic B-Disease 1 0.9998877048492432
intracranial I-Disease 1 0.9999628067016602
retinoblastoma I-Disease 1 0.9879597425460815
. O 0 0.0002228759549325332

The O 0 0.0003064629854634404
RB1 O 0 0.11233662068843842
gene O 0 0.0002283812063978985
mutation O 0 5.200946907280013e-05
was O 0 1.6665035218466073e-05
investigated O 0 1.214942767546745e-05
in O 0 1.3222166899140575e-06
a O 0 5.98040332988603e-06
child O 0 0.00015313205949496478
with O 0 2.3901840904727578e-05
ectopic B-Disease 1 0.9998074173927307
intracranial I-Disease 1 0.9992424249649048
retinoblastoma I-Disease 0 0.003674770938232541
using O 0 8.290517143905163e-06
DNA O 0 1.3602789294964168e-05
obtained O 0 1.962347823791788e-06
from O 0 5.486356826622796e-07
both O 0 5.711865469493205e-07
the O 0 1.831895701798203e-06
pineal B-Disease 0 0.0008794850436970592
and I-Disease 0 5.362933734431863e-05
retinal I-Disease 1 0.9254393577575684
tumours I-Disease 1 0.9985456466674805
of O 0 1.6056475260484149e-06
the O 0 5.755957317887805e-06
patient O 0 0.0008375160396099091
. O 0 4.799450471182354e-05

A O 0 0.0003495043783914298
nonsense O 0 0.000501240894664079
mutation O 0 6.719891825923696e-05
in O 0 4.842501311941305e-06
exon O 0 5.0783317419700325e-05
17 O 0 6.059964107407723e-06
( O 0 1.8463656488165725e-06
codon O 0 1.0243868018733338e-05
556 O 0 3.739234443855821e-06
) O 0 1.9366417802757496e-07
of O 0 5.30021431188743e-08
the O 0 7.625569651281694e-07
RB1 O 0 0.0008803353412076831
gene O 0 4.036895461467793e-06
was O 0 2.10145390155958e-06
found O 0 2.724061118897225e-07
to O 0 1.4724389529874315e-07
be O 0 1.4372986356647743e-07
present O 0 3.6265169001126196e-07
homozygously O 0 1.0276950888510328e-05
in O 0 2.991296241816599e-07
both O 0 4.5088461320119677e-07
the O 0 1.5074674593051895e-06
retinal B-Disease 0 0.0002517046232242137
and I-Disease 0 6.138675416877959e-06
the I-Disease 0 2.2353577151079662e-05
pineal I-Disease 1 0.9534981846809387
tumours I-Disease 1 0.9999222755432129
. O 0 9.58683667704463e-05

The O 0 2.7212925488129258e-05
same O 0 9.726018106448464e-06
mutation O 0 1.4388499039341696e-05
was O 0 2.5755866772669833e-06
present O 0 1.004986643238226e-06
heterozygously O 0 2.1979885787004605e-05
in O 0 3.831286221611663e-07
the O 0 1.8199486362391326e-07
DNA O 0 8.541999250155641e-07
from O 0 9.466221939646857e-08
the O 0 1.1300124924673582e-07
constitutional O 0 6.697669618915825e-07
cells O 0 5.133422291692114e-07
of O 0 4.9020368209085063e-08
the O 0 4.90340710257442e-07
patient O 0 3.0078932468313724e-05
, O 0 8.407322411585483e-07
proving O 0 7.392742645606631e-06
it O 0 1.7794266682358284e-07
to O 0 9.988411164840727e-08
be O 0 1.6113632739234163e-07
of O 0 3.3352503692185564e-07
germline O 0 6.546382792294025e-05
origin O 0 1.28911342471838e-05
. O 0 2.0646977645810694e-05

The O 0 3.3633754355832934e-05
initial O 0 5.773654265794903e-05
mutation O 0 3.0314606192405336e-05
was O 0 7.28539362171432e-06
shown O 0 1.8790451576933265e-06
to O 0 5.878742399545445e-07
have O 0 3.1087685670172505e-07
occurred O 0 1.5703266171840369e-06
in O 0 4.668732174195611e-07
the O 0 1.502038685430307e-06
paternally O 0 0.00012645660899579525
derived O 0 8.286377851618454e-05
RB1 O 0 0.009324458427727222
allele O 0 0.00038875112659297884
. O 0 4.662684295908548e-05

The O 0 3.0116359994281083e-05
mutation O 0 2.3158219846663997e-05
is O 0 6.56865154269326e-07
in O 0 3.106187307366781e-07
an O 0 1.309810215843754e-07
area O 0 1.4744610155048576e-07
of O 0 4.786801355294301e-08
the O 0 2.6318338086639415e-07
gene O 0 5.796837285743095e-07
that O 0 6.041142341928207e-08
encodes O 0 2.961919278732239e-07
the O 0 1.6674022162987967e-07
protein O 0 7.256384151332895e-07
- O 0 3.4838953979487997e-06
binding O 0 7.91193258464773e-07
region O 0 6.820409339525213e-07
known O 0 3.8693454484928225e-07
as O 0 1.5380882700810616e-07
the O 0 2.864549628611712e-07
pocket O 0 5.889943349757232e-05
region O 0 7.626631486346014e-07
and O 0 4.772510919792694e-07
has O 0 4.02986898961899e-07
been O 0 4.787221428159683e-07
detected O 0 1.8718034198172973e-06
in O 0 2.311364681872874e-07
other O 0 1.5972734956903878e-07
cases O 0 4.644329862912855e-07
of O 0 5.735140007345763e-07
retinoblastoma B-Disease 0 0.0014622359303757548
. O 0 6.7619848778122105e-06
. O 0 2.258256427012384e-05

Low O 0 0.0001369743113173172
levels O 0 1.0569028745521791e-05
of O 0 7.454402748408029e-07
beta O 0 7.787266440573148e-06
hexosaminidase O 0 3.527475200826302e-05
A O 0 3.3338876619382063e-06
in O 0 3.0018923098396044e-06
healthy O 0 8.203141078411136e-06
individuals O 0 7.538446880062111e-07
with O 0 2.2136691768537275e-06
apparent O 1 0.788505494594574
deficiency O 1 0.6126629710197449
of O 0 7.237337058541016e-07
this O 0 3.399136176085449e-06
enzyme O 0 4.881042332272045e-05
. O 0 1.405071816407144e-05

Appreciable O 0 0.0046862149611115456
beta O 0 0.000595611403696239
hexosaminidase O 0 0.0007476601749658585
A O 0 1.7748296158970334e-05
( O 0 6.3439456425840035e-06
hex O 0 1.5690102372900583e-05
A O 0 2.5496233320154715e-06
) O 0 6.751416776751284e-07
activity O 0 6.816039785917383e-07
has O 0 3.193743225438084e-07
been O 0 5.159395186637994e-07
detected O 0 6.096662673371611e-06
in O 0 2.989327867908287e-06
cultured O 0 0.4420723021030426
skin O 1 0.9771811962127686
fibroblasts O 0 0.003958915825933218
and O 0 0.00013652963389176875
melanoma B-Disease 1 0.9998999834060669
tissue O 0 0.0003323180426377803
from O 0 2.2440308384830132e-06
healthy O 0 1.351781338598812e-05
individuals O 0 2.759851440714556e-07
previously O 0 2.5128254037554143e-06
reported O 0 2.1127749278093688e-05
as O 0 1.5466592913071509e-06
having O 0 6.001204383210279e-05
deficiency B-Disease 0 0.0004377089499030262
of I-Disease 0 1.6079016518233402e-07
hex I-Disease 0 1.653322033234872e-05
A I-Disease 0 1.5878222257015295e-06
activity O 0 1.1697045465552947e-06
indistinguishable O 0 2.219361476818449e-06
from O 0 2.1509860914648016e-07
that O 0 1.5252618368322146e-07
of O 0 3.5612546867014316e-07
patients O 0 0.00018661608919501305
with O 0 0.0038224421441555023
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 0.9906136989593506
( O 0 0.00010458036558702588
TSD B-Disease 0 0.25148651003837585
) O 0 3.878758798236959e-05
. O 0 4.372836338006891e-05

Identification O 0 0.00026470181182958186
and O 0 1.779076410457492e-05
quantitation O 0 0.00022872377303428948
of O 0 2.0067272998858243e-06
hex O 0 4.886686656391248e-05
A O 0 5.219876584305894e-06
, O 0 1.1434073030613945e-06
amounting O 0 2.500153868822963e-06
to O 0 8.752735425332503e-07
3 O 0 4.074268872500397e-06
. O 0 7.407068551401608e-06

5 O 0 0.00022649593302048743
% O 0 9.40642348723486e-05
- O 0 0.00023727575899101794
6 O 0 4.425536099006422e-05
. O 0 2.0440542357391678e-05

9 O 0 8.688090747455135e-05
% O 0 7.133004146453459e-06
of O 0 4.614903161836992e-07
total O 0 1.0513772394915577e-06
beta O 0 3.5928196666645817e-06
hexosaminidase O 0 1.5237586012517568e-05
activity O 0 1.0749344028226915e-06
, O 0 1.60530447601559e-07
has O 0 9.641664888704327e-08
been O 0 1.786052195029697e-07
obtained O 0 7.070803462738695e-07
by O 0 1.1528687764439383e-06
cellulose O 0 0.0001454083394492045
acetate O 0 0.00010176161595154554
gel O 0 0.00021826682495884597
electrophoresis O 0 7.566093700006604e-05
, O 0 2.68889425569796e-06
DEAE O 0 0.00012841151328757405
- O 0 6.769855099264532e-05
cellulose O 0 5.097356188343838e-05
ion O 0 2.5874784114421345e-05
- O 0 1.7722317352308892e-05
exchange O 0 7.777788596285973e-06
chromatography O 0 3.983617352787405e-05
, O 0 2.147883606085088e-06
radial O 0 5.0453440053388476e-05
immunodiffusion O 0 8.274952415376902e-05
, O 0 2.142848643416073e-06
and O 0 3.180753765263944e-06
radioimmunoassay O 0 0.00035874207969754934
. O 0 2.1815745640196837e-05

Previous O 0 0.00031879544258117676
family O 0 7.98509136075154e-05
studies O 0 1.916035580507014e-05
suggested O 0 9.884814971883316e-06
that O 0 4.970361260348e-07
these O 0 1.588485503134507e-07
individuals O 0 3.29453939684754e-07
may O 0 1.0141270649910439e-06
be O 0 2.1204328959356644e-07
compound O 0 5.029644853493664e-06
heterozygotes O 0 1.4710785762872547e-05
for O 0 4.0869485928851645e-07
the O 0 9.211489668814465e-07
common O 0 5.214980319578899e-06
mutant O 0 7.311855006264523e-05
TSD B-Disease 0 0.0010812357068061829
gene O 0 9.365858204546385e-06
and O 0 9.958951068256283e-07
a O 0 1.9750016235775547e-06
rare O 0 1.2030166544718668e-05
( O 0 7.249851478263736e-06
allelic O 0 5.9218593378318474e-05
) O 0 7.003423888818361e-06
mutant O 0 6.982035120017827e-05
gene O 0 4.8555637476965785e-05
. O 0 1.899811286421027e-05

Thus O 0 5.198328653932549e-05
, O 0 5.03153023601044e-06
the O 0 2.146472752428963e-06
postulated O 0 1.114454153139377e-05
rate O 0 2.3095983578969026e-06
mutant O 0 8.019111191970296e-06
gene O 0 3.505180984575418e-06
appears O 0 9.971087138183066e-07
to O 0 1.632090373959727e-07
code O 0 1.7375931804508582e-07
for O 0 4.793169239292183e-08
the O 0 6.59975896155629e-08
expression O 0 3.276663278484193e-07
of O 0 8.41479277369217e-08
low O 0 1.1093853800048237e-06
amounts O 0 5.235917797108414e-07
of O 0 4.894395146948227e-07
hex O 0 4.960377191309817e-05
A O 0 1.2896703992737457e-05
. O 0 2.1974981791572645e-05

Heterozygotes O 0 0.0027164884377270937
for O 0 1.783550760592334e-05
the O 0 7.115515472833067e-06
rare O 0 3.947750883526169e-05
mutant O 0 0.00011351027205819264
may O 0 6.553230377903674e-06
be O 0 3.792338816310803e-07
indistinguishable O 0 2.750460225797724e-06
from O 0 7.57591635647259e-07
heterozygotes O 0 2.3932567273732275e-05
for O 0 9.996822427638108e-07
the O 0 3.265764917159686e-06
common O 0 3.3355667255818844e-05
TSD B-Disease 0 0.07213138043880463
mutant O 0 0.0005108589539304376
. O 0 5.746683746110648e-05

However O 0 7.813197589712217e-05
, O 0 5.019562649977161e-06
direct O 0 4.194028861093102e-06
visualization O 0 3.0784052796661854e-05
and O 0 1.9701819837791845e-06
quantitation O 0 3.577805182430893e-05
of O 0 4.789943091054738e-07
hex O 0 1.3466615200741217e-05
A O 0 6.502980909317557e-07
by O 0 3.4366101431260176e-07
the O 0 5.925663799644099e-07
methods O 0 6.827490778960055e-06
described O 0 4.074866956216283e-05
may O 0 2.713557250899612e-06
prevent O 0 1.6968075442491681e-06
false O 0 6.433452199416934e-06
- O 0 0.00010358973668189719
positive O 0 1.698391861282289e-05
prenatal O 0 0.08307455480098724
diagnosis O 0 0.11608494073152542
of O 0 1.961745510925539e-06
TSD B-Disease 0 0.22432810068130493
in O 0 1.6776704796939157e-05
fetuses O 0 8.69700888870284e-05
having O 0 8.815983960630547e-07
the O 0 7.243371555887279e-07
incomplete O 0 1.562576107971836e-05
hex B-Disease 0 0.00018962356261909008
A I-Disease 0 0.0001763919135555625
deficiency I-Disease 0 0.001227222615852952
of O 0 1.8490547404326207e-07
the O 0 9.955731457012007e-07
type O 0 2.2033127606846392e-05
described O 0 1.8978282241732813e-05
in O 0 1.1371794244041666e-06
the O 0 1.166248239314882e-06
four O 0 4.689321940531954e-06
healthy O 0 5.351296204025857e-05
individuals O 0 3.488867878331803e-05

The O 0 0.00023338028404396027
tumor B-Disease 0 0.006689633708447218
suppressor O 0 0.0008334859157912433
gene O 0 0.0001817974989535287
Smad4 O 0 0.001717910054139793
/ O 0 0.0010595133062452078
Dpc4 O 0 0.00016301919822581112
is O 0 5.394281856752059e-07
required O 0 5.815613803861197e-07
for O 0 2.495772832844523e-07
gastrulation O 0 1.5017269106465392e-05
and O 0 5.116633019497385e-07
later O 0 1.087740201910492e-06
for O 0 4.678975358274329e-07
anterior O 0 5.709802280762233e-06
development O 0 6.58142994325317e-07
of O 0 2.017596898440388e-07
the O 0 2.376841393925133e-06
mouse O 0 0.00013017424498684704
embryo O 0 0.00017164714518003166
. O 0 2.25204730668338e-05

Mutations O 0 0.0011139132548123598
in O 0 3.529106834321283e-05
the O 0 2.5981897124438547e-05
SMAD4 O 0 0.4653679132461548
/ O 1 0.8945782780647278
DPC4 O 1 0.8329493403434753
tumor B-Disease 0 0.01187277864664793
suppressor O 0 0.00016451078408863395
gene O 0 1.8458602426107973e-05
, O 0 7.107269652806281e-07
a O 0 8.645846492072451e-07
key O 0 2.304636836925056e-06
signal O 0 4.9912414397113025e-06
transducer O 0 1.839365722844377e-05
in O 0 6.87545650635002e-07
most O 0 7.727637125753972e-07
TGFbeta O 0 0.0001500225334893912
- O 0 7.45806100894697e-05
related O 0 1.8078758330375422e-06
pathways O 0 1.3484622058967943e-06
, O 0 1.485350935581664e-07
are O 0 3.839376461201027e-08
involved O 0 1.801176239268898e-07
in O 0 3.5203018455831625e-07
50 O 0 7.561912411802041e-07
% O 0 1.7745828699844424e-06
of O 0 2.8531253519759048e-06
pancreatic B-Disease 1 0.9993165731430054
cancers I-Disease 1 0.7109460830688477
. O 0 6.687455606879666e-05

Homozygous O 0 0.022910101339221
Smad4 O 0 0.23082637786865234
mutant O 0 0.027688413858413696
mice O 0 0.3720604479312897
die O 0 0.0006694452022202313
before O 0 1.0978566933772527e-05
day O 0 1.378120305162156e-05
7 O 0 2.1617284801322967e-05
. O 0 1.564559352118522e-05

5 O 0 0.00026886939303949475
of O 0 4.645928129320964e-05
embryogenesis O 0 0.0027870647609233856
. O 0 0.00014699436724185944

Mutant O 0 0.0010832126718014479
embryos O 0 0.00018469893257133663
have O 0 5.647394573315978e-06
reduced O 0 3.0647120183857623e-06
size O 0 2.680240640984266e-06
, O 0 7.019110626060865e-07
fail O 0 6.831347036495572e-06
to O 0 5.219873742134951e-07
gastrulate O 0 4.956319389748387e-05
or O 0 8.662527193337155e-07
express O 0 1.8810335404850775e-06
a O 0 9.898068356051226e-07
mesodermal O 0 2.931763265223708e-05
marker O 0 6.947452220629202e-06
, O 0 5.348023250917322e-07
and O 0 7.560117296634417e-07
show O 0 1.0431632290419657e-05
abnormal O 0 6.715908239129931e-05
visceral O 0 7.038752664811909e-05
endoderm O 0 0.00048812644672580063
development O 0 3.533023118507117e-05
. O 0 5.640824747388251e-05

Growth B-Disease 1 0.999018669128418
retardation I-Disease 1 0.9959294199943542
of O 0 3.730515118149924e-06
the O 0 8.072267519310117e-06
Smad4 O 0 0.04241419583559036
- O 0 0.3585485816001892
deficient O 0 0.027026906609535217
embryos O 0 3.4475258871680126e-05
results O 0 1.0540996299823746e-05
from O 0 1.183907102131343e-06
reduced O 0 5.528155270440038e-06
cell O 0 2.685258186829742e-05
proliferation O 0 9.735669664223678e-06
rather O 0 1.3262807669889298e-06
than O 0 1.223557660523511e-06
increased O 0 7.646726771781687e-06
apoptosis O 0 7.556885248050094e-05
. O 0 1.9548018826753832e-05

Aggregation O 0 0.0005446927389129996
of O 0 3.0474839149974287e-05
mutant O 0 0.0007253180374391377
Smad4 O 0 0.0030267457477748394
ES O 0 0.001013495260849595
cells O 0 2.717879760893993e-05
with O 0 2.9690675091842422e-06
wild O 0 1.4537321476382203e-05
- O 0 0.00018028942577075213
type O 0 3.790616392507218e-05
tetraploid O 0 0.00030360082746483386
morulae O 0 0.0008434609626419842
rescues O 0 0.00029669643845409155
the O 0 2.806064730975777e-05
gastrulation B-Disease 0 0.004705325234681368
defect I-Disease 0 0.0027989777736365795
. O 0 7.357793947448954e-05

These O 0 3.141547858831473e-05
results O 0 8.967224130174145e-05
indicate O 0 1.0635326361807529e-05
that O 0 7.636813279532362e-07
Smad4 O 0 1.43056531669572e-05
is O 0 1.5267244179995032e-07
initially O 0 7.564394195469504e-07
required O 0 2.1540836314670742e-07
for O 0 6.678254749203916e-08
the O 0 1.5721981583283196e-07
differentiation O 0 7.490439770663215e-07
of O 0 7.317412809015877e-08
the O 0 5.286780719870876e-07
visceral O 0 1.1514312063809484e-05
endoderm O 0 6.514845154015347e-05
and O 0 4.513961471275252e-07
that O 0 1.8810285951076366e-07
the O 0 8.25477286525711e-07
gastrulation B-Disease 0 0.00015175652515608817
defect I-Disease 0 3.681732778204605e-05
in O 0 6.428555252568913e-07
the O 0 8.600468959230056e-07
epiblast O 0 0.00013208833115641028
is O 0 2.2451430936598626e-07
secondary O 0 6.868758077871462e-07
and O 0 7.802756840646907e-07
non O 0 7.1871254476718605e-06
- O 0 0.00010343919711885974
cell O 0 2.866720205929596e-05
autonomous O 0 1.5130388419493102e-05
. O 0 2.1359917809604667e-05

Rescued O 0 0.0172688327729702
embryos O 0 0.0027061146683990955
show O 0 0.000876507256180048
severe O 1 0.821434497833252
anterior O 0 0.0019052022835239768
truncations O 0 0.00035096934880129993
, O 0 4.589229320117738e-06
indicating O 0 5.326895916368812e-06
a O 0 8.573092600272503e-07
second O 0 1.6509634406247642e-06
important O 0 6.96977622283157e-07
role O 0 1.824786977522308e-06
for O 0 1.5613043160556117e-06
Smad4 O 0 0.00024292993475683033
in O 0 1.0959110113617498e-05
anterior O 0 0.0004806973156519234
patterning O 0 0.0015328001463785768
during O 0 0.00013263786968309432
embryogenesis O 0 0.0022631813772022724
. O 0 0.00013254329678602517

Prevalence O 0 0.0022821188904345036
of O 0 2.146497899957467e-05
p16 O 0 0.0006063567707315087
and O 0 2.4175997168640606e-05
CDK4 O 0 0.1286618709564209
germline O 0 0.0025417578872293234
mutations O 0 9.808303002500907e-05
in O 0 1.6422576663899235e-05
48 O 0 0.0031814081594347954
melanoma B-Disease 1 0.999984860420227
- O 0 0.2156464159488678
prone O 0 0.00025216530775651336
families O 0 6.187900908116717e-06
in O 0 1.0294558705936652e-05
France O 0 0.0009452479425817728
. O 0 5.330760177457705e-05

The O 0 0.00033488846383988857
French O 0 0.09345518797636032
Familial B-Disease 1 0.9979836940765381
Melanoma I-Disease 1 0.9999903440475464
Study O 0 0.00023489919840358198
Group O 0 0.00014188775094226003
. O 0 6.879016291350126e-05

Germline O 0 0.08308945596218109
mutations O 0 0.0004208479367662221
in O 0 9.792798664420843e-06
the O 0 3.603388449846534e-06
p16 O 0 6.907690112711862e-05
and O 0 2.069871015919489e-06
CDK4 O 0 0.0011246298672631383
genes O 0 2.724447995205992e-06
have O 0 3.5054139857493283e-07
been O 0 4.569662905851146e-07
reported O 0 1.3966282494948246e-06
in O 0 2.0714810489153024e-07
a O 0 3.6138359860160563e-07
subset O 0 2.2396095573640196e-06
of O 0 1.1723457191692432e-06
melanoma B-Disease 1 0.943972647190094
pedigrees O 0 0.00011123714648419991
, O 0 8.151928341249004e-07
but O 0 5.316971964930417e-07
their O 0 9.317921012552688e-07
prevalence O 0 4.5646003854926676e-05
is O 0 2.5254112756556424e-07
not O 0 4.1003667661243526e-07
well O 0 9.115570946960361e-07
known O 0 4.563636593957199e-06
. O 0 9.735475032357499e-06

We O 0 3.2415588066214696e-05
searched O 0 4.010206976090558e-05
for O 0 1.4869794995320262e-06
such O 0 1.178347019958892e-06
germline O 0 0.00016252719797194004
mutations O 0 1.3360582670429721e-05
in O 0 2.173266238969518e-06
48 O 0 2.183227115892805e-05
French O 0 0.4028727412223816
melanoma B-Disease 1 0.9999932050704956
- O 0 0.1079440489411354
prone O 0 7.762733002891764e-05
families O 0 1.4785263147132355e-06
selected O 0 5.285858719616954e-07
according O 0 3.46077712265469e-07
to O 0 9.729524919066534e-08
two O 0 8.045103072618076e-08
major O 0 2.937950114301202e-07
criteria O 0 8.20756383745902e-07
families O 0 2.024605123551737e-07
with O 0 7.703650339863088e-08
at O 0 2.4038357082645234e-07
least O 0 1.45039209087372e-07
three O 0 1.4597449649045302e-07
affected O 0 5.17694104473776e-07
members O 0 1.7251350925562292e-07
( O 0 2.6230662797388504e-07
n O 0 6.899674076521478e-07
= O 0 8.321301265823422e-07
20 O 0 1.5460501856523479e-07
) O 0 6.947877295715443e-08
or O 0 5.776165323823079e-08
families O 0 8.648257221466338e-08
with O 0 4.631666783438959e-08
two O 0 1.5359789529156842e-07
affected O 0 9.057054057848291e-07
members O 0 1.0361235069922259e-07
, O 0 3.6237370437675054e-08
one O 0 1.772270508126894e-08
of O 0 1.345307953926067e-08
them O 0 4.068282422053926e-08
affected O 0 3.6158459693069744e-07
before O 0 9.051858285147318e-08
the O 0 6.888892301049054e-08
age O 0 2.0179433590783447e-07
of O 0 2.983239255627268e-08
50 O 0 2.7073357955487154e-07
( O 0 3.270391459864186e-07
n O 0 2.146654878742993e-06
= O 0 2.7502558168635005e-06
28 O 0 9.507973572908668e-07
) O 0 1.0737524291926093e-07
, O 0 4.139219100807168e-08
and O 0 5.1358309605120667e-08
one O 0 1.3082809857678512e-07
additional O 0 6.586931249330519e-07
minor O 0 6.696125637972727e-06
criterion O 0 2.6328298190492205e-05
. O 0 1.273509315069532e-05

Sixteen O 0 0.0006382608553394675
different O 0 7.747668860247359e-05
p16 O 0 0.0016243032878264785
germline O 0 0.0011758484179154038
mutations O 0 6.153853610157967e-05
were O 0 2.993504267578828e-06
found O 0 1.2782700196112273e-06
in O 0 8.498601573592168e-07
21 O 0 1.238934828506899e-06
families O 0 3.129812284896616e-07
, O 0 1.229877995001516e-07
while O 0 2.4786140784271993e-07
one O 0 6.268377319429419e-07
germline O 0 6.087501242291182e-05
mutation O 0 3.909370207111351e-06
, O 0 5.907455715714605e-07
Arg24His O 0 3.6100253055337816e-05
, O 0 8.575611332162225e-07
was O 0 3.5892310279450612e-06
detected O 0 4.4609573706111405e-06
in O 0 5.860767942067469e-07
the O 0 2.193965883634519e-06
CDK4 O 0 0.0011361170327290893
gene O 0 3.9154991100076586e-05
. O 0 1.3597899851447437e-05

The O 0 4.205803998047486e-05
frequency O 0 3.5710625525098294e-05
of O 0 2.61360014519596e-06
p16 O 0 0.0001505513209849596
gene O 0 1.7455718989367597e-05
mutation O 0 4.334880486567272e-06
in O 0 4.4515465447148017e-07
our O 0 3.0624985924987413e-07
sample O 0 1.6309106740663992e-06
( O 0 6.015582698637445e-07
44 O 0 9.889697594189784e-07
% O 0 5.055638325757172e-07
) O 0 1.461954610704197e-07
is O 0 3.130608661194856e-08
among O 0 3.653133617831372e-08
the O 0 8.65923368564836e-08
highest O 0 2.8451265166040685e-07
rates O 0 8.054282147895719e-07
yet O 0 9.096319217860582e-07
reported O 0 1.8841323026208556e-06
and O 0 1.2351014788691828e-07
the O 0 3.451495445006003e-07
CDK4 O 0 0.000848455005325377
mutation O 0 1.3363592188397888e-06
is O 0 5.3448214742957134e-08
the O 0 1.1774298513955728e-07
second O 0 1.7919634274221607e-06
mutation O 0 5.828534540341934e-06
detected O 0 4.430473381944466e-06
in O 0 5.066624453320401e-07
this O 0 1.108477022171428e-06
gene O 0 1.272276040253928e-05
worldwide O 0 1.1340981473040301e-05
. O 0 1.6012609194149263e-05

In O 0 0.00013907915854360908
summary O 0 0.0001421661872882396
, O 0 2.646383791216067e-06
our O 0 1.4830537793386611e-06
results O 0 4.193281256448245e-06
show O 0 1.07435016616364e-06
frequent O 0 1.227985762852768e-06
involvement O 0 2.5131225811492186e-06
of O 0 2.1700572006011498e-07
the O 0 1.2735415566567099e-06
p16 O 0 5.68441282666754e-05
gene O 0 8.538752808817662e-06
in O 0 7.837600605853368e-06
familial B-Disease 0 0.00980284996330738
melanoma I-Disease 1 0.9981279969215393
and O 0 2.44256671066978e-06
confirm O 0 4.856875875702826e-06
the O 0 2.1961585616736556e-07
role O 0 3.129230208287481e-07
of O 0 1.0568554387191398e-07
the O 0 7.916431172816374e-07
CDK4 O 0 0.0002951267524622381
gene O 0 8.088003596640192e-06
as O 0 1.209277343150461e-06
a O 0 3.8863858208060265e-05
melanoma B-Disease 1 0.9995556473731995
- O 0 0.010825379751622677
predisposing O 0 0.00016455673903692514
gene O 0 2.555322862463072e-05
. O 0 8.204909136111382e-06
. O 0 2.0428615243872628e-05

Progression O 0 0.0015379852848127484
of O 0 2.452560147503391e-05
somatic O 0 0.0006837023538537323
CTG O 0 0.002429042477160692
repeat O 0 0.00011288464884273708
length O 0 2.7385582143324427e-05
heterogeneity O 0 3.0931718356441706e-05
in O 0 2.3734460228297394e-06
the O 0 2.8564222702698316e-06
blood O 0 3.1271501939045265e-05
cells O 0 6.056898564565927e-05
of O 0 3.463633402134292e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 1 0.9993079900741577
. O 0 0.00024523804313503206

The O 0 6.315790233202279e-05
genetic O 0 9.711243910714984e-05
basis O 0 1.9991490262327716e-05
of O 0 3.10439572785981e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9164620637893677
DM B-Disease 1 1.0
) O 0 3.68974065168004e-06
is O 0 1.7452175882226584e-07
the O 0 7.623432907166716e-08
expansion O 0 4.088582272743224e-07
of O 0 1.089867254222554e-07
an O 0 1.3288697573443642e-06
unstable O 0 0.00023799986229278147
CTG O 0 0.00025346552138216794
repeat O 0 6.5314866333210375e-06
in O 0 5.811593837279361e-07
the O 0 5.940204914622882e-07
34 O 0 2.93043308374763e-06
UTR O 0 2.0133706129854545e-05
of O 0 3.820070730853331e-07
the O 0 6.320087322819745e-06
DM B-Disease 1 0.9999995231628418
protein O 0 2.3395112293655984e-05
kinase O 0 9.288224100600928e-05
gene O 0 1.730271105770953e-05
on O 0 6.648921953456011e-06
chromosome O 0 5.0760274461936206e-05
19 O 0 1.7679443772067316e-05
. O 0 1.4071059922571294e-05

One O 0 1.4624450159317348e-05
of O 0 1.1051583896914963e-06
the O 0 5.878910656065273e-07
principal O 0 1.1962653161390335e-06
features O 0 6.925100137777918e-07
of O 0 3.3703520330163883e-07
the O 0 1.6104142559925094e-05
DM B-Disease 1 1.0
mutation O 0 2.2614671252085827e-05
is O 0 4.3154963691449666e-07
an O 0 4.994794835511129e-07
extraordinarily O 0 7.711861144343857e-06
high O 0 1.2188409073132789e-06
level O 0 3.4234929557896976e-07
of O 0 1.889965517420933e-07
somatic O 0 2.867693365260493e-05
mosaicism O 0 0.0002849742886610329
, O 0 9.150297159976617e-07
due O 0 1.392047238368832e-06
to O 0 2.696716308037139e-07
an O 0 1.7484309466908599e-07
extremely O 0 1.715774487820454e-06
high O 0 7.840216085241991e-07
degree O 0 1.2926226418130682e-06
of O 0 3.6815717407989723e-07
somatic O 0 3.512061812216416e-05
instability O 0 2.9939271826151526e-06
both O 0 2.615520031667984e-07
within O 0 2.778840269002103e-07
and O 0 4.27699887950439e-07
between O 0 9.226366159964527e-07
different O 0 1.917853751365328e-06
tissues O 0 5.976646571070887e-05
. O 0 1.797367622202728e-05

This O 0 4.029389310744591e-05
instability O 0 6.284879054874182e-05
appears O 0 1.3494705854100175e-05
to O 0 6.782425430174044e-07
be O 0 2.239202672171814e-07
biased O 0 2.3944371605466586e-06
towards O 0 2.0109771980969526e-07
further O 0 1.4718646923483902e-07
expansion O 0 4.0326216321773245e-07
and O 0 7.359095377523772e-08
continuous O 0 1.9963194120009575e-07
throughout O 0 1.0574643738436862e-07
the O 0 4.790217289496468e-08
life O 0 5.914575496035468e-08
of O 0 1.4250620239408818e-08
an O 0 3.8008685976365086e-08
individual O 0 5.0811888030466434e-08
, O 0 5.582116102686996e-08
features O 0 1.7730862111875467e-07
that O 0 7.448426941891739e-08
could O 0 1.6848413508796511e-07
be O 0 4.1149974094878417e-08
associated O 0 1.5021919352875557e-07
with O 0 6.925292694859309e-08
the O 0 3.0414955176638614e-07
progressive O 0 9.5479772426188e-06
nature O 0 1.2106874009987223e-06
of O 0 3.155809906729701e-07
the O 0 1.217893986904528e-05
disease O 0 0.0003752487536985427
. O 0 1.864374462456908e-05

Although O 0 0.00016907395911403
increasing O 0 4.773506225319579e-05
measured O 0 4.894358426099643e-05
allele O 0 4.4242529838811606e-05
size O 0 8.335508027812466e-06
between O 0 4.5260280785441864e-06
patients O 0 0.00018299909424968064
clearly O 0 6.4448677221662365e-06
correlates O 0 6.5215895119763445e-06
with O 0 3.938266956993175e-07
an O 0 4.622721974101296e-07
increased O 0 6.362783551594475e-06
severity O 0 0.00048613303806632757
of O 0 1.5557602637272794e-06
symptoms O 0 0.05809004604816437
and O 0 6.373171004270262e-07
an O 0 4.159980164786248e-07
earlier O 0 7.106631073838798e-06
age O 0 1.7294588587901671e-06
of O 0 2.5394939484613133e-07
onset O 0 0.009629685431718826
, O 0 4.381169560474518e-07
this O 0 1.432130716239044e-07
correlation O 0 4.960648425367253e-07
is O 0 6.54159535429244e-08
not O 0 6.836781807351144e-08
precise O 0 6.213264782672923e-07
and O 0 2.963605822969839e-07
measured O 0 2.226701326435432e-06
allele O 0 3.905591256625485e-06
length O 0 6.586158178834012e-07
cannot O 0 4.680546226154547e-07
be O 0 7.225420972645225e-08
used O 0 1.7143746333658783e-07
as O 0 1.0411216067041096e-07
an O 0 6.955050224632942e-08
accurate O 0 1.5931278767311596e-06
predictor O 0 1.0049865522887558e-05
of O 0 3.9060691392478475e-07
age O 0 7.541671493527247e-06
of O 0 2.5063634438993176e-06
onset O 0 0.026962505653500557
. O 0 3.986330921179615e-05

In O 0 3.964198549510911e-05
order O 0 6.70170311423135e-06
to O 0 2.0105374005652266e-06
further O 0 2.2238853034650674e-06
characterize O 0 1.9345025066286325e-05
the O 0 1.9016681562789017e-06
dynamics O 0 2.8509835829026997e-05
of O 0 3.02582861877454e-06
DM B-Disease 1 0.9999998807907104
CTG O 0 0.005629189778119326
repeat O 0 3.8227724871831015e-05
somatic O 0 3.2985222787829116e-05
instability O 0 5.86827354709385e-06
, O 0 2.605313227377337e-07
we O 0 1.183457172260205e-07
have O 0 1.311388899694066e-07
studied O 0 1.1659757319648634e-06
repeat O 0 2.5536969587847125e-06
length O 0 1.5644700397388078e-06
changes O 0 4.7382985712829395e-07
over O 0 3.6256838598092145e-07
time O 0 9.934790341503685e-07
in O 0 7.251144324982306e-06
111 O 0 0.37532347440719604
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 1 0.7594500184059143
with O 0 6.600811957468977e-06
varying O 0 6.474959081970155e-05
clinical O 0 0.19484052062034607
severity O 0 0.12889429926872253
and O 0 2.2292777430266142e-05
CTG O 0 0.0016608836594969034
repeat O 0 8.354774763574824e-06
size O 0 1.2917736285089632e-06
over O 0 2.6541735564933333e-07
time O 0 2.458513961300923e-07
intervals O 0 6.945941777303233e-07
of O 0 9.207970919078434e-08
1 O 0 1.1703662039508345e-06
- O 0 2.519431109249126e-05
7 O 0 4.555518444249174e-06
years O 0 4.004662059742259e-06
. O 0 1.0018966349889524e-05

We O 0 2.2020669348421507e-05
have O 0 2.291793180120294e-06
found O 0 8.501486377099354e-07
a O 0 3.0993430755188456e-07
direct O 0 7.229707534861518e-07
progression O 0 3.6963235743314726e-06
of O 0 1.1685813205986051e-07
the O 0 4.3266473426228913e-07
size O 0 2.5748915959411534e-06
heterogeneity O 0 3.2998391361616086e-06
over O 0 6.630683060393494e-07
time O 0 8.083538887149189e-07
related O 0 7.402976507364656e-07
to O 0 4.902822752228531e-07
initial O 0 4.9798586587712634e-06
CTG O 0 0.0001768756192177534
repeat O 0 9.246667104889639e-06
size O 0 2.2208587324712425e-06
and O 0 2.446709288506099e-07
the O 0 2.578663611529919e-07
time O 0 4.242214117766707e-07
interval O 0 1.0718081284721848e-06
and O 0 2.841856314717006e-07
always O 0 8.828453132991854e-07
biased O 0 6.526448487420566e-06
towards O 0 1.8253177813676302e-06
further O 0 2.138006493623834e-06
expansion O 0 1.5148074453463778e-05
. O 0 1.913278356369119e-05

Attempts O 0 0.0002736963506322354
to O 0 2.0430485164979473e-05
mathematically O 0 7.801002357155085e-05
model O 0 1.7113625290221535e-05
the O 0 1.7424880525140907e-06
dynamics O 0 1.340764356427826e-05
have O 0 3.98048541683238e-07
proved O 0 4.338007329351967e-06
only O 0 1.7391582218806434e-07
partially O 0 1.781667606337578e-06
successful O 0 1.5649654869775986e-06
suggesting O 0 1.920681825140491e-06
that O 0 9.386609178818617e-08
individual O 0 1.2065329713095707e-07
specific O 0 3.1580046311319165e-07
genetic O 0 3.0183007311279653e-06
and O 0 2.9378957151493523e-06
/ O 0 0.014040564186871052
or O 0 1.0230257885268657e-06
environmental O 0 1.5710336356278276e-06
factors O 0 2.91250273676269e-07
also O 0 1.7996583778767672e-07
play O 0 3.1334556638284994e-07
a O 0 5.30681006694067e-07
role O 0 1.4889376416249434e-06
in O 0 2.549489636294311e-06
somatic O 0 0.00012435158714652061
mosaicism O 0 0.0006166520761325955
. O 0 1.1929538231925108e-05
. O 0 1.533209979243111e-05

Aspartylglucosaminuria B-Disease 1 0.9974027276039124
among O 0 0.00010296869004378095
Palestinian O 0 0.0005600334843620658
Arabs O 0 0.0005599039141088724
. O 0 6.095773642300628e-05

Aspartylglucosaminuria B-Disease 1 0.9999845027923584
( O 0 0.20811401307582855
AGU B-Disease 1 0.9999915361404419
) O 0 2.4265409592771903e-05
is O 0 3.3655803690635366e-06
a O 0 6.6677430368145e-06
rare O 0 0.0005750683485530317
disorder B-Disease 0 0.07576099783182144
of I-Disease 0 9.773920055522467e-07
glycoprotein I-Disease 0 0.00021913531236350536
metabolism I-Disease 0 0.00040181088843382895
caused O 0 9.121578841586597e-06
by O 0 1.6930767969824956e-06
the O 0 1.3416710316960234e-05
deficiency B-Disease 0 0.00035828218096867204
of I-Disease 0 2.0607346584711195e-07
the I-Disease 0 2.9353866466408363e-06
lysosomal I-Disease 0 0.0006775024812668562
enzyme I-Disease 0 7.241513230837882e-05
aspartylglucosaminidase I-Disease 0 0.0008706091321073472
( O 0 1.2125027751608286e-05
AGA O 0 0.02341478504240513
) O 0 1.6718187907827087e-05
. O 0 1.945777694345452e-05

AGU B-Disease 1 0.9999884366989136
is O 0 0.00017230684170499444
inherited O 0 0.09039423614740372
as O 0 2.9749215173069388e-05
an O 0 5.239472011453472e-05
autosomal O 1 0.9991818070411682
recessive O 1 0.9837464690208435
trait O 0 0.00010203407873632386
and O 0 2.422253146505682e-06
occurs O 0 1.0049213869933737e-06
with O 0 1.647336915766573e-07
a O 0 5.321019784787495e-07
high O 0 7.784375952724076e-07
frequency O 0 1.8034071445072186e-06
in O 0 8.727712383915787e-07
Finland O 0 9.051173947227653e-06
because O 0 2.855314278349397e-07
of O 0 1.1926231024972367e-07
a O 0 1.3902218825023738e-06
founder O 0 2.5011175239342265e-05
effect O 0 1.2351206351013388e-05
. O 0 1.3272297110233922e-05

While O 0 7.388307858491316e-05
very O 0 2.912196214310825e-05
few O 0 1.8319013179279864e-05
patients O 0 0.000995957525447011
with O 0 1.4229905900720041e-05
AGU B-Disease 1 0.9999998807907104
have O 0 3.4751349176076474e-06
been O 0 1.5082280242495472e-06
reported O 0 2.5284168714279076e-06
from O 0 3.934542860406509e-07
non O 0 2.109910383296665e-06
- O 0 1.0814227607625071e-05
Finnish O 0 1.2090181371604558e-05
origin O 0 8.274059268842393e-07
, O 0 6.252108164517267e-07
we O 0 3.918754373444244e-06
diagnosed O 1 0.8890517950057983
the O 0 5.073798092780635e-06
disorder O 0 0.15616706013679504
in O 0 3.457422735664295e-06
8 O 0 1.991292810998857e-05
patients O 0 1.6694813893991522e-05
originating O 0 9.683792541181901e-07
from O 0 4.2525672938609205e-07
3 O 0 5.008943162465584e-07
unrelated O 0 2.7178098207514267e-06
families O 0 5.470985229294456e-07
, O 0 1.1601443361541897e-07
all O 0 5.751013176791275e-08
Palestinian O 0 2.7075031994172605e-06
Arabs O 0 2.2703288777847774e-06
from O 0 2.8254609674149833e-07
the O 0 2.1702558683500683e-07
region O 0 6.24280801275745e-07
of O 0 4.5334095943871944e-07
Jerusalem O 0 0.00010296298569301143
. O 0 2.6133633582503535e-05

The O 0 0.0003630203427746892
clinical O 1 0.6737645864486694
diagnosis O 1 0.9991851449012756
of O 0 3.921477764379233e-05
AGU B-Disease 1 0.9999998807907104
is O 0 5.126355972606689e-06
often O 0 1.9470544430078007e-06
difficult O 0 2.0675904579547932e-06
, O 0 3.389945106846426e-07
in O 0 2.3728661346922308e-07
particular O 0 4.537847644314752e-07
early O 0 4.060548690176802e-06
in O 0 4.172289038706367e-07
the O 0 2.2939769905860885e-07
course O 0 9.831592251430266e-07
of O 0 8.144890273342753e-08
the O 0 4.410028395795962e-06
disease O 0 5.584475729847327e-05
, O 0 1.9314367705192126e-07
and O 0 9.77213403530186e-08
most O 0 6.831072596469312e-08
of O 0 3.8592290252381645e-08
the O 0 2.2948770492803305e-06
patients O 0 0.027268126606941223
are O 0 1.1655560228973627e-05
diagnosed O 1 0.9894413948059082
after O 0 3.529294190229848e-06
the O 0 6.988179279687756e-07
age O 0 1.1079126807089779e-06
of O 0 1.806056104669551e-07
5 O 0 2.3543177576357266e-06
years O 0 6.374529220920522e-06
. O 0 8.357587830687407e-06

However O 0 7.644767902093008e-05
, O 0 6.721423233102541e-06
since O 0 4.426596660778159e-06
these O 0 1.0256468385705375e-06
patients O 0 8.701190381543711e-05
excrete O 0 1.4281538824434392e-05
early O 0 3.852988811559044e-06
large O 0 5.394091431298875e-07
amounts O 0 4.6807426201667113e-07
of O 0 2.058057759768417e-07
aspartylglucosamine O 0 5.0254348025191575e-05
in O 0 2.4320884222106542e-06
urine O 0 1.708033414615784e-05
, O 0 9.483684948463633e-07
biochemical O 0 1.286160113522783e-05
screening O 0 7.5430380093166605e-06
is O 0 5.511891458809259e-07
easy O 0 3.183421313224244e-06
by O 0 2.328181153643527e-06
urine O 0 4.049003109685145e-05
chromatography O 0 5.1997467380715534e-05
. O 0 4.6238378672569524e-06
. O 0 1.2027368029521313e-05

Detection O 0 0.0005539226694963872
of O 0 1.32215000121505e-05
heterozygous O 0 0.00010569853475317359
carriers O 0 1.962576061487198e-05
of O 0 1.985352355404757e-06
the O 0 7.07148210494779e-05
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999986886978149
telangiectasia I-Disease 1 0.9999977350234985
( O 0 2.861519533325918e-05
ATM O 0 9.177124593406916e-05
) O 0 3.272143430876895e-06
gene O 0 5.6615554058225825e-06
by O 0 2.990810571645852e-06
G2 O 0 0.003550391411408782
phase O 0 5.422856702352874e-05
chromosomal O 0 0.00018158595776185393
radiosensitivity O 0 0.00014106107119005173
of O 0 4.395701580506284e-06
peripheral O 0 0.03653877601027489
blood O 0 0.0010139960795640945
lymphocytes O 0 0.006038452032953501
. O 0 8.591778168920428e-05

In O 0 0.007562027778476477
ataxia B-Disease 1 0.9999997615814209
- I-Disease 1 0.9999933242797852
telangiectasia I-Disease 1 0.9999991655349731
( O 0 0.00030543687171302736
A B-Disease 1 0.9904940724372864
- I-Disease 1 0.9999769926071167
T I-Disease 1 0.9999985694885254
) O 0 1.0108450624102261e-05
patients O 0 7.659872790100053e-05
, O 0 1.0135817092304933e-06
mutations O 0 2.201546976721147e-06
in O 0 2.2622856477028108e-07
a O 0 4.2068612060575106e-07
single O 0 8.27611870590772e-07
gene O 0 1.2237793498570682e-06
, O 0 2.4838294621076784e-07
ATM O 0 6.772938377253013e-06
, O 0 3.6714217799271864e-07
result O 0 1.2052603324264055e-06
in O 0 9.547248737362679e-06
an O 0 0.11860109865665436
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
syndrome I-Disease 1 1.0
that O 0 8.372800948563963e-06
embraces O 0 1.7233855032827705e-05
a O 0 1.2461323422030546e-06
variety O 0 7.711337843829824e-07
of O 0 3.5586268154474965e-07
clinical O 0 1.7254198610316962e-05
features O 0 3.5095993098366307e-06
and O 0 4.0187260310631245e-06
manifests O 0 2.4733330064918846e-05
extreme O 0 2.689363645913545e-05
radiosensitivity O 0 0.00023825552489142865
and O 0 1.1942306628043298e-06
a O 0 1.033325474963931e-06
strong O 0 4.765048288390972e-06
pre O 0 0.0003132769779767841
- O 0 0.0010603697737678885
disposition O 0 0.0001074795363820158
to O 0 1.0030094017565716e-05
malignancy B-Disease 0 0.0007774552796036005
. O 0 2.4635728550492786e-05

Heterozygotes O 0 0.001997832441702485
for O 0 1.5079065633472055e-05
the O 0 5.0996932259295136e-06
ATM O 0 5.8435416576685384e-05
gene O 0 6.7384817157289945e-06
have O 0 5.136056415722123e-07
no O 0 4.202245520446013e-07
clinical O 0 3.7571928714896785e-06
expression O 0 1.0104741932082106e-06
of O 0 2.8465839818636596e-07
A B-Disease 1 0.9909605383872986
- I-Disease 1 0.9999710321426392
T I-Disease 1 0.9999996423721313
but O 0 1.5629397239536047e-05
may O 0 1.7758524336386472e-05
be O 0 1.2371732509564026e-06
cancer B-Disease 0 0.00015012698713690042
prone O 0 5.664817763317842e-06
with O 0 2.6872535840993805e-07
a O 0 2.0342158677522093e-06
moderate O 0 6.665007822448388e-05
increase O 0 3.316066795377992e-06
in O 0 1.737095658427279e-06
in O 0 4.716150215244852e-06
vitro O 0 0.0005484097055159509
radiosensitivity O 0 0.0006037876009941101
. O 0 4.1337287257192656e-05

We O 0 5.946396049694158e-05
performed O 0 4.471905413083732e-05
a O 0 8.256337423517834e-06
blind O 0 7.196566730272025e-05
chromosomal O 0 9.324546408606693e-05
analysis O 0 6.023657988407649e-06
on O 0 6.998710432526423e-06
G2 O 1 0.6427392959594727
- O 0 0.0001657262328080833
phase O 0 1.86729430424748e-05
lymphocytes O 0 2.215865060861688e-05
from O 0 1.1653121418930823e-06
7 O 0 1.7533095615362981e-06
unrelated O 0 1.2046446499880403e-05
A B-Disease 1 0.9558737874031067
- I-Disease 1 0.9999946355819702
T I-Disease 1 0.9999998807907104
patients O 0 0.03386811539530754
, O 0 1.3413746273727156e-06
13 O 0 3.6048563742951956e-06
obligate O 0 2.475666769896634e-05
A B-Disease 1 0.8571881651878357
- I-Disease 1 0.9998911619186401
T I-Disease 1 0.9999983310699463
heterozygotes O 0 0.0002981599245686084
( O 0 1.2104957249903237e-06
parents O 0 6.742234859302698e-07
of O 0 6.308004429911307e-08
the O 0 7.290052508324152e-07
patients O 0 3.373146682861261e-05
) O 0 2.8441121457944973e-07
, O 0 1.3732351078488136e-07
and O 0 2.1917543335803202e-07
14 O 0 5.186617499930435e-07
normal O 0 1.0171606845688075e-06
controls O 0 2.2442941371991765e-06
following O 0 1.1728299114110996e-06
X O 0 2.326355934201274e-05
- O 0 5.728461474063806e-06
irradiation O 0 2.6889658784057247e-06
with O 0 2.1619908352477069e-07
1 O 0 5.170970780454809e-07
Gy O 0 2.889465213229414e-05
in O 0 4.4846035507362103e-07
order O 0 1.5870213587731996e-07
to O 0 1.8610049323797284e-07
evaluate O 0 1.0721965963966795e-06
this O 0 2.758409323178057e-07
cytogenetic O 0 1.448901639378164e-05
method O 0 1.4629980569225154e-06
as O 0 4.046139281399519e-07
a O 0 4.1000228634402447e-07
tool O 0 1.8984172811542521e-06
for O 0 2.494097941507789e-07
detection O 0 3.0216820050554816e-06
of O 0 9.146694424089219e-07
ATM O 0 0.0001569233718328178
carriers O 0 5.4154770623426884e-05
. O 0 1.980811430257745e-05

Both O 0 8.025941497180611e-05
A B-Disease 1 0.8244970440864563
- I-Disease 1 0.9998482465744019
T I-Disease 1 0.9999834299087524
homozygotes O 0 0.000814849860034883
and O 0 5.125373263581423e-06
heterozygotes O 0 0.00010747103078756481
showed O 0 1.6809808585094288e-05
significantly O 0 1.2280394912522752e-05
increased O 0 1.9244844224886037e-06
levels O 0 1.1251750038354658e-06
of O 0 7.114200570867979e-07
radiation O 0 0.0003742571861948818
- O 0 0.008556931279599667
induced O 0 0.0002840263186953962
chromatid O 0 0.0018718837527558208
damage O 0 3.089642996201292e-05
relative O 0 3.558006255843793e-06
to O 0 8.715934427527827e-07
that O 0 3.544959383816604e-07
of O 0 3.3734229987203435e-07
normal O 0 7.941096555441618e-06
controls O 0 6.267707794904709e-05
. O 0 3.034098153875675e-05

These O 0 3.201207800884731e-05
results O 0 2.7638028768706135e-05
show O 0 7.162246220104862e-06
that O 0 7.617966275574872e-07
the O 0 1.4471688700723462e-06
G2 O 0 0.08160969614982605
- O 0 0.0001304777106270194
phase O 0 3.2823245419422165e-05
chromosomal O 0 8.91164381755516e-05
radiosensitivity O 0 8.376614277949557e-05
assay O 0 2.7214457077207044e-05
can O 0 1.3665136577856174e-07
be O 0 3.3686930578369356e-08
used O 0 5.8574997297000664e-08
for O 0 5.041713890818755e-08
the O 0 1.0781852921581958e-07
detection O 0 1.40152496896917e-06
of O 0 4.055348767906253e-07
A B-Disease 1 0.9841868281364441
- I-Disease 1 0.9999868869781494
T I-Disease 1 0.9999967813491821
heterozygotes O 0 0.001573232002556324
. O 0 3.3372565667377785e-05

In O 0 6.635511090280488e-05
combination O 0 3.310762258479372e-05
with O 0 2.681122850844986e-06
molecular O 0 1.440942651242949e-05
genetic O 0 8.970662747742608e-06
analyses O 0 3.6514311432256363e-06
, O 0 3.555404077815183e-07
this O 0 2.0240916853708768e-07
test O 0 1.1032840120606124e-05
may O 0 5.346075226952962e-07
be O 0 1.8315651217903905e-08
of O 0 1.4151025240494164e-08
value O 0 4.249850604765015e-08
in O 0 1.4344053056447592e-07
studies O 0 2.493586634955136e-07
of O 0 1.056966354440192e-07
familial B-Disease 0 7.324461876123678e-06
and I-Disease 0 3.066328872591839e-06
sporadic I-Disease 0 0.002661217702552676
cancers I-Disease 0 0.0028809136711061
aimed O 0 3.0954843168728985e-06
at O 0 7.860460300435079e-07
determination O 0 7.92121909398702e-07
of O 0 9.261163569362907e-08
the O 0 1.8973445037318015e-07
potential O 0 3.4026092521344253e-07
involvement O 0 1.3537749055103632e-06
of O 0 2.61087222952483e-07
ATM O 0 0.00021888993796892464
mutations O 0 1.6869740647962317e-05
in O 0 8.585016985307448e-06
tumor B-Disease 0 0.011745828203856945
risk O 0 4.9830987336463295e-06
or O 0 1.1408030786697054e-06
development O 0 4.288286163500743e-06
. O 0 4.014581463707145e-06
. O 0 1.7939979443326592e-05

Ataxia B-Disease 1 0.9999997615814209
- I-Disease 1 0.9999533891677856
telangiectasia I-Disease 1 0.9999717473983765
: O 0 2.2623020413448103e-05
identification O 0 5.833578143210616e-06
and O 0 8.77489128470188e-07
detection O 0 4.386195996630704e-06
of O 0 4.1846894305308524e-07
founder O 0 4.7011526476126164e-05
- O 0 0.0005137374973855913
effect O 0 4.873239959124476e-06
mutations O 0 2.382599177508382e-06
in O 0 3.114662092684739e-07
the O 0 7.046864425319654e-07
ATM O 0 5.498603786691092e-05
gene O 0 6.933890290383715e-06
in O 0 2.284483116454794e-06
ethnic O 0 3.910335635737283e-06
populations O 0 2.5717978132888675e-05
. O 0 2.5086757887038402e-05

To O 0 1.5808711395948194e-05
facilitate O 0 1.033574608300114e-05
the O 0 1.9193450953025604e-06
evaluation O 0 5.033997240388999e-06
of O 0 3.7008308595432027e-07
ATM O 0 6.144284270703793e-05
heterozygotes O 0 4.453740984899923e-05
for O 0 9.936779861163814e-07
susceptibility O 0 1.8231419744552113e-05
to O 0 1.268542519028415e-06
other O 0 2.5419392386538675e-06
diseases O 0 0.00017336550808977336
, O 0 2.9423776481962705e-07
such O 0 2.8336722834865213e-07
as O 0 0.00024049355124589056
breast B-Disease 1 0.9999840259552002
cancer I-Disease 1 0.5078021287918091
, O 0 4.737923404718458e-07
we O 0 1.882203974901131e-07
have O 0 9.665325251262402e-08
attempted O 0 6.038291644472338e-07
to O 0 2.1049852705345984e-07
define O 0 3.8685152503603604e-07
the O 0 1.4984347274094034e-07
most O 0 2.580255511475116e-07
common O 0 1.0120152182935271e-06
mutations O 0 1.3353527492654393e-06
and O 0 1.3802608123114624e-07
their O 0 4.0768273379399034e-07
frequencies O 0 6.521564500872046e-06
in O 0 6.590705743292347e-05
ataxia B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999961853027344
telangiectasia I-Disease 1 0.9999995231628418
( O 0 9.911273809848353e-05
A B-Disease 1 0.9784501194953918
- I-Disease 1 0.9997171759605408
T I-Disease 1 0.9999622106552124
) O 0 3.221109182049986e-06
homozygotes O 0 3.197510159225203e-05
from O 0 1.0623582511470886e-06
10 O 0 2.2218544017960085e-06
ethnic O 0 3.800422746280674e-06
populations O 0 1.3983600183564704e-05
. O 0 1.5312640243791975e-05

Both O 0 7.704641757300124e-05
genomic O 0 0.00015672809968236834
mutations O 0 4.338828512118198e-05
and O 0 9.969793381969794e-07
their O 0 8.135510256579437e-07
effects O 0 6.904466772539308e-06
on O 0 1.7510302541268175e-06
cDNA O 0 1.694634738669265e-05
were O 0 7.546851520601194e-06
characterized O 0 5.031275941291824e-05
. O 0 2.143253732356243e-05

Protein O 0 0.0008653281256556511
- O 0 0.00028220031526871026
truncation O 0 0.00014846710837446153
testing O 0 1.6104311725939624e-05
of O 0 5.397554900810064e-07
the O 0 5.883363769498828e-07
entire O 0 3.2239333904726664e-06
ATM O 0 4.305422771722078e-05
cDNA O 0 5.387127021094784e-05
detected O 0 3.539822137099691e-05
92 O 0 1.2015490028716158e-05
( O 0 1.7845109141489957e-06
66 O 0 6.286501957220025e-06
% O 0 2.2592507775698323e-06
) O 0 1.3864126913176733e-06
truncating O 0 2.014106030401308e-05
mutations O 0 7.166783689172007e-06
in O 0 1.7937862821781891e-06
140 O 0 1.682262336544227e-05
mutant O 0 0.00020660540030803531
alleles O 0 0.0001032136642606929
screened O 0 0.0002780919603537768
. O 0 6.523804040625691e-05

The O 0 4.951388473273255e-05
haplotyping O 0 0.000363830360583961
of O 0 3.689870936796069e-06
patients O 0 0.0003608975966926664
with O 0 1.2836843552577193e-06
identical O 0 0.00011956595699302852
mutations O 0 1.522165348433191e-05
indicates O 0 1.7964053995456197e-06
that O 0 9.681912871428722e-08
almost O 0 6.042213840373734e-08
all O 0 1.982291308877393e-08
of O 0 2.1340428091320973e-08
these O 0 4.951228760319282e-08
represent O 0 1.4847390161776275e-07
common O 0 6.481267860181106e-07
ancestry O 0 2.589946689113276e-06
and O 0 4.995204108126927e-07
that O 0 2.900685842632811e-07
very O 0 1.1731677886928082e-06
few O 0 1.864642968030239e-06
spontaneously O 0 1.107008574763313e-05
recurring O 0 2.325812602066435e-05
ATM O 0 0.00030315713956952095
mutations O 0 3.763199129025452e-05
exist O 0 6.839801699243253e-06
. O 0 1.3910976122133434e-05

Assays O 0 0.0014883589465171099
requiring O 0 7.202127744676545e-05
minimal O 0 3.865292092086747e-05
amounts O 0 4.5614829105034005e-06
of O 0 9.235037055077555e-07
genomic O 0 1.2587087439897005e-05
DNA O 0 1.2151999726484064e-05
were O 0 1.1062477369705448e-06
designed O 0 3.6951496440451592e-06
to O 0 3.7859931012462766e-07
allow O 0 7.368954584308085e-07
rapid O 0 5.868385869689519e-06
screening O 0 7.081572675815551e-06
for O 0 9.368263818032574e-07
common O 0 5.516773853742052e-06
ethnic O 0 1.2883158888143953e-05
mutations O 0 0.00010059133637696505
. O 0 2.6964415155816823e-05

These O 0 5.126170799485408e-05
rapid O 0 0.0002300052874488756
assays O 0 0.0003340845578350127
detected O 0 7.993860344868153e-05
mutations O 0 1.118243108066963e-05
in O 0 1.2352351177469245e-06
76 O 0 5.410039648268139e-06
% O 0 7.644872539458447e-07
of O 0 1.188905187632372e-07
Costa O 0 1.8859193460230017e-06
Rican O 0 4.8595584303257056e-06
patients O 0 4.778916627401486e-05
( O 0 3.2190257570618996e-07
3 O 0 2.0971245362488844e-07
) O 0 9.128562084015357e-08
, O 0 4.750247839524491e-08
50 O 0 7.272915070188901e-08
% O 0 1.0857942100983564e-07
of O 0 8.936100925893697e-08
Norwegian O 1 0.6152253150939941
patients O 0 0.0005940332775935531
( O 0 3.9055998968251515e-07
1 O 0 1.9367877257536747e-07
) O 0 7.7794872765935e-08
, O 0 3.857124397654843e-08
25 O 0 8.351999269962107e-08
% O 0 7.109236577207412e-08
of O 0 6.444748379408338e-08
Polish O 0 0.09795314073562622
patients O 0 0.014723672531545162
( O 0 7.245803885780333e-07
4 O 0 4.213763418192684e-07
) O 0 1.2113902414512268e-07
, O 0 4.8384901418785375e-08
and O 0 5.6850854690537744e-08
14 O 0 2.1095712554597412e-07
% O 0 1.311345130261543e-07
of O 0 5.401814107131031e-08
Italian O 0 0.001404960872605443
patients O 0 0.004071444738656282
( O 0 5.81642950692185e-07
1 O 0 3.113943307653244e-07
) O 0 1.5336676995048037e-07
, O 0 4.753528770606863e-08
as O 0 6.908142324846267e-08
well O 0 1.2191507892111986e-07
as O 0 2.1200104072249815e-07
in O 0 9.20586046504468e-07
patients O 0 9.440936082683038e-06
of O 0 5.449385298561538e-07
Amish O 0 0.3523333966732025
/ O 0 0.014859936200082302
Mennonite O 0 0.0015572765842080116
and O 0 5.383076768339379e-06
Irish O 0 2.3479329684050754e-05
English O 0 1.8458145859767683e-05
backgrounds O 0 6.44380270387046e-05
. O 0 2.11510960070882e-05

Additional O 0 9.728771692607552e-05
mutations O 0 9.079425217350945e-05
were O 0 3.507177098072134e-06
observed O 0 1.978566615434829e-06
in O 0 3.4455823083590076e-07
Japanese O 0 1.3427659268927528e-06
, O 0 3.0254022931330837e-07
Utah O 0 1.0984713298967108e-06
Mormon O 0 2.519419695090619e-06
, O 0 3.1061696859069343e-07
and O 0 2.7343787678546505e-07
African O 0 3.008162821060978e-06
American O 0 5.849789886269718e-06
patients O 0 0.00014757986355107278
. O 0 1.2252600754436571e-05

These O 0 4.274159800843336e-05
assays O 0 0.0001098124630516395
should O 0 3.2606767490506172e-06
facilitate O 0 4.45341629529139e-06
screening O 0 8.819886716082692e-06
for O 0 1.4929700000720914e-06
A B-Disease 1 0.967117190361023
- I-Disease 1 0.9999681711196899
T I-Disease 1 0.9999978542327881
heterozygotes O 0 0.00034858001163229346
in O 0 2.8520478281279793e-06
the O 0 9.908503670885693e-07
populations O 0 2.5160916266031563e-06
studied O 0 5.509507900569588e-06
. O 0 3.056440391446813e-06
. O 0 1.3934663002146408e-05

The O 0 0.0004982577520422637
von B-Disease 1 0.9123126268386841
Hippel I-Disease 1 0.9583098888397217
- I-Disease 1 0.9834272861480713
Lindau I-Disease 1 0.9988705515861511
tumor I-Disease 0 0.08715121448040009
suppressor O 0 0.00013688499166164547
gene O 0 1.0248538274026942e-05
is O 0 3.662884751065576e-07
required O 0 3.3349607519994606e-07
for O 0 2.7679857339535374e-07
cell O 0 1.1157919288962148e-05
cycle O 0 4.637802248907974e-06
exit O 0 9.81042830972001e-06
upon O 0 3.931027549697319e-06
serum O 0 8.178000280167907e-05
withdrawal O 0 6.588493124581873e-05
. O 0 1.5732312022009864e-05

The O 0 7.39191600587219e-05
inactivation O 0 0.0004168756422586739
of O 0 4.999673365091439e-06
the O 0 1.1464666386018507e-05
von B-Disease 1 0.8385988473892212
Hippel I-Disease 1 0.989944577217102
- I-Disease 1 0.9861879944801331
Lindau I-Disease 1 0.995678722858429
( I-Disease 0 0.0001051657964126207
VHL I-Disease 0 0.07141058146953583
) I-Disease 0 2.6572064598440193e-05
tumor I-Disease 0 0.0007412713021039963
suppressor O 0 0.0003660326765384525
gene O 0 5.7176410336978734e-05
predisposes O 0 0.00019736409012693912
affected O 0 1.4731196642969735e-05
individuals O 0 7.438721922881086e-07
to O 0 5.995308356432361e-07
the O 0 2.5085969355131965e-06
human O 0 0.0002590614021755755
VHL B-Disease 1 0.9999997615814209
cancer I-Disease 1 0.9999998807907104
syndrome I-Disease 1 0.9999980926513672
and O 0 7.72637031332124e-06
is O 0 9.704168633106747e-07
associated O 0 2.8089827992516803e-06
with O 0 2.6043892376037547e-06
sporadic B-Disease 1 0.9712631106376648
renal I-Disease 1 1.0
cell I-Disease 1 0.9999964237213135
carcinomas I-Disease 1 1.0
( O 0 0.0006859645363874733
RCC B-Disease 1 0.9640703797340393
) O 0 6.951382147235563e-06
and O 0 1.0174935596296564e-05
brain B-Disease 0 0.0010372498072683811
hemangioblastomas I-Disease 0 0.0012659825151786208
. O 0 4.479194831219502e-05

VHL O 1 0.6800621151924133
- O 0 0.0028488971292972565
negative O 0 0.0003600198542699218
786 O 0 0.0011336893076077104
- O 0 0.0009122750489041209
0 O 0 6.796920206397772e-05
RCC B-Disease 0 0.1914035528898239
cells O 0 1.5236859326250851e-05
are O 0 5.536130061045696e-07
tumorigenic O 0 7.603182166349143e-05
in O 0 7.235401881189318e-06
nude O 0 0.006890720687806606
mice O 0 0.00013164043775759637
which O 0 3.780206156989152e-07
is O 0 1.6599403807049384e-07
suppressed O 0 1.1705013776008855e-06
by O 0 3.0082091484473494e-07
the O 0 6.943967605366197e-07
reintroduction O 0 3.797160752583295e-05
of O 0 3.400429932298721e-06
VHL B-Disease 0 0.003024744801223278
. O 0 4.417920354171656e-05

Remarkably O 0 0.015974421054124832
, O 0 1.3241246961115394e-05
this O 0 2.009057652685442e-06
occurs O 0 1.1073105952164042e-06
without O 0 3.2870920563254913e-07
affecting O 0 8.742590580368415e-07
the O 0 1.065945198774898e-07
growth O 0 8.813764793558221e-07
rate O 0 3.9404270069098857e-07
and O 0 1.6493223142788338e-07
cell O 0 2.2140154669614276e-06
cycle O 0 1.9112424070044653e-06
profile O 0 9.194437211590412e-07
of O 0 8.500953896373176e-08
these O 0 1.8286860381522274e-07
cells O 0 1.6484714251419064e-06
in O 0 1.0650607009665691e-06
culture O 0 1.5158205314946827e-05
. O 0 2.0336905436124653e-05

The O 0 5.8518613514024764e-05
786 O 0 0.0006193015724420547
- O 0 9.013115050038323e-05
0 O 0 9.331107321486343e-06
cell O 0 9.268164831155445e-06
line O 0 4.6382047003135085e-06
, O 0 3.613629360188497e-07
like O 0 2.9738606599494233e-07
many O 0 8.072445893958502e-07
cancer B-Disease 0 0.002230267971754074
cells O 0 5.063994649390224e-06
, O 0 4.1889578028531105e-07
fails O 0 1.644683834456373e-06
to O 0 1.4253126323637844e-07
exit O 0 1.5426495565407095e-06
the O 0 4.625716201189789e-07
cell O 0 5.676114597008564e-06
cycle O 0 6.833444786025211e-06
upon O 0 3.885025762428995e-06
serum O 0 7.801017636666074e-05
withdrawal O 0 7.230320625239983e-05
. O 0 2.6396381144877523e-05

Here O 0 2.9397029720712453e-05
, O 0 2.356429376959568e-06
it O 0 4.000178819296707e-07
is O 0 1.5158923361013876e-07
shown O 0 2.720312295423355e-07
that O 0 9.22762595223503e-08
reintroduction O 0 2.306450824107742e-06
of O 0 1.3687896682768042e-07
the O 0 5.003829528504866e-07
wild O 0 4.303895821067272e-06
- O 0 0.0002502807474229485
type O 0 4.000413173343986e-05
VHL B-Disease 0 0.00046529044630005956
gene O 0 1.1710746548487805e-05
restores O 0 3.158183244522661e-05
the O 0 1.161010345640534e-06
ability O 0 2.2416393221647013e-06
of O 0 1.1353026820870582e-06
VHL O 0 0.017769884318113327
- O 0 0.010339133441448212
negative O 0 0.00021742498211096972
RCC B-Disease 1 0.9999017715454102
cancer I-Disease 0 0.05467749759554863
cells O 0 1.1295818694634363e-05
to O 0 1.0053719279312645e-06
exit O 0 5.41273357157479e-06
the O 0 9.15466159767675e-07
cell O 0 1.1927741070394404e-05
cycle O 0 8.5722704170621e-06
and O 0 2.411682544334326e-06
enter O 0 1.921242983371485e-05
G0 O 0 0.027785811573266983
/ O 0 0.0003975875733885914
quiescence O 0 0.00024887704057618976
in O 0 9.731909813126549e-06
low O 0 5.4834385082358494e-05
serum O 0 0.00022283130965661258
. O 0 2.733885048655793e-05

Both O 0 0.0003602199722081423
VHL O 0 0.2724984586238861
- O 0 0.0005883437697775662
positive O 0 2.8363128876662813e-05
and O 0 9.229761417373084e-06
VHL O 0 0.004071264527738094
- O 0 0.0005212848773226142
negative O 0 3.47778586728964e-05
RCC B-Disease 0 0.00331612559966743
cells O 0 1.460602470615413e-05
exit O 0 9.127827070187777e-06
the O 0 1.6942655065577128e-06
cell O 0 2.167411003028974e-05
cycle O 0 1.285419421037659e-05
by O 0 3.4480910926504293e-06
contact O 0 1.8194839867646806e-05
inhibition O 0 6.165936792967841e-05
. O 0 2.229086385341361e-05

The O 0 0.000209169476875104
cyclin O 0 0.0016979874344542623
- O 0 0.00036929885391145945
dependent O 0 0.00012019468704238534
kinase O 0 0.00025334421661682427
inhibitor O 0 5.875430360902101e-05
, O 0 2.7884073006134713e-06
p27 O 0 4.1455798054812476e-05
, O 0 6.054800678612082e-07
accumulates O 0 2.4712483082112158e-06
upon O 0 5.384891323956253e-07
serum O 0 4.265200914232992e-06
withdrawal O 0 5.1276024350954685e-06
, O 0 1.3652240227202128e-07
only O 0 4.465790581775764e-08
in O 0 5.680109893546614e-08
the O 0 8.342113488879477e-08
presence O 0 3.3594702131267695e-07
of O 0 1.6155591708866268e-07
VHL B-Disease 0 0.000236635678447783
, O 0 2.2699794044456212e-07
as O 0 6.715450950878221e-08
a O 0 9.572145387437558e-08
result O 0 1.0709013054110983e-07
of O 0 2.993282066654501e-08
the O 0 2.2593792436964577e-07
stabilization O 0 1.7589418348507024e-06
of O 0 1.176017079274061e-07
the O 0 1.1738235343727865e-06
protein O 0 1.0382901564298663e-05
. O 0 1.171222174889408e-05

We O 0 4.0227703721029684e-05
propose O 0 4.902753425994888e-05
that O 0 1.4797237781749573e-06
the O 0 9.891527952277102e-07
loss O 0 3.132555320917163e-06
of O 0 3.131152652713354e-07
wild O 0 3.819217909040162e-06
- O 0 0.0017013952601701021
type O 0 0.00011565148452064022
VHL B-Disease 0 0.011881173588335514
gene O 0 1.7219532310264185e-05
results O 0 7.716289474046789e-06
in O 0 1.0807398211909458e-06
a O 0 8.713059287401848e-07
specific O 0 1.2137347766838502e-06
cellular O 0 5.940315168118104e-05
defect O 0 3.8214566302485764e-05
in O 0 1.931961378431879e-06
serum O 0 3.9751321310177445e-05
- O 0 3.0205010261852294e-05
dependent O 0 3.810795533354394e-06
growth O 0 1.4594361346098594e-06
control O 0 1.1310826266708318e-06
, O 0 3.050218708722241e-07
which O 0 4.124380268422101e-07
may O 0 4.259989509591833e-06
initiate O 0 2.187026257161051e-05
tumor B-Disease 0 0.00032844612724147737
formation O 0 3.0091674489085563e-05
. O 0 2.336764009669423e-05

This O 0 3.167745308019221e-05
is O 0 5.388577847043052e-06
corrected O 0 2.840259185177274e-05
by O 0 4.603004981618142e-07
the O 0 4.3878640099137556e-07
reintroduction O 0 6.9365687522804365e-06
of O 0 2.9016652547397825e-07
wild O 0 3.7331988096411806e-06
- O 0 0.0012395603116601706
type O 0 7.681598799536005e-05
VHL B-Disease 0 0.008552048355340958
, O 0 4.571799763652962e-06
implicating O 0 0.00011400818038964644
VHL B-Disease 0 0.00047461895155720413
as O 0 7.388249514406198e-07
the O 0 4.719155128896091e-07
first O 0 3.5345283322385512e-06
tumor B-Disease 0 5.558664270211011e-05
suppressor O 0 1.2490088010963518e-05
involved O 0 1.2100780395485344e-06
in O 0 5.768138748862839e-07
the O 0 4.4367888563101587e-07
regulation O 0 2.0738505099870963e-06
of O 0 3.92208278299222e-07
cell O 0 1.4403794011741411e-05
cycle O 0 8.525099474354647e-06
exit O 0 5.341180440154858e-06
, O 0 3.0508559234476706e-07
which O 0 1.1680620559673116e-07
is O 0 8.647382543358617e-08
consistent O 0 3.996312614162889e-07
with O 0 9.965898328800904e-08
its O 0 5.591609806288034e-07
gatekeeper O 0 1.3433264939521905e-05
function O 0 4.851306698583358e-07
in O 0 6.76086870043946e-07
the O 0 6.685948392259888e-06
kidney O 0 0.16694597899913788
. O 0 8.265192263934296e-06
. O 0 2.5475148504483514e-05

Piebaldism B-Disease 1 0.9998373985290527
with O 0 0.0026600572746247053
deafness B-Disease 1 0.9999997615814209
: O 0 2.6645499019650742e-05
molecular O 0 2.4017945179366507e-05
evidence O 0 3.502484332784661e-06
for O 0 1.20867662189994e-06
an O 0 6.63410128254327e-06
expanded O 0 0.010306519456207752
syndrome O 1 0.9999294281005859
. O 0 5.368193887989037e-05

In O 0 4.304198955651373e-05
a O 0 1.3951870641903952e-05
South O 0 1.861652526713442e-05
African O 0 1.3811083590553608e-05
girl O 0 2.8250342438695952e-05
of O 0 1.2007824352622265e-06
Xhosa O 0 0.007385578006505966
stock O 0 2.775445500446949e-05
with O 0 6.7548630795499776e-06
severe O 1 0.797018826007843
piebaldism B-Disease 1 0.6856275796890259
and O 0 0.00026955161592923105
profound O 1 0.9967103004455566
congenital O 1 1.0
sensorineural B-Disease 1 1.0
deafness I-Disease 1 1.0
we O 0 4.115921910852194e-05
identified O 0 1.1463256669230759e-05
a O 0 1.1892424254256184e-06
novel O 0 3.4239867545693414e-06
missense O 0 1.480565970268799e-05
substitution O 0 2.796743274302571e-06
at O 0 6.367702667375852e-07
a O 0 5.11313544393488e-07
highly O 0 1.3970824284115224e-06
conserved O 0 6.048821887816302e-07
residue O 0 1.6993889175864751e-06
in O 0 2.5485385890533507e-07
the O 0 3.7192361901361437e-07
intracellular O 0 2.466527348587988e-06
kinase O 0 5.8248001550964545e-06
domain O 0 8.066850796240033e-07
of O 0 1.5403223585508385e-07
the O 0 2.0097954802622553e-06
KIT O 0 0.055713288486003876
proto O 0 0.3377617597579956
- O 0 0.0009348067105747759
oncogene O 0 0.00030256781610660255
, O 0 8.16902411315823e-06
R796G O 0 0.00016521959332749248
. O 0 2.7439120458438993e-05

Though O 0 0.0009215696481987834
auditory B-Disease 0 0.018278656527400017
anomalies I-Disease 0 0.043303489685058594
have O 0 4.5350197979132645e-06
been O 0 2.895837042160565e-06
observed O 0 3.502864956317353e-06
in O 0 3.6552114579535555e-06
mice O 0 0.00022310727217700332
with O 0 9.155447742159595e-07
dominant O 0 0.00012541750038508326
white O 0 7.54310458432883e-05
spotting O 0 0.0002962800790555775
( O 0 1.705931754258927e-05
W O 0 0.44184190034866333
) O 0 8.658553838358785e-07
due O 0 1.123116703638516e-06
to O 0 1.2330882555033895e-06
KIT O 0 0.09299809485673904
mutations O 0 7.662218558834866e-05
, O 0 3.163889778079465e-05
deafness B-Disease 1 0.9999995231628418
is O 0 1.2723737654596334e-06
not O 0 9.93622961686924e-07
typical O 0 3.4109045827790396e-06
in O 0 2.177795522584347e-06
human O 0 5.611425876850262e-06
piebaldism B-Disease 0 0.0007103426032699645
. O 0 2.8671272957581095e-05

Thus O 0 4.9882553867064416e-05
, O 0 6.565953754034126e-06
the O 0 2.3532695649919333e-06
occurrence O 0 1.1556709978322033e-05
of O 0 3.6163605727779213e-06
sensorineural B-Disease 1 0.999993085861206
deafness I-Disease 1 1.0
in O 0 8.373452874366194e-05
this O 0 6.168533218442462e-06
patient O 0 0.00018199866462964565
extends O 0 9.975984539778437e-06
considerably O 0 3.249230940127745e-05
the O 0 6.978103215260489e-07
phenotypic O 0 6.352942364173941e-06
range O 0 9.066836810234236e-07
of O 0 2.2109487929355964e-07
piebaldism B-Disease 0 4.443924262886867e-05
due O 0 4.149925644014729e-06
to O 0 1.27777639136184e-06
KIT O 0 0.002682510996237397
gene O 0 7.015388746367535e-06
mutation O 0 3.1877111723588314e-06
in O 0 7.598621891702351e-07
humans O 0 1.5355483355961042e-06
and O 0 8.416781156483921e-07
tightens O 0 0.00023474963381886482
the O 0 1.9972801510448335e-06
clinical O 0 2.830138873832766e-05
similarity O 0 4.506504410528578e-06
between O 0 1.4847972806819598e-06
piebaldism B-Disease 0 7.682221621507779e-05
and O 0 5.762893238170363e-07
the O 0 5.086628789285896e-07
various O 0 6.730774089191982e-07
forms O 0 2.9138741410861257e-06
of O 0 1.6998288629110903e-05
Waardenburg B-Disease 1 0.9999985694885254
syndrome I-Disease 1 0.99998939037323
. O 0 2.391561611148063e-05
. O 0 2.975945608341135e-05

Cycloheximide O 0 0.0017066108994185925
facilitates O 0 9.559651516610757e-05
the O 0 6.173718702484621e-06
identification O 0 5.004420017939992e-06
of O 0 8.328645435540238e-07
aberrant O 0 3.799069963861257e-05
transcripts O 0 1.3542250599130057e-05
resulting O 0 2.3705347302893642e-06
from O 0 7.522123723902041e-07
a O 0 1.3253247743705288e-06
novel O 0 3.5412665511103114e-06
splice O 0 0.00010840479080798104
- O 0 6.775544898118824e-05
site O 0 4.548081960820127e-06
mutation O 0 5.000121745979413e-06
in O 0 9.996546168622444e-07
COL17A1 O 0 0.00018592608103062958
in O 0 3.102290520473616e-06
a O 0 9.557506928103976e-06
patient O 0 0.0003785833832807839
with O 0 4.5441269321599975e-05
generalized O 0 0.464516818523407
atrophic B-Disease 1 0.999984622001648
benign I-Disease 1 0.9998606443405151
epidermolysis I-Disease 1 0.9992626309394836
bullosa I-Disease 1 0.9919503927230835
. O 0 0.001276707393117249

Patients O 1 0.9721943140029907
with O 0 0.00037098911707289517
generalized O 0 0.37730228900909424
atrophic B-Disease 1 0.9999897480010986
benign I-Disease 1 0.9999585151672363
epidermolysis I-Disease 1 0.9996452331542969
bullosa I-Disease 1 0.9958953857421875
often O 0 0.00010872176062548533
show O 0 2.9014683605055325e-05
decreased O 0 2.3697100914432667e-05
expression O 0 3.833299615507713e-06
of O 0 7.510941486543743e-07
type O 0 6.821713031968102e-05
XVII O 1 0.9859321117401123
collagen O 0 0.0011410611914470792
, O 0 1.3062741572866798e-06
a O 0 2.088879909933894e-06
transmembrane O 0 1.6491208953084424e-05
hemidesmosomal O 0 4.7998899390222505e-05
protein O 0 3.94027210859349e-06
encoded O 0 3.7272434383339714e-06
by O 0 5.9624471759889275e-06
COL17A1 O 0 0.0007702165166847408
. O 0 4.092575181857683e-05

This O 0 4.3750766053562984e-05
report O 0 2.3573873477289453e-05
documents O 0 6.343068889691494e-06
a O 0 2.3204984245239757e-06
novel O 0 7.74918771639932e-06
splice O 0 0.00014216483396012336
- O 0 6.597364699700847e-05
site O 0 6.428502274502534e-06
mutation O 0 3.0831838557787705e-06
in O 0 8.688721209182404e-07
COL17A1 O 0 0.00023738435993436724
in O 0 2.0205000055284472e-06
a O 0 9.45212559599895e-06
patient O 0 0.00028509876574389637
with O 0 1.3584147382061929e-05
generalized O 0 0.1571647673845291
atrophic B-Disease 1 0.99998939037323
benign I-Disease 1 0.9997527003288269
epidermolysis I-Disease 1 0.9961355924606323
bullosa I-Disease 1 0.6943531036376953
, O 0 1.6327379853464663e-05
and O 0 2.174423116230173e-06
applies O 0 3.4918450637633214e-06
a O 0 7.418588552354777e-07
new O 0 1.0095214975081035e-06
methodology O 0 6.067001322662691e-06
to O 0 3.8636449062323663e-07
define O 0 1.1925678791158134e-06
and O 0 9.124138387051062e-07
characterize O 0 1.4823461242485791e-05
the O 0 9.779896572581492e-07
resulting O 0 4.883051587967202e-06
mRNA O 0 1.3751797268923838e-05
splice O 0 0.0002775820321403444
variants O 0 0.00011679431918310001
. O 0 2.4009905246202834e-05

Mutational O 0 0.004962134640663862
analysis O 0 9.277592471335083e-05
of O 0 7.456744697265094e-06
COL17A1 O 0 0.009120705537497997
identified O 0 4.2063773435074836e-05
a O 0 8.905862159735989e-06
maternally O 0 0.0015961105236783624
inherited O 0 0.008374071680009365
G O 0 0.008478859439492226
- O 0 0.00012156228331150487
to O 0 2.632644964251085e-06
- O 0 0.00028132801526226103
T O 0 0.00018894441018346697
transversion O 0 9.928587132890243e-06
at O 0 4.273692297829257e-07
the O 0 1.664070907736459e-07
- O 0 2.4857065454853e-06
1 O 0 3.6773118949895434e-07
position O 0 8.147545145220647e-07
of O 0 4.3519861492313794e-07
exon O 0 2.6295327188563533e-05
32 O 0 1.3268222573969979e-05
. O 0 1.1319619261485059e-05

This O 0 4.4143158447695896e-05
acceptor O 0 0.00022143770183902234
splice O 0 0.00042031609336845577
- O 0 0.00010546798148425296
site O 0 6.298389962466899e-06
mutation O 0 2.807748387567699e-06
led O 0 6.122143076936482e-07
to O 0 1.8547541458246997e-07
the O 0 1.9539915285804454e-07
formation O 0 6.608361218241043e-07
of O 0 1.414729382531732e-07
aberrant O 0 9.938979928847402e-06
transcripts O 0 4.832231752516236e-06
present O 0 7.735836220490455e-07
at O 0 1.4177428511175094e-06
extremely O 0 7.82062215876067e-06
low O 0 8.248357517004479e-06
levels O 0 8.941554369812366e-06
. O 0 8.614476428192575e-06

Based O 0 7.906284008640796e-05
on O 0 9.342664270661771e-06
our O 0 2.667719627424958e-06
recent O 0 4.564455139188794e-06
finding O 0 2.0244578990968876e-06
that O 0 8.994425684250018e-07
cycloheximide O 0 0.0001518511853646487
stabilized O 0 0.0008503436692990363
mutant O 0 7.099380309227854e-05
COL17A1 O 0 0.00014964095316827297
transcripts O 0 2.0167297407169826e-05
in O 0 4.0882064240577165e-06
keratinocytes O 0 0.00010005408694269136
homozygous O 0 2.4325559934368357e-05
for O 0 6.509533250209643e-07
a O 0 3.627956630225526e-06
frameshift O 0 0.0006029198411852121
mutation O 0 5.569424047280336e-06
, O 0 3.984530394518515e-07
the O 0 2.6360714855400147e-07
effects O 0 1.587688871040882e-06
of O 0 1.5572327072277403e-07
the O 0 9.708575134936837e-07
splice O 0 9.323168342234567e-05
- O 0 2.5832596293184906e-05
site O 0 3.358453113833093e-06
mutation O 0 2.1261623714963207e-06
on O 0 3.4003386417680304e-07
splicing O 0 3.807802158917184e-06
of O 0 2.701037828956032e-07
COL17A1 O 0 0.0001497595658292994
transcripts O 0 1.098940811061766e-05
were O 0 9.305266530645895e-07
determined O 0 1.1922471685466007e-06
using O 0 1.0434470141262864e-06
reverse O 0 8.949078619480133e-06
transcriptase O 0 3.791209383052774e-05
polymerase O 0 1.1969241313636303e-05
chain O 0 2.955290028694435e-06
reaction O 0 7.286480467882939e-07
of O 0 5.3925390375297866e-08
total O 0 2.1536811800615396e-07
RNA O 0 1.6401368156948593e-06
from O 0 8.160344577845535e-07
keratinocytes O 0 3.8154958019731566e-05
incubated O 0 1.2518386938609183e-05
for O 0 1.8843246607502806e-06
2 O 0 9.252965355699416e-06
. O 0 1.1054081369366031e-05

5 O 0 0.00013192745973356068
h O 0 0.00011294632713543251
in O 0 2.878932491512387e-06
the O 0 8.658835213282146e-07
presence O 0 1.5423906916112173e-06
or O 0 7.26840085008007e-07
absence O 0 1.1409586022637086e-06
of O 0 2.6288864773960086e-07
10 O 0 1.4924574998076423e-06
microg O 0 0.00016586834681220353
cycloheximide O 0 0.00030896070529706776
per O 0 3.658953937701881e-05
ml O 0 0.0018005857709795237
. O 0 2.8688533348031342e-05

Using O 0 3.865797407343052e-05
this O 0 3.695329496622435e-06
approach O 0 6.44639840174932e-06
, O 0 6.789777557969501e-07
an O 0 6.451377885241527e-07
abnormally O 0 5.475402213050984e-05
spliced O 0 6.29316782578826e-05
transcript O 0 0.00011035874922527
was O 0 8.137589247780852e-06
identified O 0 7.340589718296542e-07
that O 0 6.315564604619794e-08
contains O 0 6.262473561946535e-08
an O 0 7.142536162518809e-08
extra O 0 5.484671987687761e-07
264 O 0 2.2687900127493776e-06
bases O 0 8.514582532370696e-07
upstream O 0 2.08491769626562e-06
from O 0 4.261027584107069e-07
exon O 0 7.747332347207703e-06
32 O 0 1.8897287645813776e-06
, O 0 2.9123884814907797e-07
resulting O 0 9.656605470809154e-07
in O 0 1.333852083007514e-06
a O 0 9.894869435811415e-06
premature O 0 0.0007703148876316845
termination O 0 6.210851279320195e-05
codon O 0 4.1958050132961944e-05
27 O 0 8.603999958722852e-06
bp O 0 5.419434455689043e-05
downstream O 0 9.567283086653333e-06
from O 0 1.3926805877417792e-06
the O 0 2.993498583236942e-06
cryptic O 0 9.851252980297431e-05
splice O 0 0.0003735296777449548
site O 0 4.725244070868939e-05
. O 0 2.605653389764484e-05

Three O 0 2.4249911803053692e-05
other O 0 6.650697741861222e-06
splice O 0 0.00011377164628356695
variants O 0 1.6705978850950487e-05
, O 0 3.986647527653986e-07
including O 0 2.1093035229569068e-07
one O 0 1.7360858350912167e-07
derived O 0 3.2967489005386597e-07
from O 0 1.2100544211079978e-07
the O 0 1.2542668059722928e-07
skipping O 0 2.1302014374668943e-06
of O 0 1.2751563360779983e-07
exon O 0 5.1809897740895394e-06
32 O 0 1.2571496199598187e-06
, O 0 2.5487429411441553e-07
were O 0 7.033175393189595e-07
also O 0 1.402066459377238e-06
identified O 0 7.121849648683565e-06
. O 0 9.319314813183155e-06

These O 0 2.0496934666880406e-05
results O 0 3.9102229493437335e-05
indicate O 0 4.038720362586901e-06
the O 0 5.503560487341019e-07
usefulness O 0 7.745367838651873e-06
of O 0 4.695008612998208e-07
cycloheximide O 0 0.0003980980545748025
treatment O 0 0.0001810534595279023
in O 0 1.2105419955332763e-06
evaluating O 0 2.925030230471748e-06
the O 0 7.18186470294313e-07
abnormal O 0 4.25870575782028e-06
processing O 0 6.35776359558804e-07
of O 0 9.333603401273649e-08
mRNA O 0 1.0474210512256832e-06
due O 0 1.096638470698963e-06
to O 0 4.0247684296446096e-07
splice O 0 4.527607234194875e-05
- O 0 5.03212031617295e-05
site O 0 5.27257952853688e-06
mutations O 0 4.203162006888306e-06
, O 0 3.6857522900390904e-07
because O 0 5.016974569116428e-07
( O 0 6.418698603738449e-07
i O 0 1.5738768297524075e-06
) O 0 4.188714228803292e-07
aberrant O 0 4.164328402112005e-06
splicing O 0 6.619502528337762e-06
often O 0 4.3971550667265547e-07
generates O 0 1.4968863979447633e-06
a O 0 1.6022547697502887e-06
premature O 0 5.849674198543653e-05
termination O 0 1.5048810382722877e-05
codon O 0 1.2992436495551374e-05
, O 0 8.875643402461719e-07
( O 0 7.292917416634737e-07
ii O 0 4.940564394928515e-06
) O 0 7.393302894342924e-07
transcripts O 0 4.301695753383683e-06
with O 0 8.364049790543504e-07
premature O 0 0.000419928808696568
termination O 0 3.2216106774285436e-05
codons O 0 8.479094503854867e-06
can O 0 4.5202511955722e-07
occur O 0 5.521113735085237e-07
at O 0 3.446170637744217e-07
low O 0 1.2724731277558021e-06
or O 0 1.0100829967996106e-06
undetectable O 0 1.5299881852115504e-05
levels O 0 1.1455149433459155e-06
due O 0 1.1253263210164732e-06
to O 0 5.525834012587438e-07
nonsense O 0 7.098841706465464e-06
- O 0 8.273425919469446e-06
mediated O 0 4.699488727055723e-06
mRNA O 0 9.382426355841744e-07
decay O 0 5.95118308410747e-07
, O 0 1.1175890790582343e-07
and O 0 1.6830652782573452e-07
( O 0 2.5956092031265143e-07
iii O 0 1.8368482415098697e-06
) O 0 7.683004099590107e-08
the O 0 5.223698096301632e-08
levels O 0 5.798164437464948e-08
of O 0 2.137000087998331e-08
these O 0 3.543603099842585e-08
transcripts O 0 9.595283927410492e-07
can O 0 8.504894566385701e-08
be O 0 8.115318905765889e-08
increased O 0 4.4536270138451073e-07
by O 0 1.2558782600535778e-06
cycloheximide O 0 0.00022827129578217864
. O 0 1.629013058845885e-05

A O 0 0.00039738317718729377
deletion O 0 0.0018985909409821033
mutation O 0 0.0001244608429260552
in O 0 7.810925126250368e-06
COL17A1 O 0 0.0009388841572217643
in O 0 5.0110920710721985e-06
five O 0 3.5482642033457523e-06
Austrian O 0 0.000671739864628762
families O 0 1.655916275922209e-05
with O 0 1.5134443856368307e-05
generalized O 0 0.14174282550811768
atrophic B-Disease 1 0.9999929666519165
benign I-Disease 1 0.9996514320373535
epidermolysis I-Disease 1 0.9972715973854065
bullosa I-Disease 0 0.32745838165283203
represents O 0 5.476562000694685e-05
propagation O 0 3.6248522519599646e-05
of O 0 1.591698833180999e-06
an O 0 3.855480827041902e-06
ancestral O 0 9.439139103051275e-05
allele O 0 0.000351390044670552
. O 0 5.1232676923973486e-05

Patients O 1 0.9904776811599731
with O 0 0.0007465125527232885
generalized O 1 0.6390284299850464
atrophic B-Disease 1 0.9999899864196777
benign I-Disease 1 0.9999507665634155
epidermolysis I-Disease 1 0.9996198415756226
bullosa I-Disease 1 0.9978061318397522
, O 0 8.020234236028045e-05
a O 0 1.8230062778457068e-05
usually O 0 8.721523954591248e-06
nonlethal O 0 8.033429912757128e-05
form O 0 9.501831300440244e-06
of O 0 6.451447916333564e-06
junctional B-Disease 0 0.2262270450592041
epidermolysis I-Disease 1 0.9981932044029236
bullosa I-Disease 1 0.9889061450958252
, O 0 2.0785884771612473e-05
have O 0 6.242109520826489e-06
generalized O 0 4.2120776925003156e-05
blistering B-Disease 0 0.00440220395103097
, O 0 8.707250526640564e-05
nail B-Disease 1 0.9999806880950928
dystrophy I-Disease 1 0.999967098236084
, O 0 8.545130549464375e-05
patchy B-Disease 1 0.9996384382247925
alopecia I-Disease 1 0.9999972581863403
, O 0 5.290760600473732e-05
and O 0 0.00022569224529433995
dental B-Disease 1 0.999983549118042
abnormalities I-Disease 1 0.9999266862869263
. O 0 8.6333675426431e-05

Skin B-Disease 1 0.9999923706054688
fragility I-Disease 1 0.9243142008781433
in O 0 2.5708683097036555e-05
most O 0 3.2566210848017363e-06
cases O 0 1.4842395330560976e-06
is O 0 2.61173397575476e-07
due O 0 1.1520114640006796e-06
to O 0 5.170290364731045e-07
mutations O 0 1.8458338217897108e-06
in O 0 3.870367777381034e-07
the O 0 6.91973298216908e-07
gene O 0 5.9243693613098e-06
encoding O 0 1.4605941032641567e-05
type O 0 9.095491986954585e-05
XVII O 1 0.9755268692970276
collagen O 0 0.01835952140390873
( O 0 2.2947127945371903e-05
COL17A1 O 0 0.0009616067982278764
) O 0 1.1569546586542856e-05
. O 0 1.0861948794627097e-05

Recently O 0 0.0003200397186446935
, O 0 9.226179827237502e-06
we O 0 2.3743698420730652e-06
reported O 0 2.682012564036995e-06
five O 0 1.2460396874303115e-06
Austrian O 0 0.00017272548575419933
families O 0 7.1185900196724106e-06
with O 0 1.1631432244030293e-05
generalized O 0 0.07364001870155334
atrophic B-Disease 1 0.9999932050704956
benign I-Disease 1 0.9998912811279297
epidermolysis I-Disease 1 0.9996329545974731
bullosa I-Disease 1 0.9936211705207825
who O 0 4.092996823601425e-05
share O 0 7.488735718652606e-06
the O 0 3.4185834465461085e-06
same O 0 1.1940441254409961e-05
COL17A1 O 0 0.02578909322619438
mutation O 0 0.0001754681288730353
. O 0 5.725618393626064e-05

Affected O 0 0.0004299459687899798
individuals O 0 7.775794074404985e-06
in O 0 1.4822959428784088e-06
three O 0 5.409040682025079e-07
families O 0 6.868660307191021e-07
are O 0 1.0951976037176792e-07
homozygous O 0 2.827665184668149e-06
for O 0 2.1362627933285694e-07
4003delTC O 0 2.0595905880327336e-05
, O 0 1.6564361260407168e-07
whereas O 0 5.13481211328326e-07
those O 0 8.248873228922093e-08
in O 0 2.954919295916625e-07
two O 0 2.976323401071568e-07
others O 0 8.659825994072889e-07
are O 0 5.085624934508814e-07
compound O 0 4.224906660965644e-05
heterozygotes O 0 0.00023055619385559112
. O 0 2.6054049158119597e-05

To O 0 2.539156594139058e-05
determine O 0 6.8603071667894255e-06
if O 0 6.38650135442731e-07
the O 0 2.5393634928150277e-07
occurrence O 0 1.0041223958978662e-06
of O 0 1.3966865708425757e-07
4003delTC O 0 2.4116247004712932e-05
in O 0 4.98198346576828e-07
these O 0 2.4821480337777757e-07
unrelated O 0 3.3967712624871638e-06
families O 0 9.036003234541568e-07
signifies O 0 1.5834518762858352e-06
propagation O 0 8.407715768044e-07
of O 0 1.0321509336108647e-07
an O 0 3.2548405215493403e-07
ancestral O 0 6.932911219337257e-06
allele O 0 1.5219316992443055e-05
or O 0 1.1779077340179356e-06
a O 0 2.5523677322780713e-06
mutational O 0 0.00013707700418308377
hot O 0 1.668671211518813e-05
spot O 0 7.265091880981345e-06
, O 0 1.0653146773620392e-06
haplotypes O 0 9.918687283061445e-06
were O 0 8.157403499353677e-07
determined O 0 9.379125458508497e-07
for O 0 2.9579786087197135e-07
polymorphisms O 0 5.686430085916072e-06
both O 0 3.867106386223895e-07
within O 0 9.650768788560526e-07
and O 0 2.132634335794137e-06
flanking O 0 0.00019429170060902834
COL17A1 O 0 0.0180511511862278
. O 0 4.722009543911554e-05

Five O 0 0.00022079760674387217
intragenic O 0 0.00197971286252141
polymorphisms O 0 0.00014138776168692857
were O 0 5.53903146283119e-06
chosen O 0 2.7221290110901464e-06
based O 0 1.546352564218978e-06
on O 0 1.1646044413282652e-06
their O 0 2.9505702059395844e-06
informativeness O 0 0.0003723040863405913
. O 0 2.8507336537586525e-05

One O 0 1.0396335710538551e-05
of O 0 5.965342779745697e-07
these O 0 3.0888264745954075e-07
, O 0 2.585253184861358e-07
not O 0 1.791912467297152e-07
previously O 0 1.0745120562205557e-06
reported O 0 2.3786396923242137e-06
, O 0 1.4863115893604117e-07
was O 0 1.0500464213691885e-06
2988 O 0 3.3034034458978567e-06
A O 0 8.533995696780039e-07
or O 0 4.980933567821921e-07
C O 0 4.797266683453927e-06
that O 0 1.568295715514978e-07
introduces O 0 1.2085879461665172e-06
a O 0 4.800946840077813e-07
new O 0 9.630175554775633e-07
restriction O 0 2.905466317315586e-06
site O 0 1.8607934180181473e-06
for O 0 8.561098638892872e-07
Eco0109 O 0 9.957134170690551e-05
I O 0 4.0734528738539666e-05
. O 0 1.4895803360559512e-05

All O 0 1.162247372121783e-05
the O 0 8.163153324858285e-06
4003delTC O 0 7.152158650569618e-05
alleles O 0 1.9004908608621918e-05
showed O 0 6.062432476028334e-06
the O 0 9.846887678577332e-07
same O 0 2.7878913897438906e-06
haplotype O 0 6.894619582453743e-05
for O 0 1.130199621002248e-06
these O 0 1.3749375966654043e-06
five O 0 5.617422175419051e-06
polymorphic O 0 0.0002548792981542647
markers O 0 0.00010731313523137942
. O 0 4.738672578241676e-05

Fourteen O 0 0.0006605855887755752
microsatellite O 0 0.0014652364188805223
polymorphisms O 0 0.00020326973753981292
were O 0 5.52217989024939e-06
selected O 0 1.5780459534653346e-06
based O 0 9.748544016474625e-07
on O 0 5.307458081915684e-07
their O 0 4.3571688479460136e-07
high O 0 1.8399251757728052e-06
heterozygosity O 0 1.6533047528355382e-05
and O 0 4.7349604415103386e-07
their O 0 2.232417983805135e-07
location O 0 1.7261635321119684e-06
within O 0 1.2637102599910577e-06
10q23 O 0 8.367458212887868e-05
- O 0 7.955632463563234e-05
q25 O 0 9.505049092695117e-05
near O 0 2.2918369722901843e-05
COL17A1 O 0 0.001023625023663044
. O 0 2.672041409823578e-05

Three O 0 4.026293026981875e-05
families O 0 2.3929416784085333e-05
shared O 0 1.3679136827704497e-05
microsatellite O 0 0.00016322375449817628
polymorphisms O 0 5.281223639030941e-05
covering O 0 5.739622338296613e-06
at O 0 2.150498858100036e-06
most O 0 1.050472178576456e-06
19 O 0 3.838439624814782e-06
cM O 0 8.603047717770096e-06
, O 0 1.900857995451588e-07
whereas O 0 4.999398015570478e-07
the O 0 1.6512487377440266e-07
others O 0 2.9426050218717137e-07
shared O 0 3.1987730153559824e-07
smaller O 0 7.101457413227763e-07
regions O 0 4.828703481507546e-07
consistent O 0 1.3739308997173794e-06
with O 0 1.8043019167635066e-07
cross O 0 6.368255753841368e-07
- O 0 5.349341790861217e-06
over O 0 3.0594100053349393e-07
events O 0 2.3136207971674594e-07
during O 0 4.934216804031166e-07
passage O 0 2.892715826874337e-07
of O 0 5.579944684086513e-08
this O 0 1.8279362734574534e-07
mutation O 0 1.3044765410086256e-06
through O 0 2.4173718315978476e-07
several O 0 1.0248431863146834e-06
generations O 0 9.107228834182024e-06
. O 0 1.2565848010126501e-05

These O 0 3.345005097799003e-05
results O 0 5.916993541177362e-05
indicate O 0 8.909820280678105e-06
that O 0 1.4156797760733753e-06
4003delTC O 0 2.6513744160183705e-05
occurs O 0 8.697243742972205e-07
on O 0 4.0658005673321895e-07
a O 0 7.914506454653747e-07
single O 0 3.349081680426025e-06
ancestral O 0 2.0407098418218084e-05
allele O 0 4.7923433157848194e-05
. O 0 3.1111608223000076e-06
. O 0 1.0493184163351543e-05

The O 0 0.00024044790188781917
haptoglobin O 0 0.00463009113445878
- O 0 0.001835472066886723
gene O 0 0.00012032174709020182
deletion O 0 0.00011310239642625675
responsible O 0 2.0692095858976245e-05
for O 0 8.879252163751516e-06
anhaptoglobinemia B-Disease 0 0.0015935881529003382
. O 0 8.756776514928788e-05

We O 0 3.786150773521513e-05
have O 0 3.655640512079117e-06
found O 0 1.7251645658689085e-06
an O 0 6.934531029401114e-07
allelic O 0 1.3542225133278407e-05
deletion O 0 1.0520448995521292e-05
of O 0 4.343825992236816e-07
the O 0 2.8928420761076268e-06
haptoglobin O 0 0.00022629881277680397
( O 0 5.380670245358488e-06
Hp O 0 5.177797356736846e-05
) O 0 6.33593117527198e-07
gene O 0 9.699339216240332e-07
from O 0 1.9319489297231485e-07
an O 0 2.3784734537457553e-07
individual O 0 8.356643093065941e-07
with O 0 2.756491994659882e-06
anhaptoglobinemia B-Disease 0 0.001452597207389772
. O 0 6.339830724755302e-05

The O 0 7.78135727159679e-05
Hp O 0 0.0006544857169501483
gene O 0 1.6199010133277625e-05
cluster O 0 3.0238843464758247e-06
consists O 0 5.150216679794539e-07
of O 0 2.643699872351135e-07
coding O 0 5.698280801880173e-06
regions O 0 5.361669082049048e-07
of O 0 1.0458704480242886e-07
the O 0 3.640756176537252e-07
alpha O 0 1.4751094568055123e-06
chain O 0 1.2533548670035088e-06
and O 0 2.5762599875633896e-07
beta O 0 7.162254860304529e-07
chain O 0 5.934893465564528e-07
of O 0 4.884537219140839e-08
the O 0 3.2312854614247044e-07
haptoglobin O 0 2.9490816814359277e-05
gene O 0 3.3880005503306165e-06
( O 0 7.75399087160622e-07
Hp O 0 6.829516678408254e-06
) O 0 5.8131575997322216e-08
and O 0 3.9601026458058186e-08
of O 0 1.7671668572916133e-08
the O 0 9.450364757412899e-08
alpha O 0 7.138312980714545e-07
chain O 0 5.321496701071737e-07
and O 0 1.0982893883237921e-07
beta O 0 4.2793857346623554e-07
chain O 0 3.4822565453396237e-07
of O 0 5.764686150655507e-08
the O 0 5.489051773110987e-07
haptoglobin O 0 6.836859392933547e-05
- O 0 0.00010556164488662034
related O 0 4.672501290770015e-06
gene O 0 5.501207397173857e-06
( O 0 1.5323884099416318e-06
Hpr O 0 4.829246972803958e-05
) O 0 5.519334536074894e-07
, O 0 1.444685153728642e-07
in O 0 2.2719979142493685e-07
tandem O 0 4.137777523283148e-06
from O 0 5.377050342758594e-07
the O 0 7.503989536417066e-07
5 O 0 2.2000103854225017e-06
side O 0 5.7898259910871275e-06
. O 0 1.0877362910832744e-05

Southern O 0 0.00031678250525146723
blot O 0 0.0011290105758234859
and O 0 8.218629773182329e-06
PCR O 0 0.00010174162162002176
analyses O 0 8.795419489615597e-06
have O 0 7.167427611420862e-07
indicated O 0 1.555766175442841e-06
that O 0 6.875765024005887e-08
the O 0 5.959804738608909e-08
individual O 0 9.106042142548176e-08
with O 0 2.1698132002256898e-07
anhaptoglobinemia B-Disease 0 0.0002067884779535234
was O 0 9.764196875039488e-06
homozygous O 0 4.312934834160842e-06
for O 0 1.5634513772511127e-07
the O 0 2.7215241971134674e-07
gene O 0 1.9975432223873213e-06
deletion O 0 2.916067387559451e-06
and O 0 1.4771943313007796e-07
that O 0 9.796487887570038e-08
the O 0 2.4911619789236283e-07
gene O 0 1.283100459659181e-06
deletion O 0 2.5221120267815422e-06
was O 0 4.956099814990012e-07
included O 0 1.930188346932482e-07
at O 0 1.9133091200274066e-07
least O 0 9.173891868385908e-08
from O 0 8.857584532506735e-08
the O 0 1.606456265790257e-07
promoter O 0 3.1970425879990216e-06
region O 0 6.504816951746761e-07
of O 0 1.873791575235373e-07
Hp O 0 3.471980744507164e-05
to O 0 6.756098969162849e-07
Hpr O 0 3.431653021834791e-05
alpha O 0 2.576262204456725e-06
but O 0 3.312004253075429e-07
not O 0 1.5320595991852315e-07
to O 0 5.93555000705237e-07
Hpr O 0 9.318786032963544e-05
beta O 0 1.3662332094099838e-05
( O 0 5.029515250498662e-06
Hpdel O 0 6.762719567632303e-05
) O 0 5.501821306097554e-06
. O 0 9.270595910493284e-06

In O 0 3.3313423045910895e-05
addition O 0 5.359922397474293e-06
, O 0 7.541337936345371e-07
we O 0 2.3366975199223816e-07
found O 0 2.0463716055019177e-07
seven O 0 1.697411420309436e-07
individuals O 0 7.570817928126417e-08
with O 0 9.673495782180908e-08
hypohaptoglobinemia B-Disease 0 4.637460733647458e-05
in O 0 3.411856823731796e-07
three O 0 1.396091278138556e-07
families O 0 2.661402334069862e-07
, O 0 7.91771626040827e-08
and O 0 8.983078458868476e-08
the O 0 1.1690572421230172e-07
genotypes O 0 1.1446696817074553e-06
of O 0 1.9975262333105093e-08
six O 0 9.016499546987689e-08
of O 0 3.414212912389303e-08
the O 0 1.5360213012627355e-07
seven O 0 3.0251945304371475e-07
individuals O 0 1.3502788931418763e-07
were O 0 3.500176148918399e-07
found O 0 6.149786599962681e-07
to O 0 4.3773772517852194e-07
be O 0 1.640132040847675e-06
Hp2 O 0 0.0011741712223738432
/ O 0 0.001917750108987093
Hpdel O 0 0.0007421098998747766
. O 0 3.012543857039418e-05

The O 0 9.196012251777574e-05
phenotypes O 0 0.00029124505817890167
and O 0 6.16478700976586e-06
genotypes O 0 3.7758749385830015e-05
in O 0 5.144733563611226e-07
one O 0 1.2126062642892066e-07
of O 0 2.4883666682740113e-08
these O 0 4.033736544784006e-08
three O 0 6.867232826834879e-08
families O 0 3.7912033690190583e-07
showed O 0 3.4909726309706457e-06
the O 0 2.7714986572391354e-07
father O 0 3.339322574902326e-06
to O 0 4.0139818224815826e-07
be O 0 6.383395998454944e-07
hypohaptoglobinemic B-Disease 0 2.8118372938479297e-05
( O 0 1.2717791832983494e-06
Hp2 O 0 1.6670550394337624e-05
) O 0 5.989250553284364e-07
and O 0 5.816945076730917e-07
Hp2 O 0 0.00013188167940825224
/ O 0 7.658799586351961e-05
Hpdel O 0 2.3636366677237675e-05
, O 0 1.6926797741234623e-07
the O 0 1.8060406148379116e-07
mother O 0 1.280058427255426e-06
to O 0 2.249081774152728e-07
be O 0 1.873470125701715e-07
Hp2 O 0 1.0850778380699921e-05
- O 0 4.075527613167651e-06
1 O 0 4.4239780550014984e-07
and O 0 4.250272809258604e-07
Hp1 O 0 0.00014120088599156588
/ O 0 0.0001371742837363854
Hp2 O 0 3.099481909885071e-05
, O 0 1.5927831498174783e-07
one O 0 4.3610846489627875e-08
of O 0 1.478377420482957e-08
the O 0 6.65122925624928e-08
two O 0 1.1666037380564376e-07
children O 0 6.222212505235802e-07
to O 0 1.419211770326001e-07
be O 0 4.0470848716722685e-07
hypohaptoglobinemic B-Disease 0 2.128533014911227e-05
( O 0 7.065814884299471e-07
Hp2 O 0 1.0025867595686577e-05
) O 0 3.737636973255576e-07
and O 0 2.696513092814712e-07
Hp2 O 0 8.88347567524761e-05
/ O 0 9.222796506946906e-05
Hpdel O 0 3.1986506655812263e-05
, O 0 1.501759356870025e-07
and O 0 4.880979886934256e-08
the O 0 4.7716238071870976e-08
other O 0 8.388015970695051e-08
child O 0 1.2353269767118036e-06
to O 0 1.987421569538128e-07
be O 0 3.705839048961934e-07
Hp1 O 0 1.1593370800255798e-05
and O 0 1.6448751694042585e-06
Hp1 O 0 0.0005571504589170218
/ O 0 0.0004157689108978957
Hpdel O 0 0.00010661759733920917
, O 0 7.891014774941141e-07
showing O 0 1.7731550769894966e-06
an O 0 6.161803867144044e-07
anomalous O 0 1.7808792108553462e-05
inheritance O 0 9.066578058991581e-06
of O 0 1.2142835430495325e-06
Hp O 0 0.007229258771985769
phenotypes O 0 3.20446997648105e-05
in O 0 1.4041631857253378e-06
the O 0 1.9763281216000905e-06
child O 0 2.6800085834111087e-05
with O 0 8.383907697862014e-06
Hp1 O 0 0.00390717014670372
. O 0 7.072278094710782e-05

The O 0 0.00014140704297460616
Hp2 O 0 0.009823239408433437
/ O 0 0.014884681440889835
Hpdel O 0 0.0009008122142404318
individuals O 0 1.963941258509294e-06
had O 0 1.984521304621012e-06
an O 0 2.0932102984261292e-07
extremely O 0 1.4073941656533862e-06
low O 0 1.0956234746117843e-06
level O 0 4.329342857545271e-07
of O 0 1.777786593493147e-07
Hp O 0 8.805125253275037e-05
( O 0 1.6033889096433995e-06
mean O 0 2.97643555313698e-06
+ O 0 2.6106081350008026e-05
/ O 0 3.80875171686057e-05
- O 0 2.50362791121006e-05
SD O 0 9.843430598266423e-05
= O 0 1.0816703252203297e-05
0 O 0 3.5723953715205425e-06
. O 0 1.2474473578549805e-06
049 O 0 0.0001873241999419406
+ O 0 5.4517593525815755e-05
/ O 0 3.5328310332261026e-05
- O 0 1.1425678167142905e-05
0 O 0 2.7184657938050805e-06
. O 0 9.458557315156213e-07
043 O 0 9.623603546060622e-05
mg O 0 0.3561995327472687
/ O 0 0.0006331522017717361
ml O 0 0.00019762414740398526
; O 0 1.1500466143843369e-06
n O 0 1.6916823142310022e-06
= O 0 1.3702867818210507e-06
6 O 0 3.060577284941246e-07
) O 0 9.490319996530161e-08
, O 0 4.3512720537819405e-08
compared O 0 2.1148326823094976e-07
with O 0 3.2124866322646994e-08
the O 0 1.036694783351777e-07
level O 0 1.9736167189421394e-07
( O 0 1.3550325661526585e-07
1 O 0 1.5463450608876883e-07
. O 0 1.418476927028678e-07
64 O 0 1.6884620208656997e-06
+ O 0 1.5471769074792974e-05
/ O 0 2.3057335056364536e-05
- O 0 6.185682195791742e-06
1 O 0 5.638228799398348e-07
. O 0 8.201679975172738e-07
07 O 0 6.55820476822555e-05
mg O 0 0.022889435291290283
/ O 0 0.00012308327131904662
ml O 0 8.190877997549251e-05
) O 0 2.7850376227434026e-07
obtained O 0 3.072178174079454e-07
from O 0 2.546084942878224e-07
52 O 0 3.5054115414823173e-06
healthy O 0 5.058057922724402e-06
volunteers O 0 4.752277618536027e-06
having O 0 1.0145865417143796e-05
phenotype O 0 0.0008094951044768095
Hp2 O 0 9.054911788553e-05
, O 0 8.129561592795653e-07
whereas O 0 1.5067673757584998e-06
the O 0 4.5499811562876857e-07
serum O 0 1.1965702469751704e-05
Hp O 0 1.0788280633278191e-05
level O 0 1.6946196979006345e-07
of O 0 1.863270426838426e-08
an O 0 6.167734767359434e-08
individual O 0 2.2546203126694309e-07
with O 0 8.940709221860743e-07
Hp1 O 0 0.025085845962166786
/ O 0 0.006442569196224213
Hpdel O 0 0.00039409560849890113
was O 0 1.734253964968957e-05
0 O 0 1.996765422518365e-05
. O 0 1.9009585230378434e-05

50 O 0 0.0009333791094832122
mg O 1 0.99607253074646
/ O 0 0.11734900623559952
ml O 0 0.00377308065071702
, O 0 1.1971224012086168e-06
which O 0 2.963396923405526e-07
was O 0 4.860744979851006e-07
approximately O 0 1.7519379014174774e-07
half O 0 1.4068746168049984e-07
the O 0 8.81012027775796e-08
level O 0 1.2842019714298658e-07
of O 0 9.873850359554126e-08
Hp O 0 2.1775069399154745e-05
in O 0 3.160457140438666e-07
control O 0 1.8386026567895897e-06
sera O 0 2.1693715098081157e-05
from O 0 4.398912665237731e-07
the O 0 7.582638659187069e-07
Hp1 O 0 0.0009060109150595963
phenotype O 0 0.00017475349886808544
( O 0 5.754303629146307e-07
1 O 0 2.933529401616397e-07
. O 0 1.9792902605786367e-07
26 O 0 1.1403766393414116e-06
+ O 0 8.306456038553733e-06
/ O 0 1.013573091768194e-05
- O 0 4.616497335518943e-06
0 O 0 1.066835579877079e-06
. O 0 3.700114348248462e-07
33 O 0 4.394787538331002e-06
mg O 0 0.02871081419289112
/ O 0 0.0003962311602663249
ml O 0 0.0002923651481978595
; O 0 1.0329067663406022e-06
n O 0 2.6082145723194117e-06
= O 0 2.065830358333187e-06
9 O 0 5.514010013030202e-07
) O 0 2.0502862696503144e-07
, O 0 1.2365865131869214e-07
showing O 0 8.94727747891011e-07
a O 0 1.531866814730165e-06
gene O 0 1.4438918697123881e-05
- O 0 0.00022095852182246745
dosage O 0 0.0003192614240106195
effect O 0 3.566107989172451e-05
. O 0 2.3095448341337033e-05

The O 0 2.4773387849563733e-05
other O 0 7.1510130510432646e-06
allele O 0 6.282392860157415e-05
( O 0 3.4148754366469802e-06
Hp2 O 0 1.9980474462499842e-05
) O 0 3.0987754939815204e-07
of O 0 5.103606071088507e-08
individuals O 0 1.5388394558613072e-07
with O 0 3.171205378293962e-07
Hp2 O 0 0.04045974463224411
/ O 0 0.07913573086261749
Hpdel O 0 0.00067534064874053
was O 0 5.987153599562589e-06
found O 0 3.710818532454141e-07
to O 0 8.112517946301523e-08
have O 0 8.545985963337444e-08
, O 0 3.73677053744359e-08
in O 0 6.660052065399213e-08
all O 0 4.639447226395532e-08
exons O 0 1.1127909829156124e-06
, O 0 1.660258703850559e-07
no O 0 4.1034414266505337e-07
mutation O 0 1.3103691571814124e-06
, O 0 2.9860945005566464e-07
by O 0 8.844439207678079e-07
DNA O 0 1.2642439287446905e-05
sequencing O 0 2.8512718927231617e-05
. O 0 1.635772605368402e-05

On O 0 1.2206079190946184e-05
the O 0 8.612599913249142e-07
basis O 0 3.260171297370107e-07
of O 0 7.719845029896533e-08
the O 0 1.8298165116448217e-07
present O 0 3.4843131402340077e-07
study O 0 3.296142381259415e-07
, O 0 6.221446824383747e-08
the O 0 6.488138382110265e-08
mechanism O 0 3.1275234846361855e-07
of O 0 9.107137088903983e-08
anhaptoglobinemia B-Disease 0 2.0690753444796428e-05
and O 0 2.3945989369167364e-07
the O 0 2.670753929123748e-07
mechanism O 0 5.948720058768231e-07
of O 0 1.3845323110217578e-07
anomalous O 0 1.244764916918939e-05
inheritance O 0 5.206904916121857e-06
of O 0 1.1076358532591257e-06
Hp O 0 0.013502906076610088
phenotypes O 0 4.869493204751052e-05
were O 0 2.4885719085432356e-06
well O 0 4.306588834879221e-06
explained O 0 2.2714768419973552e-05
. O 0 1.301747852266999e-05

However O 0 8.241413161158562e-05
, O 0 3.905058747477597e-06
the O 0 1.4100045291343122e-06
mechanism O 0 5.072603016742505e-06
of O 0 1.8533937691245228e-06
hypohaptoglobinemia B-Disease 0 0.0008408124558627605
remains O 0 6.95778799126856e-05
unknown O 0 0.00012888577475678176

ATM O 0 0.004404750652611256
mutations O 0 0.0005892186309210956
and O 0 2.2311047359835356e-05
phenotypes O 0 0.0006285131676122546
in O 0 0.0004193877102807164
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999966621398926
telangiectasia I-Disease 1 0.9999984502792358
families O 0 3.375238520675339e-05
in O 0 1.9629319467640016e-06
the O 0 1.2066439012414776e-06
British O 0 9.444910392630845e-05
Isles O 0 3.324170029372908e-05
: O 0 3.0444439858001715e-07
expression O 0 4.868646215072658e-07
of O 0 1.2242819025232166e-07
mutant O 0 5.047861122875474e-06
ATM O 0 8.00832003733376e-06
and O 0 5.268535687719123e-07
the O 0 6.563804504366999e-07
risk O 0 2.130823077095556e-06
of O 0 2.6048337531392463e-06
leukemia B-Disease 1 0.9999974966049194
, O 0 0.3027361333370209
lymphoma B-Disease 1 1.0
, O 0 0.00021791334438603371
and O 0 0.04957886040210724
breast B-Disease 1 0.9999854564666748
cancer I-Disease 1 0.9444780945777893
. O 0 0.00015007318870630115

We O 0 6.29708738415502e-05
report O 0 1.306112426391337e-05
the O 0 1.0666331036190968e-06
spectrum O 0 6.266826403589221e-06
of O 0 7.484956086045713e-07
59 O 0 1.916532710311003e-05
ATM O 0 0.0003007986815646291
mutations O 0 2.472436972311698e-05
observed O 0 1.0214757821813691e-05
in O 0 5.884216807316989e-05
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999986886978149
telangiectasia I-Disease 1 0.9999997615814209
( O 0 0.00012189576227683574
A B-Disease 1 0.9969714879989624
- I-Disease 1 0.9999948740005493
T I-Disease 1 0.9999996423721313
) O 0 8.206974598579109e-06
patients O 0 2.2000140234013088e-05
in O 0 9.058746854861965e-07
the O 0 2.3792522370058578e-06
British O 0 0.0034610379952937365
Isles O 0 0.0009377317037433386
. O 0 1.9566297851270065e-05

Of O 0 2.1109643057570793e-05
51 O 0 8.211351814679801e-05
ATM O 0 0.0006252469029277563
mutations O 0 5.525790402316488e-05
identified O 0 6.9544921643682756e-06
in O 0 1.004561113404634e-06
families O 0 8.034465963646653e-07
native O 0 7.149513976401067e-07
to O 0 1.23366405091474e-07
the O 0 3.22982515399417e-07
British O 0 8.949387120082974e-05
Isles O 0 4.843350689043291e-05
, O 0 2.383298607355755e-07
11 O 0 2.4120220132317627e-07
were O 0 4.5743371401840704e-07
founder O 0 6.2334715948964e-06
mutations O 0 1.6255722812275053e-06
, O 0 9.31720336438957e-08
and O 0 1.0279406836843918e-07
2 O 0 9.999332917232095e-08
of O 0 3.250168489898897e-08
these O 0 9.16720992449882e-08
11 O 0 8.865137033353676e-07
conferred O 0 5.010404038330307e-06
a O 0 1.7371075955452397e-05
milder O 1 0.999695897102356
clinical O 1 0.9452937841415405
phenotype O 0 0.013381405733525753
with O 0 7.014433549556998e-07
respect O 0 7.111880790944269e-07
to O 0 8.533832556167908e-07
both O 0 5.448545834951801e-06
cerebellar B-Disease 0 0.2712835967540741
degeneration I-Disease 1 0.8815472722053528
and O 0 9.450953257328365e-06
cellular O 0 9.959117596736178e-05
features O 0 2.4830298571032472e-05
. O 0 2.0641386072384194e-05

We O 0 3.440667569520883e-05
report O 0 8.061935659497976e-06
, O 0 2.801850484956958e-07
in O 0 3.259658285514888e-07
two O 0 4.5816454985470045e-07
A B-Disease 1 0.6636688113212585
- I-Disease 1 0.9996192455291748
T I-Disease 1 0.9999696016311646
families O 0 2.254374066978926e-06
, O 0 2.851784870472329e-07
an O 0 3.543407842698798e-07
ATM O 0 3.428221680223942e-05
mutation O 0 6.235552518774057e-06
( O 0 1.0140225867871777e-06
7271T O 0 1.951921876752749e-05
- O 0 0.00012182813952676952
- O 0 0.0002616120327729732
> O 0 1.8134280253434554e-05
G O 0 7.53256754251197e-05
) O 0 4.0905399600887904e-07
that O 0 1.1638122288104569e-07
may O 0 6.386507607203384e-07
be O 0 6.332935242880922e-08
associated O 0 1.283543156205269e-07
with O 0 5.8157972659955703e-08
an O 0 9.833179603901954e-08
increased O 0 7.88018496677978e-07
risk O 0 1.7314112028543605e-06
of O 0 1.1380494697732502e-06
breast B-Disease 1 0.9996750354766846
cancer I-Disease 0 0.07284862548112869
in O 0 1.8498656118026702e-06
both O 0 2.032928023254499e-06
homozygotes O 0 0.00014828234270680696
and O 0 2.7014600618713303e-06
heterozygotes O 0 3.9310631109401584e-05
( O 0 8.357312140105932e-07
relative O 0 1.7260532558793784e-06
risk O 0 1.4764380011911271e-06
12 O 0 5.993850322738581e-07
. O 0 2.656011872659292e-07
7 O 0 8.97306676961307e-07
; O 0 7.09104881480016e-07
P O 0 0.00011870825255755335
= O 0 8.646937203593552e-06
. O 0 5.38074345968198e-07
0025 O 0 5.486608642968349e-05
) O 0 2.4251949071185663e-07
, O 0 8.351394598093975e-08
although O 0 9.587840565927763e-08
there O 0 5.0705583731769366e-08
is O 0 5.848724526913429e-08
a O 0 5.019061291022808e-07
less O 0 8.375852303288411e-06
severe O 1 0.9611067771911621
A B-Disease 1 0.999997615814209
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
phenotype O 0 0.005925421603024006
in O 0 5.725838718717569e-07
terms O 0 4.6553273591598554e-07
of O 0 8.176752430699707e-08
the O 0 3.278379381299601e-07
degree O 0 5.298650194163201e-06
of O 0 5.61114757147152e-06
cerebellar B-Disease 1 0.9886990189552307
degeneration I-Disease 1 0.9985129237174988
. O 0 0.00010538675996940583

This O 0 8.0332305515185e-05
mutation O 0 0.00016024927026592195
( O 0 1.8223039660369977e-05
7271T O 0 0.00015806064766366035
- O 0 0.0013031188864260912
- O 0 0.005731653887778521
> O 0 7.163304690038785e-05
G O 0 4.385640568216331e-05
) O 0 2.5637186240601295e-07
also O 0 4.587180413295755e-08
allows O 0 4.56838158413575e-08
expression O 0 8.75844889947075e-08
of O 0 2.4865352443725897e-08
full O 0 3.7750220371890464e-07
- O 0 4.461012849787949e-06
length O 0 5.520829517990933e-07
ATM O 0 6.366558864101535e-06
protein O 0 5.834590410813689e-07
at O 0 1.9655716698707693e-07
a O 0 1.4909069534496666e-07
level O 0 2.0467815886604512e-07
comparable O 0 4.610205053268146e-07
with O 0 1.0866416033650239e-07
that O 0 1.9553000640826212e-07
in O 0 1.5600970755258459e-06
unaffected O 0 0.00022310513304546475
individuals O 0 3.639891701823217e-06
. O 0 1.3115245565131772e-05

In O 0 2.575572580099106e-05
addition O 0 5.1933016038674396e-06
, O 0 1.0917267445620382e-06
we O 0 3.606702136949025e-07
have O 0 1.992507634440699e-07
studied O 0 1.3484416285791667e-06
18 O 0 3.2816180919326143e-06
A B-Disease 1 0.9940083026885986
- I-Disease 1 0.9999988079071045
T I-Disease 1 1.0
patients O 0 0.024724293500185013
, O 0 3.3543642530275974e-07
in O 0 4.0785110400065605e-07
15 O 0 3.8490040310534823e-07
families O 0 2.7959916337749746e-07
, O 0 5.06163019053929e-07
who O 0 5.308223535394063e-06
developed O 0 0.461052805185318
leukemia B-Disease 1 0.9999995231628418
, O 0 0.023400507867336273
lymphoma B-Disease 1 1.0
, O 0 3.216011464246549e-05
preleukemic O 0 0.11754900962114334
T O 1 0.6531434655189514
- O 0 0.0003588681574910879
cell O 0 4.166319558862597e-05
proliferation O 0 2.7180196411791258e-05
, O 0 3.7857325878576376e-06
or O 0 0.0007081017247401178
Hodgkin B-Disease 1 1.0
lymphoma I-Disease 1 1.0
, O 0 9.989284990297165e-06
mostly O 0 3.7074016745464178e-06
in O 0 6.980725174798863e-06
childhood O 0 0.00015126692596822977
. O 0 4.474080924410373e-05

A O 0 6.913257675478235e-05
wide O 0 2.3207563572213985e-05
variety O 0 3.933915195375448e-06
of O 0 9.861612397799036e-07
ATM O 0 0.00016045552911236882
mutation O 0 7.665184966754168e-06
types O 0 8.883637860890303e-07
, O 0 3.769873728742823e-07
including O 0 5.178837341190956e-07
missense O 0 5.1848131988663226e-05
mutations O 0 3.655549789982615e-06
and O 0 3.8963881365816633e-07
in O 0 1.5969217201927677e-06
- O 0 0.0008262320188805461
frame O 0 8.706511289346963e-05
deletions O 0 7.561404345324263e-06
, O 0 2.6653063400772226e-07
were O 0 5.826128131047881e-07
seen O 0 1.3311517932379502e-06
in O 0 6.151083198346896e-07
these O 0 1.6109081570903072e-06
patients O 0 0.00013089581625536084
. O 0 1.889964369183872e-05

We O 0 1.1548997463250998e-05
also O 0 1.04662433386693e-06
show O 0 9.770985798240872e-07
that O 0 1.0379926607129164e-07
25 O 0 1.9188530586689012e-07
% O 0 8.109423532687288e-08
of O 0 2.941394861011304e-08
all O 0 1.737916335287082e-07
A B-Disease 1 0.9992571473121643
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
patients O 0 0.007563326973468065
carried O 0 3.6000121781398775e-06
in O 0 3.303107177998754e-06
- O 0 0.00029492026078514755
frame O 0 8.514116780133918e-05
deletions O 0 1.8064580217469484e-05
or O 0 1.3215158105595037e-06
missense O 0 2.438087722111959e-05
mutations O 0 3.1914948976918822e-06
, O 0 9.070160444935027e-08
many O 0 3.0572774534221026e-08
of O 0 2.26452137042088e-08
which O 0 7.774310262220752e-08
were O 0 2.716208769015793e-07
also O 0 1.437664707282238e-07
associated O 0 2.0919411269915145e-07
with O 0 6.611526259803213e-08
expression O 0 6.237320917534817e-07
of O 0 4.1514238091622246e-07
mutant O 0 2.31309822993353e-05
ATM O 0 8.879460074240342e-05
protein O 0 2.8964312150492333e-05
. O 0 1.2992771189601626e-05

The O 0 0.00013228355965111405
DMPK O 0 0.0014829764841124415
gene O 0 0.00011608559725573286
of O 0 9.378890354128089e-06
severely O 1 0.927201509475708
affected O 1 0.877549946308136
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 1 0.9997448325157166
is O 0 1.3495143321051728e-05
hypermethylated O 0 0.001729202689602971
proximal O 0 0.0009139933972619474
to O 0 1.6020270550143323e-06
the O 0 1.917735062306747e-06
largely O 0 1.4055569408810697e-05
expanded O 0 4.681436621467583e-05
CTG O 0 0.0014916777145117521
repeat O 0 0.00016159324150066823
. O 0 6.0887781728524715e-05

Using O 0 0.00010338328866055235
methylation O 0 9.150821279035881e-05
- O 0 6.041662709321827e-05
sensitive O 0 1.5006847206677776e-05
restriction O 0 4.7559410631947685e-06
enzymes O 0 1.6435752741017495e-06
, O 0 1.257550934496976e-07
we O 0 1.348436171610956e-07
characterized O 0 1.060109525496955e-06
the O 0 2.55029902973547e-07
methylation O 0 3.99531609218684e-06
pattern O 0 2.3506293018726865e-06
on O 0 3.553323040250689e-07
the O 0 1.9590331135077577e-07
5 O 0 2.3472641430544172e-07
side O 0 1.6979974759578909e-07
of O 0 5.4437347074554054e-08
the O 0 4.434487834714673e-07
CTG O 0 8.089269249467179e-05
repeat O 0 2.868354158636066e-06
in O 0 3.591986512674339e-07
the O 0 3.9781741634214995e-07
DMPK O 0 3.441789885982871e-05
gene O 0 1.1245828090977739e-06
of O 0 8.455077704638825e-08
normal O 0 7.807654469615954e-07
individuals O 0 1.6250733381184546e-07
and O 0 2.5108033696596976e-07
of O 0 7.634126859557e-07
patients O 0 0.006577253807336092
affected O 0 7.584058039356023e-05
with O 0 0.001976648811250925
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
, O 0 6.392536761268275e-06
showing O 0 9.554891221341677e-06
expansions O 0 1.1850551345560234e-05
of O 0 4.912660642730771e-07
the O 0 1.8545289321991731e-06
repetitive O 0 0.00011451154568931088
sequence O 0 2.407981810392812e-05
. O 0 2.3730028260615654e-05

The O 0 7.53014610381797e-05
gene O 0 9.902403689920902e-05
segment O 0 5.542556755244732e-05
analyzed O 0 2.2336531401379034e-05
corresponds O 0 6.032373221387388e-06
to O 0 9.398995075571293e-07
the O 0 1.674542659202416e-06
genomic O 0 3.998304600827396e-05
SacI O 0 0.0005543271545320749
- O 0 0.000175459252204746
HindIII O 0 0.00017214361287187785
fragment O 0 3.805161759373732e-05
carrying O 0 1.1588208508328535e-05
exons O 0 3.162411667290144e-05
11 O 0 8.217572030844167e-06
- O 0 4.2178457078989595e-05
15 O 0 1.5790510587976314e-05
. O 0 1.1232794349780306e-05

There O 0 3.376046151970513e-05
is O 0 4.126518888369901e-06
constitutive O 0 6.112304254202172e-05
methylation O 0 2.309529372723773e-05
in O 0 2.691577719815541e-06
intron O 0 6.850617501186207e-05
12 O 0 1.940660695254337e-06
at O 0 6.082482286728919e-07
restriction O 0 9.078223683900433e-07
sites O 0 2.4711368951102486e-07
of O 0 1.8891472564064316e-07
SacII O 0 2.0802121071028523e-05
and O 0 9.964300033971085e-07
HhaI O 0 2.486194898665417e-05
, O 0 4.1836517539195484e-07
localized O 0 2.1368302896007663e-06
1 O 0 4.1624804225648404e-07
, O 0 1.8848068350507674e-07
159 O 0 2.4547775865357835e-06
- O 0 6.150816261651926e-06
1 O 0 6.902122322571813e-07
, O 0 4.068670875767566e-07
232 O 0 3.986129740951583e-06
bp O 0 1.1772926882258616e-05
upstream O 0 1.1900106073881034e-06
of O 0 8.776760296314023e-08
the O 0 4.347448054886627e-07
CTG O 0 4.349031951278448e-05
repeat O 0 4.2719666453194804e-06
, O 0 2.725955710047856e-07
whereas O 0 3.6659216107182147e-07
most O 0 7.479918906483363e-08
, O 0 3.8114965406066403e-08
if O 0 2.0276246459616232e-08
not O 0 1.7988616818342962e-08
all O 0 8.832106601630585e-09
, O 0 1.0540004424797189e-08
of O 0 8.553337593752985e-09
the O 0 3.674237092354815e-08
other O 0 2.546511801426732e-08
sites O 0 8.253342542730024e-08
of O 0 4.632549988059509e-08
SacII O 0 1.1966067177127115e-05
, O 0 2.870388016162906e-07
HhaI O 0 8.027390322240535e-06
, O 0 2.3998731535357365e-07
and O 0 3.1688864510215353e-07
HpaII O 0 2.0257080905139446e-05
in O 0 2.408617945093283e-07
this O 0 1.6331460983565194e-07
region O 0 6.519597945953137e-07
are O 0 1.576423045435149e-07
unmethylated O 0 1.0117313649971038e-05
, O 0 2.395441640601348e-07
in O 0 2.089719686182434e-07
normal O 0 4.997348241886357e-07
individuals O 0 7.898515264059824e-08
and O 0 6.7583293628104e-08
most O 0 1.0739306333107379e-07
of O 0 2.248061008458535e-07
the O 0 5.700906513084192e-06
patients O 0 0.000449718238087371
. O 0 1.4967356946726795e-05

In O 0 2.06746826734161e-05
a O 0 3.5861994547303766e-06
number O 0 2.576903739281988e-07
of O 0 1.3284842736993596e-07
young O 0 1.962744818229112e-06
and O 0 1.8808685808835435e-06
severely O 1 0.6005219221115112
affected O 0 7.154526247177273e-05
patients O 0 0.00023483157565351576
, O 0 4.4027527223988727e-07
however O 0 7.635116503479367e-07
, O 0 1.6226186971834977e-07
complete O 0 3.894296867201774e-07
methylation O 0 9.590690979166538e-07
of O 0 3.8179795325277155e-08
these O 0 5.980825079632268e-08
restriction O 0 6.941081096556445e-07
sites O 0 5.483971108333208e-07
was O 0 1.878135094557365e-06
found O 0 7.359901701420313e-07
in O 0 6.521376576529292e-07
the O 0 2.6005595827882644e-06
mutated O 0 0.00020067977311555296
allele O 0 0.0001851303968578577
. O 0 2.4782366381259635e-05

In O 0 2.20551391976187e-05
most O 0 2.498645244486397e-06
of O 0 4.5483673716262274e-07
these O 0 7.887011861384963e-07
patients O 0 3.6948877095710486e-05
, O 0 6.275848249970295e-07
the O 0 1.3118996093908208e-06
onset O 0 0.0007877728785388172
of O 0 1.0909066077147145e-06
the O 0 0.00042237635352648795
disease O 1 0.9913764595985413
was O 1 0.96944260597229
congenital O 1 0.9999971389770508
. O 0 0.0001890768762677908

Preliminary O 0 0.000686070357915014
in O 0 6.526212382595986e-05
vivo O 0 0.0007442962960340083
footprinting O 0 0.001037027919664979
data O 0 7.528111837018514e-06
gave O 0 3.332206006234628e-06
evidence O 0 9.456906582272495e-07
for O 0 1.7283825570757472e-07
protein O 0 1.0065500646305736e-06
- O 0 6.779206159990281e-06
DNA O 0 3.7018583043391118e-06
contact O 0 1.0321150512027089e-06
in O 0 5.703798251488479e-07
normal O 0 1.5095462231329293e-06
genes O 0 9.407558536622673e-07
at O 0 3.8258642121036246e-07
an O 0 2.651317458912672e-07
Sp1 O 0 5.677819444827037e-06
consensus O 0 6.00485236645909e-07
binding O 0 8.442426064902975e-07
site O 0 5.201804924581666e-07
upstream O 0 5.593237233370019e-07
of O 0 4.277533349750229e-08
the O 0 2.454704599585966e-07
CTG O 0 4.392320988699794e-05
repeat O 0 2.896543946917518e-06
and O 0 2.6536625341577746e-07
for O 0 1.1249480991182281e-07
a O 0 2.4985470759020245e-07
significant O 0 3.4911016655314597e-07
reduction O 0 9.018664286486455e-07
of O 0 6.474873259776359e-08
this O 0 1.0956406271134256e-07
interaction O 0 5.310211577125301e-07
in O 0 5.741334803133213e-07
cells O 0 2.4189544092223514e-06
with O 0 3.3516684538881236e-07
a O 0 5.512288225872908e-06
hypermethylated O 0 0.0012630821438506246
DMPK O 0 0.003191434545442462
gene O 0 4.9257305363425985e-05
. O 0 3.7248412354529137e-06
. O 0 9.572841008775868e-06

The O 0 0.000575465674046427
hemochromatosis B-Disease 1 0.9999902248382568
gene O 0 9.904018952511251e-05
product O 0 1.2121096915507223e-05
complexes O 0 4.758790055348072e-06
with O 0 4.288872901270224e-07
the O 0 8.779821882853867e-07
transferrin O 0 2.5736968382261693e-05
receptor O 0 5.192207026993856e-06
and O 0 6.539424362017598e-07
lowers O 0 7.64856486057397e-06
its O 0 5.324918674887158e-07
affinity O 0 2.0869185846095206e-06
for O 0 5.036932293478458e-07
ligand O 0 9.001392754726112e-06
binding O 0 1.572979090269655e-05
. O 0 1.1044598068110645e-05

We O 0 6.940995808690786e-05
recently O 0 4.70438135380391e-05
reported O 0 1.0687066605896689e-05
the O 0 1.0728552979344386e-06
positional O 0 2.3364476874121465e-05
cloning O 0 1.0370757991040591e-05
of O 0 2.97130355875197e-07
a O 0 2.3638772290723864e-06
candidate O 0 1.5486293705180287e-05
gene O 0 5.330719068297185e-05
for O 0 0.00017048463632818311
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
called O 0 0.04402069374918938
HFE O 1 0.8803613185882568
. O 0 0.0001726683258311823

The O 0 3.455860132817179e-05
gene O 0 2.2306900063995272e-05
product O 0 2.22905759983405e-06
, O 0 2.634593840866728e-07
a O 0 2.9023541969763755e-07
member O 0 2.882163698814111e-07
of O 0 3.787213032069303e-08
the O 0 2.5886674848152325e-07
major O 0 1.2355695844235015e-06
histocompatibility O 0 0.00023330238764174283
complex O 0 4.408518634591019e-06
class O 0 1.121187142416602e-05
I O 0 2.6838886697078124e-05
- O 0 1.5489558791159652e-05
like O 0 4.628518581739627e-07
family O 0 7.577281735393626e-07
, O 0 1.848492274802993e-07
was O 0 1.4454777783612371e-06
found O 0 2.8815509267587913e-07
to O 0 1.216368303857962e-07
have O 0 1.4572691497960477e-07
a O 0 5.644959628625656e-07
mutation O 0 3.0792111829214264e-06
, O 0 1.5431586462000269e-06
Cys O 0 0.0005969935446046293
- O 0 6.503647455247119e-05
282 O 0 5.28177733940538e-05
- O 0 0.0002984591410495341
- O 0 0.00029454598552547395
> O 0 3.310367537778802e-05
Tyr O 0 8.832405728753656e-05
( O 0 1.2678809753197129e-06
C282Y O 0 5.692745617125183e-06
) O 0 1.6857269713455025e-07
, O 0 5.660880120217371e-08
in O 0 1.1633884611228495e-07
85 O 0 8.415231604885776e-07
% O 0 6.938381034160557e-07
of O 0 5.504437581294042e-07
patient O 0 0.00020429292635526508
chromosomes O 0 5.950140257482417e-05
. O 0 2.2843805709271692e-05

This O 0 4.032445576740429e-05
mutation O 0 6.627410766668618e-05
eliminates O 0 3.391140853636898e-05
the O 0 1.8533196453063283e-06
ability O 0 2.7406781555328052e-06
of O 0 5.088201078251586e-07
HFE O 0 0.00035629671765491366
to O 0 1.304279976466205e-06
associate O 0 2.3294339825952193e-06
with O 0 6.231244924492785e-07
beta2 O 0 0.001017233938910067
- O 0 0.0012199501506984234
microglobulin O 0 0.00036765963886864483
( O 0 1.8562346895123483e-06
beta2m O 0 2.6311632609576918e-05
) O 0 4.335061021265574e-07
and O 0 2.8728911161124415e-07
prevents O 0 2.206616727562505e-06
cell O 0 2.424510421406012e-05
- O 0 8.407665882259607e-05
surface O 0 7.532355994044337e-06
expression O 0 1.3377094546740409e-05
. O 0 1.124906793847913e-05

A O 0 9.112949919654056e-05
second O 0 3.111479236395098e-05
mutation O 0 2.094922456308268e-05
that O 0 7.430462574120611e-07
has O 0 4.012378269635519e-07
no O 0 2.2517990316828218e-07
effect O 0 6.636282137151284e-07
on O 0 4.3111606373713585e-07
beta2m O 0 3.281573299318552e-05
association O 0 1.6419710391346598e-06
, O 0 1.993478946360483e-07
H63D O 0 6.0958722315263e-05
, O 0 3.3260772624998935e-07
was O 0 8.103777418000391e-07
found O 0 1.7016287756632664e-07
in O 0 8.616891022938944e-08
eight O 0 1.330091663476196e-07
out O 0 1.0988907916953394e-07
of O 0 9.013353263753743e-08
nine O 0 3.202776497346349e-06
patients O 0 4.304186950321309e-05
heterozygous O 0 6.995780495344661e-06
for O 0 6.574523467861582e-07
the O 0 2.329407152501517e-06
C282Y O 0 0.00030345498817041516
mutant O 0 0.00014625016774516553
. O 0 1.8953178368974477e-05

In O 0 4.427630119607784e-05
this O 0 5.383420557336649e-06
report O 0 6.378773377946345e-06
, O 0 3.125239516066358e-07
we O 0 1.762290366968955e-07
demonstrate O 0 9.886011866910849e-07
in O 0 7.579507723676215e-07
cultured O 0 0.00014034906052984297
293 O 0 5.830494410474785e-05
cells O 0 2.3036851416691206e-05
overexpressing O 0 0.00016538886120542884
wild O 0 5.624788627756061e-06
- O 0 2.380017212999519e-05
type O 0 4.735326456284383e-06
or O 0 1.4031018054083688e-06
mutant O 0 2.994133137690369e-05
HFE O 0 0.0001393506390741095
proteins O 0 1.0054927770397626e-06
that O 0 2.0866669103725144e-07
both O 0 1.7468609314619243e-07
the O 0 2.951922510874283e-07
wild O 0 1.9467167930997675e-06
- O 0 3.9772174204699695e-05
type O 0 4.0779809751256835e-06
and O 0 1.3337757991394028e-06
H63D O 0 0.0028363100718706846
HFE O 0 0.0011248590890318155
proteins O 0 2.8848387501057005e-06
form O 0 1.3365018958211294e-06
stable O 0 4.845231160288677e-06
complexes O 0 2.469784931236063e-06
with O 0 4.56074644716864e-07
the O 0 1.8615957060319488e-06
transferrin O 0 0.00019034923752769828
receptor O 0 5.0150272727478296e-05
( O 0 1.1343004189257044e-05
TfR O 0 0.0003428384952712804
) O 0 8.875594176060986e-06
. O 0 1.1667249054880813e-05

The O 0 0.00014635255502071232
C282Y O 0 0.001287710852921009
mutation O 0 6.91525565343909e-05
nearly O 0 7.141743481042795e-06
completely O 0 9.045297701959498e-06
prevents O 0 3.533429890012485e-06
the O 0 6.17464536389889e-07
association O 0 9.72255634223984e-07
of O 0 1.5788212692768866e-07
the O 0 1.360345436296484e-06
mutant O 0 3.008762541867327e-05
HFE O 0 0.0002252253470942378
protein O 0 6.091421255405294e-06
with O 0 1.1963862789343693e-06
the O 0 7.021386409178376e-06
TfR O 0 0.0016408272786065936
. O 0 2.479007343936246e-05

Studies O 0 0.0001065051110344939
on O 0 2.6782812710735016e-05
cell O 0 8.618544961791486e-05
- O 0 8.482704288326204e-05
associated O 0 5.117334239912452e-06
transferrin O 0 2.111886533384677e-05
at O 0 1.490342583565507e-06
37 O 0 1.693348167464137e-06
degrees O 0 2.2930241811991436e-06
C O 0 5.926531594013795e-05
suggest O 0 2.2553804228664376e-06
that O 0 2.3129237547436787e-07
the O 0 6.984628271311522e-07
overexpressed O 0 2.9092760087223724e-05
wild O 0 3.999921773356618e-06
- O 0 4.870742486673407e-05
type O 0 1.4602460396417882e-05
HFE O 0 0.00014487578300759196
protein O 0 2.8310030302236555e-06
decreases O 0 1.6499938055858365e-06
the O 0 4.5108026824891567e-07
affinity O 0 1.3217918422014918e-06
of O 0 1.787650631968063e-07
the O 0 1.511834057055239e-06
TfR O 0 0.00017611630028113723
for O 0 5.9484527810127474e-06
transferrin O 0 0.0005628250073641539
. O 0 3.306402140879072e-05

The O 0 0.0001701695437077433
overexpressed O 0 0.0009598300675861537
H63D O 0 0.0008615111000835896
protein O 0 1.4655053746537305e-05
does O 0 1.1383816627130727e-06
not O 0 2.2248219977427652e-07
have O 0 9.257578170718261e-08
this O 0 7.935769019695726e-08
effect O 0 3.7175129818933783e-07
, O 0 5.724692542230514e-08
providing O 0 6.84731347178058e-08
the O 0 5.2228614322302747e-08
first O 0 1.3741782822762616e-07
direct O 0 2.1609332634398015e-07
evidence O 0 4.475460855246638e-07
for O 0 9.806153400404582e-08
a O 0 5.717490125789482e-07
functional O 0 3.2597345125395805e-06
consequence O 0 3.1661240882385755e-06
of O 0 4.836888933823502e-07
the O 0 9.001410035125446e-06
H63D O 0 0.017704186961054802
mutation O 0 0.00011470870958874002
. O 0 2.799406684061978e-05

Addition O 0 8.950632764026523e-05
of O 0 1.294826597586507e-05
soluble O 0 0.00028657689108513296
wild O 0 4.2596984712872654e-05
- O 0 0.0016251690685749054
type O 0 0.0002895407087635249
HFE O 0 0.17285531759262085
/ O 0 0.0021880839485675097
beta2m O 0 0.00021158272284083068
heterodimers O 0 4.219012407702394e-05
to O 0 2.367227352806367e-06
cultured O 0 0.00020186883921269327
cells O 0 6.850527370261261e-06
also O 0 8.084062983471085e-07
decreased O 0 1.6743989590395358e-06
the O 0 1.8331927265080594e-07
apparent O 0 1.4227720157578005e-06
affinity O 0 1.0047508567367913e-06
of O 0 8.271591411812551e-08
the O 0 4.159075501775078e-07
TfR O 0 9.825783308770042e-06
for O 0 1.8173575710989098e-07
its O 0 3.603095990456495e-07
ligand O 0 2.1122457383171422e-06
under O 0 4.760596823416563e-07
steady O 0 3.869138708978426e-06
- O 0 1.047405839926796e-05
state O 0 3.9000761375973525e-07
conditions O 0 3.990834557043854e-06
, O 0 1.3219528227637056e-07
both O 0 1.205000188519989e-07
in O 0 4.041407350996451e-07
293 O 0 8.331955541507341e-06
cells O 0 3.4939068882522406e-06
and O 0 7.054146635709913e-07
in O 0 5.700204837921774e-06
HeLa O 0 0.002550098579376936
cells O 0 0.00010660976840881631
. O 0 3.5492794268066064e-05

Furthermore O 0 0.0001010642881738022
, O 0 4.014657861262094e-06
at O 0 1.530524855297699e-06
4 O 0 8.757293699090951e-07
degrees O 0 1.9953383798565483e-06
C O 0 1.6328751371474937e-05
, O 0 2.4506999807272223e-07
the O 0 3.0971770570431545e-07
added O 0 2.781947614494129e-06
soluble O 0 5.769003564637387e-06
complex O 0 1.307590309806983e-06
of O 0 1.4755667052668286e-06
HFE O 0 0.3646087944507599
/ O 0 0.019378071650862694
beta2m O 0 0.0008487370796501637
inhibited O 0 4.18189556512516e-05
binding O 0 4.569010343402624e-06
of O 0 3.918904667443712e-07
transferrin O 0 2.914438482548576e-05
to O 0 2.26715474127559e-06
HeLa O 0 0.00024211690470110625
cell O 0 9.033696551341563e-05
TfR O 0 0.00011171762162121013
in O 0 1.1011018159479136e-06
a O 0 2.1096548152854666e-06
concentration O 0 3.0050894565647468e-05
- O 0 7.756258128210902e-05
dependent O 0 2.6931724278256297e-05
manner O 0 5.311588756740093e-05
. O 0 2.6950841856887564e-05

Scatchard O 0 0.0015944760525599122
plots O 0 6.168083928059787e-05
of O 0 2.3985078314581187e-06
these O 0 1.018678858599742e-06
data O 0 1.3775336356047774e-06
indicate O 0 8.108555107355642e-07
that O 0 1.0810929040871997e-07
the O 0 2.386794619724242e-07
added O 0 1.4955152209950029e-06
heterodimer O 0 1.7772787032299675e-05
substantially O 0 1.2491374036471825e-05
reduced O 0 2.0560071334330132e-06
the O 0 4.0767341147329716e-07
affinity O 0 2.2831566184322583e-06
of O 0 6.482139269792242e-07
TfR O 0 0.0002043453132500872
for O 0 3.4615468393894844e-06
transferrin O 0 0.0006461928714998066
. O 0 3.3838852687040344e-05

These O 0 3.6037134123034775e-05
results O 0 3.8491551094921306e-05
establish O 0 9.795376172405668e-06
a O 0 4.323201210354455e-06
molecular O 0 1.180769413622329e-05
link O 0 8.259487913164776e-06
between O 0 1.828698032113607e-06
HFE O 0 0.0005372971063479781
and O 0 8.815084697744169e-07
a O 0 8.825472832540981e-07
key O 0 1.6086976302176481e-06
protein O 0 8.475242907479696e-07
involved O 0 5.014697421756864e-07
in O 0 5.061746151113766e-07
iron O 0 4.62822281406261e-05
transport O 0 2.3242548650159733e-06
, O 0 2.4208043214457575e-07
the O 0 3.349632891058718e-07
TfR O 0 3.138691681670025e-05
, O 0 1.9707597687101952e-07
and O 0 1.083533049950347e-07
raise O 0 2.064594042394674e-07
the O 0 7.736516494105672e-08
possibility O 0 3.191660766788118e-07
that O 0 2.0441636650048167e-07
alterations O 0 1.2569587852340192e-05
in O 0 4.2374909980935627e-07
this O 0 4.403563309551828e-07
regulatory O 0 5.267473170533776e-06
mechanism O 0 1.5341870494012255e-06
may O 0 8.635950052848784e-07
play O 0 2.622386148232181e-07
a O 0 2.00962759322465e-07
role O 0 4.852125812249142e-07
in O 0 4.996662141820707e-07
the O 0 2.559321728767827e-06
pathogenesis O 0 0.0002852377074304968
of O 0 3.671502054203302e-05
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 0.00027857808163389564
. O 0 7.836641452740878e-05

Genomic O 0 0.0005849743029102683
organization O 0 2.5647488655522466e-05
of O 0 1.8540762312113657e-06
the O 0 8.347359653271269e-06
UBE3A O 0 0.01450216956436634
/ O 0 0.002618786646053195
E6 O 0 0.0016319045098498464
- O 0 0.0005622273893095553
AP O 0 0.00017349018889945
gene O 0 1.5245654140016995e-05
and O 0 2.243865992568317e-06
related O 0 2.02938390430063e-05
pseudogenes O 0 0.000123579433420673
. O 0 4.3157899199286476e-05

The O 0 0.00017137026588898152
UBE3A O 0 0.003095128107815981
gene O 0 6.736727664247155e-05
encodes O 0 2.5387524146935903e-05
the O 0 3.006373162861564e-06
E6 O 0 0.00018939822621177882
- O 0 0.00016282596334349364
AP O 0 7.975252083269879e-05
ubiquitin O 0 3.245063635404222e-05
- O 0 1.3353373105928767e-05
protein O 0 1.7866478856376489e-06
ligase O 0 3.70092629964347e-06
and O 0 3.038535396626685e-07
has O 0 2.939519561095949e-07
recently O 0 1.5658313259336865e-06
been O 0 3.607730718613311e-07
shown O 0 4.2981920955753594e-07
to O 0 3.581410510378191e-07
be O 0 1.197308506561967e-06
mutated O 0 0.0002157722192350775
in O 1 0.9115266799926758
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 1 0.9932113885879517
who O 0 6.237751222215593e-05
lack O 0 0.00015419712872244418
15q11 O 0 0.06693173199892044
- O 0 0.013131463900208473
q13 O 0 0.00024116308486554772
deletions O 0 4.716091643786058e-05
or O 0 7.909935447969474e-06
chromosome O 0 6.731352914357558e-05
15 O 0 1.2973865523235872e-05
paternal O 0 0.0005401925300247967
uniparental B-Disease 0 0.3816041946411133
disomy I-Disease 0 0.045921001583337784
. O 0 0.0001100076042348519

Previous O 0 0.0007966069388203323
UBE3A O 0 0.0037765433080494404
cDNA O 0 0.0003945206990465522
analysis O 0 4.9297759687760845e-05
has O 0 4.0944028114608955e-06
shown O 0 3.767303724089288e-06
a O 0 2.1880837266508024e-06
coding O 0 1.5182757124421187e-05
region O 0 1.2405392908476642e-06
of O 0 3.485619117782335e-07
approximately O 0 1.7726647456584033e-06
2 O 0 4.869142685492989e-06
. O 0 1.4286892110249028e-05

6 O 0 0.00019732964574359357
kb O 0 0.00040214406908489764
and O 0 4.5438073357217945e-06
a O 0 2.3693617094977526e-06
3 O 0 5.3404774007503875e-06
- O 0 8.76532430993393e-05
untranslated O 0 0.00016705002053640783
region O 0 6.652981483057374e-06
( O 0 2.358241317779175e-06
UTR O 0 3.0013603463885374e-05
) O 0 3.442619345150888e-07
of O 0 1.280876205100867e-07
< O 0 4.477117727219593e-06
50 O 0 3.587837227314594e-07
bp O 0 1.0482811376277823e-05
, O 0 2.1358451363084896e-07
whereas O 0 5.874152293472434e-07
Northern O 0 7.383135880445479e-07
analysis O 0 6.225666879799974e-07
has O 0 2.74292432322909e-07
indicated O 0 9.660400337452302e-07
mRNA O 0 4.137285998240259e-07
sizes O 0 5.71451380437793e-07
of O 0 1.1986756476289884e-07
5 O 0 1.7055131138477009e-06
- O 0 5.143466478330083e-05
8 O 0 1.2687079106399324e-05
kb O 0 0.00047429261030629277
. O 0 2.699812284845393e-05

We O 0 2.4418157408945262e-05
have O 0 2.959069206553977e-06
analyzed O 0 4.616497335518943e-06
additional O 0 8.289879929179733e-07
cDNA O 0 1.3305043466971256e-05
clones O 0 1.1683059710776433e-05
and O 0 5.837073331349529e-07
provide O 0 5.723218237108085e-07
evidence O 0 7.521348948102968e-07
for O 0 2.237772491753276e-07
an O 0 2.2023353096756182e-07
additional O 0 1.0200623137279763e-06
0 O 0 1.1673025255731773e-05
. O 0 8.064480425673537e-06

5 O 0 0.00010460570047143847
kb O 0 0.0002765088283922523
of O 0 1.9698552478075726e-06
5 O 0 4.843508122576168e-06
- O 0 3.667064811452292e-05
UTR O 0 8.273634011857212e-05
and O 0 1.9129490738123422e-06
> O 0 1.074274678103393e-05
2 O 0 2.2504709704662673e-06
kb O 0 2.8966851459699683e-05
of O 0 4.832324407288979e-07
3 O 0 6.361824944178807e-06
- O 0 0.00033518901909701526
UTR O 0 0.0011850118171423674
. O 0 3.217401172150858e-05

We O 0 1.439206698705675e-05
have O 0 1.5784282823005924e-06
established O 0 8.460351068606542e-07
the O 0 3.319780148558493e-07
genomic O 0 2.698159278224921e-06
organization O 0 7.087248832249315e-07
of O 0 2.615475125367084e-07
UBE3A O 0 8.137640543282032e-05
and O 0 3.893951543432195e-07
the O 0 2.1858426180187962e-07
sequence O 0 3.868552482799714e-07
of O 0 2.7144349701302417e-07
intron O 0 0.00010326545452699065
- O 0 0.00010008557001128793
exon O 0 0.00017084443243220448
borders O 0 4.4331096432870254e-05
. O 0 6.136858428362757e-05

We O 0 2.831113488355186e-05
have O 0 2.4904047677409835e-06
also O 0 1.3007745565118967e-06
mapped O 0 4.333215201768326e-06
two O 0 3.444419007792021e-07
highly O 0 2.517757593523129e-06
homologous O 0 1.0203551028098445e-05
processed O 0 6.99269185133744e-06
pseudogenes O 0 1.97255485545611e-05
, O 0 1.2652899386011995e-06
UBE3AP1 O 0 5.7803586969384924e-05
and O 0 1.1083881190643297e-06
UBE3AP2 O 0 9.766976290848106e-05
, O 0 2.4943975063251855e-07
to O 0 9.61745669769698e-08
chromosomes O 0 5.172608439352189e-07
2 O 0 1.2899647572339745e-07
and O 0 8.276515472971369e-08
21 O 0 4.2529282495706866e-07
, O 0 1.0721070964336832e-07
respectively O 0 4.5601115061799646e-07
, O 0 1.4961985073114192e-07
and O 0 1.4314589691366564e-07
determined O 0 7.926032594696153e-07
their O 0 6.14397151821322e-07
genomic O 0 8.965668712335173e-06
organization O 0 5.647389571095118e-06
. O 0 9.93986122921342e-06

These O 0 1.346629414911149e-05
results O 0 1.858585346781183e-05
will O 0 5.123660002936958e-07
form O 0 3.3371338759025093e-07
the O 0 1.6921666201596963e-07
basis O 0 2.168542891922698e-07
for O 0 1.4529089753523294e-07
studies O 0 4.107419329102413e-07
of O 0 1.45243092219971e-07
mutation O 0 2.637779289216269e-06
and O 0 1.1399232562325778e-06
imprinting O 0 4.030350100947544e-05
of O 0 3.7999843698344193e-06
UBE3A O 0 0.0032516303472220898
. O 0 4.4995311327511445e-05

Mutation O 0 0.0010144111001864076
spectrum O 0 0.00039431918412446976
and O 0 4.802540934178978e-05
genotype O 0 0.06069071218371391
- O 0 0.3731902539730072
phenotype O 0 0.016970468685030937
analyses O 0 0.00019649452588055283
in O 0 0.0003854190290439874
Cowden B-Disease 1 0.9999783039093018
disease I-Disease 1 0.5990334153175354
and O 0 8.520646224496886e-05
Bannayan B-Disease 1 0.9996963739395142
- I-Disease 1 0.9999972581863403
Zonana I-Disease 1 0.9999926090240479
syndrome I-Disease 1 0.9999939203262329
, O 0 1.3348610991670284e-05
two O 0 2.9496695788111538e-05
hamartoma B-Disease 1 0.9987800717353821
syndromes I-Disease 1 0.9902034997940063
with O 0 9.707920253276825e-05
germline O 1 0.7506534457206726
PTEN O 1 0.7059831619262695
mutation O 0 0.0008173484238795936
. O 0 0.00010044775262940675

The O 0 0.0009917494608089328
tumour B-Disease 1 0.9999706745147705
suppressor O 0 0.003140382468700409
gene O 0 0.00023402510851155967
PTEN O 0 0.0010148093570023775
, O 0 2.6887657895713346e-06
which O 0 1.1286215340078343e-06
maps O 0 5.542534836422419e-06
to O 0 3.3341386824758956e-06
10q23 O 0 0.00017558912804815918
. O 0 2.2368823920260184e-05

3 O 0 6.0313130234135315e-05
and O 0 5.751567641709698e-06
encodes O 0 1.1979359442193527e-05
a O 0 4.931916464556707e-06
403 O 0 3.186101821484044e-05
amino O 0 1.1249077942920849e-05
acid O 0 1.5324732885346748e-05
dual O 0 1.3288078662299085e-05
specificity O 0 4.498767157201655e-05
phosphatase O 0 0.0030944235622882843
( O 0 5.831586804561084e-06
protein O 0 8.838142093736678e-06
tyrosine O 0 5.147273259353824e-05
phosphatase O 0 0.0004127170250285417
; O 0 2.194574790337356e-06
PTPase O 0 2.2703467038809322e-05
) O 0 3.6800096836486773e-07
, O 0 1.3063547044112056e-07
was O 0 7.263903398779803e-07
shown O 0 5.808136620544246e-07
recently O 0 1.0125868357135914e-06
to O 0 1.2883727151802304e-07
play O 0 4.834638502870803e-07
a O 0 3.8272253277682466e-07
broad O 0 2.1835874122189125e-06
role O 0 2.049489921773784e-06
in O 0 3.926434146706015e-06
human O 0 1.0337174899177626e-05
malignancy B-Disease 0 0.0009172405698336661
. O 0 2.0058045265614055e-05

Somatic O 0 0.023819174617528915
PTEN O 0 0.04145190864801407
deletions O 0 0.00111092918086797
and O 0 3.843817830784246e-05
mutations O 0 5.736734965466894e-05
were O 0 3.352807652845513e-06
observed O 0 3.5638950066640973e-06
in O 0 1.6104826272567152e-06
sporadic B-Disease 0 0.0003554204595275223
breast I-Disease 1 0.6263729929924011
, I-Disease 0 1.5670439097448252e-05
brain I-Disease 0 0.11637232452630997
, I-Disease 0 5.499563485500403e-05
prostate I-Disease 1 0.9999662637710571
and I-Disease 0 0.22404791414737701
kidney I-Disease 1 0.9999996423721313
cancer I-Disease 1 0.9820858240127563
cell O 0 0.0002595494734123349
lines O 0 6.253454102989053e-06
and O 0 8.221602456615074e-07
in O 0 6.391632041413686e-07
several O 0 1.16836451979907e-06
primary O 0 3.9363716496154666e-05
tumours B-Disease 1 0.9827708005905151
such O 0 2.693824626476271e-06
as O 0 2.50198118010303e-05
endometrial B-Disease 1 0.9990419745445251
carcinomas I-Disease 1 1.0
, O 1 0.9856211543083191
malignant B-Disease 1 1.0
melanoma I-Disease 1 1.0
and O 1 0.9979901313781738
thyroid B-Disease 1 0.9999991655349731
tumours I-Disease 1 0.9999947547912598
. O 0 0.0002499571710359305

In O 0 3.895755435223691e-05
addition O 0 8.434511073573958e-06
, O 0 6.8733124862774275e-06
PTEN O 0 0.000628417357802391
was O 0 9.551329640089534e-06
identified O 0 2.1890355128562078e-06
as O 0 3.992217330051062e-07
the O 0 7.424852128679049e-07
susceptibility O 0 1.2000739843642805e-05
gene O 0 4.025538601126755e-06
for O 0 1.164544528364786e-06
two O 0 3.638271664385684e-05
hamartoma B-Disease 1 0.9999899864196777
syndromes I-Disease 1 0.9999992847442627
Cowden B-Disease 1 0.9999995231628418
disease I-Disease 1 0.9921942949295044
( O 0 1.2184051229269244e-05
CD B-Disease 0 5.152567973709665e-05
; O 0 9.588619832356926e-06
MIM O 0 0.008510546758770943
158350 O 0 8.521296695107594e-05
) O 0 1.8813996121025411e-06
and O 0 1.5988722452675574e-06
Bannayan B-Disease 0 0.00035577069502323866
- I-Disease 0 0.0008164448081515729
Zonana I-Disease 0 0.0008642449392937124
( I-Disease 0 8.549605809093919e-06
BZS I-Disease 0 0.00016380609304178506
) I-Disease 0 3.369990281498758e-06
or I-Disease 0 3.7728693769167876e-06
Ruvalcaba I-Disease 0 0.0003854626847896725
- I-Disease 0 0.0009681729134172201
Riley I-Disease 0 0.00689501641318202
- I-Disease 1 0.9971038699150085
Smith I-Disease 1 0.996199905872345
syndrome I-Disease 1 0.9999551773071289
( O 0 2.1928570276941173e-05
MIM O 0 0.1409033089876175
153480 O 0 0.0003498337173368782
) O 0 1.1031640497094486e-05
. O 0 1.128258736571297e-05

Constitutive O 0 0.0026160606648772955
DNA O 0 0.00018342708062846214
from O 0 9.158616194326896e-06
37 O 0 1.1548358997970354e-05
CD B-Disease 0 1.2149277608841658e-05
families O 0 2.2213225747691467e-06
and O 0 6.508360002044355e-07
seven O 0 1.843459017436544e-06
BZS B-Disease 0 0.0001849348918767646
families O 0 5.711408903152915e-06
was O 0 7.190985343186185e-06
screened O 0 3.562171696103178e-05
for O 0 1.3145498087396845e-05
germline O 0 0.008756821975111961
PTEN O 0 0.10103758424520493
mutations O 0 0.00022483784414362162
. O 0 3.7825422623427585e-05

PTEN O 1 0.7585182189941406
mutations O 0 0.0004990208544768393
were O 0 1.344587690255139e-05
identified O 0 4.879806965618627e-06
in O 0 6.115280939411605e-07
30 O 0 3.5931105912823114e-07
of O 0 7.561438053471647e-08
37 O 0 9.784039320948068e-07
( O 0 2.897528190715093e-07
81 O 0 1.8383361748419702e-06
% O 0 6.636718694608135e-07
) O 0 2.1043589981672994e-07
CD B-Disease 0 3.0762728329136735e-06
families O 0 5.944511940469965e-07
, O 0 2.084960470938313e-07
including O 0 2.8753140668413835e-07
missense O 0 1.6982588931568898e-05
and O 0 1.3626918189402204e-06
nonsense O 0 2.2896805603522807e-05
point O 0 1.5954466334733297e-06
mutations O 0 2.802144081215374e-06
, O 0 3.934700600893848e-07
deletions O 0 3.4831844004656887e-06
, O 0 4.107830591237871e-07
insertions O 0 1.0007849596149754e-05
, O 0 8.471031947010488e-07
a O 0 2.5138945147773484e-06
deletion O 0 0.00014945826842449605
/ O 0 0.00014051361358724535
insertion O 0 3.923539043171331e-05
and O 0 7.347464361373568e-06
splice O 0 0.00044601105037145317
site O 0 7.835147698642686e-05
mutations O 0 0.00021433850633911788
. O 0 3.2782390917418525e-05

These O 0 5.8011548389913514e-05
mutations O 0 7.76548040448688e-05
were O 0 2.8858073619630886e-06
scattered O 0 1.479581328567292e-06
over O 0 3.363859377714107e-07
the O 0 2.0288361213260941e-07
entire O 0 5.752470997322234e-07
length O 0 8.433951848019205e-07
of O 0 1.830678684200393e-07
PTEN O 0 0.00023227607016451657
, O 0 2.731725317062228e-07
with O 0 5.998715835175972e-08
the O 0 9.815752832764701e-08
exception O 0 1.998910192924086e-07
of O 0 2.5104053946733984e-08
the O 0 1.0167131136995522e-07
first O 0 3.341630758768588e-07
, O 0 2.871014714855846e-07
fourth O 0 2.1968739929434378e-06
and O 0 1.1193004638698767e-06
last O 0 1.7615069737075828e-05
exons O 0 6.0241167375352234e-05
. O 0 2.3237682398757897e-05

A O 0 0.00019561014778446406
hot O 0 0.00017758180911187083
spot O 0 4.3776934035122395e-05
for O 0 7.935547728266101e-06
PTEN O 0 0.0012069058138877153
mutation O 0 1.38739205794991e-05
in O 0 1.8731926729742554e-06
CD B-Disease 0 1.0408617526991293e-05
was O 0 4.859354703512508e-06
identified O 0 1.3972356782687712e-06
in O 0 4.27717452566867e-07
exon O 0 6.728638254571706e-06
5 O 0 5.064517836217419e-07
that O 0 8.41760154912663e-08
contains O 0 7.377435196076476e-08
the O 0 2.0668912270593864e-07
PTPase O 0 6.9911648097331636e-06
core O 0 1.7202194158016937e-06
motif O 0 7.941777653286408e-07
, O 0 8.173104504294315e-08
with O 0 6.577980116162507e-08
13 O 0 1.7245989170078246e-07
of O 0 4.9641553090395973e-08
30 O 0 2.5117014956776984e-07
( O 0 2.6331042590754805e-07
43 O 0 9.108176186600758e-07
% O 0 9.584052804711973e-07
) O 0 6.228119673323818e-07
CD B-Disease 0 9.142262570094317e-06
mutations O 0 6.69774817652069e-06
identified O 0 1.928548499563476e-06
in O 0 5.731197916247766e-07
this O 0 1.4588475778509746e-06
exon O 0 8.65523616084829e-05
. O 0 1.8337015717406757e-05

Seven O 0 1.6259480617009103e-05
of O 0 1.0079842240884318e-06
30 O 0 1.3463741197483614e-06
( O 0 7.055431865410355e-07
23 O 0 1.0325314860892831e-06
% O 0 3.718381833550666e-07
) O 0 5.5021391887066784e-08
were O 0 5.958134252637137e-08
within O 0 3.0495261427176956e-08
the O 0 7.491083664490361e-08
core O 0 8.102633728412911e-07
motif O 0 4.804344939657312e-07
, O 0 6.105862837557652e-08
the O 0 4.261555730522559e-08
majority O 0 1.2919088021590142e-07
( O 0 8.334622236816358e-08
five O 0 3.3536853294435787e-08
of O 0 1.6300596428209246e-08
seven O 0 8.755759495215898e-08
) O 0 5.171079209276286e-08
of O 0 2.6000181563290425e-08
which O 0 1.5097722894097387e-07
were O 0 1.1954236924793804e-06
missense O 0 2.4844577637850307e-05
mutations O 0 3.655528644230799e-06
, O 0 1.7354815895487263e-07
possibly O 0 4.1182252630278526e-07
pointing O 0 5.482857545757724e-07
to O 0 9.887324381452345e-08
the O 0 1.1439806257840246e-07
functional O 0 5.44144540981506e-07
significance O 0 4.3462043208819523e-07
of O 0 1.6050152851221355e-07
this O 0 1.085744088413776e-06
region O 0 1.2298314686631784e-05
. O 0 2.414081791357603e-05

Germline O 0 0.4999518394470215
PTEN O 0 0.4678646922111511
mutations O 0 0.0007417917950078845
were O 0 1.4300047951110173e-05
identified O 0 5.559533292398555e-06
in O 0 3.879192149724986e-07
four O 0 1.485158236391726e-07
of O 0 7.844750626873065e-08
seven O 0 6.116534905231674e-07
( O 0 1.24145412883081e-06
57 O 0 8.317513675137889e-06
% O 0 4.356812951300526e-06
) O 0 2.490409542588168e-06
BZS B-Disease 0 0.0002171071682823822
families O 0 7.295182967936853e-06
studied O 0 3.040522824448999e-05
. O 0 2.1191312043811195e-05

Interestingly O 0 0.0018151927506551147
, O 0 5.1737360990955494e-06
none O 0 2.170782863686327e-06
of O 0 1.9202535384010844e-07
these O 0 2.692604823550937e-07
mutations O 0 3.856429430015851e-06
was O 0 4.08852611144539e-06
observed O 0 1.3909616427554283e-06
in O 0 5.723436515836511e-07
the O 0 2.2942820123716956e-06
PTPase O 0 0.0001627579767955467
core O 0 3.770269177039154e-05
motif O 0 6.635169847868383e-05
. O 0 2.1754667614004575e-05

It O 0 1.4154410564515274e-05
is O 0 1.2177964663351304e-06
also O 0 3.7621734350068436e-07
worthy O 0 6.131819532129157e-07
of O 0 9.319816740571696e-08
note O 0 8.70691224008624e-07
that O 0 1.4931082148450514e-07
a O 0 3.220484359189868e-07
single O 0 7.909246733106556e-07
nonsense O 0 6.248649242479587e-06
point O 0 1.0702290182962315e-06
mutation O 0 1.8963887669087853e-06
, O 0 2.502298173112649e-07
R233X O 0 5.87451177125331e-06
, O 0 1.6672002800532937e-07
was O 0 5.11454004481493e-07
observed O 0 2.8480422997745336e-07
in O 0 1.9348198065927136e-07
the O 0 5.058300871496613e-07
germline O 0 2.0965613657608628e-05
DNA O 0 2.3551867798232706e-06
from O 0 2.5644300194471725e-07
two O 0 2.46375492451989e-07
unrelated O 0 4.1425669223826844e-06
CD B-Disease 0 9.927753126248717e-06
families O 0 1.7494313624411006e-06
and O 0 1.481313688600494e-06
one O 0 2.990454049722757e-06
BZS B-Disease 0 0.000833170663099736
family O 0 4.0884126065066084e-05
. O 0 3.3355827326886356e-05

Genotype O 1 0.9766100645065308
- O 1 0.9694653153419495
phenotype O 0 0.22438104450702667
studies O 0 2.1647216271958314e-05
were O 0 2.842408548531239e-06
not O 0 4.2397792299198045e-07
performed O 0 1.0462210866535315e-06
on O 0 2.335280839815823e-07
this O 0 1.2324704812272103e-07
small O 0 4.073632737799926e-07
group O 0 1.261205966329726e-06
of O 0 1.003953002509661e-06
BZS B-Disease 0 0.0006689209258183837
families O 0 2.815932202793192e-05
. O 0 4.211599662085064e-05

However O 0 0.0001725664478726685
, O 0 4.722662197309546e-05
genotype O 0 0.004789883736521006
- O 0 0.022595828399062157
phenotype O 0 0.0013299771817401052
analysis O 0 9.464834874961525e-06
inthe O 0 0.00012928876094520092
group O 0 2.41816110246873e-06
of O 0 3.2483717404829804e-07
CD B-Disease 0 1.2150782822573092e-05
families O 0 1.7856141312222462e-06
revealed O 0 3.216059894839418e-06
two O 0 1.5669770903059543e-07
possible O 0 4.2251232912349224e-07
associations O 0 5.297637244439102e-07
worthy O 0 5.166485266272502e-07
of O 0 1.0659778126864694e-07
follow O 0 1.2763149470629287e-06
- O 0 1.765292472555302e-05
up O 0 9.34307649913535e-07
in O 0 8.139747365021321e-07
independent O 0 4.0412560338154435e-06
analyses O 0 1.649584919505287e-05
. O 0 1.316768248216249e-05

The O 0 1.4587498299079016e-05
first O 0 5.230226179264719e-06
was O 0 3.940035639971029e-06
an O 0 4.0858574834601313e-07
association O 0 7.917382163213915e-07
noted O 0 4.277957827980572e-07
in O 0 1.428458773489183e-07
the O 0 1.455852185472395e-07
group O 0 3.1344328021987167e-07
of O 0 1.3939587972799927e-07
CD B-Disease 0 2.037748163274955e-05
families O 0 7.709699275437742e-06
with O 0 0.00012120197061449289
breast B-Disease 1 0.9999891519546509
disease I-Disease 0 0.3324652910232544
. O 0 9.13178373593837e-05

A O 0 0.00015315733617171645
correlation O 0 7.122761599021032e-05
was O 0 1.4501152691082098e-05
observed O 0 2.210361571997055e-06
between O 0 4.970863756170729e-07
the O 0 4.7421275439774035e-07
presence O 0 2.1198738977545872e-06
/ O 0 1.9560440705390647e-05
absence O 0 1.3867273764844867e-06
of O 0 2.1285210038968216e-07
a O 0 4.29984220318147e-06
PTEN O 0 0.00172739929985255
mutation O 0 4.631817773770308e-06
and O 0 3.671246702197095e-07
the O 0 3.525139788962406e-07
type O 0 2.9042723781458335e-06
of O 0 8.954216923484637e-07
breast O 0 0.030894499272108078
involvement O 0 0.00020169722847640514
( O 0 2.9739887395408005e-05
unaffected O 0 0.00144286232534796
versus O 0 0.004042929038405418
benign O 1 0.8087109923362732
versus O 0 0.06061669439077377
malignant O 1 0.9736975431442261
) O 0 3.409363853279501e-05
. O 0 2.358129495405592e-05

Specifically O 0 6.752067565685138e-05
and O 0 2.7447113097878173e-06
more O 0 3.5891341099159035e-07
directly O 0 1.9472648205010046e-07
, O 0 8.759785430356715e-08
an O 0 8.206250612374788e-08
association O 0 6.246869475035055e-07
was O 0 9.430356158190989e-07
also O 0 1.732293526401918e-07
observed O 0 2.76922406783342e-07
between O 0 1.3778921470475325e-07
the O 0 1.38239357738712e-07
presence O 0 4.0721798200138437e-07
of O 0 1.805687617206786e-07
a O 0 7.089093287504511e-06
PTEN O 0 0.0306057371199131
mutation O 0 0.0001601945550646633
and O 0 0.0008339760825037956
malignant B-Disease 1 0.9999995231628418
breast I-Disease 1 0.9999954700469971
disease I-Disease 1 0.8602507710456848
. O 0 9.323808626504615e-05

Secondly O 0 0.018977727741003036
, O 0 1.7644222680246457e-05
there O 0 1.5764667296025436e-06
appeared O 0 5.955684628133895e-06
to O 0 2.948821702375426e-07
be O 0 2.3680826188865467e-07
an O 0 3.309765475023596e-07
interdependent O 0 1.4718812963110395e-05
association O 0 2.6193392841378227e-06
between O 0 6.084333108447026e-07
mutations O 0 2.1334544726414606e-06
upstream O 0 1.0088083399750758e-06
and O 0 1.47491945767797e-07
within O 0 1.5765763805575261e-07
the O 0 4.718043555840268e-07
PTPase O 0 2.6586079911794513e-05
core O 0 5.513650194188813e-06
motif O 0 2.180609271817957e-06
, O 0 1.7971424881579878e-07
the O 0 1.2326162845965882e-07
core O 0 9.46262616707827e-07
motif O 0 8.915941407394712e-07
containing O 0 1.6788170853487827e-07
the O 0 1.3522738129267964e-07
majority O 0 2.2943949318232626e-07
of O 0 1.9580319587930717e-07
missense O 0 3.9915154047776014e-05
mutations O 0 3.0348453492479166e-06
, O 0 1.4159307681893551e-07
and O 0 6.750612868700046e-08
the O 0 1.2877511323949875e-07
involvement O 0 4.2595607396833657e-07
of O 0 4.678519616163612e-08
all O 0 8.201869405866091e-08
major O 0 5.237096161181398e-07
organ O 0 4.498410999076441e-05
systems O 0 1.5164842807280365e-05
( O 0 8.876379524735967e-07
central O 0 1.4024702750248252e-06
nervous O 0 7.457898027496412e-05
system O 0 4.480355528357904e-06
, O 0 7.2639145400899e-06
thyroid O 1 0.5820692777633667
, O 0 1.6675321603543125e-05
breast O 1 0.9502835273742676
, O 0 0.00028273731004446745
skin O 1 0.9998492002487183
and O 0 0.022496864199638367
gastrointestinal O 1 0.9999328851699829
tract O 1 0.5256251692771912
) O 0 2.366022818023339e-05
. O 0 2.3130098270485178e-05

However O 0 5.1005801651626825e-05
, O 0 1.5961816188792e-06
these O 0 2.1334633970582217e-07
observations O 0 9.083687473321334e-07
would O 0 2.0272213419048057e-07
need O 0 1.332133052756035e-07
to O 0 6.634732585553138e-08
be O 0 7.071775343092668e-08
confirmed O 0 3.647164135145431e-07
by O 0 9.39671238597839e-08
studying O 0 2.0095663444408274e-07
a O 0 1.8724018957527733e-07
larger O 0 4.748807214127737e-07
number O 0 1.7283134923218313e-07
of O 0 2.0523718546883174e-07
CD B-Disease 0 1.786834945960436e-05
families O 0 6.621819920837879e-06
. O 0 1.7341233615297824e-05

Molecular O 0 0.021579895168542862
defects O 0 0.10627851635217667
leading O 0 1.306001558987191e-05
to O 0 2.2307972358248662e-06
human O 0 3.020218628080329e-06
complement B-Disease 0 2.0220370060997084e-05
component I-Disease 0 0.0065110609866678715
C6 I-Disease 1 1.0
deficiency I-Disease 1 0.999996542930603
in O 0 3.538137207215186e-06
an O 0 1.8155418501919485e-06
African O 0 9.18964906304609e-06
- O 0 3.7116486055310816e-05
American O 0 5.9133221839147154e-06
family O 0 1.6732077710912563e-05
. O 0 1.9323453670949675e-05

Complement B-Disease 0 0.0025669753085821867
component I-Disease 1 0.8180792331695557
C6 I-Disease 1 1.0
deficiency I-Disease 1 0.9999997615814209
( O 0 5.246697401162237e-05
C6D B-Disease 0 0.04687364399433136
) O 0 1.5207521755655762e-05
was O 0 0.001472016330808401
diagnosed O 1 0.5291612148284912
in O 0 5.040800488131936e-07
a O 0 7.435920679199626e-07
16 O 0 3.080612032135832e-06
- O 0 2.3877240892034024e-05
year O 0 1.8082188262269483e-06
- O 0 8.502122909703758e-06
old O 0 6.048376235412434e-06
African O 0 3.3641522350080777e-06
- O 0 1.2197176147310529e-05
American O 0 2.9650664146174677e-06
male O 0 1.593269917066209e-05
with O 0 2.048530768661294e-05
meningococcal B-Disease 1 0.9999951124191284
meningitis I-Disease 1 0.9999904632568359
. O 0 0.00013162237883079797

The O 0 0.00010266515164403245
patients O 0 0.007092629559338093
father O 0 1.954732942976989e-05
and O 0 1.1060735687351553e-06
two O 0 6.646422434641863e-07
brothers O 0 5.218995283939876e-06
also O 0 5.982971060802811e-07
had O 0 4.421908670337871e-06
C6D B-Disease 0 0.001203476102091372
, O 0 4.098126566987048e-07
but O 0 2.11688686135858e-07
gave O 0 4.906180492980639e-07
no O 0 2.1643610637056554e-07
history O 0 3.5585895830081427e-07
of O 0 8.964547077994212e-07
meningitis B-Disease 1 0.9990103244781494
or O 0 5.341506039258093e-06
other O 0 7.446434210578445e-06
neisserial B-Disease 1 0.8781136274337769
infection I-Disease 0 0.0026209696661680937
. O 0 2.3441898520104587e-05

By O 0 3.466058478807099e-05
using O 0 2.700386176002212e-05
exon O 0 9.595369920134544e-05
- O 0 3.6941371945431456e-05
specific O 0 3.530445383148617e-06
polymerase O 0 2.656801007105969e-05
chain O 0 1.2398565559124108e-05
reaction O 0 8.566059477743693e-06
( O 0 1.6735928056732519e-06
PCR O 0 3.3143511245725676e-05
) O 0 1.4353552160173422e-06
/ O 0 5.59378804609878e-06
single O 0 9.584803137840936e-07
- O 0 6.8692634158651344e-06
strand O 0 6.175579528644448e-06
conformation O 0 3.733148787432583e-06
polymorphism O 0 2.400741095698322e-06
as O 0 1.1023210078064949e-07
a O 0 2.719243639148772e-07
screening O 0 1.4941565495973919e-06
step O 0 5.470901669468731e-07
and O 0 1.9219812941173586e-07
nucleotide O 0 6.933367444617033e-07
sequencing O 0 9.418241120329185e-07
of O 0 7.096745946455485e-08
target O 0 9.168536507786484e-07
exons O 0 2.113003347403719e-06
, O 0 1.9183225674623827e-07
we O 0 9.920722732204013e-08
determined O 0 4.287637693778379e-07
that O 0 1.0295241281710332e-07
the O 0 3.284616241217009e-07
proband O 0 3.6806199204875156e-05
was O 0 2.258858785353368e-06
a O 0 1.0221979209745768e-06
compound O 0 9.793806384550408e-06
heterozygote O 0 1.6138579667313024e-05
for O 0 6.745528366991493e-07
two O 0 3.93349546357058e-06
C6 O 0 0.02292218804359436
gene O 0 8.83343382156454e-05
mutations O 0 7.264337182277814e-05
. O 0 2.6929490559268743e-05

The O 0 3.261928941356018e-05
first O 0 1.0177865988225676e-05
, O 0 1.6223817738136859e-06
1195delC O 0 1.2704488653980661e-05
located O 0 8.647875233691593e-07
in O 0 5.307366564011318e-07
exon O 0 5.645154942612862e-06
7 O 0 1.1492505791466101e-06
, O 0 1.7563660037467343e-07
is O 0 6.362633797607486e-08
a O 0 1.981807997708529e-07
novel O 0 8.282940484605206e-07
mutation O 0 6.514961228276661e-07
, O 0 6.94529376232822e-08
while O 0 7.762589859794389e-08
the O 0 1.3696605094537517e-07
second O 0 9.01020484889159e-07
, O 0 4.4025637180311605e-07
1936delG O 0 3.964512416132493e-06
in O 0 4.054254532093182e-07
exon O 0 5.684624738933053e-06
12 O 0 1.008461140372674e-06
, O 0 2.2779775576964312e-07
has O 0 1.7325511691979045e-07
been O 0 3.5001494325115345e-07
described O 0 1.3205079767431016e-06
before O 0 3.2993278864523745e-07
to O 0 2.682127728803607e-07
cause O 0 1.615113774278143e-06
C6D B-Disease 0 5.7883957197191194e-05
in O 0 5.521403636521427e-07
an O 0 3.9206241808642517e-07
unrelated O 0 5.998372216708958e-06
African O 0 6.906494945724262e-06
- O 0 1.973282815015409e-05
American O 0 3.2407708658865886e-06
individual O 0 3.0844425964460243e-06
. O 0 8.645716661703773e-06

Both O 0 0.00013374813715927303
mutations O 0 0.00022519208141602576
result O 0 2.6070452804560773e-05
in O 0 2.486816083546728e-05
premature O 0 0.0017256004502996802
termination O 0 0.00017242220928892493
codons O 0 8.897905354388058e-05
and O 0 1.143627378041856e-05
C6 O 0 0.006875746417790651
null O 0 0.00044394235010258853
alleles O 0 0.0001819512981455773
. O 0 4.5574503019452095e-05

Allele O 0 0.002011847449466586
- O 0 0.0002758126938715577
specific O 0 2.702630081330426e-05
PCR O 0 0.00021128133812453598
indicated O 0 1.888152110041119e-05
that O 0 5.011561370338313e-07
the O 0 4.3160355289728614e-07
probands O 0 1.4349364391819108e-05
two O 0 4.5377089463727316e-07
brothers O 0 6.298642347246641e-06
also O 0 7.737732516943652e-07
inherited O 0 1.1741924936359283e-05
the O 0 5.775520435236103e-07
1195delC O 0 3.5082757676718757e-05
mutation O 0 2.5735635063028894e-06
from O 0 3.69418756918094e-07
their O 0 5.109966991767578e-07
heterozygous O 0 1.045464705384802e-05
mother O 0 5.037652044848073e-06
and O 0 3.111236139829998e-07
the O 0 7.345477683884383e-07
1936delG O 0 2.4988907171064056e-05
mutation O 0 3.240480282329372e-06
from O 0 4.901265810985933e-07
their O 0 9.361181128042517e-07
homozygous O 0 3.5572873457567766e-05
father O 0 1.9637798686744645e-05
. O 0 3.820008714683354e-06
. O 0 1.4196277334121987e-05

PAX6 O 1 0.9788479208946228
mutations O 0 0.012450327165424824
reviewed O 0 0.0022012153640389442
. O 0 0.0003100217436440289

Mutations O 0 0.0017134625231847167
in O 0 4.1027353290701285e-05
PAX6 O 0 0.001589240855537355
are O 0 1.6108865565911401e-06
responsible O 0 2.6076722861034796e-06
for O 0 7.074594350342522e-07
human O 0 2.3194429559225682e-06
aniridia B-Disease 1 0.9929775595664978
and O 0 1.4302896715889801e-06
have O 0 5.102564841763524e-07
also O 0 4.0414340674033156e-07
been O 0 5.403565523920406e-07
found O 0 9.430500540474895e-07
in O 0 3.7959168821544154e-06
patients O 0 0.00020397527259774506
with O 0 1.2018561392324045e-05
Peters B-Disease 1 0.9999995231628418
anomaly I-Disease 1 0.999996542930603
, O 0 0.00011971290950896218
with O 0 0.10844235122203827
congenital B-Disease 1 1.0
cataracts I-Disease 1 0.9999980926513672
, O 0 3.320801624795422e-05
with O 0 2.7805905119748786e-05
autosomal B-Disease 1 0.59565669298172
dominant I-Disease 0 0.07215727120637894
keratitis I-Disease 1 0.9319596290588379
, O 0 3.830587957054377e-06
and O 0 2.216149141531787e-06
with O 0 4.5154697545513045e-06
isolated B-Disease 0 0.005369361024349928
foveal I-Disease 1 0.9999923706054688
hypoplasia I-Disease 1 0.9999730587005615
. O 0 0.0001353732805000618

No O 0 7.540695514762774e-05
locus O 0 9.541718463879079e-05
other O 0 4.365222594060469e-06
than O 0 5.985452389722923e-06
chromosome O 0 4.905282912659459e-05
11p13 O 0 7.26322250557132e-05
has O 0 1.6682212162777432e-06
been O 0 1.3720833749175654e-06
implicated O 0 7.67585061112186e-06
in O 0 3.5555503927753307e-06
aniridia B-Disease 1 0.994860053062439
, O 0 7.59550630391459e-07
and O 0 9.170897214971774e-07
PAX6 O 0 0.00037103364593349397
is O 0 2.4825340005918406e-07
clearly O 0 4.235180597333965e-07
the O 0 6.679223218952757e-08
major O 0 2.0102582709569106e-07
, O 0 1.0753593215895307e-07
if O 0 7.768188936552178e-08
not O 0 1.0010267459392708e-07
only O 0 1.297515694886897e-07
, O 0 5.281423796077434e-07
gene O 0 5.724447419197531e-06
responsible O 0 7.009344244579552e-06
. O 0 1.6118907296913676e-05

Twenty O 0 0.00018843973521143198
- O 0 0.00010046536772279069
eight O 0 4.299793090467574e-06
percent O 0 3.317850996609195e-06
of O 0 6.447958185162861e-07
identified O 0 1.3109205610817298e-05
PAX6 O 0 0.00284544937312603
mutations O 0 2.7003319701179862e-05
are O 0 9.082258429771173e-07
C O 0 0.00016007073281798512
- O 0 0.002680532867088914
T O 0 0.0004411761765368283
changes O 0 4.180579253443284e-06
at O 0 2.3544839677924756e-06
CpG O 0 2.503374889784027e-05
dinucleotides O 0 1.840516779338941e-05
, O 0 2.855088325759425e-07
20 O 0 2.3636849277863803e-07
% O 0 2.5025272520906583e-07
are O 0 6.764184234953063e-08
splicing O 0 2.660552127053961e-06
errors O 0 1.978908130695345e-06
, O 0 1.3656926967087202e-07
and O 0 6.42530650907247e-08
more O 0 4.618548743451356e-08
than O 0 8.745995216941083e-08
30 O 0 3.4762211953420774e-07
% O 0 4.610336929999903e-07
are O 0 1.7826590692493482e-07
deletion O 0 9.083428267331328e-06
or O 0 1.1193420732524828e-06
insertion O 0 2.529885205149185e-05
events O 0 1.4688663213746622e-05
. O 0 1.765257002261933e-05

There O 0 3.009990723512601e-05
is O 0 3.227508159397985e-06
a O 0 4.167709448665846e-06
noticeably O 0 0.0003955627325922251
elevated O 0 1.748699287418276e-05
level O 0 9.989989848691039e-07
of O 0 2.2446485559157736e-07
mutation O 0 2.167623961213394e-06
in O 0 3.8518021483469056e-07
the O 0 2.9013165203650715e-07
paired O 0 3.6874682791676605e-06
domain O 0 7.375296604550385e-07
compared O 0 1.0422327250125818e-06
with O 0 9.375193599225895e-08
the O 0 1.4853394247893448e-07
rest O 0 4.7574471295774856e-07
of O 0 1.4549029003774194e-07
the O 0 2.3441307348548435e-06
gene O 0 2.5445067876717076e-05
. O 0 1.4294661013991572e-05

Increased O 0 0.00018265772087033838
mutation O 0 0.00010439574543852359
in O 0 4.911409632768482e-06
the O 0 2.2792994514020393e-06
homeodomain O 0 5.828059511259198e-05
is O 0 8.916774731915211e-07
accounted O 0 1.6686541357557871e-06
for O 0 2.559787333211716e-07
by O 0 6.436002877308056e-07
the O 0 2.537698037485825e-06
hypermutable O 0 0.0006085278582759202
CpG O 0 0.00026506648282520473
dinucleotide O 0 0.000185818164027296
in O 0 8.340723070432432e-06
codon O 0 9.116269939113408e-05
240 O 0 6.237204797798768e-05
. O 0 2.508479701646138e-05

Very O 0 9.960627357941121e-05
nearly O 0 1.3979906725580804e-05
all O 0 1.925150854731328e-06
mutations O 0 7.1982240115175955e-06
appear O 0 2.558289452281315e-06
to O 0 6.287871769927733e-07
cause O 0 1.904799091789755e-06
loss O 0 1.8527381371313822e-06
of O 0 6.203862312759156e-08
function O 0 1.007182106604887e-07
of O 0 6.297076993178052e-08
the O 0 7.924521128188644e-07
mutant O 0 2.331746327399742e-05
allele O 0 5.031261480326066e-06
, O 0 9.615476415092417e-08
and O 0 5.3559755741616755e-08
more O 0 2.916701546951117e-08
than O 0 4.872152814527908e-08
80 O 0 2.1636986957673798e-07
% O 0 2.0572159087350883e-07
of O 0 1.2773081436989742e-07
exonic O 0 3.704159098560922e-05
substitutions O 0 9.048403626366053e-06
result O 0 3.1684105579188326e-06
in O 0 3.3088106192735722e-06
nonsense O 0 8.050916221691296e-05
codons O 0 0.00010320442379452288
. O 0 2.4638431568746455e-05

In O 0 5.8345602155895904e-05
a O 0 1.8439181076246314e-05
gene O 0 1.2725588021567091e-05
with O 0 8.925613883548067e-07
such O 0 8.02506235686451e-07
extraordinarily O 0 8.863437687978148e-05
high O 0 1.9490164504532004e-06
sequence O 0 6.183483947097557e-07
conservation O 0 5.598456027655629e-07
throughout O 0 3.287361778347986e-07
evolution O 0 8.142224032781087e-07
, O 0 2.2305749780571205e-07
there O 0 2.3739821131130157e-07
are O 0 2.7360036369827867e-07
presumed O 0 1.7101132470997982e-05
undiscovered O 0 3.9711081626592204e-05
missense O 0 5.112276994623244e-05
mutations O 0 6.378184025379596e-06
, O 0 3.216196660105197e-07
these O 0 9.365666642224824e-08
are O 0 9.223087005238995e-08
hypothesized O 0 1.9008756453331443e-06
to O 0 1.9413830898429296e-07
exist O 0 1.5745330017580272e-07
in O 0 2.1485094237050362e-07
as O 0 6.393277658389707e-07
- O 0 7.420965266646817e-05
yet O 0 6.468673291237792e-06
unidentified O 0 4.223662108415738e-05
phenotypes O 0 4.166660801274702e-05
. O 0 4.596324288286269e-06
. O 0 1.1767718206101563e-05

Genetic O 0 0.0021036111284047365
heterogeneity O 0 0.0007241511484608054
and O 0 2.4278419004986063e-05
penetrance O 0 0.0002886611910071224
analysis O 0 6.022624347679084e-06
of O 0 4.1225203517569753e-07
the O 0 2.243050857941853e-06
BRCA1 O 0 0.00026085085119120777
and O 0 4.565460585581604e-06
BRCA2 O 0 0.0002448642044328153
genes O 0 1.0739960998762399e-05
in O 0 8.290021651191637e-05
breast B-Disease 1 0.9999010562896729
cancer I-Disease 1 0.6422905325889587
families O 0 3.777639722102322e-05
. O 0 3.3383261325070634e-05

The O 0 0.04530221223831177
Breast B-Disease 1 0.9999998807907104
Cancer I-Disease 1 0.9999945163726807
Linkage O 0 0.012308742851018906
Consortium O 0 0.0016863556811586022
. O 0 0.00014550071500707418

The O 0 2.097417200275231e-05
contribution O 0 1.8934970285044983e-05
of O 0 2.023662545980187e-06
BRCA1 O 0 0.00035262980964034796
and O 0 7.823941814422142e-06
BRCA2 O 0 0.006287127733230591
to O 0 0.0003450121730566025
inherited B-Disease 1 1.0
breast I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
was O 0 0.0003011651278939098
assessed O 0 1.2978852282685693e-05
by O 0 6.820754379077698e-07
linkage O 0 5.7140732678817585e-06
and O 0 5.697312417396461e-07
mutation O 0 9.711168331705267e-07
analysis O 0 3.6850951801170595e-07
in O 0 3.699327919548523e-07
237 O 0 3.164599775118404e-06
families O 0 3.2423116635982296e-07
, O 0 4.936443431802218e-08
each O 0 1.614686695461387e-08
with O 0 4.81446313926881e-08
at O 0 1.667507234515142e-07
least O 0 1.0709175768397472e-07
four O 0 1.306176642401624e-07
cases O 0 3.693063774790062e-07
of O 0 1.7322684016107814e-06
breast B-Disease 1 0.9999617338180542
cancer I-Disease 0 0.06100860610604286
, O 0 4.262230675067258e-07
collected O 0 9.430797263121349e-07
by O 0 2.29021361519699e-06
the O 0 0.0007238676189444959
Breast B-Disease 1 0.9999998807907104
Cancer I-Disease 1 0.9999877214431763
Linkage O 0 0.0023676215205341578
Consortium O 0 0.0007216453086584806
. O 0 6.391155329765752e-05

Families O 0 0.0001265772443730384
were O 0 7.113337687769672e-06
included O 0 2.3791910734871635e-06
without O 0 1.1013959237970994e-06
regard O 0 1.1014851679647109e-06
to O 0 3.3583654612812097e-07
the O 0 2.835613486240618e-07
occurrence O 0 2.7337318897480145e-06
of O 0 1.2521338703663787e-06
ovarian B-Disease 1 0.6729069948196411
or I-Disease 0 6.7895452957600355e-06
other I-Disease 0 1.0425705113448203e-05
cancers I-Disease 0 0.009150675497949123
. O 0 3.974578430643305e-05

Overall O 0 0.005039335694164038
, O 0 0.0003402476431801915
disease O 0 0.015535077080130577
was O 0 2.7578395020100288e-05
linked O 0 1.262212754227221e-05
to O 0 1.6943253058343544e-06
BRCA1 O 0 8.68625138537027e-05
in O 0 2.997738874910283e-07
an O 0 1.1171308500479427e-07
estimated O 0 1.474944752999363e-07
52 O 0 3.0784369187131233e-07
% O 0 6.833731447386526e-08
of O 0 1.665179993892707e-08
families O 0 2.3482225230964104e-07
, O 0 1.5785548157509766e-07
to O 0 2.1097362434829847e-07
BRCA2 O 0 8.70545318321092e-06
in O 0 2.691487850370322e-07
32 O 0 4.782347673426557e-07
% O 0 1.1929576260172325e-07
of O 0 1.4227889089113432e-08
families O 0 1.3430626211174967e-07
, O 0 1.1246821429722331e-07
and O 0 1.2465918075577065e-07
to O 0 1.4004211834617308e-07
neither O 0 1.2613912758752122e-06
gene O 0 1.266378944819735e-06
in O 0 3.466521150130575e-07
16 O 0 7.729206572548719e-07
% O 0 3.585528247640468e-07
( O 0 2.0875467043879326e-07
95 O 0 6.000547614348761e-07
% O 0 3.879606538248481e-07
confidence O 0 1.4252001392378588e-06
interval O 0 6.610463060496841e-06
[ O 0 5.881501238036435e-06
CI O 0 0.00014945799193810672
] O 0 3.779423650485114e-06
6 O 0 8.805942570688785e-07
% O 0 5.541327823266329e-07
- O 0 7.334841029660311e-06
28 O 0 1.8709432652030955e-06
% O 0 6.378527928063704e-07
) O 0 2.189965755405865e-07
, O 0 1.852092168519448e-07
suggesting O 0 3.4550694181234576e-06
other O 0 1.357183691652608e-06
predisposition O 0 0.00014389539137482643
genes O 0 2.5256953449570574e-05
. O 0 2.9340428227442317e-05

The O 0 2.8341928555164486e-05
majority O 0 1.347960551356664e-05
( O 0 3.3531243843754055e-06
81 O 0 5.927352958678966e-06
% O 0 8.039440331231162e-07
) O 0 1.7927038697962416e-07
of O 0 7.894404063790716e-08
the O 0 9.901759767672047e-06
breast B-Disease 1 0.9999988079071045
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999996423721313
families O 0 1.090800651581958e-05
were O 0 4.078097845194861e-06
due O 0 5.378233254305087e-06
to O 0 9.444883062315057e-07
BRCA1 O 0 7.282335718628019e-05
, O 0 1.977588368617944e-07
with O 0 6.660076934394965e-08
most O 0 1.9838275022721064e-07
others O 0 6.039253435119463e-07
( O 0 3.296953252629464e-07
14 O 0 6.959620577617898e-07
% O 0 8.32809746498242e-07
) O 0 5.016108843847178e-07
due O 0 2.4083797143248376e-06
to O 0 3.2575685509073082e-06
BRCA2 O 0 0.0004697192052844912
. O 0 2.321278770978097e-05

Conversely O 0 0.00039452259079553187
, O 0 4.932720457873074e-06
the O 0 4.2362748331470357e-07
majority O 0 3.893394477927359e-07
of O 0 6.62004353557677e-08
families O 0 4.2092207763744227e-07
with O 0 3.2885466794141394e-07
male B-Disease 0 8.875374078343157e-06
and I-Disease 0 1.6414420315413736e-05
female I-Disease 0 0.19914501905441284
breast I-Disease 1 0.9998598098754883
cancer I-Disease 0 0.10583654791116714
were O 0 7.686083336011507e-06
due O 0 9.271002454624977e-06
to O 0 3.2200741770793684e-06
BRCA2 O 0 0.0003747759619727731
( O 0 3.0439380225288915e-06
76 O 0 2.281202432641294e-05
% O 0 6.207641945366049e-06
) O 0 3.930690581910312e-06
. O 0 8.623139365226962e-06

The O 0 2.3647146008443087e-05
largest O 0 1.7617303456063382e-05
proportion O 0 7.251532224472612e-06
( O 0 1.71252133895905e-06
67 O 0 2.9632769837917294e-06
% O 0 5.994141361043148e-07
) O 0 1.204549704425517e-07
of O 0 2.765367312917988e-08
families O 0 2.7088802312391635e-07
due O 0 5.663017645929358e-07
to O 0 1.8560457704097644e-07
other O 0 1.3159855427602452e-07
genes O 0 4.792483991877816e-07
was O 0 1.186583631351823e-06
found O 0 3.2909784408730047e-07
in O 0 1.2867052134879486e-07
families O 0 2.706925101847446e-07
with O 0 1.031708123377939e-07
four O 0 2.681056230358081e-07
or O 0 2.57697251981881e-07
five O 0 3.183932903993991e-07
cases O 0 3.354632838181715e-07
of O 0 5.687199404746934e-07
female O 0 0.018530478700995445
breast B-Disease 1 0.9996247291564941
cancer I-Disease 0 0.21894286572933197
only O 0 1.6574693290749565e-05
. O 0 3.6039196857018396e-05

These O 0 3.9505532186012715e-05
estimates O 0 4.700032150140032e-05
were O 0 3.941971044696402e-06
not O 0 1.2192873555250117e-06
substantially O 0 1.7557695173309185e-05
affected O 0 1.6842129753058543e-06
either O 0 2.6700459443418367e-07
by O 0 3.465175950623234e-07
changing O 0 2.117324129358167e-06
the O 0 8.450263067061314e-07
assumed O 0 5.5299165069300216e-06
penetrance O 0 2.6634348614607006e-05
model O 0 7.674972039239947e-06
for O 0 6.742839104845189e-07
BRCA1 O 0 4.149361120653339e-05
or O 0 3.541620685609814e-07
by O 0 3.4196816045550804e-07
including O 0 5.9030799093307e-07
or O 0 2.0768586637132103e-06
excluding O 0 3.754717909032479e-05
BRCA1 O 0 0.0011689717648550868
mutation O 0 4.703977538156323e-05
data O 0 1.403760597895598e-05
. O 0 1.833414899010677e-05

Among O 0 2.624629996716976e-05
those O 0 3.815191575995414e-06
families O 0 3.753608325496316e-06
with O 0 3.9900319279695395e-06
disease O 0 0.02233126387000084
due O 0 2.020080864895135e-05
to O 0 3.6197316148900427e-06
BRCA1 O 0 0.0002104236773448065
that O 0 2.312109899094139e-07
were O 0 5.872511792404111e-07
tested O 0 1.0767297453639912e-06
by O 0 8.784765981317832e-08
one O 0 5.1164910530587804e-08
of O 0 2.124174791617861e-08
the O 0 1.5237685602187412e-07
standard O 0 3.5779494282905944e-06
screening O 0 2.210544835179462e-06
methods O 0 1.3363247717279592e-06
, O 0 3.0738604550606397e-07
mutations O 0 1.2720691984213772e-06
were O 0 4.4126605303063116e-07
detected O 0 2.0554541606543353e-06
in O 0 2.02093048073948e-07
the O 0 1.742084663192145e-07
coding O 0 2.8586787266249303e-06
sequence O 0 2.4867873094081006e-07
or O 0 1.9706432397015305e-07
splice O 0 4.6751219997531734e-06
sites O 0 2.51910677206979e-07
in O 0 1.5417509757753578e-07
an O 0 1.0385174675775488e-07
estimated O 0 2.5763580424609245e-07
63 O 0 1.2099902733098133e-06
% O 0 5.696361995433108e-07
( O 0 5.567675316342502e-07
95 O 0 2.0578529529302614e-06
% O 0 3.473196557024494e-06
CI O 0 0.0012745654676109552
51 O 0 1.596110814716667e-05
% O 0 3.3821120268839877e-06
- O 0 7.831575931049883e-05
77 O 0 2.1377220036811195e-05
% O 0 5.949496426183032e-06
) O 0 3.78149661628413e-06
. O 0 7.922300028440077e-06

The O 0 2.557433799665887e-05
estimated O 0 1.0860632755793631e-05
sensitivity O 0 1.4093206118559465e-05
was O 0 2.9865041142329574e-06
identical O 0 1.5031307611934608e-06
for O 0 2.2451773418197263e-07
direct O 0 6.371864174070652e-07
sequencing O 0 2.7575883905228693e-06
and O 0 5.86387102430308e-07
other O 0 9.625813390812255e-07
techniques O 0 2.693907117645722e-05
. O 0 1.782436993380543e-05

The O 0 5.3240437409840524e-05
penetrance O 0 0.0004950949805788696
of O 0 6.652994215983199e-06
BRCA2 O 0 0.0007045650854706764
was O 0 9.461414265388157e-06
estimated O 0 1.2630788432943518e-06
by O 0 4.246885225711594e-07
maximizing O 0 3.1391914490086492e-06
the O 0 7.914483148852014e-07
LOD O 0 0.00010579716035863385
score O 0 2.9805601116095204e-06
in O 0 4.688561602961272e-06
BRCA2 O 0 0.000683402584400028
- O 0 0.00024375473731197417
mutation O 0 7.302895483007887e-06
families O 0 1.11201768504543e-06
, O 0 3.2135721994563937e-07
over O 0 3.321949577639316e-07
all O 0 4.687966281835543e-07
possible O 0 3.0558835533156525e-06
penetrance O 0 0.00011443033145042136
functions O 0 4.684539362642681e-06
. O 0 1.2096916179871187e-05

The O 0 2.8138598281657323e-05
estimated O 0 1.1248359442106448e-05
cumulative O 0 1.573055487824604e-05
risk O 0 8.911511940823402e-06
of O 0 3.0658318337373203e-06
breast B-Disease 1 0.9998958110809326
cancer I-Disease 0 0.26389080286026
reached O 0 7.013309186731931e-06
28 O 0 5.951550519966986e-06
% O 0 1.2594488225659006e-06
( O 0 4.3177070097044634e-07
95 O 0 1.4980146261223126e-06
% O 0 1.836899173213169e-06
CI O 0 0.00039160868618637323
9 O 0 3.3023641208274057e-06
% O 0 1.2378270639601396e-06
- O 0 9.380633855471388e-06
44 O 0 8.398179147661722e-07
% O 0 4.7458104290853953e-07
) O 0 1.0593014820869939e-07
by O 0 9.256501698473585e-08
age O 0 3.4534841120148485e-07
50 O 0 1.3661434650202864e-07
years O 0 2.7225365784033784e-07
and O 0 2.818159998696501e-07
84 O 0 2.888238668674603e-06
% O 0 1.3117520438754582e-06
( O 0 6.766893534404517e-07
95 O 0 1.5710411389591172e-06
% O 0 2.5131323582172627e-06
CI O 0 0.00041026691906154156
43 O 0 5.081584276922513e-06
% O 0 1.8600659359435667e-06
- O 0 1.0312864105799235e-05
95 O 0 2.5878380256472155e-06
% O 0 8.518724712303083e-07
) O 0 1.8520672995236964e-07
by O 0 2.5148389681817207e-07
age O 0 2.869686795747839e-06
70 O 0 3.553299620762118e-06
years O 0 9.766069524630439e-06
. O 0 1.4969512449169997e-05

The O 0 0.0004295588005334139
corresponding O 1 0.9053458571434021
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
risks O 0 0.0008708763052709401
were O 0 3.8743182813050225e-05
0 O 0 7.05430720699951e-05
. O 0 3.361050403327681e-05

4 O 0 8.470709144603461e-05
% O 0 1.620440343685914e-05
( O 0 3.3438029731769348e-06
95 O 0 3.736553935596021e-06
% O 0 3.012084107467672e-06
CI O 0 0.00023286814393941313
0 O 0 4.269722467142856e-06
% O 0 1.1126985555165447e-06
- O 0 7.331540473387577e-06
1 O 0 5.54035523236962e-07
% O 0 3.4161612916250306e-07
) O 0 7.065856522103786e-08
by O 0 7.834792370431387e-08
age O 0 3.2914053349486494e-07
50 O 0 1.0818417450764173e-07
years O 0 1.1529002108545683e-07
and O 0 1.2801692150787858e-07
27 O 0 1.347151055597351e-06
% O 0 5.066962671662623e-07
( O 0 3.54975327354623e-07
95 O 0 1.493619492975995e-06
% O 0 1.4967079096095404e-06
CI O 0 0.0001035031455103308
0 O 0 2.0558775304380106e-06
% O 0 1.2559740980577772e-06
- O 0 1.1495835678942967e-05
47 O 0 4.337051450420404e-06
% O 0 1.1191392559339874e-06
) O 0 2.853493299426191e-07
by O 0 3.484256296815147e-07
age O 0 2.031466692642425e-06
70 O 0 2.7563946787267923e-06
years O 0 9.591418347554281e-06
. O 0 1.2275770131964236e-05

The O 0 7.282703882083297e-05
lifetime O 0 0.00011418486246839166
risk O 0 3.681279849843122e-05
of O 0 7.75691387389088e-06
breast B-Disease 1 0.9999830722808838
cancer I-Disease 1 0.9534037709236145
appears O 0 2.0177340047666803e-05
similar O 0 2.845318704203237e-06
to O 0 5.246329237706959e-07
the O 0 8.517513947481348e-07
risk O 0 2.7296962343825726e-06
in O 0 2.1860544165974716e-06
BRCA1 O 0 0.0002799031208269298
carriers O 0 5.9371295719756745e-06
, O 0 2.3264536253009283e-07
but O 0 1.7890283743327018e-07
there O 0 8.428317244124628e-08
was O 0 3.295893975518993e-07
some O 0 5.056419638549414e-08
suggestion O 0 7.457687729583995e-07
of O 0 9.878296225451777e-08
a O 0 1.486833411945554e-06
lower O 0 5.772999065811746e-05
risk O 0 7.187386017903918e-06
in O 0 5.007141226087697e-06
BRCA2 O 0 0.0007331775850616395
carriers O 0 2.9768116291961633e-05
< O 0 3.437053965171799e-05
50 O 0 1.7562364291734411e-06
years O 0 1.1162718465129728e-06
of O 0 4.884024633611261e-07
age O 0 1.769977097865194e-05
. O 0 1.7617234334466048e-05

Eye B-Disease 1 0.9748274683952332
movement I-Disease 0 0.009824116714298725
abnormalities I-Disease 1 0.9936560392379761
correlate O 0 0.00021016845130361617
with O 0 2.528370350773912e-05
genotype O 0 0.17769788205623627
in O 0 0.0004037680337205529
autosomal O 1 0.9564551711082458
dominant O 0 0.3736402690410614
cerebellar B-Disease 1 0.9995073080062866
ataxia I-Disease 1 0.9999810457229614
type I-Disease 0 0.2750661373138428
I I-Disease 0 0.007012114394456148
. O 0 0.0001003734432742931

We O 0 9.043254249263555e-05
compared O 0 0.00015880586579442024
horizontal O 0 0.00020520635007414967
eye O 0 0.0008248990634456277
movements O 0 2.8463409762480296e-05
( O 0 5.154096470505465e-06
visually O 0 1.3262693755677901e-05
guided O 0 1.4926831681805197e-05
saccades O 0 0.0007142815738916397
, O 0 2.2661561160930432e-06
antisaccades O 0 2.063003194052726e-05
, O 0 2.513136792003934e-07
and O 0 1.8217511410512088e-07
smooth O 0 1.2936832263221731e-06
pursuit O 0 3.2739601465436863e-06
) O 0 3.1662131050325115e-07
in O 0 1.968723495338054e-07
control O 0 1.0240946721751243e-06
subjects O 0 1.9953308765252586e-06
( O 0 8.114782303891843e-07
n O 0 1.4824627214693464e-06
= O 0 1.9573315057641594e-06
14 O 0 3.6367134725878714e-07
) O 0 2.4308030788233737e-07
and O 0 2.2709127733833157e-07
patients O 0 2.9775201255688444e-06
with O 0 1.0551212881182437e-07
three O 0 2.8358056169963675e-07
forms O 0 1.2615234936674824e-06
of O 0 1.7799727629608242e-06
autosomal O 0 0.047823891043663025
dominant O 0 0.0021255032625049353
cerebellar B-Disease 0 0.06947001069784164
ataxias I-Disease 1 0.5703302621841431
type I-Disease 0 0.0006912301760166883
I I-Disease 0 0.0005898611852899194
spinocerebellar B-Disease 0 0.021720970049500465
ataxias I-Disease 0 0.00022384815383702517
1 I-Disease 0 3.5684113299794262e-06
and I-Disease 0 7.93541858001845e-07
2 I-Disease 0 8.477780966131832e-07
( O 0 6.331213739940722e-07
SCA1 B-Disease 0 1.917454028443899e-05
, O 0 4.1996577238023747e-07
n O 0 1.4867824802422547e-06
= O 0 2.242077698610956e-06
11 O 0 5.715309043807792e-07
; O 0 3.5533636832951743e-07
SCA2 B-Disease 0 1.952193633769639e-05
, O 0 6.236333547349204e-07
n O 0 2.281874458276434e-06
= O 0 2.8738329547195463e-06
10 O 0 3.409544149235444e-07
) O 0 3.424322301270877e-07
and O 0 7.090974349921453e-07
SCA3 B-Disease 1 0.9994798302650452
/ O 0 0.014124704524874687
Machado B-Disease 0 7.31152031221427e-05
- I-Disease 0 0.0011255162535235286
Joseph I-Disease 0 0.003195601049810648
disease I-Disease 0 0.005886878352612257
( O 0 7.937954251246992e-06
MJD B-Disease 1 0.9995563626289368
) O 0 3.752416205315967e-06
( O 0 2.606386942716199e-06
n O 0 8.943627108237706e-06
= O 0 1.240503479493782e-05
16 O 0 4.582983820000663e-06
) O 0 4.461403932509711e-06
. O 0 6.530676273541758e-06

In O 0 0.00014567271864507347
SCA1 B-Disease 0 0.001496857963502407
, O 0 7.784370609442703e-06
saccade O 0 7.855885633034632e-05
amplitude O 0 1.2175316442153417e-05
was O 0 5.019179752707714e-06
significantly O 0 9.888897693599574e-06
increased O 0 1.4362616411744966e-06
, O 0 7.688155392315821e-07
resulting O 0 3.4173840504081454e-06
in O 0 6.075558758311672e-06
hypermetria B-Disease 0 0.0015932407695800066
. O 0 4.427292151376605e-05

The O 0 8.236086432589218e-05
smooth O 0 0.0001563783298479393
pursuit O 0 0.00011360198550391942
gain O 0 9.418306581210345e-05
was O 0 8.907786832423881e-05
decreased O 0 0.00021761163952760398
. O 0 3.257782373111695e-05

In O 0 0.0002077715180348605
SCA2 B-Disease 0 0.0024994369596242905
, O 0 2.487788697180804e-05
saccade O 0 0.000341683451551944
velocity O 0 5.4479027312481776e-05
was O 0 3.20770159305539e-05
markedly O 0 0.0003799546102527529
decreased O 0 9.640990174375474e-05
. O 0 3.665079202619381e-05

The O 0 2.2343432647176087e-05
percentage O 0 1.0444672625453677e-05
of O 0 8.537471103409189e-07
errors O 0 6.438988748413976e-06
in O 0 2.5947551876015496e-06
antisaccades O 0 0.0007772634271532297
was O 0 1.2818644790968392e-05
greatly O 0 6.382229912560433e-06
increased O 0 7.582479497614258e-07
and O 0 3.9231974824360805e-07
was O 0 3.689607183332555e-06
significantly O 0 8.25827464723261e-06
correlated O 0 4.205980985716451e-06
with O 0 7.592848874082847e-07
age O 0 3.831959838862531e-05
at O 0 0.00021656016178894788
disease O 0 0.1883442997932434
onset O 0 0.41702762246131897
. O 0 9.291430615121499e-05

In O 0 2.2125794203020632e-05
addition O 0 5.892747140023857e-06
, O 0 9.324205620941939e-07
a O 0 1.0274070518789813e-06
correlation O 0 1.487244617237593e-06
between O 0 5.033638217355474e-07
smooth O 0 3.5488089906721143e-06
pursuit O 0 4.703044396592304e-06
gain O 0 4.3261998143862e-06
and O 0 2.0975726044980547e-07
the O 0 1.5005210229901422e-07
number O 0 1.280193657748896e-07
of O 0 2.303401203107569e-07
trinucleotide O 0 7.422811904689297e-05
repeats O 0 3.273665060987696e-05
was O 0 2.4102495444822125e-05
found O 0 8.786550097283907e-06
. O 0 9.54369897954166e-06

In O 0 0.00033669063122943044
SCA3 B-Disease 1 0.9994103908538818
, O 0 3.9706839743303135e-05
gaze B-Disease 0 0.00021371956972870976
- I-Disease 0 0.00022501713829115033
evoked I-Disease 0 0.0001287349296035245
nystagmus I-Disease 0 0.0007683687144890428
was O 0 7.0216137828538194e-06
often O 0 1.2817465631087543e-06
present O 0 7.435154998347571e-07
as O 0 4.562308504318935e-07
was O 0 3.0767539556109114e-06
saccade O 0 4.971268936060369e-05
hypometria O 0 6.645541725447401e-05
and O 0 1.0435942385811359e-06
smooth O 0 4.328700470068725e-06
pursuit O 0 1.2959260857314803e-05
gain O 0 2.0450836018426344e-05
was O 0 3.0985745979705825e-05
markedly O 0 0.00043610858847387135
decreased O 0 6.600051710847765e-05
. O 0 1.272790632356191e-05

Three O 0 3.960163667215966e-05
major O 0 2.1788093363284133e-05
criteria O 0 2.2863550839247182e-05
, O 0 2.040656909230165e-06
saccade O 0 5.0162518164142966e-05
amplitude O 0 5.851843525306322e-06
, O 0 1.1019905059583834e-06
saccade O 0 2.2001966499374248e-05
velocity O 0 3.147888492094353e-06
, O 0 2.5534433234497556e-07
and O 0 1.8142993951641984e-07
presence O 0 4.2480559159230324e-07
of O 0 2.229418214483303e-07
gaze B-Disease 0 2.1872867364436388e-05
- I-Disease 0 3.9124533941503614e-05
evoked I-Disease 0 3.1478550226893276e-05
nystagmus I-Disease 0 8.620945300208405e-05
, O 0 3.5931105912823114e-07
permitted O 0 2.60070351032482e-07
the O 0 1.5026819255581358e-07
correct O 0 2.1140151602594415e-06
assignment O 0 7.272061566254706e-07
of O 0 3.7328952373627544e-08
90 O 0 1.7210861358307739e-07
% O 0 8.955637298413421e-08
of O 0 2.2402231181217758e-08
the O 0 2.478737144429033e-07
SCA1 B-Disease 0 0.00013551226584240794
, O 0 1.8488466935195902e-07
90 O 0 2.231134601515805e-07
% O 0 1.1193874627224432e-07
of O 0 2.816259758731121e-08
the O 0 2.6300475042262406e-07
SCA2 B-Disease 0 0.00024344281700905412
, O 0 2.2099516172602307e-07
and O 0 1.0056695032290008e-07
93 O 0 7.045225061119709e-07
% O 0 1.215510110341711e-07
of O 0 3.49773934260611e-08
the O 0 1.2058662832714617e-06
patients O 0 0.0001901023933896795
with O 0 1.0469497055964894e-06
SCA3 B-Disease 1 0.9999696016311646
to O 0 7.473130381185911e-07
their O 0 6.245731469789462e-07
genetically O 0 1.652080209169071e-05
confirmed O 0 1.0854555512196384e-05
patient O 0 1.1729614016076084e-05
group O 0 8.568882776671671e-07
and O 0 3.7995280877112236e-07
, O 0 1.7955336772956798e-07
therefore O 0 3.257290472902241e-07
, O 0 2.279363826573899e-07
may O 0 8.175300649782002e-07
help O 0 1.1113614846181008e-06
orient O 0 6.380754348356277e-05
diagnoses O 0 0.0001859048061305657
of O 0 5.151292725713574e-07
SCA1 B-Disease 0 0.001494700787588954
, O 0 2.585563606771757e-06
SCA2 B-Disease 0 0.00015122827608138323
, O 0 7.489682616323989e-07
and O 0 1.0869064226426417e-06
SCA3 B-Disease 1 0.9686933159828186
at O 0 2.1591217773675453e-06
early O 0 9.68249423749512e-06
clinical O 0 1.5049585272208788e-05
stages O 0 5.4300844567478634e-06
of O 0 6.900227162986994e-07
the O 0 1.923807940329425e-05
diseases O 0 0.004789011552929878
. O 0 4.748698756884551e-06
. O 0 1.3310094800544903e-05

Genetic O 0 0.00042017491068691015
basis O 0 2.207807483500801e-05
and O 0 1.0508236300665885e-05
molecular O 0 4.69084334326908e-05
mechanism O 0 6.832976214354858e-05
for O 0 0.00019185870769433677
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 0.9999997615814209
fibrillation I-Disease 1 1.0
. O 0 0.0017405246617272496

Ventricular B-Disease 1 0.9998650550842285
fibrillation I-Disease 1 0.9997617602348328
causes O 0 0.0001604047283763066
more O 0 2.6321279165131273e-06
than O 0 7.57924055960757e-07
300 O 0 1.2556986348499777e-06
, O 0 6.251279387470277e-07
000 O 0 3.9076626308087725e-06
sudden O 0 1.3279615814099088e-05
deaths O 0 5.331256488716463e-06
each O 0 2.446501525810163e-07
year O 0 7.755381261631555e-07
in O 0 6.206667535479937e-07
the O 0 8.399540547543438e-07
USA O 0 5.86449823458679e-05
alone O 0 1.2449477253539953e-05
. O 0 1.062672890839167e-05

In O 0 2.093869807140436e-05
approximately O 0 7.988129254954401e-06
5 O 0 4.78204265164095e-06
- O 0 1.3532517186831683e-05
12 O 0 9.535806384519674e-07
% O 0 2.457913694797753e-07
of O 0 4.194310321281591e-08
these O 0 1.0608320621940948e-07
cases O 0 3.7513211736950325e-07
, O 0 2.3778612501246243e-07
there O 0 1.807529343977876e-07
are O 0 1.3996186964959634e-07
no O 0 1.3905453215556918e-06
demonstrable O 0 0.0934721827507019
cardiac O 1 0.9557356238365173
or O 0 5.193271590542281e-06
non O 0 0.00022378751600626856
- O 1 0.9952196478843689
cardiac O 1 0.9947704672813416
causes O 0 2.3247355329658603e-06
to O 0 1.9820026864181273e-07
account O 0 1.9640053494640597e-07
for O 0 6.336245661486828e-08
the O 0 1.4149763671866822e-07
episode O 0 1.5105384818525636e-06
, O 0 1.8481979680018412e-07
which O 0 1.1103395536338212e-07
is O 0 1.1719104264784619e-07
therefore O 0 6.721543854837364e-07
classified O 0 5.389405032474315e-06
as O 0 5.014166163164191e-05
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 0.9999998807907104
fibrillation I-Disease 1 1.0
( O 0 0.04385191947221756
IVF B-Disease 1 0.9999994039535522
) O 0 4.1053495806409046e-05
. O 0 3.0128077924018726e-05

A O 0 0.00010112878226209432
distinct O 0 3.4590881114127114e-05
group O 0 1.8601085685077123e-05
of O 0 4.7394150897162035e-06
IVF B-Disease 1 1.0
patients O 1 0.9795173406600952
has O 0 3.601423713917029e-06
been O 0 1.3141785757397884e-06
found O 0 5.648707883665338e-07
to O 0 1.7074646052606113e-07
present O 0 2.6315805712329166e-07
with O 0 2.8137529284322227e-07
a O 0 3.2674909107299754e-06
characteristic O 0 4.4187167077325284e-05
electrocardiographic O 0 0.0040379781275987625
pattern O 0 0.0001416575105395168
. O 0 3.201275103492662e-05

Because O 0 2.026596848736517e-05
of O 0 9.102766398427775e-07
the O 0 6.160905172691855e-07
small O 0 7.384219884443155e-07
size O 0 7.608629175592796e-07
of O 0 1.2910368241136894e-07
most O 0 3.7555128074018285e-07
pedigrees O 0 1.4233556612452958e-05
and O 0 3.550521796569228e-07
the O 0 3.223344720026944e-07
high O 0 3.4966035400429973e-06
incidence O 0 6.099430720496457e-06
of O 0 1.7800597618133907e-07
sudden B-Disease 0 5.0411497795721516e-05
death I-Disease 0 1.0172762813454028e-05
, O 0 2.79299598560101e-07
however O 0 3.9793278006072796e-07
, O 0 1.9878027046615898e-07
molecular O 0 1.098269081012404e-06
genetic O 0 1.912372908918769e-06
studies O 0 1.322935645475809e-06
of O 0 8.677864684614178e-07
IVF B-Disease 1 1.0
have O 0 1.0908359399763867e-05
not O 0 9.101889304474753e-07
yet O 0 1.5612223478456144e-06
been O 0 1.8556772829469992e-06
done O 0 5.9474314184626564e-06
. O 0 7.653614375158213e-06

Because O 0 0.0033174578566104174
IVF B-Disease 1 0.9999979734420776
causes O 0 0.10262531042098999
cardiac O 1 0.999737560749054
rhythm O 0 0.02199765294790268
disturbance O 0 0.0004530666919890791
, O 0 2.2370029455487384e-06
we O 0 7.229651828311034e-07
investigated O 0 2.7085516194347292e-06
whether O 0 7.482643127332267e-07
malfunction O 0 4.713003363576718e-05
of O 0 2.307833995018882e-07
ion O 0 7.4414788286958355e-06
channels O 0 3.6706446735479403e-06
could O 0 2.0736408714583376e-06
cause O 0 2.841310788426199e-06
the O 0 2.09321524380357e-06
disorder O 0 0.0001964550174307078
by O 0 6.869400408504589e-07
studying O 0 3.486541118036257e-06
mutations O 0 6.655373908870388e-06
in O 0 1.0356902748753782e-06
the O 0 5.086146757093957e-06
cardiac O 0 0.20924638211727142
sodium O 0 0.00013299779675435275
channel O 0 0.0001402865455020219
gene O 0 9.914053225656971e-05
SCN5A O 0 0.0006627907860092819
. O 0 3.95376373489853e-05

We O 0 3.7697442166972905e-05
have O 0 4.517274646786973e-06
now O 0 2.109799652316724e-06
identified O 0 2.951622718683211e-06
a O 0 1.207908098876942e-06
missense O 0 3.506834036670625e-05
mutation O 0 7.407407792925369e-06
, O 0 5.510062806024507e-07
a O 0 1.4959531426939066e-06
splice O 0 0.0003185508830938488
- O 0 0.0005850749439559877
donor O 0 2.6378664188086987e-05
mutation O 0 5.76352613279596e-06
, O 0 3.111245234777016e-07
and O 0 3.1614186468686967e-07
a O 0 2.506576038285857e-06
frameshift O 0 0.0003095993888564408
mutation O 0 2.7601247438724386e-06
in O 0 4.385261718198308e-07
the O 0 5.115651902087848e-07
coding O 0 8.809816790744662e-06
region O 0 9.647640126786428e-07
of O 0 2.953364059976593e-07
SCN5A O 0 0.00027209235122427344
in O 0 3.080659098486649e-06
three O 0 7.883704711275641e-06
IVF B-Disease 1 0.9999957084655762
families O 0 5.15099563926924e-05
. O 0 3.2574778742855415e-05

We O 0 3.062622272409499e-05
show O 0 1.646562486712355e-05
that O 0 9.754775192050147e-07
sodium O 0 5.155610779183917e-06
channels O 0 1.6201522612391273e-06
with O 0 3.265258783358149e-07
the O 0 1.0229712188447593e-06
missense O 0 6.440326251322404e-05
mutation O 0 1.3568959730037022e-05
recover O 0 3.263519101892598e-05
from O 0 1.3809443544232636e-06
inactivation O 0 6.403301085811108e-05
more O 0 2.6503440153646807e-07
rapidly O 0 7.914936759334523e-07
than O 0 1.3505312779216183e-07
normal O 0 4.1250885374211066e-07
and O 0 1.747799132090222e-07
that O 0 1.2182431419205386e-07
the O 0 9.554102007314214e-07
frameshift O 0 0.00023977874661795795
mutation O 0 3.7895831610512687e-06
causes O 0 9.944012617779663e-07
the O 0 3.079035764130822e-07
sodium O 0 3.3127982987934956e-06
channel O 0 3.081337808907847e-06
to O 0 3.0558263119928597e-07
be O 0 4.726257714082749e-07
non O 0 3.834623385046143e-06
- O 0 3.2533986086491495e-05
functional O 0 1.9935634554713033e-05
. O 0 1.2899385183118284e-05

Our O 0 7.27468723198399e-05
results O 0 8.948977483669296e-05
indicate O 0 1.6002335541998036e-05
that O 0 1.5994959312592982e-06
mutations O 0 5.332700766302878e-06
in O 0 1.953884975591791e-06
cardiac O 0 0.00736275827512145
ion O 0 4.755667396239005e-05
- O 0 5.3338520956458524e-05
channel O 0 5.387046257965267e-06
genes O 0 6.605224029954115e-07
contribute O 0 2.749839040916413e-07
to O 0 1.0672919614762577e-07
the O 0 1.9450486377081688e-07
risk O 0 6.33906779512472e-07
of O 0 3.235290932934731e-07
developing O 0 4.247869219398126e-05
IVF B-Disease 1 0.9999990463256836
. O 0 1.9845174392685294e-05
. O 0 2.0621435396606103e-05

Molecular O 0 0.0006343708373606205
heterogeneity O 0 0.00032528783776797354
in O 0 3.020668009412475e-05
mucopolysaccharidosis B-Disease 0 0.0013073126319795847
IVA I-Disease 0 0.002635495038703084
in O 0 2.609179773571668e-06
Australia O 0 1.9200865608581807e-06
and O 0 2.961532175049797e-07
Northern O 0 5.802046985081688e-07
Ireland O 0 1.077901060853037e-06
: O 0 2.1039835473857238e-07
nine O 0 2.460470227561018e-07
novel O 0 1.3147653135092696e-06
mutations O 0 1.601936901352019e-06
including O 0 2.860653864900087e-07
T312S O 0 3.0654744477942586e-05
, O 0 7.191871418399387e-07
a O 0 1.1886234005942242e-06
common O 0 3.833771188510582e-06
allele O 0 1.7072354239644483e-05
that O 0 1.0982859066643869e-06
confers O 0 1.4028786608832888e-05
a O 0 3.376674067112617e-05
mild O 1 0.9849173426628113
phenotype O 1 0.962273895740509
. O 0 9.896456322167069e-05

Mucopolysaccharidosis B-Disease 0 0.47658807039260864
IVA I-Disease 1 0.9937373399734497
( O 0 0.0016567087732255459
MPS B-Disease 1 0.9999762773513794
IVA I-Disease 1 0.9999662637710571
) O 0 1.578662522661034e-05
is O 0 2.5056344838958466e-06
an O 0 7.856189768062904e-06
autosomal B-Disease 1 0.8732151985168457
recessive I-Disease 1 0.9987761378288269
lysosomal I-Disease 1 0.9996742010116577
storage I-Disease 1 0.9999247789382935
disorder I-Disease 1 0.9999785423278809
caused O 0 0.00012754215276800096
by O 0 3.5319610560691217e-06
a O 0 0.0001622840645723045
genetic B-Disease 1 0.9984645843505859
defect I-Disease 1 0.9955136179924011
in O 0 6.966733053559437e-06
N O 0 0.00014836520131211728
- O 0 0.00021111017849761993
acetylgalactosamine O 0 0.000286993570625782
- O 0 0.0001046929246513173
6 O 0 1.391207752021728e-05
- O 0 0.00034029074595309794
sulfate O 0 0.0004682019934989512
sulfatase O 0 0.0008131577051244676
( O 0 1.4959581676521339e-05
GALNS O 0 0.0006247048149816692
) O 0 1.973100188479293e-05
. O 0 1.882495780591853e-05

Previous O 0 6.692349415970966e-05
studies O 0 1.7773787476471625e-05
of O 0 2.0631193820008775e-06
patients O 0 0.00011791650467785075
from O 0 6.680891715404869e-07
a O 0 3.2618181649013422e-06
British O 0 0.04554707929491997
- O 0 0.005754482001066208
Irish O 0 1.9555252947611734e-05
population O 0 5.050636104897421e-07
showed O 0 1.2156020829934278e-06
that O 0 1.0713426235042789e-07
the O 0 2.6374621597824444e-07
I113F O 0 2.576058977865614e-05
mutation O 0 1.5306897012123954e-06
is O 0 7.786672284737506e-08
the O 0 1.1833488144930016e-07
most O 0 2.9087053121656936e-07
common O 0 1.1863764939334942e-06
single O 0 2.2428305328503484e-06
mutation O 0 6.567789114342304e-06
among O 0 5.720921762986109e-06
MPS B-Disease 1 0.9999922513961792
IVA I-Disease 1 0.9999998807907104
patients O 0 0.36774882674217224
and O 0 4.89151989313541e-06
produces O 0 1.6344283721991815e-05
a O 0 4.881707354797982e-05
severe O 1 0.9948262572288513
clinical O 1 0.9811525344848633
phenotype O 1 0.9913056492805481
. O 0 0.0001833127171266824

We O 0 4.570785677060485e-05
studied O 0 5.634953049593605e-05
mutations O 0 3.15183206112124e-05
in O 0 1.489366582063667e-06
the O 0 1.571874349792779e-06
GALNS O 0 0.00021343283879105002
gene O 0 4.8114065975823905e-06
from O 0 5.760090857620526e-07
23 O 0 1.5546833083135425e-06
additional O 0 1.62745220677607e-06
MPS B-Disease 1 0.9999884366989136
IVA I-Disease 1 0.9999998807907104
patients O 0 0.30940642952919006
( O 0 7.60070918204292e-07
15 O 0 3.4269490356564347e-07
from O 0 1.8969066672980262e-07
Australia O 0 4.5198072484708973e-07
, O 0 7.223656695032332e-08
8 O 0 1.1539715671915474e-07
from O 0 5.2878949219348215e-08
Northern O 0 2.6516104867368995e-07
Ireland O 0 9.62552917371795e-07
) O 0 1.305898820191942e-07
, O 0 6.246452244340617e-08
with O 0 6.841803923407497e-08
various O 0 6.04227238909516e-07
clinical O 0 0.01831766590476036
phenotypes O 0 0.00730483140796423
( O 0 2.9509661544580013e-05
severe O 0 0.09274371713399887
, O 0 6.6185026526e-07
16 O 0 1.1719322401404497e-06
cases O 0 2.956610671844828e-07
; O 0 4.2891591078841884e-07
intermediate O 0 1.4009436881678994e-06
, O 0 2.656797164490854e-07
4 O 0 1.053981350196409e-06
cases O 0 9.663551736593945e-07
; O 0 3.463158009253675e-06
mild O 0 0.046013299375772476
, O 0 3.1349281925940886e-06
3 O 0 4.2281003516109195e-06
cases O 0 4.124893621337833e-06
) O 0 3.7641971175617073e-06
. O 0 8.414425792580005e-06

We O 0 3.4847314964281395e-05
found O 0 6.34190746495733e-06
two O 0 7.870856393310532e-07
common O 0 1.9896833691745996e-06
mutations O 0 1.929621021190542e-06
that O 0 9.357060548609297e-08
together O 0 1.457013354411174e-07
accounted O 0 4.660257957311842e-07
for O 0 9.182645044347737e-08
32 O 0 6.532081897603348e-07
% O 0 2.151593179178235e-07
of O 0 4.350168225641937e-08
the O 0 3.58041660319941e-07
44 O 0 4.3545160224311985e-06
unrelated O 0 1.3156785826140549e-05
alleles O 0 1.485647680965485e-05
in O 0 3.192112899341737e-06
these O 0 6.183423010952538e-06
patients O 0 0.0005226777284406126
. O 0 2.672306618478615e-05

One O 0 2.5983383238781244e-05
is O 0 3.6151432141195983e-06
the O 0 3.540010084179812e-06
T312S O 0 0.0001375614810967818
mutation O 0 9.321519428340252e-06
, O 0 5.865402954441379e-07
a O 0 9.208995948029042e-07
novel O 0 5.2801728998019826e-06
mutation O 0 6.745477094227681e-06
found O 0 2.4503988242940977e-06
exclusively O 0 5.181335836823564e-06
in O 0 3.629822822404094e-05
milder O 1 0.9962118864059448
patients O 0 0.10986554622650146
. O 0 7.233906944748014e-05

The O 0 2.1857040337636136e-05
other O 0 2.797676870613941e-06
is O 0 5.178032438379887e-07
the O 0 6.456953656197584e-07
previously O 0 5.538783625524957e-06
described O 0 1.656993481446989e-05
I113F O 0 4.74800071970094e-05
that O 0 1.4659183307230705e-06
produces O 0 6.840016794740222e-06
a O 0 3.0451250495389104e-05
severe O 1 0.9882861971855164
phenotype O 1 0.7379471063613892
. O 0 6.917630526004359e-05

The O 0 5.877414878341369e-05
I113F O 0 0.00034135542227886617
and O 0 9.187808245769702e-06
T312S O 0 0.0001552454923512414
mutations O 0 1.0523439414100721e-05
accounted O 0 1.8922355593531393e-06
for O 0 2.79283881354786e-07
8 O 0 1.2646301001950633e-06
( O 0 2.981282705150079e-07
18 O 0 4.886447868557298e-07
% O 0 2.9040762683507637e-07
) O 0 1.0788394178007366e-07
and O 0 1.1554119794254802e-07
6 O 0 6.23779726538487e-07
( O 0 3.4150602346016967e-07
14 O 0 4.187076569905912e-07
% O 0 2.6290771870662866e-07
) O 0 1.12691523668218e-07
of O 0 7.259360756961541e-08
44 O 0 2.1542614376812708e-06
unrelated O 0 2.0075574866496027e-05
alleles O 0 2.075054908345919e-05
, O 0 3.2361072044295724e-06
respectively O 0 1.6294559827656485e-05
. O 0 1.3456870874506421e-05

The O 0 4.168811210547574e-05
relatively O 0 6.5830179664772e-05
high O 0 2.681330261111725e-05
residual O 0 6.605100497836247e-05
GALNS O 0 0.0003076711727771908
activity O 0 4.102226739632897e-06
seen O 0 2.7363582830730593e-06
when O 0 7.471412573067937e-07
the O 0 5.328799375092785e-07
T312S O 0 1.6352454622392543e-05
mutant O 0 1.2027780030621216e-05
cDNA O 0 1.1346553037583362e-05
is O 0 8.557050250601606e-07
overexpressed O 0 1.886417157948017e-05
in O 0 1.4305597915154067e-06
mutant O 0 1.4560353520209901e-05
cells O 0 3.2359839678974822e-06
provides O 0 5.210856670601061e-07
an O 0 1.8282534597346967e-07
explanation O 0 1.082824951481598e-06
for O 0 2.9891859298913914e-07
the O 0 2.6904021979134995e-06
mild O 1 0.9782059192657471
phenotype O 1 0.9214988946914673
in O 0 0.00012790899199899286
patients O 0 0.0024746491108089685
with O 0 1.058825205291214e-06
this O 0 4.13585985370446e-06
mutation O 0 4.77507637697272e-05
. O 0 1.4278052731242497e-05

The O 0 2.319756276847329e-05
distribution O 0 6.296972514974186e-06
and O 0 1.6227980950134224e-06
relative O 0 1.4931096075088135e-06
frequencies O 0 1.5430232451763004e-06
of O 0 1.691250162139113e-07
the O 0 8.157714432854846e-07
I113F O 0 4.223536961944774e-05
and O 0 1.8260316210216843e-06
T312S O 0 8.03100920165889e-05
mutations O 0 3.1331946956925094e-06
in O 0 2.512139758437115e-07
Australia O 0 1.0806564887388959e-06
corresponded O 0 4.614867918917298e-07
to O 0 6.550047260134306e-08
those O 0 4.9912230792870105e-08
observed O 0 1.7738236124387186e-07
in O 0 9.846316828543422e-08
Northern O 0 5.907540412408707e-07
Ireland O 0 1.7806995629143785e-06
and O 0 1.358992705036144e-07
are O 0 2.41486421970194e-08
unique O 0 6.743765368355525e-08
to O 0 3.841119777803215e-08
these O 0 3.132609549538756e-08
two O 0 7.044823036039816e-08
populations O 0 2.16379149264867e-07
, O 0 1.0195073940622024e-07
suggesting O 0 4.809062374988571e-07
that O 0 6.509011285515953e-08
both O 0 1.2775542757026415e-07
mutations O 0 7.656670959477196e-07
were O 0 3.126163790057035e-07
probably O 0 5.441419261842384e-07
introduced O 0 6.630531288465136e-07
to O 0 1.113471910230146e-07
Australia O 0 5.129937221681757e-07
by O 0 2.1572475361608667e-07
Irish O 0 1.8283421923115384e-06
migrants O 0 9.674137118054205e-07
during O 0 9.634043180994922e-07
the O 0 5.944727377027448e-07
19th O 0 9.957858310372103e-06
century O 0 2.6583065846352838e-05
. O 0 1.819489261833951e-05

Haplotype O 0 0.004745109472423792
analysis O 0 3.517478035064414e-05
using O 0 8.207194696296938e-06
6 O 0 9.254766155208927e-06
RFLPs O 0 2.0342860807431862e-05
provides O 0 1.0829943448698032e-06
additional O 0 3.5940016118729545e-07
data O 0 3.6406416370482475e-07
that O 0 1.1196565452564755e-07
the O 0 5.298460905578395e-07
I113F O 0 3.329570245114155e-05
mutation O 0 3.645731567303301e-06
originated O 0 2.1695639134122757e-06
from O 0 8.122509029817593e-07
a O 0 2.0848121948802145e-06
common O 0 1.1265449757047463e-05
ancestor O 0 8.662411710247397e-05
. O 0 2.904530083469581e-05

The O 0 1.671190511842724e-05
other O 0 2.1990058485243935e-06
9 O 0 5.990209047013195e-06
novel O 0 3.665932126750704e-06
mutations O 0 7.026986168057192e-06
identified O 0 1.664924866418005e-06
in O 0 4.276668903457903e-07
these O 0 3.016851053416758e-07
23 O 0 1.080573201761581e-05
patients O 0 2.2421900212066248e-05
were O 0 4.2199485505989287e-07
each O 0 7.710971061669625e-08
limited O 0 5.073790134701994e-07
to O 0 2.0753725493705133e-07
a O 0 6.52328026262694e-07
single O 0 4.2990222937078215e-06
family O 0 1.8544456906965934e-05
. O 0 1.920414979394991e-05

These O 0 1.801158214220777e-05
data O 0 9.369109648105223e-06
provide O 0 1.5794507817190606e-06
further O 0 1.1252780041104415e-06
evidence O 0 1.3792398476653034e-06
for O 0 4.401060778036481e-07
extensive O 0 7.3165729190804996e-06
allelic O 0 8.854854240780696e-05
heterogeneity O 0 0.00012042642629239708
in O 0 3.907304198946804e-05
MPS B-Disease 1 0.9999270439147949
IVA I-Disease 1 0.9982978701591492
in O 0 1.0453740287630353e-05
British O 0 0.010261262767016888
- O 0 0.004054752178490162
Irish O 0 9.203486115438864e-05
patients O 0 1.4591380022466183e-05
and O 0 2.2175264291490748e-07
provide O 0 2.543051778047811e-07
evidence O 0 4.013507179934095e-07
for O 0 9.880670148731951e-08
their O 0 2.6845998490898637e-07
transmission O 0 3.736739245141507e-06
to O 0 3.4285312722204253e-07
Australia O 0 1.1389680594220408e-06
by O 0 5.424636810857919e-07
British O 0 4.6951357944635674e-05
- O 0 5.622285243589431e-05
Irish O 0 1.3452406165015418e-05
migrants O 0 5.572814188781194e-06
. O 0 2.76822561318113e-06
. O 0 8.401436389249284e-06

Identification O 0 9.90914850262925e-05
of O 0 9.182912435790058e-06
constitutional O 0 9.00989180081524e-05
WT1 O 0 0.16651123762130737
mutations O 0 0.00010579644731478766
, O 0 3.823004135483643e-06
in O 0 6.104353815317154e-06
patients O 0 0.00018232225556857884
with O 0 6.242383278731722e-06
isolated O 0 0.16659216582775116
diffuse B-Disease 1 0.9996514320373535
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 0.9999998807907104
, O 0 4.194653229205869e-06
and O 0 1.111854317059624e-06
analysis O 0 1.7244752825718024e-06
of O 0 1.0417309113108786e-06
genotype O 1 0.6361665725708008
/ O 1 0.8898681402206421
phenotype O 0 0.0018955373670905828
correlations O 0 5.75118383494555e-06
by O 0 5.025891596233123e-07
use O 0 7.606800522808044e-07
of O 0 1.979127830509242e-07
a O 0 2.2778283437219216e-06
computerized O 0 0.00016162346582859755
mutation O 0 4.3971274862997234e-05
database O 0 2.696199771889951e-05
. O 0 2.748156839516014e-05

Constitutional O 0 0.0001947148994076997
mutations O 0 7.838375313440338e-05
of O 0 2.0743291315739043e-06
the O 0 6.6686525315162726e-06
WT1 O 0 0.0006757848896086216
gene O 0 1.6186748325708322e-05
, O 0 1.0481295475983643e-06
encoding O 0 5.4279771575238556e-06
a O 0 4.9629802560957614e-06
zinc O 0 0.00039414121420122683
- O 0 6.834435043856502e-05
finger O 0 1.6125395632116124e-05
transcription O 0 8.251236977230292e-06
factor O 0 2.0198410766170127e-06
involved O 0 1.1836688145194785e-06
in O 0 7.185754839156289e-06
renal O 1 0.9809377789497375
and O 0 6.740866410837043e-06
gonadal O 0 0.0019650859758257866
development O 0 3.357332161613158e-06
, O 0 4.3085918832730385e-07
are O 0 8.265693196563006e-08
found O 0 3.0883524004821084e-07
in O 0 4.213305260236666e-07
most O 0 1.8295143036084482e-06
patients O 0 4.038598490296863e-05
with O 0 6.107487024564762e-06
Denys B-Disease 1 0.9999841451644897
- I-Disease 1 0.9999994039535522
Drash I-Disease 1 0.9999992847442627
syndrome I-Disease 1 0.9999998807907104
( O 0 0.0002141528093488887
DDS B-Disease 1 0.9999991655349731
) O 0 5.973090082989074e-06
, O 0 1.9380509002075996e-06
or O 0 1.083648567146156e-05
diffuse B-Disease 1 0.8790662884712219
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
( O 0 0.00025421238387934864
DMS B-Disease 1 0.9256151914596558
) O 0 2.0343088635854656e-06
associated O 0 1.227056259267556e-06
with O 0 6.625753030675696e-07
pseudohermaphroditism B-Disease 1 0.9994552731513977
and O 0 5.732043427997269e-05
/ O 1 0.7576192617416382
or O 0 0.00013151674647815526
Wilms B-Disease 1 0.9999476671218872
tumor I-Disease 1 0.6863425970077515
( O 0 5.155919279786758e-05
WT B-Disease 1 0.9994864463806152
) O 0 1.846973282226827e-05
. O 0 1.4794607523072045e-05

Most O 0 0.00016770741785876453
mutations O 0 0.0004877427709288895
in O 0 0.0002114304807037115
DDS B-Disease 1 1.0
patients O 1 0.9847933650016785
lie O 0 3.894756082445383e-05
in O 0 4.096315933566075e-06
exon O 0 3.077154906350188e-05
8 O 0 1.9414549115026603e-06
or O 0 6.262718557081826e-07
exon O 0 7.326683316932758e-06
9 O 0 2.2030717445886694e-06
, O 0 4.118382435081003e-07
encoding O 0 5.131648322276305e-06
zinc O 0 1.9277986211818643e-05
finger O 0 7.992624887265265e-06
2 O 0 8.055680495999695e-07
or O 0 8.074932225099474e-07
zinc O 0 2.3333301214734092e-05
finger O 0 7.665002158319112e-06
3 O 0 5.502411681845842e-07
, O 0 1.6563697613491968e-07
respectively O 0 4.27703980676597e-07
, O 0 1.0757121771121092e-07
with O 0 8.575899812512944e-08
a O 0 9.485783607487974e-07
hot O 0 1.524982690170873e-05
spot O 0 7.031746008578921e-06
( O 0 1.9062256342294859e-06
R394W O 0 1.1822726264654193e-05
) O 0 1.2121049621782731e-06
in O 0 1.5058481039886829e-06
exon O 0 4.910965435556136e-05
9 O 0 1.6157120626303367e-05
. O 0 1.5367746527772397e-05

We O 0 3.986038063885644e-05
analyzed O 0 1.7236534404219128e-05
a O 0 1.1074150734202703e-06
series O 0 1.2503774087235797e-06
of O 0 3.3900482776516583e-07
24 O 0 1.7742575437296182e-05
patients O 0 6.375504744937643e-05
, O 0 4.6405978082475485e-07
10 O 0 7.683259468649339e-07
with O 0 1.112673089664895e-06
isolated B-Disease 0 0.0017218014691025019
DMS I-Disease 1 0.9995492100715637
( O 0 8.745903869566973e-06
IDMS B-Disease 0 0.0004900726489722729
) O 0 1.0994899639626965e-06
, O 0 2.0931263122747623e-07
10 O 0 4.065660732521792e-07
with O 0 7.625052944604249e-07
DDS B-Disease 1 0.9999995231628418
, O 0 1.197101937577827e-06
and O 0 3.819087339707039e-07
4 O 0 1.5633276007065433e-06
with O 0 2.427745812383364e-06
urogenital B-Disease 1 0.9233541488647461
abnormalities I-Disease 1 0.9951463341712952
and O 0 3.0126786441542208e-05
/ O 0 0.3701935112476349
or O 0 0.00011197765707038343
WT B-Disease 1 0.9998923540115356
. O 0 9.626934479456395e-05

We O 0 0.0001236189273186028
report O 0 0.00011304687359370291
WT1 O 0 0.0016288155457004905
heterozygous O 0 7.642836862942204e-05
mutations O 0 2.052199124591425e-05
in O 0 2.0960758320143213e-06
16 O 0 9.52876598603325e-06
patients O 0 5.510834671440534e-05
, O 0 5.269912435323931e-07
4 O 0 9.738611197462888e-07
of O 0 2.9244623078739096e-07
whom O 0 1.1502481356728822e-05
presented O 0 1.9536166291800328e-05
with O 0 1.5920306395855732e-05
IDMS B-Disease 1 0.5999934077262878
. O 0 0.00012050373334204778

One O 0 7.207610178738832e-05
male O 0 5.0607490265974775e-05
and O 0 3.980166184192058e-06
two O 0 5.950534614385106e-06
female O 0 0.00018056710541713983
IDMS B-Disease 1 0.9795998930931091
patients O 0 0.015553312376141548
with O 0 4.404639548738487e-05
WT1 O 1 0.9941015839576721
mutations O 0 0.0013991398736834526
underwent O 0 0.4443037509918213
normal O 0 0.0003317897208034992
puberty O 0 0.0020458835642784834
. O 0 4.879041080130264e-05

Two O 0 9.669237624621019e-05
mutations O 0 0.00017900117381941527
associated O 0 1.9146236809319817e-05
with O 0 3.0360379241756164e-06
IDMS B-Disease 0 0.03967671096324921
are O 0 4.772734314428817e-07
different O 0 2.686367110982246e-07
from O 0 5.848434625477239e-07
those O 0 6.8378443529582e-07
described O 0 0.00014331875718198717
in O 0 0.0014288198435679078
DDS B-Disease 1 1.0
patients O 1 0.9812774062156677
. O 0 6.561239570146427e-05

No O 0 0.0003704939445015043
WT1 O 0 0.09294626861810684
mutations O 0 0.00023487074940931052
were O 0 1.4280258255894296e-05
detected O 0 2.0792327632079832e-05
in O 0 8.553142265554925e-07
the O 0 3.654291163002199e-07
six O 0 8.855267878971063e-07
other O 0 1.6119254269142402e-06
IDMS B-Disease 1 0.9678390026092529
patients O 0 0.005170904565602541
, O 0 2.293533725605812e-06
suggesting O 0 3.427992851356976e-05
genetic O 0 1.747570604493376e-05
heterogeneity O 0 1.3727463738177903e-05
of O 0 1.243693759533926e-06
this O 0 2.34315939451335e-05
disease O 0 0.0015964587219059467
. O 0 3.74050869140774e-05

We O 0 0.00013525148096960038
analyzed O 0 0.00040597611223347485
genotype O 0 0.09588024765253067
/ O 1 0.6382628679275513
phenotype O 0 0.011317926459014416
correlations O 0 2.0849214706686325e-05
, O 0 6.533988425871939e-07
on O 0 2.240484349158578e-07
the O 0 9.189863448000324e-08
basis O 0 7.72349721955834e-08
of O 0 2.740546634072416e-08
the O 0 1.2879500843610003e-07
constitution O 0 2.457316270465526e-07
of O 0 9.439141024358833e-08
a O 0 2.1004341306252172e-06
WT1 O 0 0.0006697246572002769
mutation O 0 3.504295136735891e-06
database O 0 7.420024417115201e-07
of O 0 2.0664968758410396e-07
84 O 0 8.385683031519875e-06
germ O 0 0.008924276567995548
- O 0 0.0004312306991778314
line O 0 1.9485203665681183e-05
mutations O 0 3.553370788722532e-06
, O 0 1.4896662037244823e-07
to O 0 1.494471604246428e-07
compare O 0 6.978223154874286e-07
the O 0 1.175775921069544e-07
distribution O 0 1.7672316232619778e-07
and O 0 1.585363378353577e-07
type O 0 5.763877197750844e-07
of O 0 8.90871874048571e-08
mutations O 0 1.6685617083567195e-06
, O 0 1.7902230808886088e-07
according O 0 3.9009762531350134e-07
to O 0 3.136197221920156e-07
the O 0 1.0684790368031827e-06
different O 0 4.232057108310983e-06
symptoms O 0 0.0025603361427783966
. O 0 2.0408462660270743e-05

This O 0 3.055784327443689e-05
demonstrated O 0 3.9579961594427004e-05
( O 0 2.2986664589552674e-06
1 O 0 8.459221589873778e-07
) O 0 2.4505504825356184e-07
the O 0 2.3206479227155796e-07
association O 0 7.392957854790438e-07
between O 0 3.9758415937285463e-07
mutations O 0 2.2033154891687445e-06
in O 0 3.700823754115845e-07
exons O 0 3.248116172471782e-06
8 O 0 8.212700208787282e-07
and O 0 2.3275588034721295e-07
9 O 0 1.1453445267761708e-06
and O 0 1.568793891237874e-06
DMS B-Disease 0 0.36143848299980164
; O 0 1.001066607386747e-06
( O 0 3.9937290807756654e-07
2 O 0 3.141390720884374e-07
) O 0 3.052436170492001e-07
among O 0 6.369348852786061e-07
patients O 0 1.541373239888344e-05
with O 0 8.455188549305603e-07
DMS B-Disease 1 0.791342556476593
, O 0 2.1876113009966502e-07
a O 0 1.7292151710535109e-07
higher O 0 2.8629000325963716e-07
frequency O 0 1.0323039987270022e-06
of O 0 9.393809108360074e-08
exon O 0 8.063142558967229e-06
8 O 0 2.532268126742565e-06
mutations O 0 2.9708662623306736e-06
among O 0 5.341851192497415e-07
46 O 0 3.4169343052781187e-06
, O 0 4.307237759348936e-06
XY O 1 0.9470320343971252
patients O 0 0.0005088712205179036
with O 0 2.432208930258639e-06
female O 0 9.911982488119975e-05
phenotype O 0 0.00025704220752231777
than O 0 1.0016949545388343e-06
among O 0 1.1603738130361307e-06
46 O 0 6.495533398265252e-06
, O 0 8.588833225076087e-06
XY O 1 0.988057017326355
patients O 0 0.00017635322001297027
with O 0 6.157122243166668e-07
sexual O 0 1.8726140069702524e-06
ambiguity O 0 3.7364434319897555e-06
or O 0 1.7213436649399227e-06
male O 0 1.9425922801019624e-05
phenotype O 0 0.0001561959506943822
; O 0 5.270566134640831e-07
and O 0 2.943424419754592e-07
( O 0 4.4331343929115974e-07
3 O 0 2.878016118756932e-07
) O 0 1.6228369759119232e-07
statistically O 0 4.552620112008299e-07
significant O 0 1.8402587897980993e-07
evidence O 0 7.293411954378826e-07
that O 0 2.829219738487154e-07
mutations O 0 1.5037801404105267e-06
in O 0 3.0401037065530545e-07
exons O 0 2.20868423639331e-06
8 O 0 4.72359459990912e-07
and O 0 2.1880244105432212e-07
9 O 0 1.0930143616860732e-06
preferentially O 0 1.909453430926078e-06
affect O 0 1.0754716868177638e-06
amino O 0 3.995862698502606e-07
acids O 0 2.930934215328307e-07
with O 0 8.854122057755376e-08
different O 0 2.276478880958166e-07
functions O 0 3.4615362665135763e-07
. O 0 1.3412287671599188e-06
. O 0 6.604035661439411e-06

The O 0 0.0001422139030182734
185delAG O 0 0.002037686062976718
BRCA1 O 0 0.0025846988428384066
mutation O 0 5.36333245690912e-05
originated O 0 1.0963960448862053e-05
before O 0 1.2529568493846455e-06
the O 0 3.42678561082721e-07
dispersion O 0 2.180734327339451e-06
of O 0 7.283034619831597e-08
Jews O 0 5.7236167094743e-07
in O 0 2.431225141208415e-07
the O 0 2.826137404099427e-07
diaspora O 0 2.2796079974796157e-06
and O 0 5.850442903465591e-07
is O 0 1.6579328132593218e-07
not O 0 2.356100594624877e-07
limited O 0 1.3541312000597827e-06
to O 0 1.643645759941137e-06
Ashkenazim O 0 0.0002456487563904375
. O 0 1.641726885281969e-05

The O 0 0.00013717598631046712
185delAG O 0 0.0009288334404118359
mutation O 0 0.00013075322203803807
in O 0 1.7316477169515565e-05
BRCA1 O 0 0.0006624475936405361
is O 0 2.2468082079285523e-06
detected O 0 1.6895164662855677e-05
in O 0 3.1909655717754504e-06
Ashkenazi O 0 0.00020667948410846293
Jews O 0 2.214784217358101e-06
both O 0 1.245929183824046e-06
in O 0 6.730698260071222e-06
familial B-Disease 0 0.020604677498340607
breast I-Disease 1 0.9998400211334229
and I-Disease 1 0.9972606897354126
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999992847442627
and O 0 2.850043983926298e-06
in O 0 1.673903966548096e-06
the O 0 1.1089167628597352e-06
general O 0 3.8656789911328815e-06
population O 0 3.871069111482939e-06
. O 0 9.545164175506216e-06

All O 0 8.162682206602767e-05
tested O 0 0.0017590573988854885
Ashkenazi O 0 0.011582503095269203
mutation O 0 4.4569831516128033e-05
carriers O 0 1.2080765372957103e-05
share O 0 4.672162958740955e-06
the O 0 1.5366777006420307e-06
same O 0 3.825980456895195e-06
allelic O 0 6.479850708274171e-05
pattern O 0 2.7581656468100846e-05
at O 0 6.2291333051689435e-06
the O 0 1.0064396519737784e-05
BRCA1 O 0 0.0007807383080944419
locus O 0 0.00025732346693985164
. O 0 4.473509397939779e-05

Our O 0 4.6089535317150876e-05
previous O 0 4.730906948680058e-05
study O 0 9.918479008774739e-06
showed O 0 1.0799818483064882e-05
that O 0 6.078452656765876e-07
this O 0 7.427741479659744e-07
Ashkenazi O 0 0.00034283753484487534
mutation O 0 1.7929653495230014e-06
also O 0 2.675934638318722e-07
occurs O 0 2.492269572940131e-07
in O 0 2.1919089476796216e-07
Iraqi O 0 2.642744675540598e-06
Jews O 0 1.4994425328040961e-06
with O 0 4.939230962008878e-07
a O 0 1.2848465757997474e-06
similar O 0 8.877304026100319e-06
allelic O 0 0.00011847879795823246
pattern O 0 8.22886431706138e-05
. O 0 2.0886825950583443e-05

We O 0 2.3135262381401844e-05
extended O 0 1.0664201909094118e-05
our O 0 1.4599693258787738e-06
analysis O 0 8.198474006348988e-07
to O 0 1.7958352316327364e-07
other O 0 1.4955622873458196e-07
non O 0 1.9052442894462729e-06
- O 0 1.979072294489015e-05
Ashkenazi O 0 1.6635927750030532e-05
subsets O 0 2.7469895940157585e-06
354 O 0 2.5335339159937575e-06
of O 0 1.227918602353384e-07
Moroccan O 0 6.444025984819746e-06
origin O 0 7.981100225151749e-07
, O 0 3.6095408972869336e-07
200 O 0 9.316224236499693e-07
Yemenites O 0 3.426091279834509e-05
and O 0 7.477750045836729e-07
150 O 0 1.4319001593321445e-06
Iranian O 0 6.673379630228737e-06
Jews O 0 1.0139375262951944e-05
. O 0 1.1432489372964483e-05

Heteroduplex O 0 0.0035952161997556686
analysis O 0 7.580934470752254e-05
complemented O 0 4.7821082262089476e-05
by O 0 2.925194849012769e-06
direct O 0 3.0646683626400772e-06
DNA O 0 7.5928078331344295e-06
sequencing O 0 9.941226380760781e-06
of O 0 1.0158906889046193e-06
abnormally O 0 9.84819998848252e-05
migrating O 0 1.3869635040464345e-05
bands O 0 9.232481716026086e-06
were O 0 4.1268294808105566e-06
employed O 0 4.63205979031045e-05
. O 0 2.5864272174658254e-05

Four O 0 1.781718310667202e-05
of O 0 1.5936415138639859e-06
Moroccan O 0 3.0516281185555272e-05
origin O 0 3.3260246254940284e-06
( O 0 5.377424372454698e-07
1 O 0 2.624004480367148e-07
. O 0 9.131783684779293e-08
1 O 0 1.7854901557257108e-07
% O 0 1.776389950691737e-07
) O 0 5.0223167846752403e-08
and O 0 4.668812181307658e-08
none O 0 1.596988568053348e-07
of O 0 2.529708709175793e-08
the O 0 3.6855942653346574e-07
Yemenites O 0 8.974632510216907e-05
or O 0 3.6870599728899833e-07
Iranians O 0 4.463318873604294e-06
was O 0 2.1756284240836976e-06
a O 0 7.472438596778375e-07
carrier O 0 4.201570845907554e-06
of O 0 3.4438838270034466e-07
the O 0 2.461822759869392e-06
185delAG O 0 0.0002671181282494217
mutation O 0 6.955525168450549e-05
. O 0 2.6917086870525964e-05

BRCA1 O 0 0.1479722559452057
allelic O 0 0.0018659151392057538
patterns O 0 0.00019043237261939794
were O 0 9.579151083016768e-06
determined O 0 2.3776281068421667e-06
for O 0 1.4281631877111067e-07
four O 0 1.1586140402641831e-07
of O 0 4.996967106762895e-08
these O 0 6.768610916196849e-08
individuals O 0 6.568600952050474e-08
and O 0 9.799497036055982e-08
for O 0 1.1403534472265164e-07
12 O 0 4.3616756784103927e-07
additional O 0 7.095946443769208e-07
non O 0 6.762030352547299e-06
- O 0 0.0024315440095961094
Ashkenazi O 0 0.0020264198537915945
185delAG O 0 0.00011660592281259596
mutation O 0 1.3304092135513201e-05
carriers O 0 1.9667768356157467e-05
who O 0 1.0797388313221745e-05
had O 0 0.15564487874507904
breast B-Disease 1 0.9999992847442627
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999990463256836
. O 0 0.00036428257590159774

Six O 0 0.00010282365838065743
non O 0 0.00013273554213810712
- O 0 0.027493776753544807
Ashkenazi O 0 0.0010117326164618134
individuals O 0 8.787989145275787e-07
shared O 0 9.070088822227262e-07
the O 0 1.2717647450699587e-06
common O 0 2.6043122488772497e-05
Ashkenazi O 1 0.8083913326263428
haplotype O 0 0.00048298618639819324
, O 0 1.2313572597122402e-06
four O 0 5.530103521778074e-07
had O 0 2.660465952430968e-06
a O 0 9.171264991891803e-07
closely O 0 2.0013492303405656e-06
related O 0 1.737090769893257e-06
pattern O 0 2.3141337806009687e-06
, O 0 1.8246392130549793e-07
and O 0 1.2186544040559966e-07
the O 0 1.7862311096905614e-07
rest O 0 8.920278560253792e-07
( O 0 5.063276944383688e-07
n O 0 1.8930946907858015e-06
= O 0 2.6480070118850563e-06
6 O 0 6.806380952184554e-07
) O 0 2.535046803586738e-07
displayed O 0 7.052821615616267e-07
a O 0 1.4469949292106321e-06
distinct O 0 1.1995465683867224e-05
BRCA1 O 0 0.0007784945773892105
allelic O 0 0.0003050222003366798
pattern O 0 0.00013356957060750574
. O 0 3.5141387343173847e-05

We O 0 5.6797096476657316e-05
conclude O 0 8.302639616886154e-05
that O 0 3.824813120445469e-06
the O 0 3.6795188407268142e-06
185delAG O 0 0.00018136897415388376
BRCA1 O 0 0.0007654870278201997
mutation O 0 1.0510109859751537e-05
occurs O 0 1.2710116834568908e-06
in O 0 3.419531537929288e-07
some O 0 3.0047513632780465e-07
non O 0 4.5772358134854585e-06
- O 0 0.0005867760628461838
Ashkenazi O 0 0.00046307346201501787
populations O 0 7.883177204348613e-07
at O 0 6.715117137900961e-07
rates O 0 7.140260436244716e-07
comparable O 0 1.1364562624294194e-06
with O 0 1.8909931043253891e-07
that O 0 3.6946210002497537e-07
of O 0 8.37250922813837e-07
Ashkenazim O 0 0.0006247623241506517
. O 0 1.8068198187393136e-05

The O 0 3.210134673281573e-05
majority O 0 1.655815140111372e-05
of O 0 1.2520215477707097e-06
Jewish O 0 1.3293159099703189e-05
185delAG O 0 0.0003486035857349634
mutation O 0 2.3108115783543326e-05
carriers O 0 8.438532859145198e-06
have O 0 6.421153670999047e-07
a O 0 1.149510353570804e-06
common O 0 2.646871053002542e-06
allelic O 0 2.189908263972029e-05
pattern O 0 7.385977824014844e-06
, O 0 5.122408879287832e-07
supporting O 0 8.667046813570778e-07
the O 0 4.0039381588030665e-07
founder O 0 4.4469229578680824e-06
effect O 0 7.144544724724256e-07
notion O 0 8.568139833187161e-07
, O 0 2.3606077093063504e-07
but O 0 2.7040715622206335e-07
dating O 0 9.967045571102062e-07
the O 0 2.123875475490422e-07
mutations O 0 9.502017519480432e-07
origin O 0 1.6048177542415942e-07
to O 0 1.4686089855331375e-07
an O 0 9.548858770358493e-08
earlier O 0 1.3984741826789104e-06
date O 0 1.2079943871867727e-06
than O 0 3.494926090752415e-07
currently O 0 6.484625032499025e-07
estimated O 0 2.135589738827548e-06
. O 0 7.994523002707865e-06

However O 0 6.0724152717739344e-05
, O 0 3.903159722540295e-06
the O 0 1.165663434221642e-06
different O 0 7.599521154588729e-07
allelic O 0 1.7262593246414326e-05
pattern O 0 6.783435765100876e-06
at O 0 1.0478886451892322e-06
the O 0 1.340819494544121e-06
BRCA1 O 0 6.692604802083224e-05
locus O 0 4.520558377407724e-06
even O 0 4.635608377157041e-07
in O 0 4.739939356568357e-07
some O 0 2.627420201406494e-07
Jewish O 0 2.6211710064671934e-06
mutation O 0 3.5670843772095395e-06
carriers O 0 1.8718659475780441e-06
, O 0 3.264788404067076e-07
might O 0 1.0635118314894498e-06
suggest O 0 1.4119314073468558e-06
that O 0 2.7927563905905117e-07
the O 0 6.811230832681758e-07
mutation O 0 6.360502084135078e-06
arose O 0 9.445321666134987e-06
independently O 0 8.03684179118136e-06
. O 0 2.433557028780342e-06
. O 0 1.0491862667549867e-05

Crystal O 0 0.000771595339756459
structure O 0 3.2604049920337275e-05
of O 0 4.770513896801276e-06
the O 0 2.3270262317964807e-05
hemochromatosis B-Disease 1 0.9999988079071045
protein O 0 4.4619882828556e-05
HFE O 0 0.0008917285013012588
and O 0 2.107211685142829e-06
characterization O 0 8.881571375241037e-06
of O 0 2.2969169322095695e-07
its O 0 6.78218611938064e-07
interaction O 0 2.061309714918025e-06
with O 0 1.6251258330157725e-06
transferrin O 0 0.00017214295803569257
receptor O 0 5.760669955634512e-05
. O 0 2.3552122002001852e-05

HFE O 0 0.03802996501326561
is O 0 2.536075953685213e-05
an O 0 6.571178346348461e-06
MHC O 0 0.00043425921467132866
- O 0 0.00011662627366604283
related O 0 2.0415229755599285e-06
protein O 0 7.872515652707079e-07
that O 0 1.6046158179960912e-07
is O 0 1.5936795705329132e-07
mutated O 0 2.0372986000438686e-06
in O 0 7.882139243520214e-07
the O 0 5.001075805921573e-06
iron B-Disease 1 0.999761164188385
- I-Disease 1 0.999994158744812
overload I-Disease 1 0.9999779462814331
disease I-Disease 1 0.9999783039093018
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 0.002521014306694269

HFE O 0 0.017455728724598885
binds O 0 0.0002761049836408347
to O 0 3.158234540023841e-05
transferrin O 0 0.00040320047992281616
receptor O 0 6.020038927090354e-05
( O 0 7.984298463270534e-06
TfR O 0 7.194645149866119e-05
) O 0 8.759031402405526e-07
and O 0 3.9506582538706425e-07
reduces O 0 1.8155762973037781e-06
its O 0 5.826100277772639e-07
affinity O 0 3.7682991660403786e-06
for O 0 8.830314186525356e-07
iron O 0 0.00017506920266896486
- O 0 2.414431764918845e-05
loaded O 0 8.492657798342407e-06
transferrin O 0 6.576986925210804e-05
, O 0 3.1589313493896043e-06
implicating O 0 0.0001068819547072053
HFE O 0 0.003281818935647607
in O 0 2.3718219381407835e-05
iron O 0 0.17938843369483948
metabolism O 0 0.0006764169665984809
. O 0 4.879436528426595e-05

The O 0 0.0002302200737176463
2 O 0 0.0002300140622537583
. O 0 0.00012427546607796103

6 O 0 0.00022226772853173316
A O 0 4.3318505049683154e-05
crystal O 0 0.00010693639342207462
structure O 0 3.8716189010301605e-06
of O 0 8.131918889375811e-07
HFE O 0 0.0009935692651197314
reveals O 0 1.0989701877406333e-05
the O 0 8.985097110780771e-07
locations O 0 3.045392531930702e-06
of O 0 2.3735885861242423e-06
hemochromatosis B-Disease 1 0.9999997615814209
mutations O 0 5.169192445464432e-05
and O 0 2.697858235478634e-06
a O 0 7.5347988968132995e-06
patch O 0 0.0005918843671679497
of O 0 3.0517315963152214e-07
histidines O 0 0.00010958703205687925
that O 0 3.4247892699568183e-07
could O 0 4.143042815485387e-07
be O 0 1.1246113018614778e-07
involved O 0 2.9605016038658505e-07
in O 0 1.959826931852149e-06
pH O 0 0.00010156191274290904
- O 0 3.666022894321941e-05
dependent O 0 9.96983999357326e-06
interactions O 0 5.917333510296885e-06
. O 0 1.0863119314308278e-05

We O 0 4.353737676865421e-05
also O 0 8.723321116121951e-06
demonstrate O 0 1.5783585695317015e-05
that O 0 3.2493865091964835e-06
soluble O 0 7.209026080090553e-05
TfR O 0 0.00019027049711439759
and O 0 3.894994279107777e-06
HFE O 0 0.0009153725113719702
bind O 0 6.154319180495804e-06
tightly O 0 4.058740614709677e-06
at O 0 7.973210927048058e-07
the O 0 3.122990221982036e-07
basic O 0 1.2610004205271252e-06
pH O 0 2.826948048095801e-06
of O 0 7.289789749620468e-08
the O 0 2.723196246279258e-07
cell O 0 7.868944521760568e-06
surface O 0 7.182070476119407e-07
, O 0 1.4242664292396512e-07
but O 0 2.4836398893057776e-07
not O 0 1.5729121116692113e-07
at O 0 4.12214689049506e-07
the O 0 1.5084697224665433e-06
acidic O 0 4.480194911593571e-05
pH O 0 1.8286898921360262e-05
of O 0 1.1554465118024382e-06
intracellular O 0 5.271603004075587e-05
vesicles O 0 0.0002001000684686005
. O 0 3.4986864193342626e-05

TfR O 0 0.151131272315979
HFE O 0 0.028950519859790802
stoichiometry O 0 0.000878156628459692
( O 0 3.552320777089335e-05
2 O 0 4.543677732726792e-06
1 O 0 1.3352661198950955e-06
) O 0 9.142690942098852e-07
differs O 0 3.731902779691154e-06
from O 0 1.4645893315901048e-06
TfR O 0 0.00011357566108927131
transferrin O 0 4.66094134026207e-05
stoichiometry O 0 1.3384942576522008e-05
( O 0 8.295565407934191e-07
2 O 0 3.276872746482695e-07
2 O 0 2.9507123144867364e-07
) O 0 1.702104270862037e-07
, O 0 8.754407332389746e-08
implying O 0 6.513954531328636e-07
a O 0 1.535208582481573e-07
different O 0 1.1950105260893906e-07
mode O 0 4.5508838297791954e-07
of O 0 6.545975850258401e-08
binding O 0 1.0203493729932234e-06
for O 0 4.577880758915853e-07
HFE O 0 0.00012939285079482943
and O 0 1.1255409617660916e-06
transferrin O 0 2.8926326194778085e-05
to O 0 1.3360124739847379e-06
TfR O 0 4.237850953359157e-05
, O 0 3.289302696884988e-07
consistent O 0 6.718787517456803e-07
with O 0 1.0006220207969818e-07
our O 0 2.554634477291984e-07
demonstration O 0 3.008822659467114e-06
that O 0 5.176995614419866e-07
HFE O 0 3.8675447285640985e-05
, O 0 5.69171390907286e-07
transferrin O 0 1.652656646911055e-05
, O 0 6.902557174726098e-07
and O 0 1.4275451576395426e-06
TfR O 0 0.000116869414341636
form O 0 2.5521899260638747e-06
a O 0 3.2166551591217285e-06
ternary O 0 4.099672514712438e-05
complex O 0 3.292689143563621e-05
. O 0 3.652950545074418e-05

Identification O 0 6.942068284843117e-05
of O 0 2.854839976862422e-06
three O 0 2.2112997157819336e-06
novel O 0 5.393718765844824e-06
mutations O 0 3.899870989698684e-06
and O 0 3.2738677191446186e-07
a O 0 5.143477324054402e-07
high O 0 7.015697747192462e-07
frequency O 0 8.403338256357529e-07
of O 0 9.955012814089059e-08
the O 0 5.790305976915988e-07
Arg778Leu O 0 0.00011482580157462507
mutation O 0 3.861231562041212e-06
in O 0 1.6545603784834384e-06
Korean O 0 5.9923626395175233e-05
patients O 0 0.00037071193219162524
with O 0 1.3770995792583562e-05
Wilson B-Disease 0 0.09374452382326126
disease I-Disease 0 0.01105682086199522
. O 0 4.7562436520820484e-05

Four O 0 0.0001247488398803398
mutations O 0 0.0003237980999983847
- O 0 0.00025123351952061057
- O 0 0.00012802124547306448
R778L O 0 7.562155224150047e-05
, O 0 2.2230030936043477e-06
A874V O 0 1.4880497474223375e-05
, O 0 5.986018436487939e-07
L1083F O 0 6.473771009041229e-06
, O 0 2.440596347241808e-07
and O 0 3.761297762139293e-07
2304delC O 0 2.2928052203496918e-05
- O 0 3.4036042052321136e-05
- O 0 1.0448576176713686e-05
in O 0 4.6306197987178166e-07
the O 0 3.2866876154002966e-07
copper O 0 3.4311583476664964e-06
- O 0 3.0773733215028187e-06
transporting O 0 2.9014124720561085e-06
enzyme O 0 4.673454895964824e-06
, O 0 5.562060323427431e-07
P O 0 5.7539658882888034e-05
- O 0 1.8376318621449172e-05
type O 0 9.037667041411623e-06
ATPase O 0 0.00011067424929933622
( O 0 3.001142204084317e-06
ATP7B O 0 5.99128870817367e-05
) O 0 3.714047238645435e-07
, O 0 1.2257656578640308e-07
were O 0 3.5980446000394295e-07
identified O 0 6.87158888013073e-07
in O 0 6.720274541294202e-07
Korean O 0 5.066553421784192e-05
Patients O 0 0.00012738705845549703
with O 0 5.656169832946034e-06
Wilson B-Disease 0 0.09888111054897308
disease I-Disease 0 0.0041436790488660336
. O 0 3.5295714042149484e-05

Arg778Leu O 0 0.0032943349797278643
, O 0 1.0871949598367792e-05
the O 0 1.1724373507604469e-06
most O 0 6.857480912003666e-07
frequently O 0 1.526077994640218e-06
reported O 0 3.521981398080243e-06
mutation O 0 7.550087843810616e-07
of O 0 5.334961983294306e-08
this O 0 9.256871891238916e-08
enzyme O 0 1.2350914175840444e-06
, O 0 1.5499519179229537e-07
was O 0 8.980403549685434e-07
found O 0 2.1554789952915598e-07
in O 0 1.0282348483769965e-07
six O 0 1.454549050095011e-07
of O 0 7.847773986213724e-08
eight O 0 2.1770022158307256e-06
unrelated O 0 0.00018616167653817683
patients O 0 0.001822901889681816
studied O 0 1.4323168215923943e-05
, O 0 1.0747160104074283e-06
an O 0 8.233906214627496e-07
allele O 0 1.2039934517815709e-05
frequency O 0 8.206787242670543e-06
of O 0 1.4113094266576809e-06
37 O 0 3.190480128978379e-05
. O 0 2.1966159692965448e-05

5 O 0 7.130407175282016e-05
% O 0 8.572140359319746e-06
, O 0 4.6058195835030347e-07
which O 0 2.717364111504139e-07
is O 0 8.815027996433855e-08
considerably O 0 1.9593148863350507e-06
higher O 0 2.9531614131883543e-07
than O 0 8.586359001583332e-08
those O 0 1.0049561893765713e-07
in O 0 2.980521003337344e-07
other O 0 6.157674192763807e-07
Asian O 0 8.385267392441165e-06
populations O 0 1.1418957001296803e-05
. O 0 1.1379713214410003e-05

The O 0 3.5197030229028314e-05
novel O 0 2.263374517497141e-05
single O 0 8.00652469479246e-06
nucleotide O 0 1.3696263522433583e-05
deletion O 0 2.0874900656053796e-05
, O 0 6.513569701382949e-07
2304delC O 0 1.2389275070745498e-05
, O 0 2.8553606057357683e-07
was O 0 1.2492570249378332e-06
found O 0 6.631341307183902e-07
in O 0 8.409832616962376e-07
one O 0 3.0830572086415486e-06
patient O 0 0.0001459960185457021
. O 0 2.6787973183672875e-05

Since O 0 0.00022608986182603985
a O 0 2.9550947147072293e-05
mutation O 0 3.887883576680906e-05
at O 0 6.216338533704402e-06
cDNA O 0 4.6867120545357466e-05
nucleotide O 0 4.2445088183740154e-05
2302 O 0 0.0005702662165276706
( O 0 3.880460099026095e-06
2302insC O 0 1.6299454728141427e-05
) O 0 1.107174284697976e-06
had O 0 1.696553567853698e-06
been O 0 6.78368053286249e-07
previously O 0 1.660665475355927e-06
described O 0 2.4174278223654255e-06
, O 0 1.2091985013285012e-07
this O 0 5.211696318951908e-08
region O 0 1.1237043651135536e-07
of O 0 4.7954188175936e-08
the O 0 7.232817438307393e-07
ATP7B O 0 0.06538224220275879
gene O 0 1.639381480345037e-05
may O 0 3.525143483784632e-06
be O 0 5.597495373876882e-07
susceptible O 0 1.3390431377047207e-05
to O 0 2.4032999590417603e-06
gene O 0 2.592759301478509e-05
rearrangements O 0 0.0001515828334959224
causing O 0 0.00018524004553910345
Wilson B-Disease 0 0.005607100203633308
disease I-Disease 0 0.005965421441942453
. O 0 5.172313831280917e-05

Disruption O 0 0.000911348091904074
of O 0 9.358143870485947e-06
splicing O 0 9.55380019149743e-05
regulated O 0 2.7392217816668563e-05
by O 0 2.613837068565772e-06
a O 0 4.557586635201005e-06
CUG O 0 0.0011200594017282128
- O 0 0.00020144775044173002
binding O 0 4.046849062433466e-05
protein O 0 2.4666926037753e-05
in O 0 6.948783266125247e-05
myotonic B-Disease 1 0.9999991655349731
dystrophy I-Disease 1 0.9999996423721313
. O 0 0.00026010829606093466

Myotonic B-Disease 1 0.9999998807907104
dystrophy I-Disease 1 1.0
( O 1 0.9790828824043274
DM B-Disease 1 1.0
) O 0 2.5985367756220512e-05
is O 0 1.0221998536508181e-06
caused O 0 1.6249460941253346e-06
by O 0 1.758367034199182e-07
a O 0 3.3750740158211556e-07
CTG O 0 1.785918175301049e-05
expansion O 0 1.1278200418018969e-06
in O 0 3.2529942473047413e-07
the O 0 3.230256595543324e-07
3 O 0 1.6180460988834966e-06
untranslated O 0 2.6504490961087868e-05
region O 0 2.3803279418643797e-06
of O 0 8.919700462683977e-07
the O 0 2.677867450984195e-05
DM B-Disease 1 0.9999998807907104
gene O 0 0.0002082258724840358
. O 0 3.578760879463516e-05

One O 0 4.6789951738901436e-05
model O 0 8.30427889013663e-05
of O 0 1.4882285540807061e-05
DM B-Disease 1 1.0
pathogenesis O 0 0.025167958810925484
suggests O 0 1.0694805496314075e-05
that O 0 8.721430617697479e-07
RNAs O 0 6.897305866004899e-06
from O 0 3.58971959713017e-07
the O 0 2.401104666205356e-07
expanded O 0 1.5909598687358084e-06
allele O 0 3.0372079891094472e-06
create O 0 2.4929374831117457e-07
a O 0 3.649933830729424e-07
gain O 0 1.4905089074090938e-06
- O 0 2.717478082558955e-06
of O 0 1.1833714097519987e-07
- O 0 4.84293968838756e-06
function O 0 1.716180548783086e-07
mutation O 0 3.318843084798573e-07
by O 0 1.1801211741158113e-07
the O 0 2.5618217591727444e-07
inappropriate O 0 2.2266015093919123e-06
binding O 0 5.10968447997584e-07
of O 0 7.984201033650606e-08
proteins O 0 2.1840340025391924e-07
to O 0 3.354280693201872e-07
the O 0 2.1179298528295476e-06
CUG O 0 0.0008865639101713896
repeats O 0 0.00012856147077400237
. O 0 3.9463015127694234e-05

Data O 0 0.00013603037223219872
presented O 0 2.9051172532490455e-05
here O 0 4.1571620386093855e-06
indicate O 0 3.189997869412764e-06
that O 0 2.688996687538747e-07
the O 0 2.9238375987006293e-07
conserved O 0 2.0867455532425083e-06
heterogeneous O 0 1.3297254554345272e-05
nuclear O 0 3.149854819639586e-05
ribonucleoprotein O 0 0.00011876214557560161
, O 0 1.729635300762311e-06
CUG O 0 8.83402390172705e-05
- O 0 1.4620713045587763e-05
binding O 0 4.31248236054671e-06
protein O 0 2.3634602257516235e-06
( O 0 9.70616838458227e-07
CUG O 0 0.00013905476953368634
- O 0 0.00019654548668768257
BP O 0 0.00030506198527291417
) O 0 5.410206540545914e-07
, O 0 2.8714802624563163e-07
may O 0 6.915695394127397e-07
mediate O 0 5.153217443876201e-06
the O 0 7.699425736973353e-07
trans O 0 2.1873620426049456e-05
- O 0 2.050510920525994e-05
dominant O 0 6.146600298961857e-06
effect O 0 8.495716201650794e-07
of O 0 1.6725400087125308e-07
the O 0 1.44205762353522e-06
RNA O 0 1.5242818335536867e-05
. O 0 1.3732570550928358e-05

CUG O 1 0.7076513171195984
- O 0 0.12403085827827454
BP O 0 0.027151111513376236
was O 0 1.3036312338954303e-05
found O 0 1.5297688378268504e-06
to O 0 3.045498147002945e-07
bind O 0 1.0621698720569839e-06
to O 0 2.505617544557026e-07
the O 0 9.150821256298514e-07
human O 0 7.251013357745251e-06
cardiac O 1 0.993681788444519
troponin O 1 0.997323215007782
T O 0 0.413684219121933
( O 0 3.443188234086847e-06
cTNT O 0 2.7508025596034713e-05
) O 0 9.628623729440733e-07
pre O 0 1.1074140275013633e-05
- O 0 1.3570318515121471e-05
messenger O 0 5.073352895124117e-06
RNA O 0 1.0313318625776446e-06
and O 0 2.447948475037265e-07
regulate O 0 2.0150619093328714e-06
its O 0 1.3965509424451739e-06
alternative O 0 1.3304611456987914e-05
splicing O 0 0.0001180797626147978
. O 0 2.699549622775521e-05

Splicing O 0 0.001423006528057158
of O 0 3.525756255839951e-05
cTNT O 0 0.0006457415875047445
was O 0 7.398516754619777e-05
disrupted O 0 0.0004731885564979166
in O 0 0.00018295789777766913
DM B-Disease 1 1.0
striated O 0 0.39173707365989685
muscle O 0 0.0009389646584168077
and O 0 1.2482495321819442e-06
in O 0 1.5478751720365835e-06
normal O 0 7.5899120020039845e-06
cells O 0 6.883670721435919e-06
expressing O 0 4.796352186531294e-06
transcripts O 0 1.3458834473567549e-05
that O 0 1.4782527841816773e-06
contain O 0 8.86505404196214e-06
CUG O 0 0.0003812083159573376
repeats O 0 0.00012999909813515842
. O 0 2.739864430623129e-05

Altered O 0 0.0005905888392589986
expression O 0 2.7222738935961388e-05
of O 0 2.411011109870742e-06
genes O 0 1.53911405504914e-05
regulated O 0 1.7316211597062647e-05
posttranscriptionally O 0 7.634663779754192e-05
by O 0 6.79967934047454e-06
CUG O 0 0.01830894686281681
- O 0 0.00805211067199707
BP O 0 0.002178973751142621
therefore O 0 4.763885044667404e-06
may O 0 3.3764044928830117e-06
contribute O 0 4.872245426668087e-06
to O 0 1.6570693333051167e-05
DM B-Disease 1 0.9999998807907104
pathogenesis O 0 0.005065505392849445
. O 0 2.2873933630762622e-05
. O 0 2.7613737984211184e-05

Identification O 0 0.0001136539940489456
of O 0 3.985499006375903e-06
a O 0 1.196806533698691e-05
novel O 0 1.932640043378342e-05
nonsense O 0 0.00011368856212357059
mutation O 0 1.4067181837162934e-05
and O 0 1.1128280448247097e-06
a O 0 1.7056431715900544e-06
missense O 0 2.4670242055435665e-05
substitution O 0 4.97816381539451e-06
in O 0 1.7391278106515529e-06
the O 0 2.5975159587687813e-06
vasopressin O 0 4.037790131405927e-05
- O 0 4.8614430852467194e-05
neurophysin O 0 7.522295345552266e-05
II O 0 8.085907757049426e-05
gene O 0 4.834854735236149e-06
in O 0 7.439566047651169e-07
two O 0 8.587240927226958e-07
Spanish O 0 9.803469765756745e-06
kindreds O 0 0.00012879508722107857
with O 0 1.1358613846823573e-05
familial B-Disease 0 0.00935218296945095
neurohypophyseal I-Disease 1 0.9999672174453735
diabetes I-Disease 1 0.9999984502792358
insipidus I-Disease 1 0.9996618032455444
. O 0 0.0005920451367273927

Familial B-Disease 1 0.996482253074646
neurohypophyseal I-Disease 1 0.99997878074646
diabetes I-Disease 1 0.9999998807907104
insipidus I-Disease 1 0.9999923706054688
( O 0 0.018245134502649307
FNDI B-Disease 1 0.9999934434890747
) O 0 1.2629123375518247e-05
is O 0 1.4812105746386806e-06
an O 0 5.60049784326111e-06
autosomal B-Disease 1 0.8984946012496948
dominant I-Disease 1 0.9992066025733948
disease I-Disease 1 0.9962769150733948
caused O 0 0.0022374005056917667
by O 0 0.000448984676040709
deficiency O 1 0.8553844094276428
in O 0 4.65743733002455e-06
the O 0 7.081566309352638e-06
antidiuretic O 0 0.000646206084638834
hormone O 0 8.437921496806666e-05
arginine O 0 3.701496825669892e-05
vasopressin O 0 5.078671165392734e-05
( O 0 4.369604539533611e-06
AVP O 0 6.386310997186229e-05
) O 0 6.900786502228584e-07
encoded O 0 7.644661650374474e-07
by O 0 3.8244451161517645e-07
the O 0 1.067959487954795e-06
AVP O 0 0.0005922982236370444
- O 0 8.458310912828892e-05
neurophysin O 0 0.00011383154196664691
II O 0 0.0002813460014294833
( O 0 8.046474249567837e-06
AVP O 0 0.0010472004069015384
- O 0 7.065651880111545e-05
NPII O 0 0.00013745384057983756
) O 0 1.7067789030988934e-06
gene O 0 6.397976449079579e-06
on O 0 4.107899712835206e-06
chromosome O 0 6.14250311627984e-05
20p13 O 0 0.0002003509143833071
. O 0 2.8188796932226978e-05

In O 0 2.8649081286857836e-05
this O 0 2.3575755676574772e-06
study O 0 3.103429662587587e-06
, O 0 4.687470323005982e-07
we O 0 2.90774295308438e-07
analyzed O 0 1.0307792308594799e-06
two O 0 1.8107073174178367e-07
families O 0 5.515977363756974e-07
with O 0 5.157801297173137e-07
FNDI B-Disease 1 0.840566873550415
using O 0 1.5250900560204173e-06
direct O 0 1.5378403759314097e-06
automated O 0 6.908326213306282e-06
fluorescent O 0 7.820629434718285e-06
, O 0 5.309103130457515e-07
solid O 0 1.27126270399458e-06
phase O 0 2.4349731120310025e-06
, O 0 3.3375255270584603e-07
single O 0 9.797026905289385e-07
- O 0 1.2302491086302325e-05
stranded O 0 6.922697139088996e-06
DNA O 0 6.507225862151245e-06
sequencing O 0 4.866088147537084e-06
of O 0 1.0275824706695857e-06
PCR O 0 0.0001958185894181952
- O 0 0.00011385640391381457
amplified O 0 0.00022007922234479338
AVP O 0 0.0032836883328855038
- O 0 0.0002131349319824949
NPII O 0 0.0006933684926480055
DNA O 0 0.00013086124090477824
. O 0 3.0934221285860986e-05

In O 0 1.1599198842304759e-05
one O 0 7.289788186426449e-07
of O 0 7.996362683115876e-08
the O 0 1.9045052113142447e-07
families O 0 6.143819177850673e-07
, O 0 2.8408049956851755e-07
affected O 0 1.2606479913301882e-06
individuals O 0 1.164528455888103e-07
presented O 0 8.823386110634601e-07
a O 0 1.026413997351483e-06
novel O 0 3.890954758389853e-06
nonsense O 0 2.308536204509437e-05
mutation O 0 1.6277409713438828e-06
in O 0 5.19644515861728e-07
exon O 0 4.034909125039121e-06
3 O 0 4.0423941527478746e-07
of O 0 6.527013596269171e-08
the O 0 2.3163319440300256e-07
gene O 0 7.665445309612551e-07
, O 0 9.854283433696764e-08
consisting O 0 8.192160549924665e-08
in O 0 1.4663068270692747e-07
a O 0 9.489212402513658e-07
G O 0 0.00015736542991362512
to O 0 1.5918370763756684e-06
T O 0 7.759246364003047e-05
transition O 0 1.9262545265519293e-06
at O 0 6.27585450274637e-07
nucleotide O 0 4.119790446566185e-06
2101 O 0 2.7042467991122976e-05
, O 0 3.048892267543124e-07
which O 0 1.3547715127515403e-07
produces O 0 2.802724452521943e-07
a O 0 2.3347041633314802e-07
stop O 0 1.0734406714618672e-06
signal O 0 2.7009862151317066e-06
in O 0 8.191690312742139e-07
codon O 0 1.4009413462190423e-05
82 O 0 7.891234417911619e-06
( O 0 2.2930241811991436e-06
Glu O 0 0.00016056127788033336
) O 0 1.1539599427123903e-06
of O 0 7.521779252783745e-07
NPII O 0 0.000679529388435185
. O 0 1.9264809452579357e-05

The O 0 0.00013788558135274798
premature O 0 0.001778362668119371
termination O 0 0.00012195774615975097
eliminates O 0 2.4725453840801492e-05
part O 0 1.3023595784034114e-06
of O 0 1.1752333506365176e-07
the O 0 7.153564638429089e-07
C O 0 4.6824501623632386e-05
- O 0 4.632682248484343e-05
terminal O 0 6.161590135889128e-06
domain O 0 8.526225769855955e-07
of O 0 1.600506180921002e-07
NPII O 0 5.561494981520809e-05
, O 0 1.775561884187482e-07
including O 0 1.0291334717749123e-07
a O 0 3.408520399261761e-07
cysteine O 0 2.099418907164363e-06
residue O 0 1.766673449310474e-06
in O 0 3.1666871791458107e-07
position O 0 7.712117167102406e-07
85 O 0 4.906232220491802e-07
, O 0 1.1429446544752864e-07
which O 0 1.2268345983557083e-07
could O 0 1.6139176750584738e-07
be O 0 5.1414176027719805e-08
involved O 0 1.4256090707931435e-07
in O 0 3.5906577977584675e-07
the O 0 8.419173127549584e-07
correct O 0 1.8285765690961853e-05
folding O 0 1.0716041288105771e-05
of O 0 5.930225484007678e-07
the O 0 1.0501043107069563e-05
prohormone O 0 0.0038599371910095215
. O 0 6.861640576971695e-05

In O 0 2.2188743969309144e-05
the O 0 3.6329388422018383e-06
second O 0 5.460619831865188e-06
family O 0 3.062550149479648e-06
, O 0 4.12161995200222e-07
a O 0 7.230320875351026e-07
G279A O 0 5.610644620901439e-06
substitution O 0 1.4248249726733775e-06
at O 0 5.518213583854958e-07
position O 0 6.38721985524171e-07
- O 0 1.3417686659522587e-06
1 O 0 9.144385870740734e-08
of O 0 2.6955072840451066e-08
the O 0 1.1579667358319057e-07
signal O 0 1.9980880097136833e-06
peptide O 0 7.313025207622559e-07
was O 0 8.942355407270952e-07
observed O 0 5.419656758931524e-07
in O 0 2.2504679009216488e-07
all O 0 4.168840632701176e-07
affected O 0 3.4736835914372932e-06
individuals O 0 1.7081092664739117e-06
. O 0 1.0164431841985788e-05

This O 0 8.634537516627461e-05
missense O 0 0.0006414832314476371
mutation O 0 8.108516340143979e-05
, O 0 2.9704497137572616e-06
which O 0 2.3114957912184764e-06
replaces O 0 9.750848403200507e-05
Ala O 0 0.001986077753826976
with O 0 2.882369471990387e-06
Thr O 1 0.6528924703598022
, O 0 1.0348214800615096e-06
is O 0 2.2333996696488612e-07
frequent O 0 1.7189731806865893e-06
among O 0 3.857823685393669e-06
FNDI B-Disease 1 0.9999998807907104
patients O 0 0.13274526596069336
and O 0 9.507574532108265e-07
is O 0 1.418159172317246e-07
thought O 0 3.3402574217689107e-07
to O 0 9.704690029366247e-08
reduce O 0 2.8756264214280236e-07
the O 0 1.4504044543173222e-07
efficiency O 0 1.0756481287899078e-06
of O 0 2.0919291898735537e-07
cleavage O 0 9.970335668185726e-06
by O 0 2.033763848885428e-06
signal O 0 3.2124502467922866e-05
peptidases O 0 0.0001580763200763613
. O 0 7.332092536671553e-06
. O 0 1.942745984706562e-05

Genetic O 0 0.0015998840099200606
heterogeneity O 0 0.0006793453940190375
of O 0 2.1504871256183833e-05
Saethre B-Disease 1 0.9565934538841248
- I-Disease 1 0.9999754428863525
Chotzen I-Disease 1 0.9999938011169434
syndrome I-Disease 1 0.9999967813491821
, O 0 2.287810275447555e-06
due O 0 4.718570835393621e-06
to O 0 1.4699710391141707e-06
TWIST O 0 0.00010267092875437811
and O 0 1.0524352546781301e-05
FGFR O 0 0.018238496035337448
mutations O 0 9.292484173784032e-05
. O 0 1.9013283235835843e-05

Thirty O 0 0.000587773451115936
- O 0 0.00039344129618257284
two O 0 8.935936421039514e-06
unrelated O 0 0.00017392117297276855
patients O 0 0.00015315806376747787
with O 0 7.708675866524572e-07
features O 0 3.638389216575888e-06
of O 0 1.781102014319913e-06
Saethre B-Disease 1 0.981969952583313
- I-Disease 1 0.9999812841415405
Chotzen I-Disease 1 0.9999960660934448
syndrome I-Disease 1 0.9999954700469971
, O 0 2.0922252588206902e-06
a O 0 1.0605507668515202e-05
common O 0 0.0006562756025232375
autosomal B-Disease 1 0.9335107803344727
dominant I-Disease 0 0.16711008548736572
condition I-Disease 0 0.09192825853824615
of O 0 4.687989530793857e-06
craniosynostosis B-Disease 1 0.9910972118377686
and O 0 0.003536300966516137
limb B-Disease 1 0.9940721392631531
anomalies I-Disease 0 0.014765964820981026
, O 0 5.587676241702866e-07
were O 0 6.485119570243114e-07
screened O 0 2.7557903194974642e-06
for O 0 3.265492125592573e-07
mutations O 0 1.872371171884879e-06
in O 0 4.4353632233651297e-07
TWIST O 0 8.179302676580846e-05
, O 0 2.405134182481561e-06
FGFR2 O 0 0.0003667380951810628
, O 0 1.4820980140939355e-06
and O 0 2.773029336822219e-06
FGFR3 O 0 0.0010858182795345783
. O 0 2.554896673245821e-05

Nine O 0 0.00010415491124149412
novel O 0 2.804125142574776e-05
and O 0 3.7146533031773288e-06
three O 0 2.301821041328367e-06
recurrent O 0 0.00011347833788022399
TWIST O 0 0.00421205023303628
mutations O 0 2.6079656890942715e-05
were O 0 1.7789952835300937e-06
found O 0 1.5030389022285817e-06
in O 0 1.3243760577097419e-06
12 O 0 4.293425263313111e-06
families O 0 8.71208067110274e-06
. O 0 2.146280894521624e-05

Seven O 0 5.9785099438158795e-05
families O 0 1.2549248822324444e-05
were O 0 2.2841063582745846e-06
found O 0 9.191377330353134e-07
to O 0 2.359793001005528e-07
have O 0 2.95010437412202e-07
the O 0 3.792776226418937e-07
FGFR3 O 0 0.0006832870421931148
P250R O 0 0.00010403063060948625
mutation O 0 2.5988390461861854e-06
, O 0 1.1569743918471431e-07
and O 0 8.856435584903011e-08
one O 0 7.897295262182524e-08
individual O 0 7.49306963143681e-08
was O 0 9.846718285189127e-07
found O 0 2.463508224082034e-07
to O 0 1.0488269452935128e-07
have O 0 3.1431616775989824e-07
an O 0 7.410936859741923e-07
FGFR2 O 0 0.0006298032822087407
VV269 O 0 0.0002408005530014634
- O 0 0.00023167028848547488
270 O 0 6.292789475992322e-05
deletion O 0 0.0003256052441429347
. O 0 3.127692616544664e-05

To O 0 2.9560869734268636e-05
date O 0 2.3345121007878333e-05
, O 0 8.806068763078656e-07
our O 0 5.852127742400626e-07
detection O 0 2.5634201392676914e-06
rate O 0 6.877548344164097e-07
for O 0 2.757620052307175e-07
TWIST O 0 4.7188852477120236e-05
or O 0 5.236884135229047e-06
FGFR O 0 0.0021272776648402214
mutations O 0 6.727836080244742e-06
is O 0 3.42417195042799e-07
68 O 0 3.2495879622729262e-06
% O 0 1.1568026820896193e-06
in O 0 9.282841801905306e-07
our O 0 4.6134960030030925e-06
Saethre B-Disease 1 0.7789899110794067
- I-Disease 1 0.9999710321426392
Chotzen I-Disease 1 0.999997615814209
syndrome I-Disease 1 0.9999998807907104
patients O 0 0.0012088564690202475
, O 0 5.304148089635419e-07
including O 0 3.038040290448407e-07
our O 0 1.1790721146098804e-06
five O 0 3.370861350049381e-06
patients O 0 0.00012733350740745664
elsewhere O 0 1.4883023141010199e-05
reported O 0 4.152575274929404e-05
with O 0 3.2094085327116773e-06
TWIST O 0 0.008328469470143318
mutations O 0 9.054473048308864e-05
. O 0 2.9781916964566335e-05

More O 0 1.2259203685971443e-05
than O 0 2.3877421426732326e-06
35 O 0 1.652887021919014e-06
different O 0 6.919257771187404e-07
TWIST O 0 9.889248030958697e-05
mutations O 0 5.053680069977418e-06
are O 0 1.1570946867323073e-07
now O 0 3.509260579903639e-07
known O 0 3.215543245005392e-07
in O 0 2.948495421151165e-07
the O 0 6.772561960133316e-07
literature O 0 6.375824796123197e-06
. O 0 1.7023123291437514e-05

The O 0 2.8568132620421238e-05
most O 0 5.9790972954942845e-06
common O 0 5.184321253182134e-06
phenotypic O 0 1.4531444321619347e-05
features O 0 1.332518309027364e-06
, O 0 2.9541021717705007e-07
present O 0 1.8246147703848692e-07
in O 0 1.5608144110501598e-07
more O 0 5.152383053541598e-08
than O 0 3.8671132074341585e-08
a O 0 9.494103636598084e-08
third O 0 3.38936956723046e-07
of O 0 9.551754942549451e-08
our O 0 1.250544301001355e-06
patients O 0 3.25947257806547e-05
with O 0 8.183959039342881e-07
TWIST O 0 0.005831583868712187
mutations O 0 8.889655873645097e-06
, O 0 3.8691277381985856e-07
are O 0 2.2612741190641827e-07
coronal B-Disease 0 5.928374230279587e-05
synostosis I-Disease 0 0.00011076390364905819
, O 0 1.55014720348845e-06
brachycephaly B-Disease 0 4.168517261859961e-05
, O 0 2.289091298735002e-06
low B-Disease 0 3.6550893128151074e-05
frontal I-Disease 1 0.9628907442092896
hairline I-Disease 1 0.9999668598175049
, O 0 6.793344073230401e-05
facial B-Disease 1 0.8975463509559631
asymmetry I-Disease 0 0.0010369837982580066
, O 0 1.6091784345917404e-05
ptosis B-Disease 0 0.31495529413223267
, O 0 1.4204767467163038e-05
hypertelorism B-Disease 0 0.0021152421832084656
, O 0 3.5316243156557903e-06
broad B-Disease 0 1.7038975784089416e-05
great I-Disease 0 1.82204857992474e-05
toes I-Disease 0 0.00037041553878225386
, O 0 1.2296438853809377e-06
and O 0 2.6593550046527525e-06
clinodactyly B-Disease 0 0.0004594142665155232
. O 0 2.7451604182715528e-05

Significant O 0 0.00022701628040522337
intra O 0 0.000729830062482506
- O 0 0.0004804052587132901
and O 0 7.499842013203306e-06
interfamilial O 0 0.00021137682779226452
phenotypic O 0 7.380295573966578e-05
variability O 0 2.166010017390363e-05
is O 0 3.943780484405579e-07
present O 0 4.211690054489736e-07
for O 0 3.347857386870601e-07
either O 0 3.582811814339948e-06
TWIST O 0 0.0011744971852749586
mutations O 0 5.6979755754582584e-05
or O 0 1.0653700883267447e-05
FGFR O 0 0.02228708378970623
mutations O 0 0.0001919000642374158
. O 0 2.6640853320714086e-05

The O 0 3.568019747035578e-05
overlap O 0 2.7395064535085112e-05
in O 0 5.301238161337096e-06
clinical O 0 3.0549683287972584e-05
features O 0 1.566999458191276e-06
and O 0 3.659026788227493e-07
the O 0 1.6236960220794572e-07
presence O 0 3.9021409747874714e-07
, O 0 6.853180423149752e-08
in O 0 7.253630940340372e-08
the O 0 5.867317298680064e-08
same O 0 2.2173827574079041e-07
genes O 0 1.7438200927699654e-07
, O 0 5.50365051310564e-08
of O 0 4.778017270723467e-08
mutations O 0 4.0512128407499404e-07
for O 0 4.040227352675174e-08
more O 0 4.175878842715974e-08
than O 0 1.2225703471813176e-07
one O 0 3.846952552066796e-07
craniosynostotic B-Disease 0 0.006056912709027529
condition I-Disease 0 0.002446154598146677
- O 0 2.34761737374356e-05
such O 0 2.5039238948920683e-07
as O 0 3.954246494686231e-07
Saethre B-Disease 0 5.05000316479709e-05
- I-Disease 0 5.5799402616685256e-05
Chotzen I-Disease 0 3.2270621886709705e-05
, I-Disease 0 6.234026272977644e-07
Crouzon I-Disease 0 1.5621453712810762e-05
, I-Disease 0 4.890498530585319e-07
and I-Disease 0 3.0845601486362284e-06
Pfeiffer I-Disease 0 0.11227232962846756
syndromes I-Disease 0 0.003601011587306857
- O 0 1.2773811249644496e-05
support O 0 8.289626407531614e-07
the O 0 4.839297389480635e-07
hypothesis O 0 2.711774641284137e-06
that O 0 2.3240298219207034e-07
TWIST O 0 7.175523933256045e-06
and O 0 5.098396513858461e-07
FGFRs O 0 7.326627383008599e-06
are O 0 3.472506193702429e-08
components O 0 1.5778338990912744e-07
of O 0 1.6891910092908802e-08
the O 0 6.575758959570521e-08
same O 0 2.1186824028518458e-07
molecular O 0 7.71821646594617e-07
pathway O 0 7.618576773893437e-07
involved O 0 3.449876260219753e-07
in O 0 3.7890453086220077e-07
the O 0 7.211734214251919e-07
modulation O 0 6.473974735854426e-06
of O 0 8.676168476995372e-07
craniofacial O 1 0.5302666425704956
and O 0 2.1674317395081744e-05
limb O 0 0.05392088368535042
development O 0 6.1932378230267204e-06
in O 0 4.158633146289503e-06
humans O 0 4.317301318224054e-06
. O 0 2.1243058654363267e-06
. O 0 6.791151918150717e-06

Mutation O 0 0.0011984171578660607
analysis O 0 0.00017079393728636205
of O 0 5.7808763813227415e-05
UBE3A O 1 0.9985969662666321
in O 1 0.9998248219490051
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 1 0.9998546838760376
. O 0 0.0004122943209949881

Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.0011624796316027641
AS B-Disease 0 0.031725794076919556
) O 0 2.679039653230575e-06
is O 0 3.775965069507947e-07
caused O 0 3.6042479223397095e-06
by O 0 1.6279210512948339e-06
chromosome O 0 2.9852777515770867e-05
15q11 O 0 0.00011282652121735737
- O 0 9.004652383737266e-05
q13 O 0 4.462669312488288e-05
deletions O 0 1.1635515875241254e-05
of O 0 3.5618725746644486e-07
maternal O 0 9.867608241620474e-06
origin O 0 2.1111320620548213e-06
, O 0 8.472155741401366e-07
by O 0 2.5271440335927764e-06
paternal O 0 0.00048390281153842807
uniparental B-Disease 0 0.2719704508781433
disomy I-Disease 0 0.12474570423364639
( O 0 4.1393381252419204e-05
UPD B-Disease 1 0.9982877373695374
) O 0 1.6492010672664037e-06
15 O 0 8.660428534312814e-07
, O 0 1.9542002860362118e-07
by O 0 7.975644962243678e-07
imprinting O 0 0.00034473746200092137
defects O 0 0.05238206684589386
, O 0 8.126747843562043e-07
and O 0 5.065145955995831e-07
by O 0 9.586366331859608e-07
mutations O 0 5.004224476579111e-06
in O 0 9.851818276729318e-07
the O 0 3.854319402307738e-06
UBE3A O 0 0.0011043986305594444
gene O 0 5.3554977057501674e-05
. O 0 1.5309617083403282e-05

UBE3A O 0 0.01034992840141058
encodes O 0 0.00038154717185534537
a O 0 7.697164983255789e-05
ubiquitin O 0 0.00036133176763541996
- O 0 0.00012158233585068956
protein O 0 1.251505636901129e-05
ligase O 0 1.6543046513106674e-05
and O 0 1.2177882808828144e-06
shows O 0 1.1755750165320933e-05
brain O 0 0.0005851260502822697
- O 0 0.00012998669990338385
specific O 0 1.8036111214314587e-05
imprinting O 0 0.00046340483822859824
. O 0 3.5527067666407675e-05

Here O 0 0.00016509031411260366
we O 0 2.0863275494775735e-05
describe O 0 6.405994645319879e-05
UBE3A O 0 0.0018565357895568013
coding O 0 0.0004455958551261574
- O 0 0.0003472103853709996
region O 0 2.2338404960464686e-05
mutations O 0 2.396753552602604e-05
detected O 0 8.881995199772064e-06
by O 0 1.1719869235093938e-06
SSCP O 0 9.709622827358544e-05
analysis O 0 1.5887975450823433e-06
in O 0 7.095201794982131e-07
13 O 0 1.9090782643615967e-06
AS B-Disease 0 3.7024321500211954e-05
individuals O 0 2.5543249648762867e-07
or O 0 8.121649557324417e-07
families O 0 3.7861625514779007e-06
. O 0 1.0444104191265069e-05

Two O 0 4.6698838559677824e-05
identical O 0 0.0001225676096510142
de O 0 4.588744559441693e-05
novo O 0 0.0001104275943362154
5 O 0 2.08318633667659e-05
- O 0 5.571124711423181e-05
bp O 0 7.26622820366174e-05
duplications O 0 2.0737177692353725e-05
in O 0 2.396283207417582e-06
exon O 0 3.8991525798337534e-05
16 O 0 6.1422697399393655e-06
were O 0 4.357511443231488e-06
found O 0 7.363478744082386e-06
. O 0 1.3230896911409218e-05

Among O 0 1.8029542843578383e-05
the O 0 2.066015440504998e-06
other O 0 4.621430207407684e-07
11 O 0 7.027261972325505e-07
unique O 0 6.638782679146971e-07
mutations O 0 3.195362751284847e-06
, O 0 2.2872465876844217e-07
8 O 0 4.663250194880675e-07
were O 0 3.82342392413193e-07
small O 0 4.6560779765059124e-07
deletions O 0 6.061495696485508e-06
or O 0 6.492397233159863e-07
insertions O 0 1.0935556019830983e-05
predicted O 0 5.314682312018704e-06
to O 0 4.3728380205720896e-07
cause O 0 1.3038559245615033e-06
frameshifts O 0 2.0657120330724865e-05
, O 0 3.039054377040884e-07
1 O 0 4.328698821609578e-07
was O 0 1.0709396747188293e-06
a O 0 4.420633956669917e-07
mutation O 0 9.66661218626541e-07
to O 0 2.176764581918178e-07
a O 0 3.587830406104331e-07
stop O 0 2.141886170647922e-06
codon O 0 5.795322977064643e-06
, O 0 3.1935118727233203e-07
1 O 0 4.11566162483723e-07
was O 0 7.774368100399442e-07
a O 0 7.221382816169353e-07
missense O 0 2.200454764533788e-05
mutation O 0 2.7548758225748315e-06
, O 0 1.7276788355502504e-07
and O 0 1.4979059415054508e-07
1 O 0 3.950499944949115e-07
was O 0 4.903275566903176e-06
predicted O 0 2.7643711746350164e-06
to O 0 1.3394286213497253e-07
cause O 0 5.673050509358291e-07
insertion O 0 1.263543936147471e-06
of O 0 1.4166181472319295e-07
an O 0 7.919935001154954e-07
isoleucine O 0 5.024055644753389e-05
in O 0 1.0273257657900103e-06
the O 0 6.645262828897103e-07
hect O 0 1.295876700169174e-05
domain O 0 8.925980523599719e-07
of O 0 1.4037385653864476e-07
the O 0 5.562569640460424e-07
UBE3A O 0 5.976709144306369e-05
protein O 0 1.3377809864323353e-06
, O 0 1.2987945297027181e-07
which O 0 6.518553163914476e-08
functions O 0 1.0078989021167217e-07
in O 0 5.073524107501726e-07
E2 O 0 3.1398620194522664e-05
binding O 0 2.800039283101796e-06
and O 0 8.61131013607519e-07
ubiquitin O 0 1.9306376998429187e-05
transfer O 0 1.094618892238941e-05
. O 0 8.738391443330329e-06

Eight O 0 3.365682641742751e-05
of O 0 1.9432202407188015e-06
the O 0 1.933795374498004e-06
cases O 0 3.0185424293449614e-06
were O 0 3.7380009416665416e-06
familial O 0 3.1251049222191796e-05
, O 0 1.4360218756337417e-06
and O 0 6.35358162526245e-07
five O 0 9.055517011802294e-07
were O 0 4.3179556996619795e-06
sporadic O 0 9.329411113867536e-05
. O 0 3.591212225728668e-05

In O 0 5.888140367460437e-05
two O 0 1.4633324099122547e-05
familial O 0 0.00021819023822899908
cases O 0 9.28838380787056e-06
and O 0 1.5406925513161696e-06
one O 0 1.152659820036206e-06
sporadic O 0 2.105027851939667e-05
case O 0 5.346694706531707e-06
, O 0 9.108063068197225e-07
mosaicism O 0 2.5963370717363432e-05
for O 0 1.1328453410897055e-06
UBE3A O 0 0.0011041966499760747
mutations O 0 1.3055620001978241e-05
was O 0 4.3454601836856455e-06
detected O 0 4.148255356994923e-06
in O 0 2.6401573904877296e-07
the O 0 1.8648992750058824e-07
mother O 0 1.4414690667763352e-06
of O 0 6.516129502642798e-08
three O 0 1.8630434794886241e-07
AS B-Disease 0 0.0005398553912527859
sons O 0 3.560215554898605e-05
, O 0 2.1916267201049777e-07
in O 0 1.8939981316634658e-07
the O 0 2.7624108156487637e-07
maternal O 0 8.28103566163918e-06
grandfather O 0 5.243425675871549e-06
of O 0 8.249644167790393e-08
two O 0 1.932162660978065e-07
AS B-Disease 0 1.8446989997755736e-05
first O 0 7.878539349803759e-07
cousins O 0 4.877410901826806e-06
, O 0 1.3662868525443628e-07
and O 0 6.420810905183316e-08
in O 0 1.3557912836859032e-07
the O 0 1.3642231522226211e-07
mother O 0 1.2692808013525791e-06
of O 0 9.917449972363102e-08
an O 0 1.0112820518770604e-06
AS B-Disease 0 0.012844282202422619
daughter O 0 0.038537755608558655
. O 0 3.284697959315963e-05

The O 0 1.439199968444882e-05
frequencies O 0 1.937463639478665e-05
with O 0 8.537919029549812e-07
which O 0 5.050559366281959e-07
we O 0 3.9733666312713467e-07
detected O 0 2.2559697754331864e-06
mutations O 0 6.944471238057304e-07
were O 0 1.8763273601507535e-07
5 O 0 2.908430758452596e-07
( O 0 2.134340491011244e-07
14 O 0 2.410989452528156e-07
% O 0 1.563737583865077e-07
) O 0 5.192526231212469e-08
of O 0 3.732261788513824e-08
35 O 0 2.525654849705461e-07
in O 0 2.812548416386562e-07
sporadic O 0 1.1310134141240269e-05
cases O 0 8.933909043662425e-07
and O 0 3.5468903547553055e-07
8 O 0 8.285327339763171e-07
( O 0 2.206723053177484e-07
80 O 0 2.0784348464530922e-07
% O 0 1.5583469803459593e-07
) O 0 7.134883617254673e-08
of O 0 3.4004091986616913e-08
10 O 0 2.8420052444744215e-07
in O 0 1.506893909208884e-06
familial O 0 6.33992167422548e-05
cases O 0 8.051670192799065e-06
. O 0 5.563054401136469e-06
. O 0 1.5997316950233653e-05

The O 0 0.0007948246784508228
hemochromatosis B-Disease 1 0.9999794960021973
845 O 0 0.010503994300961494
G O 0 0.23668253421783447
- O 0 0.004768782295286655
- O 0 0.0002625397755764425
> O 0 1.25775950436946e-05
A O 0 1.0224124480373575e-06
and O 0 3.690909124998143e-07
187 O 0 3.0931500987207983e-06
C O 0 3.5982531699119136e-05
- O 0 0.0003281444078311324
- O 0 0.0015859454870224
> O 0 7.581787212984636e-05
G O 0 0.0005789453280158341
mutations O 0 1.4641586858488154e-05
: O 0 2.008102001127554e-06
prevalence O 0 1.2166425221948884e-05
in O 0 2.2588565116166137e-06
non O 0 3.071208993787877e-05
- O 0 0.02059570699930191
Caucasian O 0 0.0005487880553118885
populations O 0 3.0366978535312228e-05
. O 0 2.422356374154333e-05

Hemochromatosis B-Disease 1 0.9998546838760376
, O 0 0.00016473085270263255
the O 0 0.0003435211256146431
inherited B-Disease 1 0.9999998807907104
disorder I-Disease 1 0.9999994039535522
of I-Disease 0 6.18034619037644e-06
iron I-Disease 1 0.8400653600692749
metabolism I-Disease 0 0.0001569780142745003
, O 0 8.92949628905626e-07
leads O 0 1.228949940923485e-06
, O 0 6.061208068786073e-07
if O 0 1.1218490953979199e-06
untreated O 0 0.00014168195775710046
, O 0 6.610088689740223e-07
to O 0 1.0673516044334974e-06
progressive O 0 0.000267512135906145
iron B-Disease 0 0.4011746048927307
overload I-Disease 0 0.0011109854094684124
and O 0 1.1226155947952066e-05
premature B-Disease 0 0.004313881043344736
death I-Disease 0 7.524620014009997e-05
. O 0 3.125146758975461e-05

The O 0 0.0006023173336870968
hemochromatosis B-Disease 1 0.9999967813491821
gene O 0 0.00017036536883097142
, O 0 1.2126946785429027e-05
HFE O 0 0.003000611672177911
, O 0 2.6964153221342713e-06
recently O 0 5.197909558773972e-06
has O 0 5.921641559325508e-07
been O 0 4.7216758503054734e-07
identified O 0 4.994351456844015e-07
, O 0 5.976423267384234e-08
and O 0 8.554108177349917e-08
characterization O 0 1.2000772358078393e-06
of O 0 3.8371069877030095e-08
this O 0 1.5447739087903756e-07
gene O 0 7.611625960635138e-07
has O 0 1.432767362530285e-07
shown O 0 1.928841300014028e-07
that O 0 4.6854232493842574e-08
it O 0 3.805511283871965e-08
contains O 0 3.737405052106624e-08
two O 0 8.642205528985869e-08
mutations O 0 7.011149705249409e-07
that O 0 7.745670416170469e-08
result O 0 4.063334984039102e-07
in O 0 6.013528945914004e-07
amino O 0 1.260455746887601e-06
acid O 0 1.397604933117691e-06
substitutions O 0 3.1187894364848034e-06
- O 0 5.505705303221475e-06
cDNA O 0 1.0220965123153292e-05
nucleotides O 0 1.0824535820574965e-05
845 O 0 4.6344233851414174e-05
G O 0 0.00019655712821986526
- O 0 0.0001189772883662954
- O 0 0.00011058354721171781
> O 0 8.439096745860297e-06
A O 0 1.3073359923509997e-06
( O 0 9.686046951173921e-07
C282Y O 0 5.5347913985315245e-06
) O 0 2.8432577892090194e-07
and O 0 3.067763145736535e-07
187 O 0 7.549817382823676e-06
C O 0 0.00010114362521562725
- O 0 0.0010949752759188414
- O 0 0.0030115931294858456
> O 0 0.00013171276077628136
G O 0 0.0006686446140520275
( O 0 1.3554305041907355e-05
H63D O 0 0.00048573146341368556
) O 0 8.813951353658922e-06
. O 0 1.1571642971830443e-05

Although O 0 0.1364791989326477
hemochromatosis B-Disease 1 0.9999979734420776
is O 0 1.703473571978975e-05
common O 0 1.0131670933333226e-05
in O 0 6.9680422711826395e-06
Caucasians O 0 0.00012937140127178282
, O 0 1.1144784366479144e-06
affecting O 0 4.70520217277226e-06
> O 0 1.909033744595945e-05
= O 0 1.2655370483116712e-05
1 O 0 1.4256050917538232e-06
/ O 0 1.490515387558844e-05
300 O 0 3.1244292131304974e-07
individuals O 0 6.381971218161198e-08
of O 0 3.4090071210357564e-08
northern O 0 9.207248012899072e-07
European O 0 3.106085614490439e-06
origin O 0 5.437248091766378e-07
, O 0 1.7824415010636585e-07
it O 0 1.0437918973593696e-07
has O 0 1.6602903940565739e-07
not O 0 9.354741337119776e-08
been O 0 2.690140661343321e-07
recognized O 0 2.1238247427390888e-07
in O 0 2.740890181485156e-07
other O 0 7.359403753071092e-07
populations O 0 4.3155805542482994e-06
. O 0 1.065000378730474e-05

The O 0 3.6493151128524914e-05
present O 0 1.0489932719792705e-05
study O 0 4.211359282635385e-06
used O 0 2.1964717689115787e-06
PCR O 0 3.448130519245751e-05
and O 0 6.338711386888463e-07
restriction O 0 3.028155560969026e-06
- O 0 7.946755431476049e-06
enzyme O 0 2.7369324016035534e-06
digestion O 0 3.028161245310912e-06
to O 0 1.9404335205308598e-07
analyze O 0 6.891355610605387e-07
the O 0 1.211205500339929e-07
frequency O 0 5.122076345287496e-07
of O 0 6.21127398403587e-08
the O 0 4.0789390709505824e-07
845 O 0 2.601710548333358e-05
G O 0 0.0034109156113117933
- O 0 0.00023588628391735256
- O 0 8.590704237576574e-05
> O 0 4.256809461367084e-06
A O 0 6.741707920809858e-07
and O 0 4.474512991237134e-07
187 O 0 4.752413587993942e-06
C O 0 3.1627194402972236e-05
- O 0 0.00024640385527163744
- O 0 0.000603103544563055
> O 0 6.106339424150065e-05
G O 0 0.00024291835143230855
mutations O 0 1.1982030628132634e-05
in O 0 3.2104155707202153e-06
HLA O 0 0.0202310960739851
- O 0 3.405961615499109e-05
typed O 0 9.839360245678108e-06
samples O 0 2.1745245248894207e-06
from O 0 4.5673493787035113e-07
non O 0 5.429686098068487e-06
- O 0 9.519089508103207e-05
Caucasian O 0 3.2679166906746104e-05
populations O 0 8.822586892165418e-07
, O 0 1.468933845671927e-07
comprising O 0 3.1185467719296867e-07
Australian O 0 2.721300916164182e-06
Aboriginal O 0 1.3018964182265336e-06
, O 0 1.0639830350100965e-07
Chinese O 0 1.7122849271800078e-07
, O 0 2.3812582128357462e-07
and O 0 9.736484116729116e-07
Pacific O 0 7.57703855924774e-06
Islanders O 0 3.217778430553153e-05
. O 0 1.1880026249855291e-05

Results O 0 0.0005319067277014256
showed O 0 3.1967967515811324e-05
that O 0 1.0066383993034833e-06
the O 0 9.415178965355153e-07
845 O 0 5.042457632953301e-05
G O 0 0.01144336722791195
- O 0 0.0029781486373394728
- O 0 0.0005985902971588075
> O 0 1.2335385690676048e-05
A O 0 2.6324541977373883e-06
mutation O 0 3.2150110200745985e-06
was O 0 1.220753347297432e-06
present O 0 2.6614304715621984e-07
in O 0 2.2228580576211243e-07
these O 0 1.8611272878388263e-07
populations O 0 8.523128940396418e-07
( O 0 7.056016784190433e-07
allele O 0 2.35468382925319e-06
frequency O 0 1.324973482041969e-06
0 O 0 5.414377142187732e-07
. O 0 1.4367984135787992e-07
32 O 0 2.496696538401011e-07
% O 0 1.5577317924453382e-07
) O 0 6.364005145087503e-08
, O 0 3.26364855141037e-08
and O 0 6.063363855446369e-08
, O 0 9.068119766197924e-08
furthermore O 0 3.622752728915657e-07
, O 0 8.247268112882011e-08
it O 0 8.39723668377701e-08
was O 0 7.401641823889804e-07
always O 0 2.399268907993246e-07
seen O 0 3.2601775501461816e-07
in O 0 2.2030117463600618e-07
conjunction O 0 1.4507229479931993e-06
with O 0 1.6031091263357666e-06
HLA O 1 0.863764226436615
haplotypes O 0 5.604000762104988e-05
common O 0 2.284361016791081e-06
in O 0 1.969419372471748e-06
Caucasians O 0 3.518055018503219e-05
, O 0 6.095577305131883e-07
suggesting O 0 2.3330578642344335e-06
that O 0 4.836123252971447e-07
845 O 0 3.9887032471597195e-05
G O 0 0.005940196104347706
- O 0 0.013035701587796211
- O 0 0.009289395064115524
> O 0 3.317677692393772e-05
A O 0 3.629773573265993e-06
may O 0 2.4152964215318207e-06
have O 0 1.5870985237143032e-07
been O 0 1.365247470630493e-07
introduced O 0 4.1208184597962827e-07
into O 0 1.4141062365524704e-07
these O 0 1.5950678289300413e-07
populations O 0 8.752125495448126e-07
by O 0 1.788501094779349e-06
Caucasian O 0 0.00025111233117058873
admixture O 0 0.0002387016429565847
. O 0 4.202820855425671e-05

187 O 0 0.0006238329224288464
C O 0 0.001506446162238717
- O 0 0.006899693515151739
- O 0 0.007065250538289547
> O 0 0.0001274456299142912
G O 0 0.00013244488218333572
was O 0 2.216967004642356e-06
present O 0 3.741374428045674e-07
at O 0 4.1830097075035155e-07
an O 0 2.3219629952109244e-07
allele O 0 4.586945578921586e-06
frequency O 0 2.045647079285118e-06
of O 0 4.5235111656438676e-07
2 O 0 7.0061691985756624e-06
. O 0 1.448455350328004e-05

68 O 0 0.0004751497181132436
% O 0 2.0832199879805557e-05
in O 0 1.8052396626444533e-06
the O 0 8.83722236721951e-07
two O 0 6.328467065941368e-07
populations O 0 1.6707399481674656e-06
analyzed O 0 2.6793795768753625e-06
( O 0 7.008722491264052e-07
Australian O 0 2.956547405119636e-06
Aboriginal O 0 3.1968229450285435e-06
and O 0 5.644943712468375e-07
Chinese O 0 1.4736499451828422e-06
) O 0 2.1119315078976797e-06
. O 0 5.998641427140683e-06

In O 0 3.9009824831737205e-05
the O 0 9.982836672861595e-06
Australian O 0 2.6558687750366516e-05
Aboriginal O 0 1.2749895176966675e-05
samples O 0 3.4145107292715693e-06
, O 0 5.89892636071454e-07
187 O 0 4.8386468733951915e-06
C O 0 4.9045065679820254e-05
- O 0 0.0005040609976276755
- O 0 0.008381166495382786
> O 0 8.959146362030879e-05
G O 0 0.0006925343768671155
was O 0 5.5402147154381964e-06
found O 0 3.6136464132141555e-07
to O 0 1.1976655400758318e-07
be O 0 9.829242486603107e-08
associated O 0 4.0850002847037103e-07
with O 0 8.004600999811373e-07
HLA O 1 0.9860907793045044
haplotypes O 0 0.00016751069051679224
common O 0 3.5670366287376964e-06
in O 0 3.054855142181623e-06
Caucasians O 0 8.016762149054557e-05
, O 0 4.5212340182843036e-07
suggesting O 0 2.0461895928747253e-06
that O 0 1.4342876397677173e-07
it O 0 1.5085375082435348e-07
was O 0 7.889253765824833e-07
introduced O 0 1.2523404393505189e-06
by O 0 7.987047183632967e-07
recent O 0 7.440457011398394e-06
admixture O 0 0.0001139179730671458
. O 0 1.9201110262656584e-05

In O 0 2.3243135728989728e-05
the O 0 1.891023202915676e-06
Chinese O 0 1.371299845231988e-06
samples O 0 2.420590590190841e-06
analyzed O 0 1.9592569060478127e-06
, O 0 3.994620669800497e-07
187 O 0 2.8347772058623377e-06
C O 0 3.351154737174511e-05
- O 0 0.0002854523481801152
- O 0 0.0004699135315604508
> O 0 2.317783764738124e-05
G O 0 8.311924466397613e-05
was O 0 2.8143483632447897e-06
present O 0 4.2500454355831607e-07
in O 0 4.591482820615056e-07
association O 0 8.988542958832113e-07
with O 0 9.786403154521395e-08
a O 0 3.401304979888664e-07
wide O 0 6.420137310669816e-07
variety O 0 6.229259952306165e-07
of O 0 5.00543308135093e-07
HLA O 1 0.6951625347137451
haplotypes O 0 5.967283505015075e-05
, O 0 1.0276147577314987e-06
showing O 0 2.1178409497224493e-06
this O 0 2.3840645724249043e-07
mutation O 0 9.120554409491888e-07
to O 0 1.0414413509352016e-07
be O 0 1.0876597400510946e-07
widespread O 0 6.538408001688367e-07
and O 0 4.478423534237663e-07
likely O 0 1.0674136774468934e-06
to O 0 1.9974504539277405e-07
predate O 0 5.7938032114179805e-06
the O 0 2.86068114974114e-07
more O 0 3.1998837357605225e-07
genetically O 0 4.686796273745131e-06
restricted O 0 4.138306394452229e-06
845 O 0 9.97865354293026e-05
G O 0 0.03991411626338959
- O 0 0.01578289456665516
- O 0 0.006041400600224733
> O 0 6.96580100338906e-05
A O 0 2.7898708140128292e-05
mutation O 0 7.475827442249283e-05
. O 0 1.89047641470097e-05

Genotype O 1 0.9907229542732239
- O 1 0.9819969534873962
phenotype O 1 0.5745148062705994
correlations O 0 0.0019002615008503199
in O 0 0.000854741723742336
attenuated B-Disease 1 0.9986703395843506
adenomatous I-Disease 1 0.9999896287918091
polyposis I-Disease 1 0.9998581409454346
coli I-Disease 1 0.9996086955070496
. O 0 0.0005465782596729696

Germ O 0 0.2487691044807434
- O 0 0.0018646082608029246
line O 0 7.971442391863093e-05
mutations O 0 2.483695061528124e-05
of O 0 8.018651556085388e-07
the O 0 3.760720346690505e-06
tumor B-Disease 0 0.001899670111015439
suppressor O 0 0.0004314197867643088
APC O 0 0.00027733418392017484
are O 0 1.3471421880240086e-06
implicated O 0 7.038362673483789e-05
in O 0 8.217940194299445e-05
attenuated B-Disease 1 0.9929543137550354
adenomatous I-Disease 1 0.9999959468841553
polyposis I-Disease 1 0.9999822378158569
coli I-Disease 1 0.9999756813049316
( O 0 0.0012313518673181534
AAPC B-Disease 1 0.999985933303833
) O 0 5.985178631817689e-06
, O 0 1.3349605296752998e-06
a O 0 3.27841485159297e-06
variant O 0 0.0004105341504327953
of O 0 2.3128422981244512e-05
familial B-Disease 1 0.9999867677688599
adenomatous I-Disease 1 0.9999668598175049
polyposis I-Disease 1 0.9999982118606567
( O 0 0.0016682411078363657
FAP B-Disease 0 0.006684658117592335
) O 0 4.840607653022744e-05
. O 0 3.752474003704265e-05

AAPC B-Disease 1 0.9998862743377686
is O 0 3.236743214074522e-05
recognized O 0 7.688767254876439e-06
by O 0 1.680426635175536e-06
the O 0 1.259554437638144e-06
occurrence O 0 4.939603059028741e-06
of O 0 7.822314387340157e-07
< O 0 3.8963942643022165e-05
100 O 0 2.1737328097515274e-06
colonic B-Disease 0 0.00027633539866656065
adenomas I-Disease 0 0.0008152179652824998
and O 0 1.1633799203991657e-06
a O 0 2.211502078353078e-06
later O 0 5.903810597374104e-05
onset O 1 0.5802568793296814
of O 0 0.0018631693674251437
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 0.0001665131567278877
age O 0 0.00012235088797751814
> O 0 8.315856393892318e-05
40 O 0 4.963027549820254e-06
years O 0 5.037008122599218e-06
) O 0 6.099238817114383e-06
. O 0 1.3179037523514125e-05

The O 0 1.8992930563399568e-05
aim O 0 1.1966262718487997e-05
of O 0 4.504879029809672e-07
this O 0 5.327981398295378e-07
study O 0 1.2605013353095273e-06
was O 0 2.920952056228998e-06
to O 0 1.711153231553908e-06
assess O 0 0.0001381840993417427
genotype O 0 0.0497332401573658
- O 0 0.14147815108299255
phenotype O 0 0.0027998804580420256
correlations O 0 6.758986273780465e-05
in O 0 4.444975274964236e-05
AAPC B-Disease 1 0.9999253749847412
families O 0 8.705457003088668e-05
. O 0 4.1244635212933645e-05

By O 0 8.518542017554864e-05
protein O 0 0.00011019586236216128
- O 0 6.550578837050125e-05
truncation O 0 0.00011561554129002616
test O 0 2.6299037926946767e-05
( O 0 2.6959446586261038e-06
PTT O 0 2.2459049432654865e-05
) O 0 7.056077606648614e-07
assay O 0 4.147357685724273e-06
, O 0 1.2615232947155164e-07
the O 0 9.279074930645947e-08
entire O 0 9.397838311997475e-07
coding O 0 4.4070179683330934e-06
region O 0 3.638128589500411e-07
of O 0 7.338937990652994e-08
the O 0 5.90617105444835e-07
APC B-Disease 0 2.242814480268862e-05
gene O 0 2.0030811356264167e-06
was O 0 1.710337642180093e-06
screened O 0 6.355524419632275e-06
in O 0 1.1246139592913096e-06
affected O 0 2.1801354250783334e-06
individuals O 0 2.2210630845620472e-07
from O 0 7.706588007749815e-07
11 O 0 1.8884566088672727e-05
AAPC B-Disease 1 0.9998723268508911
kindreds O 0 0.00027777449577115476
, O 0 1.440463279323012e-06
and O 0 4.413620047216682e-07
their O 0 1.1732640814443585e-06
phenotypic O 0 2.218901863670908e-05
differences O 0 1.0074219062516931e-05
were O 0 1.080886613635812e-05
examined O 0 0.0001571321045048535
. O 0 1.814829374779947e-05

Five O 0 0.00013501297507900745
novel O 0 0.00015882312436588109
germ O 0 0.010583203285932541
- O 0 0.0011854423210024834
line O 0 0.00014050731260795146
APC B-Disease 0 0.0003500189050100744
mutations O 0 2.0941672119079158e-05
were O 0 2.6979457743436797e-06
identified O 0 6.203812972671585e-06
in O 0 2.939941850854666e-06
seven O 0 1.4064928109291941e-05
kindreds O 0 0.0006671309820376337
. O 0 4.4480704673333094e-05

Mutations O 0 0.00032661849400028586
were O 0 7.28843042452354e-06
located O 0 2.0383947685331805e-06
in O 0 3.8531322843482485e-07
three O 0 1.481080573739746e-07
different O 0 7.681143188165152e-08
regions O 0 1.2791245751486713e-07
of O 0 4.035544520775147e-08
the O 0 2.806051497827866e-07
APC B-Disease 0 2.285068876517471e-05
gene O 0 1.1750702242352418e-06
( O 0 2.1244467518499732e-07
1 O 0 1.6645105915813474e-07
) O 0 9.972801251478813e-08
at O 0 1.1619248141414573e-07
the O 0 9.291063918226428e-08
5 O 0 3.379157647032116e-07
end O 0 5.811605205963133e-07
spanning O 0 9.130492344411323e-07
exons O 0 1.5616824384778738e-06
4 O 0 3.2668472726982145e-07
and O 0 9.826842273241709e-08
5 O 0 1.7624365966639743e-07
, O 0 5.6174375373529983e-08
( O 0 9.344665841126698e-08
2 O 0 1.357482233288465e-07
) O 0 7.179358618714105e-08
within O 0 7.022311621085464e-08
exon O 0 1.8006506934398203e-06
9 O 0 3.651058477771585e-07
, O 0 6.563616494759117e-08
and O 0 6.469552715770988e-08
( O 0 1.0321686971792587e-07
3 O 0 1.178483586272705e-07
) O 0 8.836760656549814e-08
at O 0 9.69823261698366e-08
the O 0 1.560492961516502e-07
3 O 0 7.966097541611816e-07
distal O 0 1.5944160622893833e-05
end O 0 1.2879344239991042e-06
of O 0 2.895569650718244e-07
the O 0 2.028872359005618e-06
gene O 0 2.4926073820097372e-05
. O 0 9.696725101093762e-06

Variability O 0 0.001050444901920855
in O 0 1.0563446267042309e-05
the O 0 1.7388525748174288e-06
number O 0 8.780893949733581e-07
of O 0 8.709007488505449e-06
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999995231628418
was O 0 0.00015180082118604332
most O 0 9.672274927652325e-07
apparent O 0 9.97486222331645e-06
in O 0 1.2076707207597792e-06
individuals O 0 1.9455903554899123e-07
with O 0 3.250041800129111e-07
mutations O 0 3.002665607709787e-06
in O 0 5.640971494358382e-07
region O 0 8.568074463255471e-07
1 O 0 7.42145402909955e-07
, O 0 4.2932677501994476e-07
and O 0 2.5212534637830686e-06
upper O 0 0.02423878014087677
- O 1 0.9833930134773254
gastrointestinal O 1 0.5961236357688904
manifestations O 0 7.473781442968175e-05
were O 0 8.961770618043374e-06
more O 0 2.569061280155438e-06
severe O 0 0.0019156511407345533
in O 0 3.82591133529786e-06
them O 0 4.449807875062106e-06
. O 0 2.9535875000874512e-05

In O 0 4.623502536560409e-05
individuals O 0 2.522655677239527e-06
with O 0 8.43865848310088e-07
mutations O 0 3.5855873647960834e-06
in O 0 5.674689873558236e-07
either O 0 3.563870620837406e-07
region O 0 7.433964128722437e-07
2 O 0 4.858223974224529e-07
or O 0 1.4015448357440619e-07
region O 0 3.0925787086744094e-07
3 O 0 2.775903169549565e-07
, O 0 5.913887690667252e-08
the O 0 4.6363687999928516e-08
average O 0 2.3712055963187595e-07
number O 0 8.275789298295422e-08
of O 0 1.1033495184165076e-07
adenomas B-Disease 0 0.00015094877744559199
tended O 0 5.964977844996611e-06
to O 0 2.0725026672607783e-07
be O 0 1.019396691503971e-07
lower O 0 4.4867255155622843e-07
than O 0 8.527619144160781e-08
those O 0 5.60925741410756e-08
in O 0 1.6543569358873356e-07
individuals O 0 9.93558799677885e-08
with O 0 1.779107634547472e-07
mutations O 0 1.7252616544283228e-06
in O 0 3.762015694519505e-07
region O 0 4.764103209708992e-07
1 O 0 3.288443508608907e-07
, O 0 1.6584814943598758e-07
although O 0 7.051059469631582e-07
age O 0 3.794874373852508e-06
at O 0 8.614427315478679e-06
diagnosis O 1 0.8079500794410706
was O 0 8.769630221650004e-05
similar O 0 2.1404412109404802e-05
. O 0 2.407823376415763e-05

In O 0 9.678766218712553e-05
all O 0 2.4782177206361666e-05
AAPC B-Disease 1 0.9996647834777832
kindreds O 0 0.0009296297212131321
, O 0 4.932142019242747e-06
a O 0 3.024319994437974e-06
predominance O 0 3.5113782359985635e-05
of O 0 1.8893973674494191e-06
right O 0 0.0003986623778473586
- O 1 0.9997840523719788
sided O 1 0.999998927116394
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999974966049194
and O 0 0.002339527942240238
rectal B-Disease 1 0.9994696974754333
polyp I-Disease 0 0.33454203605651855
sparing O 0 0.00037925454671494663
was O 0 7.785024354234338e-05
observed O 0 5.7505709264660254e-05
. O 0 2.41881516558351e-05

No O 0 0.0008375127799808979
desmoid B-Disease 1 0.9992935657501221
tumors I-Disease 1 0.9999982118606567
were O 0 1.738858009048272e-05
found O 0 4.4113194235251285e-06
in O 0 1.98194516087824e-06
these O 0 2.57994543062523e-06
kindreds O 0 0.00026997056556865573
. O 0 3.685843330458738e-05

Our O 0 3.134004145977087e-05
data O 0 1.2766382496920414e-05
suggest O 0 5.214527845964767e-06
that O 0 3.981461134117126e-07
, O 0 4.0187774175137747e-07
in O 0 2.554685806899215e-06
AAPC B-Disease 1 0.9999599456787109
families O 0 2.3540617348771775e-06
, O 0 1.7437368171613343e-07
the O 0 1.0360701452327703e-07
location O 0 3.37427593422035e-07
of O 0 1.186696252375441e-07
the O 0 2.1608520910376683e-06
APC B-Disease 0 0.006237484049052
mutation O 0 2.1621552150463685e-05
may O 0 6.024336016707821e-06
partially O 0 2.038105776591692e-05
predict O 0 1.4386742805072572e-05
specific O 0 2.3856050574977417e-06
phenotypic O 0 4.4174445065436885e-05
expression O 0 2.3481770767830312e-05
. O 0 2.5025061404448934e-05

This O 0 1.4645051123807207e-05
should O 0 2.6583227281662403e-06
help O 0 8.699143450030533e-07
in O 0 4.095817587312922e-07
the O 0 1.49508025515388e-07
design O 0 1.5324527566917823e-06
of O 0 2.4937077114373096e-07
tailored O 0 0.026233449578285217
clinical O 0 0.4545758068561554
- O 1 0.7499492764472961
management O 0 4.464052835828625e-05
protocols O 0 2.3782087737345137e-05
in O 0 6.955825142540562e-07
this O 0 3.685819081056252e-07
subset O 0 4.202609034109628e-06
of O 0 1.4612982113249018e-06
FAP B-Disease 0 0.002340055536478758
patients O 0 0.0008930788026191294
. O 0 5.777107617177535e-06
. O 0 1.8343051124247722e-05

Wilms B-Disease 1 0.9992896318435669
' I-Disease 0 0.003604704048484564
tumor I-Disease 0 0.0010347249917685986
1 O 0 1.0610151548462454e-05
and O 0 4.509789050644031e-06
Dax O 0 0.08879505097866058
- O 0 3.6135454138275236e-05
1 O 0 1.6244022162936744e-06
modulate O 0 1.1540827472344972e-05
the O 0 1.7629639614824555e-06
orphan O 0 5.611647793557495e-05
nuclear O 0 2.575582402641885e-05
receptor O 0 2.4171480617951602e-05
SF O 0 0.0018952306127175689
- O 0 1.1193325008207466e-05
1 O 0 5.886006988475856e-07
in O 0 4.377398283850198e-07
sex O 0 2.064363116005552e-06
- O 0 5.186213911656523e-06
specific O 0 1.095480229196255e-06
gene O 0 8.292462553072255e-06
expression O 0 9.959549061022699e-06
. O 0 1.0877280146814883e-05

Products O 0 0.00019177219655830413
of O 0 8.803946002444718e-06
steroidogenic O 0 0.0004769455117639154
factor O 0 1.4487814041785896e-05
1 O 0 6.020683485985501e-06
( O 0 3.998556167061906e-06
SF O 0 0.3043956160545349
- O 0 4.735475158668123e-05
1 O 0 2.715617938520154e-06
) O 0 1.2916849527755403e-06
and O 0 2.2991225705482066e-06
Wilms B-Disease 1 0.8547021150588989
tumor I-Disease 0 0.00022529796115122736
1 O 0 3.0516491733578732e-06
( O 0 2.6314726255805e-06
WT1 O 0 0.00018694327445700765
) O 0 7.552709462288476e-07
genes O 0 4.98581414376531e-07
are O 0 6.541882413557687e-08
essential O 0 3.163439146192104e-07
for O 0 2.8451538014451216e-07
mammalian O 0 1.3489056982507464e-05
gonadogenesis O 0 3.119902248727158e-05
prior O 0 3.0704227356181946e-06
to O 0 1.3324547580850776e-06
sexual O 0 5.160559339856263e-06
differentiation O 0 2.6345202059019357e-05
. O 0 1.3975588444736786e-05

In O 0 7.517655467381701e-05
males O 0 4.8265577788697556e-05
, O 0 7.317047220567474e-06
SF O 0 0.19646719098091125
- O 0 3.4235174098284915e-05
1 O 0 1.2382166687530116e-06
participates O 0 1.0158219083677977e-06
in O 0 2.219896373389929e-07
sexual O 0 5.742506914430123e-07
development O 0 3.676866526802769e-07
by O 0 2.3564197704217804e-07
regulating O 0 1.2858848776886589e-06
expression O 0 5.258456212686724e-07
of O 0 1.2038928787205805e-07
the O 0 1.3555265923059778e-06
polypeptide O 0 2.6982421331922524e-05
hormone O 0 4.746189370052889e-05
Mullerian O 0 0.00021760707022622228
inhibiting O 0 7.93513681855984e-05
substance O 0 7.269610068760812e-05
( O 0 1.8202630599262193e-05
MIS O 0 0.0009049467043951154
) O 0 1.333684031123994e-05
. O 0 1.9216551663703285e-05

Here O 0 5.1373088354012e-05
, O 0 3.439919510128675e-06
we O 0 1.0547314559516963e-06
show O 0 3.7329386941564735e-06
that O 0 1.3631491810883745e-06
WT1 O 0 0.0006168700638227165
- O 0 0.0001457520411349833
KTS O 0 0.0005559111014008522
isoforms O 0 2.3309305106522515e-05
associate O 0 4.113830527785467e-06
and O 0 1.3087818615531432e-06
synergize O 0 7.937391637824476e-05
with O 0 5.040395990363322e-06
SF O 1 0.9858312606811523
- O 0 7.830306276446208e-05
1 O 0 1.6872917285581934e-06
to O 0 1.0232356544292998e-06
promote O 0 5.27132760907989e-06
MIS O 0 0.0002563642628956586
expression O 0 2.9577224267995916e-05
. O 0 2.099430639646016e-05

In O 0 0.00017717895389068872
contrast O 0 0.0002353067247895524
, O 0 5.2721261454280466e-05
WT1 O 0 0.007917367853224277
missense O 0 0.0009539956226944923
mutations O 0 0.00010068115807371214
, O 0 2.4962923816929106e-06
associated O 0 3.000129481733893e-06
with O 0 1.6259349422398373e-06
male B-Disease 0 4.059700950165279e-05
pseudohermaphroditism I-Disease 1 0.9965215921401978
in O 0 0.00010524253593757749
Denys B-Disease 1 0.9997482895851135
- I-Disease 1 0.9999920129776001
Drash I-Disease 1 0.9999934434890747
syndrome I-Disease 1 0.9999966621398926
, O 0 3.5310852126713144e-06
fail O 0 2.6060311938636005e-05
to O 0 1.5364886394308996e-06
synergize O 0 7.922585791675374e-05
with O 0 4.890018317382783e-06
SF O 1 0.996911883354187
- O 0 0.00033233544672839344
1 O 0 1.5616762539139017e-05
. O 0 1.4835779438726604e-05

Additionally O 0 0.00015243046800605953
, O 0 5.855103154317476e-06
the O 0 1.8679303366297972e-06
X O 0 5.1590923249023035e-05
- O 0 5.412296741269529e-05
linked O 0 5.037161827203818e-06
, O 0 4.670834528042178e-07
candidate O 0 3.1508288884651847e-06
dosage O 0 7.992563769221306e-05
- O 0 5.192739627091214e-05
sensitive O 0 9.025608051160816e-06
sex O 0 4.3100567381770816e-06
- O 0 1.4148202353680972e-05
reversal O 0 1.0456133168190718e-05
gene O 0 3.4805809718818637e-06
, O 0 6.232480700418819e-07
Dax O 0 0.004728317726403475
- O 0 7.027033007034333e-06
1 O 0 6.995153967181977e-07
, O 0 3.63649149903722e-07
antagonizes O 0 1.0045122508017812e-05
synergy O 0 5.837245680595515e-06
between O 0 1.2826490092265885e-06
SF O 0 0.26031023263931274
- O 0 1.5187913049885537e-05
1 O 0 6.726988317495852e-07
and O 0 4.80951598547108e-07
WT1 O 0 5.570301436819136e-05
, O 0 2.447418410156388e-07
most O 0 1.0329052457791477e-07
likely O 0 2.3808881621789624e-07
through O 0 7.796436563012321e-08
a O 0 2.2451558834291063e-07
direct O 0 7.324045441237104e-07
interaction O 0 1.3995095287100412e-06
with O 0 1.3265387224237202e-06
SF O 1 0.9819077849388123
- O 0 0.000279459694866091
1 O 0 1.1841761079267599e-05
. O 0 1.1991279279754963e-05

We O 0 6.858815322630107e-05
propose O 0 0.00010829752136487514
that O 0 6.772492270101793e-06
WT1 O 0 0.0003869270731229335
and O 0 6.778158876841189e-06
Dax O 1 0.9329266548156738
- O 0 0.0001404951181029901
1 O 0 2.461623125782353e-06
functionally O 0 4.742534201795934e-06
oppose O 0 1.3949842241345323e-06
each O 0 1.4311450513559976e-07
other O 0 1.8251562039495184e-07
in O 0 6.526341280732595e-07
testis O 0 2.3482465621782467e-05
development O 0 2.8023016511724563e-06
by O 0 3.2713696782593615e-06
modulating O 0 0.00017455880879424512
SF O 1 0.8494870066642761
- O 0 0.000185126336873509
1 O 0 7.521143743360881e-06
- O 0 0.0001070876169251278
mediated O 0 0.00010782969184219837
transactivation O 0 0.0003045041230507195
. O 0 9.845930435403716e-06
. O 0 1.54683457367355e-05

A O 0 0.00038360379403457046
mouse O 0 0.0009233697201125324
model O 0 0.00031988811679184437
for O 0 0.00010546717385295779
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 0.9999997615814209
imprinting O 0 0.03635609149932861
- O 0 0.1320071816444397
centre O 0 0.0011329288827255368
mutations O 0 0.0002726688690017909
. O 0 4.0123639337252825e-05

Imprinting O 0 0.0021562930196523666
in O 0 2.491081613698043e-05
the O 0 7.245877441164339e-06
15q11 O 0 0.0002579063002485782
- O 0 0.0001577731891302392
q13 O 0 4.428824468050152e-05
region O 0 2.2864469428895973e-06
involves O 0 1.4911714742993354e-06
an O 0 9.880355946734198e-07
imprinting O 0 1.822237936721649e-05
centre O 0 1.711385448288638e-05
( O 0 1.7717233049552306e-06
IC O 0 5.076521119917743e-05
) O 0 4.3310606656632444e-07
, O 0 1.4276606918883772e-07
mapping O 0 6.931291522960237e-07
in O 0 1.849550415045087e-07
part O 0 2.3732236797968653e-07
to O 0 1.566149450127341e-07
the O 0 2.1843257513864955e-07
promoter O 0 4.06930985263898e-06
and O 0 2.9000108270338387e-07
first O 0 1.596271431481e-06
exon O 0 1.5863397493376397e-05
of O 0 1.3753900702795363e-06
SNRPN O 0 0.0008825428667478263
. O 0 3.794681833824143e-05

Deletion O 0 0.0012001615250483155
of O 0 8.67642756929854e-06
this O 0 6.95058042765595e-06
IC O 0 0.00040184042882174253
abolishes O 0 0.00015272566815838218
local O 0 8.650087693240494e-06
paternally O 0 8.256452565547079e-05
derived O 0 9.730285455589183e-06
gene O 0 7.992358405317646e-06
expression O 0 2.3925815639813663e-06
and O 0 1.2335751762293512e-06
results O 0 5.2378039981704205e-05
in O 0 0.0028364150784909725
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.00309869647026062
PWS B-Disease 1 0.9999980926513672
) O 0 6.362761632772163e-05
. O 0 4.305591210140847e-05

We O 0 2.4918253984651528e-05
have O 0 2.561551127655548e-06
created O 0 1.6619806046946906e-06
two O 0 7.468712510672049e-07
deletion O 0 3.16848854708951e-05
mutations O 0 1.0157338692806661e-05
in O 0 3.332072537887143e-06
mice O 0 0.0001128928197431378
to O 0 9.075470757125004e-07
understand O 0 1.0604659109958448e-05
PWS B-Disease 1 0.9999762773513794
and O 0 9.203297395288246e-07
the O 0 2.1867832344923954e-07
mechanism O 0 7.177017096182681e-07
of O 0 1.63579116474466e-07
this O 0 1.131955627897696e-06
IC O 0 0.0006189455161802471
. O 0 2.1116953575983644e-05

Mice O 0 0.23953695595264435
harbouring O 0 0.0021346164867281914
an O 0 2.8033871785737574e-05
intragenic O 0 0.001208459842018783
deletion O 0 0.00021525273041334003
in O 0 7.584586455777753e-06
Snrpn O 0 0.0002756139438133687
are O 0 1.1682308240779093e-06
phenotypically O 0 0.00012866732140537351
normal O 0 7.062493295961758e-06
, O 0 8.430140496784588e-07
suggesting O 0 3.1946226499712793e-06
that O 0 3.522310123571515e-07
mutations O 0 1.2171241223768448e-06
of O 0 1.775042051122e-07
SNRPN O 0 0.00025512120919302106
are O 0 4.291626396479842e-07
not O 0 5.14623479830334e-07
sufficient O 0 2.895649231504649e-06
to O 0 4.782430096383905e-06
induce O 0 0.0003290466556791216
PWS B-Disease 1 0.9999790191650391
. O 0 0.0001113541002268903

Mice O 0 0.2530067563056946
with O 0 1.1707464182109106e-05
a O 0 6.266264790610876e-06
larger O 0 1.21412967928336e-05
deletion O 0 4.377054574433714e-05
involving O 0 3.6845119666395476e-06
both O 0 2.267526724608615e-06
Snrpn O 0 0.0001064702810253948
and O 0 2.1938005829724716e-06
the O 0 3.4891288578364765e-06
putative O 0 0.00032821641070768237
PWS O 1 0.9999972581863403
- O 0 0.00684409448876977
IC O 0 0.0003293193585705012
lack O 0 4.973446721123764e-06
expression O 0 1.2910013538203202e-06
of O 0 1.8296367443326744e-07
the O 0 8.866574603416666e-07
imprinted O 0 4.0408871427644044e-05
genes O 0 1.1850098417198751e-05
Zfp127 O 0 6.5416403231211e-05
( O 0 2.6592178983264603e-06
mouse O 0 1.2357309060462285e-05
homologue O 0 2.3594882804900408e-05
of O 0 3.927142984139209e-07
ZNF127 O 0 8.350957068614662e-05
) O 0 1.2215499509693473e-06
, O 0 6.61724072870129e-07
Ndn O 0 5.3151357860770077e-05
and O 0 1.4957049643271603e-06
Ipw O 0 0.00025715521769598126
, O 0 5.514862095878925e-07
and O 0 7.724107717876905e-07
manifest O 0 3.6188994272379205e-06
several O 0 1.3007125971853384e-06
phenotypes O 0 8.375640027225018e-05
common O 0 1.9624076230684295e-05
to O 0 0.0001612121850484982
PWS B-Disease 1 0.9999998807907104
infants O 1 0.9712082147598267
. O 0 8.315269951708615e-05

These O 0 1.466440789954504e-05
data O 0 7.816885954525787e-06
demonstrate O 0 2.8281938284635544e-06
that O 0 1.7030770038672927e-07
both O 0 6.133877406000465e-08
the O 0 5.4048957309760226e-08
position O 0 1.3284588362694194e-07
of O 0 3.0143311846586585e-08
the O 0 2.0093764874218323e-07
IC O 0 2.1135689166840166e-05
and O 0 1.150525577031658e-07
its O 0 1.1056711457513302e-07
role O 0 1.7618600622881786e-07
in O 0 9.693812330624496e-08
the O 0 1.2178632857740013e-07
coordinate O 0 5.24987797234644e-07
expression O 0 4.972769716005132e-07
of O 0 5.5563994294516306e-08
genes O 0 3.2736056709836703e-07
is O 0 5.714350592711526e-08
conserved O 0 1.6767930333116965e-07
between O 0 1.476442150760704e-07
mouse O 0 3.425377826715703e-06
and O 0 3.7035354694126e-07
human O 0 2.9984022376083885e-07
, O 0 1.560762257213355e-07
and O 0 1.724233840150191e-07
indicate O 0 4.4927028852725925e-07
that O 0 6.206146707654625e-08
the O 0 1.894097465537925e-07
mouse O 0 2.7529401904757833e-06
is O 0 6.735076141239915e-08
a O 0 1.31807553316321e-07
suitable O 0 7.877480356910382e-07
model O 0 2.6692925985116744e-06
system O 0 5.584644782175019e-07
in O 0 1.7158058085442462e-07
which O 0 1.1559862400645216e-07
to O 0 1.223565249119929e-07
investigate O 0 6.164507908579253e-07
the O 0 3.362223708336387e-07
molecular O 0 1.6308905514961225e-06
mechanisms O 0 8.673430329508847e-07
of O 0 1.7832303456088994e-07
imprinting O 0 8.45840168040013e-06
in O 0 6.929520282028534e-07
this O 0 2.9433851977955783e-07
region O 0 4.3787551362584054e-07
of O 0 1.2581531905198062e-07
the O 0 9.145830404122535e-07
genome O 0 7.07250273990212e-06
. O 0 3.1843444503465435e-06
. O 0 9.851059076027013e-06

Mutations O 0 0.0003254203184042126
of O 0 4.493389496929012e-06
the O 0 4.827013981412165e-06
ATM O 0 9.395146480528638e-05
gene O 0 2.16699354496086e-05
detected O 0 1.6137995771714486e-05
in O 0 3.911432486347621e-06
Japanese O 0 0.0023768004029989243
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999997615814209
telangiectasia I-Disease 1 1.0
patients O 1 0.970112681388855
: O 0 1.7298677903454518e-06
possible O 0 8.515085596627614e-07
preponderance O 0 9.205175047100056e-06
of O 0 1.728153478097738e-07
the O 0 6.077362399992126e-07
two O 0 1.6070415540525573e-06
founder O 0 8.68712886585854e-05
mutations O 0 5.711918856832199e-05
4612del165 O 0 0.00013703425065614283
and O 0 1.172543124994263e-05
7883del5 O 0 0.0004377865407150239
. O 0 4.623215500032529e-05

The O 0 7.649733743164688e-05
ATM O 0 0.0007687773904763162
( O 0 3.111894693574868e-05
A O 0 0.05007539317011833
- O 1 0.975885808467865
T O 1 0.9998743534088135
, O 0 3.1468618999497266e-06
mutated O 0 1.9031240299227647e-05
) O 0 1.339216964879597e-06
gene O 0 3.6815895327890757e-06
on O 0 2.9268526304804254e-06
human O 0 7.036159786366625e-06
chromosome O 0 8.040695684030652e-05
11q22 O 0 0.00028543491498567164
. O 0 3.3170832466566935e-05

3 O 0 0.0001007445462164469
has O 0 8.96990968612954e-06
recently O 0 8.26515315566212e-06
been O 0 8.719376296539849e-07
identified O 0 8.944555247580865e-07
as O 0 1.1388231513365099e-07
the O 0 1.2402500715325004e-07
gene O 0 8.11379948117974e-07
responsible O 0 3.1042833370520384e-07
for O 0 2.503577718471206e-07
the O 0 3.4670244986045873e-06
human O 0 0.00016444131324533373
recessive B-Disease 1 0.9999392032623291
disease I-Disease 1 0.9999854564666748
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.005813060328364372
A B-Disease 1 0.9997766613960266
- I-Disease 1 0.9999899864196777
T I-Disease 1 0.9999923706054688
) O 0 1.243654332938604e-05
. O 0 1.3094274436298292e-05

In O 0 2.645055610628333e-05
order O 0 4.403018920129398e-06
to O 0 8.579709174227901e-07
define O 0 2.0211627997923642e-06
the O 0 5.26557187185972e-07
types O 0 1.8547093532106373e-06
of O 0 1.25580879739573e-06
disease O 0 0.003418909851461649
- O 0 0.0023348783142864704
causing O 0 1.44064042615355e-05
ATM O 0 0.00018556939903646708
mutations O 0 5.269040684652282e-06
in O 0 4.6480744231303106e-07
Japanese O 0 7.63222124078311e-06
A B-Disease 1 0.962723433971405
- I-Disease 1 0.999988317489624
T I-Disease 1 0.9999998807907104
patients O 0 0.0023987027816474438
as O 0 4.154992438998306e-07
well O 0 2.904516804846935e-07
as O 0 1.6581383022185037e-07
to O 0 1.1607043148842422e-07
look O 0 6.641492404924065e-07
for O 0 1.589600913121103e-07
possible O 0 9.448946798329416e-07
mutational O 0 6.359783583320677e-05
hotspots O 0 2.1823756469530053e-05
, O 0 9.689002808954683e-07
reverse O 0 7.992022801772691e-06
- O 0 8.170552064257208e-06
transcribed O 0 3.485194383756607e-06
RNA O 0 6.964035605960817e-07
derived O 0 4.631993419934588e-07
from O 0 1.3039051793839462e-07
ten O 0 5.891084242648503e-07
patients O 0 3.1851766379986657e-06
belonging O 0 7.501942604903888e-07
to O 0 1.7209482905400364e-07
eight O 0 5.363996251617209e-07
unrelated O 0 4.477485163079109e-06
Japanese O 0 1.904890814330429e-05
A B-Disease 1 0.8729313015937805
- I-Disease 1 0.9989816546440125
T I-Disease 1 0.9999104738235474
families O 0 3.7944835185044212e-06
was O 0 5.5020359468471725e-06
analyzed O 0 3.1512495297647547e-06
for O 0 4.3839864360961656e-07
mutations O 0 2.6463787889952073e-06
by O 0 4.1229722569369187e-07
the O 0 6.933526037755655e-07
restriction O 0 1.1704405551427044e-05
endonuclease O 0 0.000150696694618091
fingerprinting O 0 0.0001284634490730241
method O 0 4.4929536670679227e-05
. O 0 2.7158715965924785e-05

As O 0 3.246595588279888e-05
has O 0 4.91941136715468e-06
been O 0 1.7440873989471584e-06
reported O 0 2.0127283733017975e-06
by O 0 4.14204720300404e-07
others O 0 9.94184119917918e-07
, O 0 4.6228760197664087e-07
mutations O 0 1.3556843896367354e-06
that O 0 1.7600314095034264e-07
lead O 0 6.536843102367129e-07
to O 0 5.056593295194034e-07
exon O 0 1.1627194908214733e-05
skipping O 0 1.4539913536282256e-05
or O 0 3.435663757045404e-06
premature O 0 5.048943785368465e-05
protein O 0 2.9857665140298195e-06
truncation O 0 1.520274963695556e-05
were O 0 1.822711965360213e-06
also O 0 8.336615451298712e-07
predominant O 0 6.37060384178767e-06
in O 0 1.5761539771119715e-06
our O 0 4.601429736794671e-06
mutants O 0 0.00010829308303073049
. O 0 1.3318055607669521e-05

Six O 0 6.618960469495505e-05
different O 0 9.399144801136572e-06
mutations O 0 1.7367579857818782e-05
were O 0 2.0472709820751334e-06
identified O 0 1.6000070672816946e-06
on O 0 3.8988861206235015e-07
12 O 0 2.6685771103984735e-07
of O 0 7.864976225846476e-08
the O 0 6.607415912185388e-07
16 O 0 1.1877998076670337e-05
alleles O 0 4.171985710854642e-05
examined O 0 0.00018880609422922134
. O 0 4.441305645741522e-05

Four O 0 3.0968432838562876e-05
were O 0 1.4477954209723976e-05
deletions O 0 3.436346014495939e-05
involving O 0 3.7518079807341564e-06
a O 0 2.280221224282286e-06
loss O 0 3.9992160054680426e-06
of O 0 1.7421793074845482e-07
a O 0 1.0704086434998317e-06
single O 0 1.9384115148568526e-06
exon O 0 2.6070603780681267e-05
exon O 0 1.8657561668078415e-05
7 O 0 3.0175524443620816e-06
, O 0 7.824874046491459e-07
exon O 0 7.701380127400625e-06
16 O 0 1.362322791464976e-06
, O 0 3.8170992411323823e-07
exon O 0 1.0488891348359175e-05
33 O 0 3.873007244692417e-06
or O 0 1.8603871012601303e-06
exon O 0 4.373532647150569e-05
35 O 0 1.6723193766665645e-05
. O 0 1.9494624211802147e-05

The O 0 3.8399746699724346e-05
others O 0 1.3172028047847562e-05
were O 0 3.0678263556183083e-06
minute O 0 5.521585080714431e-06
deletions O 0 1.36738544824766e-05
, O 0 1.0364481113356305e-06
4649delA O 0 1.0258199836243875e-05
in O 0 1.1094531373601058e-06
exon O 0 1.335388242296176e-05
33 O 0 3.5522118650987977e-06
and O 0 1.7520092114864383e-06
7883del5 O 0 3.2452153391204774e-05
in O 0 4.796343091584276e-06
exon O 0 0.00011000718950526789
55 O 0 4.0686620195629075e-05
. O 0 2.0126910385442898e-05

The O 0 7.117581844795495e-05
mutations O 0 0.00011944039579248056
4612del165 O 0 7.79166366555728e-05
and O 0 1.6396863884438062e-06
7883del5 O 0 4.3324409489287063e-05
were O 0 7.769979788463388e-07
found O 0 2.0122453747717373e-07
in O 0 5.8468394570354576e-08
more O 0 2.005600663324003e-08
than O 0 2.9568013815151062e-08
two O 0 4.276668619240809e-08
unrelated O 0 6.801806193834636e-07
families O 0 4.5365928258433996e-07
; O 0 4.796644930138427e-07
44 O 0 1.71264707660157e-06
% O 0 9.153177416010294e-07
( O 0 2.2865202708999277e-07
7 O 0 2.1134395922217664e-07
of O 0 5.576742267976442e-08
16 O 0 2.930364075837133e-07
) O 0 6.77443594554461e-08
of O 0 2.6496712379753262e-08
the O 0 3.0749043844480184e-07
mutant O 0 7.672718311368953e-06
alleles O 0 1.9371530015632743e-06
had O 0 4.091511698334216e-07
one O 0 6.850422096249531e-08
of O 0 5.132902813897999e-08
the O 0 6.092055286899267e-07
two O 0 1.8884712744693388e-06
mutations O 0 2.97949281957699e-05
. O 0 1.3661654520547017e-05

The O 0 5.7523033319739625e-05
4612del165 O 0 0.0004429024993441999
mutations O 0 1.543844336993061e-05
in O 0 5.647215743920242e-07
three O 0 1.2623742406958627e-07
different O 0 9.305163217732115e-08
families O 0 2.152422382550867e-07
were O 0 3.318836832022498e-07
all O 0 8.08022662113217e-08
ascribed O 0 1.239469042957353e-06
to O 0 1.3021518441291846e-07
the O 0 2.859126482235297e-07
same O 0 1.455667756999901e-06
T O 0 0.0032438538037240505
- O 0 0.00012558180605992675
- O 0 3.876499249599874e-05
> O 0 3.389047378732357e-06
A O 0 6.791098030589637e-07
substitution O 0 9.569814665155718e-07
at O 0 4.4073274807487905e-07
the O 0 3.6648799550675903e-07
splice O 0 2.350298746023327e-05
donor O 0 8.77537877386203e-06
site O 0 4.870572865911527e-06
in O 0 4.963964784110431e-06
intron O 0 0.00034436481655575335
33 O 0 5.179821528145112e-05
. O 0 1.9511737264110707e-05

Microsatellite O 0 0.00290197366848588
genotyping O 0 0.0007826548535376787
around O 0 1.2055272236466408e-05
the O 0 2.7748096727009397e-06
ATM O 0 4.22118537244387e-05
locus O 0 9.1170659288764e-06
also O 0 1.3909432254877174e-06
indicated O 0 3.7827844607818406e-06
that O 0 1.8146556612919085e-07
a O 0 9.988883675760007e-07
common O 0 5.76151524001034e-06
haplotype O 0 0.00025111614377237856
was O 0 3.064504653593758e-06
shared O 0 6.850441423011944e-07
by O 0 4.96429265695042e-07
the O 0 9.894217782857595e-07
mutant O 0 1.635560329305008e-05
alleles O 0 8.855057785694953e-06
in O 0 1.5039880736367195e-06
both O 0 4.456105671124533e-06
mutations O 0 5.052980486652814e-05
. O 0 1.468338359700283e-05

This O 0 2.131781366188079e-05
suggests O 0 1.256416999240173e-05
that O 0 5.990198701510963e-07
these O 0 1.0804600947267318e-07
two O 0 2.4607473392279644e-07
founder O 0 5.118897388456389e-05
mutations O 0 1.2752801012538839e-05
may O 0 1.8783141513267765e-06
be O 0 3.256675427110167e-07
predominant O 0 4.022844677820103e-06
among O 0 9.839199037742219e-07
Japanese O 0 9.245555702364072e-06
ATM O 0 0.00018216953321825713
mutant O 0 0.00019953212176915258
alleles O 0 0.00015616213204339147
. O 0 3.053075124626048e-05

W474C O 0 0.0043159662745893
amino O 0 0.000138469273224473
acid O 0 5.4159987485036254e-05
substitution O 0 2.781502735160757e-05
affects O 0 9.84829785011243e-06
early O 0 1.9739509298233315e-06
processing O 0 8.277571055259614e-07
of O 0 5.2342503664704054e-08
the O 0 1.7878159042084008e-07
alpha O 0 1.0212157803834998e-06
- O 0 1.375026727146178e-06
subunit O 0 8.700122862137505e-07
of O 0 1.7482476266650337e-07
beta O 0 2.390503823335166e-06
- O 0 1.0910045602940954e-05
hexosaminidase O 0 1.662326030782424e-05
A O 0 1.2766837471644976e-06
and O 0 6.027642029948765e-07
is O 0 3.68235475889378e-07
associated O 0 1.703091356830555e-06
with O 0 1.9585058907978237e-06
subacute O 1 0.8446297645568848
G B-Disease 1 0.9177313446998596
( I-Disease 0 1.9991624867543578e-05
M2 I-Disease 0 0.0007758545107208192
) I-Disease 0 1.259830423805397e-05
gangliosidosis I-Disease 0 0.00017641042359173298
. O 0 1.9181967218173668e-05

Mutations O 0 0.00041290122317150235
in O 0 1.19863734653336e-05
the O 0 5.578216132562375e-06
HEXA O 0 0.001191090326756239
gene O 0 1.0911564459092915e-05
, O 0 4.397683426304866e-07
encoding O 0 1.3159093441572622e-06
the O 0 3.6849334605904005e-07
alpha O 0 1.4046387377675273e-06
- O 0 1.4035674666956766e-06
subunit O 0 8.480708402203163e-07
of O 0 1.4308788820471818e-07
beta O 0 1.4767069842491765e-06
- O 0 9.608996151655447e-06
hexosaminidase O 0 1.798238736228086e-05
A O 0 2.336261786695104e-06
( O 0 1.0678270427888492e-06
Hex O 0 5.172043984202901e-06
A O 0 8.14367638213298e-07
) O 0 2.4823944499985373e-07
, O 0 1.0687444529366985e-07
that O 0 1.7121199391567643e-07
abolish O 0 4.108957455173368e-06
Hex O 0 9.757466614246368e-06
A O 0 1.5218618045764742e-06
enzyme O 0 6.0668739934044424e-06
activity O 0 8.294162398669869e-06
cause O 0 0.00012481179146561772
Tay B-Disease 1 1.0
- I-Disease 1 0.9999995231628418
Sachs I-Disease 1 1.0
disease I-Disease 0 0.17117340862751007
( O 0 7.698773515585344e-06
TSD B-Disease 0 0.005711639765650034
) O 0 8.033968015297432e-07
, O 0 2.711325066684367e-07
the O 0 8.931224897423817e-07
fatal O 0 0.000627596746198833
infantile B-Disease 0 0.00033201309270225465
form I-Disease 0 1.5472980976483086e-06
of I-Disease 0 6.683173410237941e-07
G I-Disease 0 0.004130511078983545
( I-Disease 0 3.482446800262551e-06
M2 I-Disease 0 9.426482574781403e-05
) I-Disease 0 1.5412055063279695e-06
gangliosidosis I-Disease 0 2.9351764169405214e-05
, I-Disease 0 1.152978711616015e-06
Type I-Disease 0 7.176016424637055e-06
1 I-Disease 0 6.170022061269265e-06
. O 0 7.942906449898146e-06

Less O 0 0.0023568624164909124
severe O 1 0.9507278203964233
, O 0 8.775318565312773e-05
subacute O 1 0.9842431545257568
( O 0 0.00036059398553334177
juvenile O 0 0.28596222400665283
- O 1 0.9330739378929138
onset O 1 0.9121332168579102
) O 0 4.3300633478793316e-06
and O 0 1.7003558241412975e-05
chronic O 1 0.9930457472801208
( O 0 1.2520821655925829e-05
adult O 0 9.135285654338077e-05
- O 1 0.8630111217498779
onset O 0 0.2640407383441925
) O 0 3.127683385173441e-06
variants O 0 5.977586170047289e-06
are O 0 3.451633574513835e-07
characterized O 0 3.4911756756628165e-06
by O 0 3.0700286401952326e-07
a O 0 6.296777428360656e-07
broad O 0 2.362338136663311e-06
spectrum O 0 2.407865395070985e-06
of O 0 2.863295947008737e-07
clinical O 0 0.0001221999991685152
manifestations O 0 3.252731403335929e-05
and O 0 1.524114509265928e-06
are O 0 1.6139622971422796e-07
associated O 0 8.381760494557966e-07
with O 0 3.1212303497341054e-07
residual O 0 9.45550618780544e-06
levels O 0 6.529753022732621e-07
of O 0 2.2982931113801897e-07
Hex O 0 1.2660235370276496e-05
A O 0 3.967258180637145e-06
enzyme O 0 1.5615511074429378e-05
activity O 0 1.1492459634609986e-05
. O 0 1.1448277291492559e-05

We O 0 4.0182381781050935e-05
identified O 0 2.1968842702335678e-05
a O 0 8.59016836329829e-06
1422 O 0 0.022190243005752563
G O 0 0.07366745918989182
- O 0 0.010166222229599953
- O 0 0.0009651110740378499
> O 0 4.1325067286379635e-05
C O 0 3.635483517427929e-05
( O 0 1.3148794550943421e-06
amino O 0 1.1342334573782864e-06
acid O 0 1.242485723196296e-06
W474C O 0 2.2295253074844368e-06
) O 0 1.1313863268469504e-07
substitution O 0 3.4708116913861886e-07
in O 0 1.2442521324373956e-07
the O 0 9.805199141510457e-08
first O 0 2.5009288151522924e-07
position O 0 2.9695812031604873e-07
of O 0 6.755120551815708e-08
exon O 0 3.4416650578350527e-06
13 O 0 5.138134042681486e-07
of O 0 1.1915567910136815e-07
HEXA O 0 7.439054024871439e-05
of O 0 1.4668843562049005e-07
a O 0 1.3408963468464208e-06
non O 0 4.579864253173582e-06
- O 0 1.963268732652068e-05
Jewish O 0 7.306879979296355e-06
proband O 0 0.00036185418139211833
who O 0 5.140112079971004e-06
manifested O 0 2.429240703349933e-05
a O 0 7.194284989964217e-06
subacute O 0 0.005927137564867735
variant O 0 0.00024950545048341155
of O 0 4.206193807476666e-06
G B-Disease 0 0.04923945665359497
( I-Disease 0 1.5669513231841847e-05
M2 I-Disease 0 0.0004234348307363689
) I-Disease 0 1.0787364772113506e-05
gangliosidosis I-Disease 0 0.00024362208205275238
. O 0 2.4665348973940127e-05

On O 0 4.597311999532394e-05
the O 0 7.961502888065297e-06
second O 0 2.6671226805774495e-05
maternally O 0 0.000986176892183721
inherited O 0 0.002946586813777685
allele O 0 6.426798063330352e-05
, O 0 1.3536703136196593e-06
we O 0 7.08578909325297e-07
identified O 0 2.078590341625386e-06
the O 0 7.846798553146073e-07
common O 0 0.0001752866810420528
infantile O 1 0.9999614953994751
disease O 1 0.9233163595199585
- O 0 0.009206682443618774
causing O 0 1.66113895829767e-05
4 O 0 9.782717825146392e-06
- O 0 0.00015342188999056816
bp O 0 9.310046880273148e-05
insertion O 0 1.6726671674405225e-05
, O 0 1.9264234651927836e-06
+ O 0 2.0465155103011057e-05
TATC O 0 0.00012408458860591054
1278 O 0 0.000338923855451867
, O 0 1.2643636182474438e-06
in O 0 1.5877433270361507e-06
exon O 0 7.936907059047371e-05
11 O 0 1.7269114323426038e-05
. O 0 1.3922986909165047e-05

Pulse O 0 0.00657778000459075
- O 0 0.001019792864099145
chase O 0 0.00010752618254628032
analysis O 0 1.3691366802959237e-05
using O 0 8.679985512571875e-06
proband O 0 0.0001933657913468778
fibroblasts O 0 0.000138231655000709
revealed O 0 8.868926670402288e-06
that O 0 2.0695657099167875e-07
the O 0 2.6360993388152565e-07
W474C O 0 7.512226147809997e-06
- O 0 2.4857965854607755e-06
containing O 0 3.897837643762614e-07
alpha O 0 1.6586363926762715e-06
- O 0 1.941673417604761e-06
subunit O 0 1.693664671620354e-06
precursor O 0 3.2830926102178637e-06
was O 0 9.174641490972135e-07
normally O 0 6.940015282452805e-07
synthesized O 0 2.8579590889421524e-06
, O 0 2.0355106755687302e-07
but O 0 2.0237250453192246e-07
not O 0 1.1880312911216606e-07
phosphorylated O 0 2.007171360673965e-06
or O 0 2.344662277664611e-07
secreted O 0 1.289399392589985e-06
, O 0 1.7220614267898782e-07
and O 0 1.3111800001297524e-07
the O 0 5.606256650025898e-07
mature O 0 4.512155101110693e-06
lysosomal O 0 2.4150074750650674e-05
alpha O 0 4.279526820027968e-06
- O 0 5.746978331444552e-06
subunit O 0 3.0094799967628205e-06
was O 0 2.3330844669544604e-06
not O 0 1.653208755669766e-06
detected O 0 3.340307011967525e-05
. O 0 1.1654949048534036e-05

When O 0 4.0314302168553695e-05
the O 0 7.411944807245163e-06
W474C O 0 6.0768521507270634e-05
- O 0 1.1192609235877171e-05
containing O 0 1.6404543430326157e-06
alpha O 0 5.381234132073587e-06
- O 0 4.959346370014828e-06
subunit O 0 5.070208771940088e-06
was O 0 4.1126386349787936e-06
transiently O 0 2.389186374784913e-05
co O 0 6.28530915491865e-06
- O 0 2.9882048693252727e-06
expressed O 0 3.532738901412813e-07
with O 0 1.1901916252554656e-07
the O 0 2.491782424840494e-07
beta O 0 1.5016806855783216e-06
- O 0 2.534524810471339e-06
subunit O 0 1.2841668421970098e-06
to O 0 2.695561818200076e-07
produce O 0 5.970886718387192e-07
Hex O 0 6.147509338916279e-06
A O 0 1.7130506648754817e-06
( O 0 1.2142256764491322e-06
alphabeta O 0 8.661512765684165e-06
) O 0 4.735375966902211e-07
in O 0 5.262690478957666e-07
COS O 0 0.00016653221973683685
- O 0 1.0207376362814102e-05
7 O 0 9.338052677776432e-07
cells O 0 5.246959631222126e-07
, O 0 7.444819516422285e-08
the O 0 8.632567727318019e-08
mature O 0 8.220897029787011e-07
alpha O 0 8.52776338433614e-07
- O 0 7.698001240896701e-07
subunit O 0 5.787016448266513e-07
was O 0 4.847902914661972e-07
present O 0 1.1938885791096254e-07
, O 0 4.799371566832633e-08
but O 0 6.910448036023809e-08
its O 0 5.310677764214233e-08
level O 0 1.0808372508108732e-07
was O 0 2.20267153849818e-07
much O 0 1.5236072670177236e-07
lower O 0 4.943467502016574e-07
than O 0 6.540222585726951e-08
that O 0 4.036499490212009e-08
from O 0 7.573172666752725e-08
normal O 0 3.994228165993263e-07
alpha O 0 8.607845529695624e-07
- O 0 1.0466621915838914e-06
subunit O 0 1.080609081327566e-06
transfections O 0 4.9531026888871565e-06
, O 0 1.148200681200251e-07
although O 0 1.5312313905724295e-07
higher O 0 1.3889626870877692e-07
than O 0 9.282614854555504e-08
in O 0 1.7614534897347767e-07
those O 0 2.3705567286924634e-07
cells O 0 2.515659616619814e-06
transfected O 0 1.134880403697025e-05
with O 0 3.7819947351636074e-07
an O 0 5.618995828626794e-07
alpha O 0 3.849110271403333e-06
- O 0 5.989734745526221e-06
subunit O 0 9.784555004443973e-06
associated O 0 7.223557076940779e-06
with O 0 5.955933829682181e-06
infantile O 0 0.22776354849338531
TSD B-Disease 0 0.4462602734565735
. O 0 0.0001225227169925347

Furthermore O 0 0.00010851048136828467
, O 0 3.6640062717196997e-06
the O 0 9.056432190845953e-07
precursor O 0 4.839186658500694e-06
level O 0 2.534217458105559e-07
of O 0 6.565482379983223e-08
the O 0 2.206388529657488e-07
W474C O 0 9.132241757470183e-06
alpha O 0 2.8215449674462434e-06
- O 0 3.4362144560873276e-06
subunit O 0 2.5582112357369624e-06
was O 0 1.4231274008125183e-06
found O 0 3.677533015888912e-07
to O 0 2.52727858196522e-07
accumulate O 0 1.2490223753047758e-06
in O 0 2.518655151106941e-07
comparison O 0 9.740226687426912e-07
to O 0 1.9000859197149111e-07
the O 0 3.844462241886504e-07
normal O 0 2.4122830382111715e-06
alpha O 0 5.077675268694293e-06
- O 0 8.470874490740243e-06
subunit O 0 9.053220310306642e-06
precursor O 0 2.352960655116476e-05
levels O 0 8.978923688118812e-06
. O 0 7.512455795222195e-06

We O 0 6.245775148272514e-05
conclude O 0 5.150248762220144e-05
that O 0 1.6282905335174291e-06
the O 0 1.6383296497224364e-06
1422 O 0 0.0013002908090129495
G O 0 0.03857169300317764
- O 0 0.00843866914510727
- O 0 0.002603498287498951
> O 0 3.9454735087929294e-05
C O 0 5.143073576618917e-05
mutation O 0 3.7496190543606644e-06
is O 0 1.756240379791052e-07
the O 0 2.287098226361195e-07
cause O 0 1.1444972187746316e-06
of O 0 6.587220013898332e-07
Hex B-Disease 0 0.0005865700077265501
A I-Disease 0 0.004032079596072435
enzyme I-Disease 1 0.9999595880508423
deficiency I-Disease 1 0.9999173879623413
in O 0 7.147883025027113e-06
the O 0 9.61207570071565e-06
proband O 0 0.0024171846453100443
. O 0 4.7734058171045035e-05

The O 0 5.467502705869265e-05
resulting O 0 3.984248178312555e-05
W474C O 0 0.00015771001926623285
substitution O 0 3.4043154300889e-05
clearly O 0 1.0392766853328794e-05
interferes O 0 1.4225862287275959e-05
with O 0 5.878658271285531e-07
alpha O 0 1.9474407508823788e-06
- O 0 1.458864176129282e-06
subunit O 0 6.924136073394038e-07
processing O 0 4.1914313442248385e-07
, O 0 6.842495992032127e-08
but O 0 5.12212530168199e-08
because O 0 3.163442130471594e-08
the O 0 3.25183044935784e-08
base O 0 2.24897888756459e-07
substitution O 0 9.158539455711434e-07
falls O 0 1.7732852484186878e-06
at O 0 1.4915283941263624e-07
the O 0 5.028892502423332e-08
first O 0 1.5098990502337983e-07
position O 0 2.4021719013944676e-07
of O 0 7.478107022507174e-08
exon O 0 4.917103979096282e-06
13 O 0 1.6226820207521087e-06
, O 0 3.6989715113122656e-07
aberrant O 0 1.2499787771957926e-05
splicing O 0 1.482409697928233e-05
may O 0 3.258832975916448e-06
also O 0 2.2867274651616754e-07
contribute O 0 3.845261744572781e-07
to O 0 6.183036020956933e-07
Hex B-Disease 0 6.279637455008924e-05
A I-Disease 0 0.00031719772960059345
deficiency I-Disease 0 0.03190333768725395
in O 0 1.8514576822781237e-06
this O 0 1.4627412383561023e-06
proband O 0 0.00041178465471602976
. O 0 7.612819445057539e-06
. O 0 1.627097481105011e-05

Two O 0 0.00021920657309237868
frequent O 0 0.0005287593230605125
missense O 0 0.008043906651437283
mutations O 0 0.002816954627633095
in O 0 0.00436552707105875
Pendred B-Disease 1 0.9999998807907104
syndrome I-Disease 1 1.0
. O 0 0.00037057799636386335

Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 0.00215069018304348
an O 0 0.4116848111152649
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 1 0.8085830211639404
by O 0 0.00010314322571502998
early O 0 0.39438074827194214
childhood O 1 0.9986483454704285
deafness B-Disease 1 1.0
and O 1 0.714240550994873
goiter B-Disease 1 0.9999996423721313
. O 0 0.00019383724429644644

A O 0 6.473403482232243e-05
century O 0 2.8833404940087348e-05
after O 0 5.76221827941481e-06
its O 0 9.239626024282188e-07
recognition O 0 1.6634362509648781e-06
as O 0 1.0853734693228034e-06
a O 0 4.6327706513693556e-05
syndrome O 1 0.9509609341621399
by O 0 2.0084926291019656e-06
Vaughan O 0 0.007605930790305138
Pendred O 0 0.000294334051432088
, O 0 1.3711271549254889e-06
the O 0 4.412922862684354e-06
disease O 0 0.00046792509965598583
gene O 0 2.6865338440984488e-05
( O 0 1.040895494952565e-05
PDS O 0 0.08083964884281158
) O 0 2.1773012122139335e-06
was O 0 6.373034011630807e-06
mapped O 0 1.891753163363319e-05
to O 0 3.8579964893870056e-06
chromosome O 0 6.872077938169241e-05
7q22 O 0 0.00024159577151294798
- O 0 0.00039712298894301057
q31 O 0 0.0004817852168343961
. O 0 4.914179226034321e-05

1 O 0 4.261689173290506e-05
and O 0 6.8207682488719e-06
, O 0 1.7308630049228668e-06
recently O 0 3.540186071404605e-06
, O 0 5.902348334529961e-07
found O 0 6.273436383708031e-07
to O 0 4.6097173367343203e-07
encode O 0 4.090893526154105e-06
a O 0 6.017905889166286e-06
putative O 0 0.00022950451239012182
sulfate O 0 0.0011456023203209043
transporter O 0 0.0019116010516881943
. O 0 5.026374492445029e-05

We O 0 7.759675645502284e-05
performed O 0 4.6233701141318306e-05
mutation O 0 1.3381010830926243e-05
analysis O 0 1.6084582057374064e-06
of O 0 3.1830890634410025e-07
the O 0 1.8337555047764909e-06
PDS B-Disease 0 0.0162624791264534
gene O 0 7.414828814944485e-06
in O 0 2.9742905098828487e-06
patients O 0 4.287991760065779e-05
from O 0 1.0832825410034275e-06
14 O 0 2.2565423023479525e-06
Pendred B-Disease 0 2.412132926110644e-05
families O 0 5.92131414123287e-07
originating O 0 1.056468022397894e-06
from O 0 2.883596152969403e-07
seven O 0 3.8716675021532865e-07
countries O 0 3.293590680186753e-07
and O 0 4.72900353543082e-07
identified O 0 2.2446815819421317e-06
all O 0 1.087980763259111e-06
mutations O 0 1.871965650934726e-05
. O 0 1.111563960876083e-05

The O 0 0.00010816234134836122
mutations O 0 6.606461829505861e-05
include O 0 1.8744437966233818e-06
three O 0 1.0132889656233601e-06
single O 0 1.2254728289917693e-06
base O 0 2.656817514434806e-06
deletions O 0 1.1453857950982638e-05
, O 0 8.743465969018871e-07
one O 0 8.997153599921148e-07
splice O 0 4.591340257320553e-05
site O 0 6.094396212574793e-06
mutation O 0 7.314744834729936e-06
and O 0 1.3149384585631196e-06
10 O 0 5.7859124353853986e-06
missense O 0 0.00033708594855852425
mutations O 0 0.0001630170299904421
. O 0 2.422328725515399e-05

One O 0 0.00017939569079317153
missense O 0 0.0010373692493885756
mutation O 0 0.00012337845691945404
( O 0 1.0496986760699656e-05
L236P O 0 3.68222790712025e-05
) O 0 9.931976592270075e-07
was O 0 1.4070492397877388e-06
found O 0 4.740662404856266e-07
in O 0 2.093519668733279e-07
a O 0 8.615984370408114e-07
homozygous O 0 5.900867563468637e-06
state O 0 2.54277040312445e-07
in O 0 2.3555568873234733e-07
two O 0 2.6400667252346466e-07
consanguineous O 0 1.9201916074962355e-05
families O 0 9.298719874095696e-07
and O 0 3.333793756610248e-07
in O 0 4.0390185063188255e-07
a O 0 7.700064657001349e-07
heterozygous O 0 4.149204869463574e-06
state O 0 2.6152579835070355e-07
in O 0 3.486892694581911e-07
five O 0 4.1503824377286946e-07
additional O 0 7.78537071255414e-07
non O 0 1.0046961506304797e-05
- O 0 0.00023650670482311398
consanguineous O 0 0.0005840812809765339
families O 0 2.6726327632786706e-05
. O 0 3.2473730243509635e-05

Another O 0 0.0004044911765959114
missense O 0 0.0023348259273916483
mutation O 0 0.00018710554286371917
( O 0 1.0158878467336763e-05
T416P O 0 7.310195360332727e-05
) O 0 1.7170464161608834e-06
was O 0 2.217925157310674e-06
found O 0 3.814435558524565e-07
in O 0 1.3709203017242544e-07
a O 0 4.947443130731699e-07
homozygous O 0 4.543452178040752e-06
state O 0 1.3435840173769975e-07
in O 0 2.5081970989049296e-07
one O 0 1.9027824293971207e-07
family O 0 4.928879207000136e-07
and O 0 1.7974406318899128e-07
in O 0 2.7418835202297487e-07
a O 0 7.201315384008922e-07
heterozygous O 0 3.1103866149351234e-06
state O 0 1.317900739650213e-07
in O 0 3.1491535423811e-07
four O 0 6.611992375837872e-07
families O 0 3.4098411560989916e-06
. O 0 1.191900810226798e-05

Pendred B-Disease 1 0.8929773569107056
patients O 0 0.12096339464187622
in O 0 1.1748196811822709e-05
three O 0 2.0680954548879527e-06
non O 0 9.918668183672708e-06
- O 0 0.00010300837311660871
consanguineous O 0 0.00011025292769772932
families O 0 1.5041387086967006e-06
were O 0 7.279069222931867e-07
shown O 0 5.820291448799253e-07
to O 0 2.3703215390469268e-07
be O 0 2.6884529802373436e-07
compound O 0 4.35124911746243e-06
heterozygotes O 0 1.6565669284318574e-05
for O 0 6.305658644123469e-07
L236P O 0 6.067795766284689e-05
and O 0 4.564045866572997e-06
T416P O 0 0.00022257819364313036
. O 0 2.5945499146473594e-05

In O 0 3.075130734941922e-05
total O 0 3.425260274525499e-06
, O 0 6.510489356514881e-07
one O 0 1.7066960822376132e-07
or O 0 1.3486405237017607e-07
both O 0 1.0433559793909808e-07
of O 0 6.011326547650242e-08
these O 0 1.8682388258639548e-07
mutations O 0 1.3381957160163438e-06
were O 0 5.594346248471993e-07
found O 0 4.922978860122385e-07
in O 0 1.3041726276696863e-07
nine O 0 1.4870374798192643e-07
of O 0 5.797047109012965e-08
the O 0 5.573880912379536e-07
14 O 0 3.287554136477411e-06
families O 0 4.254240593581926e-06
analyzed O 0 2.567955198173877e-05
. O 0 1.947422424564138e-05

The O 0 1.717281156743411e-05
identification O 0 6.89506987328059e-06
of O 0 5.707395303033991e-07
two O 0 1.466108415115741e-06
frequent O 0 1.71336141647771e-05
PDS B-Disease 1 0.9323738813400269
mutations O 0 1.2327930562605616e-05
will O 0 5.535686113944394e-07
facilitate O 0 1.79455616944324e-06
the O 0 2.300504320373875e-06
molecular O 0 9.093444532481954e-05
diagnosis O 1 0.9907615780830383
of O 0 0.0002884870336856693
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 0.00031704932916909456

Insertional O 0 0.01104701217263937
mutation O 0 0.0003005727776326239
by O 0 1.7339381884085014e-05
transposable O 0 0.00026133854407817125
element O 0 1.8293876564712264e-05
, O 0 3.0446058190136682e-06
L1 O 0 0.0001563483674544841
, O 0 1.0577947477941052e-06
in O 0 1.3791584478894947e-06
the O 0 6.452980414906051e-06
DMD B-Disease 1 0.9999995231628418
gene O 0 3.705590279423632e-05
results O 0 9.39826622925466e-06
in O 0 3.6055955661140615e-06
X B-Disease 0 0.29461678862571716
- I-Disease 1 0.9327527284622192
linked I-Disease 0 0.3656989336013794
dilated I-Disease 1 0.9983142614364624
cardiomyopathy I-Disease 1 0.9999936819076538
. O 0 0.00012751491158269346

X B-Disease 1 0.9879337549209595
- I-Disease 1 0.9946578145027161
linked I-Disease 1 0.6463007926940918
dilated I-Disease 1 0.999963641166687
cardiomyopathy I-Disease 1 0.9999996423721313
( O 0 9.704144031275064e-05
XLDCM B-Disease 0 0.01050950214266777
) O 0 3.3948929285543272e-06
is O 0 4.3449199438327923e-07
a O 0 2.6609277483657934e-06
clinical O 0 0.0002965310122817755
phenotype O 0 0.00021204541553743184
of O 0 5.375486580305733e-07
dystrophinopathy B-Disease 0 0.0012154063442721963
which O 0 1.1443017911005882e-06
is O 0 3.071870651183417e-07
characterized O 0 2.909878048740211e-06
by O 0 1.7794652649172349e-06
preferential O 0 0.0003072576073464006
myocardial B-Disease 1 0.9014281034469604
involvement I-Disease 0 1.8568065570434555e-05
without O 0 2.1930391085334122e-06
any O 0 1.3636057474286645e-06
overt O 0 4.06893013860099e-05
clinical O 0 0.0002678878081496805
signs O 0 0.00012699143553618342
of O 0 0.00016608534497208893
skeletal B-Disease 1 1.0
myopathy I-Disease 1 1.0
. O 0 0.0006619833875447512

To O 0 4.022440771223046e-05
date O 0 2.344234599149786e-05
, O 0 1.877221961876785e-06
several O 0 9.144365549218492e-07
mutations O 0 5.198182407184504e-06
in O 0 1.587187853147043e-06
the O 0 3.969328463426791e-05
Duchenne B-Disease 1 0.9999853372573853
muscular I-Disease 1 0.9999942779541016
dystrophy I-Disease 1 0.9999679327011108
gene O 0 8.644341141916811e-05
, O 0 2.315998608537484e-05
DMD O 1 0.9999994039535522
, O 0 4.688722583523486e-06
have O 0 6.493108912764001e-07
been O 0 9.528542364023451e-07
identified O 0 1.957189624590683e-06
in O 0 1.843251538957702e-06
patients O 0 4.5099786802893505e-05
with O 0 7.63886021104554e-07
XLDCM B-Disease 0 0.11369774490594864
, O 0 9.34061802126962e-07
but O 0 6.220853947525029e-07
a O 0 7.622915632055083e-07
pathogenic O 0 3.3768747016438283e-06
correlation O 0 6.749730232513684e-07
of O 0 1.218317464690699e-07
these O 0 3.69797334087707e-07
cardiospecific O 0 0.0005246998625807464
mutations O 0 2.3891954697319306e-05
in O 0 1.6203832274186425e-05
DMD O 1 0.9999954700469971
with O 0 2.0187915197311668e-06
the O 0 8.64507364894962e-06
XLDCM B-Disease 1 0.9544063806533813
phenotype O 0 0.03527039289474487
has O 0 1.7905626918945927e-06
remained O 0 4.27135591962724e-06
to O 0 1.0646432428984554e-06
be O 0 2.0323425360402325e-06
elucidated O 0 0.00010784986079670489
. O 0 1.3177227629057597e-05

We O 0 3.7669371522497386e-05
report O 0 2.088117071252782e-05
here O 0 1.1949769032071345e-06
the O 0 3.047003076517285e-07
identification O 0 4.91634466470714e-07
of O 0 8.843201726449479e-08
a O 0 6.913994070600893e-07
unique O 0 1.2825964859075611e-06
de O 0 6.260184363782173e-06
novo O 0 4.432412242749706e-05
L1 O 0 0.00010049747652374208
insertion O 0 1.2504079677455593e-05
in O 0 1.568740003676794e-06
the O 0 1.1559347967704525e-06
muscle O 0 3.3612814149819314e-05
exon O 0 1.5821033230167814e-05
1 O 0 2.0446757389436243e-06
in O 0 6.5034291765186936e-06
DMD O 1 0.9999980926513672
in O 0 4.3034360714955255e-06
three O 0 2.6589364097162616e-06
XLDCM B-Disease 1 0.6594756245613098
patients O 0 0.00017036747885867953
from O 0 6.201779569892096e-07
two O 0 8.543441367692139e-07
unrelated O 0 1.6218036762438715e-05
Japanese O 0 2.034860517596826e-05
families O 0 1.6937057807808742e-05
. O 0 1.7167554688057862e-05

The O 0 3.92884794564452e-05
insertion O 0 9.750569734023884e-05
was O 0 1.1434823136369232e-05
a O 0 2.2921910840523196e-06
5 O 0 2.7064058940595714e-06
- O 0 1.5362265912699513e-05
truncated O 0 1.10561686597066e-05
form O 0 8.711289183338522e-07
of O 0 2.4822097088872397e-07
human O 0 1.341294023404771e-06
L1 O 0 5.5977194278966635e-05
inversely O 0 1.2597222848853562e-05
integrated O 0 4.804446234629722e-06
in O 0 8.566007636545692e-07
the O 0 7.211638148874044e-07
5 O 0 1.6814943819554173e-06
- O 0 1.889694067358505e-05
untranslated O 0 2.2802716557634994e-05
region O 0 8.427495572504995e-07
in O 0 3.739844203209941e-07
the O 0 4.101798367628362e-07
muscle O 0 1.0148701221623924e-05
exon O 0 4.164781330473488e-06
1 O 0 4.1861741806314967e-07
, O 0 1.437579726371041e-07
which O 0 1.3130645015735354e-07
affected O 0 2.0537227385375445e-07
the O 0 8.32143811635433e-08
transcription O 0 4.7612917342121364e-07
or O 0 8.546247443064203e-08
the O 0 7.409644098288481e-08
stability O 0 2.0407198064731347e-07
of O 0 4.1395189498416585e-08
the O 0 2.7633222998701967e-07
muscle O 0 1.1169150639034342e-05
form O 0 3.8772577681811526e-07
of O 0 1.6882174236343417e-07
dystrophin O 0 4.786351200891659e-05
transcripts O 0 5.790433533547912e-06
but O 0 3.823208771791542e-07
not O 0 3.9084159908497895e-08
that O 0 1.0017560114761181e-08
of O 0 1.3344950033911118e-08
the O 0 3.316492325211584e-07
brain O 0 6.480808951891959e-05
or O 0 1.531383304609335e-06
Purkinje O 0 0.0003954462008550763
cell O 0 2.328315531485714e-05
form O 0 1.0794626632559812e-06
, O 0 6.508751653200306e-07
probably O 0 1.6901567505556159e-06
due O 0 5.256270014797337e-07
to O 0 1.025349973815537e-07
its O 0 1.6954021475612535e-07
unique O 0 2.9294980663507886e-07
site O 0 7.576190910185687e-07
of O 0 2.727086894083186e-07
integration O 0 1.1575527423701715e-05
. O 0 1.874756344477646e-05

We O 0 4.7376524889841676e-05
speculate O 0 4.1792241972871125e-05
that O 0 5.162604566066875e-07
this O 0 2.0792911925582303e-07
insertion O 0 1.3768415101367282e-06
of O 0 7.606758600786634e-08
an O 0 3.798963064127747e-07
L1 O 0 6.020802538841963e-05
sequence O 0 2.0694762952189194e-06
in O 0 9.232428965333384e-06
DMD O 1 0.9999996423721313
is O 0 6.474935503320012e-07
responsible O 0 3.315217895760725e-07
for O 0 7.540339197475987e-08
some O 0 5.444627859674256e-08
of O 0 2.192581760596113e-08
the O 0 8.262619388688108e-08
population O 0 1.1932466748021398e-07
of O 0 7.05856919580583e-08
Japanese O 0 2.3608386982232332e-05
patients O 0 6.292033503996208e-05
with O 0 1.971618075913284e-06
XLDCM B-Disease 0 0.13640114665031433
. O 0 8.413655450567603e-06
. O 0 1.515430358267622e-05

Severe O 1 0.9977012276649475
early O 0 0.11111673712730408
- O 1 0.9999446868896484
onset O 1 0.9999921321868896
obesity B-Disease 1 0.9999977350234985
, O 0 0.0005035042413510382
adrenal B-Disease 1 0.9999455213546753
insufficiency I-Disease 1 0.9999990463256836
and O 0 0.0008722234051674604
red O 0 0.41865092515945435
hair O 1 0.9999765157699585
pigmentation O 1 0.9800904393196106
caused O 0 0.00038773607229813933
by O 0 4.241416900185868e-05
POMC O 1 0.9205429553985596
mutations O 0 9.028366184793413e-05
in O 0 1.1591490874707233e-05
humans O 0 2.6010184228653088e-05
. O 0 2.4129956727847457e-05

Sequential O 0 0.0004934283206239343
cleavage O 0 0.0001544867700431496
of O 0 2.1304961137502687e-06
the O 0 2.10956432056264e-06
precursor O 0 1.7979402400669642e-05
protein O 0 5.675216016243212e-06
pre O 0 2.9064141926937737e-05
- O 0 6.115056748967618e-05
pro O 0 4.91685132146813e-05
- O 0 0.00031738198595121503
opiomelanocortin O 0 0.00021760955860372633
( O 0 5.4616821216768585e-06
POMC O 0 0.0002364794199820608
) O 0 1.3485341696650721e-06
generates O 0 2.8815172754548257e-06
the O 0 1.60830484219332e-06
melanocortin O 0 0.00024261418730020523
peptides O 0 2.8448645025491714e-05
adrenocorticotrophin O 0 0.00011866863496834412
( O 0 8.514505680068396e-06
ACTH O 0 0.00010244648001389578
) O 0 1.9753595097427024e-06
, O 0 8.098462558336905e-07
melanocyte O 0 9.870011854218319e-05
- O 0 8.037997031351551e-05
stimulating O 0 5.4013093176763505e-05
hormones O 0 2.1514040781767108e-05
( O 0 3.44321802003833e-06
MSH O 0 0.00011663315672194585
) O 0 6.440724291678634e-07
alpha O 0 1.1007637112925295e-06
, O 0 1.5897268212938798e-07
beta O 0 6.177920113259461e-07
and O 0 1.414884565065222e-07
gamma O 0 6.358922064464423e-07
as O 0 7.573259352966488e-08
well O 0 1.3662751996434963e-07
as O 0 1.6859439710970037e-07
the O 0 3.2660216220392613e-07
opioid O 0 9.883853635983542e-06
- O 0 1.9114841052214615e-05
receptor O 0 1.3244783076515887e-05
ligand O 0 2.0414223399711773e-05
beta O 0 2.6069084924529307e-05
- O 0 9.625759412301704e-05
endorphin O 0 0.0010720361024141312
. O 0 4.420714685693383e-05

While O 0 5.810268339700997e-05
a O 0 1.4144531633064616e-05
few O 0 9.71796180238016e-06
cases O 0 3.0644637263321783e-06
of O 0 1.7867075712274527e-06
isolated O 1 0.8546660542488098
ACTH B-Disease 1 0.9999862909317017
deficiency I-Disease 1 0.9516805410385132
have O 0 1.5205908994175843e-06
been O 0 2.068805542876362e-06
reported O 0 2.518917062843684e-05
( O 0 6.857429070805665e-06
OMIM O 0 0.0026750355027616024
201400 O 0 4.598214945872314e-05
) O 0 1.2794457688869443e-06
, O 0 5.559865030591027e-07
an O 0 1.7627791066843201e-06
inherited O 0 0.0619598813354969
POMC O 1 0.9996379613876343
defect O 0 0.06262195110321045
has O 0 3.609359055189998e-06
not O 0 8.467688417113095e-07
been O 0 1.1752338195947232e-06
described O 0 7.213561275420943e-06
so O 0 1.5275631994882133e-06
far O 0 5.404284820542671e-06
. O 0 1.0164470950257964e-05

Recent O 0 0.0001560150703880936
studies O 0 6.11642753938213e-05
in O 0 9.839322956395335e-06
animal O 0 1.5979385352693498e-05
models O 0 1.943607821885962e-05
elucidated O 0 1.87058267329121e-05
a O 0 6.692013130304986e-07
central O 0 6.36127538200526e-07
role O 0 7.207966064015636e-07
of O 0 2.520995963095629e-07
alpha O 0 7.744148206256796e-06
- O 0 2.8940925403730944e-05
MSH O 0 0.00017247581854462624
in O 0 4.802137141268759e-07
the O 0 2.9026728043390904e-07
regulation O 0 9.932506372933858e-07
of O 0 1.2356150591585902e-07
food O 0 1.3734697859035805e-06
intake O 0 3.563201744327671e-06
by O 0 2.8417451858331333e-07
activation O 0 1.0538949481997406e-06
of O 0 1.0358448321312608e-07
the O 0 9.112372936215252e-07
brain O 0 9.020465950015932e-05
melanocortin O 0 0.0001350426027784124
- O 0 3.3754989999579266e-05
4 O 0 3.3621381589910015e-06
- O 0 2.0710536773549393e-05
receptor O 0 1.3833413504471537e-05
( O 0 2.935011480076355e-06
MC4 O 0 0.00029795989394187927
- O 0 6.302416295511648e-05
R O 0 4.38471652159933e-05
; O 0 1.0830220844582072e-06
refs O 0 1.4202166312315967e-05
3 O 0 9.59715066528588e-07
- O 0 4.414939212438185e-06
5 O 0 3.763479696772265e-07
) O 0 9.79405925249921e-08
and O 0 4.851084867141253e-08
the O 0 8.895185743540424e-08
linkage O 0 1.782706135600165e-06
of O 0 2.133695460315721e-07
human O 0 4.595969585352577e-06
obesity B-Disease 0 0.07300636917352676
to O 0 9.930205351338373e-07
chromosome O 0 4.8547963160672225e-06
2 O 0 4.313126282795565e-07
in O 0 2.2010209477230092e-07
close O 0 4.507427320277202e-07
proximity O 0 7.509107717851293e-07
to O 0 3.6242144574316626e-07
the O 0 7.840417879378947e-07
POMC O 0 0.00019994804461020976
locus O 0 3.4849022085836623e-06
, O 0 1.6383499712446792e-07
led O 0 2.553421438733494e-07
to O 0 8.962335584783432e-08
the O 0 1.1218069317919799e-07
proposal O 0 4.349944902060088e-07
of O 0 6.259762841409611e-08
an O 0 2.7451486062091135e-07
association O 0 1.7691688753984636e-06
of O 0 7.280520435415383e-07
POMC O 0 0.004099082667380571
with O 0 8.412275747105014e-06
human O 0 8.458553202217445e-05
obesity B-Disease 1 0.8421024084091187
. O 0 5.559650526265614e-05

The O 0 1.5103531040949747e-05
dual O 0 2.1244002709863707e-05
role O 0 3.7041677387605887e-06
of O 0 9.439444283998455e-07
alpha O 0 1.7034069969668053e-05
- O 0 8.463805716019124e-05
MSH O 0 0.0004858518368564546
in O 0 1.5004123952166992e-06
regulating O 0 5.51652146896231e-06
food O 0 2.1625526187563082e-06
intake O 0 1.636679189687129e-05
and O 0 2.2530498426931445e-06
influencing O 0 7.950459257699549e-05
hair O 1 0.9776124358177185
pigmentation O 0 0.05666201934218407
predicts O 0 4.820955655304715e-05
that O 0 8.35760715744982e-07
the O 0 1.6687687320882105e-06
phenotype O 0 0.0008042445406317711
associated O 0 2.6462373625690816e-06
with O 0 5.424104188023193e-07
a O 0 1.0599967026792001e-05
defect O 0 0.0004492209991440177
in O 0 3.332536380185047e-06
POMC O 0 0.001072946935892105
function O 0 8.511943860867177e-07
would O 0 7.679618079237116e-07
include O 0 2.005070655286545e-06
obesity B-Disease 0 0.41548997163772583
, O 0 3.326551222926355e-06
alteration O 0 0.00013519528147298843
in O 0 5.027942097513005e-05
pigmentation O 1 0.8744089603424072
and O 0 0.012227036990225315
ACTH B-Disease 1 0.9999117851257324
deficiency I-Disease 1 0.8369560837745667
. O 0 4.615295983967371e-05

The O 0 3.590024061850272e-05
observation O 0 4.554851693683304e-05
of O 0 1.4967079096095404e-06
these O 0 2.387355152677628e-06
symptoms O 0 0.018976394087076187
in O 0 1.2211887678859057e-06
two O 0 5.046356363891391e-07
probands O 0 0.00011660892778309062
prompted O 0 3.833204573311377e-06
us O 0 8.326723559548554e-07
to O 0 1.480104856455e-07
search O 0 6.219726742529019e-07
for O 0 4.6360591454686073e-07
mutations O 0 3.3391568194929278e-06
within O 0 8.402616913372185e-07
their O 0 4.714355782198254e-06
POMC O 0 0.007953008636832237
genes O 0 6.637062324443832e-05
. O 0 2.491366831236519e-05

Patient O 0 0.006631192285567522
1 O 0 3.2976917282212526e-05
was O 0 1.7845410184236243e-05
found O 0 1.2344979722911376e-06
to O 0 2.77192157227546e-07
be O 0 9.91973934105772e-08
a O 0 3.326089768052043e-07
compound O 0 2.6349910058343085e-06
heterozygote O 0 8.274364518001676e-06
for O 0 2.413612207874394e-07
two O 0 2.706850352751644e-07
mutations O 0 1.7601449826543103e-06
in O 0 5.271465965961397e-07
exon O 0 1.1037963304261211e-05
3 O 0 1.3176422726246528e-06
( O 0 7.513577884310507e-07
G7013T O 0 7.6288815762382e-06
, O 0 3.208213286143291e-07
C7133delta O 0 8.501312549924478e-06
) O 0 1.8691584102725756e-07
which O 0 1.2939803184508492e-07
interfere O 0 8.012872285689809e-07
with O 0 1.0195093835818625e-07
appropriate O 0 4.6550434262826457e-07
synthesis O 0 1.3276296613184968e-06
of O 0 3.7357304449869844e-07
ACTH O 0 7.487064431188628e-05
and O 0 2.567442379586282e-06
alpha O 0 3.8658636185573414e-05
- O 0 0.00020527152810245752
MSH O 0 0.003936586901545525
. O 0 3.0271678042481653e-05

Patient O 0 0.029985034838318825
2 O 0 5.5867865739855915e-05
was O 0 2.06434924621135e-05
homozygous O 0 2.0706782379420474e-05
for O 0 7.836329132260289e-07
a O 0 1.8410415805192315e-06
mutation O 0 5.5641262406425085e-06
in O 0 1.1541767435119255e-06
exon O 0 2.0844501705141738e-05
2 O 0 4.038754923385568e-06
( O 0 3.1196698273561196e-06
C3804A O 0 2.5963567168219015e-05
) O 0 1.5503837857977487e-06
which O 0 2.6019215511041693e-06
abolishes O 0 0.00010960009967675433
POMC O 0 0.0016385354101657867
translation O 0 0.00010070198914036155
. O 0 4.36861882917583e-05

These O 0 2.2674124920740724e-05
findings O 0 3.3754153264453635e-05
represent O 0 1.0852802461158717e-06
the O 0 3.626828402047977e-07
first O 0 4.855093038713676e-07
examples O 0 4.908109190182586e-07
of O 0 1.9256340522133542e-07
a O 0 2.9995517252245918e-05
genetic B-Disease 1 0.9738184809684753
defect I-Disease 1 0.9795035123825073
within O 0 1.5498294487770181e-06
the O 0 3.411714715184644e-06
POMC O 0 0.003073072759434581
gene O 0 7.2637067205505446e-06
and O 0 9.036658070726844e-07
define O 0 6.150681656436063e-06
a O 0 7.867984095355496e-06
new O 0 0.00019458422320894897
monogenic B-Disease 1 0.9991306662559509
endocrine I-Disease 1 0.9839506149291992
disorder I-Disease 0 0.04056014120578766
resulting O 0 7.240999821078731e-06
in O 0 5.40925520908786e-06
early O 0 0.0059176175855100155
- O 1 0.9999097585678101
onset O 1 0.9999810457229614
obesity B-Disease 1 0.9999902248382568
, O 0 0.00041590610635466874
adrenal B-Disease 1 0.9999494552612305
insufficiency I-Disease 1 0.9999984502792358
and O 0 0.0005762996734119952
red O 0 0.09708812832832336
hair O 1 0.9998108744621277
pigmentation O 0 0.49079370498657227
. O 0 1.84818545676535e-05
. O 0 2.7700145437847823e-05

A O 0 0.00040615841862745583
European O 0 0.00024171835684683174
multicenter O 0 0.0033257766626775265
study O 0 3.585599552025087e-05
of O 0 2.2387666831491515e-05
phenylalanine B-Disease 1 0.9999992847442627
hydroxylase I-Disease 1 0.9999992847442627
deficiency I-Disease 1 0.9999998807907104
: O 0 3.4062106806231895e-06
classification O 0 4.658405487134587e-06
of O 0 2.0705489589545323e-07
105 O 0 5.752741799369687e-06
mutations O 0 3.3924395665962948e-06
and O 0 1.607263868663722e-07
a O 0 3.795736063239019e-07
general O 0 9.593371714800014e-07
system O 0 1.4323045434139203e-06
for O 0 1.0349202739234897e-06
genotype O 0 0.0003828274493571371
- O 0 9.630313434172422e-05
based O 0 9.64246555668069e-06
prediction O 0 4.37531853094697e-05
of O 0 5.526958375412505e-06
metabolic O 0 0.09445901960134506
phenotype O 0 0.16122998297214508
. O 0 7.261013524839655e-05

Phenylketonuria B-Disease 1 0.9996416568756104
( O 0 0.0019904247019439936
PKU B-Disease 1 0.9960761666297913
) O 0 4.725879625766538e-05
and O 0 2.870161370083224e-05
mild B-Disease 1 0.998981773853302
hyperphenylalaninemia I-Disease 1 0.9999997615814209
( O 0 0.009581764228641987
MHP B-Disease 1 0.999997615814209
) O 0 9.106125617108773e-06
are O 0 2.280836724821711e-06
allelic B-Disease 0 0.001706424867734313
disorders I-Disease 1 0.9969195127487183
caused O 0 3.407683834666386e-05
by O 0 3.3659687233011937e-06
mutations O 0 7.658316462766379e-06
in O 0 1.0703126918087946e-06
the O 0 3.2172379178518895e-06
gene O 0 2.6093883207067847e-05
encoding O 0 5.0543683755677193e-05
phenylalanine O 0 0.0006522851181216538
hydroxylase O 0 0.0062924949452281
( O 0 7.692279177717865e-05
PAH O 0 0.003712850622832775
) O 0 1.562777288199868e-05
. O 0 1.9713363144546747e-05

Previous O 0 0.00020500806567724794
studies O 0 3.502198524074629e-05
have O 0 3.569895397959044e-06
suggested O 0 3.796546707235393e-06
that O 0 3.173749689722172e-07
the O 0 9.751148581926827e-07
highly O 0 7.805728273524437e-06
variable O 0 5.6979428336489946e-05
metabolic O 0 0.005575289484113455
phenotypes O 0 0.0005359919159673154
of O 0 6.898888386785984e-05
PAH B-Disease 1 0.9999994039535522
deficiency I-Disease 1 0.9998916387557983
correlate O 0 0.0012467679334804416
with O 0 0.00012907393102068454
PAH O 1 0.9980841875076294
genotypes O 0 0.0050382474437355995
. O 0 0.00011001851089531556

We O 0 3.289958112873137e-05
identified O 0 1.6647769371047616e-05
both O 0 2.6643074306775816e-06
causative O 0 4.9783986469265074e-05
mutations O 0 1.9878318198607303e-05
in O 0 8.699876161699649e-06
686 O 0 0.02565419301390648
patients O 0 0.000651344598736614
from O 0 1.7069090745280846e-06
seven O 0 2.7158873763255542e-06
European O 0 1.667284050199669e-05
centers O 0 2.1913683667662553e-05
. O 0 2.0446565031306818e-05

On O 0 2.0580238924594596e-05
the O 0 1.910739456434385e-06
basis O 0 9.011218935484067e-07
of O 0 2.5100516154452635e-07
the O 0 7.184701189544285e-07
phenotypic O 0 8.26568157208385e-06
characteristics O 0 1.2493225085563608e-06
of O 0 3.326825606109196e-07
297 O 0 4.2083513108082116e-05
functionally O 0 6.948929512873292e-05
hemizygous O 0 0.008800791576504707
patients O 0 0.000281877611996606
, O 0 3.396054069071397e-07
105 O 0 7.900615059952543e-07
of O 0 6.647285033523076e-08
the O 0 6.399048402272456e-07
mutations O 0 2.2484330202132696e-06
were O 0 4.6399338771152543e-07
assigned O 0 4.21192339672416e-07
to O 0 7.50026245555091e-08
one O 0 8.636685322471749e-08
of O 0 7.341625973822374e-08
four O 0 8.067212320383987e-07
arbitrary O 0 1.0690655471989885e-05
phenotype O 0 0.0007273617084138095
categories O 0 1.4602780538552906e-05
. O 0 1.4397985069081187e-05

We O 0 2.3103821149561554e-05
proposed O 0 9.706903256301302e-06
and O 0 2.0066354409209453e-06
tested O 0 6.448864041885827e-06
a O 0 6.566302772625932e-07
simple O 0 1.09717302620993e-06
model O 0 3.482712600089144e-06
for O 0 4.1430664055042143e-07
correlation O 0 2.0141355889791157e-06
between O 0 1.999942924157949e-06
genotype O 0 8.336182509083301e-05
and O 0 3.48335697708535e-06
phenotypic O 0 6.544397183461115e-05
outcome O 0 4.87038487335667e-05
. O 0 2.472295454936102e-05

The O 0 9.131836122833192e-05
observed O 0 0.00013172044418752193
phenotype O 0 0.0009808611357584596
matched O 0 2.6745476134237833e-05
the O 0 4.578767857310595e-06
predicted O 0 7.778835424687713e-05
phenotype O 0 0.00012990071263629943
in O 0 1.0721701073634904e-06
79 O 0 6.629319614148699e-06
% O 0 4.796379471372347e-07
of O 0 6.492161475080138e-08
the O 0 4.5355196220953076e-07
cases O 0 6.679981083834718e-07
, O 0 1.7462498647091707e-07
and O 0 1.7516104833248392e-07
in O 0 1.5281649723419832e-07
only O 0 6.800625840241992e-08
5 O 0 1.0388126980842571e-07
of O 0 8.677056939632166e-08
184 O 0 1.4551954336639028e-05
patients O 0 0.00028208812000229955
was O 0 8.32067962619476e-06
the O 0 1.0612059213599423e-06
observed O 0 5.3533985919784755e-06
phenotype O 0 4.391106267576106e-05
more O 0 7.829144976767566e-08
than O 0 6.734433810606788e-08
one O 0 9.008609680449808e-08
category O 0 3.082120656472398e-07
away O 0 3.4585366393002914e-07
from O 0 3.1794601795809285e-07
that O 0 7.109439366104198e-07
expected O 0 4.0544773582951166e-06
. O 0 6.888661573611898e-06

Among O 0 2.6684458134695888e-05
the O 0 2.654943045854452e-06
seven O 0 1.062184082911699e-06
contributing O 0 1.394720925418369e-06
centers O 0 6.228297593224852e-07
, O 0 1.589493336950909e-07
the O 0 1.4644173518263415e-07
proportion O 0 6.964580734347692e-07
of O 0 2.271317782742699e-07
patients O 0 3.869676947942935e-05
for O 0 4.0448469462717185e-07
whom O 0 4.256744432495907e-06
the O 0 1.1549640248631476e-06
observed O 0 1.1306004125799518e-05
phenotype O 0 0.0002096550742862746
did O 0 2.151106173187145e-06
not O 0 2.9820620284226607e-07
match O 0 1.2786259731001337e-06
the O 0 4.2535612010397017e-07
predicted O 0 1.1544922926987056e-05
phenotype O 0 3.058532820432447e-05
was O 0 1.484678364249703e-06
4 O 0 6.418239308914053e-07
% O 0 8.849763162288582e-07
- O 0 8.171877198037691e-06
23 O 0 1.8257391047882265e-06
% O 0 1.9356571101525333e-06
( O 0 1.6177191355382092e-06
P O 0 0.0003034043766092509
< O 0 2.436038266750984e-05
. O 0 6.668892069683352e-07
0001 O 0 3.819347693934105e-05
) O 0 3.0415739615818893e-07
, O 0 1.3269078635858023e-07
suggesting O 0 7.228162530736881e-07
that O 0 9.329029637683561e-08
differences O 0 4.5507971435654326e-07
in O 0 2.570850483607501e-07
methods O 0 9.813671795200207e-07
used O 0 5.085969405627111e-07
for O 0 4.333977869919181e-07
mutation O 0 3.3977489692915697e-06
detection O 0 6.1809173530491535e-06
or O 0 5.745657745137578e-06
phenotype O 0 0.14224626123905182
classification O 0 0.00012626829266082495
may O 0 4.589198852045229e-06
account O 0 3.772865966311656e-07
for O 0 8.95837075631789e-08
a O 0 4.5160626882534416e-07
considerable O 0 1.3689974593944498e-06
proportion O 0 3.241558943045675e-06
of O 0 1.9904614418919664e-06
genotype O 0 0.09250856190919876
- O 1 0.8996419310569763
phenotype O 0 0.04437374696135521
inconsistencies O 0 0.0003662259259726852
. O 0 6.597409083042294e-05

Our O 0 3.406881296541542e-05
data O 0 1.4948201169318054e-05
indicate O 0 5.400935606303392e-06
that O 0 8.228552133004996e-07
the O 0 3.6240041936252965e-06
PAH O 0 0.20463158190250397
- O 0 0.009392541833221912
mutation O 0 2.3343229258898646e-05
genotype O 0 4.467941107577644e-05
is O 0 3.158405093017791e-07
the O 0 2.9764709097435116e-07
main O 0 1.262876594410045e-06
determinant O 0 4.478651135286782e-06
of O 0 8.139281817420851e-07
metabolic O 0 0.05719039961695671
phenotype O 0 0.036855608224868774
in O 0 1.2789511856681202e-05
most O 0 8.383087697438896e-05
patients O 1 0.7647953629493713
with O 0 0.0560506172478199
PAH B-Disease 1 0.9999992847442627
deficiency I-Disease 1 0.9997380375862122
. O 0 9.194820449920371e-05

In O 0 2.369152025494259e-05
the O 0 3.1951433356880443e-06
present O 0 1.4305080640042434e-06
study O 0 1.2182133559690556e-06
, O 0 4.0410219526165747e-07
the O 0 4.706368201823352e-07
classification O 0 4.7482590161962435e-06
of O 0 4.6676061060679785e-07
105 O 0 0.000442944117821753
PAH O 1 0.9875229001045227
mutations O 0 3.842810110654682e-05
may O 0 1.9846386294375407e-06
allow O 0 4.6158359623404976e-07
the O 0 5.04295485370676e-07
prediction O 0 4.639509825210553e-06
of O 0 1.1076552652866667e-07
the O 0 8.183772024494829e-07
biochemical O 0 0.00013310322538018227
phenotype O 0 0.00047691346844658256
in O 0 2.3140873963711783e-06
> O 0 8.956079909694381e-06
10 O 0 3.575629250462953e-07
, O 0 2.3723480069293146e-07
000 O 0 1.3125478517395095e-06
genotypes O 0 4.843373972107656e-06
, O 0 1.4848026808067516e-07
which O 0 1.54971857568853e-07
may O 0 3.6801361602556426e-07
be O 0 3.126526948449282e-08
useful O 0 1.2409103078425687e-07
for O 0 6.595971058231953e-08
the O 0 3.690247183385509e-07
management O 0 3.61534671355912e-06
of O 0 7.810887154846569e-07
hyperphenylalaninemia B-Disease 1 0.9998084902763367
in O 0 0.00013937322364654392
newborns O 0 0.09964412450790405
. O 0 3.162960638292134e-05

Somatic O 0 0.0025601908564567566
instability O 0 0.00016851129475980997
of O 0 5.561229500017362e-06
the O 0 8.128879017021973e-06
CTG O 0 0.0007920167408883572
repeat O 0 6.575613224413246e-05
in O 0 8.83820939634461e-06
mice O 0 0.0001164124914794229
transgenic O 0 2.0556739400490187e-05
for O 0 1.4383259667738457e-06
the O 0 3.295095666544512e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
region O 0 3.6489011108642444e-05
is O 0 1.5457862900802866e-06
age O 0 2.7789487830887083e-06
dependent O 0 1.5061224303281051e-06
but O 0 4.0320449556929816e-07
not O 0 1.305917578520166e-07
correlated O 0 4.6336370473909483e-07
to O 0 9.632253039626448e-08
the O 0 2.971416961372597e-07
relative O 0 4.068914222443709e-06
intertissue O 0 6.486695929197595e-05
transcription O 0 2.1639330952893943e-05
levels O 0 3.818005552602699e-06
and O 0 5.22682557857479e-06
proliferative O 0 0.03015315532684326
capacities O 0 0.00013449348625726998
. O 0 4.643877764465287e-05

A O 0 0.0002267167146783322
( O 0 3.3862419513752684e-05
CTG O 0 0.0003931265673600137
) O 0 2.5025610739248805e-06
nexpansion O 0 1.0799922165460885e-05
in O 0 3.8628749621238967e-07
the O 0 3.81446824349041e-07
3 O 0 2.268625621582032e-06
- O 0 7.840169564587995e-05
untranslated O 0 9.666582627687603e-05
region O 0 3.126576984868734e-06
( O 0 1.9952851744164946e-06
UTR O 0 3.117442611255683e-05
) O 0 4.626722045486531e-07
of O 0 1.1491746221281574e-07
the O 0 3.039372586499667e-06
DM O 1 0.9999990463256836
protein O 0 1.586303551448509e-05
kinase O 0 8.634232654003426e-05
gene O 0 1.5384770449600182e-05
( O 0 2.4711985133762937e-06
DMPK O 0 9.529243834549561e-05
) O 0 7.19399793069897e-07
is O 0 3.077638268678129e-07
responsible O 0 2.0192401279928163e-06
for O 0 3.5841480894305278e-06
causing O 0 0.017133869230747223
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.31859007477760315
DM B-Disease 1 1.0
) O 0 6.654592289123684e-05
. O 0 3.3953798265429214e-05

Major O 0 0.00015151796105783433
instability O 0 0.00012746654101647437
, O 0 2.6067000362672843e-06
with O 0 4.308369909722387e-07
very O 0 7.201727498795663e-07
large O 0 4.783826170751126e-07
expansions O 0 3.928752903448185e-06
between O 0 3.567577095964225e-07
generations O 0 6.710750994898262e-07
and O 0 2.1602882327442785e-07
high O 0 5.318031526257982e-07
levels O 0 4.1159873376273026e-07
of O 0 3.025076296125917e-07
somatic O 0 3.536704389262013e-05
mosaicism O 0 0.00024648464750498533
, O 0 1.0151139804293052e-06
is O 0 5.463690513352049e-07
observed O 0 2.9878799523430644e-06
in O 0 8.585262548876926e-06
patients O 0 0.00037000380689278245
. O 0 1.8872971850214526e-05

There O 0 2.2529626221512444e-05
is O 0 1.7206658640134265e-06
a O 0 9.658263024903135e-07
good O 0 1.4310593314803555e-06
correlation O 0 1.348688556390698e-06
between O 0 4.037065934880957e-07
repeat O 0 2.5920890038833022e-06
size O 0 1.3513484873328707e-06
( O 0 3.0561469088752347e-07
at O 0 1.5588642554575927e-07
least O 0 1.3780221763681766e-07
in O 0 2.6638909389475884e-07
leucocytes O 0 5.875693750567734e-05
) O 0 6.143432074168231e-07
, O 0 6.115875521572889e-07
clinical O 0 6.784732977394015e-05
severity O 0 0.0021467439364641905
and O 0 1.0636300430633128e-05
age O 0 2.6415238608024083e-05
of O 0 2.954196816062904e-06
onset O 0 0.2776835560798645
. O 0 8.806653204374015e-05

The O 0 0.00021134258713573217
trinucleotide O 0 0.0035409885458648205
repeat O 0 0.00027158489683642983
instability O 0 6.869183562230319e-05
mechanisms O 0 2.2604497644351795e-05
involved O 0 1.1373246707080398e-05
in O 0 3.7523415812756866e-05
DM B-Disease 1 1.0
and O 0 1.0584501978883054e-05
other O 0 4.7197768253681716e-06
human O 0 0.00012415867240633816
genetic B-Disease 1 0.9998464584350586
diseases I-Disease 1 0.999929666519165
are O 0 2.4250107344414573e-06
unknown O 0 2.3443060854333453e-05
. O 0 1.569557934999466e-05

We O 0 3.123829446849413e-05
studied O 0 3.5381010093260556e-05
somatic O 0 7.600145181640983e-05
instability O 0 1.6492136637680233e-05
by O 0 1.2116045127186226e-06
measuring O 0 5.508320555236423e-06
the O 0 1.2801878028767533e-06
CTG O 0 0.00013238565588835627
repeat O 0 7.965656550368294e-06
length O 0 1.855243681347929e-06
at O 0 3.1838416703067196e-07
several O 0 3.0394454597626464e-07
ages O 0 1.3113842669554288e-06
in O 0 3.957792955588957e-07
various O 0 3.8002383462298894e-07
tissues O 0 3.6976068713556742e-06
of O 0 4.510974918048305e-07
transgenic O 0 0.00010907254909398034
mice O 0 5.273116403259337e-05
carrying O 0 2.7447611046227394e-06
a O 0 3.437836767261615e-06
( O 0 5.583288384514162e-06
CTG O 0 0.0002355661999899894
) O 0 2.8367135200824123e-06
55expansion O 0 1.863299257820472e-05
surrounded O 0 2.58469572145259e-06
by O 0 6.442475068979547e-07
45 O 0 1.1274028111074585e-06
kb O 0 1.1129374797747005e-05
of O 0 1.8708776394760207e-07
the O 0 1.2658754258154659e-06
human O 0 1.610778235772159e-05
DM B-Disease 1 0.9999998807907104
region O 0 6.977357315918198e-06
, O 0 5.284265967020474e-07
using O 0 1.0382080972703989e-06
small O 0 2.566468083387008e-06
- O 0 4.825711584999226e-05
pool O 0 2.946483982668724e-05
PCR O 0 0.00034299088292755187
. O 0 3.814873707597144e-05

These O 0 4.584803536999971e-05
mice O 0 0.0013256492093205452
have O 0 1.0959316796288476e-06
been O 0 7.290476560228853e-07
shown O 0 7.523271960963029e-07
to O 0 3.108584678557236e-07
reproduce O 0 2.8559318252519006e-06
the O 0 4.360577463558002e-07
intergenerational O 0 8.21150024421513e-06
and O 0 7.293710382327845e-07
somatic O 0 1.269114545721095e-05
instability O 0 3.5725383895623963e-06
of O 0 1.7097426052714582e-07
the O 0 6.100648874962644e-07
55 O 0 5.428567419585306e-06
CTG O 0 0.00017989192565437406
repeat O 0 1.0741599908214994e-05
suggesting O 0 4.623079348675674e-06
that O 0 1.8204485741080134e-07
surrounding O 0 5.245909164841578e-07
sequences O 0 4.2433995872670494e-07
and O 0 1.8706812454638566e-07
the O 0 3.266065391471784e-07
chromatin O 0 6.294126706052339e-06
environment O 0 2.9246734811749775e-06
are O 0 1.9001258522166609e-07
involved O 0 7.748823804831773e-07
in O 0 2.3648176465940196e-06
instability O 0 1.8932585589936934e-05
mechanisms O 0 3.582769932108931e-05
. O 0 1.964677358046174e-05

As O 0 4.339685256127268e-05
observed O 0 1.573096051288303e-05
in O 0 1.3889575711800717e-06
some O 0 1.7344756031434372e-07
of O 0 1.4351824972891336e-07
the O 0 7.159243295973283e-07
tissues O 0 1.5578785678371787e-05
of O 0 7.054160050756764e-06
DM B-Disease 1 1.0
patients O 1 0.9865238070487976
, O 0 1.4760635167476721e-06
there O 0 3.7988539247635345e-07
is O 0 1.1030339663875566e-07
a O 0 3.301468325389578e-07
tendency O 0 2.123481635862845e-06
for O 0 4.5338117615756346e-07
repeat O 0 5.922041964367963e-06
length O 0 3.1815275178814773e-06
and O 0 1.134938884206349e-06
somatic O 0 3.167521572322585e-05
mosaicism O 0 5.793923992314376e-05
to O 0 3.9345505342680553e-07
increase O 0 7.961631354191923e-07
with O 0 1.5585163737341645e-07
the O 0 2.775302050395112e-07
age O 0 9.047834055309067e-07
of O 0 1.8763954301448393e-07
the O 0 2.4094824766507372e-06
mouse O 0 9.197845065500587e-05
. O 0 2.1640486011165194e-05

Furthermore O 0 0.00025643809931352735
, O 0 7.325034857785795e-06
we O 0 9.759177146406728e-07
observed O 0 1.4124808558335644e-06
no O 0 3.5425091482466087e-07
correlation O 0 1.291586272600398e-06
between O 0 3.339585532557976e-07
the O 0 8.4888648643755e-07
somatic O 0 2.779933129204437e-05
mutation O 0 6.656523055426078e-06
rate O 0 2.3579173102916684e-06
and O 0 1.8576744196252548e-06
tissue O 0 0.00012471697118598968
proliferation O 0 3.518451194395311e-05
capacity O 0 1.4228440704755485e-05
. O 0 1.3804130503558554e-05

The O 0 8.246931247413158e-05
somatic O 0 0.0005142679437994957
mutation O 0 7.369288505287841e-05
rates O 0 8.18004809843842e-06
in O 0 8.240614874921448e-07
different O 0 5.605214141723991e-07
tissues O 0 5.423853508546017e-06
were O 0 6.598839377147669e-07
also O 0 3.2063320531960926e-07
not O 0 1.5689867893797782e-07
correlated O 0 6.676254997728392e-07
to O 0 1.1765240515160258e-07
the O 0 1.8897040376941732e-07
relative O 0 1.0182942560277297e-06
inter O 0 9.0144676505588e-06
- O 0 0.003495725803077221
tissue O 0 1.6068688637460582e-05
difference O 0 7.638990950908919e-07
in O 0 3.6330041552901093e-07
transcriptional O 0 2.661473445186857e-06
levels O 0 2.442687332404603e-07
of O 0 4.0254434452435817e-08
the O 0 1.210394913186974e-07
three O 0 3.1303224545808916e-07
genes O 0 1.2939966609337716e-06
( O 0 1.427191364200553e-06
DMAHP O 0 7.901294156908989e-05
, O 0 1.0120152182935271e-06
DMPK O 0 4.600460670189932e-05
and O 0 7.542755042777571e-07
59 O 0 2.997758429046371e-06
) O 0 2.6778542405736516e-07
surrounding O 0 7.688434493502427e-07
the O 0 8.721505651010375e-07
repeat O 0 1.6463896827190183e-05
. O 0 5.31398291059304e-06
. O 0 1.7391050278092735e-05

A O 0 0.00036911899223923683
novel O 0 0.0001808514352887869
missense O 0 0.0008433765033259988
mutation O 0 6.66626583551988e-05
in O 0 1.1306025044177659e-05
patients O 0 0.00033159140730276704
from O 0 3.5607351946964627e-06
a O 0 3.685431875055656e-05
retinoblastoma B-Disease 1 0.5972080826759338
pedigree O 0 0.0023524381686002016
showing O 0 3.093959094258025e-05
only O 0 2.728400204432546e-06
mild O 0 0.00011499586253194138
expression O 0 1.9610085928434273e-06
of O 0 5.405271394920419e-07
the O 0 1.6739277270971797e-05
tumor B-Disease 0 0.35970133543014526
phenotype O 0 0.004711768124252558
. O 0 5.239807069301605e-05

We O 0 2.0755338482558727e-05
have O 0 1.6581112731728354e-06
used O 0 1.444926510885125e-06
single O 0 1.8046373497782042e-06
strand O 0 1.2876156688435003e-05
conformation O 0 9.957202564692125e-06
polymorphism O 0 5.918338047194993e-06
analysis O 0 1.4632184957008576e-06
to O 0 3.835066024748812e-07
study O 0 6.661893507953209e-07
the O 0 3.0559138508579053e-07
27 O 0 1.0907859859798918e-06
exons O 0 1.5938968545015086e-06
of O 0 1.0456190580043767e-07
the O 0 1.2784869340976002e-06
RB1 O 0 0.0007751220837235451
gene O 0 2.2707899915985763e-06
in O 0 2.824876332852e-07
individuals O 0 1.291318767471239e-07
from O 0 1.9161723230354255e-07
a O 0 1.1384468052710872e-06
family O 0 9.402792784385383e-06
showing O 0 3.7199759390205145e-05
mild O 0 0.00046824078890495
expression O 0 4.547310254565673e-06
of O 0 8.391430128540378e-07
the O 0 1.1584495950955898e-05
retinoblastoma B-Disease 1 0.5396643280982971
phenotype O 0 0.09694970399141312
. O 0 5.166078335605562e-05

In O 0 5.4385487601393834e-05
this O 0 6.773661425540922e-06
family O 0 1.3499507076630834e-05
affected O 0 1.2237360351718962e-05
individuals O 0 1.6164080989256036e-06
developed O 0 7.309455395443365e-05
unilateral B-Disease 0 0.05781417712569237
tumors I-Disease 1 0.9999951124191284
and O 0 1.681183334767411e-06
, O 0 3.587898902424058e-07
as O 0 1.7962634046853054e-07
a O 0 2.3335221044362697e-07
result O 0 3.8622448528258246e-07
of O 0 1.426316202923772e-07
linkage O 0 1.0015564839704894e-05
analysis O 0 3.1587385365128284e-06
, O 0 1.4468514564214274e-06
unaffected O 0 0.00012099942978238687
mutation O 0 4.9602404033066705e-06
carriers O 0 2.498145022400422e-06
were O 0 7.795230203555548e-07
also O 0 3.7257859730743803e-07
identified O 0 9.85146243692725e-07
within O 0 3.89722060845088e-07
the O 0 1.4720711760674021e-06
pedigree O 0 0.00014659433509223163
. O 0 2.442803088342771e-05

A O 0 0.00010872922575799748
single O 0 2.154093272110913e-05
band O 0 1.799583696993068e-05
shift O 0 1.095606876333477e-05
using O 0 2.783141781037557e-06
SSCP O 0 0.0001676343526924029
was O 0 4.950434686179506e-06
identified O 0 2.0696461433544755e-06
in O 0 7.124629632926371e-07
exon O 0 1.4520943295792677e-05
21 O 0 2.3072186650097137e-06
which O 0 4.61899787751463e-07
resulted O 0 1.5093705769686494e-06
in O 0 7.982303031894844e-07
a O 0 1.9989151951449458e-06
missense O 0 3.9408598240697756e-05
mutation O 0 5.1356532821955625e-06
converting O 0 5.47895024283207e-06
a O 0 1.0682776519388426e-05
cys O 0 0.3289921283721924
- O 0 0.002587710740044713
- O 0 0.0005458075320348144
> O 0 2.720970951486379e-05
arg O 0 2.8222068067407236e-05
at O 0 8.626656153865042e-07
nucleotide O 0 2.9379239094851073e-06
position O 0 9.970534620151739e-07
28 O 0 1.6832816527312389e-06
in O 0 5.891685077585862e-07
the O 0 1.7699770751278265e-06
exon O 0 9.848576155491173e-05
. O 0 2.2183410692377947e-05

The O 0 7.249230839079246e-05
mutation O 0 0.00010005637159338221
destroyed O 0 4.529684883891605e-05
an O 0 5.631110525428085e-06
NdeI O 0 0.0001607679296284914
restriction O 0 3.694000042742118e-05
enzyme O 0 3.975510480813682e-05
site O 0 3.246462802053429e-05
. O 0 2.778692578431219e-05

Analysis O 0 3.98243973904755e-05
of O 0 1.3672452041646466e-06
all O 0 4.906096933154913e-07
family O 0 1.7401631566826836e-06
members O 0 3.803508832334046e-07
demonstrated O 0 1.3847385389453848e-06
that O 0 1.8135018819975812e-07
the O 0 3.6452968288358534e-07
missense O 0 2.7988913643639535e-05
mutation O 0 6.8631270551122725e-06
co O 0 1.1085150617873296e-05
- O 0 3.0071418223087676e-05
segregated O 0 1.1361908036633395e-05
with O 0 1.805058900572476e-06
patients O 0 0.003389122663065791
with O 0 4.460558920982294e-05
tumors B-Disease 1 0.9999994039535522
or O 0 2.155928314095945e-06
who O 0 8.268261808552779e-07
, O 0 1.2038630359256786e-07
as O 0 8.018447061886036e-08
a O 0 1.31679016135422e-07
result O 0 2.026714867042756e-07
of O 0 6.858802947817821e-08
linkage O 0 1.0078880222863518e-05
analysis O 0 1.7701796650726465e-06
had O 0 6.053292509022867e-06
been O 0 1.4070063798499177e-06
predicted O 0 1.8873713543143822e-06
to O 0 1.7821490416736196e-07
carry O 0 8.133904429996619e-07
the O 0 1.8763645357466885e-06
predisposing O 0 0.0001067804842023179
mutation O 0 4.890892523690127e-05
. O 0 1.784469532140065e-05

These O 0 2.8612439564312808e-05
observations O 0 3.234879477531649e-05
point O 0 4.4636890379479155e-06
to O 0 7.482450428142329e-07
another O 0 6.872224389553594e-07
region O 0 1.0031671990873292e-06
of O 0 2.582101785719715e-07
the O 0 3.3193985018442618e-06
RB1 O 0 0.001610992127098143
gene O 0 7.210357580333948e-06
where O 0 7.252779710142931e-07
mutations O 0 2.0065913304279093e-06
only O 0 1.3773021123597573e-07
modify O 0 1.3674591627932386e-06
the O 0 1.3839381551861152e-07
function O 0 8.79469084225093e-08
of O 0 2.4831182443563193e-08
the O 0 1.324298608551544e-07
gene O 0 6.322084686871676e-07
and O 0 8.471688772715424e-08
raise O 0 2.1861534094114177e-07
important O 0 1.3789674824238318e-07
questions O 0 2.814037429743621e-07
for O 0 2.1373162439886073e-07
genetic O 0 3.288379048171919e-06
counseling O 0 6.492845386674162e-06
in O 0 1.1141852382934303e-06
families O 0 1.1918527889065444e-06
with O 0 3.367939029885747e-07
these O 0 6.93150241204421e-07
distinctive O 0 4.993790571461432e-05
phenotypes O 0 0.00011563042789930478
. O 0 3.343174739711685e-06
. O 0 1.2399440493027214e-05

Maternal B-Disease 0 0.05172593891620636
disomy I-Disease 0 0.3876675069332123
and O 0 0.18914441764354706
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 0.9999998807907104
consistent O 0 4.347572030383162e-05
with O 0 3.5451457733870484e-06
gamete O 0 0.0002201705501647666
complementation O 0 0.004858420230448246
in O 0 1.9501264887367142e-06
a O 0 1.5230639291985426e-06
case O 0 1.6802760001155548e-06
of O 0 4.208173152164818e-07
familial O 0 3.4825287002604455e-05
translocation O 0 0.00017394722090102732
( O 0 2.0895174657198368e-06
3 O 0 8.019163715289324e-07
; O 0 5.390317028286518e-07
15 O 0 8.64845219439303e-07
) O 0 5.615947884507477e-07
( O 0 1.0700749726311187e-06
p25 O 0 4.601149703375995e-05
; O 0 1.587275619385764e-06
q11 O 0 1.7985561498790048e-05
. O 0 5.841477559442865e-07
2 O 0 1.7081174519262277e-06
) O 0 2.671531092346413e-06
. O 0 7.275992629729444e-06

Maternal B-Disease 0 0.27767905592918396
uniparental I-Disease 1 0.8847111463546753
disomy I-Disease 1 0.6196413636207581
( I-Disease 0 0.0003675679618027061
UPD I-Disease 1 0.9998743534088135
) I-Disease 0 5.205544312048005e-06
for I-Disease 0 9.253214443560864e-07
chromosome I-Disease 0 5.64162428418058e-06
15 I-Disease 0 4.931949320052809e-07
is O 0 6.717603184824839e-08
responsible O 0 1.8736380980044487e-07
for O 0 5.639767763909731e-08
an O 0 1.5282248000403342e-07
estimated O 0 3.602504818900343e-07
30 O 0 2.8963322051822615e-07
% O 0 1.9350596858203062e-07
of O 0 1.2191507892111986e-07
cases O 0 1.99647297449701e-06
of O 0 5.6304306781385094e-05
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.002536891493946314
PWS B-Disease 1 0.9999970197677612
) O 0 5.5636912293266505e-05
. O 0 2.2664742573397234e-05

We O 0 2.9921839086455293e-05
report O 0 1.0316326552128885e-05
on O 0 8.292322490888182e-07
an O 0 3.04523695149328e-07
unusual O 0 1.4556039786839392e-06
case O 0 9.679924914962612e-07
of O 0 3.8466333762698923e-07
maternal B-Disease 0 0.0001875256421044469
disomy I-Disease 0 0.001982466084882617
15 I-Disease 0 5.634301487589255e-06
in O 0 1.2445892934920266e-05
PWS B-Disease 1 0.9999984502792358
that O 0 1.6719991435820702e-06
is O 0 1.9407352169764636e-07
most O 0 1.98324102029801e-07
consistent O 0 9.007609946820594e-07
with O 0 1.459715690543817e-07
adjacent O 0 8.326461511387606e-07
- O 0 7.1485173975816e-06
1 O 0 5.425200697573018e-07
segregation O 0 1.2537290103864507e-06
of O 0 9.158628699879046e-08
a O 0 1.5665856381019694e-06
paternal O 0 0.00047602420090697706
t O 0 0.0005693904822692275
( O 0 7.801521633155062e-07
3 O 0 6.946127086848719e-07
; O 0 3.620939139636903e-07
15 O 0 6.334203135338612e-07
) O 0 3.5257312447356526e-07
( O 0 4.523618883922609e-07
p25 O 0 1.7310254406766035e-05
; O 0 7.103820962583995e-07
q11 O 0 6.196416052262066e-06
. O 0 2.912766490226204e-07
2 O 0 4.0282935742652626e-07
) O 0 1.7271533181428822e-07
with O 0 1.295345839480433e-07
simultaneous O 0 4.0575177990831435e-06
maternal O 0 0.0001692823861958459
meiotic O 0 0.0009671130101196468
nondisjunction O 0 0.0002751912106759846
for O 0 8.709837857168168e-06
chromosome O 0 0.00010112088057212532
15 O 0 2.1085819753352553e-05
. O 0 2.9235940019134432e-05

The O 0 0.00015297882782761008
patient O 0 0.003319722367450595
( O 0 3.314281639177352e-05
J O 0 0.0017456962959840894
. O 0 1.7875871662909049e-06
B O 0 7.813390766386874e-06
. O 0 3.0086738433965365e-07
) O 0 1.3911115104292548e-07
, O 0 5.367971667169513e-08
a O 0 1.776669620312532e-07
17 O 0 1.059343389897549e-06
- O 0 1.0455484698468354e-05
year O 0 1.2795518387065385e-06
- O 0 2.5453435227973387e-05
old O 0 5.080492701381445e-05
white O 0 1.6755886463215575e-05
male O 0 3.608178758440772e-06
with O 0 1.4119165143711143e-06
PWS B-Disease 1 0.9999986886978149
, O 0 1.4151613640933647e-06
was O 0 3.7719735246355413e-06
found O 0 1.979813220032156e-07
to O 0 7.070696028677048e-08
have O 0 1.0570045816393758e-07
47 O 0 6.247286705729493e-07
chromosomes O 0 7.275397706507647e-07
with O 0 1.0927166727014992e-07
a O 0 9.7775659924082e-07
supernumerary O 0 9.863369632512331e-05
, O 0 1.0007859145844122e-06
paternal O 0 0.00014853379980195314
der O 0 0.014682971872389317
( O 0 5.684065058630949e-07
15 O 0 2.413667345990689e-07
) O 0 5.8702383398667735e-08
consisting O 0 5.6469364295708147e-08
of O 0 2.8574845600815024e-08
the O 0 2.5708774842314597e-07
short O 0 2.9191951398388483e-06
arm O 0 6.86528001097031e-05
and O 0 1.110770085688273e-06
the O 0 1.284093286813004e-06
proximal O 0 0.00039488644688390195
long O 0 1.0711178219935391e-05
arm O 0 7.313450623769313e-05
of O 0 4.467895564630453e-07
chromosome O 0 1.0632284102030098e-05
15 O 0 1.4728224186910666e-06
, O 0 7.825366878932982e-07
and O 0 4.770158739120234e-06
distal O 0 0.03298356011509895
chromosome O 0 0.0009016811964102089
arm O 0 0.07014020532369614
3p O 0 0.2086883783340454
. O 0 9.954341658158228e-05

The O 0 9.415055683348328e-05
t O 0 0.0006466764607466757
( O 0 2.757517449936131e-06
3 O 0 1.0733137969509698e-06
; O 0 4.0547726598560985e-07
15 O 0 3.487048729766684e-07
) O 0 2.7398078827900463e-07
was O 0 5.650480261465418e-07
present O 0 1.5892159410668683e-07
in O 0 2.0431930636277684e-07
the O 0 1.3017769617817976e-07
balanced O 0 5.931973987571837e-07
state O 0 1.781503442543908e-07
in O 0 4.240207829298015e-07
the O 0 1.341447614322533e-06
patients O 0 4.436200833879411e-05
father O 0 8.05975196271902e-06
and O 0 2.455133426337852e-06
a O 0 9.304591003456153e-06
sister O 0 0.0011296888114884496
. O 0 4.6382836444536224e-05

Fluorescent O 0 0.001186209381558001
in O 0 6.550260877702385e-05
situ O 0 0.00013627861335407943
hybridization O 0 2.5283005015808158e-05
analysis O 0 8.694318239577115e-06
demonstrated O 0 1.0400163773738313e-05
that O 0 1.0998297739206464e-06
the O 0 3.735484824574087e-06
PWS B-Disease 1 0.9999921321868896
critical O 0 1.8580962205305696e-05
region O 0 6.53132383376942e-06
resided O 0 8.446037099929526e-06
on O 0 6.979780664551072e-07
the O 0 4.1036645370695624e-07
derivative O 0 4.766939127875958e-06
chromosome O 0 3.6875246678391704e-06
3 O 0 3.556164074325352e-07
and O 0 9.995881811164509e-08
that O 0 7.154507386530895e-08
there O 0 7.720993266957521e-08
was O 0 5.627812242892105e-07
no O 0 2.2720976744494692e-07
deletion O 0 1.8335002778258058e-06
of O 0 1.1858330850600396e-07
the O 0 3.830642981483834e-06
PWS B-Disease 1 0.9999992847442627
region O 0 2.710138232941972e-06
on O 0 8.795275334705366e-07
the O 0 3.5809733844871516e-07
normal O 0 1.1129129688924877e-06
pair O 0 1.200040628646093e-06
of O 0 2.7137878078065114e-07
15s O 0 2.462755401211325e-05
present O 0 2.0283073354221415e-06
in O 0 1.0797903087222949e-05
J O 0 0.2912110686302185
. O 0 4.3060303141828626e-05

B O 0 0.013922205194830894
. O 0 0.0006647002883255482

Methylation O 0 0.0002702788624446839
analysis O 0 2.9723667466896586e-05
at O 0 4.744565558212344e-06
exon O 0 1.6414731362601742e-05
alpha O 0 2.1152150111447554e-06
of O 0 1.1849682124420724e-07
the O 0 2.490580186531588e-07
small O 0 1.472497956456209e-06
nuclear O 0 1.8565197024145164e-05
ribonucleoprotein O 0 0.0002373153402004391
- O 0 5.519197293324396e-05
associated O 0 5.928517566644587e-06
polypeptide O 0 1.0731278962339275e-05
N O 0 8.726367013878189e-06
( O 0 8.471428145639948e-07
SNRPN O 0 2.9023789466009475e-05
) O 0 6.162562158351648e-07
gene O 0 1.1178537988598691e-06
showed O 0 1.4427027963392902e-06
a O 0 4.5398215320346935e-07
pattern O 0 2.3940719984238967e-06
characteristic O 0 7.038603371256613e-07
of O 0 5.8635020394604e-08
only O 0 1.7124416729075165e-07
the O 0 1.1375742587915738e-06
maternal O 0 0.00020332612621132284
chromosome O 0 3.509972520987503e-05
15 O 0 4.130113211431308e-06
in O 0 8.931923730415292e-06
J O 0 0.2813098132610321
. O 0 5.39144421054516e-05

B O 0 0.014581453986465931
. O 0 0.0008797608898021281

Maternal B-Disease 0 0.023876400664448738
disomy I-Disease 0 0.02172919549047947
was O 0 0.00016983269597403705
confirmed O 0 1.9149687432218343e-05
by O 0 1.5329774214478675e-06
polymerase O 0 2.0425888578756712e-05
chain O 0 7.833236850274261e-06
reaction O 0 2.4208238755818456e-06
analysis O 0 7.68644042636879e-07
of O 0 2.2067757754484774e-07
microsatellite O 0 2.206990757258609e-05
repeats O 0 6.863769158371724e-06
at O 0 1.7374104572809301e-06
the O 0 9.956178246284253e-07
gamma O 0 1.3307810149854049e-05
- O 0 2.3601094653713517e-05
aminobutyric O 0 6.574709550477564e-05
acid O 0 1.0942807421088219e-05
receptor O 0 9.638310984882992e-06
beta3 O 0 4.2098487028852105e-05
subunit O 0 2.070911432383582e-05
( O 0 4.887556315225083e-06
GABRB3 O 0 0.00011790773714892566
) O 0 5.1595852710306644e-06
locus O 0 3.0757761123823e-05
. O 0 1.3637379197461996e-05

A O 0 0.0002860134991351515
niece O 0 0.004296243190765381
( O 0 1.1411815648898482e-05
B O 0 1.575071655679494e-05
. O 0 4.6100382178337895e-07
B O 0 2.293822490173625e-06
. O 0 1.7613797353988048e-07
) O 0 9.399795430908853e-08
with O 0 6.374708760858994e-08
45 O 0 2.6923069640361064e-07
chromosomes O 0 6.210735250533617e-07
and O 0 9.596311656423495e-08
the O 0 7.782618638429994e-08
derivative O 0 7.395637453555537e-07
3 O 0 2.3059683940118703e-07
but O 0 1.0934527239214731e-07
without O 0 1.9392145134133898e-07
the O 0 4.806425408787618e-07
der O 0 0.0003683751856442541
( O 0 5.491366437126999e-07
15 O 0 3.290489019036613e-07
) O 0 1.7746680214258959e-07
demonstrated O 0 9.536487937111815e-07
a O 0 9.971200825020787e-07
phenotype O 0 9.480056178290397e-05
consistent O 0 3.5142011256539263e-06
with O 0 4.4856946601612435e-07
that O 0 4.864566562901018e-07
reported O 0 2.262752786919009e-06
for O 0 3.2675669103809923e-07
haploinsufficiency O 0 3.8367386878235266e-05
of O 0 1.1717053212123574e-06
distal O 0 0.0005929223843850195
3 O 0 3.0076209441176616e-05
p O 0 0.0005906377919018269
. O 0 2.616984238557052e-05

Uniparental B-Disease 1 0.9997816681861877
disomy I-Disease 1 0.9989176988601685
associated O 0 0.0002207727957284078
with O 0 1.166425681731198e-05
unbalanced O 0 0.00039626137004233897
segregation O 0 3.6767298297490925e-05
of O 0 7.026706043689046e-07
non O 0 1.0304362149327062e-05
- O 0 0.0004547195276245475
Robertsonian O 0 0.00024059515271801502
translocations O 0 9.315978240920231e-05
has O 0 1.3445559261526796e-06
been O 0 8.300661988869251e-07
reported O 0 2.8735535124724265e-06
previously O 0 5.316982196745812e-07
but O 0 2.1827680996011622e-07
has O 0 1.057121536973682e-07
not O 0 6.348657421995085e-08
, O 0 4.09133136258788e-08
to O 0 3.444852225698014e-08
our O 0 8.989454158836452e-08
knowledge O 0 1.8953804215016135e-07
, O 0 1.27050725495792e-07
been O 0 2.862812493731326e-07
observed O 0 4.117769663025683e-07
in O 0 2.8941121854586527e-07
a O 0 1.0348728665121598e-06
case O 0 7.263956376846181e-06
of O 0 8.020013410714455e-06
PWS B-Disease 1 0.999994158744812
. O 0 9.939962183125317e-05

Furthermore O 0 0.00027948367642238736
, O 0 1.0386922440375201e-05
our O 0 3.3485353014839347e-06
findings O 0 5.920827334193746e-06
are O 0 1.5449123225153016e-07
best O 0 3.0773480830248445e-07
interpreted O 0 1.0879871297220234e-06
as O 0 3.895392524100316e-07
true O 0 2.098884351653396e-06
gamete O 0 3.8039099308662117e-05
complementation O 0 0.00025319811538793147
resulting O 0 6.296894753177185e-06
in O 0 8.401348168263212e-06
maternal B-Disease 0 0.06971229612827301
UPD I-Disease 1 0.9999938011169434
15 I-Disease 0 9.236948972102255e-05
and O 0 8.386797708226368e-05
PWS B-Disease 1 0.9999806880950928

Schwartz B-Disease 1 0.9946809411048889
- I-Disease 1 0.9999366998672485
Jampel I-Disease 1 0.9999634027481079
syndrome I-Disease 1 0.9999855756759644
type I-Disease 0 4.400156467454508e-05
2 I-Disease 0 1.0508506420592312e-05
and O 0 8.318536856677383e-06
Stuve B-Disease 1 0.9834163188934326
- I-Disease 1 0.9999966621398926
Wiedemann I-Disease 1 0.9999997615814209
syndrome I-Disease 1 0.9999957084655762
: O 0 2.5278309294662904e-06
a O 0 1.616913891666627e-06
case O 0 1.998758762056241e-06
for O 0 4.999345719625126e-07
" O 0 3.9503556763520464e-06
lumping O 0 2.8646294595091604e-05
" O 0 9.141870577877853e-06
. O 0 6.851481430203421e-06

Recent O 0 8.903259731596336e-05
studies O 0 2.8804932298953645e-05
demonstrated O 0 6.8687263592437375e-06
the O 0 6.952078024369257e-07
existence O 0 8.972476166491106e-07
of O 0 9.068672568446345e-08
a O 0 1.6309170405293116e-06
genetically O 0 6.4910127548500896e-06
distinct O 0 7.396582759611192e-07
, O 0 4.3745811240114563e-07
usually O 0 3.444077663061762e-07
lethal O 0 1.8312284737476148e-06
form O 0 2.066847883952505e-07
of O 0 1.4565452488568553e-07
the O 0 3.3533419809828047e-06
Schwartz B-Disease 0 0.08065109699964523
- I-Disease 1 0.9993230104446411
Jampel I-Disease 1 0.9999909400939941
syndrome I-Disease 1 0.9999991655349731
( O 0 5.6908727856352925e-05
SJS B-Disease 1 0.9702717065811157
) O 0 2.785563538054703e-06
of O 0 1.1687924370562541e-06
myotonia B-Disease 1 0.514850914478302
and O 0 0.0009285440901294351
skeletal B-Disease 1 0.9999966621398926
dysplasia I-Disease 1 0.9999911785125732
, O 0 2.6418754259793786e-06
which O 0 1.478808258070785e-06
we O 0 9.637957418817678e-07
called O 0 1.1487462870718446e-05
SJS B-Disease 1 0.7656769156455994
type I-Disease 0 2.0865882106591016e-05
2 I-Disease 0 6.884425602038391e-06
. O 0 1.2489933396864217e-05

This O 0 0.0007777531864121556
disorder O 1 0.8463437557220459
is O 0 3.0575656637665816e-06
reminiscent O 0 1.8768207155517302e-05
of O 0 4.16376281009434e-07
another O 0 3.345755430927966e-06
rare O 0 5.9898895415244624e-05
condition O 0 0.0028776831459254026
, O 0 1.1223029332541046e-06
the O 0 6.792330168536864e-06
Stuve B-Disease 1 0.9992825388908386
- I-Disease 1 0.9999996423721313
Wiedemann I-Disease 1 0.9999998807907104
syndrome I-Disease 1 0.9999990463256836
( O 0 4.3526579247554764e-05
SWS B-Disease 1 0.8644377589225769
) O 0 8.6000426335886e-07
, O 0 1.0889965551541536e-07
which O 0 9.489469476875456e-08
comprises O 0 4.935106403536338e-07
campomelia B-Disease 0 1.761565545166377e-05
at O 0 1.5123619050427806e-06
birth O 0 2.010622847592458e-05
with O 0 1.9069066183874384e-05
skeletal B-Disease 1 0.9999767541885376
dysplasia I-Disease 1 0.9999966621398926
, O 0 1.371691541862674e-05
contractures B-Disease 0 0.0024440353736281395
, O 0 1.3397994962360826e-06
and O 0 1.121689820138272e-06
early B-Disease 0 3.2950923923635855e-05
death I-Disease 0 5.6272419897140935e-05
. O 0 2.06842232728377e-05

To O 0 2.850336932169739e-05
test O 0 2.438376031932421e-05
for O 0 1.3133267202647403e-06
possible O 0 1.902292069644318e-06
nosologic O 0 6.661595398327336e-05
identity O 0 2.3877446437836625e-06
between O 0 1.2944286709171138e-06
these O 0 2.2776414425607072e-06
disorders O 0 0.2716831564903259
, O 0 4.6792339958301454e-07
we O 0 1.7811261443512194e-07
reviewed O 0 6.324581818262232e-07
the O 0 8.693987041397122e-08
literature O 0 2.304422821453045e-07
and O 0 2.0133663269916724e-07
obtained O 0 2.7340422548149945e-07
a O 0 2.3313465646879195e-07
follow O 0 4.2992252247131546e-07
- O 0 2.4142898382706335e-06
up O 0 1.3458782177622197e-07
of O 0 2.6158412325116842e-08
the O 0 6.234680682837279e-08
only O 0 8.337420354109781e-08
two O 0 3.304596134512394e-07
surviving O 0 9.119514288613573e-05
patients O 0 4.667906614486128e-05
, O 0 1.7122651740919537e-07
one O 0 3.005054907134763e-07
with O 0 1.025989263325755e-06
SJS B-Disease 1 0.9617397785186768
type I-Disease 0 3.1553906865156023e-06
2 I-Disease 0 3.368526790836768e-07
at O 0 2.956246873964119e-07
age O 0 6.663011618002201e-07
10 O 0 1.3857382441528898e-07
years O 0 1.533717437496307e-07
and O 0 1.0586632015474606e-07
another O 0 4.311715713356534e-07
with O 0 1.1888409972016234e-06
SWS B-Disease 1 0.7225796580314636
at O 0 5.158901331014931e-06
age O 0 5.109287485538516e-06
7 O 0 3.085875277974992e-06
years O 0 5.5802115639380645e-06
. O 0 6.785046934965067e-06

Patients O 1 0.9969695210456848
reported O 0 0.00035086748539470136
as O 0 1.076162516255863e-05
having O 0 1.9878241801052354e-05
either O 0 9.66626830631867e-05
neonatal O 1 1.0
SJS B-Disease 1 0.9999992847442627
or O 0 0.00026245092158205807
SWS B-Disease 1 0.9148079752922058
presented O 0 1.547466126794461e-05
a O 0 2.1929890863248147e-06
combination O 0 7.302888207050273e-06
of O 0 6.094722948546405e-07
a O 0 7.941346666484606e-06
severe O 0 0.2999592423439026
, O 0 9.436681284569204e-05
prenatal O 1 0.9999905824661255
- O 1 0.9999995231628418
onset O 1 0.9999997615814209
neuromuscular B-Disease 1 0.9999998807907104
disorder I-Disease 1 0.9999986886978149
( O 0 0.00028871544054709375
with O 0 0.00024212429707404226
congenital B-Disease 1 0.9999997615814209
joint I-Disease 1 0.8983383178710938
contractures I-Disease 1 0.999985933303833
, O 0 0.007115329150110483
respiratory O 1 0.9776504039764404
and O 0 1.422750483470736e-05
feeding O 0 4.5995217078598216e-05
difficulties O 0 4.367222936707549e-05
, O 0 1.1258941867708927e-06
tendency O 0 5.0777721298800316e-06
to O 0 2.347289409954101e-06
hyperthermia B-Disease 0 0.06609822064638138
, O 0 5.635578759211057e-07
and O 0 2.692774216939142e-07
frequent O 0 2.0705188035208266e-06
death O 0 1.3612651855510194e-05
in O 0 8.773797162575647e-06
infancy O 0 0.010759669356048107
) O 0 8.935468258641777e-07
with O 0 2.624627768454957e-07
a O 0 2.5297240426880307e-06
distinct O 0 1.3685857084055897e-05
campomelic B-Disease 0 0.41120433807373047
- I-Disease 1 0.9948360919952393
metaphyseal I-Disease 1 0.9975977540016174
skeletal I-Disease 1 0.999872088432312
dysplasia I-Disease 1 0.9999550580978394
. O 0 0.00019761623116210103

The O 0 1.681522735452745e-05
similarity O 0 1.257801523024682e-05
of O 0 4.3111688796670933e-07
the O 0 1.5913421975710662e-06
clinical O 0 3.743895285879262e-05
and O 0 8.476296898152214e-06
radiographic O 1 0.9225042462348938
findings O 0 0.0021955801639705896
is O 0 4.911648829875048e-07
so O 0 5.065817276772577e-07
extensive O 0 1.9689273358380888e-06
that O 0 8.186581794689118e-07
these O 0 1.9555177459551487e-06
disorders O 1 0.5268421173095703
appear O 0 3.724784392034053e-06
to O 0 2.860940355731145e-07
be O 0 1.4892002297983709e-07
a O 0 3.939840951261431e-07
single O 0 2.4671765004313784e-06
entity O 0 1.085371695808135e-05
. O 0 1.03137690530275e-05

The O 0 2.9048705982859246e-05
follow O 0 1.9275890736025758e-05
- O 0 1.994215745071415e-05
up O 0 1.0817896054504672e-06
observation O 0 2.140411879736348e-06
of O 0 6.845198186056223e-08
an O 0 2.0492561247920094e-07
identical O 0 1.4249867490434553e-06
and O 0 3.577743825644575e-07
unique O 0 7.811945010871568e-07
pattern O 0 2.947552502519102e-06
of O 0 1.037089873534569e-06
progressive O 1 0.9462429881095886
bone B-Disease 1 0.9999884366989136
dysplasia I-Disease 1 0.9999958276748657
in O 0 4.7415260269190185e-06
the O 0 8.330329706041084e-07
two O 0 2.1991797893861076e-06
patients O 0 0.00012876465916633606
( O 0 5.540006213777815e-07
one O 0 3.974151070451626e-07
with O 0 2.8803358418372227e-06
SJS B-Disease 1 0.9858304858207703
type I-Disease 0 5.059770955995191e-06
2 I-Disease 0 9.299766361436923e-07
, O 0 2.525283946397394e-07
one O 0 2.1434256325392198e-07
with O 0 7.351742965511221e-07
SWS B-Disease 1 0.5385353565216064
) O 0 1.0637288596626604e-06
surviving O 0 3.364749090906116e-06
beyond O 0 4.516029548540246e-06
infancy O 0 0.0002021724358201027
adds O 0 3.5804719118459616e-06
to O 0 1.4200809062003827e-07
the O 0 1.6618412246316439e-07
evidence O 0 3.283579701474082e-07
in O 0 1.9310316190512822e-07
favor O 0 5.390347723732702e-07
of O 0 2.9444717597471026e-07
identity O 0 8.619390428066254e-06
. O 0 1.3967513041279744e-05

The O 0 6.816119275754318e-05
hypothesis O 0 0.00017957213276531547
that O 0 1.2194839655421674e-05
SWS B-Disease 1 0.538713812828064
and O 0 2.3829286874388345e-05
SJS B-Disease 1 0.9976733326911926
type I-Disease 0 7.397129138553282e-06
2 I-Disease 0 7.232658276734583e-07
are O 0 9.219182572905993e-08
the O 0 2.525982267798099e-07
same O 0 8.401452760153916e-06
disorder O 0 0.060956429690122604
should O 0 4.853231985180173e-07
be O 0 1.6186035622922645e-07
testable O 0 2.505039674360887e-06
by O 0 5.461351406665926e-07
molecular O 0 5.202199645282235e-06
methods O 0 7.25192603567848e-06
. O 0 2.690569090191275e-06
. O 0 7.235043085529469e-06

A O 0 0.0006198365590535104
mouse O 0 0.0009612628491595387
model O 0 0.00021548004588112235
of O 0 2.6362569769844413e-05
severe O 1 0.9999936819076538
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
: O 0 0.002925645327195525
defects O 1 0.9483292698860168
in O 0 6.390375347109511e-05
hemostasis O 0 0.37163200974464417
and O 0 0.0005037195514887571
thrombosis B-Disease 1 0.994413435459137
. O 0 0.00014351090067066252

von B-Disease 1 0.9986016154289246
Willebrand I-Disease 1 0.9950520396232605
factor I-Disease 0 0.0015094056725502014
( I-Disease 0 0.00038401829078793526
vWf I-Disease 0 0.27473482489585876
) I-Disease 0 0.0031109137926250696
deficiency I-Disease 1 0.999953031539917
causes O 1 0.7740150690078735
severe O 1 0.9999998807907104
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
in O 0 0.0013567822752520442
humans O 0 0.00012413122749421746
. O 0 4.736536357086152e-05

We O 0 2.7801077521871775e-05
generated O 0 1.181974948849529e-05
a O 0 5.870042514288798e-06
mouse O 0 4.3480697058839723e-05
model O 0 1.1724793694156688e-05
for O 0 1.0327274821975152e-06
this O 0 2.7574201340030413e-06
disease O 0 2.435018541291356e-05
by O 0 1.1095356740042916e-06
using O 0 3.472262505965773e-06
gene O 0 1.2881217116955668e-05
targeting O 0 2.8488908355939202e-05
. O 0 1.8106355128111318e-05

vWf B-Disease 1 0.9829157590866089
- I-Disease 1 0.9998294115066528
deficient I-Disease 1 0.999882698059082
mice O 0 0.02233254164457321
appeared O 0 4.229776095598936e-05
normal O 0 6.4985310928022955e-06
at O 0 2.2417912077798974e-06
birth O 0 6.438755008275621e-06
; O 0 7.013744038886216e-07
they O 0 3.4206698273919756e-07
were O 0 1.3811485359838116e-06
viable O 0 1.201969735120656e-05
and O 0 3.772153377212817e-06
fertile O 0 5.391331069404259e-05
. O 0 2.759073322522454e-05

Neither O 0 0.005394582636654377
vWf O 0 0.026404326781630516
nor O 0 0.0017458616057410836
vWf O 0 0.01332620158791542
propolypeptide O 0 0.03357758745551109
( O 0 0.00016727509500924498
von B-Disease 0 0.10026440024375916
Willebrand I-Disease 0 0.11802058666944504
antigen O 0 0.0005917263915762305
II O 0 0.00040538940811529756
) O 0 1.3915017689214437e-06
were O 0 6.53797826544178e-07
detectable O 0 2.7572150429477915e-06
in O 0 5.231794943938439e-07
plasma O 0 8.471633918816224e-06
, O 0 5.511518565981532e-07
platelets O 0 7.922133590909652e-06
, O 0 4.3398964066909684e-07
or O 0 7.019860390755639e-07
endothelial O 0 2.816490814439021e-05
cells O 0 2.2489111870527267e-06
of O 0 3.276897757586994e-07
the O 0 2.97378846880747e-06
homozygous O 0 0.0004998258664272726
mutant O 0 0.0007227123714983463
mice O 0 0.0008984284359030426
. O 0 5.3161340474616736e-05

The O 0 0.00022322215954773128
mutant O 0 0.013598417863249779
mice O 1 0.8039610385894775
exhibited O 0 0.1806875467300415
defects O 1 0.757087767124176
in O 0 8.914749741961714e-06
hemostasis O 0 0.000737827445846051
with O 0 2.1198536614974728e-06
a O 0 1.067986431735335e-05
highly O 0 6.202026997925714e-05
prolonged O 0 0.3144932687282562
bleeding O 1 0.538661003112793
time O 0 3.263473445258569e-06
and O 0 1.575964688527165e-06
spontaneous O 0 1.2206858627905603e-05
bleeding O 0 0.00029545274446718395
events O 0 7.20986349733721e-07
in O 0 2.7742433417188295e-07
approximately O 0 5.32710259903979e-07
10 O 0 4.918576905765804e-07
% O 0 7.451949954884185e-07
of O 0 7.877382586229942e-07
neonates O 0 0.0028759550768882036
. O 0 3.969320823671296e-05

As O 0 1.5733452528365888e-05
in O 0 2.9194568469392834e-06
the O 0 1.7031237575793057e-06
human O 0 4.938156962452922e-06
disease O 0 3.8528127333847806e-05
, O 0 1.8058028672385262e-07
the O 0 2.0543416212603915e-07
factor O 0 1.1217379096706281e-06
VIII O 0 0.006272728089243174
level O 0 5.832905003444466e-07
in O 0 3.450053895903693e-07
these O 0 5.100584417050413e-07
mice O 0 5.2355913794599473e-05
was O 0 1.5865022078287438e-06
reduced O 0 6.549860245286254e-07
strongly O 0 5.614989504465484e-07
as O 0 1.6423501847384614e-07
a O 0 1.722209077570369e-07
result O 0 2.90603793473565e-07
of O 0 4.067777936711536e-08
the O 0 1.2119889447603782e-07
lack O 0 6.611884941776225e-07
of O 0 2.1722044607486168e-07
protection O 0 1.702199824649142e-06
provided O 0 3.231992877772427e-06
by O 0 7.243514119181782e-06
vWf O 0 0.0004380967002362013
. O 0 2.5053739591385238e-05

Defective O 1 0.9956132173538208
thrombosis B-Disease 1 0.9994322657585144
in O 0 0.00018141411419492215
mutant O 0 0.002987900050356984
mice O 0 0.004400626756250858
was O 0 8.183200407074764e-06
also O 0 8.338222414749907e-07
evident O 0 1.5990109432095778e-06
in O 0 4.0342371221413487e-07
an O 0 4.085335376657895e-07
in O 0 1.1243984090469894e-06
vivo O 0 6.474021211033687e-05
model O 0 2.2722895664628595e-05
of O 0 5.839211098646047e-06
vascular B-Disease 1 0.9999895095825195
injury I-Disease 1 0.9712371230125427
. O 0 0.000115912378532812

In O 0 2.763845259323716e-05
this O 0 2.7084768134955084e-06
model O 0 6.11403174843872e-06
, O 0 4.836062998947455e-07
the O 0 5.739254334002908e-07
exteriorized O 0 5.2192106522852555e-05
mesentery O 0 8.970704220701009e-05
was O 0 1.322378284385195e-05
superfused O 0 6.005337490933016e-05
with O 0 1.3771632438874803e-06
ferric O 0 0.0002660625905264169
chloride O 0 1.0243907127005514e-05
and O 0 7.241507091748645e-07
the O 0 5.418643809207424e-07
accumulation O 0 2.4786004360066727e-06
of O 0 4.7218424015227356e-07
fluorescently O 0 0.00014673151599708945
labeled O 0 7.333893154282123e-05
platelets O 0 0.00022214147611521184
was O 0 1.6079879060271196e-05
observed O 0 8.035546670726035e-06
by O 0 4.769385668623727e-06
intravital O 0 0.00035385548835620284
microscopy O 0 0.00062085798708722
. O 0 4.1089486330747604e-05

We O 0 3.2766918593551964e-05
conclude O 0 5.500366023625247e-05
that O 0 1.986236839002231e-06
these O 0 1.099104224522307e-06
mice O 0 7.939315401017666e-05
very O 0 4.077934136148542e-06
closely O 0 1.6269732441287488e-05
mimic O 0 0.03646990656852722
severe O 1 0.9945766925811768
human O 0 0.003524146741256118
von B-Disease 1 1.0
Willebrand I-Disease 1 0.9999998807907104
disease I-Disease 1 0.9999996423721313
and O 0 2.6032046662294306e-05
will O 0 2.220257329099695e-06
be O 0 2.4465879278068314e-07
very O 0 2.833567123161629e-07
useful O 0 2.3623914557902026e-07
for O 0 7.016407010951298e-08
investigating O 0 4.3463370502649923e-07
the O 0 1.3743381543918076e-07
role O 0 4.322849065374612e-07
of O 0 2.358515160949537e-07
vWf O 0 1.630806946195662e-05
in O 0 9.982599067370757e-07
normal O 0 7.038965122774243e-06
physiology O 0 5.7955818192567676e-05
and O 0 2.39240125665674e-06
in O 0 0.00018094698316417634
disease O 0 0.002784158568829298
models O 0 3.439611100475304e-05
. O 0 3.789543370658066e-06
. O 0 1.0078697414428461e-05

Oral O 0 0.0042840116657316685
contraceptives O 0 0.012679070234298706
and O 0 2.1330728486645967e-05
the O 0 5.6200165090558585e-06
risk O 0 2.565889008110389e-05
of O 0 2.956137905130163e-05
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999994039535522
. O 0 0.0005249582463875413

Hereditary B-Disease 1 0.9999988079071045
Ovarian I-Disease 1 0.9999997615814209
Cancer I-Disease 1 0.9999803304672241
Clinical O 1 0.8169041872024536
Study O 0 0.0006993384449742734
Group O 0 0.00048257943126372993
. O 0 0.00012486583727877587

BACKGROUND O 0 0.0007940215291455388
Women O 0 7.715861283941194e-05
with O 0 2.847897576430114e-06
mutations O 0 6.725738330715103e-06
in O 0 4.070797672284243e-07
either O 0 5.93440688589908e-07
the O 0 1.1409956641728058e-06
BRCA1 O 0 6.669762660749257e-05
or O 0 1.4051397556613665e-06
the O 0 1.4439511915043113e-06
BRCA2 O 0 0.00010784162441268563
gene O 0 2.947656639662455e-06
have O 0 2.6128898866772943e-07
a O 0 6.057665586922667e-07
high O 0 3.7466877529368503e-06
lifetime O 0 1.674360282777343e-05
risk O 0 3.158936306135729e-05
of O 0 0.00012124729255447164
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999991655349731
. O 0 0.00018093369726557285

Oral O 0 0.0020563574507832527
contraceptives O 0 0.06593838334083557
protect O 0 0.0002932797360699624
against O 0 0.39866259694099426
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999861717224121
in O 0 2.093111561407568e-06
general O 0 1.4694750234411913e-06
, O 0 2.714095899136737e-07
but O 0 2.2360083562489308e-07
it O 0 6.016546194587136e-08
is O 0 3.8434720295299485e-08
not O 0 5.782569445500485e-08
known O 0 1.2542153626782238e-07
whether O 0 1.4297154393716482e-07
they O 0 1.5540710762707022e-07
also O 0 2.0323393812304857e-07
protect O 0 6.424742764465918e-07
against O 0 2.1418145479401574e-06
hereditary B-Disease 0 0.00029648354393430054
forms I-Disease 0 6.970015874685487e-06
of I-Disease 0 0.00016529191634617746
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999984502792358
. O 0 0.00019847486692015082

METHODS O 0 0.0004556606581900269
We O 0 2.4185452275560237e-05
enrolled O 0 4.61787567473948e-05
207 O 0 0.0001228300534421578
women O 0 2.8334334274404682e-05
with O 0 6.431867950595915e-05
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999991655349731
and O 0 4.633036951418035e-06
161 O 0 8.435427844233345e-06
of O 0 1.7027942078584601e-07
their O 0 2.738238151778205e-07
sisters O 0 5.944143140368396e-06
as O 0 3.275091842169786e-07
controls O 0 1.7647286085775704e-06
in O 0 6.568644721482997e-07
a O 0 1.876178544080176e-06
case O 0 8.935817277233582e-06
- O 0 9.45493156905286e-05
control O 0 1.8261262084706686e-05
study O 0 9.794629477255512e-06
. O 0 1.7965521692531183e-05

All O 0 2.3062084437697195e-05
the O 0 1.2708547728834674e-05
patients O 0 0.00030139434966258705
carried O 0 7.3489923124725465e-06
a O 0 5.795571269118227e-06
pathogenic O 0 2.4950806619017385e-05
mutation O 0 5.094555035611847e-06
in O 0 8.287950663543597e-07
either O 0 3.401957656024024e-06
BRCA1 O 0 0.00016696292732376605
( O 0 1.8142851558877737e-06
179 O 0 5.8599748626875225e-06
women O 0 4.412855560076423e-06
) O 0 1.0371857115387684e-06
or O 0 1.4048638377062161e-06
BRCA2 O 0 0.00021548621589317918
( O 0 3.91404819310992e-06
28 O 0 7.584694685647264e-06
women O 0 1.0225361620541662e-05
) O 0 3.6453457141760737e-06
. O 0 7.591193025291432e-06

The O 0 3.694803308462724e-05
control O 0 3.7236386560834944e-05
women O 0 9.163002687273547e-06
were O 0 1.2366565442789579e-06
enrolled O 0 1.927057610373595e-06
regardless O 0 5.158696581020195e-07
of O 0 5.6445024654294684e-08
whether O 0 4.6852176183165284e-07
or O 0 3.2185405984819226e-07
not O 0 4.314418049489177e-07
they O 0 4.044704269290378e-07
had O 0 3.892264885507757e-06
either O 0 4.67779818791314e-06
mutation O 0 2.2201591491466388e-05
. O 0 1.0586652933852747e-05

Lifetime O 0 0.00044193840585649014
histories O 0 0.00011089506006101146
of O 0 8.124399755615741e-06
oral O 0 9.593229333404452e-05
- O 0 0.020876318216323853
contraceptive O 0 0.0030477233231067657
use O 0 2.46623335442564e-06
were O 0 8.340027761732927e-07
obtained O 0 5.085057637188584e-07
by O 0 4.3162702922927565e-07
interview O 0 5.495952791534364e-06
or O 0 2.480399530213617e-07
by O 0 1.36181313337147e-07
written O 0 4.330048852807522e-07
questionnaire O 0 1.6255753507721238e-06
and O 0 1.453255435990286e-07
were O 0 3.202509333277703e-07
compared O 0 1.4654485767096048e-06
between O 0 5.528179372049635e-07
patients O 0 1.0409174137748778e-05
and O 0 3.1576672654409776e-07
control O 0 1.105858473238186e-06
women O 0 1.9119879652862437e-06
, O 0 1.9683855612129264e-07
after O 0 4.227464671657799e-07
adjustment O 0 1.0036351341113914e-06
for O 0 9.75665770397427e-08
year O 0 2.2255625253819744e-07
of O 0 1.0236090020043775e-07
birth O 0 4.5159822548157535e-06
and O 0 1.858665086729161e-06
parity O 0 2.969357774418313e-05
. O 0 1.41661712405039e-05

RESULTS O 0 0.0005231049144640565
The O 0 1.5389907275675796e-05
adjusted O 0 5.9459314798004925e-05
odds O 0 7.526650733780116e-05
ratio O 0 5.834053808939643e-05
for O 0 0.001327847014181316
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999996423721313
associated O 0 1.0957458471239079e-05
with O 0 4.978160177415702e-07
any O 0 2.737580189204891e-07
past O 0 2.7116536216453824e-07
use O 0 4.130028514737205e-07
of O 0 2.2223852624847495e-07
oral O 0 1.4927116353646852e-05
contraceptives O 0 0.00413794768974185
was O 0 5.749956835643388e-05
0 O 0 2.3050870368024334e-05
. O 0 1.8033564629149623e-05

5 O 0 6.697692151647061e-05
( O 0 6.12252688370063e-06
95 O 0 5.297877123666694e-06
percent O 0 2.831345909726224e-06
confidence O 0 2.6146299205720425e-06
interval O 0 2.105199200741481e-06
, O 0 2.4792191766209726e-07
0 O 0 5.426794587037875e-07
. O 0 9.258214106466767e-08
3 O 0 1.4209722110081202e-07
to O 0 1.3445568924908002e-07
0 O 0 1.3431026673060842e-06
. O 0 4.994809046365845e-07
8 O 0 2.4662874693603953e-06
) O 0 2.1110213310748804e-06
. O 0 4.5682518248213455e-06

The O 0 8.148496999638155e-05
risk O 0 0.00011820199142675847
decreased O 0 2.7226764359511435e-05
with O 0 5.799430482511525e-07
increasing O 0 7.344091272898368e-07
duration O 0 2.0810082332900492e-06
of O 0 1.2987797504138143e-07
use O 0 1.1568247373361373e-06
( O 0 9.454903988626029e-07
P O 0 8.435034033027478e-06
for O 0 2.0121819943597075e-07
trend O 0 2.1303842459019506e-06
, O 0 3.4279295846317837e-07
< O 0 2.532540975153097e-06
0 O 0 5.658148438669741e-07
. O 0 2.2088327966685029e-07
001 O 0 5.925832738284953e-06
) O 0 1.3276027743813756e-07
; O 0 3.520844771287557e-08
use O 0 6.19248936573058e-08
for O 0 3.0777613346799626e-08
six O 0 1.4203517650912545e-07
or O 0 9.603709116845494e-08
more O 0 5.721374307654514e-08
years O 0 3.746976915408595e-07
was O 0 1.4261545402405318e-06
associated O 0 2.6001629294114537e-07
with O 0 5.522052148876355e-08
a O 0 4.389885361888446e-07
60 O 0 1.6697824776201742e-06
percent O 0 6.327957180474186e-06
reduction O 0 4.8451661314175e-06
in O 0 3.7113884445716394e-06
risk O 0 2.1407675376394764e-05
. O 0 1.8975497368955985e-05

Oral O 0 0.0055518546141684055
- O 0 0.008945071138441563
contraceptive O 0 0.008651780895888805
use O 0 2.5336174076073803e-05
protected O 0 7.924890087451786e-05
against O 0 0.08052606135606766
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9998754262924194
both O 0 7.721633323853894e-07
for O 0 3.9492644532401755e-07
carriers O 0 1.7034390111803077e-06
of O 0 2.2414269551518373e-07
the O 0 2.3084819531504763e-06
BRCA1 O 0 0.0013095687609165907
mutation O 0 9.092215805139858e-06
( O 0 6.668797141173854e-07
odds O 0 4.066888777742861e-06
ratio O 0 1.136180003413756e-06
, O 0 1.5570915934404184e-07
0 O 0 4.1280677010036015e-07
. O 0 1.0450469289935427e-07
5 O 0 1.2658497894335596e-07
; O 0 1.1538681121692207e-07
95 O 0 5.300537964103569e-07
percent O 0 7.936871497804532e-07
confidence O 0 9.910082781061647e-07
interval O 0 6.446672387028229e-07
, O 0 1.2900534329673974e-07
0 O 0 1.9901490588836168e-07
. O 0 7.39092840262856e-08
3 O 0 6.404629004919116e-08
to O 0 9.223649755085717e-08
0 O 0 3.4142624372179853e-07
. O 0 9.5029996316498e-08
9 O 0 2.296146135449817e-07
) O 0 5.4505292723661114e-08
and O 0 3.374834989244846e-08
for O 0 3.602676201808208e-08
carriers O 0 3.32294433746938e-07
of O 0 5.3046740333684284e-08
the O 0 9.79956894298084e-07
BRCA2 O 0 0.00033145584166049957
mutation O 0 4.607138180290349e-06
( O 0 6.984907940932317e-07
odds O 0 3.119985422017635e-06
ratio O 0 1.2048891449012444e-06
, O 0 2.944148889127973e-07
0 O 0 3.8130170310068934e-07
. O 0 8.079563684759705e-08
4 O 0 1.3523963104944414e-07
; O 0 1.0410580841835326e-07
95 O 0 3.2286177997775667e-07
percent O 0 6.021855938342924e-07
confidence O 0 6.717333462802344e-07
interval O 0 5.893837169423932e-07
, O 0 7.006791946650992e-08
0 O 0 1.9164136233484896e-07
. O 0 4.6589022417720116e-08
2 O 0 9.729599526053789e-08
to O 0 6.168017563368267e-08
1 O 0 2.167988668588805e-07
. O 0 2.869692536933144e-07
1 O 0 1.0094936442328617e-06
) O 0 1.3255397561806603e-06
. O 0 4.313387307774974e-06

CONCLUSIONS O 0 0.0024545651394873857
Oral O 0 0.0009414217784069479
- O 0 0.019883977249264717
contraceptive O 0 0.037856098264455795
use O 0 1.4695641766593326e-05
may O 0 8.602063644502778e-06
reduce O 0 2.795084810713888e-06
the O 0 7.970793376443908e-07
risk O 0 4.20848891735659e-06
of O 0 1.3121375559421722e-05
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999984502792358
in O 0 3.494421616778709e-05
women O 0 4.5749893615720794e-05
with O 0 3.2780185392766725e-06
pathogenic O 0 3.7581645301543176e-05
mutations O 0 1.031974079523934e-05
in O 0 1.5740090475446777e-06
the O 0 4.57813939647167e-06
BRCA1 O 0 0.0011152989463880658
or O 0 3.2010182621888816e-05
BRCA2 O 0 0.00213936110958457
gene O 0 0.00042213647975586355

A O 0 0.0001710121432552114
Japanese O 0 0.00018959642329718918
family O 0 0.00010385440691607073
with O 0 2.040205981757026e-05
adrenoleukodystrophy B-Disease 1 0.9999829530715942
with O 0 3.818974164460087e-06
a O 0 7.134704446798423e-06
codon O 0 4.675886520999484e-05
291 O 0 2.7489431886351667e-05
deletion O 0 2.0081837647012435e-05
: O 0 1.2478639064283925e-06
a O 0 1.6865018324097036e-06
clinical O 0 4.586731665767729e-05
, O 0 1.8976570572704077e-06
biochemical O 0 6.97214127285406e-05
, O 0 3.4477818644518266e-06
pathological O 0 0.00010698748519644141
, O 0 1.2321031590545317e-06
and O 0 3.1850247523834696e-06
genetic O 0 5.2040573791600764e-05
report O 0 3.4693854104261845e-05
. O 0 1.5566132788080722e-05

We O 0 4.9568869144422933e-05
report O 0 1.4412834389077034e-05
a O 0 3.415236960790935e-06
Japanese O 0 1.626075027161278e-05
family O 0 2.3811613573343493e-05
with O 0 6.798774847993627e-05
adrenoleukodystrophy B-Disease 1 1.0
( O 0 0.18473361432552338
ALD B-Disease 1 0.9999997615814209
) O 0 1.6660685560054844e-06
with O 0 1.193599388216171e-07
a O 0 5.340684765542392e-07
three O 0 4.4080928773837513e-07
base O 0 1.3886104852645076e-06
pair O 0 6.069171377021121e-06
deletion O 0 2.478763781255111e-05
( O 0 2.4072501219052356e-06
delGAG O 0 3.3548130886629224e-05
291 O 0 1.3843799933965784e-05
) O 0 9.670862937127822e-07
in O 0 1.205158014272456e-06
the O 0 1.6467602108605206e-05
ALD B-Disease 1 0.9999943971633911
gene O 0 9.1896130470559e-05
. O 0 2.4560991732869297e-05

A O 0 0.00010618445958243683
variety O 0 1.7971038687392138e-05
of O 0 1.736138415253663e-06
phenotypes O 0 7.793024269631132e-05
were O 0 4.598174655257026e-06
observed O 0 3.412420710446895e-06
within O 0 8.727263320906786e-07
this O 0 9.89945533547143e-07
family O 0 1.1207284842384979e-05
. O 0 1.4901273061695974e-05

While O 0 5.0596543587744236e-05
the O 0 1.0716532415244728e-05
proband O 0 0.0005139393615536392
( O 0 8.062189408519771e-06
patient O 0 1.6422889530076645e-05
1 O 0 1.6607795032541617e-06
) O 0 5.368150368667557e-07
was O 0 2.3581917503179284e-06
classified O 0 1.2429348998921341e-06
as O 0 2.4622261207696283e-07
having O 0 6.14922328168177e-07
a O 0 8.989040338747145e-07
rare O 0 3.0407261419895804e-06
intermediate O 0 3.2154464406630723e-06
type O 0 3.085725438722875e-06
of O 0 2.9759090125480725e-07
adult O 0 1.5947080100886524e-05
cerebral O 0 0.007988841272890568
and O 0 1.7742459021974355e-05
cerebello O 1 0.8865684866905212
- O 1 0.8977354764938354
brain O 0 0.0005648664082400501
stem O 0 3.5833652418659767e-06
forms O 0 3.76831707171732e-07
, O 0 1.69654398973762e-07
his O 0 5.224206347520521e-07
younger O 0 1.3919032426201738e-05
brother O 0 1.7247355572180822e-05
( O 0 1.6299250091833528e-06
patient O 0 5.413972303358605e-06
2 O 0 6.033122872395325e-07
) O 0 2.7718792239284085e-07
and O 0 5.348803711058281e-07
nephew O 0 0.0001595894427737221
( O 0 4.361128048913088e-06
patient O 0 2.8312373615335673e-05
3 O 0 2.560647317295661e-06
) O 0 1.632264570616826e-06
had O 0 7.064184046612354e-06
a O 0 2.703372410906013e-05
childhood O 0 0.2631871998310089
ALD B-Disease 1 0.9999991655349731
type O 0 0.0016973641468212008
. O 0 8.378060738323256e-05

Another O 0 0.0001211823255289346
nephew O 0 0.0018022037111222744
( O 0 3.0344974220497534e-05
patient O 0 4.20239994127769e-05
4 O 0 1.5228924894472584e-06
) O 0 2.889961194796342e-07
of O 0 1.5843689027406072e-07
patient O 0 2.0372934159240685e-05
1 O 0 2.0642371509893565e-06
was O 0 2.8551925424835645e-05
classified O 0 2.09027075470658e-06
as O 0 3.5177143331566185e-07
having O 0 1.0333510545024183e-06
an O 0 1.2763283621097798e-06
adolescent O 0 7.57378147682175e-05
form O 0 1.1283996173006017e-05
. O 0 1.6097770640044473e-05

The O 0 3.140718399663456e-05
tau O 0 4.8266865633195266e-05
level O 0 2.9470661502273288e-06
in O 0 1.0194311244049459e-06
the O 0 1.8271987300977344e-06
cerebrospinal O 0 0.00042827025754377246
fluid O 0 0.00017580458370503038
( O 0 1.0828778613358736e-05
CSF O 1 0.5995593667030334
) O 0 5.811992878079764e-07
in O 0 5.921686465626408e-07
patient O 0 6.032436431269161e-06
1 O 0 4.487666842578619e-07
was O 0 8.550125016881793e-07
as O 0 1.3508957863450632e-07
high O 0 2.2395657595097873e-07
as O 0 7.578605476510347e-08
that O 0 1.0048430709730383e-07
of O 0 3.197662863385631e-07
patients O 0 0.0002960011188406497
with O 0 0.0003830793430097401
Alzheimers B-Disease 1 1.0
disease I-Disease 1 0.9957872033119202
( O 0 3.1716659577796236e-05
AD B-Disease 0 0.0014509630855172873
) O 0 1.5487314158235677e-05
. O 0 1.3042952559771948e-05

His O 0 0.0008739645127207041
brain O 0 0.001955196028575301
magnetic O 0 8.547559264115989e-05
resonance O 0 0.00012922886526212096
image O 0 5.776826219516806e-05
( O 0 8.560171409044415e-06
MRI O 1 0.65531986951828
) O 0 4.389782134239795e-06
showed O 0 0.0004166026774328202
abnormalities B-Disease 0 0.016235291957855225
in I-Disease 0 6.078533374420658e-07
the I-Disease 0 6.956057063689514e-07
bilateral I-Disease 0 9.185232556774281e-06
cerebellar I-Disease 0 0.0006650342838838696
hemispheres I-Disease 0 0.0003096106229349971
and O 0 2.6309624445275404e-05
brain O 0 0.0007793668191879988
stem O 0 5.9384315136412624e-06
, O 0 3.952557392494782e-07
but O 0 2.3590234832226997e-07
not O 0 1.2739457133648102e-07
in O 0 2.5397483227607154e-07
the O 0 2.5099491267610574e-06
cerebral O 1 0.7437213063240051
white O 0 5.775229510618374e-05
matter O 0 1.7959908973352867e-06
, O 0 2.4790350039438636e-07
where O 0 1.5148894760841358e-07
marked O 0 6.970201980038837e-07
reductions O 0 1.6053902527346509e-06
of O 0 1.199794184003622e-07
the O 0 1.1994410442639492e-06
cerebral O 0 0.02605488896369934
blood O 0 5.850225079484517e-06
flow O 0 1.2808827705157455e-06
and O 0 9.098245072891586e-07
oxygen O 0 3.363256837474182e-05
metabolism O 0 1.1906965482921805e-05
were O 0 8.967804774329124e-07
clearly O 0 2.198330548708327e-06
demonstrated O 0 3.5492626011546236e-06
by O 0 1.9982749108748976e-06
positron O 0 0.0003050515369977802
emission O 0 0.00011057152005378157
tomography O 0 0.0007549385773018003
( O 0 2.4934155590017326e-05
PET O 0 0.0002542104630265385
) O 0 1.844466896727681e-05
. O 0 2.555520404712297e-05

In O 0 0.00021186715457588434
patients O 0 0.00043111559352837503
2 O 0 3.2293742151523475e-06
and O 0 6.988852305767068e-07
3 O 0 7.046085670481261e-07
, O 0 2.9833248049726535e-07
the O 0 1.173671421383915e-06
autopsy O 0 0.1860206574201584
findings O 0 9.572897397447377e-05
showed O 0 3.238913632230833e-05
massive O 0 3.2285395718645304e-05
demyelination B-Disease 1 0.9746710658073425
of I-Disease 0 7.875196388340555e-07
the I-Disease 0 2.3100272301235236e-05
cerebral I-Disease 1 0.9940074682235718
white I-Disease 0 7.750225631752983e-05
matter I-Disease 0 1.1387921858840855e-06
with O 0 2.1965544760860212e-07
sparing O 0 3.144021093248739e-06
of O 0 2.4983020807667344e-07
the O 0 1.3617446938951616e-06
U O 0 0.0013176528736948967
- O 0 0.0004827321390621364
fibers O 0 2.7654454243020155e-05
, O 0 3.3042843483599427e-07
compatible O 0 1.5913725519567379e-06
with O 0 3.108383168637374e-07
the O 0 1.066274080585572e-06
findings O 0 1.0557272617006674e-05
of O 0 2.140399601557874e-06
childhood O 0 0.007548712659627199
ALD B-Disease 1 0.9999973773956299
. O 0 0.00022868822270538658

Oleic O 0 0.0061414120718836784
and O 0 8.084172441158444e-05
erucic O 0 0.003806348657235503
acids O 0 3.006155566254165e-05
( O 0 3.950965947296936e-06
Lorenzos O 0 1.6657360902172513e-05
Oil O 0 3.323944156363723e-06
) O 0 3.4562717132757825e-07
were O 0 3.1481235396313423e-07
administered O 0 7.014185712250764e-07
to O 0 4.195318581423635e-07
patients O 0 5.400121608545305e-06
1 O 0 1.6856594697856053e-07
and O 0 1.1843931702060218e-07
4 O 0 3.4406042459522723e-07
, O 0 1.1328999960369401e-07
but O 0 1.6387141954510298e-07
sufficient O 0 6.38070616787445e-07
effectiveness O 0 6.716501957271248e-06
was O 0 4.583044756145682e-06
not O 0 1.3644538512380677e-06
obtained O 0 8.336477549164556e-06
. O 0 1.2174503353890032e-05

The O 0 3.309645035187714e-05
findings O 0 5.701943882741034e-05
in O 0 2.1711639419663697e-06
this O 0 8.14924703718134e-07
family O 0 2.2360836737789214e-06
suggest O 0 2.2693764094583457e-06
that O 0 2.960589142730896e-07
delGAG291 O 0 5.634344688587589e-06
is O 0 1.0622007096117159e-07
part O 0 1.2838700058637187e-07
of O 0 9.236360654085729e-08
the O 0 4.1985126131294237e-07
cause O 0 2.3182246877695434e-06
of O 0 7.72180214880791e-07
Japanese O 0 0.0022493505384773016
ALD B-Disease 1 0.9999924898147583
with O 0 1.0871058293560054e-05
phenotypic O 0 0.00018362463742960244
variations O 0 9.223728557117283e-05
. O 0 3.2588075555395335e-05

Moreover O 0 0.0001940898655448109
, O 0 4.617597824108088e-06
although O 0 9.644751344239921e-07
the O 0 1.5921726514989132e-07
scale O 0 4.2687392465268204e-07
of O 0 5.128890379069162e-08
the O 0 1.958446489425114e-07
study O 0 2.767436626527342e-07
is O 0 6.434995469817295e-08
limited O 0 3.26513401205375e-07
, O 0 1.1394304522127641e-07
there O 0 6.57419221283817e-08
is O 0 3.230342215942983e-08
a O 0 1.334477701675496e-07
possibility O 0 4.5627129452441295e-07
that O 0 3.6712816608996945e-07
PET O 0 1.7994500012719072e-05
can O 0 6.74514183174324e-07
detect O 0 8.084224646154325e-06
an O 0 1.4442653082369361e-06
insidious B-Disease 0 0.0022690691985189915
lesion I-Disease 0 0.1379602551460266
which O 0 6.596159209948382e-07
is O 0 2.6801845365298504e-07
undetectable O 0 3.2752093375165714e-06
by O 0 4.739704024814273e-07
computed O 0 6.554385890922276e-06
tomogram O 0 5.699089160771109e-05
( O 0 2.3878014872025233e-06
CT O 0 0.13800948858261108
) O 0 4.3361976054256957e-07
or O 0 2.7243962108514097e-07
MRI O 0 0.0006772552151232958
analysis O 0 6.011550794937648e-07
, O 0 7.782485056395672e-08
and O 0 3.747591037495113e-08
that O 0 2.709207436168981e-08
the O 0 3.927089764488301e-08
higher O 0 1.1618217143904985e-07
level O 0 9.79418999236259e-08
of O 0 5.5885085004092616e-08
tau O 0 1.0320185310774832e-06
reflects O 0 1.0133545629287255e-06
the O 0 3.6164115613246395e-07
process O 0 9.904640592139913e-07
of O 0 9.797157645152765e-07
neuronal B-Disease 0 0.0009144254727289081
degeneration I-Disease 1 0.8829125761985779
in O 0 0.0006661068764515221
ALD B-Disease 1 0.9999982118606567
. O 0 0.00011831284064101055

Lorenzos O 0 0.00223504938185215
Oil O 0 5.3320156439440325e-05
should O 0 2.981794068546151e-06
be O 0 2.676649444310897e-07
given O 0 1.5351193383139616e-07
in O 0 2.2516893238844204e-07
the O 0 2.505134943930898e-07
early O 0 3.6302756143413717e-06
stage O 0 1.610551043995656e-05
. O 0 2.052772515526158e-06
. O 0 6.545672931679292e-06

Nonsense O 0 0.002662122715264559
mutation O 0 0.00017655464762356132
in O 0 9.262518688046839e-06
exon O 0 5.095932647236623e-05
4 O 0 3.3394210277037928e-06
of O 0 6.067870685910748e-07
human O 0 1.5988432551239384e-06
complement O 0 5.1812617130053695e-06
C9 O 0 0.0008805092074908316
gene O 0 8.196901035262272e-06
is O 0 2.9009677859903604e-07
the O 0 2.3524812320374622e-07
major O 0 1.0740428706412786e-06
cause O 0 1.867296191448986e-06
of O 0 4.135112590120116e-07
Japanese O 0 3.816391108557582e-05
complement B-Disease 0 0.0004131776513531804
C9 I-Disease 1 0.9998526573181152
deficiency I-Disease 1 0.9816068410873413
. O 0 8.300874469568953e-05

Deficiency B-Disease 1 0.9829517006874084
of I-Disease 0 5.15892133989837e-06
the I-Disease 0 2.2436026938521536e-06
ninth I-Disease 0 7.388415269815596e-06
component I-Disease 0 1.927099674503552e-06
of I-Disease 0 2.3720177466657333e-07
human I-Disease 0 7.184166292972805e-07
complement I-Disease 0 3.0316750780912116e-06
( O 0 1.936203716468299e-06
C9 O 0 0.00030475910170935094
) O 0 3.742252374649979e-07
is O 0 5.363642685551895e-08
the O 0 8.53938715295044e-08
most O 0 3.542961906077835e-07
common O 0 1.2953342775290366e-05
complement B-Disease 1 0.9995430707931519
deficiency I-Disease 1 0.9999971389770508
in O 0 2.415515155007597e-06
Japan O 0 8.043635716603603e-06
but O 0 1.3611280564873596e-06
is O 0 1.7197423574089044e-07
rare O 0 5.833182967762696e-07
in O 0 4.2858144411184185e-07
other O 0 3.7048710055387346e-07
countries O 0 1.5337218428612687e-06
. O 0 7.902364814071916e-06

We O 0 2.657809636730235e-05
studied O 0 2.0176474208710715e-05
the O 0 1.4158769090499845e-06
molecular O 0 2.695541070352192e-06
basis O 0 8.648501648167439e-07
of O 0 1.8003089508056291e-06
C9 B-Disease 1 0.9999675750732422
deficiency I-Disease 1 0.9059327840805054
in O 0 1.5099465144885471e-06
four O 0 1.4875553233650862e-06
Japanese O 0 3.198400736437179e-05
C9 B-Disease 1 0.9943011999130249
- I-Disease 1 0.9998399019241333
deficient I-Disease 1 0.999913215637207
patients O 0 0.14061778783798218
who O 0 2.9482436730177142e-05
had O 0 0.009665874764323235
suffered O 1 0.9999704360961914
from O 0 0.05320991575717926
meningococcal B-Disease 1 0.9999996423721313
meningitis I-Disease 1 0.9999985694885254
. O 0 0.0004556671774480492

Direct O 0 8.669179806020111e-05
sequencing O 0 0.00013130622392054647
of O 0 5.032605258747935e-06
amplified O 0 0.00013801580644212663
C9 O 0 0.00039154652040451765
cDNA O 0 4.2695890442701057e-05
and O 0 3.833387381746434e-06
DNA O 0 1.2605767551576719e-05
revealed O 0 6.1750374698021915e-06
a O 0 1.470439315198746e-06
nonsense O 0 8.896609870134853e-06
substitution O 0 5.4051192819315474e-06
( O 0 2.9792981877108105e-06
CGA O 0 0.00010010332334786654
- O 0 0.000129038977320306
- O 0 0.00020072532061021775
> O 0 2.8771608413080685e-05
TGA O 0 0.00011310660192975774
) O 0 1.052109382726485e-06
at O 0 5.256184749669046e-07
codon O 0 2.7876121748704463e-06
95 O 0 6.69745929826604e-07
in O 0 2.39396854340157e-07
exon O 0 3.852635927614756e-06
4 O 0 5.908779598939873e-07
in O 0 3.5712062640413933e-07
the O 0 4.1009417373061297e-07
four O 0 3.433220399529091e-06
C9 B-Disease 1 0.943386435508728
- I-Disease 1 0.971348226070404
deficient I-Disease 0 0.15123538672924042
individuals O 0 5.7989218475995585e-06
. O 0 1.4028947589395102e-05

An O 0 0.00012501142919063568
allele O 0 0.00041564233833923936
- O 0 7.854882278479636e-05
specific O 0 8.895482096704654e-06
polymerase O 0 5.265693835099228e-05
chain O 0 1.5173551219049841e-05
reaction O 0 8.188001629605424e-06
system O 0 2.0512889022938907e-06
designed O 0 3.3346727832395118e-06
to O 0 4.636788730749686e-07
detect O 0 2.443563971610274e-06
exclusively O 0 3.6033364381182764e-07
only O 0 5.151203907871604e-08
one O 0 2.5438612993866627e-08
of O 0 1.552219153211354e-08
the O 0 9.486102925393425e-08
normal O 0 7.10057634023542e-07
and O 0 4.847685772801924e-07
mutant O 0 8.777311450103298e-06
alleles O 0 2.0417840005393373e-06
indicated O 0 1.1502023653520155e-06
that O 0 5.318959850342253e-08
all O 0 2.139108445931015e-08
the O 0 1.1383129105979606e-07
four O 0 5.432770535662712e-07
patients O 0 7.835410542611498e-06
were O 0 7.054758839331043e-07
homozygous O 0 2.3231134491652483e-06
for O 0 8.849546162537081e-08
the O 0 2.1606942368634918e-07
mutation O 0 6.594750061594823e-07
in O 0 2.1994431165239803e-07
exon O 0 3.2906723390624393e-06
4 O 0 4.2895069896076166e-07
and O 0 1.3199888826420647e-07
that O 0 8.554172836738871e-08
the O 0 9.85529808872343e-08
parents O 0 6.699036703139427e-07
of O 0 2.551332727307454e-07
patient O 0 3.038435897906311e-05
2 O 0 3.523197392496513e-06
were O 0 8.910925316740759e-06
heterozygous O 0 7.211494812509045e-05
. O 0 1.8971080862684175e-05

The O 0 4.394097049953416e-05
common O 0 2.3240476366481744e-05
mutation O 0 1.2092476026737131e-05
at O 0 1.6756418972363463e-06
codon O 0 7.827561603335198e-06
95 O 0 1.3167341421649326e-06
in O 0 5.598562893283088e-07
exon O 0 8.139684723573737e-06
4 O 0 1.1812725233539823e-06
might O 0 6.70490408083424e-07
be O 0 1.246566938561955e-07
responsible O 0 2.655401658557821e-07
for O 0 2.455325045502832e-07
most O 0 1.346652766187617e-06
Japanese O 0 0.0003316043585073203
C9 B-Disease 1 0.999958872795105
deficiency I-Disease 1 0.9386255145072937
. O 0 1.0346417184337042e-05
. O 0 1.2101208085368853e-05

BRCA1 O 0 0.003058876609429717
required O 0 3.5358407330932096e-05
for O 0 5.276427600620082e-06
transcription O 0 4.9196274630958214e-05
- O 0 0.0001809178211260587
coupled O 0 0.00013232407218310982
repair O 0 0.0009256599587388337
of O 0 3.493503982099355e-06
oxidative O 0 0.0004794692504219711
DNA O 0 0.00028013510745950043
damage O 0 0.00025333045050501823
. O 0 3.949709207518026e-05

The O 0 0.00047824959619902074
breast B-Disease 1 0.9995474219322205
and I-Disease 1 0.962832510471344
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999996423721313
susceptibility O 0 0.018034059554338455
gene O 0 0.00010899623157456517
BRCA1 O 0 0.0003546553780324757
encodes O 0 1.417858038621489e-05
a O 0 5.225529548624763e-06
zinc O 0 0.0001774753473000601
finger O 0 3.408298289286904e-05
protein O 0 2.200287553932867e-06
of O 0 3.8908038391127775e-07
unknown O 0 6.116755230323179e-06
function O 0 5.321955086401431e-06
. O 0 1.4003231626702473e-05

Association O 0 6.310932076303288e-05
of O 0 2.0082684386579785e-06
the O 0 3.816523985733511e-06
BRCA1 O 0 7.073843880789354e-05
protein O 0 2.0344098174973624e-06
with O 0 1.4828528094312787e-07
the O 0 5.094094603919075e-07
DNA O 0 1.1688097401929554e-05
repair O 0 0.0003721960529219359
protein O 0 6.8271915552031714e-06
Rad51 O 0 9.588419197825715e-05
and O 0 7.7741157156197e-07
changes O 0 5.55612302832742e-07
in O 0 1.881357007960105e-07
the O 0 1.4413122073619888e-07
phosphorylation O 0 8.579979748901678e-07
and O 0 2.204991744747531e-07
cellular O 0 3.008260364367743e-06
localization O 0 1.253932282452297e-06
of O 0 5.974782624207364e-08
the O 0 2.077059662042302e-07
protein O 0 5.706888828171941e-07
after O 0 4.603228660471359e-07
exposure O 0 1.360797114102752e-06
to O 0 2.8737295565406384e-07
DNA O 0 4.720973720395705e-06
- O 0 1.3819818377669435e-05
damaging O 0 4.811296548723476e-06
agents O 0 4.760960337080178e-07
are O 0 5.201606256832747e-08
consistent O 0 3.461608741872624e-07
with O 0 6.574592958941139e-08
a O 0 4.2478896489228646e-07
role O 0 9.682148629508447e-07
for O 0 1.3189221590437228e-06
BRCA1 O 0 0.0001218043253174983
in O 0 9.041623343364336e-06
DNA O 0 0.00015767617151141167
repair O 0 0.007095715496689081
. O 0 3.716585706570186e-05

Here O 0 4.397211523610167e-05
, O 0 3.028692844964098e-06
it O 0 5.404755825111351e-07
is O 0 1.3682532085113053e-07
shown O 0 5.715156703445246e-07
that O 0 3.2104722436088196e-07
mouse O 0 1.6851539839990437e-05
embryonic O 0 5.860684905201197e-05
stem O 0 6.526087963720784e-05
cells O 0 5.966964454273693e-05
deficient B-Disease 0 0.0009770935866981745
in I-Disease 0 5.1559800340328366e-06
BRCA1 I-Disease 0 0.00019388453802093863
are O 0 4.602526644248428e-07
defective O 0 3.4477525332476944e-05
in O 0 4.628809620044194e-07
the O 0 1.9413941743096075e-07
ability O 0 6.874689120195399e-07
to O 0 1.1410018174728975e-07
carry O 0 2.7863660534421797e-07
out O 0 3.364773704106483e-07
transcription O 0 5.241481176199159e-06
- O 0 1.6196785509237088e-05
coupled O 0 1.580664684297517e-05
repair O 0 0.00013091664004605263
of O 0 9.669784049037844e-07
oxidative O 0 7.891851419117302e-05
DNA O 0 4.5613367547048256e-05
damage O 0 2.2214426280697808e-05
, O 0 5.368606252886821e-07
and O 0 5.118975536788639e-07
are O 0 3.153655541154876e-07
hypersensitive O 0 4.929874558001757e-05
to O 0 2.460918949509505e-06
ionizing O 0 3.511077011353336e-05
radiation O 0 4.812443512491882e-05
and O 0 3.0363739824679215e-06
hydrogen O 0 1.8941434973385185e-05
peroxide O 0 0.0012927650241181254
. O 0 3.5420340282144025e-05

These O 0 5.953636718913913e-05
results O 0 6.0874896007589996e-05
suggest O 0 8.440030796919018e-06
that O 0 1.735016212478513e-06
BRCA1 O 0 5.3619824029738083e-05
participates O 0 3.45929265677114e-06
, O 0 3.88149373975466e-07
directly O 0 2.4975588530651294e-07
or O 0 3.2027779184318206e-07
indirectly O 0 9.708519428386353e-07
, O 0 1.4360189481976704e-07
in O 0 4.871930059380247e-07
transcription O 0 9.863591003522743e-06
- O 0 6.699889490846545e-05
coupled O 0 2.6155974410357885e-05
repair O 0 0.00012329014134593308
of O 0 1.0049780030385591e-06
oxidative O 0 0.00016360613517463207
DNA O 0 0.00013000999751966447
damage O 0 8.056529622990638e-05
. O 0 6.006873718433781e-06
. O 0 1.8709733922150917e-05

Truncation O 0 0.006562582217156887
mutations O 0 0.000506654498167336
in O 0 2.285692244186066e-05
the O 0 8.291774065583013e-06
transactivation O 0 0.00013315363321453333
region O 0 6.093623142078286e-06
of O 0 1.2920581866637804e-06
PAX6 O 0 0.0021177560556679964
result O 0 8.856468411977403e-06
in O 0 4.346235527918907e-06
dominant O 0 8.396369230467826e-05
- O 0 0.0003366997989360243
negative O 0 3.585120794014074e-05
mutants O 0 0.00020119515829719603
. O 0 2.5004497729241848e-05

PAX6 O 0 0.018329329788684845
is O 0 1.1044271559512708e-05
a O 0 3.7571819575532572e-06
transcription O 0 6.4939849835354835e-06
factor O 0 8.463110816592234e-07
with O 0 1.7104601113260287e-07
two O 0 3.203981577826198e-07
DNA O 0 5.408904598880326e-06
- O 0 2.1474786990438588e-05
binding O 0 2.011582637351239e-06
domains O 0 1.820411966946267e-06
( O 0 5.544287660086411e-07
paired O 0 2.5026420189533383e-06
box O 0 2.6344810066802893e-06
and O 0 1.926616505443235e-06
homeobox O 0 8.63814348122105e-05
) O 0 5.386175416788319e-07
and O 0 3.3421790135435003e-07
a O 0 1.435759145351767e-06
proline O 0 2.902201777033042e-05
- O 0 2.626202149258461e-05
serine O 0 4.719655044027604e-05
- O 0 6.9062938564457e-05
threonine O 0 0.0001366802171105519
( O 0 7.2668385655561e-06
PST O 0 0.00046358685358427465
) O 0 3.4105337363143917e-06
- O 0 2.0773200958501548e-05
rich O 0 9.971941835829057e-06
transactivation O 0 0.00015110055392142385
domain O 0 2.5805515178944916e-05
. O 0 1.6491743735969067e-05

PAX6 O 0 0.48898041248321533
regulates O 0 0.004243708215653896
eye O 0 0.005118195433169603
development O 0 2.6495117708691396e-05
in O 0 1.1666981663438492e-05
animals O 0 4.438334599399241e-06
ranging O 0 5.441758730739821e-06
from O 0 2.7336457151250215e-06
jellyfish O 0 1.584798883413896e-05
to O 0 1.3006516610403196e-06
Drosophila O 0 1.1083607205364387e-05
to O 0 2.5236711280740565e-06
humans O 0 9.269314432458486e-06
. O 0 1.0086467227665707e-05

Heterozygous O 0 0.0026746857911348343
mutations O 0 0.00021034787641838193
in O 0 5.98188034928171e-06
the O 0 2.288447376486147e-06
human O 0 3.353811962369946e-06
PAX6 O 0 0.001133787096478045
gene O 0 1.1868939509440679e-05
result O 0 1.6650440102239372e-06
in O 0 5.148896207174403e-07
various O 0 7.211114620986336e-07
phenotypes O 0 2.4020528144319542e-05
, O 0 1.2795665043086046e-06
including O 0 4.60441469840589e-06
aniridia B-Disease 1 0.9999914169311523
, O 0 0.00013996507914271206
Peters B-Disease 1 0.9999854564666748
anomaly I-Disease 1 0.999920129776001
, O 0 7.116950291674584e-05
autosomal B-Disease 0 0.02758944034576416
dominant I-Disease 0 0.005306705366820097
keratitis I-Disease 1 0.9248883724212646
, O 0 1.3464496078086086e-05
and O 0 4.287173942429945e-05
familial B-Disease 0 0.14501085877418518
foveal I-Disease 1 0.9999490976333618
dysplasia I-Disease 1 0.9999972581863403
. O 0 0.00019392892136238515

It O 0 2.4984950869111344e-05
is O 0 2.1544094579439843e-06
believed O 0 3.4510978821344906e-06
that O 0 3.717605068231933e-07
the O 0 7.993234589775966e-07
mutated O 0 2.1109321096446365e-05
allele O 0 1.0306445801688824e-05
of O 0 6.038136461938848e-07
PAX6 O 0 0.0005085759912617505
produces O 0 4.3392155930632725e-06
an O 0 9.997976349040982e-07
inactive O 0 9.194312951876782e-06
protein O 0 2.4813391519273864e-06
and O 0 1.2890255902675563e-06
aniridia B-Disease 1 0.9884422421455383
is O 0 1.91442018149246e-06
caused O 0 1.0113792086485773e-05
due O 0 4.948938567395089e-06
to O 0 3.3759120015020017e-06
genetic O 0 4.4326654460746795e-05
haploinsufficiency O 0 0.0012760271783918142
. O 0 4.51274863735307e-05

However O 0 5.966384560451843e-05
, O 0 4.877601440966828e-06
several O 0 1.0659274494173587e-06
truncation O 0 3.795513839577325e-05
mutations O 0 7.914198249636684e-06
have O 0 3.523607006172824e-07
been O 0 5.439919164018647e-07
found O 0 2.5152371563308407e-07
to O 0 1.1584351256033187e-07
occur O 0 1.811294509934669e-07
in O 0 7.032337379087039e-08
the O 0 2.398916478796309e-07
C O 0 3.966649092035368e-05
- O 0 2.7947919079451822e-05
terminal O 0 5.8296068345953245e-06
half O 0 7.747960353299277e-07
of O 0 4.4515763875097036e-07
PAX6 O 0 0.0008976933895610273
in O 0 1.969876029761508e-05
patients O 0 0.00021912946249358356
with O 0 1.5358176597146667e-06
Aniridia B-Disease 1 0.9995549321174622
resulting O 0 5.107031938678119e-06
in O 0 1.0587353926894139e-06
mutant O 0 5.97861799178645e-06
proteins O 0 2.8562402576426393e-07
that O 0 8.775354132239954e-08
retain O 0 7.337887950598088e-07
the O 0 3.3177229852299206e-07
DNA O 0 2.51369783654809e-06
- O 0 4.664198058890179e-06
binding O 0 9.138899486060836e-07
domains O 0 5.990164027025457e-07
but O 0 1.6355026843939413e-07
have O 0 1.2036093721690122e-07
lost O 0 6.782153718631889e-07
most O 0 1.0009771500563147e-07
of O 0 1.1508834063533868e-07
the O 0 1.4211527741281316e-06
transactivation O 0 0.00016778403369244188
domain O 0 3.099535024375655e-05
. O 0 1.7665470295469277e-05

It O 0 3.172552169417031e-05
is O 0 1.8829414329957217e-06
not O 0 6.713016773574054e-07
clear O 0 9.724124083732022e-07
whether O 0 5.499053941093734e-07
such O 0 4.1821439822342654e-07
mutants O 0 0.00015341983817052096
really O 0 7.932731932669412e-06
behave O 0 5.437800609797705e-06
as O 0 4.004774609711603e-07
loss O 0 3.3157757570734248e-06
- O 0 3.252396936659352e-06
of O 0 2.34801646570304e-07
- O 0 1.9220475223846734e-05
function O 0 1.2117351388951647e-06
mutants O 0 2.234443491033744e-05
as O 0 1.2235669828442042e-06
predicted O 0 6.816118457209086e-06
by O 0 2.8889796794828726e-06
haploinsufficiency O 0 0.0002927201858256012
. O 0 3.136300801998004e-05

Contrary O 0 0.00018650740094017237
to O 0 4.316564172768267e-06
this O 0 8.159838671417674e-07
theory O 0 7.845810614526272e-07
, O 0 1.4306769458016788e-07
our O 0 1.8413103930470243e-07
data O 0 4.306316156998946e-07
showed O 0 8.18221963072574e-07
that O 0 5.330771557510161e-08
these O 0 1.0738814637534233e-07
mutants O 0 5.749741376348538e-06
are O 0 1.2261293136361928e-07
dominant O 0 4.140509190619923e-06
- O 0 8.443846127192955e-06
negative O 0 1.6361966572731035e-06
in O 0 9.100414217755315e-07
transient O 0 1.1413251741032582e-05
transfection O 0 3.7597346818074584e-05
assays O 0 1.1295968761260156e-05
when O 0 7.644537163287168e-07
they O 0 1.6537495639568078e-07
are O 0 1.305895125369716e-07
coexpressed O 0 8.866018106346019e-06
with O 0 5.441585244625458e-07
wild O 0 8.87623718881514e-06
- O 0 0.0005876292707398534
type O 0 0.00010093396849697456
PAX6 O 0 0.0039668213576078415
. O 0 4.564269329421222e-05

We O 0 2.6923402401735075e-05
found O 0 4.550264748104382e-06
that O 0 4.357293619250413e-07
the O 0 3.4595558418004657e-07
dominant O 0 1.2698698810709175e-05
- O 0 4.424105281941593e-05
negative O 0 3.2430432383989682e-06
effects O 0 2.07088987735915e-06
result O 0 4.608301935604686e-07
from O 0 2.7477418029775436e-07
the O 0 2.2734002413926646e-07
enhanced O 0 3.423993121032254e-06
DNA O 0 2.642787649165257e-06
binding O 0 1.56714895638288e-06
ability O 0 1.0476528586877976e-06
of O 0 2.840851038854453e-07
these O 0 1.605531110726588e-06
mutants O 0 0.00012933314428664744
. O 0 2.5772385924938135e-05

Kinetic O 0 0.000168972896062769
studies O 0 1.8816306692315266e-05
of O 0 6.570392656612967e-07
binding O 0 4.370367150841048e-06
and O 0 1.0513753068153164e-06
dissociation O 0 1.2937651263200678e-05
revealed O 0 6.484998721134616e-06
that O 0 2.5514569301776646e-07
various O 0 4.162147035913222e-07
truncation O 0 1.9670957044581883e-05
mutants O 0 2.0512481569312513e-05
have O 0 4.7416256165888626e-07
3 O 0 6.220581099114497e-07
- O 0 5.112265625939472e-06
5 O 0 8.040161105782317e-07
- O 0 3.6594701668946072e-06
fold O 0 1.6777604514572886e-06
higher O 0 2.8158279974377365e-07
affinity O 0 4.48654560614159e-07
to O 0 1.0699049823870155e-07
various O 0 1.353659655478623e-07
DNA O 0 1.8846517377824057e-06
- O 0 3.028224909940036e-06
binding O 0 6.113601784818457e-07
sites O 0 2.693161889055773e-07
when O 0 1.9177061005848373e-07
compared O 0 5.218689125285891e-07
with O 0 1.3715440161377046e-07
the O 0 5.671633402926091e-07
wild O 0 7.241186722239945e-06
- O 0 0.0005377662018872797
type O 0 9.532986587146297e-05
PAX6 O 0 0.003936284221708775
. O 0 4.341722160461359e-05

These O 0 3.487460344331339e-05
results O 0 3.4013301046798006e-05
provide O 0 3.0050400710024405e-06
a O 0 1.5486665461139637e-06
new O 0 3.458174660408986e-06
insight O 0 1.085248550225515e-05
into O 0 4.0486366970071686e-07
the O 0 4.112499141228909e-07
role O 0 1.5199586869130144e-06
of O 0 4.645503963729425e-07
mutant O 0 3.14345998049248e-05
PAX6 O 0 0.0008006083662621677
in O 0 9.63241109275259e-06
causing O 0 3.725578062585555e-05
aniridia B-Disease 1 0.9910763502120972
. O 0 1.429366511729313e-05
. O 0 2.1885782189201564e-05

Reversal O 0 0.0040910313837230206
of O 0 0.00014217756688594818
severe O 1 0.999994158744812
hypertrophic B-Disease 1 0.9999992847442627
cardiomyopathy I-Disease 1 0.9999998807907104
and O 0 8.601688023190945e-05
excellent O 0 0.00018559524323791265
neuropsychologic O 0 0.01477980986237526
outcome O 0 3.8722242607036605e-05
in O 0 4.692538368544774e-06
very B-Disease 0 9.180504093819764e-06
- I-Disease 0 0.00012167837849119678
long I-Disease 0 1.0016261512646452e-05
- I-Disease 0 0.00012711041199509054
chain I-Disease 0 2.533711631258484e-05
acyl I-Disease 0 0.00010898958134930581
- I-Disease 0 0.00023014788166619837
coenzyme I-Disease 0 0.0002908632450271398
A I-Disease 0 0.00028221672982908785
dehydrogenase I-Disease 1 0.9147247672080994
deficiency I-Disease 0 0.30519500374794006
. O 0 5.253305789665319e-05

Very B-Disease 0 0.00023721242905594409
- I-Disease 0 0.0008967376779764891
long I-Disease 0 6.37394841760397e-05
- I-Disease 0 0.00025441605248488486
chain I-Disease 0 5.0013775762636214e-05
acyl I-Disease 0 0.00020962908456567675
- I-Disease 0 0.00018360679678153247
coenzyme I-Disease 0 5.425075505627319e-05
A I-Disease 0 1.1510074727993924e-05
dehydrogenase I-Disease 0 0.0002711236011236906
( I-Disease 0 1.1304828149150126e-05
VLCAD I-Disease 0 0.14578916132450104
) I-Disease 0 5.773643351858482e-05
deficiency I-Disease 0 0.00886289868503809
is O 0 3.5593055258686945e-07
a O 0 5.99474105911213e-06
disorder O 0 0.005036545917391777
of O 0 5.655138579641061e-07
fatty O 0 7.91308866610052e-06
acid O 0 4.305681159166852e-06
beta O 0 1.9068165784119628e-06
oxidation O 0 1.1722349881893024e-06
that O 0 1.7980320876631595e-07
reportedly O 0 2.0268494154151995e-06
has O 0 2.782364560971473e-07
high O 0 6.06785363288509e-07
rates O 0 1.0190927923758863e-06
of O 0 5.510346454684623e-07
morbidity O 0 0.03094126656651497
and O 0 1.9118560885544866e-05
mortality O 0 0.0006841106805950403
. O 0 3.4002467145910487e-05

We O 0 2.5875722712953575e-05
describe O 0 1.313815482717473e-05
the O 0 7.72928785863769e-07
outcome O 0 2.2139436168799875e-06
of O 0 1.2317337905187742e-07
a O 0 4.6383942731154093e-07
5 O 0 1.1040217486879556e-06
- O 0 4.317732964409515e-05
year O 0 4.261078174749855e-06
- O 0 8.305688970722258e-05
old O 0 6.518120062537491e-05
girl O 0 0.00017596389807295054
with O 0 1.7672717149253003e-05
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 0.9999997615814209
who O 0 5.2487835091596935e-06
was O 0 2.096339812851511e-06
first O 0 3.5987895330436004e-07
seen O 0 5.940663641013089e-07
at O 0 1.9874538281783316e-07
5 O 0 2.0858652760580298e-07
months O 0 4.443975001322542e-07
of O 0 1.1583069436937876e-07
age O 0 5.700172550859861e-06
with O 0 2.800074071274139e-05
severe O 1 0.9999984502792358
hypertrophic B-Disease 1 0.9999997615814209
cardiomyopathy I-Disease 1 1.0
, O 0 0.23605771362781525
hepatomegaly B-Disease 1 1.0
, O 0 0.02985246665775776
encephalopathy B-Disease 1 0.9328619241714478
, O 0 6.57729788144934e-06
and O 0 1.3648022104462143e-05
hypotonia B-Disease 1 0.8554807305335999
. O 0 4.768273720401339e-05

Biochemical O 0 0.011648534797132015
studies O 0 0.004242147319018841
indicated O 1 0.9997515082359314
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
caused O 0 0.0003538503951858729
by O 0 4.05403261538595e-06
a O 0 6.6992174652114045e-06
stable O 0 6.030760778230615e-05
yet O 0 1.1185075891262386e-05
inactive O 0 3.295186616014689e-05
enzyme O 0 2.521286478440743e-05
. O 0 1.0049789125332609e-05

Molecular O 0 0.0008788371342234313
genetic O 0 0.00013067942927591503
analysis O 0 1.3860379112884402e-05
of O 0 2.02309706764936e-06
her O 0 3.3500557037768885e-05
VLCAD O 0 0.14195454120635986
gene O 0 3.324236604385078e-05
revealed O 0 3.593596920836717e-05
a O 0 5.820252226840239e-06
T1372C O 0 0.0001639329711906612
( O 0 6.109024525358109e-06
F458L O 0 3.5822027712129056e-05
) O 0 2.071071548925829e-06
missense O 0 2.8141013899585232e-05
mutation O 0 6.917799964867299e-06
and O 0 1.438335630155052e-06
a O 0 1.909818638523575e-05
1668 O 1 0.8743881583213806
ACAG O 0 0.28617173433303833
1669 O 0 0.022285327315330505
splice O 0 0.0012367689050734043
site O 0 0.00015536011778749526
mutation O 0 0.00021177103917580098
. O 0 3.6609435483114794e-05

After O 0 0.00018588070815894753
initial O 0 0.00011977958638453856
treatment O 0 0.00033327494747936726
with O 0 3.927007128368132e-06
intravenous O 0 0.00010486746759852394
glucose O 0 7.202876440715045e-05
and O 0 2.1807777557114605e-06
carnitine O 0 4.660194827010855e-05
, O 0 3.8262146517809015e-07
the O 0 4.529779289441649e-07
patient O 0 1.3363131984078791e-05
has O 0 4.2591790361257154e-07
thrived O 0 5.724638413084904e-06
on O 0 5.181085498406901e-07
a O 0 5.262223794488818e-07
low O 0 4.977479875378776e-06
- O 0 8.622614404885098e-05
fat O 0 1.3560989827965386e-05
diet O 0 6.635929821641184e-06
supplemented O 0 3.0164821964717703e-06
with O 0 5.320756031323981e-07
medium O 0 1.5431116480613127e-05
- O 0 5.109133053338155e-05
chain O 0 7.185069534898503e-06
triglyceride O 0 1.0246857527818065e-05
oil O 0 2.6764196263684426e-06
and O 0 1.1732338407455245e-06
carnitine O 0 2.460520772729069e-05
and O 0 1.3624617167806718e-06
avoidance O 0 9.410769052919932e-06
of O 0 1.6166225123015465e-06
fasting O 0 0.0002744360826909542
. O 0 2.420855344098527e-05

Her O 0 0.015636073425412178
ventricular O 1 0.9986897110939026
hypertrophy O 1 0.9897426962852478
resolved O 0 0.00038556757499463856
significantly O 0 3.478038343018852e-05
over O 0 1.2619470908248331e-06
1 O 0 8.408694043282594e-07
year O 0 4.697933491115691e-07
, O 0 1.8371024168573058e-07
and O 0 3.3579200930944353e-07
cognitively O 0 8.318157051689923e-05
, O 0 2.4183839286706643e-07
she O 0 5.150216679794539e-07
is O 0 4.366411587852781e-08
in O 0 7.535106050227114e-08
the O 0 1.9358753888809588e-07
superior O 0 2.2923156848264625e-06
range O 0 1.040021629705734e-06
for O 0 4.4242904095881386e-07
age O 0 7.384498530882411e-06
. O 0 7.994195584615227e-06

Clinical O 0 0.002225769218057394
recognition O 0 7.546601409558207e-05
of O 0 7.356811693171039e-05
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
is O 0 1.4710439018017496e-06
important O 0 3.569217597032548e-07
because O 0 2.813500827869575e-07
it O 0 9.112227417062968e-08
is O 0 2.8268670959619158e-08
one O 0 2.8667377804936223e-08
of O 0 2.9763279840722134e-08
the O 0 3.343798482546845e-07
few O 0 1.3766668871539878e-06
directly O 0 5.074054115539184e-06
treatable O 0 0.026598064228892326
causes O 0 1.302162399952067e-05
of O 0 4.185581929050386e-06
cardiomyopathy B-Disease 1 0.9999986886978149
in O 0 0.0001302450109506026
children O 0 5.864056583959609e-05
. O 0 7.37736763767316e-06
. O 0 1.944746145454701e-05

Cloning O 0 0.00036322700907476246
of O 0 3.467771875875769e-06
a O 0 2.5677093162812525e-06
novel O 0 4.2885967559413984e-06
member O 0 9.540781320538372e-07
of O 0 1.3347283811526722e-07
the O 0 7.122414444893366e-07
low O 0 8.339507076016162e-06
- O 0 0.00015203446673694998
density O 0 1.1306144187983591e-05
lipoprotein O 0 0.00016657904780004174
receptor O 0 6.178255716804415e-05
family O 0 2.541700450819917e-05
. O 0 2.409858825558331e-05

A O 0 0.00013907159154769033
gene O 0 9.950621461030096e-05
encoding O 0 3.170915806549601e-05
a O 0 6.025306902301963e-06
novel O 0 6.823748208262259e-06
transmembrane O 0 1.2108052942494396e-05
protein O 0 2.585095217000344e-06
was O 0 1.7409365682397038e-06
identified O 0 1.1832624977614614e-06
by O 0 3.2392583193541213e-07
DNA O 0 1.815069140320702e-06
sequence O 0 4.069214014634781e-07
analysis O 0 6.050743195373798e-07
within O 0 1.760823664653799e-07
the O 0 1.575631017658452e-06
insulin B-Disease 0 0.03157377243041992
- I-Disease 1 0.9969545602798462
dependent I-Disease 1 0.9975770115852356
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
( O 0 0.0003154913429170847
IDDM B-Disease 0 0.11208156496286392
) O 0 1.2855334716732614e-05
locus O 0 4.4580163375940174e-05
IDDM4 O 0 0.0003880942240357399
on O 0 3.371139973751269e-05
chromosome O 0 0.00017275562277063727
11q13 O 0 0.0002378397184656933
. O 0 2.652009243320208e-05

Based O 0 4.936630648444407e-05
on O 0 6.035134902049322e-06
its O 0 3.234552195863216e-06
chromosomal O 0 3.512389594106935e-05
position O 0 2.2910394363861997e-06
, O 0 2.863699819499743e-07
this O 0 2.0574650250182458e-07
gene O 0 1.2253840395715088e-06
is O 0 1.1425044021962094e-07
a O 0 3.2725785104048555e-07
candidate O 0 1.930226517288247e-06
for O 0 9.287871876040299e-07
conferring O 0 3.547222513589077e-05
susceptibility O 0 0.00026025864644907415
to O 0 0.00010119514627149329
diabetes B-Disease 1 0.9946162104606628
. O 0 7.49434984754771e-05

The O 0 3.820506026386283e-05
gene O 0 2.7488096748129465e-05
, O 0 2.4980211037473055e-06
termed O 0 1.928787969518453e-05
low O 0 1.1855977390951011e-05
- O 0 4.320204243413173e-05
density O 0 4.750179869006388e-06
lipoprotein O 0 2.373982897552196e-05
receptor O 0 3.94900325773051e-06
related O 0 1.1988487358394195e-06
protein O 0 1.120740307669621e-06
5 O 0 1.2000371043541236e-06
( O 0 8.461512948088057e-07
LRP5 O 0 4.366131906863302e-05
) O 0 3.9873509649623884e-07
, O 0 1.0933192129414238e-07
encodes O 0 4.260345178863645e-07
a O 0 2.1481938006218115e-07
protein O 0 3.498354033126816e-07
of O 0 1.4686747817904688e-07
1615 O 0 8.652720134705305e-05
amino O 0 9.631993407310802e-07
acids O 0 2.84351273194261e-07
that O 0 6.506678573714453e-08
contains O 0 7.446267602517764e-08
conserved O 0 2.3331482168487128e-07
modules O 0 9.273356909034192e-07
which O 0 1.439858721141718e-07
are O 0 4.4923858411038964e-08
characteristic O 0 2.7239209998697334e-07
of O 0 5.4466635646122086e-08
the O 0 5.488303713718778e-07
low O 0 1.4143521184450947e-05
- O 0 0.0001246294705197215
density O 0 6.8618574005085975e-06
lipoprotein O 0 0.00021186633966863155
( O 0 7.838490091671702e-06
LDL O 0 4.945507680531591e-05
) O 0 2.525312993384432e-06
receptor O 0 1.7725054931361228e-05
family O 0 1.2833983419113792e-05
. O 0 1.6557078197365627e-05

These O 0 1.8836019080481492e-05
modules O 0 2.525863965274766e-05
include O 0 3.315990852570394e-06
a O 0 3.0387116112251533e-06
putative O 0 2.270454933750443e-05
signal O 0 5.163478817848954e-06
peptide O 0 1.1303008022878203e-06
for O 0 2.0700908009985142e-07
protein O 0 6.988319682932342e-07
export O 0 4.997243649995653e-07
, O 0 2.1155224771973735e-07
four O 0 3.8713423577974027e-07
epidermal O 0 1.6600051822024398e-05
growth O 0 2.700313871173421e-06
factor O 0 2.8445074349292554e-06
( O 0 1.323827973465086e-06
EGF O 0 2.5913752324413508e-05
) O 0 8.514858791386359e-07
repeats O 0 2.95750623990898e-06
with O 0 5.402554847933061e-07
associated O 0 2.7397113626648206e-06
spacer O 0 3.933673360734247e-05
domains O 0 3.17062017529679e-06
, O 0 4.0079456198327534e-07
three O 0 7.995430451046559e-07
LDL O 0 2.642960134835448e-05
- O 0 2.6184496164205484e-05
receptor O 0 7.471928711311193e-06
( O 0 1.1691736290231347e-06
LDLR O 0 2.745063648035284e-05
) O 0 5.244573344498349e-07
repeats O 0 1.4600918802898377e-06
, O 0 1.4059317265946447e-07
a O 0 2.9532233725149126e-07
single O 0 7.426516503983294e-07
transmembrane O 0 2.7264700293017086e-06
spanning O 0 1.3117319213051815e-06
domain O 0 1.0497500397832482e-06
, O 0 2.461596864122839e-07
and O 0 5.492377113114344e-07
a O 0 2.233732857348514e-06
cytoplasmic O 0 4.166903454461135e-05
domain O 0 2.06718614208512e-05
. O 0 1.404056547471555e-05

The O 0 2.1784144337289035e-05
encoded O 0 1.7990449123317376e-05
protein O 0 7.246257155202329e-06
has O 0 6.97932819093694e-07
a O 0 3.1934783351061924e-07
unique O 0 4.2134337263632915e-07
organization O 0 4.981911843060516e-07
of O 0 1.9244096449710923e-07
EGF O 0 2.596005106170196e-05
and O 0 8.370289492631855e-07
LDLR O 0 9.006523760035634e-05
repeats O 0 7.867098247515969e-06
; O 0 5.270555902825436e-07
therefore O 0 5.391731292547775e-07
, O 0 2.827784442160919e-07
LRP5 O 0 6.304165435722098e-05
likely O 0 1.6581872159804334e-06
represents O 0 4.095575434348575e-07
a O 0 3.3283046718679543e-07
new O 0 5.508985623237095e-07
category O 0 4.7283810999942943e-07
of O 0 9.34320425471924e-08
the O 0 1.6512910860910779e-06
LDLR O 0 0.02721628174185753
family O 0 8.745544619159773e-05
. O 0 3.071127139264718e-05

Both O 0 5.693770799553022e-05
human O 0 1.880145282484591e-05
and O 0 6.223154286999488e-06
mouse O 0 0.00011684122000588104
LRP5 O 0 0.0013529029674828053
cDNAs O 0 0.00018165887740906328
have O 0 1.0958721077258815e-06
been O 0 6.28262114332756e-07
isolated O 0 1.4157850500851055e-06
and O 0 1.4736933451331424e-07
the O 0 1.4885598886849039e-07
encoded O 0 5.506768729901523e-07
mature O 0 6.31039938525646e-07
proteins O 0 8.533850603953397e-08
are O 0 2.6547855469516435e-08
95 O 0 3.271348987254896e-07
% O 0 4.427380133620318e-07
identical O 0 1.7480938367953058e-06
, O 0 4.253873555626342e-07
indicating O 0 2.366396756769973e-06
a O 0 8.524283430233481e-07
high O 0 9.55135078584135e-07
degree O 0 1.809229729587969e-06
of O 0 3.172587810240657e-07
evolutionary O 0 7.12816199666122e-06
conservation O 0 4.412758698890684e-06
. O 0 2.181366426157183e-06
. O 0 6.423832928703632e-06

The O 0 0.00018020505376625806
APC B-Disease 0 0.0009227223927155137
variants O 0 0.00012856563262175769
I1307K O 0 0.00011712455307133496
and O 0 3.228031573598855e-06
E1317Q O 0 3.537325028446503e-05
are O 0 6.816572408752108e-07
associated O 0 1.0581010428722948e-05
with O 0 0.011800086125731468
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 3.549394750734791e-05
but O 0 2.022138460233691e-06
not O 0 2.9140278456907254e-07
always O 0 2.772133029793622e-07
with O 0 2.2835870083781629e-07
a O 0 1.7479004554843414e-06
family O 0 7.850280780985486e-06
history O 0 1.0547914826020133e-05
. O 0 2.604073961265385e-05

Classical O 0 0.07989732921123505
familial B-Disease 1 0.999991774559021
adenomatous I-Disease 1 0.9999675750732422
polyposis I-Disease 1 0.9999988079071045
( O 0 0.0027943633031100035
FAP B-Disease 0 0.0061639221385121346
) O 0 1.242796042788541e-05
is O 0 7.850968017919513e-07
a O 0 2.534341092541581e-06
high O 0 6.672976451227441e-05
- O 1 0.9992755055427551
penetrance O 1 0.9989874958992004
autosomal B-Disease 1 0.9991670846939087
dominant I-Disease 1 0.9738718867301941
disease I-Disease 0 0.2912042737007141
that O 0 2.7120540835312568e-06
predisposes O 0 6.231954466784373e-05
to O 0 5.401282692218956e-07
hundreds O 0 1.0565144066276844e-06
or O 0 5.823994797538035e-07
thousands O 0 1.0421382512504351e-06
of O 0 1.0410017239337321e-05
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999998807907104
and I-Disease 1 0.9867475032806396
carcinoma I-Disease 1 1.0
and O 0 5.2479181249509566e-06
that O 0 8.326842362293974e-07
results O 0 3.4741340186883463e-06
from O 0 9.331464525530464e-07
truncating O 0 1.732873533910606e-05
mutations O 0 5.855996732861968e-06
in O 0 1.504185888734355e-06
the O 0 4.44697798229754e-06
APC B-Disease 0 0.00021550410019699484
gene O 0 5.99813720327802e-05
. O 0 1.8954931874759495e-05

A O 0 0.0005181730957701802
variant O 0 0.001265461090952158
of O 0 2.1101250240462832e-05
FAP B-Disease 0 0.0028691685292869806
is O 0 5.788378985016607e-05
attenuated B-Disease 1 0.9236332178115845
adenomatous I-Disease 1 0.9999904632568359
polyposis I-Disease 1 0.999893069267273
coli I-Disease 1 0.9946898221969604
, O 0 1.0998037396348082e-05
which O 0 2.4221494641096797e-06
results O 0 4.88306068291422e-06
from O 0 1.6095905266411137e-06
germ O 0 0.00231740390881896
- O 0 0.00015908139175735414
line O 0 1.1448049008322414e-05
mutations O 0 3.3022254228853853e-06
in O 0 2.041107194372671e-07
the O 0 2.00444617348694e-07
5 O 0 2.4139345100593346e-07
and O 0 1.6806721703233052e-07
3 O 0 2.672810524018132e-07
regions O 0 3.23221627240855e-07
of O 0 2.0173371240161941e-07
the O 0 2.6048164727399126e-06
APC B-Disease 0 0.0002208877558587119
gene O 0 5.0278129492653534e-05
. O 0 2.5187129722326063e-05

Attenuated B-Disease 1 0.9997919201850891
adenomatous I-Disease 1 0.9999973773956299
polyposis I-Disease 1 0.999997615814209
coli I-Disease 1 0.9999992847442627
patients O 1 0.9998420476913452
have O 0 2.655377465998754e-05
" O 0 1.1034785529773217e-05
multiple O 0 1.637778404983692e-05
" O 0 0.40003854036331177
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999979734420776
( O 0 6.6114089349866845e-06
typically O 0 1.3015836657359614e-06
fewer O 0 3.234331700241455e-07
than O 0 1.0139147832433082e-07
100 O 0 2.573885069523385e-07
) O 0 2.1280115447552816e-07
without O 0 2.8528648954306846e-07
the O 0 1.931345877892454e-06
florid O 0 0.005616876762360334
phenotype O 0 0.0006053769611753523
of O 0 3.708897565957159e-06
classical O 0 9.604945807950571e-05
FAP B-Disease 0 0.0020827034022659063
. O 0 0.00011865122360177338

Another O 0 6.262934039114043e-05
group O 0 2.3287886506295763e-05
of O 0 2.8513297820609296e-06
patients O 0 0.00012908599455840886
with O 0 1.6482985074617318e-06
multiple O 0 2.3756500013405457e-05
adenomas B-Disease 0 0.16578835248947144
has O 0 2.5891019959090045e-06
no O 0 1.0665181662261602e-06
mutations O 0 2.1915275283390656e-06
in O 0 3.014797300693317e-07
the O 0 7.328922606575361e-07
APC B-Disease 0 2.3300039174500853e-05
gene O 0 1.5530533801211277e-06
, O 0 1.3031208823122142e-07
and O 0 2.531620850731997e-07
their O 0 1.2296920886001317e-06
phenotype O 0 0.0013879943871870637
probably O 0 5.937140485912096e-06
results O 0 2.1717312392866006e-06
from O 0 3.311429281893652e-07
variation O 0 1.4484971870842855e-06
at O 0 6.083393486733257e-07
a O 0 8.469004342259723e-07
locus O 0 4.221979452267988e-06
, O 0 3.997737962890824e-07
or O 0 4.6064960201874783e-07
loci O 0 2.515239884814946e-06
, O 0 3.198468050413794e-07
elsewhere O 0 1.064445314113982e-06
in O 0 7.70276756156818e-07
the O 0 2.800960601234692e-06
genome O 0 1.8194839867646806e-05
. O 0 1.9462899217614904e-05

Recently O 0 0.0003559387696441263
, O 0 7.5318389463063795e-06
however O 0 2.9768671083729714e-06
, O 0 8.0215050957122e-07
a O 0 1.5370045503004803e-06
missense O 0 4.9560974730411544e-05
variant O 0 4.2995834519388154e-05
of O 0 1.1303084193059476e-06
APC B-Disease 0 0.00010623945854604244
( O 0 1.4665027947557974e-06
I1307K O 0 1.3234353900770657e-05
) O 0 6.468047217822459e-07
was O 0 1.1755264495150186e-06
described O 0 2.327073616470443e-06
that O 0 1.770222297636792e-07
confers O 0 7.756926834190381e-07
an O 0 2.5926254920705105e-07
increased O 0 1.748990939631767e-06
risk O 0 5.289799446472898e-06
of O 0 8.953500946518034e-05
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 7.438179636665154e-06
including O 0 1.8620022501636413e-06
multiple O 0 1.1181844456586987e-05
adenomas B-Disease 0 0.0016273816581815481
, O 0 3.5700145417649765e-06
in O 0 7.79409492679406e-06
Ashkenazim O 0 0.0008662876207381487
. O 0 3.420632128836587e-05

We O 0 2.944377229141537e-05
have O 0 2.9281982278916985e-06
studied O 0 2.842638878064463e-06
a O 0 7.670286663596926e-07
set O 0 8.478023119096179e-07
of O 0 5.025570430916559e-07
164 O 0 9.97983297565952e-05
patients O 0 0.0004983534454368055
with O 0 1.3246552043710835e-05
multiple O 1 0.9468295574188232
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999996423721313
and I-Disease 0 0.05250098556280136
/ I-Disease 1 0.9998666048049927
or I-Disease 0 0.09420976042747498
carcinoma I-Disease 1 0.9999998807907104
and O 0 2.0742456399602816e-05
analyzed O 0 5.3194966312730685e-05
codons O 0 5.8343375712865964e-05
1263 O 0 0.0007983247051015496
- O 0 0.0007300099241547287
1377 O 0 0.0022370407823473215
( O 0 1.0438319804961793e-05
exon O 0 3.927866418962367e-05
15G O 0 6.072426913306117e-05
) O 0 7.451807846337033e-07
of O 0 1.3346559057936247e-07
the O 0 5.426820166576363e-07
APC B-Disease 0 2.4772110919002444e-05
gene O 0 4.301318313082447e-06
for O 0 9.566246035319637e-07
germ O 0 0.0015436374815180898
- O 0 0.000269625656073913
line O 0 7.891505083534867e-05
variants O 0 9.777627565199509e-05
. O 0 2.7525346013135277e-05

Three O 0 0.00010399205348221585
patients O 0 0.0009964611381292343
with O 0 2.776286692096619e-06
the O 0 4.1062662603508215e-06
I1307K O 0 0.0003098876331932843
allele O 0 5.1271781558170915e-05
were O 0 4.9993204811471514e-06
detected O 0 8.837796485750005e-06
, O 0 5.018573006054794e-07
each O 0 3.359729703333869e-07
of O 0 9.379626249028661e-07
Ashkenazi O 0 0.0014652891550213099
descent O 0 0.00013103704259265214
. O 0 4.1718263673828915e-05

Four O 0 0.000329650443745777
patients O 0 0.1093340665102005
had O 0 5.30896577402018e-05
a O 0 2.791659426293336e-05
germ O 0 0.2215246707201004
- O 0 0.0009289245354011655
line O 0 5.287401654641144e-05
E1317Q O 0 0.00014575663954019547
missense O 0 7.839407044230029e-05
variant O 0 3.118947643088177e-05
of O 0 7.35799972062523e-07
APC O 0 3.0422923373407684e-05
that O 0 2.8156588882666256e-07
was O 0 5.68601706163463e-07
not O 0 9.547310497737271e-08
present O 0 9.557112434777082e-08
in O 0 1.706823127278767e-07
controls O 0 1.992071929635131e-06
; O 0 2.3272812654795416e-07
one O 0 4.7421004012448975e-08
of O 0 2.2866352367145737e-08
these O 0 5.849628337273316e-08
individuals O 0 9.650550936157742e-08
had O 0 1.641152152842551e-06
an O 0 3.139833211207588e-07
unusually O 0 7.05557931723888e-06
large O 0 2.8796992523894005e-07
number O 0 1.720715232522707e-07
of O 0 3.212377066574845e-07
metaplastic B-Disease 0 0.001958030741661787
polyps I-Disease 0 2.73862351605203e-05
of I-Disease 0 3.0640700288131484e-07
the I-Disease 0 2.9811315016559092e-06
colorectum I-Disease 0 0.0007528787828050554
. O 0 3.0407258236664347e-05

There O 0 1.960260487976484e-05
is O 0 1.3123288908900577e-06
increasing O 0 1.0905945373451686e-06
evidence O 0 7.24491883374867e-07
that O 0 1.537681981744754e-07
there O 0 1.0752588508466943e-07
exist O 0 3.6079785559195443e-07
germ O 0 0.00013090168067719787
- O 0 1.4710392861161381e-05
line O 0 1.3776228797723888e-06
variants O 0 9.134368497143441e-07
of O 0 4.9738130059040486e-08
the O 0 3.2523362847314274e-07
APC B-Disease 0 1.1564394299057312e-05
gene O 0 1.16874673494749e-06
that O 0 1.6540145963972464e-07
predispose O 0 2.3665320441068616e-06
to O 0 1.3452340397179796e-07
the O 0 1.963668125881668e-07
development O 0 8.451206667814404e-07
of O 0 7.531053256570885e-07
multiple O 0 0.02269611693918705
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9908945560455322
carcinoma I-Disease 1 1.0
, O 0 2.981595116580138e-06
but O 0 8.633051038486883e-07
without O 0 7.05179957094515e-07
the O 0 8.751983955335163e-07
florid O 0 0.001290290616452694
phenotype O 0 0.00010310899961041287
of O 0 4.3976456254313234e-07
classical O 0 5.844074621563777e-06
FAP B-Disease 0 6.813188520027325e-05
, O 0 4.957673809258267e-07
and O 0 2.9027776804468886e-07
possibly O 0 6.373425662786758e-07
with O 0 1.4180523066897877e-07
importance O 0 2.8426416065485682e-06
for O 0 0.1384633183479309
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
risk O 0 0.00010840705363079906
in O 0 2.529670837247977e-06
the O 0 1.3104016716170008e-06
general O 0 2.6113827971130377e-06
population O 0 2.0711784145532874e-06
. O 0 2.9263808301038807e-06
. O 0 8.675715434947051e-06

Genomic O 0 0.0006494317203760147
structure O 0 6.169011612655595e-05
of O 0 6.788625796616543e-06
the O 0 2.863081135728862e-05
human O 0 0.0068259877152740955
congenital B-Disease 1 1.0
chloride I-Disease 1 0.999997615814209
diarrhea I-Disease 1 1.0
( O 0 0.09866014122962952
CLD B-Disease 1 0.9997324347496033
) O 0 4.095034091733396e-05
gene O 0 9.320324170403183e-05
. O 0 3.164921508869156e-05

Congenital B-Disease 1 1.0
chloride I-Disease 1 0.9999918937683105
diarrhea I-Disease 1 1.0
( O 0 0.020029645413160324
CLD B-Disease 1 0.9998874664306641
) O 0 1.3875125659978949e-05
is O 0 1.099575911212014e-06
caused O 0 4.384794920042623e-06
by O 0 1.4161320223138318e-06
mutations O 0 4.9278492042503785e-06
in O 0 8.889485343388515e-07
a O 0 1.8862466504288022e-06
gene O 0 4.930844170303317e-06
which O 0 9.57666202339169e-07
encodes O 0 5.964380761724897e-06
an O 0 3.2936297884589294e-06
intestinal O 0 0.0009547763038426638
anion O 0 0.0009479201980866492
transporter O 0 0.005733675789088011
. O 0 9.649893763707951e-05

We O 0 2.8218759325682186e-05
report O 0 1.3361805940803606e-05
here O 0 5.677239300894144e-07
the O 0 1.8340548990636307e-07
complete O 0 8.243491720349994e-07
genomic O 0 2.6548468667897396e-06
organization O 0 4.349608673237526e-07
of O 0 1.0926166282843042e-07
the O 0 9.55647237788071e-07
human O 0 5.134129878570093e-06
CLD B-Disease 0 0.2515728175640106
gene O 0 8.407751920458395e-06
which O 0 8.21981529952609e-07
spans O 0 3.278408712503733e-06
approximately O 0 6.792847102587984e-07
39kb O 0 1.965464252862148e-05
, O 0 7.249653322105587e-07
and O 0 5.344434157450451e-07
comprises O 0 2.4630203370179515e-06
21 O 0 8.47063165565487e-06
exons O 0 9.701951057650149e-05
. O 0 2.7224297809880227e-05

All O 0 9.327533916803077e-05
exon O 0 0.0009935882408171892
/ O 0 0.00038475156179629266
intron O 0 0.000359579105861485
boundaries O 0 2.1496362023754045e-05
conform O 0 6.639087951043621e-05
to O 0 3.686374839162454e-06
the O 0 1.1911417459486984e-05
GT O 1 0.9988601207733154
/ O 1 0.9529484510421753
AG O 1 0.9996404647827148
rule O 0 0.00010380351886851713
. O 0 4.89717822347302e-05

An O 0 1.6356789274141192e-05
analysis O 0 8.513263310305774e-06
of O 0 6.779153522984416e-07
the O 0 1.8305125877304818e-06
putative O 0 3.33231728291139e-05
promoter O 0 2.576476617832668e-05
region O 0 2.64820641859842e-06
sequence O 0 1.2804014204448322e-06
shows O 0 1.5501826737818192e-06
a O 0 2.765489398370846e-06
putative O 0 5.9428242821013555e-05
TATA O 0 0.020181788131594658
box O 0 1.1931130757147912e-05
and O 0 1.444838289899053e-06
predicts O 0 1.9283723304397427e-05
multiple O 0 2.0367256183817517e-06
transcription O 0 9.63654565566685e-06
factor O 0 3.61284082828206e-06
binding O 0 8.121145583572797e-06
sites O 0 8.599618922744412e-06
. O 0 1.048761168931378e-05

The O 0 3.06760921375826e-05
genomic O 0 6.078486330807209e-05
structure O 0 1.0750915862445254e-05
was O 0 4.098723366041668e-06
determined O 0 1.6703799019524013e-06
using O 0 6.063931436983694e-07
DNA O 0 1.576657723489916e-06
from O 0 1.504623554637874e-07
several O 0 1.629578605388815e-07
sources O 0 2.106431082893323e-07
including O 0 1.3197559667332825e-07
multiple O 0 8.199990588764194e-07
large O 0 1.0962630767608061e-06
- O 0 5.772085569333285e-05
insert O 0 2.7434592993813567e-05
libaries O 0 3.6115092370891944e-05
and O 0 1.3987996680953074e-06
genomic O 0 1.2735239579342306e-05
DNA O 0 2.0172068616375327e-05
from O 0 7.267698038049275e-06
Finnish O 1 0.5772679448127747
CLD B-Disease 1 0.9999823570251465
patients O 0 0.018276765942573547
and O 0 8.902940862753894e-06
controls O 0 0.00015254678146447986
. O 0 2.4259556084871292e-05

Exon O 0 0.001698541920632124
- O 0 0.00016402099572587758
specific O 0 8.567677468818147e-06
primers O 0 4.692633228842169e-05
developed O 0 8.027650437725242e-06
in O 0 6.308780484687304e-07
this O 0 2.4110471485983e-07
study O 0 3.5667540032591205e-07
will O 0 1.6224949206389283e-07
facilitate O 0 1.2223936209920794e-06
mutation O 0 2.44282318817568e-06
screening O 0 3.573758021957474e-06
studies O 0 1.0388854434495443e-06
of O 0 5.381031087381416e-07
patients O 0 0.0005246108630672097
with O 0 4.566719326248858e-06
the O 0 0.00035309186205267906
disease O 0 0.09483177959918976
. O 0 3.193640077370219e-05

Genomic O 0 0.00047820177860558033
sequencing O 0 5.837008575326763e-05
of O 0 3.331367224745918e-06
a O 0 1.5072941096150316e-05
BAC O 0 0.02932491898536682
clone O 0 0.001615735818631947
H O 1 0.9989670515060425
_ O 0 7.393207852146588e-06
RG364P16 O 0 3.267658030381426e-05
revealed O 0 3.532250502757961e-06
the O 0 9.046939197787651e-08
presence O 0 1.600667900447661e-07
of O 0 2.6549374254614122e-08
another O 0 1.5892796056959924e-07
, O 0 1.92067489024339e-07
highly O 0 4.1446827481195214e-07
homologous O 0 1.8754235497908667e-06
gene O 0 8.552171948394971e-07
3 O 0 2.378605046260418e-07
of O 0 8.363142711687033e-08
the O 0 1.0692782552723656e-06
CLD B-Disease 1 0.6275606751441956
gene O 0 4.2399997255415656e-06
, O 0 2.2546890932062524e-07
with O 0 5.989364382230633e-08
a O 0 2.672315702056949e-07
similar O 0 5.848004889230651e-07
genomic O 0 1.998934294533683e-06
structure O 0 1.098821257983218e-06
, O 0 2.7586565920501016e-07
recently O 0 2.311473508598283e-06
identified O 0 9.36144942897954e-07
as O 0 6.105962597757753e-07
the O 0 2.2884667487232946e-05
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
gene O 0 0.00016892635903786868
( O 0 2.20838664972689e-05
PDS B-Disease 0 0.0070485505275428295
) O 0 4.626511326932814e-06
. O 0 2.4290102373925038e-06
. O 0 9.034960385179147e-06

The O 0 9.241320367436856e-05
APCI1307K O 0 0.004978914745151997
allele O 0 0.0005856914795003831
and O 0 5.772883741883561e-05
cancer B-Disease 0 0.25649315118789673
risk O 0 6.014818609401118e-06
in O 0 1.2297905414015986e-06
a O 0 1.434744717698777e-06
community O 0 2.083103254335583e-06
- O 0 4.4658532715402544e-05
based O 0 2.1005062080803327e-06
study O 0 1.955851757884375e-06
of O 0 8.13842063962511e-07
Ashkenazi O 0 0.0007273603114299476
Jews O 0 2.600564585009124e-05
. O 0 2.2578924472327344e-05

Mutations O 0 0.0020227287895977497
in O 0 9.180713823297992e-05
APC O 0 0.0013055948074907064
are O 0 5.723442882299423e-06
classically O 0 0.007436523213982582
associated O 0 5.7353459851583466e-05
with O 0 6.613988807657734e-05
familial B-Disease 1 0.9999971389770508
adenomatous I-Disease 1 0.9999936819076538
polyposis I-Disease 1 0.9999996423721313
( O 0 0.0006845779716968536
FAP B-Disease 0 0.004794277250766754
) O 0 1.1272832125541754e-05
, O 0 3.1032611786940834e-06
a O 0 2.0581259377649985e-05
highly O 0 0.008806928992271423
penetrant O 1 0.9999606609344482
autosomal B-Disease 1 0.9999998807907104
dominant I-Disease 1 0.9999938011169434
disorder I-Disease 1 1.0
characterized O 0 0.011216904036700726
by O 0 3.040424235223327e-05
multiple O 0 0.0008167147752828896
intestinal O 1 0.9979946613311768
polyps B-Disease 0 0.0008846190175972879
and O 0 1.403704118274618e-06
, O 0 4.3239703018116415e-07
without O 0 7.814597893229802e-07
surgical O 0 0.0027362157125025988
intervention O 0 1.2446295841073152e-05
, O 0 5.282446409182739e-07
the O 0 6.098752010075259e-07
development O 0 4.934550815960392e-06
of O 0 0.00030957930721342564
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 0.0006912308163009584
CRC B-Disease 0 0.058914680033922195
) O 0 1.3320975995156914e-05
. O 0 1.3178534572944045e-05

APC B-Disease 0 0.009446840733289719
is O 0 3.3951793739106506e-05
a O 0 8.787729166215286e-05
tumour O 1 0.9999963045120239
- O 0 0.006970720365643501
suppressor O 0 0.00016675911319907755
gene O 0 1.5406385500682518e-05
, O 0 1.1717141887856997e-06
and O 0 1.7326879060419742e-06
somatic O 0 6.780542025808245e-05
loss O 0 0.00011931459448533133
occurs O 0 1.0153396942769177e-05
in O 0 3.237144119339064e-05
tumours B-Disease 1 0.9998685121536255
. O 0 3.7187201087363064e-05

The O 0 0.00012386588787194341
germline O 0 0.003997921012341976
T O 0 0.007817653007805347
- O 0 9.330549801234156e-05
to O 0 1.9115650502499193e-06
- O 0 1.72625277627958e-05
A O 0 2.3738127765682293e-06
transversion O 0 1.2716222045128234e-05
responsible O 0 8.118722689687274e-07
for O 0 2.464246051658847e-07
the O 0 5.897542791899468e-07
APC O 0 2.953857801912818e-05
I1307K O 0 1.7071604816010222e-05
allele O 0 6.9552615968859755e-06
converts O 0 2.5077406462514773e-06
the O 0 4.064901020228717e-07
wild O 0 1.4253781728257309e-06
- O 0 6.822010618634522e-06
type O 0 9.56941335061856e-07
sequence O 0 2.1640370562181488e-07
to O 0 1.7640088856296643e-07
a O 0 9.81942093858379e-07
homopolymer O 0 0.011535665951669216
tract O 0 0.003086221870034933
( O 0 4.902648925053654e-06
A8 O 0 0.3000026345252991
) O 0 7.574623168693506e-07
that O 0 2.3395092796363315e-07
is O 0 6.131047598501027e-07
genetically O 0 1.2307690667512361e-05
unstable O 0 9.618116018828005e-05
and O 0 3.319699317216873e-06
prone O 0 3.7261641409713775e-05
to O 0 5.845306077389978e-06
somatic O 0 0.0002507053723093122
mutation O 0 0.00013679794210474938
. O 0 3.50075242749881e-05

The O 0 0.00010610581375658512
I1307K O 0 0.0008811278967186809
allele O 0 0.0002821701345965266
was O 0 2.3311817130888812e-05
found O 0 4.126109615754103e-06
in O 0 3.1115823730942793e-06
6 O 0 1.2445548236428294e-05
. O 0 2.040929757640697e-05

1 O 0 5.482393316924572e-05
% O 0 9.728671102493536e-06
of O 0 1.9847805106110172e-06
unselected O 0 0.0030492276418954134
Ashkenazi O 0 0.01659460924565792
Jews O 0 7.4527420110825915e-06
and O 0 1.289160877604445e-06
higher O 0 1.73973171513353e-06
proportions O 0 1.9017496697415481e-06
of O 0 1.7194489032590354e-07
Ashkenazim O 0 0.000100030614703428
with O 0 5.233670776760846e-07
family O 0 2.480411467331578e-06
or O 0 7.067311571518076e-07
personal O 0 2.553887043177383e-06
histories O 0 5.0742237363010645e-06
of O 0 1.2717622439595289e-06
CRC B-Disease 0 0.010255883447825909
( O 0 4.96268694405444e-06
ref O 0 0.000989300780929625
. O 0 1.3410382280198974e-06
2 O 0 2.3762022465234622e-06
) O 0 2.2312206056085415e-06
. O 0 6.261963335418841e-06

To O 0 4.58955873909872e-05
evaluate O 0 2.559222048148513e-05
the O 0 1.3233344589025364e-06
role O 0 1.5069025494085508e-06
of O 0 5.275454100228671e-07
I1307K O 0 0.0001605181023478508
in O 0 5.7517991081112996e-05
cancer B-Disease 0 0.024048784747719765
, O 0 8.841352610033937e-07
we O 0 5.876954105588084e-07
genotyped O 0 3.4976994356838986e-05
5 O 0 1.8240023109683534e-06
, O 0 1.388213377140346e-06
081 O 0 0.0003868796629831195
Ashkenazi O 0 0.00036124634789302945
volunteers O 0 6.189281975821359e-06
in O 0 1.176905016109231e-06
a O 0 1.625166078156326e-06
community O 0 5.641699317493476e-06
survey O 0 2.6138492103200406e-05
. O 0 1.1296669981675223e-05

Risk O 0 0.0004057010228279978
of O 0 1.560723285365384e-05
developing O 0 0.012289348989725113
colorectal B-Disease 1 0.9999997615814209
, I-Disease 0 0.00019492146384436637
breast I-Disease 1 0.7856715321540833
and I-Disease 0 1.4255236237659119e-05
other I-Disease 0 9.67707637755666e-06
cancers I-Disease 0 0.0037728387396782637
were O 0 2.3897516712168e-06
compared O 0 4.896616701444145e-06
between O 0 8.102657034214644e-07
genotyped O 0 6.30347421974875e-05
I1307K O 0 3.471411037025973e-05
carriers O 0 2.0726661205117125e-06
and O 0 2.1550269480030693e-07
non O 0 1.6056566209954326e-06
- O 0 7.960675247886684e-06
carriers O 0 7.442071705554554e-07
and O 0 7.530192647209333e-08
their O 0 1.3638783968872303e-07
first O 0 1.5220315390251926e-06
- O 0 3.742756598512642e-05
degree O 0 8.076672202150803e-06
relatives O 0 2.725307786022313e-05
. O 0 1.91573599295225e-05

Sperm O 0 0.000965521321631968
DNA O 0 0.0001840883051045239
analysis O 0 2.1503106836462393e-05
in O 0 7.778389772283845e-06
a O 0 3.394596205907874e-05
Friedreich B-Disease 1 0.9839110374450684
ataxia I-Disease 1 0.9986181259155273
premutation O 0 0.11984989792108536
carrier O 0 0.00025852376711554825
suggests O 0 8.894896382116713e-06
both O 0 1.5023194919194793e-06
meiotic O 0 4.768355574924499e-05
and O 0 2.161408474421478e-06
mitotic O 0 2.7096268240711652e-05
expansion O 0 4.070047452842118e-06
in O 0 1.0731449719969532e-06
the O 0 2.8895142349938396e-06
FRDA B-Disease 0 0.0006247780402190983
gene O 0 4.9849455535877496e-05
. O 0 2.3805641831131652e-05

Friedreich B-Disease 1 0.9998294115066528
ataxia I-Disease 1 0.9999021291732788
is O 0 7.057684706524014e-05
usually O 0 1.9671933841891587e-05
caused O 0 8.765850907366257e-06
by O 0 3.2215439205174334e-07
an O 0 1.9492343028559844e-07
expansion O 0 9.872528607957065e-07
of O 0 2.3031903140235954e-07
a O 0 2.87410171040392e-06
GAA O 0 0.00014254299458116293
trinucleotide O 0 0.0001425550872227177
repeat O 0 1.241362770088017e-05
in O 0 1.7214175613844418e-06
intron O 0 3.152036151732318e-05
1 O 0 8.16898818811751e-07
of O 0 2.559655740697053e-07
the O 0 2.7453136226540664e-06
FRDA B-Disease 0 0.0015938939759507775
gene O 0 4.953182360623032e-05
. O 0 1.8753107724478468e-05

Occasionally O 0 0.0001361620961688459
, O 0 3.82830194212147e-06
a O 0 2.432781911920756e-06
fully O 0 2.846398729161592e-06
expanded O 0 3.7261665966070723e-06
allele O 0 7.939885108498856e-06
has O 0 4.208076802569849e-07
been O 0 2.812272441587993e-07
found O 0 2.622001034069399e-07
to O 0 1.5063882585764077e-07
arise O 0 6.336293267850124e-07
from O 0 2.4158367750715115e-07
a O 0 6.655854463133437e-07
premutation O 0 1.236985463037854e-05
of O 0 1.919039789299859e-07
100 O 0 5.485634915203264e-07
or O 0 1.3413681472229655e-06
less O 0 4.185578291071579e-06
triplet O 0 0.0005285685765556991
repeats O 0 0.00013248489995021373
. O 0 3.096169893979095e-05

We O 0 2.754178422037512e-05
have O 0 5.405645424616523e-06
examined O 0 1.1658873518172186e-05
the O 0 8.37706238598912e-07
sperm O 0 8.982323379314039e-06
DNA O 0 6.509739705506945e-06
of O 0 5.422852495939878e-07
a O 0 1.2349510143394582e-05
premutation O 0 0.0021429965272545815
carrier O 0 0.0005515647353604436
. O 0 5.5215972679434344e-05

This O 0 8.266678196378052e-05
mans O 0 0.0010114579927176237
leucocyte O 0 0.0011546737514436245
DNA O 0 8.808483835309744e-05
showed O 0 2.0720808606711216e-05
one O 0 1.3202561603975482e-06
normal O 0 3.570007720554713e-06
allele O 0 8.445287676295266e-06
and O 0 3.142124853638961e-07
one O 0 4.5433384343596117e-07
allele O 0 5.7456632021057885e-06
of O 0 2.776787368929945e-07
approximately O 0 1.458768224438245e-06
100 O 0 4.001554316346301e-06
repeats O 0 6.963005580473691e-05
. O 0 3.4284996218048036e-05

His O 0 0.00012614144361577928
sperm O 0 0.00018485874170437455
showed O 0 2.7995189157081768e-05
an O 0 1.2348099289738457e-06
expanded O 0 5.636026799038518e-06
allele O 0 1.2566471013997216e-05
in O 0 5.915760539210169e-07
a O 0 7.620829478582891e-07
tight O 0 6.11795121585601e-06
range O 0 2.1979469693178544e-06
centering O 0 3.123575879726559e-06
on O 0 7.097963248270389e-07
a O 0 4.3872404376088525e-07
size O 0 1.1835220448119799e-06
of O 0 2.5754346211215307e-07
approximately O 0 2.492445673851762e-06
320 O 0 3.263799226260744e-05
trinucleotide O 0 0.00035876582842320204
repeats O 0 0.00019002394401468337
. O 0 4.103791434317827e-05

His O 0 0.00023547548335045576
affected O 0 0.00027745208353735507
son O 0 0.000504752213601023
has O 0 6.094413492974127e-06
repeat O 0 1.3125018085702322e-05
sizes O 0 4.943759904563194e-06
of O 0 7.871352067922999e-07
1040 O 0 6.564686191268265e-05
and O 0 4.670117959904019e-06
540 O 0 0.0001449210976716131
. O 0 2.319798295502551e-05

These O 0 4.4083502871217206e-05
data O 0 2.1201398340053856e-05
suggest O 0 5.735332706535701e-06
that O 0 4.1039621123672987e-07
expansion O 0 1.7109084637922933e-06
occurs O 0 4.119105483368912e-07
in O 0 1.3151938560440612e-07
two O 0 1.0447340059727139e-07
stages O 0 7.864051667638705e-07
, O 0 1.0223836000022857e-07
the O 0 9.607849449366768e-08
first O 0 2.7327337193128187e-07
during O 0 7.98944711277727e-07
meiosis O 0 2.4524588297936134e-06
followed O 0 6.845504003649694e-07
by O 0 2.6536270070209866e-07
a O 0 6.963092573641916e-07
second O 0 4.579645974445157e-06
mitotic O 0 9.037893323693424e-05
expansion O 0 3.6636953154811636e-05
. O 0 3.250852023484185e-05

We O 0 1.7466009012423456e-05
also O 0 2.8701847440970596e-06
show O 0 3.791383505813428e-06
that O 0 3.1196356076179654e-07
in O 0 1.7465696089402627e-07
all O 0 1.2348611733159487e-07
informative O 0 2.6528980470175156e-06
carrier O 0 4.841425379709108e-06
father O 0 2.919423195635318e-06
to O 0 6.060381565475836e-07
affected O 0 1.9216838609281695e-06
child O 0 5.8443583839107305e-06
transmissions O 0 2.969320848933421e-05
, O 0 1.887834315539294e-07
with O 0 6.592210155531575e-08
the O 0 1.2927344528179674e-07
notable O 0 2.952102704512072e-07
exception O 0 4.563200377560861e-07
of O 0 8.717865540575076e-08
the O 0 6.788417294956162e-07
premutation O 0 0.00012868974590674043
carrier O 0 7.096377885318361e-06
, O 0 1.9945591134273855e-07
the O 0 1.828161231287595e-07
expansion O 0 2.2627073121839203e-06
size O 0 4.189587343716994e-06
decreases O 0 9.883033271762542e-06
. O 0 1.5245985878209467e-06
. O 0 7.027234005363425e-06

The O 0 0.00011935499787796289
R496H O 0 0.0007789591909386218
mutation O 0 2.327838410565164e-05
of O 0 1.4828331131866435e-06
arylsulfatase O 0 0.00028584475512616336
A O 0 2.4089213184197433e-05
does O 0 7.724255738139618e-06
not O 0 7.604228358104592e-06
cause O 0 0.00017052348994184285
metachromatic B-Disease 1 0.999969482421875
leukodystrophy I-Disease 1 0.9999804496765137
. O 0 0.00035027493140660226

Deficiency B-Disease 1 0.9984492063522339
of I-Disease 0 3.914554326911457e-05
arylsulfatase I-Disease 0 0.005693924613296986
A I-Disease 0 0.00010800196469062939
( O 0 4.324000110500492e-05
ARSA O 0 0.0031432334799319506
) O 0 1.0774328075058293e-05
enzyme O 0 2.7302918169880286e-05
activity O 0 1.3252667486085556e-05
causes O 0 5.7046516303671524e-05
metachromatic B-Disease 1 0.9999790191650391
leukodystrophy I-Disease 1 0.999998927116394
( O 0 0.0017252506222575903
MLD B-Disease 1 0.9999904632568359
) O 0 6.325700087472796e-05
. O 0 3.941648901673034e-05

A O 0 4.401247497298755e-05
number O 0 3.7866245747864014e-06
of O 0 2.198370566475205e-06
ARSA O 0 0.023503048345446587
gene O 0 3.4872144169639796e-05
mutations O 0 1.5477007764275186e-05
responsible O 0 3.4020031307591125e-06
for O 0 3.059668642890756e-06
MLD B-Disease 1 0.9999983310699463
have O 0 1.327639984083362e-05
been O 0 9.388966645929031e-06
identified O 0 1.6546044207643718e-05
. O 0 1.257407075172523e-05

Recently O 0 0.0002636623103171587
, O 0 7.343450306507293e-06
the O 0 2.811059857776854e-06
R496H O 0 5.8326299040345475e-05
mutation O 0 5.544537998503074e-06
of O 0 5.650684897773317e-07
ARSA O 0 0.0019612342584878206
was O 0 7.207847829704406e-06
proposed O 0 1.709608682176622e-06
to O 0 2.4871454229469236e-07
be O 0 1.3418066657777672e-07
a O 0 4.415026069182204e-07
cause O 0 2.2436713607021375e-06
of O 0 1.0315442295905086e-06
MLD B-Disease 1 0.9999985694885254
( O 0 2.1519477741094306e-05
Draghia O 0 0.0008123708539642394
et O 0 8.247922960435972e-05
al O 0 2.38068460021168e-05
. O 0 1.1879004659931525e-06
, O 0 8.155031423484616e-07
1997 O 0 5.151433470018674e-06
) O 0 3.7657914617739152e-06
. O 0 1.1585037100303452e-05

We O 0 2.124631282640621e-05
have O 0 3.0251478619902628e-06
investigated O 0 7.949833161546849e-06
the O 0 9.846991133599658e-07
R496H O 0 5.1563227316364646e-05
mutation O 0 3.7528134271269664e-06
and O 0 3.3053274250960385e-07
found O 0 3.3603004112592316e-07
this O 0 1.737359411890793e-07
mutation O 0 9.365967912344786e-07
at O 0 1.8555996916802542e-07
a O 0 2.350427195096927e-07
relatively O 0 6.810230956943997e-07
high O 0 5.500344286701875e-07
frequency O 0 7.621461577400623e-07
in O 0 2.3098839108115499e-07
an O 0 1.1122323684276125e-07
African O 0 3.848199980893696e-07
American O 0 6.383237973750511e-07
population O 0 4.5147751848162443e-07
( O 0 5.231694899521244e-07
f O 0 2.6545835680735763e-06
= O 0 2.1871910576010123e-06
0 O 0 5.363694413063058e-07
. O 0 2.662681879428419e-07
09 O 0 5.564513685385464e-06
, O 0 3.1578539960719354e-07
n O 0 2.277198518640944e-06
= O 0 4.8249885367113166e-06
61 O 0 3.439355168666225e-06
subjects O 0 4.2249521357007325e-06
) O 0 3.3819410418800544e-06
. O 0 7.3643846008053515e-06

The O 0 0.00011259470193181187
ARSA O 0 0.004440788179636002
enzyme O 0 7.317406561924145e-05
activity O 0 1.0652441233105492e-05
in O 0 1.4743050087417942e-06
subjects O 0 1.625590812182054e-06
with O 0 2.280816460142887e-07
and O 0 4.200390719688585e-07
without O 0 4.2207372530356224e-07
the O 0 6.453389573835011e-07
R496H O 0 7.697538967477158e-05
mutation O 0 4.004039965366246e-06
was O 0 2.411073182884138e-06
determined O 0 1.7709429585011094e-06
and O 0 3.865465600938478e-07
found O 0 9.590471563569736e-07
to O 0 3.845107698907668e-07
be O 0 4.996576308258227e-07
normal O 0 5.391620561567834e-06
. O 0 1.0712607945606578e-05

It O 0 1.8865144738811068e-05
is O 0 1.3804532272843062e-06
therefore O 0 1.413273253092484e-06
concluded O 0 3.4072761536663165e-06
that O 0 1.8636316667652864e-07
the O 0 4.3781119529739954e-07
R496H O 0 2.3565691662952304e-05
mutation O 0 3.171757498421357e-06
of O 0 3.153360808028083e-07
ARSA O 0 0.0021271028090268373
does O 0 1.5797354535607155e-06
not O 0 3.788553897265956e-07
negatively O 0 1.3868159385310719e-06
influence O 0 5.106663820697577e-07
the O 0 2.7498310828377726e-07
activity O 0 4.4795513076678617e-07
of O 0 1.5161988642375945e-07
ARSA O 0 0.0009795851074159145
and O 0 1.0745839063019957e-06
is O 0 2.479488898643467e-07
not O 0 3.6820213722421613e-07
a O 0 1.5062473721627612e-06
cause O 0 1.5248866475303657e-05
of O 0 1.5908195564406924e-05
MLD B-Disease 1 0.9999916553497314

Down O 0 0.0006230052094906569
- O 0 0.0003250649606343359
regulation O 0 7.091640145517886e-05
of O 0 5.859985776623944e-06
transmembrane O 0 0.0001471594296162948
carbonic O 0 0.0005304468795657158
anhydrases O 0 0.0049598328769207
in O 0 0.010211396031081676
renal B-Disease 1 0.9999998807907104
cell I-Disease 1 0.9999947547912598
carcinoma I-Disease 1 1.0
cell O 0 0.004338586237281561
lines O 0 2.6757516025099903e-05
by O 0 4.171511136519257e-06
wild O 0 1.6294061424559914e-05
- O 0 0.0009154052822850645
type O 0 0.00024575437419116497
von B-Disease 0 0.24541199207305908
Hippel I-Disease 0 0.4845447540283203
- I-Disease 0 0.08355098962783813
Lindau I-Disease 0 0.10502192378044128
transgenes O 0 0.0021094728726893663
. O 0 8.86522902874276e-05

To O 0 7.953614112921059e-05
discover O 0 0.0001449473638786003
genes O 0 3.0621460609836504e-05
involved O 0 1.4988281691330485e-05
in O 0 2.8263224521651864e-05
von B-Disease 1 0.8737601637840271
Hippel I-Disease 1 0.9446533918380737
- I-Disease 1 0.8016347289085388
Lindau I-Disease 1 0.9123942255973816
( O 0 6.979305180720985e-05
VHL B-Disease 0 0.0027499315328896046
) O 0 1.088400404114509e-05
- O 0 0.00011001158418366686
mediated O 0 0.0001732517994241789
carcinogenesis O 0 0.0006027262425050139
, O 0 2.5816509605647298e-06
we O 0 2.7724395295081194e-06
used O 0 7.869351975386962e-05
renal B-Disease 1 0.9999990463256836
cell I-Disease 1 0.9999927282333374
carcinoma I-Disease 1 1.0
cell O 0 0.0192699171602726
lines O 0 6.423875311156735e-05
stably O 0 0.0001574361085658893
transfected O 0 0.00019328374764882028
with O 0 5.323229288478615e-06
wild O 0 2.3761302145430818e-05
- O 0 0.001125652459450066
type O 0 0.0002577251580078155
VHL O 0 0.05070162191987038
- O 0 0.0006262738024815917
expressing O 0 0.00017767565441317856
transgenes O 0 0.0015868411865085363
. O 0 0.00011834658653242514

Large O 0 6.945325731066987e-05
- O 0 0.00015376313240267336
scale O 0 2.2966196411289275e-05
RNA O 0 9.591327398084104e-06
differential O 0 6.648161161137978e-06
display O 0 2.690040673769545e-06
technology O 0 3.751085387193598e-06
applied O 0 7.670016088923148e-07
to O 0 1.768948152403027e-07
these O 0 1.1558781665144124e-07
cell O 0 2.902444748542621e-06
lines O 0 9.785709380594199e-07
identified O 0 9.768097015694366e-07
several O 0 3.060854680825287e-07
differentially O 0 4.030448053526925e-06
expressed O 0 9.120388426708814e-07
genes O 0 1.350596107840829e-06
, O 0 1.4297125972007052e-07
including O 0 1.845976669301308e-07
an O 0 6.645566941188008e-07
alpha O 0 1.5029921996756457e-05
carbonic O 0 0.00010323255992261693
anhydrase O 0 0.00025037574232555926
gene O 0 2.5524903321638703e-05
, O 0 6.260291229409631e-06
termed O 0 0.00013244879664853215
CA12 O 0 0.0026096494402736425
. O 0 5.253205381450243e-05

The O 0 3.375257438165136e-05
deduced O 0 4.368318695924245e-05
protein O 0 4.742308192362543e-06
sequence O 0 1.2661614618991734e-06
was O 0 1.5169842981777037e-06
classified O 0 6.830335905760876e-07
as O 0 1.2976308028100902e-07
a O 0 2.595158434814948e-07
one O 0 6.392521640918858e-07
- O 0 3.123269561911002e-05
pass O 0 1.5563017541353474e-06
transmembrane O 0 4.832835656998213e-06
CA O 0 2.5598124011594336e-06
possessing O 0 1.4156823908706428e-06
an O 0 4.5253020175550773e-07
apparently O 0 7.749254109512549e-06
intact O 0 7.476946848328225e-06
catalytic O 0 8.602539310231805e-06
domain O 0 1.4460790680459468e-06
in O 0 7.960803714013309e-07
the O 0 2.1112830381753156e-06
extracellular O 0 2.016460530285258e-05
CA O 0 4.1386436350876465e-05
module O 0 0.00010730269423220307
. O 0 2.14997253351612e-05

Reintroduced O 0 0.002452212618663907
wild O 0 0.0002493896463420242
- O 0 0.0013592401519417763
type O 0 0.00026597961550578475
VHL B-Disease 0 0.00480731762945652
strongly O 0 2.252923877676949e-05
inhibited O 0 3.218963320250623e-05
the O 0 1.3585537317339913e-06
overexpression O 0 6.0786132962675765e-06
of O 0 1.6379672729271988e-07
the O 0 1.1113804703200003e-06
CA12 O 0 0.0003561352496035397
gene O 0 7.1691893026581965e-06
in O 0 1.3863929098079097e-06
the O 0 8.197173883672804e-06
parental O 0 0.40408504009246826
renal B-Disease 1 1.0
cell I-Disease 1 0.9999974966049194
carcinoma I-Disease 1 1.0
cell O 0 0.027388757094740868
lines O 0 0.0002002837136387825
. O 0 6.306894647423178e-05

Similar O 0 0.00013574905460700393
results O 0 5.4929114412516356e-05
were O 0 2.7702433271770133e-06
obtained O 0 2.2711712972522946e-06
with O 0 7.490754114769516e-07
CA9 O 0 0.03979989513754845
, O 0 1.3535204743675422e-06
encoding O 0 5.1196720960433595e-06
another O 0 1.8549216065366636e-06
transmembrane O 0 1.189008071378339e-05
CA O 0 7.823270607332233e-06
with O 0 3.8128715118546097e-07
an O 0 1.1493985994093237e-06
intact O 0 3.0322009479277767e-05
catalytic O 0 7.541730883531272e-05
domain O 0 3.368681427673437e-05
. O 0 2.3370403141598217e-05

Although O 0 4.625562360160984e-05
both O 0 3.7888135011598933e-06
domains O 0 3.0173396226018667e-06
of O 0 2.3195593712443952e-07
the O 0 1.290769887418719e-06
VHL B-Disease 0 0.00037521778722293675
protein O 0 4.201454885333078e-06
contribute O 0 1.104957163988729e-06
to O 0 2.4467954062856734e-07
regulation O 0 1.98201701095968e-06
of O 0 2.647413737122406e-07
CA12 O 0 0.00012184046499896795
expression O 0 1.327866471001471e-06
, O 0 2.0008556589345972e-07
the O 0 3.90196589705738e-07
elongin O 0 2.0652827515732497e-05
binding O 0 3.326303385620122e-06
domain O 0 1.7042416402546223e-06
alone O 0 1.8641236465555266e-06
could O 0 1.2344813740128302e-06
effectively O 0 6.2933586377766915e-06
regulate O 0 7.050683052511886e-05
CA9 O 0 0.004257747437804937
expression O 0 7.441495108650997e-05
. O 0 5.625771882478148e-05

We O 0 0.00027166929794475436
mapped O 0 0.0007508840062655509
CA12 O 0 0.0027634347788989544
and O 0 3.669381112558767e-05
CA9 O 0 0.058373115956783295
loci O 0 8.906614675652236e-05
to O 0 6.7536775532062165e-06
chromosome O 0 5.153501479071565e-05
bands O 0 1.997363506234251e-05
15q22 O 0 9.704153490019962e-05
and O 0 7.71449413150549e-06
17q21 O 0 0.0003648111887741834
. O 0 2.3643626263947226e-05

2 O 0 4.323929897509515e-05
respectively O 0 1.859292751760222e-05
, O 0 1.3309029327501776e-06
regions O 0 2.747974804151454e-06
prone O 0 8.740825251152273e-06
to O 0 6.968154480091471e-07
amplification O 0 1.9729854102479294e-05
in O 0 1.5609201682309504e-06
some O 0 1.506240096205147e-06
human O 0 1.61981770361308e-05
cancers B-Disease 0 0.000803072820417583
. O 0 2.7030555429519154e-05

Additional O 0 4.9143200158141553e-05
experiments O 0 4.3420863221399486e-05
are O 0 8.141145144691109e-07
needed O 0 1.3587714420282282e-06
to O 0 3.503161565276969e-07
define O 0 6.170913025016489e-07
the O 0 2.4773476070549805e-07
role O 0 8.953534234024119e-07
of O 0 4.0487833530278294e-07
CA O 0 5.637958020088263e-05
IX O 0 0.004099358804523945
and O 0 3.305849077150924e-06
CA O 0 4.598806845024228e-05
XII O 0 0.000127524632262066
enzymes O 0 1.8202314322479651e-06
in O 0 2.14896630268413e-07
the O 0 1.5636004491170752e-07
regulation O 0 9.966922789317323e-07
of O 0 1.462703380639141e-07
pH O 0 5.876253908354556e-06
in O 0 4.1032535591511987e-07
the O 0 5.918530519011256e-07
extracellular O 0 3.435906364757102e-06
microenvironment O 0 1.4109102266957052e-05
and O 0 3.1681491918789106e-07
its O 0 2.961309064630768e-07
potential O 0 6.102440579525137e-07
impact O 0 2.1705759536416736e-06
on O 0 7.583530532428995e-06
cancer B-Disease 0 0.003364857751876116
cell O 0 0.00025014212587848306
growth O 0 2.3763115677866153e-05
. O 0 1.5715666449978016e-05

A O 0 0.00022333305969368666
gene O 0 0.0001025379533530213
encoding O 0 4.884790541836992e-05
a O 0 7.364735665760236e-06
transmembrane O 0 2.1988103981129825e-05
protein O 0 4.183104010735406e-06
is O 0 9.282903761231864e-07
mutated O 0 2.2410911697079428e-05
in O 0 2.6747540687210858e-05
patients O 1 0.5661954283714294
with O 1 0.6131267547607422
diabetes B-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 1 0.9971223473548889
optic B-Disease 1 0.9999997615814209
atrophy I-Disease 1 0.9999829530715942
( O 1 0.6914540529251099
Wolfram B-Disease 1 0.9999997615814209
syndrome I-Disease 1 1.0
) O 0 6.367241439875215e-05
. O 0 4.068072303198278e-05

Wolfram B-Disease 1 0.9999997615814209
syndrome I-Disease 1 1.0
( O 0 0.010289247147738934
WFS B-Disease 1 0.998778760433197
; O 0 0.0004704089951701462
OMIM O 1 0.8184093832969666
222300 O 0 0.0020522703416645527
) O 0 1.9365344996913336e-05
is O 0 3.527483841025969e-06
an O 0 3.787183595704846e-05
autosomal B-Disease 1 0.9999610185623169
recessive I-Disease 1 0.9999995231628418
neurodegenerative I-Disease 1 1.0
disorder I-Disease 1 0.9999774694442749
defined O 0 1.38516570586944e-05
by O 0 7.83072755439207e-06
young O 0 9.604286606190726e-05
- O 0 0.017811987549066544
onset O 0 0.012204251252114773
non O 0 8.339330815942958e-05
- O 0 0.12550680339336395
immune O 0 0.0006763640558347106
insulin B-Disease 0 0.052053339779376984
- I-Disease 1 0.9962988495826721
dependent I-Disease 1 0.9906045794487
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 0 0.03286474198102951
progressive O 1 0.9943273663520813
optic B-Disease 1 0.9999496936798096
atrophy I-Disease 0 0.07256307452917099
. O 0 0.00010442142229294404

Linkage O 0 0.0012980011524632573
to O 0 3.386913886060938e-05
markers O 0 5.638296715915203e-05
on O 0 1.5075730516400654e-05
chromosome O 0 0.00013630719331558794
4p O 0 0.010234849527478218
was O 0 2.168653554690536e-05
confirmed O 0 6.125458639871795e-06
in O 0 1.017302224681771e-06
five O 0 1.6222858221226488e-06
families O 0 7.430572168232175e-06
. O 0 1.315748886554502e-05

On O 0 3.2700958399800584e-05
the O 0 3.4189974940090906e-06
basis O 0 1.6622230987195508e-06
of O 0 1.1201173037989065e-06
meiotic O 0 0.00040554945007897913
recombinants O 0 0.0885603129863739
and O 0 0.00024654599837958813
disease O 0 0.026961196213960648
- O 0 0.0012054421240463853
associated O 0 2.972128459077794e-05
haplotypes O 0 8.202172466553748e-05
, O 0 2.9045991141174454e-06
the O 0 3.891596861649305e-06
WFS B-Disease 0 0.10002593696117401
gene O 0 1.877873182820622e-05
was O 0 5.104353931528749e-06
localized O 0 1.0417555131425615e-05
to O 0 1.1583616696952959e-06
a O 0 7.300890047190478e-06
BAC O 0 0.05389849841594696
/ O 0 0.0024744041729718447
P1 O 0 0.0019124827813357115
contig O 0 6.215668690856546e-05
of O 0 4.3694737428268127e-07
less O 0 1.8157841168431332e-06
than O 0 1.6196408978430554e-06
250 O 0 1.4200055375113152e-05
kb O 0 0.0008200688171200454
. O 0 6.098901212681085e-05

Mutations O 0 0.000786246673669666
in O 0 1.7945483705261722e-05
a O 0 8.038297892198898e-06
novel O 0 1.263805097551085e-05
gene O 0 2.0572271751007065e-05
( O 0 2.813130095091765e-06
WFS1 O 0 4.767737118527293e-05
) O 0 6.379732440109365e-07
encoding O 0 1.6492167560500093e-06
a O 0 6.496509854514443e-07
putative O 0 7.098435162333772e-06
transmembrane O 0 3.381373517186148e-06
protein O 0 8.170515002348111e-07
were O 0 4.380902112188778e-07
found O 0 2.8529871087812353e-07
in O 0 1.6123962609526643e-07
all O 0 1.0216174928245891e-07
affected O 0 5.602996111520042e-07
individuals O 0 1.0482730061767143e-07
in O 0 5.429310476756655e-07
six O 0 5.114162377140019e-06
WFS B-Disease 0 0.3337971866130829
families O 0 1.8395602410237188e-06
, O 0 3.353551676354982e-07
and O 0 1.6048407758262329e-07
these O 0 1.6311614103869942e-07
mutations O 0 1.5806184592292993e-06
were O 0 5.530193902814062e-07
associated O 0 1.5970130107234581e-06
with O 0 1.2456226841095486e-06
the O 0 0.00021845065930392593
disease O 1 0.9002197980880737
phenotype O 1 0.7692804336547852
. O 0 0.00011542310676304623

WFS1 O 0 0.01437534112483263
appears O 0 7.141676906030625e-05
to O 0 2.790053940771031e-06
function O 0 1.7198373143401113e-06
in O 0 1.2928470596307307e-06
survival O 0 1.3427872545435093e-05
of O 0 5.335725745680975e-07
islet O 0 5.534376032301225e-05
beta O 0 1.5867726688156836e-05
- O 0 9.771511395229027e-05
cells O 0 6.707866759825265e-06
and O 0 1.0976680187013699e-06
neurons O 0 1.5615154552506283e-05
. O 0 2.4246614884759765e-06
. O 0 9.561244951328263e-06

Stable O 0 0.0003441261942498386
interaction O 0 1.5210030142043252e-05
between O 0 2.5125116280833026e-06
the O 0 6.566709771504975e-07
products O 0 1.5477363604077254e-06
of O 0 1.518916832310424e-07
the O 0 9.739809456732473e-07
BRCA1 O 0 0.00022739607084076852
and O 0 9.3509897851618e-06
BRCA2 O 0 0.017181450501084328
tumor B-Disease 0 0.0007369291270151734
suppressor O 0 8.53611491038464e-05
genes O 0 1.403815440426115e-05
in O 0 4.959601938026026e-06
mitotic O 0 0.00020439519721549004
and O 0 2.611868330859579e-05
meiotic O 0 0.0029718121513724327
cells O 0 0.0003399434790480882
. O 0 4.675908712670207e-05

BRCA1 O 0 0.014826631173491478
and O 0 5.485091605805792e-05
BRCA2 O 0 0.00034515693550929427
account O 0 3.590788764995523e-06
for O 0 4.966442475051736e-07
most O 0 5.399917881732108e-07
cases O 0 4.841836585001147e-07
of O 0 2.4341437665498233e-07
familial O 0 1.9242979760747403e-05
, O 0 3.6673554859589785e-06
early O 0 0.015447668731212616
onset O 1 0.9994444251060486
breast B-Disease 1 0.6526342034339905
and I-Disease 0 9.435548417968675e-05
/ I-Disease 1 0.9998382329940796
or I-Disease 1 0.9435504674911499
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999535083770752
and O 0 1.7320139704679605e-06
encode O 0 2.8828751510445727e-06
products O 0 2.14581973523309e-06
that O 0 1.5384506468762993e-07
each O 0 1.1606898908667063e-07
interact O 0 9.324259053755668e-07
with O 0 8.628902605778421e-07
hRAD51 O 0 0.00012791644257958978
. O 0 2.518667133699637e-05

Results O 0 0.0005029399180784822
presented O 0 3.39822108799126e-05
here O 0 4.0399263525614515e-06
show O 0 5.45576813237858e-06
that O 0 8.75186685789231e-07
BRCA1 O 0 5.01829017593991e-05
and O 0 2.3424122446158435e-06
BRCA2 O 0 0.00020154631056357175
coexist O 0 4.986093699699268e-06
in O 0 6.457052563746402e-07
a O 0 1.220721856043383e-06
biochemical O 0 1.0999620826623868e-05
complex O 0 1.5718788972662878e-06
and O 0 1.1014368510586792e-06
colocalize O 0 3.489649679977447e-05
in O 0 1.5741201195851318e-06
subnuclear O 0 5.510056871571578e-05
foci O 0 2.7250816856394522e-05
in O 0 1.5012626590760192e-06
somatic O 0 2.414553819107823e-05
cells O 0 3.980849214713089e-06
and O 0 3.3072981864279427e-07
on O 0 4.174094954123575e-07
the O 0 3.2707751529414963e-07
axial O 0 2.8729616587952478e-06
elements O 0 1.0091615649798769e-06
of O 0 4.238032715875306e-07
developing O 0 1.1199207619938534e-05
synaptonemal O 0 0.0003849568893201649
complexes O 0 6.060659507056698e-05
. O 0 1.800163954612799e-05

Like O 0 0.00035653734812512994
BRCA1 O 0 0.0023257455322891474
and O 0 4.0751816413830966e-05
RAD51 O 0 0.010197318159043789
, O 0 1.811616493796464e-05
BRCA2 O 0 0.00021172966808080673
relocates O 0 0.00013588438741862774
to O 0 8.610040822532028e-06
PCNA O 0 0.00042567698983475566
+ O 0 2.114685958076734e-05
replication O 0 6.662206942564808e-06
sites O 0 1.139855839937809e-06
following O 0 1.373568011331372e-06
exposure O 0 3.6216617900208803e-06
of O 0 3.3400058896404516e-07
S O 0 0.0001105430637835525
phase O 0 1.796929063857533e-05
cells O 0 7.141273727029329e-06
to O 0 2.7063388188253157e-06
hydroxyurea O 0 0.00017698899318929762
or O 0 1.212562983710086e-05
UV O 0 0.000659643264953047
irradiation O 0 0.0003685769916046411
. O 0 5.264419087325223e-05

Thus O 0 7.264885061886162e-05
, O 0 1.848573265306186e-05
BRCA1 O 0 0.0002271184785058722
and O 0 1.8148095932701835e-06
BRCA2 O 0 4.940851067658514e-05
participate O 0 7.426757520079263e-07
, O 0 3.1334138839156367e-07
together O 0 1.9048032129376224e-07
, O 0 1.0455233478978698e-07
in O 0 1.4950003901503806e-07
a O 0 4.287171293526626e-07
pathway O 0 1.0795130265250918e-06
( O 0 4.234195216668013e-07
s O 0 4.8753317969385535e-06
) O 0 1.3342079796530015e-07
associated O 0 1.6185262552426138e-07
with O 0 3.6583216456165246e-08
the O 0 8.591781863742654e-08
activation O 0 8.572005185669695e-07
of O 0 9.526173982976616e-08
double O 0 1.64628920629184e-06
- O 0 9.030286310007796e-05
strand O 0 3.117086089332588e-05
break O 0 1.0345044756832067e-05
repair O 0 0.0005472413613460958
and O 0 5.121503363625379e-06
/ O 0 0.00017524791473988444
or O 0 3.5914190448238514e-06
homologous O 0 2.6603302103467286e-05
recombination O 0 7.373688276857138e-05
. O 0 3.3424479624954984e-05

Dysfunction O 0 0.009392239153385162
of O 0 3.9746355469105765e-06
this O 0 2.028541530307848e-06
pathway O 0 1.254199833056191e-05
may O 0 7.155508228606777e-06
be O 0 1.0552560780752174e-07
a O 0 2.0863623717559676e-07
general O 0 4.7324505203505396e-07
phenomenon O 0 8.353073326361482e-07
in O 0 1.781744600748425e-07
the O 0 1.1658607235176532e-07
majority O 0 2.267640439868046e-07
of O 0 7.427062342912905e-08
cases O 0 3.895270026532671e-07
of O 0 7.553602472398779e-07
hereditary B-Disease 1 0.9990887641906738
breast I-Disease 1 0.997189462184906
and I-Disease 0 0.01007836777716875
/ I-Disease 1 0.999980092048645
or I-Disease 1 0.9882925152778625
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999988079071045
. O 0 2.3500881070503965e-05
. O 0 3.507683504722081e-05

A O 0 0.0003702356480062008
novel O 0 0.0002289980766363442
Arg362Ser O 0 0.0009623523219488561
mutation O 0 4.0323760913452134e-05
in O 0 3.6576070669980254e-06
the O 0 2.403020289420965e-06
sterol O 0 0.00017500446119811386
27 O 0 2.2168629584484734e-05
- O 0 0.0001242776052094996
hydroxylase O 0 0.0001354706473648548
gene O 0 9.848796253209002e-06
( O 0 8.78224227562896e-07
CYP27 O 0 2.34975650528213e-05
) O 0 3.3665165233287553e-07
: O 0 1.1608061356582766e-07
its O 0 2.0241013487520831e-07
effects O 0 8.72386806349823e-07
on O 0 4.798017130269727e-07
pre O 0 8.913381861930247e-06
- O 0 6.967138233449077e-06
mRNA O 0 1.3920180208515376e-06
splicing O 0 6.561215286637889e-06
and O 0 1.3854834151061368e-06
enzyme O 0 1.0294971616531257e-05
activity O 0 7.112733783287695e-06
. O 0 1.2126832189096604e-05

A O 0 7.750092481728643e-05
novel O 0 4.060595529153943e-05
C O 0 4.9366070015821606e-05
to O 0 1.1828517472167732e-06
A O 0 3.3382302717654966e-06
mutation O 0 3.472073785815155e-06
in O 0 4.824174197892717e-07
the O 0 1.4290681065176614e-06
sterol O 0 0.00015900799189694226
27 O 0 2.1749003281001933e-05
- O 0 0.0001503900421084836
hydroxylase O 0 0.00019472121493890882
gene O 0 1.0630377801135182e-05
( O 0 1.8968464701174526e-06
CYP27 O 0 8.869119483279064e-05
) O 0 6.668110472674016e-07
was O 0 1.3851848734702799e-06
identified O 0 6.705824944219785e-07
by O 0 2.7188002604816575e-07
sequencing O 0 5.769443305325694e-06
amplified O 0 1.930451617226936e-05
CYP27 O 0 0.000117622381367255
gene O 0 8.428262844972778e-06
products O 0 3.0059229629841866e-06
from O 0 7.943262403387052e-07
a O 0 3.050866325793322e-06
patient O 0 6.969881360419095e-05
with O 0 1.1428587640693877e-05
cerebrotendinous B-Disease 1 0.9999932050704956
xanthomatosis I-Disease 1 0.9999924898147583
( O 0 0.00022117308981250972
CTX B-Disease 1 0.7710756659507751
) O 0 2.609943476272747e-05
. O 0 1.6403653717134148e-05

The O 0 0.00012160553887952119
mutation O 0 0.00014471259783022106
changed O 0 5.021028482588008e-05
the O 0 7.5974580795445945e-06
adrenodoxin O 0 0.00022498902399092913
cofactor O 0 0.0002349439891986549
binding O 0 2.7705429602065124e-05
residue O 0 3.149413532810286e-05
362Arg O 0 4.838355380343273e-05
to O 0 3.6211438327882206e-06
362Ser O 0 6.619515625061467e-05
( O 0 4.800653641723329e-06
CGT O 0 9.344868158223107e-05
362Arg O 0 3.2142794225364923e-05
to O 0 2.558796950324904e-06
AGT O 0 0.0004820286703761667
362Ser O 0 2.3070046154316515e-05
) O 0 4.3359705159673467e-07
, O 0 7.626632481105844e-08
and O 0 8.749415769671032e-08
was O 0 7.310981686714513e-07
responsible O 0 1.0118985755980248e-06
for O 0 3.993609880126314e-06
deficiency O 0 0.012187965214252472
in O 0 1.0135933052879409e-06
the O 0 1.760180225574004e-06
sterol O 0 0.00016602009418420494
27 O 0 1.1371207619959023e-05
- O 0 2.803472671075724e-05
hydroxylase O 0 2.3115677322493866e-05
activity O 0 1.1604048495428287e-06
, O 0 1.7988725176110165e-07
as O 0 1.3601129467133433e-07
confirmed O 0 3.612302634792286e-07
by O 0 1.0241421222190183e-07
expression O 0 4.57539300668941e-07
of O 0 1.393670174820727e-07
mutant O 0 9.565996151650324e-06
cDNA O 0 1.4879163245495874e-05
into O 0 5.152156063559232e-06
COS O 0 0.00045884883729740977
- O 0 3.9391088648699224e-05
1 O 0 5.527163921215106e-06
cells O 0 2.3541033442597836e-05
. O 0 1.1914449714822695e-05

Quantitative O 0 0.0008316835155710578
analysis O 0 6.514857523143291e-05
showed O 0 1.6846413927851245e-05
that O 0 4.457587579054234e-07
the O 0 1.9537510809186642e-07
expression O 0 7.794292855578533e-07
of O 0 1.9431018927207333e-07
CYP27 O 0 3.852459849440493e-05
gene O 0 3.3541350603627507e-06
mRNA O 0 9.732771104609128e-07
in O 0 4.065866221480974e-07
the O 0 1.0005988997363602e-06
patient O 0 3.0139461159706116e-05
represented O 0 1.0365428352088202e-05
52 O 0 5.37320229341276e-05
. O 0 2.4399741960223764e-05

5 O 0 6.077901343815029e-05
% O 0 8.513839020451996e-06
of O 0 5.679015089299355e-07
the O 0 1.8056013004752458e-06
normal O 0 1.3948850209999364e-05
level O 0 1.2818950381188188e-05
. O 0 1.3011520422878675e-05

As O 0 3.4810014767572284e-05
the O 0 6.727489562763367e-06
mutation O 0 1.5697602066211402e-05
occurred O 0 5.430840701592388e-06
at O 0 4.564767266401759e-07
the O 0 2.99818509574834e-07
penultimate O 0 1.1032861038984265e-05
nucleotide O 0 1.311952246396686e-06
of O 0 9.871515516124418e-08
exon O 0 3.9273327274713665e-06
6 O 0 1.0793164619826712e-06
( O 0 3.980223652888526e-07
- O 0 9.75202169684053e-07
2 O 0 2.0922044541293872e-07
position O 0 3.0124954264465487e-07
of O 0 7.524276668391394e-08
exon O 0 5.52491383132292e-06
6 O 0 2.058956170003512e-06
- O 0 1.038621849147603e-05
intron O 0 2.7237438189331442e-05
6 O 0 2.098660161209409e-06
splice O 0 1.40267920869519e-05
site O 0 1.0132398529094644e-06
) O 0 1.2304974461585516e-07
of O 0 2.9332039019891454e-08
the O 0 1.311737776177324e-07
gene O 0 7.697436217313225e-07
, O 0 9.739830630905999e-08
we O 0 1.4248450952436542e-07
hypothesized O 0 1.1651976592474966e-06
that O 0 1.2491148027038435e-07
the O 0 4.4392058384801203e-07
mutation O 0 2.544798917369917e-06
may O 0 1.4190725323715014e-06
partially O 0 2.6453467398823705e-06
affect O 0 9.806028629100183e-07
the O 0 2.500814275663288e-07
normal O 0 1.297300741498475e-06
splicing O 0 4.4847329263575375e-06
efficiency O 0 1.8081171901940252e-06
in O 0 7.008435431998805e-07
exon O 0 7.996750355232507e-06
6 O 0 6.71138479901856e-07
and O 0 2.2019426637598372e-07
cause O 0 5.899292432332004e-07
alternative O 0 1.4294374750534189e-06
splicing O 0 5.86095848120749e-06
elsewhere O 0 2.0044321900059003e-06
, O 0 2.3455770303826284e-07
which O 0 2.00039195874524e-07
resulted O 0 9.744305771164363e-07
in O 0 8.501341426381259e-07
decreased O 0 1.4685861970065162e-05
transcript O 0 2.6234411052428186e-05
in O 0 1.8832395198842278e-06
the O 0 5.616281669063028e-06
patient O 0 0.00023344346845988184
. O 0 1.7355758245685138e-05

Transfection O 0 0.0018699789652600884
of O 0 1.4106800335866865e-05
constructed O 0 6.397227116394788e-05
minigenes O 0 0.00037429018993861973
, O 0 1.283147071262647e-06
with O 0 1.415753843048151e-07
or O 0 1.563457203701546e-07
without O 0 1.4081659571729688e-07
the O 0 1.491172838541388e-07
mutation O 0 8.947158107730502e-07
, O 0 1.2301197216402215e-07
into O 0 3.6387186241881864e-07
COS O 0 0.00028791168006137013
- O 0 1.5084313417901285e-05
1 O 0 8.256874934886582e-07
cells O 0 1.5625197420376935e-06
confirmed O 0 6.125893037278729e-07
that O 0 7.393705914182647e-08
the O 0 2.3650153480048175e-07
mutant O 0 6.234601187316002e-06
minigene O 0 2.0428420612006448e-05
was O 0 1.445003704247938e-06
responsible O 0 2.9471939910763467e-07
for O 0 1.059521679280806e-07
a O 0 3.799248986524617e-07
mRNA O 0 1.334367425442906e-06
species O 0 3.706323070673534e-07
alternatively O 0 1.8600729845275055e-06
spliced O 0 5.942669304204173e-06
at O 0 6.237927436814061e-07
an O 0 8.698852980160154e-07
activated O 0 1.7865741028799675e-05
cryptic O 0 2.4152977857738733e-05
5 O 0 2.2087854176788824e-06
splice O 0 3.1642219255445525e-05
site O 0 2.9193734008003958e-06
88 O 0 4.024076133646304e-06
bp O 0 1.2008433259325102e-05
upstream O 0 1.303809881392226e-06
from O 0 1.7843990463006776e-07
the O 0 1.2750042799325456e-07
3 O 0 3.662119922864804e-07
end O 0 6.303891382231086e-07
of O 0 3.5886003502128005e-07
exon O 0 3.3271830034209415e-05
6 O 0 1.2950414202350657e-05
. O 0 2.0734962163260207e-05

Our O 0 3.600055424612947e-05
data O 0 1.0154113624594174e-05
suggest O 0 2.319637815162423e-06
that O 0 1.8407993707114656e-07
the O 0 2.909620775426447e-07
C O 0 4.607709342963062e-06
to O 0 4.606609991242294e-07
A O 0 1.5445028793692472e-06
mutation O 0 1.5270868516381597e-06
at O 0 3.882252599396452e-07
the O 0 3.5619339655568183e-07
penultimate O 0 1.6900385162443854e-05
nucleotide O 0 1.3800544138575788e-06
of O 0 1.4934870762317587e-07
exon O 0 4.476631147554144e-06
6 O 0 4.483445081859827e-07
of O 0 7.759836506693318e-08
the O 0 6.389365125869517e-07
CYP27 O 0 0.000536702573299408
gene O 0 3.5787820706900675e-06
not O 0 2.819243150042894e-07
only O 0 1.98064782352958e-07
causes O 0 1.6991424445222947e-06
the O 0 8.74711258802563e-06
deficiency B-Disease 0 0.005820909049361944
in I-Disease 0 6.268729748626356e-07
the I-Disease 0 1.2817343986171181e-06
sterol I-Disease 0 8.789313142187893e-05
27 I-Disease 0 1.3905312698625494e-05
- I-Disease 0 2.25440689973766e-05
hydroxylase I-Disease 0 2.7185795261175372e-05
activity I-Disease 0 1.2438598560038372e-06
, O 0 1.3544951116273296e-07
but O 0 1.7248093797661568e-07
also O 0 1.9431055875429593e-07
partially O 0 1.2674082654484664e-06
leads O 0 4.114315572678606e-07
to O 0 1.775551652372087e-07
alternative O 0 1.0678596709112753e-06
pre O 0 1.1706872101058252e-05
- O 0 8.426358363067266e-06
mRNA O 0 1.575766191308503e-06
splicing O 0 6.207630121934926e-06
of O 0 3.4019083727798716e-07
the O 0 2.4873047550499905e-06
gene O 0 3.0485507522826083e-05
. O 0 1.7166490579256788e-05

To O 0 1.7914211639435962e-05
our O 0 4.589290711010108e-06
knowledge O 0 2.0359661903057713e-06
, O 0 5.093152708468551e-07
this O 0 9.901309283577575e-08
is O 0 6.505412386559328e-08
the O 0 1.0068613676139648e-07
first O 0 7.334411407100561e-07
report O 0 1.0499793461349327e-06
regarding O 0 8.083801503744326e-07
effects O 0 1.864523710537469e-06
on O 0 7.232817438307393e-07
pre O 0 8.480420547130052e-06
- O 0 3.388010100024985e-06
mRNA O 0 9.66126663115574e-07
splicing O 0 1.614182224329852e-06
of O 0 6.261709017962858e-08
a O 0 4.315031389978685e-07
mutation O 0 1.2170532954769442e-06
at O 0 3.905406060766836e-07
the O 0 2.1749012546479207e-07
- O 0 3.7577269722532947e-06
2 O 0 3.5554177202357096e-07
position O 0 4.118307970202295e-07
of O 0 9.70211715412006e-08
a O 0 1.1727482842616155e-06
5 O 0 3.7014415283920243e-06
splice O 0 0.00013801870227325708
site O 0 3.5493405448505655e-05
. O 0 2.0758507162099704e-05

ATM O 0 0.016223659738898277
germline O 0 0.010321238078176975
mutations O 0 0.0006895142723806202
in O 0 3.771491537918337e-05
classical O 0 0.008568827994167805
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 1 0.9983242154121399
in O 0 7.503218967030989e-06
the O 0 2.279764657941996e-06
Dutch O 0 0.0002620771119836718
population O 0 9.248051355825737e-06
. O 0 1.5150372746575158e-05

Germline O 0 0.019091378897428513
mutations O 0 0.00028337768162600696
in O 0 9.498859981249552e-06
the O 0 4.005193204648094e-06
ATM O 0 9.430429781787097e-05
gene O 0 8.330247510457411e-06
are O 0 3.1393301469506696e-07
responsible O 0 1.535639057692606e-06
for O 0 2.7663543278322322e-06
the O 0 0.0921538770198822
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.00527592096477747
A B-Disease 1 0.9992315769195557
- I-Disease 1 0.9999852180480957
T I-Disease 1 0.9999903440475464
) O 0 1.423669255018467e-05
. O 0 1.4265027857618406e-05

In O 0 2.7680735001922585e-05
our O 0 3.629226739576552e-06
study O 0 2.074513076877338e-06
, O 0 2.616722554193984e-07
we O 0 1.4271488169015356e-07
have O 0 8.348002467073457e-08
determined O 0 2.9281488878041273e-07
the O 0 2.658508151398564e-07
ATM O 0 2.5052162527572364e-05
mutation O 0 3.4217732718389016e-06
spectrum O 0 2.343475898669567e-06
in O 0 7.21378398793604e-07
19 O 0 1.7255085822398541e-06
classical O 0 5.559353212447604e-06
A B-Disease 1 0.9964338541030884
- I-Disease 1 0.9999985694885254
T I-Disease 1 1.0
patients O 0 0.004448924213647842
, O 0 3.018025154233328e-07
including O 0 1.5124412300338008e-07
some O 0 1.8208514518391894e-07
immigrant O 0 2.717763209147961e-06
populations O 0 5.639175810756569e-07
, O 0 1.030935052881432e-07
as O 0 6.162161270140132e-08
well O 0 7.796004553028979e-08
as O 0 9.226219077618225e-08
12 O 0 1.6761902088546776e-07
of O 0 9.764104191845036e-08
Dutch O 0 1.3409025086730253e-05
ethnic O 0 1.2774327160514076e-06
origin O 0 6.464350008172914e-06
. O 0 9.42402402870357e-06

Both O 0 1.9096474716207013e-05
the O 0 4.747054845211096e-06
protein O 0 7.379035650956212e-06
truncation O 0 3.402105357963592e-05
test O 0 1.9351115042809397e-05
( O 0 1.4611714505008422e-06
PTT O 0 1.2048652024532203e-05
) O 0 3.5287251876070513e-07
and O 0 2.0240531739545986e-07
the O 0 2.967157683997357e-07
restriction O 0 6.695627689623507e-06
endonuclease O 0 7.29454040993005e-05
fingerprinting O 0 4.9468195356894284e-05
( O 0 2.855468892448698e-06
REF O 0 0.00010111837036674842
) O 0 2.4370473283852334e-07
method O 0 2.3720900799162337e-07
were O 0 1.4404396608824754e-07
used O 0 1.0509535997016428e-07
and O 0 7.350874398071028e-08
compared O 0 2.91440585442615e-07
for O 0 3.707563323018803e-08
their O 0 1.074965609859646e-07
detection O 0 1.2836145515393582e-06
efficiency O 0 1.1430616950747208e-06
, O 0 2.162894077173405e-07
identifying O 0 7.78926278144354e-07
76 O 0 2.0480420062085614e-06
% O 0 2.962489702440507e-07
and O 0 1.2421487838309986e-07
60 O 0 2.3292686535114626e-07
% O 0 1.8238475263387954e-07
of O 0 7.196825890787295e-08
the O 0 8.923630616664013e-07
mutations O 0 6.465768365160329e-06
, O 0 1.003178681457939e-06
respectively O 0 1.1932975212403107e-05
. O 0 1.4650415323558263e-05

Most O 0 0.00030281831277534366
patients O 0 0.07570259273052216
were O 0 1.2274481377971824e-05
found O 0 4.631959200196434e-06
to O 0 1.2619243534572888e-06
be O 0 2.1774217202619184e-06
compound O 0 5.8069002989213914e-05
heterozygote O 0 0.0006484031328000128
. O 0 6.785133882658556e-05

Seventeen O 0 0.0005710350233130157
mutations O 0 0.00013783801114186645
were O 0 2.8844590360677103e-06
distinct O 0 8.5101663671594e-07
, O 0 1.230829553833246e-07
of O 0 3.06674472483337e-08
which O 0 1.0522613536068093e-07
10 O 0 2.1480832401721273e-07
were O 0 7.327831781367422e-07
not O 0 6.865883506179671e-07
reported O 0 1.2938970030518249e-05
previously O 0 1.7475589629611932e-05
. O 0 1.2922017049277201e-05

Mutations O 0 0.0010582412360236049
are O 0 9.922509889292996e-06
small O 0 7.214889592432883e-06
deletions O 0 6.126864900579676e-05
or O 0 5.184533620194998e-06
point O 0 6.830532583990134e-06
mutations O 0 1.7520427718409337e-05
frequently O 0 1.003596935333917e-05
affecting O 0 1.9760153008974157e-05
splice O 0 0.00025585075491108
sites O 0 2.3465987396775745e-05
. O 0 2.371575465076603e-05

Moreover O 0 0.0006399712874554098
, O 0 2.4938437491073273e-05
a O 0 1.4833402929070871e-05
16 O 0 3.517055665724911e-05
. O 0 2.214006417489145e-05

7 O 0 0.00047033795272000134
- O 0 0.0009446627227589488
kb O 0 0.0007876903400756419
genomic O 0 4.9346919695381075e-05
deletion O 0 1.88192479981808e-05
of O 0 2.1626773616389983e-07
the O 0 3.7856827361792966e-07
3 O 0 3.7690506360377185e-07
end O 0 3.5215106208852376e-07
of O 0 4.8425896181925054e-08
the O 0 1.879637068213924e-07
gene O 0 9.769130429049255e-07
, O 0 1.1706559632784774e-07
most O 0 1.3263613141134556e-07
likely O 0 3.7508669947783346e-07
a O 0 1.7165784527151118e-07
result O 0 2.281806246173801e-07
of O 0 2.884689997983969e-08
recombination O 0 7.26469295386778e-07
between O 0 1.6504472455380892e-07
two O 0 1.2641500291010743e-07
LINE O 0 3.0540891202690545e-06
elements O 0 1.0184127177126356e-06
, O 0 8.104434527922422e-07
was O 0 3.6942335555067984e-06
identified O 0 5.613791472569574e-06
. O 0 6.279647095652763e-06

The O 0 2.6426074327901006e-05
most O 0 3.428364834690001e-06
frequently O 0 4.503170657699229e-06
found O 0 1.6510438172190334e-06
mutation O 0 2.4214841687353328e-06
, O 0 2.3791926651028916e-07
identified O 0 5.891336627428245e-07
in O 0 3.1738616712573275e-07
three O 0 3.876189396123664e-07
unrelated O 0 5.536834578379057e-06
Turkish O 0 2.8193257094244473e-05
A B-Disease 1 0.9964967370033264
- I-Disease 1 0.9999233484268188
T I-Disease 1 0.9999957084655762
individuals O 0 6.681012791887042e-07
, O 0 2.7170429461875756e-07
was O 0 1.427689539923449e-06
previously O 0 1.1367110346327536e-06
described O 0 1.791642375792435e-06
to O 0 1.2072591459855175e-07
be O 0 1.114483296760227e-07
a O 0 3.6876369335914205e-07
Turkish O 0 1.2497571333369706e-05
A B-Disease 1 0.9095566272735596
- I-Disease 1 0.9989122152328491
T I-Disease 1 0.9999607801437378
founder O 0 0.0002640577731654048
mutation O 0 8.746178355067968e-05
. O 0 1.8870399799197912e-05

The O 0 1.343837720924057e-05
presence O 0 5.6192711781477556e-06
of O 0 5.122008701619052e-07
a O 0 1.7350756706946413e-06
founder O 0 5.799207792733796e-05
mutation O 0 5.081822109787026e-06
among O 0 3.675558843951876e-07
relatively O 0 6.901431106598466e-07
small O 0 3.455315891187638e-07
ethnic O 0 2.926309150552697e-07
population O 0 1.1711930625324385e-07
groups O 0 8.085206815167112e-08
in O 0 2.0496040065154375e-07
Western O 0 1.5998621165635996e-06
Europe O 0 4.3730101424444e-06
could O 0 6.642734433626174e-07
indicate O 0 5.612735094473464e-07
a O 0 3.4190489373031596e-07
high O 0 1.1720539987436496e-06
carrier O 0 6.045660029485589e-06
frequency O 0 3.3082142181228846e-06
in O 0 1.1816387086582836e-06
such O 0 9.640430107538123e-07
communities O 0 9.323261110694148e-06
. O 0 1.9202025214326568e-05

In O 0 0.00021994876442477107
patients O 0 0.0003646216937340796
of O 0 1.3186340765969362e-06
Dutch O 0 4.429707405506633e-05
ethnic O 0 8.42294809899613e-07
origin O 0 1.370422637592128e-06
, O 0 2.5650879820204864e-07
however O 0 3.096589296092134e-07
, O 0 9.232696385197414e-08
no O 0 1.4276565707405098e-07
significant O 0 2.9624021635754616e-07
founder O 0 6.295796083577443e-06
effect O 0 1.4412381688089226e-06
could O 0 5.829834890391794e-07
be O 0 5.153671054358711e-07
identified O 0 4.885151611233596e-06
. O 0 4.8577003326499835e-06

The O 0 6.234843749552965e-05
observed O 0 6.615577876800671e-05
genetic O 0 3.093036139034666e-05
heterogeneity O 0 1.6574093024246395e-05
including O 0 9.445080877412693e-07
the O 0 6.422978913178667e-07
relative O 0 1.997718527491088e-06
high O 0 1.8598938140712562e-06
percentage O 0 2.2717777028447017e-06
of O 0 3.458154083091358e-07
splice O 0 0.00021969557565171272
- O 0 0.0006478815921582282
site O 0 1.2647298717638478e-05
mutations O 0 7.551985163445352e-06
had O 0 1.5803969972694176e-06
no O 0 4.996814482183254e-07
reflection O 0 2.600056177470833e-06
on O 0 1.4057536645850632e-06
the O 0 4.857112344325287e-06
phenotype O 0 0.0013391210231930017
. O 0 2.1721123630413786e-05

All O 0 8.246758079621941e-05
patients O 0 0.002648311899974942
manifested O 0 0.00017137581016868353
classical O 0 9.86466693575494e-05
A B-Disease 1 0.9976255297660828
- I-Disease 1 0.9978912472724915
T I-Disease 1 0.999087929725647
and O 0 3.727413968590554e-06
increased O 0 9.987294106394984e-06
cellular O 0 7.158155494835228e-05
radioresistant O 0 0.00019762622832786292
DNA O 0 6.075832061469555e-05
synthesis O 0 8.182525198208168e-05
. O 0 3.612749424064532e-05

Determination O 0 0.00011291554983472452
of O 0 2.16745252146211e-06
the O 0 2.081516413454665e-06
genomic O 0 4.753066150442464e-06
structure O 0 2.09243285098637e-06
of O 0 3.1338410622083757e-07
the O 0 1.4162873185341596e-06
COL4A4 O 0 0.002206340664997697
gene O 0 5.797931862616679e-06
and O 0 6.799471066187834e-07
of O 0 8.250546557064808e-07
novel O 0 2.9578070098068565e-05
mutations O 0 0.0005021279794164002
causing O 0 0.007373213302344084
autosomal B-Disease 1 0.9999918937683105
recessive I-Disease 1 0.9999996423721313
Alport I-Disease 1 1.0
syndrome I-Disease 1 0.9999997615814209
. O 0 0.0005986699252389371

Autosomal B-Disease 1 0.9999980926513672
recessive I-Disease 1 0.9999995231628418
Alport I-Disease 1 0.9999998807907104
syndrome I-Disease 1 0.9999998807907104
is O 0 6.20100399828516e-05
a O 0 7.63710995670408e-05
progressive O 0 0.25611361861228943
hematuric B-Disease 1 0.9978359341621399
glomerulonephritis I-Disease 1 0.9999871253967285
characterized O 0 0.0012829951010644436
by O 0 3.6096364055993035e-05
glomerular B-Disease 0 0.008847752586007118
basement I-Disease 0 0.4340774416923523
membrane I-Disease 0 0.004415333736687899
abnormalities I-Disease 1 0.9487996101379395
and O 0 2.3761299416946713e-06
associated O 0 2.6244701984978747e-06
with O 0 4.889291176368715e-07
mutations O 0 2.871624928957317e-06
in O 0 3.835534130303131e-07
either O 0 2.958695120014454e-07
the O 0 4.7276958525799273e-07
COL4A3 O 0 8.746903768042102e-05
or O 0 4.380496534395206e-07
the O 0 4.6355376071005594e-07
COL4A4 O 0 9.776583465281874e-05
gene O 0 1.5985932577677886e-06
, O 0 1.3670297960288735e-07
which O 0 8.187833344663886e-08
encode O 0 6.672626682302507e-07
the O 0 4.054312228163326e-07
alpha3 O 0 1.9564655303838663e-05
and O 0 2.3339880499406718e-06
alpha4 O 0 0.00033111032098531723
type O 0 8.637080463813618e-05
IV O 1 0.5586745738983154
collagen O 0 0.0003698881482705474
chains O 0 4.072516821906902e-05
, O 0 3.902906883013202e-06
respectively O 0 1.6412166587542742e-05
. O 0 1.7463909898651764e-05

To O 0 2.316069367225282e-05
date O 0 1.81934519787319e-05
, O 0 1.5778895203766297e-06
mutation O 0 3.309467047074577e-06
screening O 0 3.322308884889935e-06
in O 0 3.725668875631527e-07
the O 0 2.2461966864284477e-07
two O 0 2.7700824034582183e-07
genes O 0 1.1788686151703587e-06
has O 0 4.500254533468251e-07
been O 0 1.0011525546360645e-06
hampered O 0 7.196518708951771e-05
by O 0 3.3169132507282484e-07
the O 0 3.8516478184646985e-07
lack O 0 1.1146486258439836e-06
of O 0 2.676567589787737e-07
genomic O 0 1.0631533768901136e-05
structure O 0 9.501251952315215e-06
information O 0 9.092554137168918e-06
. O 0 1.978953332582023e-05

We O 0 5.364447497413494e-05
report O 0 1.7350230336887762e-05
here O 0 6.313462677098869e-07
the O 0 2.5017448024300393e-07
complete O 0 6.476602720795199e-07
characterization O 0 3.0505345876008505e-06
of O 0 9.315728277670132e-08
the O 0 2.1003690164889122e-07
48 O 0 7.311232366191689e-07
exons O 0 1.068527922143403e-06
of O 0 6.874781632859595e-08
the O 0 7.054247816995485e-07
COL4A4 O 0 0.00047910146531648934
gene O 0 3.438236944930395e-06
, O 0 2.97079907340958e-07
a O 0 4.092654819487507e-07
comprehensive O 0 3.3134301702375524e-06
gene O 0 3.233867346352781e-06
screen O 0 2.5256019853259204e-06
, O 0 2.650268413617596e-07
and O 0 1.1318513770675054e-07
the O 0 1.6273702385660727e-07
subsequent O 0 9.287003877034294e-07
detection O 0 1.7596347561266157e-06
of O 0 1.636621362877122e-07
10 O 0 7.908394650257833e-07
novel O 0 3.934369487978984e-06
mutations O 0 6.722076705045765e-06
in O 0 2.464500539645087e-06
eight O 0 0.0002399722143309191
patients O 1 0.9997835755348206
diagnosed O 1 0.9999991655349731
with O 1 0.5208273530006409
autosomal B-Disease 1 0.9999997615814209
recessive I-Disease 1 0.9999998807907104
Alport I-Disease 1 1.0
syndrome I-Disease 1 0.9999998807907104
. O 0 0.0006520752795040607

Furthermore O 0 0.00015176217129919678
, O 0 5.22770278621465e-06
we O 0 8.013017236407904e-07
identified O 0 1.080402853403939e-06
a O 0 5.024674010201124e-07
glycine O 0 6.018387466610875e-06
to O 0 5.664497848556493e-07
alanine O 0 4.4391686060407665e-06
substitution O 0 1.3006107337787398e-06
in O 0 5.084451117909339e-07
the O 0 5.754556582360237e-07
collagenous O 0 4.68601101601962e-05
domain O 0 1.258374254575756e-06
that O 0 2.755464549863973e-07
is O 0 2.8353269954095595e-07
apparently O 0 2.3288650936592603e-06
silent O 0 4.812012321053771e-06
in O 0 7.671889079574612e-07
the O 0 7.95246421603224e-07
heterozygous O 0 1.1880026249855291e-05
carriers O 0 5.234966465650359e-06
, O 0 9.688948239272577e-07
in O 0 1.9625538243417395e-06
11 O 0 8.528124453732744e-06
. O 0 1.3252313692646567e-05

5 O 0 3.1509724067291245e-05
% O 0 2.729170546444948e-06
of O 0 1.1443015068834939e-07
all O 0 9.847782678207295e-08
control O 0 6.093264346418437e-07
individuals O 0 8.652299499090077e-08
, O 0 9.39518898235292e-08
and O 0 2.4327931669176905e-07
in O 0 2.6628495675140584e-07
one O 0 2.4566062961639545e-07
control O 0 1.0013701512434636e-06
individual O 0 3.5224144312451244e-07
homozygous O 0 3.9749161260260735e-06
for O 0 3.338228964366863e-07
this O 0 1.1626158311628387e-06
glycine O 0 3.3751286537153646e-05
substitution O 0 3.368408215465024e-05
. O 0 1.876094211183954e-05

There O 0 2.198531547037419e-05
has O 0 3.1058191325428197e-06
been O 0 6.740614821865165e-07
no O 0 2.3590550313201675e-07
previous O 0 3.8479984709738346e-07
finding O 0 2.959711196126591e-07
of O 0 4.686566867917463e-08
a O 0 3.9981918575904274e-07
glycine O 0 5.105317995912628e-06
substitution O 0 9.154024951385509e-07
that O 0 1.148312449572586e-07
is O 0 6.647500327972011e-08
not O 0 1.0088663771057327e-07
associated O 0 2.4505598616997304e-07
with O 0 8.343243251829335e-08
any O 0 3.3595887316550943e-07
obvious O 0 3.1785148166818544e-05
phenotype O 0 0.013124315068125725
in O 0 9.422980838280637e-06
homozygous O 0 0.0001359875750495121
individuals O 0 3.831442882074043e-06
. O 0 1.0527995982556604e-05

Founder O 0 0.0053390259854495525
BRCA1 O 0 0.013013039715588093
and O 0 6.25489410595037e-05
BRCA2 O 0 0.0034331390634179115
mutations O 0 7.808995724190027e-05
in O 0 6.224513526831288e-06
French O 0 0.00021019310224801302
Canadian O 0 0.013283834792673588
breast B-Disease 1 0.9994319081306458
and I-Disease 1 0.9603766798973083
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999979734420776
families O 0 0.0003441933367867023
. O 0 0.00011046233703382313

We O 0 3.328573075123131e-05
have O 0 4.196584995952435e-06
identified O 0 2.760251163635985e-06
four O 0 5.027329734730301e-07
mutations O 0 9.947447097147233e-07
in O 0 8.513415394872936e-08
each O 0 4.182718171819033e-08
of O 0 7.953164526952605e-08
the O 0 1.6326242985087447e-05
breast B-Disease 1 0.9999469518661499
cancer I-Disease 1 0.9805333614349365
- O 0 0.12090970575809479
susceptibility O 0 0.00012161969061708078
genes O 0 4.555948635243112e-06
, O 0 9.981685025195475e-07
BRCA1 O 0 6.407979526557028e-05
and O 0 1.9856154267472448e-06
BRCA2 O 0 8.812097075860947e-05
, O 0 9.9083536042599e-07
in O 0 1.1901501011379878e-06
French O 0 7.695579552091658e-05
Canadian O 0 0.003488922258839011
breast B-Disease 1 0.9969170093536377
cancer I-Disease 1 0.8964766263961792
and O 0 0.13760928809642792
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999994039535522
families O 0 3.990476398030296e-05
from O 0 1.2441145372577012e-05
Quebec O 0 0.00042773698805831373
. O 0 5.599523865384981e-05

To O 0 9.241284715244547e-05
identify O 0 7.289477798622102e-05
founder O 0 8.952254574978724e-05
effects O 0 3.232733070035465e-05
, O 0 1.0526222240514471e-06
we O 0 4.570752594190708e-07
examined O 0 3.92267656934564e-06
independently O 0 1.7588881746632978e-06
ascertained O 0 7.877714779169764e-06
French O 0 2.4653780201333575e-05
Canadian O 0 0.000586728157941252
cancer B-Disease 0 0.0010100154904648662
families O 0 5.005466618968057e-07
for O 0 8.107257798428691e-08
the O 0 1.630579760103501e-07
distribution O 0 3.339139595937013e-07
of O 0 1.1675453492898669e-07
these O 0 3.497126499496517e-07
eight O 0 3.8134858186822385e-06
mutations O 0 3.161070344503969e-05
. O 0 1.3483127986546606e-05

Mutations O 0 0.0009610842098481953
were O 0 2.9034223189228214e-05
found O 0 6.669676622550469e-06
in O 0 2.2974368221184704e-06
41 O 0 4.901204192719888e-06
of O 0 6.643064125455567e-07
97 O 0 2.7414482246967964e-05
families O 0 1.2915609659103211e-05
. O 0 2.855630918929819e-05

Six O 0 2.665233660081867e-05
of O 0 1.981461309696897e-06
eight O 0 3.720134145623888e-06
mutations O 0 5.928223799855914e-06
were O 0 1.221976390297641e-06
observed O 0 1.5064528042785241e-06
at O 0 9.919320973494905e-07
least O 0 1.0159914154428407e-06
twice O 0 7.765122063574381e-06
. O 0 1.2238691851962358e-05

The O 0 0.0001790472597349435
BRCA1 O 0 0.0073760682716965675
C4446T O 0 0.0009194419835694134
mutation O 0 1.8889915736508556e-05
was O 0 2.3869044980528997e-06
the O 0 4.3182586750845076e-07
most O 0 6.47025615307939e-07
common O 0 1.736539047669794e-06
mutation O 0 3.170369382132776e-06
found O 0 5.867691470484715e-07
, O 0 2.8533460749713413e-07
followed O 0 1.0989930387950153e-06
by O 0 1.1987572179350536e-06
the O 0 5.868436346645467e-06
BRCA2 O 0 0.0006681566592305899
8765delAG O 0 0.00045333412708714604
mutation O 0 9.547197259962559e-05
. O 0 2.0940235117450356e-05

Together O 0 4.599543899530545e-05
, O 0 3.2063765047496418e-06
these O 0 6.421772127396252e-07
mutations O 0 2.862252131308196e-06
were O 0 5.023380253987852e-07
found O 0 3.289848677923146e-07
in O 0 1.84372467515459e-07
28 O 0 1.816314494362814e-07
of O 0 4.0259116929064476e-08
41 O 0 1.0165477988266503e-06
families O 0 5.062171339886845e-07
identified O 0 1.2265134046174353e-06
to O 0 2.640801994857611e-07
have O 0 8.841884096000285e-07
a O 0 5.112801773066167e-06
mutation O 0 2.778957423288375e-05
. O 0 1.0241983545711264e-05

The O 0 4.517916022450663e-05
odds O 0 7.960595394251868e-05
of O 0 1.6786294736448326e-06
detection O 0 6.827464858361054e-06
of O 0 2.128537204271197e-07
any O 0 2.9345281404857815e-07
of O 0 1.347068518953165e-07
the O 0 1.0628020845615538e-06
four O 0 1.2013656487397384e-05
BRCA1 O 0 0.003491463139653206
mutations O 0 3.220252983737737e-05
was O 0 1.9499664631439373e-05
18 O 0 1.8697017367230728e-05
. O 0 2.069629954348784e-05

7x O 0 0.10406234115362167
greater O 0 5.3716139518655837e-05
if O 0 4.563205948215909e-06
one O 0 5.506979050551308e-07
or O 0 3.052281840609794e-07
more O 0 1.8751609331957297e-07
cases O 0 5.756335212936392e-07
of O 0 1.1630821973085403e-05
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999990463256836
were O 0 1.477941987104714e-05
also O 0 1.0398300673841732e-06
present O 0 5.328037104845862e-07
in O 0 7.958746550684737e-07
the O 0 1.8257425153933582e-06
family O 0 1.9312399672344327e-05
. O 0 1.75588829733897e-05

The O 0 3.6552079109242186e-05
odds O 0 4.5451241021510214e-05
of O 0 7.510969908253173e-07
detection O 0 3.447838025749661e-06
of O 0 1.2124583292916213e-07
any O 0 1.5964755561981292e-07
of O 0 1.0229629765490245e-07
the O 0 6.638788931923045e-07
four O 0 5.387272267398657e-06
BRCA2 O 0 0.0009451912483200431
mutations O 0 1.2983791748411022e-05
was O 0 5.836761374666821e-06
5 O 0 5.9166222854400985e-06
. O 0 1.2770399735018145e-05

3x O 0 0.007711218670010567
greater O 0 5.806867193314247e-05
if O 0 6.529586244141683e-06
there O 0 8.412310990024707e-07
were O 0 4.5737743903373484e-07
at O 0 2.5262545477744425e-07
least O 0 2.2198264559847303e-07
five O 0 3.5071997217528406e-07
cases O 0 7.434162512254261e-07
of O 0 1.424394326932088e-06
breast B-Disease 1 0.9999871253967285
cancer I-Disease 1 0.6736695170402527
in O 0 5.503175088961143e-06
the O 0 6.389197096723365e-06
family O 0 5.031218097428791e-05
. O 0 2.687564119696617e-05

Interestingly O 0 0.000666520616505295
, O 0 3.878610186802689e-06
the O 0 5.586908855548245e-07
presence O 0 1.0278509989802842e-06
of O 0 2.19518483390857e-07
a O 0 7.798621663823724e-05
breast B-Disease 1 0.9999226331710815
cancer I-Disease 1 0.6033636927604675
case O 0 3.9714945160085335e-05
< O 0 5.181649248697795e-05
36 O 0 1.4066521316635772e-06
years O 0 3.2843092867551604e-07
of O 0 8.122194117277104e-08
age O 0 1.5063779983393033e-06
was O 0 1.3218221965871635e-06
strongly O 0 9.231162607648002e-07
predictive O 0 1.4831132375547895e-06
of O 0 4.343055337585611e-08
the O 0 7.940099067127449e-08
presence O 0 1.3609887616894412e-07
of O 0 3.247888002988475e-08
any O 0 5.263955316081592e-08
of O 0 4.329012170956048e-08
the O 0 5.16668251293595e-07
eight O 0 4.180806627118727e-06
mutations O 0 1.4326994460134301e-05
screened O 0 5.4771262512076646e-05
. O 0 2.0055711502209306e-05

Carriers O 0 0.0001456645259167999
of O 0 2.187603968195617e-06
the O 0 1.2708311487585888e-06
same O 0 1.568811853758234e-06
mutation O 0 2.6057259674416855e-06
, O 0 2.20639691406177e-07
from O 0 1.4449511809289106e-07
different O 0 1.885587010974632e-07
families O 0 5.399330689215276e-07
, O 0 1.6880483144632308e-07
shared O 0 5.313160045261611e-07
similar O 0 2.969197794300271e-06
haplotypes O 0 3.798932084464468e-05
, O 0 7.642656782991253e-07
indicating O 0 1.6832335631988826e-06
that O 0 1.6138453418079735e-07
the O 0 3.5790748142972006e-07
mutant O 0 5.520363174582599e-06
alleles O 0 2.037599870163831e-06
were O 0 4.509572590905009e-07
likely O 0 4.2088475993296015e-07
to O 0 7.048492278727281e-08
be O 0 4.719776214301419e-08
identical O 0 2.931009817075392e-07
by O 0 1.480707680912019e-07
descent O 0 1.163991555586108e-06
for O 0 1.2122235659717262e-07
a O 0 5.567835046349501e-07
mutation O 0 1.8635282685863785e-06
in O 0 6.150725084808073e-07
the O 0 1.3166450116841588e-06
founder O 0 4.1795032302616164e-05
population O 0 6.653730451944284e-06
. O 0 1.2955850252183154e-05

The O 0 2.7973088435828686e-05
identification O 0 2.1226665921858512e-05
of O 0 2.2318824903777568e-06
common O 0 3.377044413355179e-05
BRCA1 O 0 0.010489403270184994
and O 0 3.252356327720918e-05
BRCA2 O 0 0.00798084493726492
mutations O 0 1.2361550943751354e-05
will O 0 5.608486617347808e-07
facilitate O 0 2.0149079773545964e-06
carrier O 0 6.938262231415138e-06
detection O 0 5.827639142808039e-06
in O 0 1.6041934713939554e-06
French O 0 0.00019785888434853405
Canadian O 0 0.012177458964288235
breast B-Disease 1 0.9991046786308289
cancer I-Disease 1 0.8890909552574158
and O 0 0.17217326164245605
breast B-Disease 1 0.9999998807907104
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999995231628418
families O 0 0.0002974010130856186
. O 0 0.00013461397611536086

Are O 0 7.591510802740231e-05
Dp71 O 0 0.0010687850881367922
and O 0 2.9760991310467944e-05
Dp140 O 0 0.0018154338467866182
brain O 0 0.0024061009753495455
dystrophin O 0 0.0009769725147634745
isoforms O 0 0.00015828355390112847
related O 0 2.4887924155336805e-05
to O 0 1.235200761584565e-05
cognitive B-Disease 0 0.0025423355400562286
impairment I-Disease 1 0.7793897986412048
in O 0 0.011287744157016277
Duchenne B-Disease 1 0.999998927116394
muscular I-Disease 1 0.9999985694885254
dystrophy I-Disease 1 0.999993085861206
? O 0 0.0016685414593666792

Molecular O 0 0.0005056514637544751
study O 0 7.67744641052559e-05
and O 0 9.823327673075255e-06
neuropsychological O 0 0.0005289757973514497
analysis O 0 5.777608748758212e-06
were O 0 2.7407720608607633e-06
performed O 0 4.868529686063994e-06
concurrently O 0 2.0996210423618322e-06
on O 0 2.5877836833387846e-06
49 O 0 3.5303157346788794e-05
patients O 0 0.0003536013828124851
with O 0 0.00011118273687316105
Duchenne B-Disease 1 0.9999995231628418
muscular I-Disease 1 0.9999998807907104
dystrophy I-Disease 1 0.9999997615814209
( O 0 0.001802121289074421
DMD B-Disease 1 0.9999994039535522
) O 0 2.5152928628813243e-06
in O 0 3.9407464669238834e-07
order O 0 1.7740367752594466e-07
to O 0 1.3496801898327249e-07
find O 0 4.0778735410640365e-07
a O 0 5.440339805318217e-07
molecular O 0 1.3832575405103853e-06
explanation O 0 2.3866039100539638e-06
for O 0 4.06649064643716e-07
the O 0 3.709371640070458e-06
cognitive B-Disease 0 0.0004978962242603302
impairment I-Disease 0 0.007160991430282593
observed O 0 1.1505431757541373e-05
in O 0 7.787341019138694e-06
most O 0 0.00020175396639388055
DMD B-Disease 1 1.0
patients O 1 0.9603509306907654
. O 0 0.00010048031981568784

Complete O 0 9.044427133630961e-05
analysis O 0 1.283682377106743e-05
of O 0 6.983256071180222e-07
the O 0 2.2044798697606893e-06
dystrophin O 0 0.00028098170878365636
gene O 0 1.0294912499375641e-05
was O 0 7.830749382264912e-06
performed O 0 2.445993459332385e-06
to O 0 3.6046284890289826e-07
define O 0 7.648847031305195e-07
the O 0 2.1711460362894286e-07
localization O 0 1.8390270497548045e-06
of O 0 1.0279916295985458e-07
deletions O 0 4.888745024800301e-06
and O 0 8.200726142604253e-07
duplications O 0 6.852370006527053e-06
in O 0 4.963090418641514e-07
relation O 0 1.1089558711319114e-06
to O 0 4.435350433595886e-07
the O 0 1.6922615486691939e-06
different O 0 8.034696293179877e-06
DMD B-Disease 1 0.9999934434890747
promoters O 0 0.0007185026770457625
. O 0 5.616123235085979e-05

Qualitative O 0 0.00035042286617681384
analysis O 0 1.6767044144216925e-05
of O 0 7.371899641839263e-07
the O 0 1.8227727878183941e-06
Dp71 O 0 8.58855783008039e-05
transcript O 0 2.7536636480363086e-05
and O 0 5.427389737633348e-07
testing O 0 1.3429464615910547e-06
for O 0 9.999123307125046e-08
the O 0 1.1339658101405803e-07
specific O 0 1.1094356011653872e-07
first O 0 3.7219328419269004e-07
exon O 0 2.214247615484055e-06
of O 0 1.344518381074522e-07
Dp140 O 0 1.1630289009190165e-05
were O 0 9.137094707512006e-07
also O 0 4.0735938000580063e-07
carried O 0 2.1441035187308444e-06
out O 0 1.5035622027426143e-06
. O 0 5.4738943617849145e-06

Neuropsychological O 0 0.021439965814352036
analysis O 0 0.00026453984901309013
assessed O 0 0.00019166198035236448
verbal O 0 8.681854524184018e-05
and O 0 8.36314484331524e-06
visuospatial O 0 0.00037296320078894496
intelligence O 0 2.0440736989257857e-05
, O 0 1.73821581483935e-06
verbal O 0 8.307461939693894e-06
memory O 0 6.391525403159903e-06
, O 0 6.45638749574573e-07
and O 0 6.708626756335434e-07
reading O 0 1.265450191567652e-05
skills O 0 3.2327174267265946e-05
. O 0 2.1781943360110745e-05

Comparison O 0 0.00015764475392643362
of O 0 4.683413862949237e-06
molecular O 0 2.4309953005285934e-05
and O 0 4.7068720050447155e-06
psychometric O 0 0.0012879278510808945
findings O 0 8.270132093457505e-05
demonstrated O 0 5.872383098903811e-06
that O 0 4.4269788190831605e-07
deletions O 0 4.227781573717948e-06
and O 0 3.3718629310897086e-07
duplications O 0 3.612737600633409e-06
that O 0 2.8134124363532464e-07
were O 0 4.7078182774384914e-07
localized O 0 2.4484390905854525e-06
in O 0 3.994148300989764e-07
the O 0 3.741456566785928e-07
distal O 0 1.011068707157392e-05
part O 0 5.418850719252077e-07
of O 0 1.377802760771374e-07
the O 0 4.126457611164369e-07
gene O 0 2.847156338248169e-06
seemed O 0 2.8760978239006363e-06
to O 0 3.448840288911015e-07
be O 0 3.115479216830863e-07
preferentially O 0 3.862160156131722e-06
associated O 0 3.2798661777633242e-06
with O 0 3.2285795441566734e-06
cognitive B-Disease 0 0.00232005026191473
impairment I-Disease 0 0.3842822313308716
. O 0 5.235446951701306e-05

Two O 0 8.402630919590592e-05
altered O 0 0.0003775117511395365
Dp71 O 0 0.00031519850017502904
transcripts O 0 2.3671553208259866e-05
and O 0 1.0426911103422754e-06
two O 0 6.104477847657108e-07
deleted O 0 7.136773547244957e-06
Dp140 O 0 1.413668451277772e-05
DNA O 0 2.0241373022145126e-06
sequences O 0 4.4208363192410616e-07
were O 0 3.014929745859263e-07
found O 0 3.384879505574645e-07
in O 0 3.9172232391138095e-07
four O 0 4.717306183010805e-06
patients O 0 0.0005747199174948037
with O 0 1.8784105122904293e-05
severe O 1 0.9999967813491821
cerebral B-Disease 1 0.9999991655349731
dysfunction I-Disease 1 0.9997989535331726
. O 0 0.00020256951393093914

These O 0 3.769927570829168e-05
findings O 0 7.461021596100181e-05
suggest O 0 6.53199049338582e-06
that O 0 2.2828054113688268e-07
some O 0 1.0915543668943428e-07
sequences O 0 2.7351947551323974e-07
located O 0 1.8071396823415853e-07
in O 0 1.8631661191648163e-07
the O 0 3.8853752926115703e-07
distal O 0 9.98346513370052e-06
part O 0 2.821610394221352e-07
of O 0 6.909723282433333e-08
the O 0 2.1968121188820078e-07
gene O 0 8.423534154644585e-07
and O 0 1.6436318617252255e-07
, O 0 1.3251728603336232e-07
in O 0 1.650089984650549e-07
particular O 0 3.0507976589433383e-07
, O 0 2.2873381055887876e-07
some O 0 5.388620820667711e-07
DMD B-Disease 1 0.99992835521698
isoforms O 0 1.0511673281143885e-05
expressed O 0 9.759148724697297e-07
in O 0 7.717384846728237e-07
the O 0 3.887946604663739e-06
brain O 0 0.043299637734889984
may O 0 5.794322532892693e-06
be O 0 2.2929533827209525e-07
related O 0 5.561880129789643e-07
to O 0 3.2767007951406413e-07
the O 0 1.1949061899940716e-06
cognitive B-Disease 0 0.0005722656496800482
impairment I-Disease 0 0.07027416676282883
associated O 0 2.3020071239443496e-05
with O 0 3.840348290395923e-05
DMD B-Disease 1 0.9999998807907104
. O 0 6.954710988793522e-05
. O 0 3.208069028914906e-05

I1307K O 0 0.011475562117993832
APC O 0 0.0033285943791270256
and O 0 4.9315345677314326e-05
hMLH1 O 0 0.0005097955581732094
mutations O 0 2.599448816908989e-05
in O 0 1.4784387758481898e-06
a O 0 1.079206299436919e-06
non O 0 5.248017714620801e-06
- O 0 1.8981976609211415e-05
Jewish O 0 5.4171227930055466e-06
family O 0 6.781921911169775e-06
with O 0 5.73125907976646e-06
hereditary B-Disease 1 0.9800969958305359
non I-Disease 1 0.9662503600120544
- I-Disease 1 0.9999998807907104
polyposis I-Disease 1 0.9999992847442627
colorectal I-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
. O 0 0.00041132132173515856

We O 0 3.10025061480701e-05
describe O 0 2.2647933292319067e-05
a O 0 4.580327185976785e-06
French O 0 9.240165672963485e-05
Canadian O 0 0.00027961638988927007
hereditary B-Disease 1 0.8274909853935242
non I-Disease 0 0.4890240430831909
- I-Disease 1 0.9999998807907104
polyposis I-Disease 1 0.9999998807907104
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 0.2462868094444275
HNPCC B-Disease 1 0.9994157552719116
) O 0 1.6957892512436956e-05
kindred O 0 0.0001140208842116408
which O 0 9.065591939361184e-07
carries O 0 1.6808497775855358e-06
a O 0 2.413488800812047e-06
novel O 0 1.3044470506429207e-05
truncating O 0 0.00019303547742310911
mutation O 0 5.888190935365856e-05
in O 0 1.3675641639565583e-05
hMLH1 O 0 0.00044006435200572014
. O 0 4.509466452873312e-05

Interestingly O 0 0.0014005036791786551
, O 0 1.4902893781254534e-05
the O 0 5.970720849290956e-06
I1307K O 0 0.00014029632438905537
APC O 0 0.00011098445247625932
polymorphism O 0 1.600576979399193e-05
, O 0 5.176082140678773e-07
associated O 0 4.66315213998314e-07
with O 0 8.202886192520964e-08
an O 0 1.6212281650496152e-07
increased O 0 2.0261034023860702e-06
risk O 0 7.792577889631502e-06
of O 0 7.162272959249094e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 8.282197086373344e-06
is O 0 3.1458728244615486e-07
also O 0 2.396702996065869e-07
present O 0 2.953725015686359e-07
in O 0 8.44340831918089e-07
this O 0 1.431476903235307e-06
family O 0 1.4373797057487536e-05
. O 0 1.5273057215381414e-05

The O 0 7.128422294044867e-05
I1307K O 0 0.0004364843771327287
polymorphism O 0 0.00011642692697932944
has O 0 2.976651330754976e-06
previously O 0 2.5913598165061558e-06
only O 0 3.70065436072764e-07
been O 0 8.465435712423641e-07
identified O 0 8.454971407445555e-07
in O 0 2.1249472581530426e-07
individuals O 0 1.0795825033937945e-07
of O 0 1.292608828862285e-07
self O 0 3.344380093039945e-05
- O 0 0.03415048494935036
reported O 0 9.452983795199543e-05
Ashkenazi O 0 0.00012939728912897408
Jewish O 0 1.2533127119240817e-05
origins O 0 0.00010688245674828067
. O 0 3.03522410831647e-05

In O 0 1.9316579709993675e-05
addition O 0 4.030955096823163e-06
, O 0 6.590927341676434e-07
in O 0 3.8401825008804735e-07
this O 0 1.6280966974591138e-07
family O 0 9.666538289820892e-07
, O 0 1.9591021782616735e-07
there O 0 1.3092170547679416e-07
appears O 0 6.86942030370119e-07
to O 0 9.65371711458829e-08
be O 0 6.011831743535367e-08
no O 0 9.231393960362766e-08
relationship O 0 2.8180284061818384e-07
between O 0 9.93664883708334e-08
the O 0 3.2417983675259165e-07
I1307K O 0 1.4169145288178697e-05
polymorphism O 0 3.5174734875909053e-06
and O 0 1.2572093055496225e-07
the O 0 8.258538741756638e-08
presence O 0 2.4473973780914093e-07
or O 0 1.9382530069833592e-07
absence O 0 1.2332610594967264e-06
of O 0 7.599354034937278e-07
cancer B-Disease 0 0.0034072203561663628
. O 0 7.108867976057809e-06
. O 0 2.2238375095184892e-05

Identification O 0 8.943193824961782e-05
of O 0 3.798223588091787e-06
a O 0 5.83622704652953e-06
novel O 0 5.241271082923049e-06
mutation O 0 3.338207989145303e-06
of O 0 2.8247552563698264e-07
the O 0 1.0199678399658296e-06
CPO O 0 7.287227344932035e-05
gene O 0 5.0523308345873374e-06
in O 0 1.189271984003426e-06
a O 0 3.8140713058965048e-06
Japanese O 0 8.675075514474884e-05
hereditary B-Disease 0 0.05643342435359955
coproporphyria I-Disease 0 0.0038259441498667
family O 0 0.00012839448754675686
. O 0 4.651164272218011e-05

Hereditary B-Disease 1 0.9990052580833435
coproporphyria I-Disease 1 0.9374037981033325
( O 0 0.0010365907801315188
HCP B-Disease 0 0.06791163235902786
) O 0 7.25452719052555e-06
is O 0 1.6598390857325285e-06
an O 0 8.546540811948944e-06
autosomal B-Disease 1 0.985482931137085
dominant I-Disease 1 0.9994089603424072
disease I-Disease 1 0.9364959597587585
characterized O 0 0.00020384597883094102
by O 0 1.2714331205643248e-05
a O 0 0.0006770470645278692
deficiency B-Disease 0 0.022167693823575974
of I-Disease 0 5.297889629218844e-07
coproporphyrinogen I-Disease 0 0.00022780796280130744
oxidase I-Disease 0 4.9567166570341215e-05
( O 0 2.473374706823961e-06
CPO O 0 1.8631410057423636e-05
) O 0 5.389401849242859e-07
caused O 0 7.465280305041233e-07
by O 0 1.987421569538128e-07
a O 0 1.0425796972413082e-06
mutation O 0 2.3469513052987168e-06
in O 0 5.721663001168054e-07
the O 0 1.660719362917007e-06
CPO O 0 0.00016989865980576724
gene O 0 3.129968899884261e-05
. O 0 1.309705930907512e-05

Only O 0 3.728332376340404e-05
11 O 0 2.0679672161350027e-05
mutations O 0 6.4517248574702535e-06
of O 0 1.370160873648274e-07
the O 0 5.38547681117052e-07
gene O 0 2.4340374693565536e-06
have O 0 5.884149345547485e-07
been O 0 1.697914740361739e-06
reported O 0 1.6717325706849806e-05
in O 0 5.164501999388449e-05
HCP B-Disease 1 0.9824362993240356
patients O 0 0.0025470606051385403
. O 0 3.492350151645951e-05

We O 0 5.356856490834616e-05
report O 0 2.2845157218398526e-05
another O 0 3.370317926965072e-06
mutation O 0 6.186125119711505e-06
in O 0 9.909052778311889e-07
a O 0 2.157273229386192e-06
Japanese O 0 2.4995102648972534e-05
family O 0 2.1667952751158737e-05
. O 0 1.8487355191609822e-05

Polymerase O 0 0.0013415783178061247
chain O 0 0.00030827661976218224
reaction O 0 9.428766497876495e-05
- O 0 4.977292337571271e-05
single O 0 6.834995929239085e-06
strand O 0 3.7556026654783636e-05
conformational O 0 1.1601245205383748e-05
polymorphism O 0 1.0105000001203734e-05
and O 0 4.6568905531785276e-07
direct O 0 7.548612757091178e-07
sequence O 0 1.155511540673615e-06
analyses O 0 3.866644874506164e-06
demonstrated O 0 1.993466867133975e-06
a O 0 7.871915386203909e-07
C O 0 9.237096492142882e-06
to O 0 3.9457029288314516e-07
T O 0 1.5357856682385318e-05
substitution O 0 1.4139229733700631e-06
in O 0 7.369734476014855e-07
exon O 0 5.05349680679501e-06
1 O 0 3.078017130064836e-07
of O 0 9.048095250818733e-08
the O 0 3.6173773310110846e-07
CPO O 0 1.739643994369544e-05
gene O 0 1.8237204812976415e-06
at O 0 3.749157428956096e-07
nucleotide O 0 1.0534889725022367e-06
position O 0 7.78917296884174e-07
85 O 0 5.695731601917942e-07
, O 0 1.0788517812443388e-07
which O 0 7.10468199827119e-08
lies O 0 2.1119505788647075e-07
in O 0 1.1807875210934071e-07
the O 0 2.556535321218689e-07
putative O 0 4.902265573036857e-06
presequence O 0 1.4035384083399549e-05
for O 0 2.937863143870345e-07
targeting O 0 3.2795001061458606e-06
to O 0 1.746870680108259e-06
mitochondria O 0 7.993006147444248e-05
. O 0 1.8416019884170964e-05

This O 0 4.276088293408975e-05
mutation O 0 4.465708843781613e-05
changes O 0 5.687796601705486e-06
the O 0 1.1421714134485228e-06
codon O 0 8.964309017756023e-06
for O 0 5.148301625013119e-07
glutamine O 0 8.933678145695012e-06
to O 0 4.893475420431059e-07
a O 0 1.3179062534618424e-06
termination O 0 1.800205063773319e-05
codon O 0 2.087233224301599e-05
at O 0 2.6177986001130193e-06
amino O 0 4.050701591040706e-06
acid O 0 7.76259730628226e-06
position O 0 7.381836894637672e-06
29 O 0 2.0061124814674258e-05
. O 0 1.0064031812362373e-05

MaeI O 0 0.0019169714068993926
restriction O 0 9.739083907334134e-05
analysis O 0 1.3201302863308229e-05
showed O 0 4.846035153605044e-06
two O 0 2.3089479839200067e-07
other O 0 1.9889935742867237e-07
carriers O 0 1.5884612594163627e-06
in O 0 4.350575295575254e-07
the O 0 1.1499259926495142e-06
family O 0 1.8446849935571663e-05
. O 0 1.5704625184298493e-05

The O 0 9.40331956371665e-05
C O 0 0.02177923172712326
- O 1 0.8216091990470886
T O 0 0.28869035840034485
mutation O 0 1.0372152246418409e-05
is O 0 2.79645291811903e-07
located O 0 5.148424406797858e-07
within O 0 2.493883641818684e-07
a O 0 8.38793368984625e-07
recently O 0 3.043679726033588e-06
proposed O 0 3.38086397277948e-06
putative O 0 7.325635579036316e-06
alternative O 0 3.6228775570634753e-06
translation O 0 6.695104275422636e-06
initiation O 0 6.160355951578822e-06
codon O 0 1.8349823221797124e-05
( O 0 2.5889464723150013e-06
TIC O 0 7.435565203195438e-05
- O 0 4.60423007098143e-06
1 O 0 3.9254990724657546e-07
) O 0 1.3263525033835322e-07
, O 0 8.252523286955693e-08
supporting O 0 4.527503278950462e-07
that O 0 4.667516861900367e-07
TIC O 0 0.00024464717716909945
- O 0 8.638678991701454e-06
1 O 0 5.217484613240231e-07
is O 0 1.2276305483283068e-07
the O 0 3.1493277674599085e-07
real O 0 2.458223661960801e-06
TIC O 0 0.00014984383597038686
rather O 0 1.658133442106191e-06
than O 0 1.5889112319200649e-06
TIC O 0 0.0003622039803303778
- O 0 1.6930227502598427e-05
2 O 0 2.5488939172646496e-06
. O 0 2.0350753402453847e-06
. O 0 5.826283086207695e-06

Human B-Disease 0 0.00043134953011758626
complement I-Disease 0 0.0007775297854095697
factor I-Disease 0 0.002895846962928772
H I-Disease 1 1.0
deficiency I-Disease 1 0.999991774559021
associated O 0 0.005854063201695681
with O 1 0.751455545425415
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 0.9999998807907104
. O 0 0.0014763000654056668

This O 0 2.7551031962502748e-05
study O 0 1.5147743397392333e-05
reports O 0 6.775108431611443e-06
on O 0 1.4759058331037522e-06
six O 0 1.777323291207722e-06
cases O 0 1.2532688060673536e-06
of O 0 1.170060500044201e-06
deficiency B-Disease 0 0.4297010600566864
in I-Disease 0 1.3362929394133971e-06
the I-Disease 0 7.344805226239259e-07
human I-Disease 0 9.252579502572189e-07
complement I-Disease 0 4.030812760902336e-06
regulatory I-Disease 0 1.0173615919484291e-05
protein I-Disease 0 3.723822146639577e-06
Factor I-Disease 0 4.913812972517917e-06
H I-Disease 1 0.9831480979919434
( O 0 1.1612391062953975e-05
FH O 0 0.02892877161502838
) O 0 4.913893008051673e-07
in O 0 2.552425826252147e-07
the O 0 2.0843718573360093e-07
context O 0 1.2085879461665172e-06
of O 0 7.359417395491619e-07
an O 0 0.00043315617949701846
acute B-Disease 1 1.0
renal I-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 0.0011168261989951134

Five O 0 2.3543452698504552e-05
of O 0 9.939138863046537e-07
the O 0 9.666372307037818e-07
cases O 0 8.981448331724096e-07
were O 0 6.678063755316543e-07
observed O 0 9.85783344731317e-07
in O 0 8.172860930244497e-07
children O 0 4.658294983528322e-06
presenting O 0 7.055215974105522e-05
with O 0 0.3819998502731323
idiopathic O 1 1.0
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.3481401205062866
HUS B-Disease 1 0.9999990463256836
) O 0 0.0001121863751905039
. O 0 3.78013719455339e-05

Two O 0 9.598938959243242e-06
of O 0 1.2108687315048883e-06
the O 0 1.5475136478926288e-06
children O 0 1.0961305633827578e-05
exhibited O 0 0.0017040424281731248
a O 0 0.004282529000192881
homozygous O 1 0.9993923902511597
deficiency O 1 0.9972949624061584
characterized O 0 6.8456356530077755e-06
by O 0 4.405024753850739e-07
the O 0 4.206468133816088e-07
absence O 0 7.193133910732286e-07
of O 0 8.294610154280235e-08
the O 0 2.6618289439284126e-07
150 O 0 1.9049862203246448e-06
- O 0 3.643014497356489e-05
kD O 0 3.0294897442217916e-05
form O 0 3.5539193277145387e-07
of O 0 8.890047098475407e-08
Factor O 0 9.139508847511024e-07
H O 0 0.03672168403863907
and O 0 2.6337849590163387e-07
the O 0 1.8944624002870114e-07
presence O 0 2.2295989765552804e-07
, O 0 6.954877562748152e-08
upon O 0 9.028425296264686e-08
immunoblotting O 0 2.133663883796544e-06
, O 0 5.160753246968852e-08
of O 0 3.932704117914909e-08
the O 0 2.976323401071568e-07
42 O 0 4.852227448282065e-06
- O 0 5.397617496782914e-05
kD O 0 0.00012727754074148834
Factor O 0 3.94996777686174e-06
H O 1 0.5646609663963318
- O 0 1.1750179510272574e-05
like O 0 5.072590170129843e-07
protein O 0 1.0951137028314406e-06
1 O 0 6.91527361595945e-07
( O 0 1.0735185469457065e-06
FHL O 0 0.00012718145444523543
- O 0 1.049938964570174e-05
1 O 0 4.683868439769867e-07
) O 0 2.395025830992381e-07
and O 0 1.2554923500829318e-07
other O 0 6.252263347050757e-07
FH O 1 0.6382470726966858
- O 0 0.00011757361789932474
related O 0 5.148422587808454e-06
protein O 0 4.487454134505242e-06
( O 0 2.0227557797625195e-06
FHR O 0 8.768425323069096e-05
) O 0 3.2032405670179287e-06
bands O 0 1.583285120432265e-05
. O 0 1.8875691239372827e-05

Southern O 0 0.0006295707426033914
blot O 0 0.0016018563183024526
and O 0 9.201716238749214e-06
PCR O 0 6.531909457407892e-05
analysis O 0 1.5739115042379126e-06
of O 0 1.443913788534701e-07
DNA O 0 8.587953175265284e-07
of O 0 9.819142121614277e-08
one O 0 9.250673542737786e-07
patient O 0 6.017673877067864e-05
with O 0 1.7032834875863045e-05
homozygous O 1 0.9959225654602051
deficiency O 1 0.9711456894874573
ruled O 0 1.2157007404312026e-05
out O 0 3.5030211620323826e-07
the O 0 1.6599261698502232e-07
presence O 0 3.0230921765905805e-07
of O 0 4.1191203337120896e-08
a O 0 2.3753905509238393e-07
large O 0 3.548832410160685e-07
deletion O 0 3.836349605990108e-06
of O 0 1.291858211516228e-07
the O 0 1.086911652237177e-06
FH O 0 0.3962979018688202
gene O 0 2.5021768124133814e-06
as O 0 3.514763591283554e-07
the O 0 9.621041954233078e-07
underlying O 0 1.73557909874944e-05
defect O 0 7.862068014219403e-05
for O 0 2.9333716611290583e-06
the O 0 9.344414138467982e-05
deficiency O 1 0.5554428100585938
. O 0 5.285103543428704e-05

The O 0 1.4284180906543043e-05
other O 0 1.8146503180105356e-06
four O 0 1.383265384902188e-06
children O 0 2.859971345969825e-06
presented O 0 3.2869866117835045e-06
with O 0 6.8662634475913364e-06
heterozygous O 0 0.4977976679801941
deficiency O 1 0.8201985955238342
and O 0 3.0514686386595713e-06
exhibited O 0 7.725344767095521e-05
a O 0 3.4032686926366296e-06
normal O 0 1.183710901386803e-05
immunoblotting O 0 9.25278291106224e-05
pattern O 0 3.5704265428648796e-06
of O 0 1.1540508637608582e-07
proteins O 0 1.9476901513826306e-07
of O 0 1.179132311790454e-07
the O 0 2.9906993859185604e-06
FH O 1 0.9932624697685242
family O 0 4.452081338968128e-05
. O 0 1.933812745846808e-05

Factor B-Disease 0 0.3536897301673889
H I-Disease 1 0.9999998807907104
deficiency I-Disease 1 0.9997288584709167
is O 0 3.945232037949609e-06
the O 0 2.916762923632632e-06
only O 0 6.071423285902711e-06
complement B-Disease 1 0.9987710118293762
deficiency I-Disease 1 0.9999992847442627
associated O 0 8.390525181312114e-05
with O 0 3.624299279181287e-05
HUS B-Disease 1 0.9999985694885254
. O 0 0.00028628032305277884

These O 0 2.772754851321224e-05
observations O 0 3.868171916110441e-05
suggest O 0 6.321811270026956e-06
a O 0 1.071845986189146e-06
role O 0 2.4269540972454706e-06
for O 0 8.465661949230707e-07
FH O 1 0.8129295110702515
and O 0 1.0140584890905302e-05
/ O 0 0.0031280110124498606
or O 0 7.288965207408182e-06
FH O 0 0.1890876591205597
receptors O 0 7.24474421076593e-06
in O 0 1.1212930530746235e-06
the O 0 2.5636109057813883e-06
pathogenesis O 0 0.00015489134239032865
of O 0 8.737266398384236e-06
idiopathic O 1 0.9999706745147705
HUS B-Disease 1 0.9999997615814209
. O 0 0.0001405897201038897
. O 0 8.296602027257904e-05

Further O 0 8.520702976966277e-05
evidence O 0 1.639930451347027e-05
for O 0 1.6215681171161123e-06
a O 0 1.5708732234998024e-06
major O 0 3.22172672895249e-06
ancient O 0 1.6452831914648414e-05
mutation O 0 0.00018691938021220267
underlying O 0 0.03623523190617561
myotonic B-Disease 1 0.9999998807907104
dystrophy I-Disease 1 0.9999998807907104
from O 0 3.7812475056853145e-05
linkage O 0 0.0005174877587705851
disequilibrium O 0 0.0015661251964047551
studies O 0 7.777647624607198e-06
in O 0 2.151282615159289e-06
the O 0 2.0764844066434307e-06
Japanese O 0 1.2883268027508166e-05
population O 0 6.6184861680085305e-06
. O 0 1.3069933629594743e-05

The O 0 0.026910586282610893
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.8784964680671692
DM B-Disease 1 1.0
) O 0 4.670133057516068e-05
mutation O 0 1.4375181308423635e-05
is O 0 5.65379536965338e-07
an O 0 1.3075778042548336e-06
unstable O 0 0.00022815837292000651
( O 0 4.619897481461521e-06
CTG O 0 0.0001045062963385135
) O 0 8.957121622188424e-07
n O 0 1.2806810900656274e-06
repeat O 0 1.1588676898099948e-06
, O 0 9.256147848191176e-08
present O 0 1.3965308198748971e-07
at O 0 1.6947151948443206e-07
a O 0 1.5876693737482128e-07
copy O 0 7.873011327319546e-07
number O 0 5.344434228504724e-08
of O 0 2.7845750594224228e-08
5 O 0 2.5852210683297017e-07
- O 0 1.7586886542630964e-06
37 O 0 4.789870331478596e-07
repeats O 0 1.0247503041682648e-06
on O 0 3.683169893520244e-07
normal O 0 1.0534085959079675e-06
chromosomes O 0 1.2377739722069236e-06
but O 0 2.5332533937216795e-07
amplified O 0 2.3268382847163593e-06
to O 0 3.239925661091547e-07
50 O 0 5.236227593741205e-07
- O 0 6.8256813392508775e-06
3000 O 0 1.3075543392915279e-05
copies O 0 4.465247457119403e-06
on O 0 2.7293390303384513e-05
DM B-Disease 1 0.9999966621398926
chromosomes O 0 0.0001881635980680585
. O 0 2.6378262191428803e-05

Previous O 0 0.00034874086850322783
findings O 0 0.0001884262601379305
in O 0 1.186877034342615e-05
Caucasian O 0 0.0002464334247633815
populations O 0 3.542823833413422e-06
of O 0 5.923155299569771e-07
a O 0 6.493335968116298e-05
DM B-Disease 1 1.0
founder O 0 0.0024008830077946186
chromosome O 0 3.45435764756985e-05
raise O 0 2.6885811621468747e-06
a O 0 6.230305871213204e-07
question O 0 6.823870535299648e-07
about O 0 3.1629807040189917e-07
the O 0 3.3511793162688264e-07
molecular O 0 1.7338880979878013e-06
events O 0 5.026869303037529e-07
involved O 0 6.460687131948362e-07
in O 0 6.891913812978601e-07
the O 0 1.597795971974847e-06
expansion O 0 2.768820741039235e-05
mutation O 0 5.513389260158874e-05
. O 0 1.620934926904738e-05

To O 0 3.3161119063152e-05
investigate O 0 2.2471582269645296e-05
whether O 0 2.990896064147819e-06
a O 0 3.832356924249325e-06
founder O 0 3.253739851061255e-05
chromosome O 0 1.6013846106943674e-05
for O 0 7.389010647784744e-07
the O 0 1.0852371815417428e-05
DM B-Disease 1 1.0
mutation O 0 1.6374442566302605e-05
exists O 0 9.493811035099498e-07
in O 0 2.9644201049450203e-07
the O 0 2.0327851757429016e-07
Japanese O 0 1.4462776789514464e-06
population O 0 2.5482421506239916e-07
, O 0 1.094114026045645e-07
we O 0 1.1333118266065867e-07
genotyped O 0 1.2704609616775997e-05
families O 0 6.71390068873734e-07
using O 0 1.6585192952334182e-06
polymorphic O 0 1.405758121109102e-05
markers O 0 2.36366099670704e-06
near O 0 1.6143515040312195e-06
the O 0 9.934448144122143e-07
( O 0 2.9272682695591357e-06
CTG O 0 0.00018678700143937021
) O 0 2.315135816388647e-06
n O 0 3.1971460430213483e-06
repeat O 0 2.9447569431795273e-06
region O 0 1.7965733150049346e-06
and O 0 1.4137031030259095e-06
constructed O 0 4.432995410752483e-05
haplotypes O 0 0.00043835549149662256
. O 0 3.1785421015229076e-05

Six O 0 8.659612649353221e-05
different O 0 1.4587622899853159e-05
haplotypes O 0 0.0001310322986682877
were O 0 9.793339813768398e-06
found O 0 9.483762369200122e-06
and O 0 5.272558337310329e-05
DM B-Disease 1 1.0
alleles O 0 7.740343426121399e-05
were O 0 1.3071167813905049e-05
always O 0 1.4621062291553244e-05
haplotype O 0 0.00030899341800250113
A O 0 4.903899389319122e-05
. O 0 4.638314567273483e-05

To O 0 1.7628462956054136e-05
find O 0 6.130759629741078e-06
an O 0 6.138067760730337e-07
origin O 0 6.697171670566604e-07
of O 0 1.2130723803238652e-07
the O 0 5.701655823031615e-07
( O 0 1.9968117612734204e-06
CTG O 0 0.00011817945778602734
) O 0 1.236574007634772e-06
n O 0 2.105375642713625e-06
repeat O 0 1.6966035900622956e-06
mutation O 0 8.595278586653876e-07
and O 0 9.496494612903916e-08
to O 0 1.0426816032804709e-07
investigate O 0 4.4382954911270645e-07
the O 0 7.401551016528174e-08
mechanism O 0 1.6342023911875003e-07
of O 0 3.1116659471308594e-08
the O 0 1.259010105059133e-07
expansion O 0 1.6971279137578676e-06
mutation O 0 1.01775833627471e-06
in O 0 1.8798773737671581e-07
the O 0 1.3309050928000943e-07
Japanese O 0 8.712867725080287e-07
population O 0 1.348209792695343e-07
we O 0 5.8915393452707576e-08
have O 0 8.255672412360582e-08
studied O 0 4.956459065397212e-07
90 O 0 7.855259127609315e-07
Japanese O 0 2.4732338715693913e-05
DM B-Disease 1 0.9999997615814209
families O 0 4.875229478784604e-06
comprising O 0 2.558514097472653e-06
190 O 0 8.546165190637112e-06
affected O 0 4.544479452306405e-06
and O 0 1.033473267852969e-06
130 O 0 8.04739465820603e-06
unaffected O 0 0.00013480111374519765
members O 0 8.52903576742392e-06
. O 0 2.2689309844281524e-05

The O 0 3.578903852030635e-05
results O 0 6.215377652551979e-05
suggest O 0 5.488332135428209e-06
that O 0 3.20425044719741e-07
a O 0 4.992851927454467e-07
few O 0 9.993896128435154e-07
common O 0 1.9611804873420624e-06
ancestral O 0 1.1097441529273055e-05
mutations O 0 5.057807356934063e-06
in O 0 8.188706601686135e-07
both O 0 8.145361789502203e-07
Caucasian O 0 3.07516565953847e-05
and O 0 4.895127858617343e-07
Japanese O 0 2.8836118417530088e-06
populations O 0 8.634467576484894e-07
have O 0 1.3913820851030323e-07
originated O 0 3.3180583614011994e-07
by O 0 7.25951352364973e-08
expansion O 0 3.2256664894703135e-07
of O 0 2.9540954571416478e-08
an O 0 1.4244294277432346e-07
ancestral O 0 2.2687033833790338e-06
n O 0 6.0201955420779996e-06
= O 0 4.934052412863821e-06
5 O 0 6.720363785461814e-07
repeat O 0 1.2154885098425439e-06
to O 0 3.397460091036919e-07
n O 0 2.7749922537623206e-06
= O 0 4.731385615741601e-06
19 O 0 2.3315762973652454e-06
- O 0 1.033524313243106e-05
37 O 0 4.2682936509663705e-06
copies O 0 8.197877832571976e-06
. O 0 1.2489338587329257e-05

These O 0 3.495694909361191e-05
data O 0 1.8766275388770737e-05
support O 0 7.631326297996566e-06
multistep O 0 6.32492738077417e-05
models O 0 1.2493066606111825e-05
of O 0 5.260402531348518e-07
triplet O 0 5.024878919357434e-05
repeat O 0 3.933630523533793e-06
expansion O 0 1.6410050420745392e-06
that O 0 2.0358970687084366e-07
have O 0 1.3289796640947316e-07
been O 0 1.379779064336617e-07
proposed O 0 3.5674446507982793e-07
for O 0 2.616740175653831e-07
both O 0 3.464558858468081e-06
DM B-Disease 1 1.0
and O 0 7.471614662790671e-05
Friedreichs B-Disease 0 0.17987185716629028
ataxia I-Disease 0 0.3304165303707123
. O 0 1.3317281627678312e-05
. O 0 1.8479175196262076e-05

The O 0 5.523177605937235e-05
molecular O 0 4.090616130270064e-05
basis O 0 1.676285501162056e-05
of O 0 2.1224641386652365e-05
C6 B-Disease 1 1.0
deficiency I-Disease 1 0.9999992847442627
in O 0 7.312652542168507e-06
the O 0 2.4393498279096093e-06
western O 0 1.0158917575608939e-05
Cape O 0 2.841632885974832e-05
, O 0 1.6018498172343243e-06
South O 0 4.420757704792777e-06
Africa O 0 1.5753781553939916e-05
. O 0 1.1941921911784448e-05

Deficiency B-Disease 1 0.9745903611183167
of I-Disease 0 3.2465677577420138e-06
the I-Disease 0 2.4791677333269035e-06
sixth I-Disease 0 8.785385034570936e-06
component I-Disease 0 2.1785037915833527e-06
of I-Disease 0 1.6159984284058737e-07
human I-Disease 0 8.00639497811062e-07
complement I-Disease 0 2.911823912654654e-06
( O 0 2.068190042336937e-06
C6 O 0 0.0014973559882491827
) O 0 3.772560148718185e-07
has O 0 1.8697198811423732e-07
been O 0 2.95533368444012e-07
reported O 0 8.477117603433726e-07
in O 0 9.114956611711023e-08
a O 0 6.811193031808216e-08
number O 0 3.3391199139032324e-08
of O 0 2.429782597346275e-08
families O 0 2.3519227454471547e-07
from O 0 1.9726456912394497e-07
the O 0 3.1556805879517924e-07
western O 0 4.21507593273418e-06
Cape O 0 1.7713717170408927e-05
, O 0 9.035503012455592e-07
South O 0 4.474044544622302e-06
Africa O 0 1.5725125194876455e-05
. O 0 1.1187913514731918e-05

Meningococcal B-Disease 1 0.9999921321868896
disease I-Disease 1 0.9998249411582947
is O 0 3.483595355646685e-05
endemic O 0 5.362877345760353e-05
in O 0 2.2407780306821223e-06
the O 0 1.183713948194054e-06
Cape O 0 1.5357183656306006e-05
and O 0 3.3665037335595116e-07
almost O 0 1.7455037948366225e-07
all O 0 8.66352891648603e-08
pedigrees O 0 4.222511506668525e-06
of O 0 6.082395316298062e-07
total O 0 0.0003048927756026387
C6 B-Disease 1 1.0
deficiency I-Disease 1 0.9999998807907104
( O 0 1.6064153896877542e-05
C6Q0 O 0 0.0027313302271068096
) O 0 1.268223172701255e-06
have O 0 3.4063916132254235e-07
been O 0 7.600311278110894e-07
ascertained O 0 6.235784439923009e-06
because O 0 7.367176522166119e-07
of O 0 2.2931139938009437e-06
recurrent O 1 0.5806059837341309
disease O 1 0.5665171146392822
. O 0 5.6331798987230286e-05

We O 0 1.6932972357608378e-05
have O 0 2.566024932093569e-06
sequenced O 0 6.2455151237372775e-06
the O 0 3.648872279882198e-07
expressed O 0 6.3123434301815e-07
exons O 0 1.85578153377719e-06
of O 0 1.0582028409089617e-07
the O 0 8.528966759513423e-07
C6 O 0 0.0003715160710271448
gene O 0 3.6443827866605716e-06
from O 0 4.458437956600392e-07
selected O 0 7.343607535403862e-07
cases O 0 4.155753288159758e-07
and O 0 2.2049707126825524e-07
have O 0 3.3362684348503535e-07
found O 0 4.954549694957677e-07
three O 0 3.5211010640523455e-07
molecular O 0 1.6681779015925713e-05
defects O 0 0.0016961286310106516
leading O 0 1.6163619420694886e-06
to O 0 5.366604227674543e-07
total O 0 6.881819444970461e-06
deficiency O 0 0.022948822006583214
879delG O 0 3.048356120416429e-05
, O 0 3.279992881743965e-07
which O 0 1.0547248763259631e-07
is O 0 5.9756715131698e-08
the O 0 1.6268519686946092e-07
common O 0 2.7274686544842552e-06
defect O 0 2.7214509827899747e-05
in O 0 6.692204124192358e-07
the O 0 7.823336432011274e-07
Cape O 0 1.561217686685268e-05
and O 0 1.0016328815254383e-06
hitherto O 0 2.205351847806014e-05
unreported O 0 8.608916687080637e-06
, O 0 3.6529041835819953e-07
and O 0 5.332647674549662e-07
1195delC O 0 8.031501238292549e-06
and O 0 3.4255111813763506e-07
1936delG O 0 1.07993655547034e-05
, O 0 2.1523976556636626e-07
which O 0 8.139408436136364e-08
have O 0 1.26722795812384e-07
been O 0 3.665082601855829e-07
previously O 0 1.191860746985185e-06
reported O 0 2.7825260531244567e-06
in O 0 1.1397481785024866e-06
African O 0 6.638645572820678e-06
- O 0 8.752603025641292e-05
Americans O 0 9.480308108322788e-06
. O 0 9.027871783473529e-06

We O 0 1.8324570191907696e-05
also O 0 2.138800027751131e-06
show O 0 1.9568535662983777e-06
that O 0 1.490926848646268e-07
the O 0 2.583591935945151e-07
879delG O 0 1.5842731954762712e-05
and O 0 3.134757662337506e-06
1195delC O 0 0.06576792895793915
defects O 0 0.02852855809032917
are O 0 3.0671401418658206e-07
associated O 0 1.9902336134691723e-06
with O 0 1.6456957609989331e-06
characteristic O 0 0.00018772706971503794
C6 O 1 0.9995437264442444
/ O 0 0.3662629723548889
C7 O 0 0.009070123545825481
region O 0 2.0114361177547835e-05
DNA O 0 4.326664566178806e-05
marker O 0 1.8210044800071046e-05
haplotypes O 0 4.844597788178362e-05
, O 0 1.0700208576963632e-06
although O 0 1.1881859336426714e-06
small O 0 9.60388888415764e-07
variations O 0 6.757195478712674e-06
were O 0 4.277739662938984e-06
observed O 0 1.3244328329165e-05
. O 0 8.077218808466569e-06

The O 0 0.00011095005902461708
1936delG O 0 0.005263957194983959
defect O 0 0.0009716357453726232
was O 0 6.228527581697563e-06
observed O 0 1.458222982364532e-06
only O 0 1.1635481911298484e-07
once O 0 2.0321861882166559e-07
in O 0 1.797987607687901e-07
the O 0 1.966724880730908e-07
Cape O 0 5.11445023221313e-06
, O 0 1.4960872363189992e-07
but O 0 1.56976810217202e-07
its O 0 4.378358369194757e-07
associated O 0 1.182993219117634e-05
haplotype O 0 0.0002977855037897825
could O 0 2.8848689908045344e-06
be O 0 1.6499985804330208e-06
deduced O 0 3.0381401302292943e-05
. O 0 1.0663865396054462e-05

The O 0 2.0170989955659024e-05
data O 0 7.636320333404001e-06
from O 0 1.0269055792377912e-06
the O 0 8.878030826053873e-07
haplotypes O 0 2.653529190865811e-05
indicate O 0 2.1325145098671783e-06
that O 0 1.260942354974759e-07
these O 0 6.518142470213206e-08
three O 0 2.293222252092164e-07
molecular O 0 1.246477768290788e-05
defects O 0 0.00022019425523467362
account O 0 3.5126291209053306e-07
for O 0 1.662397579593744e-07
the O 0 2.5426302272535395e-06
defects O 0 0.017482582479715347
in O 0 3.4769672652146255e-07
all O 0 1.0493191382465739e-07
the O 0 2.0081313323316863e-07
38 O 0 1.7345298601867398e-06
unrelated O 0 9.264214895665646e-06
C6Q0 O 0 0.005100686568766832
individuals O 0 5.787645136479114e-07
we O 0 2.5493798716524907e-07
have O 0 2.8595681555998453e-07
studied O 0 2.0008280898764497e-06
from O 0 9.300316037297307e-07
the O 0 3.645203378255246e-06
Cape O 0 0.000232668622629717
. O 0 2.2079970221966505e-05

We O 0 2.8612057576538064e-05
have O 0 4.3771660784841515e-06
also O 0 1.2789455468009692e-06
observed O 0 1.297049607273948e-06
the O 0 5.714273925150337e-07
879delG O 0 6.783103162888438e-05
defect O 0 1.926229197124485e-05
in O 0 9.126722488872474e-07
two O 0 2.5473850655544084e-06
Dutch O 1 0.8296341896057129
C6 B-Disease 1 0.9999997615814209
- I-Disease 1 0.9997046589851379
deficient I-Disease 1 0.9999818801879883
kindreds O 0 0.00011119535338366404
, O 0 7.505398684770626e-07
but O 0 3.924177747194335e-07
the O 0 4.4203557081345934e-07
879delG O 0 9.513881377642974e-05
defect O 0 2.680259058251977e-05
in O 0 5.035860795032931e-07
the O 0 7.264609962476243e-07
Cape O 0 2.7232606953475624e-05
probably O 0 2.72853822025354e-06
did O 0 5.004020522392238e-07
not O 0 1.1581148129380381e-07
come O 0 1.6525861212812742e-07
from O 0 1.833197984524304e-07
The O 0 4.204634933557827e-07
Netherlands O 0 7.425131570926169e-06
. O 0 1.6324357829944347e-06
. O 0 5.997302650939673e-06

Complement B-Disease 1 0.9283345937728882
C7 I-Disease 1 0.9999998807907104
deficiency I-Disease 1 0.9999991655349731
: O 0 1.6506644897162914e-05
seven O 0 4.121476649743272e-06
further O 0 5.785404937341809e-06
molecular O 0 7.764635665807873e-05
defects O 0 0.005335552152246237
and O 0 1.8800704992827377e-06
their O 0 3.5505829600879224e-06
associated O 0 2.7688445698004216e-05
marker O 0 8.307502139359713e-05
haplotypes O 0 0.0006651477888226509
. O 0 5.66994676773902e-05

Seven O 0 7.777388964314014e-05
further O 0 1.9374543626327068e-05
molecular O 0 2.9691538657061756e-05
bases O 0 1.1025793355656788e-05
of O 0 3.0416249501286075e-05
C7 B-Disease 1 1.0
deficiency I-Disease 1 0.9999997615814209
are O 0 1.3993085303809494e-05
described O 0 0.0002762308286037296
. O 0 4.7440447815461084e-05

All O 0 1.3334996765479445e-05
these O 0 2.715571326916688e-06
new O 0 1.1535259545780718e-05
molecular O 0 7.537044439231977e-05
defects O 0 0.0005858053336851299
involve O 0 1.8259828493683017e-06
single O 0 2.2483836801256984e-06
- O 0 9.082657925318927e-06
nucleotide O 0 1.8228927274321904e-06
events O 0 5.28024088453094e-07
, O 0 2.1049329745892464e-07
deletions O 0 2.7597091047937283e-06
and O 0 2.4861637371031975e-07
substitutions O 0 1.437305741092132e-06
, O 0 9.966620950763172e-08
some O 0 3.245757440595298e-08
of O 0 3.2417052153732584e-08
which O 0 4.2873514871644147e-07
alter O 0 7.741135959804524e-06
splice O 0 1.1799949788837694e-05
sites O 0 8.319317998939368e-07
, O 0 3.3769154583751515e-07
and O 0 3.353020758822822e-07
others O 0 2.0145162125118077e-06
codons O 0 3.164137160638347e-05
. O 0 1.3220023902249523e-05

They O 0 1.9940272977692075e-05
are O 0 9.920379397954093e-07
distributed O 0 6.284364530984021e-07
along O 0 4.0001671663958405e-07
the O 0 7.778780286571418e-07
C7 O 0 0.0007048296392895281
gene O 0 5.214816155785229e-06
, O 0 3.031126425412367e-07
but O 0 2.4540563003938587e-07
predominantly O 0 5.154334417056816e-07
towards O 0 5.28951943579159e-07
the O 0 5.664551849804411e-07
3 O 0 1.6486270624227473e-06
end O 0 7.615331469423836e-06
. O 0 9.212165423377883e-06

All O 0 1.578021328896284e-05
were O 0 1.1332710528222378e-05
found O 0 4.238430847181007e-06
in O 0 2.3727966436126735e-06
compound O 0 5.3532559832092375e-05
heterozygous O 0 7.251347415149212e-05
individuals O 0 6.092228431953117e-06
. O 0 1.4598826055589598e-05

The O 0 0.00046140546328388155
C6 O 1 0.9948588609695435
/ O 1 0.7260647416114807
C7 O 0 0.21434025466442108
marker O 0 0.0002956418029498309
haplotypes O 0 0.0004661728162318468
associated O 0 2.3595264792675152e-05
with O 0 3.850087068713037e-06
most O 0 7.162253314163536e-05
C7 B-Disease 1 0.9999713897705078
defects I-Disease 1 0.8476473689079285
are O 0 1.6583359183641733e-06
tabulated O 0 7.38349772291258e-05
. O 0 5.1273141252750065e-06
. O 0 9.46278578339843e-06

A O 0 0.00027974334079772234
genome O 0 0.0001471151044825092
- O 0 5.738114123232663e-05
wide O 0 5.861495083081536e-06
search O 0 5.805025011795806e-06
for O 0 2.1168052626308054e-06
chromosomal O 0 8.384454849874601e-05
loci O 0 2.461422081978526e-05
linked O 0 2.086092899844516e-05
to O 0 3.4100523862434784e-06
mental O 0 0.06315646320581436
health O 0 0.00023316564329434186
wellness O 0 0.0005178417777642608
in O 0 6.563918759638909e-06
relatives O 0 1.2586355296662077e-05
at O 0 4.0483573684468865e-06
high O 0 1.0656120139174163e-05
risk O 0 2.7556365239433944e-05
for O 0 6.647335248999298e-05
bipolar B-Disease 1 1.0
affective I-Disease 1 0.9999940395355225
disorder I-Disease 1 0.9995777010917664
among O 0 2.952906697828439e-06
the O 0 2.8888914584968006e-06
Old O 0 5.824380787089467e-05
Order O 0 8.347096809302457e-06
Amish O 0 0.001130938297137618
. O 0 3.452401142567396e-05

Bipolar B-Disease 1 0.9999997615814209
affective I-Disease 1 0.9999890327453613
disorder I-Disease 1 0.9999901056289673
( O 0 0.002984806429594755
BPAD B-Disease 1 0.9999960660934448
; O 0 0.08800242096185684
manic B-Disease 1 0.9999996423721313
- I-Disease 1 0.9999994039535522
depressive I-Disease 1 1.0
illness I-Disease 1 0.9993773102760315
) O 0 5.166724804439582e-06
is O 0 6.461524435508181e-07
characterized O 0 3.5493437735567568e-06
by O 0 5.476957198879973e-07
episodes O 0 1.8999206758962828e-06
of O 0 5.37505059128307e-07
mania B-Disease 0 0.0007412931299768388
and O 0 6.77517346048262e-06
/ O 0 0.00885947234928608
or O 0 5.10159952682443e-06
hypomania B-Disease 0 0.0009804326109588146
interspersed O 0 1.4670379641756881e-05
with O 0 1.6957091020231019e-06
periods O 0 1.6000030882423744e-05
of O 0 3.1640624911233317e-06
depression B-Disease 0 0.0006942059844732285
. O 0 2.848456279025413e-05

Compelling O 0 0.0004298741987440735
evidence O 0 6.483367906184867e-05
supports O 0 1.648768738959916e-05
a O 0 3.6493981951934984e-06
significant O 0 4.131452897127019e-06
genetic O 0 8.953227734309621e-06
component O 0 3.974301762355026e-06
in O 0 1.0887645203183638e-06
the O 0 2.3607706225448055e-06
susceptibility O 0 3.4636665077414364e-05
to O 0 6.073739768908126e-06
develop O 0 0.00012054097169311717
BPAD B-Disease 1 0.9998669624328613
. O 0 4.449198968359269e-05

To O 0 2.504461372154765e-05
date O 0 1.4746010492672212e-05
, O 0 1.0518064073039568e-06
however O 0 1.0204787486145506e-06
, O 0 1.813410079876121e-07
linkage O 0 5.037503342464333e-06
studies O 0 1.3141335557520506e-06
have O 0 2.139902477438227e-07
attempted O 0 1.6117226095957449e-06
only O 0 2.645291488079238e-07
to O 0 4.1520098648106796e-07
identify O 0 4.054616510984488e-06
chromosomal O 0 2.634087832120713e-05
loci O 0 6.371557446982479e-06
that O 0 6.906046792209963e-07
cause O 0 1.8921489299827954e-06
or O 0 7.261797918545199e-07
increase O 0 1.3215422995926929e-06
the O 0 1.3144845070200972e-06
risk O 0 2.9520620046241675e-06
of O 0 1.0137808885701816e-06
developing O 0 7.775713311275467e-05
BPAD B-Disease 1 0.9999536275863647
. O 0 8.179677388397977e-05

To O 0 4.923288361169398e-05
determine O 0 1.6440848412457854e-05
whether O 0 3.4557613162178313e-06
there O 0 7.215118671410892e-07
could O 0 1.0093366427099681e-06
be O 0 2.3703940144059743e-07
protective O 0 7.63452953833621e-06
alleles O 0 1.9200188035028987e-06
that O 0 1.4499384803912108e-07
prevent O 0 5.672038696502568e-07
or O 0 4.995118274564447e-07
reduce O 0 1.4733561783941695e-06
the O 0 4.994842015548784e-07
risk O 0 9.012852046907938e-07
of O 0 1.6286976745050197e-07
developing O 0 2.953657713078428e-05
BPAD B-Disease 1 0.9999880790710449
, O 0 8.457624289803789e-07
similar O 0 2.386072992521804e-07
to O 0 1.335838817340118e-07
what O 0 1.8678611013456248e-07
is O 0 9.748435303436054e-08
observed O 0 4.0767574205347046e-07
in O 0 9.856536280494765e-07
other O 0 1.4444593034568243e-05
genetic B-Disease 1 0.9999889135360718
disorders I-Disease 1 0.9999997615814209
, O 0 2.323527724001906e-06
we O 0 1.1138632771690027e-06
used O 0 1.1029641427739989e-05
mental O 0 0.1290302723646164
health O 0 0.0003751945623662323
wellness O 0 0.004877331200987101
( O 0 1.767583398759598e-06
absence O 0 1.5052291928441264e-06
of O 0 2.1390353310835053e-07
any O 0 9.930906344379764e-06
psychiatric B-Disease 1 0.9999994039535522
disorder I-Disease 1 0.9990956783294678
) O 0 1.9766748664551415e-06
as O 0 6.018325393597479e-07
the O 0 1.1510779813761474e-06
phenotype O 0 0.0001824450446292758
in O 0 1.3534418030758388e-06
our O 0 1.476639340580732e-06
genome O 0 6.39736663288204e-06
- O 0 1.2081836757715791e-05
wide O 0 3.5020566429011524e-06
linkage O 0 3.5062421375187114e-05
scan O 0 3.44340514857322e-05
of O 0 1.7800851992433309e-07
several O 0 5.088676289233263e-07
large O 0 1.1665030115182162e-06
multigeneration O 0 3.2680229196557775e-05
Old O 0 1.3947094885224942e-05
Order O 0 1.7106196992244804e-06
Amish O 0 0.0002631301758810878
pedigrees O 0 0.00010959466453641653
exhibiting O 0 3.110565376118757e-05
an O 0 3.591442919059773e-06
extremely O 0 4.259739216649905e-05
high O 0 1.8098069631378166e-05
incidence O 0 0.00016107237024698406
of O 0 9.282149221689906e-06
BPAD B-Disease 1 0.9999747276306152
. O 0 8.974871889222413e-05

We O 0 3.347934762132354e-05
have O 0 3.071090304729296e-06
found O 0 1.3100068372295937e-06
strong O 0 9.549256674290518e-07
evidence O 0 8.584374882047996e-07
for O 0 1.869725281267165e-07
a O 0 9.989884119931958e-07
locus O 0 9.23039533518022e-06
on O 0 5.7298980209452566e-06
chromosome O 0 5.110483107273467e-05
4p O 0 0.0005555358366109431
at O 0 3.0847131711198017e-06
D4S2949 O 0 2.6288504159310833e-05
( O 0 1.0199543112321408e-06
maximum O 0 1.5683571064073476e-06
GENEHUNTER O 0 9.76186347543262e-05
- O 0 2.0489058442763053e-05
PLUS O 0 8.783055818639696e-06
nonparametric O 0 3.392123835510574e-05
linkage O 0 1.3813401892548427e-05
score O 0 2.4420078261755407e-06
= O 0 5.987370968796313e-06
4 O 0 9.690592150946031e-07
. O 0 6.074790235288674e-07
05 O 0 2.9473329050233588e-05
, O 0 8.329678280460939e-07
P O 0 2.2528422050527297e-05
= O 0 2.791480483210762e-06
5 O 0 3.572200739654363e-07
. O 0 8.067122081456546e-08
22 O 0 4.799765633833886e-07
x O 0 1.668969048296276e-06
10 O 0 3.895106317486352e-07
( O 0 5.309584025781078e-07
- O 0 3.4457407309673727e-06
4 O 0 5.872320798516739e-07
) O 0 2.694741851883009e-07
; O 0 3.330527249545412e-07
SIBPAL O 0 2.6605128368828446e-05
Pempirical O 0 9.168376891466323e-06
value O 0 4.4192807990839356e-07
< O 0 3.440345835770131e-06
3 O 0 4.7246848566828703e-07
x O 0 2.0626648620236665e-06
10 O 0 3.514964532769227e-07
( O 0 4.967470772498928e-07
- O 0 3.403431037440896e-06
5 O 0 3.051408725696092e-07
) O 0 1.4424439598315075e-07
) O 0 8.603588241840043e-08
and O 0 1.1895176044163236e-07
suggestive O 0 3.078283043578267e-06
evidence O 0 4.3831667539961927e-07
for O 0 1.8458058548276313e-07
a O 0 1.0842478559425217e-06
locus O 0 7.555997399322223e-06
on O 0 8.72159125719918e-06
chromosome O 0 8.837773202685639e-05
4q O 0 0.025893284007906914
at O 0 5.130655154061969e-06
D4S397 O 0 3.0225437512854114e-05
( O 0 1.5432572126883315e-06
maximum O 0 2.2499323222291423e-06
GENEHUNTER O 0 7.271073991432786e-05
- O 0 1.4043136616237462e-05
PLUS O 0 9.56199255597312e-06
nonparametric O 0 4.908923801849596e-05
linkage O 0 1.4323032701213378e-05
score O 0 2.2041015199647518e-06
= O 0 5.029457497585099e-06
3 O 0 7.038381681923056e-07
. O 0 2.1846902598099405e-07
29 O 0 6.87601982463093e-07
, O 0 3.270697277457657e-07
P O 0 2.1103182007209398e-05
= O 0 2.243301196358516e-06
2 O 0 3.4413065463922976e-07
. O 0 1.6996371243749309e-07
57 O 0 8.699806812728639e-07
x O 0 2.0411064269865165e-06
10 O 0 3.342807133321912e-07
( O 0 3.343001537814416e-07
- O 0 2.1816140360897407e-06
3 O 0 3.5605077641776006e-07
) O 0 2.2512472241942305e-07
; O 0 2.1964413576824882e-07
SIBPAL O 0 3.121956251561642e-05
Pempirical O 0 1.4994072444096673e-05
value O 0 3.9076115854186355e-07
< O 0 2.4036919512582244e-06
1 O 0 2.8174557087368157e-07
x O 0 1.3687938462680904e-06
10 O 0 2.591149836916884e-07
( O 0 3.235102781218302e-07
- O 0 2.688286258489825e-06
3 O 0 3.8378391309379367e-07
) O 0 1.4541356563313457e-07
) O 0 7.07552558765201e-08
that O 0 4.203344161624045e-08
are O 0 5.997515017952537e-08
linked O 0 4.266543783160159e-06
to O 0 5.169992618903052e-06
mental O 0 0.144399031996727
health O 0 0.001678713713772595
wellness O 0 0.03964706137776375
. O 0 6.424200546462089e-05

These O 0 2.6885403713095002e-05
findings O 0 5.418101136456244e-05
are O 0 6.166665684759209e-07
consistent O 0 2.1735338577855146e-06
with O 0 1.705118108930037e-07
the O 0 4.330829312948481e-07
hypothesis O 0 2.9914638162154006e-06
that O 0 1.9933933970150974e-07
certain O 0 3.785971216530015e-07
alleles O 0 2.8955939797015162e-06
could O 0 7.281061584762938e-07
prevent O 0 1.0220223884971347e-06
or O 0 7.784828426338208e-07
modify O 0 7.050494332361268e-06
the O 0 1.0697739298848319e-06
clinical O 0 2.8775777536793612e-05
manifestations O 0 6.828448476881022e-06
of O 0 7.083931450324599e-07
BPAD B-Disease 1 0.9999855756759644
and O 0 6.762920293112984e-06
perhaps O 0 4.235537744534668e-06
other O 0 3.956505224778084e-06
related O 0 0.0001832788111642003
affective B-Disease 1 0.9918569326400757
disorders I-Disease 1 0.9990212917327881
. O 0 9.582587517797947e-05

Segregation O 0 0.014523761346936226
distortion O 0 0.032048583030700684
in O 0 0.008548444136977196
myotonic B-Disease 1 0.9999995231628418
dystrophy I-Disease 1 0.9999996423721313
. O 0 0.0010354261612519622

Myotonic B-Disease 1 0.9999998807907104
dystrophy I-Disease 1 1.0
( O 1 0.9944233298301697
DM B-Disease 1 1.0
) O 0 7.582423859275877e-05
is O 0 3.7742261156381574e-06
an O 0 5.344981673260918e-06
autosomal B-Disease 1 0.5374845862388611
dominant I-Disease 1 0.9064123630523682
disease I-Disease 0 0.07431522011756897
which O 0 7.263861903084035e-07
, O 0 2.3393799608584231e-07
in O 0 2.8564610943249136e-07
the O 0 3.565407382666308e-07
typical O 0 1.0538935384829529e-05
pedigree O 0 6.623936496907845e-05
, O 0 5.20643027357437e-07
shows O 0 6.085703034841572e-07
a O 0 4.945745217810327e-07
three O 0 5.97152450154681e-07
generation O 0 1.1328085747663863e-05
anticipation O 0 1.894810156954918e-05
cascade O 0 7.266450120368972e-05
. O 0 1.4535699847328942e-05

This O 0 9.498815052211285e-05
results O 0 0.00020047878206241876
in O 0 8.258129673777148e-05
infertility B-Disease 1 0.999900221824646
and O 1 0.9611966013908386
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.0008156989933922887
CDM B-Disease 0 0.006548458710312843
) O 0 1.6582031321377144e-06
with O 0 3.0630857850155735e-07
the O 0 5.986412361380644e-07
disappearance O 0 8.876474566932302e-06
of O 0 1.316152861363662e-06
DM B-Disease 1 1.0
in O 0 3.319469396956265e-05
that O 0 8.48554918775335e-06
pedigree O 0 0.0001471476280130446
. O 0 2.453187153150793e-05

The O 0 1.0696019671740942e-05
concept O 0 9.43993654800579e-06
of O 0 1.3338686812858214e-06
segregation O 0 2.3858416170696728e-05
distortion O 0 3.087583900196478e-05
, O 0 3.63558285698673e-07
where O 0 1.0690645524391584e-07
there O 0 9.304471149107485e-08
is O 0 6.829144894027195e-08
preferential O 0 1.5377831914520357e-06
transmission O 0 1.7102348692787928e-06
of O 0 7.534961810051755e-08
the O 0 3.1469289751839824e-07
larger O 0 1.3766510846835445e-06
allele O 0 6.268362540140515e-06
at O 0 9.010394137476396e-07
the O 0 3.632789912444423e-06
DM B-Disease 1 0.9999998807907104
locus O 0 1.0108199603564572e-05
, O 0 6.770773097741767e-07
has O 0 2.5970675210373884e-07
been O 0 1.749730387246018e-07
put O 0 2.5019880922627635e-07
forward O 0 3.837228064185183e-07
to O 0 1.8051382255634962e-07
explain O 0 1.0111990604855237e-06
partially O 0 1.647377530389349e-06
the O 0 4.553792791739397e-07
maintenance O 0 6.147714429971529e-06
of O 0 1.0544378028498613e-06
DM B-Disease 1 1.0
in O 0 6.678664249193389e-06
the O 0 1.6092868690975592e-06
population O 0 3.894117526215268e-06
. O 0 6.509969807666494e-06

In O 0 4.641903069568798e-05
a O 0 1.1017331416951492e-05
survey O 0 1.1853829164465424e-05
of O 0 1.9317255919304444e-06
DM B-Disease 1 1.0
in O 0 6.017543910274981e-06
Northern O 0 3.913021373591619e-06
Ireland O 0 5.970248366793385e-06
, O 0 6.932031055839616e-07
59 O 0 7.513623586419271e-06
pedigrees O 0 5.726481322199106e-05
were O 0 1.3120537914801389e-05
ascertained O 0 0.00011316961172269657
. O 0 1.2191211681056302e-05

Sibships O 0 0.00041075318586081266
where O 0 2.3126290216168854e-06
the O 0 3.6200208342052065e-07
status O 0 2.0473008532917447e-07
of O 0 1.8737445373062656e-08
all O 0 2.0329842698174616e-08
the O 0 5.596241337002539e-08
members O 0 1.261064994650951e-07
had O 0 1.0862225963137462e-06
been O 0 2.922064936683455e-07
identified O 0 6.722563057337538e-07
were O 0 7.74719126184209e-07
examined O 0 4.270500085112872e-06
to O 0 1.4515516966184805e-07
determine O 0 2.9215269137239375e-07
the O 0 2.0843599202180485e-07
transmission O 0 2.577542545623146e-06
of O 0 1.6783239686901652e-07
the O 0 2.9203868052718462e-06
DM B-Disease 1 0.9999991655349731
expansion O 0 7.955613000376616e-06
from O 0 1.2313772685956792e-06
affected O 0 1.8563391677162144e-06
parents O 0 1.288398834731197e-06
to O 0 4.489893115078303e-07
their O 0 2.0037591639265884e-06
offspring O 0 3.005218241014518e-05
. O 0 1.1557745892787352e-05

Where O 0 4.154516136622988e-05
the O 0 1.3996208508615382e-05
transmitting O 0 7.772428944008425e-05
parent O 0 7.666326564503834e-05
was O 0 2.0518156816251576e-05
male O 0 1.609852370165754e-05
, O 0 2.547858912294032e-06
58 O 0 2.9695416742470115e-05
. O 0 1.9032691852771677e-05

3 O 0 4.542618989944458e-05
% O 0 4.252070539223496e-06
of O 0 2.0876244377632247e-07
the O 0 3.8511777233907196e-07
offspring O 0 3.2699067560315598e-06
were O 0 6.212286507434328e-07
affected O 0 9.802008662518347e-07
, O 0 1.4032941919595032e-07
and O 0 1.0531990568551919e-07
in O 0 1.2988181197215454e-07
the O 0 1.1396924293194388e-07
case O 0 3.403865491691249e-07
of O 0 5.499631683392181e-08
a O 0 1.0704902706493158e-06
female O 0 8.694269126863219e-06
transmitting O 0 2.6813022486749105e-05
parent O 0 2.744752237049397e-05
, O 0 3.674420213428675e-06
68 O 0 4.227755925967358e-05
. O 0 1.6960302673396654e-05

7 O 0 0.00045834435150027275
% O 0 6.7241104261484e-05
were O 0 2.1569940145127475e-05
affected O 0 7.02121396898292e-05
. O 0 3.338695387355983e-05

Studies O 0 0.0001705672184471041
on O 0 1.6814248738228343e-05
meiotic O 0 0.0002950718626379967
drive O 0 2.795290492940694e-05
in O 0 5.7644996559247375e-05
DM B-Disease 1 0.9999998807907104
have O 0 2.7108412723464426e-06
shown O 0 9.799821327760583e-07
increased O 0 6.92719424932875e-07
transmission O 0 1.9153551420458825e-06
of O 0 5.101990652178756e-08
the O 0 1.4007991921971552e-07
larger O 0 9.63173647505755e-07
allele O 0 8.841378985380288e-06
at O 0 1.352405661236844e-06
the O 0 4.52978520115721e-06
DM B-Disease 1 0.9999991655349731
locus O 0 1.790251371858176e-05
in O 0 5.487390353664523e-06
non O 0 0.00011709932005032897
- O 1 0.9177988171577454
DM O 1 0.9999997615814209
heterozygotes O 0 0.001007597427815199
for O 0 1.6204974599531852e-05
CTGn O 0 0.0007652211934328079
. O 0 4.2889569158433005e-05

This O 0 3.807713437709026e-05
study O 0 1.5783118215040304e-05
provides O 0 3.7794561649207026e-06
further O 0 1.7344074194625136e-06
evidence O 0 2.2003841877449304e-06
that O 0 6.666997478532721e-07
the O 0 2.803263896566932e-06
DM B-Disease 1 0.9999994039535522
expansion O 0 1.2825211342715193e-05
tends O 0 6.740410299244104e-06
to O 0 7.352192028520221e-07
be O 0 9.417469186701055e-07
transmitted O 0 1.9371716916793957e-05
preferentially O 0 3.5483459214447066e-05
. O 0 1.5827990864636377e-05

Diagnosis O 1 0.9998650550842285
of O 0 0.0007444125949405134
hemochromatosis B-Disease 1 0.9999984502792358
. O 0 0.0019086438696831465

If O 0 0.0010653254576027393
untreated O 1 0.9936578869819641
, O 0 0.0014526995364576578
hemochromatosis B-Disease 1 1.0
can O 0 4.4676256948150694e-05
cause O 0 0.00019112216250505298
serious O 0 0.009843545965850353
illness O 0 0.10001032799482346
and O 0 2.0261943518562475e-06
early B-Disease 0 9.137357847066596e-05
death I-Disease 0 2.5350385840283707e-05
, O 0 6.508769843094342e-07
but O 0 1.4648688875240623e-06
the O 0 7.015308710833779e-06
disease O 0 0.00016765577311161906
is O 0 5.799789732918725e-07
still O 0 4.283740963728633e-06
substantially O 0 0.00022040557814761996
under O 0 0.00033732078736647964
- O 1 0.9999504089355469
diagnosed O 1 0.9989376664161682
. O 0 3.7657126085832715e-05

The O 0 2.4122502509271726e-05
cornerstone O 0 5.367845733417198e-05
of O 0 1.120241222452023e-06
screening O 0 2.2161842935020104e-05
and O 0 1.5402005146825104e-06
case O 0 2.8250076411495684e-06
detection O 0 3.85935800295556e-06
is O 0 1.5648414830593538e-07
the O 0 2.1176259679123177e-07
measurement O 0 2.101850895996904e-06
of O 0 2.9280511171236867e-07
serum O 0 2.7659911211230792e-05
transferrin O 0 2.2074096705182455e-05
saturation O 0 4.938872734783217e-06
and O 0 6.880881073811906e-07
the O 0 7.136897579584911e-07
serum O 0 3.819445919361897e-05
ferritin O 0 0.00016596628120169044
level O 0 2.356798358960077e-05
. O 0 2.8955557354493067e-05

Once O 0 0.0002810626174323261
the O 0 3.917680442100391e-05
diagnosis O 1 0.8934684991836548
is O 0 2.73011301032966e-06
suspected O 0 3.6074234230909497e-05
, O 0 2.4729431515879696e-06
physicians O 0 3.065088458242826e-05
must O 0 1.0750799219749752e-06
use O 0 2.6096925012097927e-06
serum O 0 6.296943320194259e-05
ferritin O 0 0.00018758283113129437
levels O 0 7.243894287967123e-06
and O 0 3.3812443689384963e-06
hepatic O 0 0.000834961305372417
iron O 0 0.0005042640841566026
stores O 0 2.9138853278709576e-05
on O 0 3.370201011421159e-05
liver O 0 0.2337081879377365
biopsy O 1 0.9568365216255188
specimens O 0 1.6222336853388697e-05
to O 0 1.8622279185365187e-06
assess O 0 0.00013550205039791763
patients O 0 3.968177770730108e-05
for O 0 3.6018454352415574e-07
the O 0 4.2667858224376687e-07
presence O 0 3.168730927427532e-06
of O 0 1.4759044688616996e-06
iron B-Disease 0 0.09976103901863098
overload I-Disease 0 0.001767337671481073
. O 0 3.508794179651886e-05

Liver O 1 0.999987006187439
biopsy O 1 0.9998131394386292
is O 0 4.64449476567097e-06
also O 0 7.889329367571918e-07
used O 0 3.085608568653697e-07
to O 0 1.6806080793685396e-07
establish O 0 3.489500386422151e-07
the O 0 1.5026088817648997e-07
presence O 0 3.684610305754177e-07
or O 0 1.7957428610770876e-07
absence O 0 7.90857541232981e-07
of O 0 3.652294537914713e-07
cirrhosis B-Disease 0 0.011414200067520142
, O 0 7.94949926330446e-07
which O 0 8.62259355471906e-07
can O 0 1.1080753665737575e-06
affect O 0 2.4689801648491994e-05
prognosis O 1 0.9429012537002563
and O 0 1.811188121791929e-05
management O 0 0.00017142077558673918
. O 0 3.382717113709077e-05

A O 0 0.0002578957355581224
DNA O 0 0.00014711903349962085
- O 0 8.02754148025997e-05
based O 0 5.712841357308207e-06
test O 0 4.669886493502418e-06
for O 0 4.044661636726232e-07
the O 0 6.901865958752751e-07
HFE O 0 0.00022732453362550586
gene O 0 2.719853227972635e-06
is O 0 1.8647108390723588e-07
commercially O 0 1.2348440350251622e-06
available O 0 3.4418383165757405e-07
, O 0 1.0052418275563468e-07
but O 0 6.900635440842962e-08
its O 0 7.045709793374044e-08
place O 0 1.3290620870520797e-07
in O 0 2.0658842458942672e-07
the O 0 1.141255779657513e-06
diagnosis O 0 0.4418140947818756
of O 0 9.565440450387541e-06
hemochromatosis B-Disease 1 1.0
is O 0 5.327444796421332e-06
still O 0 4.771879048348637e-06
being O 0 9.607163519831374e-06
evaluated O 0 5.7095774536719546e-05
. O 0 1.4120018931862433e-05

Currently O 0 2.2278578398982063e-05
, O 0 1.1166732747369679e-06
the O 0 1.818560804167646e-07
most O 0 1.049035063260817e-07
useful O 0 1.9690877195444045e-07
role O 0 1.5061023361795378e-07
for O 0 6.233146621070773e-08
this O 0 7.273497715232224e-08
test O 0 8.082097906481067e-07
is O 0 4.852232393659506e-08
in O 0 7.937554613590692e-08
the O 0 9.960007929521453e-08
detection O 0 1.4967594097470283e-06
of O 0 9.879263416223694e-07
hemochromatosis B-Disease 1 0.9999994039535522
in O 0 3.127099034827552e-06
the O 0 4.377677953470993e-07
family O 0 1.1700113873303053e-06
members O 0 3.4598696174725774e-07
of O 0 2.67264198328121e-07
patients O 0 3.8031732401577756e-05
with O 0 3.1010668521957996e-07
a O 0 2.932219331341912e-06
proven O 0 2.445264362904709e-05
case O 0 1.5940214552756515e-06
of O 0 3.973529487666383e-07
the O 0 2.630480594234541e-05
disease O 0 0.002484729280695319
. O 0 1.4833431123406626e-05

It O 0 3.277076393715106e-05
is O 0 6.302493602561299e-06
crucial O 0 2.68943804258015e-05
to O 0 6.938103615539148e-05
diagnose O 1 0.9999964237213135
hemochromatosis B-Disease 1 1.0
before O 1 0.5076543092727661
hepatic B-Disease 1 0.999972939491272
cirrhosis I-Disease 1 0.9989699125289917
develops O 0 0.0010693458607420325
because O 0 6.69622968416661e-05
phlebotomy O 0 0.4999738037586212
therapy O 0 0.15627916157245636
can O 0 1.3280908206070308e-05
avert O 0 0.3653452694416046
serious O 1 0.9999538660049438
chronic O 1 1.0
disease O 1 0.9946211576461792
and O 0 7.107797500793822e-06
can O 0 7.001140716056398e-07
even O 0 4.756326745791739e-07
lead O 0 6.406217494259181e-07
to O 0 3.770315686324466e-07
normal O 0 2.7004168714483967e-06
life O 0 5.777989372290904e-06
expectancy O 0 2.9232456654426642e-05
. O 0 2.5518857000861317e-06
. O 0 8.257762601715513e-06

Prevalence O 0 0.0013643320417031646
of O 0 4.482680651562987e-06
the O 0 6.887617018946912e-06
I1307K O 0 0.0003176359459757805
APC B-Disease 0 0.00021278770873323083
gene O 0 1.3079011296213139e-05
variant O 0 2.0547391613945365e-05
in O 0 8.199927492569259e-07
Israeli O 0 2.7627133931673598e-06
Jews O 0 7.287758876373118e-07
of O 0 1.0789011639644741e-07
differing O 0 9.340278666059021e-07
ethnic O 0 3.8756385833949025e-07
origin O 0 1.006918637358467e-06
and O 0 3.0227483875933103e-06
risk O 0 3.421918154344894e-05
for O 0 0.002783037256449461
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999996423721313
. O 0 0.00032084411941468716

BACKGROUND O 0 0.001404935377649963
& O 0 0.0005086309392936528
AIMS O 0 3.885107071255334e-05
Israeli O 0 1.4819051102676895e-05
Jews O 0 3.1413985652761767e-06
of O 0 3.5621445704236976e-07
European O 0 5.486479949468048e-06
birth O 0 9.312775546277408e-06
, O 0 4.3205406541346747e-07
i O 0 1.254588937626977e-06
. O 0 2.637668501392909e-07
e O 0 6.741412335031782e-07
. O 0 1.0255396887259849e-07
, O 0 1.5977352063600847e-07
Ashkenazim O 0 1.021708612825023e-05
, O 0 1.3112813235238718e-07
have O 0 1.4348842114486615e-07
the O 0 2.319715349585749e-06
highest O 1 0.8261609077453613
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
incidence O 0 0.0012154780561104417
of O 0 3.2651993819854397e-07
any O 0 9.181083555631631e-07
Israeli O 0 3.087401273660362e-05
ethnic O 0 3.173515096932533e-06
group O 0 1.0781111996038817e-05
. O 0 1.1820109648397192e-05

The O 0 0.00014558580005541444
I1307K O 0 0.0022136587649583817
APC B-Disease 0 0.0010769586078822613
gene O 0 0.00010570882295724005
variant O 0 0.00022087532852310687
was O 0 2.8671463951468468e-05
found O 0 6.7297742134542204e-06
in O 0 3.86123565476737e-06
6 O 0 1.7879718143376522e-05
. O 0 1.8320271919947118e-05

1 O 0 3.1704501452622935e-05
% O 0 4.479103608900914e-06
of O 0 2.5177570250889403e-07
American O 0 6.856709546809725e-07
Jews O 0 1.3990116940476582e-06
, O 0 2.3331169529683393e-07
28 O 0 6.638579748141638e-07
% O 0 2.0946801271293225e-07
of O 0 1.953808919097355e-07
their O 0 4.676345633924939e-05
familial O 1 0.999998927116394
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
cases O 0 9.30993992369622e-05
, O 0 1.5882174011494499e-06
but O 0 7.759916229588271e-07
not O 0 2.6659037644094496e-07
in O 0 7.666432679798163e-07
non O 0 5.922612217545975e-06
- O 0 5.294051516102627e-05
Jews O 0 9.303313163400162e-06
. O 0 1.4112411918176804e-05

We O 0 8.123221050482243e-05
assessed O 0 0.00011669033847283572
the O 0 6.851958460174501e-06
I1307K O 0 0.0003246227279305458
prevalence O 0 0.00011693238775478676
in O 0 1.8761749061013688e-06
Israeli O 0 7.0156297624635044e-06
Jews O 0 2.381410922680516e-06
of O 0 2.618507721763308e-07
differing O 0 1.65511266914109e-06
ethnic O 0 1.111505525841494e-06
origin O 0 3.698639829963213e-06
and O 0 5.2050977501494344e-06
risk O 0 5.337306356523186e-05
for O 0 0.003317804541438818
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
. O 0 0.00027702286024577916

METHODS O 0 0.0005135551909916103
DNA O 0 0.00017035496421158314
samples O 0 1.3054585906502325e-05
from O 0 1.3377209597820183e-06
500 O 0 1.4632170177719672e-06
unrelated O 0 1.55484360675473e-06
Jews O 0 5.806552962894784e-07
of O 0 1.1148000567118288e-07
European O 0 1.582814888934081e-06
or O 0 3.369076466697152e-07
non O 0 1.3448969866658445e-06
- O 0 8.41286873765057e-06
European O 0 8.981105565908365e-07
origin O 0 2.3563836748508038e-07
, O 0 9.046715376825887e-08
with O 0 6.433768362512637e-08
or O 0 1.0152131579843626e-07
without O 0 1.2574778907037398e-07
a O 0 1.9531009343154437e-07
personal O 0 1.1611498393904185e-06
and O 0 4.5094620872987434e-06
/ O 0 0.007039825432002544
or O 0 5.766587491962127e-07
family O 0 5.407911203292315e-07
history O 0 2.7480064090923406e-07
of O 0 3.091938935995131e-07
neoplasia B-Disease 0 0.0012129025999456644
, O 0 9.07528033167182e-07
were O 0 1.6326848708558828e-06
examined O 0 6.5081194406957366e-06
for O 0 2.6558879540061753e-07
the O 0 1.1643145398920751e-06
I1307K O 0 6.451033550547436e-05
variant O 0 1.988286749110557e-05
by O 0 5.831419684909633e-07
the O 0 1.1608276508923154e-06
allele O 0 2.1817200831719674e-05
- O 0 1.4634538274549413e-05
specific O 0 4.193577296973672e-06
oligonucleotide O 0 0.00023812880681362003
( O 0 2.4574863346060738e-05
ASO O 0 0.03165998309850693
) O 0 6.706734893668909e-06
method O 0 2.222820148745086e-05
. O 0 1.6778336430434138e-05

RESULTS O 0 0.0009255718905478716
In O 0 2.1691874280804768e-05
persons O 0 8.81835694599431e-06
at O 0 3.2701404961699154e-06
average O 0 9.389154911332298e-06
risk O 0 2.3810614948160946e-05
for O 0 0.0030058915726840496
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 6.580694753210992e-05
I1307K O 0 0.002949765883386135
was O 0 5.915047222515568e-05
found O 0 4.039101895614294e-06
in O 0 2.316045765837771e-06
5 O 0 7.688085133850109e-06
. O 0 1.245127077709185e-05

0 O 0 9.032723028212786e-05
% O 0 9.948026672645938e-06
of O 0 7.887373385528917e-07
120 O 0 2.22063431465358e-06
European O 0 4.411799181980314e-06
and O 0 1.6597820149399922e-06
1 O 0 5.517515546671348e-06
. O 0 1.0447251042933203e-05

6 O 0 7.050117710605264e-05
% O 0 8.353276825801004e-06
of O 0 7.847067990951473e-07
188 O 0 1.3445184777083341e-05
non O 0 9.688092177384533e-06
- O 0 6.989216490183026e-05
European O 0 6.976272743486334e-06
Jews O 0 4.424798589752754e-06
( O 0 1.9343449366715504e-06
P O 0 4.391248512547463e-05
= O 0 6.49672256258782e-06
0 O 0 2.0626962395908777e-06
. O 0 7.162261681514792e-07
08 O 0 2.479872819094453e-05
) O 0 3.187209358657128e-06
. O 0 5.710493951482931e-06

It O 0 7.323912723222747e-05
occurred O 0 8.469796011922881e-05
in O 0 1.594221430423204e-05
15 O 0 3.0173050618031994e-05
. O 0 2.601253981993068e-05

4 O 0 7.137774809962139e-05
% O 0 9.103330739890225e-06
of O 0 1.0158190661968547e-06
52 O 0 1.6256146409432404e-05
Ashkenazi O 0 0.00214477744884789
Israelis O 0 8.244202035712078e-05
with O 0 7.468509011232527e-06
familial O 1 0.640122652053833
cancer B-Disease 1 0.9794278740882874
( O 0 2.113528535119258e-05
P O 0 0.0017868118593469262
= O 0 1.601408985152375e-05
0 O 0 1.9270005395810585e-06
. O 0 6.865470822958741e-07
02 O 0 1.751693525875453e-05
) O 0 2.3230948897889903e-07
and O 0 1.7558602394274203e-07
was O 0 9.11103427370108e-07
not O 0 2.689789084797667e-07
detected O 0 2.0754096112796105e-06
in O 0 4.7404907377313066e-07
51 O 0 2.0728421077365056e-06
non O 0 2.364657348152832e-06
- O 0 1.500627513451036e-05
European O 0 2.0707793737528846e-06
Jews O 0 2.2516408080264227e-06
at O 0 3.5735845358431106e-06
increased O 0 6.886392657179385e-05
cancer B-Disease 0 0.053113825619220734
risk O 0 2.946065433206968e-05
. O 0 1.6608775695203803e-05

Colorectal B-Disease 1 0.9998319149017334
neoplasia I-Disease 1 0.7734073400497437
occurred O 0 0.00039035093504935503
personally O 0 5.4206644563237205e-05
or O 0 1.5768306411700905e-06
in O 0 4.84773238440539e-07
the O 0 1.462964291931712e-07
families O 0 1.8841095084098924e-07
of O 0 3.627056344157609e-08
13 O 0 2.339373281756707e-07
of O 0 8.685070440606069e-08
20 O 0 1.4627999007643666e-06
Ashkenazi O 0 0.0006925106863491237
I1307K O 0 5.089978003525175e-05
carriers O 0 2.4258342818939127e-06
, O 0 1.1241502306802431e-07
8 O 0 1.765055515079439e-07
of O 0 2.6641595596288425e-08
whom O 0 6.402759709089878e-07
also O 0 4.081581437276327e-07
had O 0 1.044989630827331e-06
a O 0 2.9345309826567245e-07
personal O 0 2.2401711703423643e-06
or O 0 1.1524202818691265e-06
family O 0 3.2913910672505153e-06
history O 0 2.0669181139965076e-06
of O 0 2.862366955014295e-06
noncolonic O 0 0.07650768011808395
neoplasia B-Disease 0 0.09341342002153397
. O 0 7.550366717623547e-05

CONCLUSIONS O 0 0.000784895964898169
The O 0 6.423642480513081e-05
I1307K O 0 0.0017283131601288915
APC O 0 0.002968804445117712
variant O 0 0.0014676443533971906
may O 0 1.08566155176959e-05
represent O 0 1.3901978945796145e-06
a O 0 2.091000624204753e-06
susceptibility O 0 2.9673788958461955e-05
gene O 0 8.365003850485664e-06
for O 0 5.384632459026761e-06
colorectal B-Disease 1 0.9999754428863525
, I-Disease 0 1.0680450941435993e-06
or I-Disease 0 6.501120424218243e-07
other I-Disease 0 3.948277935705846e-07
, I-Disease 0 2.732608209043974e-06
cancers I-Disease 0 0.0003360848349984735
in O 0 4.383937721286202e-06
Ashkenazi O 0 0.002653146628290415
Jews O 0 2.89727336166834e-06
, O 0 4.0089815911414917e-07
and O 0 2.3614275335148704e-07
partially O 0 2.435683882140438e-06
explains O 0 1.110008838622889e-06
the O 0 5.3790608944837e-07
higher O 0 5.244841304374859e-06
incidence O 0 0.00032086248393170536
of O 0 0.0003925840719603002
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
in O 0 0.00011414762411732227
European O 0 0.00039759950595907867
Israelis O 0 0.0006782534765079618
. O 0 5.270914698485285e-05

Systematic O 0 0.0005809706635773182
analysis O 0 8.765675738686696e-05
of O 0 1.3665341612068005e-05
coproporphyrinogen O 0 0.0014013200998306274
oxidase O 0 0.0009528102818876505
gene O 0 0.00048739180783741176
defects O 0 0.013379479758441448
in O 0 2.546931864344515e-05
hereditary B-Disease 0 0.1542511135339737
coproporphyria I-Disease 0 0.05521085113286972
and O 0 6.613313598791137e-05
mutation O 0 0.00012552182306535542
update O 0 0.0004150129680056125
. O 0 5.3503114031627774e-05

Hereditary B-Disease 1 0.998986542224884
coproporphyria I-Disease 1 0.8400834798812866
( O 0 0.0005882260156795382
HC B-Disease 1 0.996271014213562
) O 0 2.75898401014274e-05
is O 0 5.924211109231692e-06
an O 0 2.8722366550937295e-05
acute O 1 0.999983549118042
hepatic B-Disease 1 0.9999992847442627
porphyria I-Disease 1 0.9999997615814209
with O 0 0.0860300287604332
autosomal O 1 0.9989545345306396
dominant O 0 0.0281540434807539
inheritance O 0 0.002881406806409359
caused O 0 0.00018797638767864555
by O 0 6.319677140709246e-06
deficient B-Disease 0 0.00046752230264246464
activity I-Disease 0 2.2970689315116033e-06
of I-Disease 0 8.27578787720995e-07
coproporphyrinogen I-Disease 0 0.0004005609080195427
III I-Disease 0 0.0010234684450551867
oxidase I-Disease 0 0.00013510879944078624
( O 0 1.3081019460514653e-05
CPO O 0 0.00010591303725959733
) O 0 6.141227459011134e-06
. O 0 9.952543223334942e-06

Clinical O 0 0.014673730358481407
manifestations O 0 0.0002639319282025099
of O 0 5.410544872574974e-06
the O 0 9.869474888546392e-05
disease O 0 0.0725090503692627
are O 0 1.3758951808995334e-06
characterized O 0 7.218257087515667e-05
by O 0 1.76265457412228e-05
acute O 0 0.22376471757888794
attacks O 0 0.0003344532451592386
of O 0 4.284566603018902e-05
neurological B-Disease 1 0.9999908208847046
dysfunction I-Disease 1 0.9434881806373596
often O 0 1.2857051842729561e-05
precipitated O 0 9.251071605831385e-05
by O 0 1.7899310478242114e-06
drugs O 0 6.2134281506587286e-06
, O 0 1.0445590987728792e-06
fasting O 0 1.9688712200149894e-05
, O 0 1.8948793467643554e-06
cyclical O 0 7.674817607039586e-05
hormonal O 0 8.594998507760465e-05
changes O 0 5.3166136240179185e-06
, O 0 4.027804152428871e-06
or O 0 3.715887578437105e-05
infectious B-Disease 0 0.3857336938381195
diseases I-Disease 0 0.3599538505077362
. O 0 7.769878720864654e-05

Skin O 1 0.9999992847442627
photosensitivity O 1 0.9997251629829407
may O 0 0.0010109676513820887
also O 0 4.334707227826584e-06
be O 0 1.152767595158366e-06
present O 0 3.227849902032176e-06
. O 0 9.346220394945703e-06

The O 0 2.1548041331698187e-05
seven O 0 9.324382517661434e-06
exons O 0 2.4776671125437133e-05
, O 0 1.0496870572751504e-06
the O 0 1.5994471596059157e-06
exon O 0 4.541579619399272e-05
/ O 0 3.699344233609736e-05
intron O 0 4.883169458480552e-05
boundaries O 0 2.5992258088081144e-06
and O 0 4.051904340940382e-07
part O 0 4.870485099672806e-07
of O 0 1.430971678928472e-07
3 O 0 8.270374678431835e-07
noncoding O 0 5.381711616792018e-06
sequence O 0 4.4334896642794774e-07
of O 0 1.0213349810328509e-07
the O 0 5.800680469292274e-07
CPO O 0 1.840574805100914e-05
gene O 0 2.6327579689677805e-06
were O 0 6.342496590150404e-07
systematically O 0 2.927966534116422e-06
analyzed O 0 1.3279690165290958e-06
by O 0 3.5552278632167145e-07
an O 0 4.85756629586831e-07
exon O 0 1.303116550843697e-05
- O 0 1.1712869309121743e-05
by O 0 5.359191618481418e-06
- O 0 7.424617797369137e-05
exon O 0 0.00022155301121529192
denaturing O 0 0.0008582035661675036
gradient O 0 0.00029778011958114803
gel O 0 0.0006129199173301458
electrophoresis O 0 0.000168094047694467
( O 0 1.0006036063714419e-05
DGGE O 0 6.812994251959026e-05
) O 0 7.890367328400316e-07
strategy O 0 1.4052684491616674e-06
followed O 0 5.229071007306629e-07
by O 0 1.4621483046539652e-07
direct O 0 4.3046489395237586e-07
sequencing O 0 1.3016432376389275e-06
in O 0 3.502660490539711e-07
seven O 0 9.695879725768464e-07
unrelated O 0 1.922566480061505e-05
heterozygous O 0 0.00020571846107486635
HC B-Disease 1 0.9996860027313232
patients O 0 0.004268495831638575
from O 0 1.6960763105089427e-06
France O 0 0.00013184746785555035
, O 0 1.3029050478507997e-06
Holland O 0 3.836654286715202e-05
, O 0 4.448049821803579e-07
and O 0 6.737607805007428e-07
Czech O 0 7.920743883005343e-06
Republic O 0 4.129183707846096e-06
. O 0 8.984927262645215e-06

Seven O 0 0.00011315752635709941
novel O 0 5.8813337091123685e-05
mutations O 0 2.5212166292476468e-05
and O 0 1.6083278069345397e-06
two O 0 9.6506403224339e-07
new O 0 6.915728590684012e-06
polymorphisms O 0 4.0225251723313704e-05
were O 0 1.0151014976145234e-05
detected O 0 7.751023804303259e-05
. O 0 1.956133564817719e-05

Among O 0 3.709306110977195e-05
these O 0 3.45032799486944e-06
mutations O 0 1.284297013626201e-05
two O 0 5.707041168534488e-07
are O 0 4.3828370621668e-07
missense O 0 3.0332770620589145e-05
( O 0 2.6755926683108555e-06
G197W O 0 3.4358512493781745e-05
, O 0 1.026142854243517e-06
W427R O 0 2.3123504433897324e-05
) O 0 3.7472986491593474e-07
, O 0 1.09413697657601e-07
two O 0 5.5830742695661684e-08
are O 0 6.923258411006827e-08
nonsense O 0 5.0525909500720445e-06
( O 0 5.562506544265489e-07
Q306X O 0 5.7721345001482405e-06
, O 0 3.5657404851008323e-07
Q385X O 0 1.0812742402777076e-05
) O 0 1.620546470348927e-07
, O 0 7.103015065013096e-08
two O 0 4.029699240959417e-08
are O 0 5.1105317311339604e-08
small O 0 3.2578714126429986e-07
deletions O 0 5.608558240055572e-06
( O 0 1.0181155403188313e-06
662de14bp O 0 1.3560214938479476e-05
; O 0 7.086512141540879e-07
1168del3bp O 0 8.71809788804967e-06
removing O 0 1.6381968634959776e-06
a O 0 5.259860813566775e-07
glycine O 0 3.0747271466680104e-06
at O 0 2.979396072078089e-07
position O 0 6.038424089638283e-07
390 O 0 2.0338547983556055e-06
) O 0 1.6933725532908284e-07
, O 0 4.0584623661743535e-08
and O 0 4.600568814794315e-08
one O 0 4.906826589490265e-08
is O 0 8.793718109245674e-08
a O 0 5.570054781856015e-07
splicing O 0 2.884209607145749e-05
mutation O 0 9.807490641833283e-06
( O 0 2.8680531158897793e-06
IVS1 O 0 0.00016665960720274597
- O 0 0.00016234227223321795
15c O 0 0.00024719632347114384
- O 0 0.0003379732952453196
- O 0 0.0002965609892271459
> O 0 1.4649660442955792e-05
g O 0 9.625550774217118e-06
) O 0 3.7292628007890016e-07
which O 0 1.5526075003435835e-07
creates O 0 5.510257210517011e-07
a O 0 5.402740725912736e-07
new O 0 2.8933636713190936e-06
acceptor O 0 2.7414011128712445e-05
splice O 0 0.0001493186573497951
site O 0 2.8035103241563775e-05
. O 0 1.7570575437275693e-05

The O 0 6.680929072899744e-05
pathological O 0 0.00014830326836090535
significance O 0 3.4744455206237035e-06
of O 0 2.850452460734232e-07
the O 0 5.191590730646567e-07
point O 0 2.6629459171090275e-06
mutations O 0 5.174679245101288e-06
G197W O 0 1.1842247658933047e-05
, O 0 5.316363740348606e-07
W427R O 0 5.152809535502456e-06
, O 0 1.1691453494222515e-07
and O 0 5.876612974020645e-08
the O 0 1.0417969775744496e-07
in O 0 7.709058422733506e-07
- O 0 0.00017385336104780436
frame O 0 0.00013358841533772647
deletion O 0 2.4023211153689772e-05
390delGly O 0 1.6961612345767207e-05
were O 0 9.198699331136595e-07
assessed O 0 1.5927572576401872e-06
by O 0 1.121800536907358e-07
their O 0 7.532691626011001e-08
respective O 0 2.8211664471200493e-07
expression O 0 2.896528030760237e-07
in O 0 1.8463306616922637e-07
a O 0 5.002040097679128e-07
prokaryotic O 0 1.6339419062205707e-06
system O 0 1.1762799658754375e-06
using O 0 1.4217898751667235e-06
site O 0 4.8838201109902e-06
- O 0 1.6912252249312587e-05
directed O 0 8.924788744479883e-06
mutagenesis O 0 0.00015134828572627157
. O 0 2.5940995328710414e-05

These O 0 6.431304063880816e-05
mutations O 0 8.010717283468693e-05
resulted O 0 1.8316008208785206e-05
in O 0 2.1147127426957013e-06
the O 0 1.0268516916767112e-06
absence O 0 7.2153229666582774e-06
or O 0 1.0637675131874857e-06
a O 0 1.7963711798074655e-06
dramatic O 0 1.2716489436570555e-05
decrease O 0 8.993191841000225e-06
of O 0 1.1090331781815621e-06
CPO O 0 9.113288979278877e-05
activity O 0 1.607509511813987e-05
. O 0 1.0712506991694681e-05

The O 0 2.8295993615756743e-05
two O 0 7.458970685547683e-06
polymorphisms O 0 2.8412181563908234e-05
were O 0 2.0920099359500455e-06
localized O 0 7.700226888118777e-06
in O 0 1.4439993947235052e-06
noncoding O 0 9.899418728309684e-06
part O 0 4.344915680576378e-07
of O 0 7.568868909402227e-08
the O 0 3.2125700499818777e-07
gene O 0 1.1614954473770922e-06
1 O 0 3.2726813969929935e-07
) O 0 3.0763357017349335e-07
a O 0 8.037202405830612e-07
C O 0 0.00011396002810215577
/ O 0 0.0006114172283560038
G O 0 0.00036383088445290923
polymorphism O 0 1.853272260632366e-05
in O 0 7.888990012361319e-07
the O 0 9.34796048568387e-07
promotor O 0 4.564608752843924e-05
region O 0 2.1295027181622572e-06
, O 0 5.671697635989403e-07
142 O 0 2.3386935481539695e-06
bp O 0 7.744466529402416e-06
upstream O 0 1.2049247288814513e-06
from O 0 1.1756682738450763e-07
the O 0 1.4786699864544062e-07
transcriptional O 0 1.58609373102081e-06
initiation O 0 1.3951545270174392e-06
site O 0 1.9270482880529016e-06
( O 0 1.0923495210590772e-06
- O 0 3.5426419344730675e-05
142C O 0 9.669034625403583e-05
/ O 0 0.00016489822883158922
G O 0 6.32571245660074e-05
) O 0 2.764569444480003e-07
, O 0 6.551459819092997e-08
and O 0 8.406546925243674e-08
2 O 0 2.1029065067068586e-07
) O 0 1.393631805512996e-07
a O 0 2.1800325100684859e-07
6 O 0 1.7155814475700026e-06
bp O 0 4.365869608591311e-05
deletion O 0 1.652154060138855e-05
polymorphism O 0 7.325167644012254e-06
in O 0 4.918168770018383e-07
the O 0 3.485971546979272e-07
3 O 0 7.106429507075518e-07
noncoding O 0 5.628254257317167e-06
part O 0 4.83153201003006e-07
of O 0 1.1718980630348597e-07
the O 0 4.5899727751930186e-07
CPO O 0 1.6677069652359933e-05
gene O 0 2.2229055502975825e-06
, O 0 4.026788076316734e-07
574 O 0 6.020907676429488e-06
bp O 0 1.2290880476939492e-05
downstream O 0 1.5560866586383781e-06
of O 0 6.549572617586819e-08
the O 0 2.1039093667241104e-07
last O 0 8.455349984615168e-07
base O 0 3.9128323692239064e-07
of O 0 7.294685389069855e-08
the O 0 4.82029747672641e-07
normal O 0 4.955242729920428e-06
termination O 0 4.033560981042683e-05
codon O 0 4.595330756274052e-05
( O 0 5.543185125134187e-06
+ O 0 3.573645153664984e-05
574 O 0 9.454877726966515e-05
delATTCTT O 0 0.00023641537700314075
) O 0 1.3046398635196965e-05
. O 0 1.8272741726832464e-05

Five O 0 0.00022314833768177778
intragenic O 0 0.0020977903623133898
dimorphisms O 0 0.0011234167031943798
are O 0 1.410450977346045e-06
now O 0 9.412673307451769e-07
well O 0 5.102730256112409e-07
characterized O 0 1.8044100897895987e-06
and O 0 2.2248791253787203e-07
the O 0 2.620788563945098e-07
high O 0 6.62570244003291e-07
degree O 0 1.2025622027067584e-06
of O 0 3.145992764075345e-07
allelic O 0 3.1777268304722384e-05
heterogeneity O 0 3.963575363741256e-05
in O 0 1.8147464288631454e-05
HC B-Disease 1 0.9670995473861694
is O 0 7.52292066863447e-07
demonstrated O 0 1.6202110373342293e-06
with O 0 1.4057025055080885e-07
seven O 0 2.609378668694262e-07
new O 0 5.278775461192708e-07
different O 0 1.5773900940985186e-07
mutations O 0 6.909103262842109e-07
making O 0 1.2926372505717154e-07
a O 0 1.1818037393140912e-07
total O 0 1.1202055105741238e-07
of O 0 1.6147951953371376e-07
nineteen O 0 2.3291862817131914e-05
CPO O 0 0.0006635613390244544
gene B-Disease 0 5.931552004767582e-05
defects I-Disease 0 0.003427055897191167
reported O 0 9.798048267839476e-06
so O 0 1.1849698466903646e-06
far O 0 3.5291795938974246e-06
. O 0 2.840053866748349e-06
. O 0 1.2115179742977489e-05

Coincidence O 0 0.00031980150379240513
of O 0 4.915303634334123e-06
two O 0 2.4976902750495356e-06
novel O 0 1.3438032510748599e-05
arylsulfatase O 0 0.00019896846788469702
A O 0 1.3275463061290793e-05
alleles O 0 2.7504118406795897e-05
and O 0 3.736083499461529e-06
mutation O 0 1.9690140106831677e-05
459 O 0 0.00011879023077199236
+ O 0 0.00024293805472552776
1G O 0 0.004731703083962202
> O 0 4.9118367314804345e-05
A O 0 2.2823098788649077e-06
within O 0 5.952601895842236e-07
a O 0 1.6048377347033238e-06
family O 0 5.012521341996035e-06
with O 0 6.8386866587388795e-06
metachromatic B-Disease 1 0.9999978542327881
leukodystrophy I-Disease 1 0.9999706745147705
: O 0 3.84490203941823e-06
molecular O 0 3.715716275110026e-06
basis O 0 1.140846507041715e-06
of O 0 1.4778931927139638e-06
phenotypic O 0 0.0001295488909818232
heterogeneity O 0 0.0003068261139560491
. O 0 7.453227590303868e-05

In O 0 5.61443084734492e-05
a O 0 1.287090162804816e-05
family O 0 6.375040356942918e-06
with O 0 6.13162626450503e-07
three O 0 7.289927452802658e-07
siblings O 0 1.7896572899189778e-05
, O 0 4.62047836435886e-07
one O 0 3.3418538691876165e-07
developed O 0 3.4282800243090605e-06
classical O 0 1.5966938008205034e-05
late O 0 0.03487132117152214
infantile O 1 0.9935884475708008
metachromatic B-Disease 1 0.9999972581863403
leukodystrophy I-Disease 1 0.9999969005584717
( O 0 0.00033437737147323787
MLD B-Disease 1 0.9999864101409912
) O 0 5.398103439802071e-06
, O 0 1.6638518900435884e-06
fatal O 0 3.468935392447747e-05
at O 0 1.2014673984594992e-06
age O 0 1.4697581036671181e-06
5 O 0 4.748666810883151e-07
years O 0 8.99655276498379e-07
, O 0 2.7972825478173036e-07
with O 0 1.5134844488784438e-06
deficient O 0 0.2939086854457855
arylsulfatase O 0 0.00130589643958956
A O 0 2.1364196072681807e-05
( O 0 6.257009772525635e-06
ARSA O 0 0.000515621853992343
) O 0 1.00347153875191e-06
activity O 0 7.44436420063721e-07
and O 0 3.7458516999322455e-07
increased O 0 2.685075969566242e-06
galactosylsulfatide O 0 0.000357526121661067
( O 0 1.7175692846649326e-05
GS O 1 0.9999552965164185
) O 0 1.1178421118529513e-05
excretion O 0 7.291341171367094e-05
. O 0 1.5286273992387578e-05

The O 0 1.0777226634672843e-05
two O 0 1.7247483583560097e-06
other O 0 8.451182225144294e-07
siblings O 0 9.8467944553704e-06
, O 0 4.722571986803814e-07
apparently O 0 4.474753040994983e-06
healthy O 0 2.4682403818587773e-06
at O 0 3.9853094335740025e-07
12 O 0 5.488157057698118e-07
( O 0 1.8843790883238398e-07
1 O 0 2.9156180403333565e-07
/ O 0 7.610263764945557e-06
2 O 0 2.926549313997384e-07
) O 0 6.89938559617076e-08
and O 0 7.58410010348598e-08
15 O 0 1.5283792720310885e-07
years O 0 1.6119918200274697e-07
, O 0 6.509557692879753e-08
respectively O 0 2.7203304853173904e-07
, O 0 5.8427705340591274e-08
and O 0 4.6044316803772745e-08
their O 0 1.0657500837396583e-07
father O 0 4.674836873164168e-06
, O 0 5.654534334098571e-07
apparently O 0 4.182122665952193e-06
healthy O 0 1.6530619859622675e-06
as O 0 1.9533150918960018e-07
well O 0 3.214105390725308e-07
, O 0 4.4680149358100607e-07
presented O 0 3.6924300275131827e-06
ARSA O 0 0.001651264145039022
and O 0 4.074730895808898e-06
GS O 1 0.9966926574707031
values O 0 6.375943257808103e-07
within O 0 1.6243900802237476e-07
the O 0 2.3449797481589485e-07
range O 0 2.019848807321978e-06
of O 0 3.7901002087892266e-06
MLD B-Disease 1 0.9999990463256836
patients O 0 0.30806469917297363
. O 0 6.236027547856793e-05

Mutation O 0 0.0003994239668827504
screening O 0 0.00010450689296703786
and O 0 2.8551992272696225e-06
sequence O 0 2.497268724255264e-06
analysis O 0 2.208686282756389e-06
disclosed O 0 1.4712272786709946e-05
the O 0 3.658461480426922e-07
involvement O 0 1.5095232583917095e-06
of O 0 1.2155703643657034e-07
three O 0 4.477014670101198e-07
different O 0 1.4619101875723572e-06
ARSA O 0 0.10073473304510117
mutations O 0 8.104240805550944e-06
being O 0 6.539337391586741e-07
the O 0 4.187356239526707e-07
molecular O 0 1.4759706346012536e-06
basis O 0 6.963956025174411e-07
of O 0 1.0724440926423995e-06
intrafamilial O 0 0.001045819604769349
phenotypic O 0 0.00031660706736147404
heterogeneity O 0 0.00032679448486305773
. O 0 8.460231038043275e-05

The O 0 0.0001838997268350795
late O 0 0.0033068715129047632
infantile O 1 0.994864284992218
patient O 1 0.9681300520896912
inherited O 0 0.17014352977275848
from O 0 8.850811354932375e-06
his O 0 1.93623000086518e-05
mother O 0 5.517402314580977e-05
the O 0 1.5876465795372496e-06
frequent O 0 7.848603672755416e-06
0 O 0 1.7120531992986798e-05
- O 0 0.0002244088682346046
type O 0 2.3518907255493104e-05
mutation O 0 1.3193725862947758e-05
459 O 0 3.145595110254362e-05
+ O 0 4.73202126158867e-05
1G O 0 0.0003805164888035506
> O 0 1.826030529628042e-05
A O 0 1.6591426401646459e-06
, O 0 1.4248750801471033e-07
and O 0 5.927088153612203e-08
from O 0 1.184109734708727e-07
his O 0 6.245803092497226e-07
father O 0 5.136279924045084e-06
a O 0 7.315521770578925e-07
novel O 0 1.0822334388649324e-06
, O 0 2.4549058252887335e-07
single O 0 4.967915856468608e-07
basepair O 0 1.1377021110092755e-05
microdeletion O 0 5.675914053426823e-06
of O 0 1.1969176227921707e-07
guanine O 0 2.0698021216958296e-06
at O 0 4.142078751101508e-07
nucleotide O 0 1.4803759995629662e-06
7 O 0 6.823011631240661e-07
in O 0 3.8364265719792456e-07
exon O 0 1.555234848638065e-05
1 O 0 3.4668062198761618e-06
( O 0 2.9830368930561235e-06
7delG O 0 4.557867214316502e-05
) O 0 7.367201305896742e-06
. O 0 1.1367857041477691e-05

The O 0 3.832876973319799e-05
two O 0 2.797178240143694e-05
clinically O 0 0.035164739936590195
unaffected O 0 0.0015632436843588948
siblings O 0 6.978214514674619e-05
carried O 0 6.822153864050051e-06
the O 0 2.1946145807305584e-06
maternal O 0 6.063370528863743e-05
mutation O 0 1.9682629499584436e-05
459 O 0 5.9628298913594335e-05
+ O 0 9.226403926732019e-05
1G O 0 0.0008711477275937796
> O 0 1.5125814570637885e-05
A O 0 1.2079241287210607e-06
and O 0 3.296909198979847e-07
, O 0 1.6414200842973514e-07
on O 0 2.0613086348930665e-07
their O 0 2.413124207123474e-07
paternal O 0 3.1178173230728135e-05
allele O 0 7.320641998376232e-06
, O 0 2.5632613187553943e-07
a O 0 5.36221136826498e-07
novel O 0 1.9602232441684464e-06
cytosine O 0 5.239147412794409e-06
to O 0 1.1759132121369475e-06
thymidine O 0 3.31949777319096e-05
transition O 0 5.271704594633775e-06
at O 0 2.157658173018717e-06
nucleotide O 0 7.3446622081974056e-06
2435 O 0 6.97875366313383e-05
in O 0 1.3557709053202416e-06
exon O 0 1.131746012106305e-05
8 O 0 8.460697813461593e-07
, O 0 1.260598452290651e-07
resulting O 0 3.361508618127118e-07
in O 0 1.9373419490875676e-07
substitution O 0 1.059993110175128e-06
of O 0 4.5561469619315176e-07
alanine O 0 3.1490861147176474e-05
464 O 0 2.9931114113423973e-05
by O 0 6.444861810450675e-06
valine O 0 0.0009932781103998423
( O 0 1.17373683679034e-05
A464V O 0 0.00010393583943368867
) O 0 1.0439624020364136e-05
. O 0 1.4542325516231358e-05

The O 0 0.00012689254072029144
fathers O 0 0.0004942499799653888
genotype O 0 0.001191442832350731
thus O 0 5.326572500052862e-05
was O 0 7.235583325382322e-05
7delG O 0 0.0014076202642172575
/ O 0 0.0032297230791300535
A464V O 0 0.0007035257876850665
. O 0 6.086456050979905e-05

Mutation O 0 0.0012990623945370317
A464V O 0 0.0011043451959267259
was O 0 3.1082730856724083e-05
not O 0 1.9271878954896238e-06
found O 0 2.2469089344667736e-06
in O 0 1.992318857446662e-06
18 O 0 1.2501206583692692e-05
unrelated O 0 0.0018591433763504028
MLD B-Disease 1 1.0
patients O 1 0.779589056968689
and O 0 6.2634267123939935e-06
50 O 0 8.641069143777713e-06
controls O 0 6.811454659327865e-05
. O 0 2.1120396922924556e-05

A464V O 0 0.002795213833451271
, O 0 2.5548526537022553e-05
although O 0 1.291735861741472e-05
clearly O 0 1.716457336442545e-05
modifying O 0 5.3292860684450716e-05
ARSA O 0 0.002942112972959876
and O 0 2.5190491214743815e-05
GS O 1 0.9999972581863403
levels O 0 5.6123781178030185e-06
, O 0 6.095629601077235e-07
apparently O 0 4.527807050180854e-06
bears O 0 3.1334277537098387e-06
little O 0 2.415197059235652e-06
significance O 0 2.001835810006014e-06
for O 0 1.19781782359496e-06
clinical O 0 3.347692472743802e-05
manifestation O 0 4.2220952309435233e-05
of O 0 4.767402970173862e-06
MLD B-Disease 1 0.9999932050704956
, O 0 9.894010872812942e-06
mimicking O 0 7.60340626584366e-05
the O 0 8.763912774156779e-06
frequent O 0 7.811751856934279e-05
ARSA O 0 0.25147852301597595
pseudodeficiency O 0 0.003127499483525753
allele O 0 0.000503816525451839
. O 0 6.163138459669426e-05

Our O 0 7.27783699403517e-05
results O 0 4.296202678233385e-05
demonstrate O 0 9.209107702190522e-06
that O 0 6.143139330561098e-07
in O 0 8.282530075121031e-07
certain O 0 1.3290688229972147e-06
genetic O 0 5.426706047728658e-05
conditions O 0 0.17877984046936035
MLD B-Disease 1 0.9999997615814209
- O 0 0.10620883852243423
like O 0 1.0285619282512926e-05
ARSA O 0 0.006092769559472799
and O 0 8.295729458041023e-06
GS O 1 0.9972378015518188
values O 0 1.0953914397759945e-06
need O 0 3.9138103602454066e-07
not O 0 1.696586053867577e-07
be O 0 1.1107717057257105e-07
paralleled O 0 4.100787464267341e-06
by O 0 4.391587026475463e-06
clinical O 1 0.9009969830513
disease O 0 0.008680231869220734
, O 0 7.453293164871866e-07
a O 0 1.4868618336549844e-06
finding O 0 2.5708482098707464e-06
with O 0 2.1009529973525787e-06
serious O 0 0.0008101637940853834
diagnostic O 0 0.1501598358154297
and O 0 5.6130178563762456e-05
prognostic O 0 0.012469219975173473
implications O 0 0.0002252229896839708
. O 0 5.8181194617645815e-05

Moreover O 0 0.0004864802467636764
, O 0 2.5096229364862666e-05
further O 0 3.367852696101181e-05
ARSA O 0 0.00809958204627037
alleles O 0 0.00010986335837515071
functionally O 0 5.509268885361962e-05
similar O 0 2.5512822503515054e-06
to O 0 1.1171174492119462e-06
A464V O 0 4.461801654542796e-05
might O 0 1.552626940792834e-06
exist O 0 2.0697908098554763e-07
which O 0 8.480709823288635e-08
, O 0 4.5967972539529e-08
together O 0 5.905501154757076e-08
with O 0 1.1780475972500426e-07
0 O 0 4.928676844428992e-06
- O 0 0.002620857674628496
type O 0 2.660789505171124e-05
mutations O 0 8.428737601207104e-06
, O 0 1.3908185110267368e-06
may O 0 8.798674571153242e-06
cause O 0 8.823041753203142e-06
pathological O 0 0.00024207538808695972
ARSA O 0 0.11999310553073883
and O 0 2.5305364033556543e-05
GS O 1 0.9999974966049194
levels O 0 3.194460987288039e-06
, O 0 2.787700452699937e-07
but O 0 3.757540696369688e-07
not O 0 3.7858919199607044e-07
clinical O 0 2.3110740585252643e-05
outbreak O 0 1.6173431504284963e-05
of O 0 4.524762289292994e-07
the O 0 7.496758189518005e-05
disease O 0 0.007714360021054745
. O 0 5.817644250782905e-06
. O 0 1.7741205738275312e-05

Human O 0 0.01621932163834572
MLH1 O 1 0.9998319149017334
deficiency O 1 0.999942421913147
predisposes O 0 0.015569017268717289
to O 0 0.00016346547636203468
hematological B-Disease 1 0.9916953444480896
malignancy I-Disease 1 0.996462881565094
and O 0 0.0005570792709477246
neurofibromatosis B-Disease 1 0.9998835325241089
type I-Disease 0 0.0005399603396654129
1 I-Disease 0 5.6125791161321104e-05
. O 0 3.2935211493168026e-05

Heterozygous O 0 0.004665616434067488
germ O 0 0.04283180460333824
- O 0 0.0006377094541676342
line O 0 4.6336277591763064e-05
mutations O 0 2.0293005945859477e-05
in O 0 1.8938278572022682e-06
the O 0 1.9519497982400935e-06
DNA O 0 2.7669120754580945e-05
mismatch O 0 0.00040337289101444185
repair O 0 0.006345096509903669
genes O 0 1.082069593394408e-05
lead O 0 8.766980499785859e-06
to O 0 2.5059833205887116e-05
hereditary B-Disease 1 0.999983549118042
nonpolyposis I-Disease 1 0.9999998807907104
colorectal I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
. O 0 0.00023351138224825263

The O 0 0.000440230272943154
disease O 0 0.10242666304111481
susceptibility O 0 6.972267874516547e-05
of O 0 9.79102196652093e-07
individuals O 0 1.7297820704698097e-06
who O 0 4.010219527117442e-06
constitutionally O 0 1.454528137401212e-05
lack O 0 4.485840690904297e-06
both O 0 1.555939661557204e-06
wild O 0 7.463702786481008e-06
- O 0 0.00211138604208827
type O 0 2.0339231923571788e-05
alleles O 0 9.753801350598224e-06
is O 0 9.368504834128544e-07
unknown O 0 8.808237907942384e-06
. O 0 1.1199527762073558e-05

We O 0 2.2045338482712395e-05
have O 0 3.0099533887550933e-06
identified O 0 2.8775682494597277e-06
three O 0 3.5194696579310403e-07
offspring O 0 3.522179440551554e-06
in O 0 1.7462959931435762e-06
a O 0 0.00011324322258587927
hereditary B-Disease 1 0.9999982118606567
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 0.002326356479898095
who O 0 7.928132981760427e-05
developed O 0 0.00997235905379057
hematological B-Disease 1 0.9942693710327148
malignancy I-Disease 0 0.44486358761787415
at O 0 4.121645815757802e-06
a O 0 7.808741884218762e-07
very O 0 7.674186690564966e-07
early O 0 2.9796619855915196e-06
age O 0 1.965007186299772e-06
, O 0 1.1068802052704996e-07
and O 0 8.035319609689395e-08
at O 0 9.72292113488038e-08
least O 0 4.0473850049238536e-08
two O 0 2.49731506585249e-08
of O 0 2.7006997527223575e-08
them O 0 9.316884330701214e-08
displayed O 0 1.6791370853752596e-06
signs O 0 1.9424549009272596e-06
of O 0 9.555697033647448e-07
neurofibromatosis B-Disease 1 0.9718195199966431
type I-Disease 0 7.894208101788536e-05
1 I-Disease 0 1.1626596460700966e-05
( O 0 1.4294374523160513e-05
NF1 B-Disease 0 0.0014440830564126372
) O 0 1.3111794032738544e-05
. O 0 1.35416057673865e-05

DNA O 0 0.0002709881810005754
sequence O 0 1.7913136616698466e-05
analysis O 0 8.598824024375062e-06
and O 0 2.503279574739281e-06
allele O 0 3.239117722841911e-05
- O 0 1.4742931853106711e-05
specific O 0 1.785006134014111e-06
amplification O 0 2.3281336325453594e-05
in O 0 1.4276840829552384e-06
two O 0 1.4939528227841947e-06
siblings O 0 7.445718802046031e-05
revealed O 0 3.8554811908397824e-05
a O 0 9.046453669725452e-06
homozygous O 0 0.0002856350038200617
MLH1 O 0 0.039408840239048004
mutation O 0 6.08093905611895e-05
( O 0 8.105354027065914e-06
C676T O 0 0.0001642747229197994
- O 0 0.0008851509774103761
- O 0 0.0007998624932952225
> O 0 0.00012229487765580416
Arg226Stop O 0 0.00021642018691636622
) O 0 9.007636435853783e-06
. O 0 1.3131991181580815e-05

Thus O 0 0.00013237656094133854
, O 0 1.2952811630384531e-05
a O 0 1.3217969353718217e-05
homozygous O 0 0.00023688557848799974
germ O 0 0.010861662216484547
- O 0 0.0008077690145000815
line O 0 8.292384882224724e-05
MLH1 O 0 0.003533440874889493
mutation O 0 4.4873060687677935e-05
and O 0 4.856259693042375e-06
consequent O 0 0.0026446720585227013
mismatch O 1 0.9992904663085938
repair O 1 0.9999996423721313
deficiency O 1 0.9999887943267822
results O 0 0.00019387899374123663
in O 0 7.570999969175318e-06
a O 0 3.666127668111585e-05
mutator O 1 0.9940449595451355
phenotype O 0 0.4490349292755127
characterized O 0 0.00012862819130532444
by O 0 2.7464986487757415e-05
leukemia B-Disease 1 0.9998852014541626
and O 0 0.0003733249905053526
/ O 1 0.9997524619102478
or O 1 0.7120988368988037
lymphoma B-Disease 1 1.0
associated O 0 0.00022306024038698524
with O 0 2.8096579626435414e-05
neurofibromatosis B-Disease 1 0.9995610117912292
type I-Disease 0 5.211536699789576e-05
1 I-Disease 0 5.491211595654022e-06
. O 0 3.4409692943881964e-06
. O 0 9.905244951369241e-06

Missense O 0 0.006542797200381756
mutations O 0 0.00026827582041732967
in O 0 3.0615776722697774e-06
the O 0 6.746847134309064e-07
most O 0 2.754051138253999e-07
ancient O 0 6.162920840324659e-07
residues O 0 8.058946150413249e-07
of O 0 1.460560952182277e-07
the O 0 1.1128640835522674e-06
PAX6 O 0 0.0008710364927537739
paired O 0 3.0230219635996036e-05
domain O 0 1.0867803212022409e-05
underlie O 0 1.8677574189496227e-05
a O 0 2.396603122178931e-06
spectrum O 0 2.547368967498187e-05
of O 0 5.058825081505347e-06
human O 0 0.0055683753453195095
congenital B-Disease 1 0.9999998807907104
eye I-Disease 1 0.9999648332595825
malformations I-Disease 1 0.9999260902404785
. O 0 0.0001798315643100068

Mutations O 0 0.0003564937796909362
of O 0 6.111227321525803e-06
the O 0 8.441205864073709e-06
human O 0 2.668679917405825e-05
PAX6 O 0 0.09002754837274551
gene O 0 0.0004400740144774318
underlie O 0 0.10271074622869492
aniridia B-Disease 1 0.9999995231628418
( O 0 0.17859990894794464
congenital B-Disease 1 0.999915599822998
absence I-Disease 0 9.248854439647403e-06
of I-Disease 0 5.475693001244508e-07
the I-Disease 0 4.087122761120554e-06
iris I-Disease 0 0.05284890532493591
) O 0 1.0533392469369574e-06
, O 0 3.8115916822789586e-07
a O 0 1.2073783182131592e-06
rare O 0 2.799721733026672e-05
dominant O 0 0.0019574975594878197
malformation B-Disease 1 0.5647380352020264
of I-Disease 0 1.2036579164487193e-06
the I-Disease 0 9.826401765167248e-06
eye I-Disease 0 0.010331595316529274
. O 0 3.9467944588977844e-05

The O 0 5.349459024728276e-05
spectrum O 0 0.00010479969932930544
of O 0 7.18792034604121e-06
PAX6 O 0 0.054145634174346924
mutations O 0 0.00011156475375173613
in O 0 3.954834755859338e-05
aniridia B-Disease 1 0.9999988079071045
patients O 0 0.05092357471585274
is O 0 5.052548885942088e-07
highly O 0 9.936741207638988e-07
biased O 0 7.659807124582585e-06
, O 0 1.345470082014799e-07
with O 0 1.0012444562335077e-07
92 O 0 2.557201469244319e-06
% O 0 1.9476659929296147e-07
of O 0 3.134378800950799e-08
all O 0 1.5515566076373943e-07
reported O 0 1.4367450603458565e-05
mutations O 0 1.886917743831873e-06
leading O 0 7.476922405658115e-07
to O 0 8.964076982920233e-07
premature O 0 4.430771878105588e-05
truncation O 0 5.994352250127122e-06
of O 0 1.9667962192215782e-07
the O 0 5.028317104915914e-07
protein O 0 1.4765533933314146e-06
( O 0 5.027890779274458e-07
nonsense O 0 3.0480773602903355e-06
, O 0 3.2077360856419546e-07
splicing O 0 2.9779121177853085e-06
, O 0 1.8847079275019496e-07
insertions O 0 1.9477790829114383e-06
and O 0 3.014469882600679e-07
deletions O 0 2.8240458505024435e-06
) O 0 1.4263297032357514e-07
and O 0 9.637508924242866e-08
just O 0 1.0070284872654156e-07
2 O 0 1.1523835041771235e-07
% O 0 6.723140444364617e-08
leading O 0 6.384942707882146e-08
to O 0 4.757882265948865e-08
substitution O 0 2.778670875613898e-07
of O 0 4.944311271515289e-08
one O 0 3.205705354503152e-07
amino O 0 7.711896614637226e-07
acid O 0 1.178482989416807e-06
by O 0 4.5676412696593616e-07
another O 0 1.6168276033567963e-06
( O 0 3.850608663924504e-06
missense O 0 5.17814296472352e-05
) O 0 7.33945262254565e-06
. O 0 8.621576853329316e-06

The O 0 2.4699247660464607e-05
extraordinary O 0 3.064240809180774e-05
conservation O 0 3.9288388506975025e-06
of O 0 3.143923379411717e-07
the O 0 8.443568617622077e-07
PAX6 O 0 0.0002869610325433314
protein O 0 3.385322997928597e-06
at O 0 6.33925537840696e-07
the O 0 3.292962276191247e-07
amino O 0 7.558783750027942e-07
acid O 0 1.386030589856091e-06
level O 0 4.59841544397932e-07
amongst O 0 8.661444894642045e-07
vertebrates O 0 5.813523330289172e-06
predicts O 0 1.5728381185908802e-05
that O 0 1.0074816145788645e-06
pathological O 0 9.098293958231807e-05
missense O 0 0.00012472055095713586
mutations O 0 1.4104339243203867e-05
should O 0 4.5567509232569137e-07
in O 0 3.882052794779156e-07
fact O 0 3.9280453734136245e-07
be O 0 1.4093845379647973e-07
common O 0 3.7176971545704873e-07
even O 0 3.300350783774775e-07
though O 0 3.601570313094271e-07
they O 0 2.409178705420345e-07
are O 0 1.2571491936341772e-07
hardly O 0 2.1333016775315627e-06
ever O 0 1.980057731998386e-06
seen O 0 4.250408437656006e-06
in O 0 1.4043645023775753e-05
aniridia B-Disease 1 0.9999746084213257
patients O 0 0.02439909614622593
. O 0 3.794591611949727e-05

This O 0 2.5117062250501476e-05
indicates O 0 1.920495560625568e-05
that O 0 5.631790713778173e-07
there O 0 2.2321006554193445e-07
is O 0 1.1208744865598419e-07
a O 0 3.814653553035896e-07
heavy O 0 2.2343667296809144e-05
ascertainment O 0 8.337676990777254e-05
bias O 0 2.0042230971739627e-05
in O 0 4.287465742436325e-07
the O 0 1.7106803795741143e-07
selection O 0 5.149058210918156e-07
of O 0 2.892211057314853e-07
patients O 0 1.0975855730066542e-05
for O 0 7.546784104306425e-07
PAX6 O 0 0.035418566316366196
mutation O 0 8.392003110202495e-06
analysis O 0 1.307471848122077e-06
and O 0 4.087198419711058e-07
that O 0 2.516364929761039e-07
the O 0 1.493249101258698e-06
missing O 0 3.2063711842056364e-05
PAX6 O 0 0.06474056839942932
missense O 0 0.0009616342140361667
mutations O 0 7.654536602785811e-05
frequently O 0 2.2469848772743717e-05
may O 0 3.410372301004827e-05
underlie O 0 0.00016310038336087018
phenotypes O 0 0.00010028926044469699
distinct O 0 1.2082608009222895e-05
from O 0 1.1408354112063535e-05
textbook O 0 0.006219117436558008
aniridia B-Disease 1 0.9997753500938416
. O 0 0.00010832169937202707

Here O 0 6.548430974362418e-05
we O 0 3.9905758058012e-06
present O 0 3.123930355286575e-06
four O 0 3.2309912967320997e-06
novel O 0 1.634297404962126e-05
PAX6 O 0 0.0029375022277235985
missense O 0 0.00026348064420744777
mutations O 0 2.265076182084158e-05
, O 0 8.74506724812818e-07
two O 0 3.2334926913790696e-07
in O 0 1.527407334833697e-06
association O 0 5.083707947051153e-06
with O 0 2.9107386581017636e-06
atypical O 0 0.020856959745287895
phenotypes O 0 0.002444884506985545
ectopia B-Disease 0 0.035165153443813324
pupillae I-Disease 0 0.005157332867383957
( O 0 8.468136002193205e-06
displaced B-Disease 0 1.041235100274207e-05
pupils I-Disease 0 1.308173068537144e-05
) O 0 2.633461008372251e-06
and O 0 3.0438011890510097e-05
congenital B-Disease 1 0.999996542930603
nystagmus I-Disease 0 0.013783769682049751
( O 0 1.8925207996289828e-06
searching B-Disease 0 2.080696731354692e-06
gaze I-Disease 0 3.6043304589838954e-06
) O 0 1.8956552594318055e-07
, O 0 5.500963951021731e-08
and O 0 5.4047720965400003e-08
two O 0 1.0007251205479406e-07
in O 0 6.304774728960183e-07
association O 0 7.229569405353686e-07
with O 0 2.859917458408745e-07
more O 0 1.3986862086312613e-06
recognizable O 0 9.07996145542711e-05
aniridia B-Disease 1 0.9992203712463379
phenotypes O 0 0.001310216961428523
. O 0 6.542749906657264e-05

Strikingly O 0 0.003187531139701605
, O 0 5.923222488490865e-06
all O 0 4.475943171655672e-07
four O 0 6.723768137817387e-07
mutations O 0 1.59565968260722e-06
are O 0 6.13703718954639e-08
located O 0 2.532854921355465e-07
within O 0 1.960956410584913e-07
the O 0 5.489758336807427e-07
PAX6 O 0 0.0002813047030940652
paired O 0 7.454746537405299e-06
domain O 0 1.5835349813642097e-06
and O 0 3.537829798005987e-07
affect O 0 1.0539159802647191e-06
amino O 0 3.296783575024165e-07
acids O 0 1.5880598880357866e-07
which O 0 5.212232778717407e-08
are O 0 2.7685443271252552e-08
highly O 0 2.023288914188015e-07
conserved O 0 3.5713625834432605e-07
in O 0 3.19363664402772e-07
all O 0 2.1906403446791956e-07
known O 0 1.6759502159402473e-06
paired O 0 1.2065693226759322e-05
domain O 0 5.517436875379644e-06
proteins O 0 4.0390173126070295e-06
. O 0 7.951471161504742e-06

Our O 0 2.5915134756360203e-05
results O 0 2.089164627250284e-05
support O 0 1.8053912071991363e-06
the O 0 5.74060095459572e-07
hypothesis O 0 3.299546506241313e-06
that O 0 2.0379776799472893e-07
the O 0 1.7179736744310503e-07
under O 0 6.93902904913557e-07
- O 0 5.3897028919891454e-06
representation O 0 4.5615468025062e-07
of O 0 2.4445773760817247e-07
missense O 0 0.00010605977877276018
mutations O 0 1.0681636013032403e-05
is O 0 7.952691589707683e-07
caused O 0 4.332875960244564e-06
by O 0 2.0004731595690828e-06
ascertainment O 0 8.107093162834644e-05
bias O 0 1.9875285943271592e-05
and O 0 7.328055744437734e-07
suggest O 0 1.2936659459228395e-06
that O 0 1.3537835741317394e-07
a O 0 3.771801289076393e-07
substantial O 0 1.369457208966196e-06
burden O 0 8.350823918590322e-06
of O 0 1.8398936845187563e-06
PAX6 B-Disease 1 0.994724452495575
- I-Disease 1 0.9971900582313538
related I-Disease 0 0.1176413744688034
disease I-Disease 0 0.02102716453373432
remains O 0 5.376422450353857e-06
to O 0 8.557417459087446e-07
be O 0 1.2811771057386068e-06
uncovered O 0 2.864850830519572e-05
. O 0 3.552886028046487e-06
. O 0 9.53114613366779e-06

The O 0 4.474652814678848e-05
chromosomal O 0 0.00015031464863568544
order O 0 3.0759354103793157e-06
of O 0 6.068084417165664e-07
genes O 0 2.631309598655207e-06
controlling O 0 3.1037761800689623e-06
the O 0 1.4713189102621982e-06
major O 0 4.208805421512807e-06
histocompatibility O 0 0.0003010666696354747
complex O 0 1.0700538950914051e-05
, O 0 2.008228193517425e-06
properdin O 0 2.7919415515498258e-05
factor O 0 2.694495151445153e-06
B O 0 1.196532593894517e-05
, O 0 7.391279837065667e-07
and O 0 6.193739864102099e-06
deficiency B-Disease 0 9.227090049535036e-05
of I-Disease 0 6.463583446247867e-08
the I-Disease 0 2.143589341585539e-07
second I-Disease 0 7.59685406137578e-07
component I-Disease 0 1.377025341753324e-06
of I-Disease 0 4.695845916558028e-07
complement I-Disease 0 1.175253237306606e-05
. O 0 2.0837307602050714e-05

The O 0 2.1365927750593983e-05
relationship O 0 1.2656842955038883e-05
of O 0 4.993727884539112e-07
the O 0 1.1776099881899427e-06
genes O 0 3.5816296986013185e-06
coding O 0 1.4341908354253974e-05
for O 0 1.0073913472297136e-06
HLA O 0 0.0017117210663855076
to O 0 6.398242931027198e-07
those O 0 3.9274985397241835e-07
coding O 0 4.864111360802781e-06
for O 0 6.987999654484156e-07
properdin O 0 3.73342409147881e-05
Factor O 0 3.127382342427154e-06
B O 0 1.1740111403923947e-05
allotypes O 0 4.2911498894682154e-05
and O 0 6.822334626122029e-07
for O 0 2.0453467186598573e-06
deficiency B-Disease 0 8.261209586635232e-05
of I-Disease 0 4.839468203954311e-08
the I-Disease 0 1.7899243687224953e-07
second I-Disease 0 8.185309638975014e-07
component I-Disease 0 8.184958915080642e-07
of I-Disease 0 1.175252393181836e-07
complement I-Disease 0 2.336208353881375e-06
( O 0 2.05987339541025e-06
C2 O 0 0.0001676755928201601
) O 0 2.915242589551781e-07
was O 0 6.2915609078118e-07
studied O 0 5.968250889054616e-07
in O 0 3.265987515987945e-07
families O 0 5.407462708717503e-07
of O 0 6.883900027787604e-07
patients O 0 0.003689023433253169
with O 0 0.00012736045755445957
connective O 1 0.9999799728393555
tissue O 1 0.9999971389770508
disorders O 1 0.9999226331710815
. O 0 0.00011867587454617023

Patients O 1 0.736459493637085
were O 0 2.0172145013930276e-05
selected O 0 4.16237116951379e-06
because O 0 1.333895397692686e-06
they O 0 6.694796184092411e-07
were O 0 1.351469677501882e-06
heterozygous O 0 1.1631487723207101e-05
or O 0 2.27299778998713e-06
homozygous O 0 0.00016638411034364253
for O 0 0.0003006338083650917
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999991655349731
. O 0 8.828825957607478e-05

12 O 0 0.00011256046127527952
families O 0 1.970031917153392e-05
with O 0 3.1244637739291647e-06
15 O 0 5.29315002495423e-06
matings O 0 0.0001509739668108523
informative O 0 0.00010123356332769617
for O 0 0.0012128385715186596
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999998807907104
were O 0 7.673537766095251e-05
found O 0 3.60598205588758e-05
. O 0 2.149945794371888e-05

Of O 0 2.0864510588580742e-05
57 O 0 7.07132785464637e-05
informative O 0 6.302368274191394e-05
meioses O 0 0.00022467820963356644
, O 0 1.0814524102897849e-06
two O 0 2.699976846542995e-07
crossovers O 0 4.633841399481753e-06
were O 0 7.702385573793435e-07
noted O 0 1.539304662401264e-06
between O 0 1.0193484740739223e-06
the O 0 8.737625466892496e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999700784683228
gene O 0 3.3938829346880084e-06
and O 0 3.293684756044968e-07
the O 0 1.308119180976064e-06
HLA O 0 0.035277366638183594
- O 0 5.618850263999775e-05
B O 0 1.0310495781595819e-05
gene O 0 1.7120314623753075e-06
, O 0 1.8274481305979862e-07
with O 0 1.0976108910654148e-07
a O 0 5.989427336317021e-07
recombinant O 0 5.113572569825919e-06
fraction O 0 1.876278588497371e-06
of O 0 9.72567249846179e-07
0 O 0 1.8129057934856974e-05
. O 0 1.8277798517374322e-05

035 O 0 0.23560862243175507
. O 0 0.0036333671305328608

A O 0 0.0001584815327078104
lod O 0 0.0004044375673402101
score O 0 6.769373612769414e-06
of O 0 7.711293505963113e-07
13 O 0 2.322504315088736e-06
was O 0 2.127028437826084e-06
calculated O 0 2.502584948160802e-06
for O 0 4.93371317134006e-07
linkage O 0 5.5661803344264627e-05
between O 0 0.00016848476661834866
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999953508377075
and O 0 1.1354043635947164e-05
HLA O 1 0.602719783782959
- O 0 8.849672303767875e-05
B O 0 9.821567800827324e-06
at O 0 3.557785248631262e-07
a O 0 1.682137735770084e-07
maximum O 0 2.785855883757904e-07
likelihood O 0 3.451090719863714e-07
value O 0 4.524978081121844e-08
of O 0 3.409124005315789e-08
the O 0 2.833664325407881e-07
recombinant O 0 2.772259676930844e-06
fraction O 0 1.3350064591577393e-06
of O 0 4.2509941522439476e-07
0 O 0 7.4247209340683185e-06
. O 0 1.0609383025439456e-05

04 O 0 0.07507210969924927
. O 0 0.000943727558478713

18 O 0 0.00011723986972356215
families O 0 1.813296512409579e-05
with O 0 1.9587619135563727e-06
21 O 0 5.864469585503684e-06
informative O 0 1.1914325114048552e-05
matings O 0 3.7006357160862535e-05
for O 0 7.844502079024096e-07
both O 0 1.5819848613318754e-06
properdin O 0 5.156991392141208e-05
Factor O 0 4.660778358811513e-06
B O 0 1.7966600353247486e-05
allotype O 0 5.826736378367059e-05
and O 0 5.248213255981682e-06
HLA O 0 0.19641099870204926
- O 0 0.0002178393624490127
B O 0 4.0373819501837716e-05
were O 0 5.864782451681094e-06
found O 0 1.1978410839219578e-05
. O 0 1.580147545610089e-05

Of O 0 4.128804357605986e-05
72 O 0 0.00012939557200297713
informative O 0 0.00011305355292279273
meioses O 0 0.00025512633146718144
, O 0 1.012171651382232e-06
three O 0 5.582626272371272e-07
recombinants O 0 3.261661549913697e-05
were O 0 1.2629584489332046e-06
found O 0 6.779968089176691e-07
, O 0 1.483609395336316e-07
giving O 0 3.71490472161895e-07
a O 0 7.596709110657685e-07
recombinant O 0 5.97126154389116e-06
fraction O 0 2.0099853372812504e-06
of O 0 7.493898692700895e-07
0 O 0 1.6191257600439712e-05
. O 0 1.7794480299926363e-05

042 O 0 0.03129057586193085
. O 0 0.0016427240334451199

A O 0 0.00024190785188693553
lod O 0 0.0004707084153778851
score O 0 6.264328931138152e-06
of O 0 5.124637141307176e-07
16 O 0 1.9399667507968843e-06
between O 0 1.312769427386229e-06
HLA O 0 0.01718844100832939
- O 0 6.778899114578962e-05
B O 0 6.8738172558369115e-06
and O 0 5.303688226376835e-07
Factor O 0 1.3859751106792828e-06
B O 0 6.2656135924044065e-06
allotypes O 0 1.864851037680637e-05
was O 0 1.2502081290222122e-06
calculated O 0 7.688647087888967e-07
at O 0 3.1087358820514055e-07
a O 0 3.2881925449146365e-07
maximum O 0 6.03051091729867e-07
likelihood O 0 6.202537292665511e-07
value O 0 8.048633048929332e-08
of O 0 5.288258009272795e-08
the O 0 3.4468573062440555e-07
recombinant O 0 4.6776731323916465e-06
fraction O 0 1.6806094436105923e-06
of O 0 6.577828912668338e-07
0 O 0 1.779704325599596e-05
. O 0 1.3808593394060154e-05

04 O 0 0.1867344081401825
. O 0 0.0015090765664353967

A O 0 5.0735543482005596e-05
crossover O 0 5.938462709309533e-05
was O 0 1.3154778571333736e-05
shown O 0 1.987493078559055e-06
to O 0 1.907575466475464e-07
have O 0 1.6421699911006726e-07
occurred O 0 5.547524324356345e-07
between O 0 1.0089260626955365e-07
genes O 0 2.81907119870084e-07
for O 0 1.2668496651713212e-07
Factor O 0 7.413489129248774e-07
B O 0 6.078874321246985e-06
and O 0 1.9720205273188185e-06
HLA O 0 0.15557704865932465
- O 0 0.00032980195828713477
D O 0 0.00010286339238518849
, O 0 3.9925907913129777e-07
in O 0 4.716050625575008e-07
which O 0 1.6509351326021715e-06
HLA O 0 0.07993926852941513
- O 0 0.00025104123051278293
D O 0 0.00013540583313442767
segregared O 0 5.4197498684516177e-05
with O 0 1.8478945094102528e-06
HLA O 0 0.0643225759267807
- O 0 2.4903833036660217e-05
A O 0 2.627483127071173e-06
and O 0 2.87047214442282e-06
B O 0 3.867449049721472e-05
. O 0 1.309280105488142e-05

These O 0 1.3744520401814952e-05
studies O 0 1.1212063327548094e-05
suggest O 0 3.4537386000010883e-06
that O 0 2.4876604243218026e-07
the O 0 1.848818413918707e-07
genes O 0 3.726809438830969e-07
for O 0 1.7227084470050613e-07
Factor O 0 1.4828628991381265e-06
B O 0 0.00010362530883867294
and O 0 0.02148180827498436
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999949932098389
are O 0 2.1123433668890357e-07
located O 0 4.46319830871289e-07
outside O 0 3.612474870351434e-07
those O 0 1.407286589483192e-07
for O 0 3.329904814108886e-07
HLA O 0 0.042138490825891495
, O 0 3.6008836445944326e-07
that O 0 4.592091684685329e-08
the O 0 7.097449383763887e-08
order O 0 6.832792820432587e-08
of O 0 8.792577688154779e-08
genese O 0 3.660405855043791e-05
is O 0 8.958513717516325e-07
HLA O 0 0.0011291783303022385
- O 0 8.249977327068336e-06
A O 0 1.6837183238749276e-06
, O 0 4.619095079760882e-07
- O 0 6.747214683855418e-06
B O 0 5.758197403338272e-06
, O 0 6.506976433229283e-07
- O 0 2.1275611288729124e-05
D O 0 2.4979161025839858e-05
, O 0 4.348020468114555e-07
Factor O 0 1.816322878767096e-06
B O 0 1.8360657122684643e-05
allotype O 0 0.0012841104762628675
, O 0 0.0008396998746320605
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999933242797852
, O 0 9.522465234113042e-07
that O 0 2.4709459012228763e-07
the O 0 5.210940798860975e-07
genes O 0 3.5165144254278857e-06
coding O 0 4.381385224405676e-05
for O 0 5.330317435436882e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999974966049194
and O 0 1.8760209741230938e-06
Factor O 0 1.9541012079571374e-06
B O 0 8.533599611837417e-06
allotypes O 0 1.1937539056816604e-05
are O 0 6.150172993102387e-08
approximately O 0 8.439304366447686e-08
3 O 0 2.444120639211178e-07
- O 0 2.9398406695690937e-06
- O 0 2.861236907847342e-06
5 O 0 3.9635642679058947e-07
centimorgans O 0 2.967652108054608e-06
from O 0 3.0263228723015345e-07
the O 0 8.24651920083852e-07
HLA O 0 0.004666687920689583
- O 0 6.368684353219578e-06
A O 0 1.707754222479707e-06
and O 0 1.9719846022780985e-06
HLA O 0 0.008433360606431961
- O 0 2.7640982807497494e-05
B O 0 5.3553289944829885e-06
loci O 0 2.4767714421614073e-06
, O 0 1.2515138791968639e-07
and O 0 7.308332783395599e-08
that O 0 7.156418035947354e-08
the O 0 1.2813148941859254e-07
apparent O 0 2.1438563635456376e-06
lack O 0 9.193577739097236e-07
of O 0 1.282009094438763e-07
recombinants O 0 9.466035407967865e-06
between O 0 2.2512901409754704e-07
the O 0 3.331893196900637e-07
Factor O 0 1.2380123735056259e-06
B O 0 1.053916730597848e-05
gene O 0 1.4254515917855315e-05
and O 0 0.00020178801787551492
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999986886978149
gene O 0 6.70557119519799e-06
suggests O 0 1.3299069223648985e-06
that O 0 8.98571741458909e-08
these O 0 5.0393680339766433e-08
two O 0 1.2459904041861591e-07
genes O 0 5.057644898442959e-07
lie O 0 4.1028076225302357e-07
in O 0 1.5089202065610152e-07
close O 0 4.02317965608745e-07
proximity O 0 1.0750511592050316e-06
to O 0 3.3249796160816913e-07
one O 0 5.429942007140198e-07
another O 0 4.332082880864618e-06
. O 0 1.3383843906922266e-05

Distribution O 0 4.0288283344125375e-05
of O 0 4.346471996541368e-06
emerin O 0 0.00022387162607628852
and O 0 5.799204245704459e-06
lamins O 0 0.0006198460469022393
in O 0 3.795793645622325e-06
the O 0 2.2275614810496336e-06
heart O 0 3.9267735701287165e-05
and O 0 1.6443104868812952e-06
implications O 0 1.3489185221260414e-05
for O 0 8.321584573423024e-06
Emery B-Disease 1 0.9992573857307434
- I-Disease 1 0.9999595880508423
Dreifuss I-Disease 1 0.999891996383667
muscular I-Disease 1 0.9999597072601318
dystrophy I-Disease 1 0.9997022747993469
. O 0 0.00015064423496369272

Emerin O 0 0.002629402093589306
is O 0 7.292747795872856e-06
a O 0 2.3340346615441376e-06
nuclear O 0 6.538909474329557e-06
membrane O 0 3.1401284559251508e-06
protein O 0 9.73337478171743e-07
which O 0 1.8046168293039955e-07
is O 0 1.1012449618874598e-07
missing O 0 1.0932666327789775e-06
or O 0 1.2146125527578988e-06
defective O 0 0.00020867068087682128
in O 0 6.245393888093531e-05
Emery B-Disease 1 0.999121367931366
- I-Disease 1 0.9999237060546875
Dreifuss I-Disease 1 0.999954342842102
muscular I-Disease 1 0.9999954700469971
dystrophy I-Disease 1 0.9999889135360718
( O 0 0.00016295471868943423
EDMD B-Disease 1 0.9998759031295776
) O 0 2.5130957510555163e-05
. O 0 1.90361406566808e-05

It O 0 1.7031828974722885e-05
is O 0 8.972492651082575e-07
one O 0 3.1767353902978357e-07
member O 0 2.564087537848536e-07
of O 0 4.4333116733241695e-08
a O 0 4.0863642425392754e-07
family O 0 9.889132570606307e-07
of O 0 3.6700876648865233e-07
lamina O 0 0.007175828795880079
- O 0 0.0007661000709049404
associated O 0 1.662560748627584e-06
proteins O 0 2.956765854378318e-07
which O 0 1.1895789242544197e-07
includes O 0 3.7404791441986163e-07
LAP1 O 0 7.146465213736519e-05
, O 0 1.7562297216500156e-06
LAP2 O 0 0.00012191972200525925
and O 0 3.8060593396949116e-06
lamin O 0 0.0006885535549372435
B O 0 8.749240078032017e-05
receptor O 0 6.180723721627146e-05
( O 0 1.2617506399692502e-05
LBR O 0 0.00041071069426834583
) O 0 1.2515998605522327e-05
. O 0 1.628335849090945e-05

A O 0 0.00023306938237510622
panel O 0 8.721725316718221e-05
of O 0 2.2504516437038546e-06
16 O 0 8.51258937473176e-06
monoclonal O 0 3.3139971492346376e-05
antibodies O 0 1.7605176253709942e-05
( O 0 3.440568889345741e-06
mAbs O 0 6.232114537851885e-05
) O 0 6.4482156858503e-07
has O 0 2.647600467753364e-07
been O 0 2.324344592352645e-07
mapped O 0 1.1400961739127524e-06
to O 0 1.4558771965766937e-07
six O 0 1.3375866103615408e-07
specific O 0 9.55521741730081e-08
sites O 0 1.6239253852745605e-07
throughout O 0 3.275116853274085e-07
the O 0 3.385008540135459e-07
emerin O 0 9.588061402610037e-06
molecule O 0 1.495433934906032e-06
using O 0 1.2565263887154288e-06
phage O 0 7.194072168204002e-06
- O 0 2.432693690934684e-06
displayed O 0 6.729285360052017e-07
peptide O 0 4.403676427955361e-07
libraries O 0 3.2344982514587173e-07
and O 0 1.2752171585361793e-07
has O 0 1.7124547468938545e-07
been O 0 1.4554134963873366e-07
used O 0 2.975874906496756e-07
to O 0 2.8332482315818197e-07
localize O 0 1.6396066712331958e-05
emerin O 0 5.543228326132521e-05
in O 0 1.714119321150065e-06
human O 0 2.2536839878739556e-06
and O 0 7.248828751471592e-06
rabbit O 0 0.001666010357439518
heart O 0 0.0009650862193666399
. O 0 6.497672438854352e-05

Several O 0 0.00011725629883585498
mAbs O 0 0.0005808375426568091
against O 0 1.1527517926879227e-05
different O 0 3.7029421946499497e-06
emerin O 0 0.00026467579300515354
epitopes O 0 0.00011329863627906889
did O 0 6.515341738122515e-06
not O 0 1.0528441407586797e-06
recognize O 0 2.4134219529514667e-06
intercalated O 0 2.3012607925920747e-05
discs O 0 1.1777429790527094e-05
in O 0 1.3098692761559505e-06
the O 0 1.118405180022819e-06
heart O 0 7.866320083849132e-05
, O 0 4.686343686444161e-07
though O 0 6.52697622172127e-07
they O 0 3.597145621370146e-07
recognized O 0 5.248396064416738e-07
cardiomyocyte O 0 1.4113193174125627e-05
nuclei O 0 2.2922565676708473e-06
strongly O 0 1.946712927747285e-06
, O 0 2.0402606537572865e-07
both O 0 1.3503213835974748e-07
at O 0 2.9805295298501733e-07
the O 0 2.99361346378646e-07
rim O 0 5.207674348639557e-06
and O 0 4.4470911575444916e-07
in O 0 7.510554382861301e-07
intranuclear O 0 4.15140348195564e-05
spots O 0 4.205972800264135e-06
or O 0 1.8238247321278322e-06
channels O 0 1.788232839317061e-05
. O 0 8.505479854648001e-06

A O 0 0.0009119791793636978
polyclonal O 0 0.009569689631462097
rabbit O 0 0.002723617944866419
antiserum O 0 0.0017100470140576363
against O 0 5.4931842896621674e-05
emerin O 0 0.0009985350770875812
did O 0 1.1048306078009773e-05
recognize O 0 3.0067574243730633e-06
both O 0 7.786618425598135e-07
nuclear O 0 7.80560185376089e-06
membrane O 0 4.732567958853906e-06
and O 0 9.903893669616082e-07
intercalated O 0 2.2733056539436802e-05
discs O 0 1.026577410812024e-05
but O 0 4.3685361106327036e-07
, O 0 1.1290376278338954e-07
after O 0 2.512305172786e-07
affinity O 0 9.125391784436943e-07
purification O 0 2.229295660072239e-06
against O 0 7.929359640002076e-07
a O 0 8.939559847931378e-07
pure O 0 5.444286671263399e-06
- O 0 0.00011534179793670774
emerin O 0 5.133087688591331e-05
band O 0 2.9230170639493736e-06
on O 0 4.3724787701648893e-07
a O 0 4.6733205749660556e-07
western O 0 2.737679096753709e-06
blot O 0 0.00024411175400018692
, O 0 6.15886108334962e-07
it O 0 3.8992618556221714e-07
stained O 0 2.0372215658426285e-05
only O 0 3.1650961318518966e-07
the O 0 6.777226531085034e-07
nuclear O 0 1.3318030141817871e-05
membrane O 0 1.8806566004059277e-05
. O 0 9.39394703891594e-06

These O 0 2.6018271455541253e-05
results O 0 3.566842497093603e-05
would O 0 1.448265038561658e-06
not O 0 2.307398290213314e-07
be O 0 1.2313215336234862e-07
expected O 0 3.0881963652973354e-07
if O 0 1.4635196521339822e-07
immunostaining O 0 1.0653822755557485e-05
at O 0 8.01103851699736e-07
intercalated O 0 1.125167455029441e-05
discs O 0 8.652538781461772e-06
were O 0 5.086386067887361e-07
due O 0 4.4292465872786124e-07
to O 0 5.943231684568673e-08
a O 0 1.1545660782985578e-07
product O 0 1.717249773491858e-07
of O 0 3.5304211110087635e-08
the O 0 1.9354638425284065e-07
emerin O 0 2.290003794769291e-05
gene O 0 1.4242313000067952e-06
and O 0 2.4406125476161833e-07
, O 0 1.2726184195344104e-07
therefore O 0 1.5631978556029935e-07
, O 0 1.2748972721965401e-07
cast O 0 3.2880168987503566e-07
some O 0 8.024888842328437e-08
doubt O 0 6.027584618095716e-07
upon O 0 2.208535789804955e-07
the O 0 4.2021255808322167e-07
hypothesis O 0 1.1036795513064135e-05
that O 0 5.953265372227179e-06
cardiac B-Disease 1 0.9997703433036804
defects I-Disease 1 0.9846267104148865
in O 0 0.00012076785787940025
EDMD B-Disease 1 0.9999988079071045
are O 0 1.0698697678890312e-06
caused O 0 2.2286792500381125e-06
by O 0 3.8534520285793405e-07
absence O 0 1.8962857666338095e-06
of O 0 5.152274979991489e-07
emerin O 0 0.00016903785581234843
from O 0 7.733719940006267e-06
intercalated O 0 0.00042080500861629844
discs O 0 0.000266870716586709
. O 0 3.7423746107378975e-05

Although O 0 0.00022895701113156974
emerin O 0 0.0007488013943657279
was O 0 1.2666648217418697e-05
abundant O 0 2.908596115958062e-06
in O 0 5.573636485678435e-07
the O 0 3.3712908020788745e-07
membranes O 0 1.1805527719843667e-06
of O 0 1.6886488651834952e-07
cardiomyocyte O 0 3.373362051206641e-05
nuclei O 0 2.24826135308831e-06
, O 0 2.443856885747664e-07
it O 0 1.410772370036284e-07
was O 0 8.256378691839927e-07
absent O 0 1.3233520803623833e-06
from O 0 1.2327585352522874e-07
many O 0 1.2684697026088543e-07
non O 0 3.386013986528269e-06
- O 0 0.00032822234788909554
myocyte O 0 0.005398393142968416
cells O 0 7.069912953738822e-06
in O 0 9.718320370666333e-07
the O 0 2.4025414404604817e-06
heart O 0 0.00018714068573899567
. O 0 2.1121786630828865e-05

This O 0 1.2566746590891853e-05
distribution O 0 6.13585962128127e-06
of O 0 1.1338688636897132e-06
emerin O 0 0.0002522235445212573
was O 0 8.761657227296382e-06
similar O 0 8.141315674947691e-07
to O 0 2.0463950534121977e-07
that O 0 9.94040263435636e-08
of O 0 1.0296302122014822e-07
lamin O 0 5.655270433635451e-05
A O 0 9.221994332619943e-07
, O 0 2.2419442302634707e-07
a O 0 3.070327068144252e-07
candidate O 0 1.626639118512685e-06
gene O 0 1.6301037248922512e-06
for O 0 3.328094919652358e-07
an O 0 1.980004981305683e-06
autosomal O 0 0.00022980953508522362
form O 0 5.422431058832444e-06
of O 0 6.727136678819079e-06
EDMD B-Disease 1 0.9999877214431763
. O 0 8.355083264177665e-05

In O 0 7.621839176863432e-05
contrast O 0 9.797076927497983e-05
, O 0 1.9104232706013136e-05
lamin O 0 0.009890122339129448
B1 O 1 0.5867027640342712
was O 0 1.9049763068323955e-05
absent O 0 1.1436721251811832e-05
from O 0 1.613417339285661e-06
cardiomyocyte O 0 2.3730481188977137e-05
nuclei O 0 5.676238743035356e-06
, O 0 4.813067562281503e-07
showing O 0 2.3155334929469973e-06
that O 0 1.2286253650017898e-06
lamin O 0 0.0019630773458629847
B1 O 0 0.027217581868171692
is O 0 2.651754869020806e-07
not O 0 1.0106575132340367e-07
essential O 0 2.053898953136013e-07
for O 0 1.0438735387197084e-07
localization O 0 2.3395277821691707e-06
of O 0 1.3371199258926936e-07
emerin O 0 1.9269513359176926e-05
to O 0 4.3138791738783766e-07
the O 0 1.1713320873241173e-06
nuclear O 0 9.722093818709254e-05
lamina O 0 0.0004898225888609886
. O 0 2.9476672352757305e-05

Lamin O 1 0.9889324903488159
B1 O 1 0.9810822010040283
is O 0 1.3254866644274443e-05
also O 0 2.015934342125547e-06
almost O 0 1.242663415723655e-06
completely O 0 9.923078323481604e-06
absent O 0 3.8988211599644274e-05
from O 0 1.0419820682727732e-05
skeletal O 0 0.1304929554462433
muscle O 0 0.001710784388706088
nuclei O 0 9.864920866675675e-05
. O 0 3.801824641413987e-05

In O 0 0.00044766071368940175
EDMD B-Disease 1 0.9990873336791992
, O 0 5.183633675187593e-06
the O 0 1.2518281664597453e-06
additional O 0 1.0379387731518364e-06
absence O 0 3.3781018373701954e-06
of O 0 9.175394097837852e-07
lamin O 0 0.20036087930202484
B1 O 1 0.9287649989128113
from O 0 1.3234795915195718e-05
heart O 0 0.0007002174970693886
and O 0 2.776120527414605e-05
skeletal O 1 0.6532776951789856
muscle O 0 0.000402510748244822
nuclei O 0 7.483887657144805e-06
which O 0 9.156914302366204e-07
already O 0 1.7450057612222736e-06
lack O 0 6.070682047720766e-06
emerin O 0 0.004151563160121441
may O 0 7.162601377785904e-06
offer O 0 8.44425358081935e-07
an O 0 2.538310184263537e-07
alternative O 0 1.204663931275718e-06
explanation O 0 1.4689734371131635e-06
of O 0 2.141247819054115e-07
why O 0 2.1624064174829982e-06
these O 0 5.010796826354635e-07
tissues O 0 8.633359357190784e-06
are O 0 2.9593724093501805e-07
particularly O 0 4.2924016270262655e-06
affected O 0 9.500843589194119e-06
. O 0 4.856658051721752e-06
. O 0 1.340374456049176e-05

Genetic O 0 0.0006556950975209475
mapping O 0 6.094570198911242e-05
of O 0 2.0014026631542947e-06
the O 0 4.677388005802641e-06
copper B-Disease 0 6.390466296579689e-05
toxicosis I-Disease 0 0.0008610179647803307
locus O 0 2.771137405943591e-05
in O 0 6.349302566377446e-06
Bedlington O 0 0.0023200104478746653
terriers O 0 0.00033684936352074146
to O 0 2.4775888505246257e-06
dog O 0 4.8043504648376256e-05
chromosome O 0 1.2285009688639548e-05
10 O 0 6.556491598530556e-07
, O 0 1.6538821512313007e-07
in O 0 2.698509717902198e-07
a O 0 6.696999435007456e-07
region O 0 3.3789267490647035e-06
syntenic O 0 0.0001503015955677256
to O 0 1.771806068973092e-06
human O 0 4.237364009895828e-06
chromosome O 0 1.7596548786968924e-05
region O 0 1.0218284842267167e-05
2p13 O 0 0.0008450166205875576
- O 0 0.0019325956236571074
p16 O 0 0.000694738351739943
. O 0 5.5286258429987356e-05

Abnormal O 1 0.9934927821159363
hepatic B-Disease 1 0.9963037967681885
copper I-Disease 0 0.0017003231914713979
accumulation I-Disease 0 6.935503915883601e-05
is O 0 2.0241952825017506e-06
recognized O 0 1.4795093647990143e-06
as O 0 1.7443818478568573e-06
an O 0 2.8432183171389624e-05
inherited B-Disease 1 1.0
disorder I-Disease 1 0.9999998807907104
in O 0 4.872814679401927e-05
man O 0 0.0012723961845040321
, O 0 4.2169735934294295e-06
mouse O 0 4.5657849113922566e-05
, O 0 4.4804151002608705e-06
rat O 0 0.00032345560612156987
and O 0 6.89802982378751e-06
dog O 0 0.000217909793718718
. O 0 3.0271099603851326e-05

The O 0 2.9075396014377475e-05
major O 0 1.9384488041396253e-05
cause O 0 1.986566167033743e-05
of O 0 4.833647381019546e-06
hepatic B-Disease 1 0.7023316025733948
copper I-Disease 0 0.0017778878100216389
accumulation I-Disease 0 3.427551928325556e-05
in O 0 4.586542672768701e-06
man O 0 2.7739477445720695e-05
is O 0 6.970973345232778e-07
a O 0 2.511158072593389e-06
dysfunctional O 0 0.0002359143691137433
ATP7B O 0 0.004974734503775835
gene O 0 2.5474395442870446e-05
, O 0 3.938679583370686e-06
causing O 0 5.759538180427626e-05
Wilson B-Disease 0 0.017859885469079018
disease I-Disease 0 0.10826882719993591
( O 0 3.934720007237047e-05
WD B-Disease 1 0.9916017651557922
) O 0 2.2327052647597156e-05
. O 0 1.782952131179627e-05

Mutations O 0 0.0008066872833296657
in O 0 2.710032458708156e-05
the O 0 9.611928362573963e-06
ATP7B O 0 0.0014462588587775826
genes O 0 6.047955139365513e-06
have O 0 5.943718406342668e-07
also O 0 3.414132265788794e-07
been O 0 4.4628660589296487e-07
demonstrated O 0 4.008529231214197e-06
in O 0 1.9747737951547606e-06
mouse O 0 5.9557998611126095e-05
and O 0 9.75501006905688e-06
rat O 0 0.0012514162808656693
. O 0 2.9252756576170214e-05

The O 0 6.325331924017519e-05
ATP7B O 0 0.003976970911026001
gene O 0 3.609078339650296e-05
has O 0 1.1943296840399853e-06
been O 0 9.021107416629093e-07
excluded O 0 3.5379246128286468e-06
in O 0 5.18924935022369e-07
the O 0 4.5656773295377207e-07
much O 0 3.2895331969484687e-06
rarer O 0 0.0004799857852049172
human O 0 7.811469004082028e-06
copper B-Disease 0 0.0019645567517727613
overload I-Disease 0 0.4857916235923767
disease O 0 0.00048022030387073755
non B-Disease 0 2.33647006098181e-05
- I-Disease 0 0.00035246345214545727
Indian I-Disease 0 2.6444957256899215e-05
childhood I-Disease 0 0.0004845318617299199
cirrhosis I-Disease 0 0.3366766571998596
, O 0 1.7363621736876667e-05
indicating O 0 0.00023710458481218666
genetic O 0 8.47510527819395e-05
heterogeneity O 0 0.00034997903276234865
. O 0 0.00010067193943541497

By O 0 9.242571104550734e-05
investigating O 0 0.0001077094639185816
the O 0 2.3884504116722383e-05
common O 0 0.0006874329992569983
autosomal O 1 0.9974580407142639
recessive O 1 0.9934006929397583
copper B-Disease 0 0.08821970224380493
toxicosis I-Disease 1 0.8323442339897156
( O 0 6.906563794473186e-05
CT B-Disease 1 0.9954591989517212
) O 0 4.718237505585421e-06
in O 0 4.178136350674322e-06
Bedlington O 0 0.0022541347425431013
terriers O 0 0.0003156155871693045
, O 0 7.641453976248158e-07
we O 0 2.2843494207336335e-07
have O 0 1.4976775730701775e-07
identified O 0 6.621861530220485e-07
a O 0 4.820849426323548e-07
new O 0 2.1297951207088772e-06
locus O 0 8.49484513310017e-06
involved O 0 4.18644049204886e-06
in O 0 8.992777293315157e-05
progressive O 1 0.9999713897705078
liver B-Disease 1 1.0
disease I-Disease 1 0.9999972581863403
. O 0 0.0003161103231832385

We O 0 7.810746319591999e-05
examined O 0 0.00018694841128308326
whether O 0 1.813320704968646e-05
the O 0 1.1058794370910618e-05
WD B-Disease 1 0.5555322170257568
gene O 0 6.445788312703371e-05
ATP7B O 0 0.00027649462572298944
was O 0 7.27767837815918e-06
also O 0 1.9839271772070788e-06
causative O 0 5.049565970693948e-06
for O 0 7.120499390111945e-07
CT B-Disease 0 0.12189440429210663
by O 0 9.789144996830146e-07
investigating O 0 2.618232883833116e-06
the O 0 1.3433115100269788e-06
chromosomal O 0 6.938110163901001e-05
co O 0 1.5899004210950807e-05
- O 0 2.6984582291333936e-05
localization O 0 1.0062946785183158e-05
of O 0 2.9983078775330796e-07
ATP7B O 0 8.067546150414273e-05
and O 0 1.2534671895991778e-06
C04107 O 0 1.8115371858584695e-05
, O 0 5.459153840092767e-07
using O 0 8.913747819860873e-07
fluorescence O 0 7.049163286865223e-06
in O 0 1.4272511634771945e-06
situ O 0 2.1457302864291705e-05
hybridization O 0 1.1698580237862188e-05
( O 0 2.4728065000090282e-06
FISH O 0 4.489997081691399e-06
) O 0 4.068680937052704e-06
. O 0 6.703844974254025e-06

C04107 O 0 0.0025262401904910803
is O 0 1.1401122719689738e-05
an O 0 3.539851604728028e-06
anonymous O 0 1.800584686861839e-05
microsatellite O 0 0.0001287592458538711
marker O 0 3.635518078226596e-05
closely O 0 2.0543197024380788e-05
linked O 0 3.2377800380345434e-05
to O 0 2.2526144675794058e-05
CT B-Disease 1 0.9994744658470154
. O 0 8.252863335656002e-05

However O 0 0.00020444687106646597
, O 0 3.006281804118771e-05
BAC O 0 0.000732566462829709
clones O 0 8.389949653064832e-05
containing O 0 1.3842573025613092e-05
ATP7B O 0 0.00034306998713873327
and O 0 7.461140739906114e-06
C04107 O 0 8.683634223416448e-05
mapped O 0 1.927328048623167e-05
to O 0 1.3782945416096481e-06
the O 0 2.0225299977028044e-06
canine O 0 7.378457667073235e-05
chromosome O 0 1.6695275917300023e-05
regions O 0 2.4708429009479005e-06
CFA22q11 O 0 3.2327825465472415e-05
and O 0 1.0417487601444009e-06
CFA10q26 O 0 3.961421316489577e-05
, O 0 2.30946326951198e-07
respectively O 0 6.130451311037177e-07
, O 0 1.3862153025456792e-07
demonstrating O 0 1.106394279304368e-06
that O 0 4.566012137274811e-07
WD B-Disease 0 0.007831096649169922
cannot O 0 1.5673193729526247e-06
be O 0 4.743882584534731e-07
homologous O 0 7.000098321441328e-06
to O 0 4.420875484356657e-06
CT B-Disease 1 0.896769106388092
. O 0 4.074291791766882e-05

The O 0 6.911840318934992e-05
copper O 0 0.00013747898628935218
transport O 0 4.8933783546090126e-05
genes O 0 1.766761124599725e-05
CTR1 O 0 0.00012859002163168043
and O 0 2.729175776039483e-06
CTR2 O 0 0.00030371404136531055
were O 0 2.0568993477354525e-06
also O 0 5.759277996730816e-07
excluded O 0 1.8243049453303684e-06
as O 0 3.073910193052143e-07
candidate O 0 1.0412630899736541e-06
genes O 0 1.0222213404631475e-06
for O 0 5.886417397960031e-07
CT B-Disease 1 0.9935872554779053
since O 0 9.755186511029024e-06
they O 0 7.064096507747308e-07
both O 0 7.972344633344619e-07
mapped O 0 1.4116625607130118e-05
to O 0 2.7226401471125428e-06
canine O 0 0.00023916774080134928
chromosome O 0 0.00011469086894067004
region O 0 4.500019713304937e-05
CFA11q22 O 0 0.001248958520591259
. O 0 6.871947698527947e-05

2 O 0 0.0007322384626604617
- O 0 0.0014069390017539263
22 O 0 0.00015500631707254797
. O 0 6.737229705322534e-05

5 O 0 0.0011505475267767906
. O 0 0.00032641366124153137

A O 0 0.0001396749576088041
transcribed O 0 8.063731365837157e-05
sequence O 0 6.199052222655155e-06
identified O 0 3.0742255603399826e-06
from O 0 3.8338885133271106e-07
the O 0 4.779899427376222e-07
C04107 O 0 1.5472565792151727e-05
- O 0 6.0970578488195315e-06
containing O 0 7.335908094319166e-07
BAC O 0 6.751623732270673e-05
was O 0 3.162409257129184e-06
found O 0 2.9512526111830084e-07
to O 0 1.1808720756789626e-07
be O 0 8.349100966142942e-08
homologous O 0 3.987495347246295e-07
to O 0 1.0677359085775606e-07
a O 0 5.690367288480047e-07
gene O 0 1.6442681953776628e-06
expressed O 0 6.100473797232553e-07
from O 0 5.692082254427078e-07
human O 0 1.4999402537796414e-06
chromosome O 0 1.7683874830254354e-05
2p13 O 0 5.9346697526052594e-05
- O 0 0.00017106416635215282
p16 O 0 4.935204560752027e-05
, O 0 4.6139876985762385e-07
a O 0 4.5126142822482507e-07
region O 0 6.618686256842921e-07
devoid O 0 2.1745433969044825e-06
of O 0 1.5674284270517091e-07
any O 0 6.200490361152333e-07
positional O 0 3.9419119275407866e-05
candidate O 0 3.754274075618014e-05
genes O 0 3.3034615626093e-05
. O 0 2.0023413526359946e-05

Molecular O 0 0.00018814940995071083
analysis O 0 1.3348470929486211e-05
of O 0 7.939339639051468e-07
the O 0 2.8911019853694597e-06
APC B-Disease 0 5.1109025662299246e-05
gene O 0 4.424101916811196e-06
in O 0 8.471218393424351e-07
205 O 0 7.6158544288773555e-06
families O 0 1.046995635078929e-06
: O 0 9.922007393470267e-07
extended O 0 9.45279225561535e-06
genotype O 0 0.0031567136757075787
- O 0 0.03518762066960335
phenotype O 0 0.0007390871178358793
correlations O 0 1.6103605958051048e-05
in O 0 2.7327439511282137e-06
FAP B-Disease 0 2.763792326732073e-05
and O 0 6.98063900017587e-07
evidence O 0 5.47542697404424e-07
for O 0 9.472561401935309e-08
the O 0 1.2989073638891568e-07
role O 0 3.757873798804212e-07
of O 0 2.672078665000299e-07
APC B-Disease 0 2.9026030460954644e-05
amino O 0 3.6530543638946256e-06
acid O 0 8.893149242794607e-06
changes O 0 1.6828655134304427e-05
in O 0 0.2353544980287552
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
predisposition O 0 0.23825959861278534
. O 0 0.00012667456758208573

BACKGROUND O 0 0.0032238431740552187
/ O 0 0.0021658805198967457
AIMS O 0 9.776620572665706e-05
The O 0 6.029301857779501e-06
development O 0 1.7411128283129074e-05
of O 0 9.751592006068677e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
and O 0 1.3534632671508007e-05
a O 0 3.974938863393618e-06
variable O 0 4.9039258556149434e-06
range O 0 1.7765149777915212e-06
of O 0 8.154867714438296e-07
extracolonic O 0 0.00032312521943822503
manifestations O 0 6.983446655794978e-05
in O 0 0.00011885164713021368
familial B-Disease 1 0.9999802112579346
adenomatous I-Disease 1 0.9999516010284424
polyposis I-Disease 1 0.9999985694885254
( O 0 0.00014083768473938107
FAP B-Disease 0 0.0008680711034685373
) O 0 1.8701280168897938e-06
is O 0 1.7017455888890254e-07
the O 0 1.845749579842959e-07
result O 0 3.2682558526175853e-07
of O 0 9.586177185383349e-08
the O 0 7.757053026580252e-07
dominant O 0 4.537985660135746e-05
inheritance O 0 8.899041131371632e-05
of O 0 4.5096945541445166e-05
adenomatous B-Disease 1 0.9999967813491821
polyposis I-Disease 1 0.9999476671218872
coli I-Disease 1 0.9998972415924072
( O 0 0.00011493381316540763
APC B-Disease 0 0.0009421908180229366
) O 0 1.0995529919455294e-05
gene O 0 4.205302684567869e-05
mutations O 0 5.370743019739166e-05
. O 0 2.112442598445341e-05

In O 0 2.691454574232921e-05
this O 0 2.4451908302580705e-06
study O 0 1.4459561725743697e-06
, O 0 2.3210397159800777e-07
direct O 0 4.0501350895283394e-07
mutation O 0 9.774628324521473e-07
analysis O 0 2.4967346234916477e-07
of O 0 8.310826160595752e-08
the O 0 8.623004532637424e-07
APC B-Disease 0 4.829624595004134e-05
gene O 0 3.0147220968501642e-06
was O 0 1.411076596014027e-06
performed O 0 1.377165858684748e-06
to O 0 8.078514497356082e-07
determine O 0 3.8781035982538015e-06
genotype O 0 0.0004194771172478795
- O 0 0.000989363295957446
phenotype O 0 0.00015756303037051111
correlations O 0 1.1679862836899702e-05
for O 0 6.334565227916755e-07
nine O 0 2.2440478915086715e-06
extracolonic O 0 5.67804163438268e-05
manifestations O 0 4.397814791445853e-06
and O 0 4.4126858256277046e-07
to O 0 3.4265337944816565e-07
investigate O 0 1.7354796000290662e-06
the O 0 6.458641337303561e-07
incidence O 0 1.1080943295382895e-05
of O 0 6.704514134980855e-07
APC B-Disease 0 0.00026803245418705046
mutations O 0 1.284429345105309e-05
in O 0 4.851251105719712e-06
non O 0 0.00040467240614816546
- O 1 0.9999369382858276
FAP O 1 0.9999767541885376
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999994039535522
. O 0 0.00021193949214648455

METHODS O 0 0.00035233833477832377
The O 0 2.4096703782561235e-05
APC B-Disease 0 0.00023305385548155755
gene O 0 2.7274840249447152e-05
was O 0 6.259133442654274e-06
analysed O 0 1.2381703527353238e-05
in O 0 2.0897487047477625e-06
190 O 0 1.2752959264616948e-05
unrelated O 0 2.3166612663771957e-05
FAP B-Disease 0 8.934762445278466e-05
and O 0 2.4130952169798547e-06
15 O 0 9.580339792591985e-06
non O 0 0.0001675667444942519
- O 1 0.9997120499610901
FAP O 1 0.9999871253967285
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 0.07040514796972275
using O 0 2.119042255799286e-05
denaturing O 0 0.001967515330761671
gradient O 0 0.00015727004210930318
gel O 0 0.00030974761466495693
electrophoresis O 0 3.328693856019527e-05
, O 0 6.882003162900219e-07
the O 0 2.6460887170287606e-07
protein O 0 8.63362799918832e-07
truncation O 0 6.01302917857538e-06
test O 0 4.065834218636155e-06
, O 0 3.215779429410759e-07
and O 0 4.098916122075025e-07
direct O 0 3.2196719530475093e-06
sequencing O 0 6.604276859434322e-05
. O 0 1.776350472937338e-05

RESULTS O 0 0.0011067601153627038
Chain O 0 0.0001318922295467928
terminating O 0 7.748200732748955e-05
signals O 0 1.8416441889712587e-05
were O 0 1.7552066537973587e-06
only O 0 3.7942268704682647e-07
identified O 0 1.4662679177490645e-06
in O 0 1.7328483181699994e-06
patients O 0 2.7724508981918916e-05
belonging O 0 3.785909711950808e-06
to O 0 6.715104632348812e-07
the O 0 1.9974002043454675e-06
FAP B-Disease 0 9.218558989232406e-05
group O 0 1.2367436283966526e-05
( O 0 7.049768100841902e-06
105 O 0 5.687563316314481e-05
patients O 0 0.0002931164635811001
) O 0 8.235608220275026e-06
. O 0 1.8778016965370625e-05

Amino O 0 0.0001964806579053402
acid O 0 5.777140177087858e-05
changes O 0 7.533283223892795e-06
were O 0 1.121358195632638e-06
identified O 0 1.1170259313075803e-06
in O 0 3.8999385765237093e-07
four O 0 1.1609981811488979e-06
patients O 0 3.651508450275287e-05
, O 0 1.7850355504833715e-07
three O 0 6.954267206538134e-08
of O 0 8.086548319852227e-08
whom O 0 2.049589511443628e-06
belonged O 0 7.24872506907559e-06
to O 0 3.507554424686532e-07
the O 0 6.582509968211525e-07
non O 0 7.055377409415087e-06
- O 0 0.00020093575585633516
FAP O 0 0.0001464759698137641
group O 0 3.017374183400534e-05
of O 0 0.0001439936604583636
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 1 0.9763758182525635
. O 0 0.0001395029976265505

Genotype O 1 0.9955516457557678
- O 1 0.9941102862358093
phenotype O 1 0.7098401188850403
correlations O 0 0.00023911325843073428
identified O 0 2.6157918910030276e-05
significant O 0 3.25652808896848e-06
differences O 0 3.862694029521663e-06
in O 0 7.663801397939096e-07
the O 0 4.3662035409397504e-07
nature O 0 8.282609655907436e-07
of O 0 1.7370281568673818e-07
certain O 0 1.0612079677230213e-06
extracolonic O 0 0.00011129953054478392
manifestations O 0 2.496335218893364e-05
in O 0 1.06675788629218e-05
FAP B-Disease 0 0.008063829503953457
patients O 0 0.0001644174917601049
belonging O 0 5.2410014177439734e-06
to O 0 1.0648027455317788e-06
three O 0 1.284284394387214e-06
mutation O 0 1.3233167919679545e-05
subgroups O 0 2.3152013454819098e-05
. O 0 1.3759510693489574e-05

CONCLUSIONS O 0 0.0024616168811917305
Extended O 0 0.0008031635079532862
genotype O 0 0.474688321352005
- O 1 0.5204859375953674
phenotype O 0 0.003967271652072668
correlations O 0 3.194584132870659e-05
made O 0 3.032172344319406e-06
in O 0 1.1071638255089056e-06
this O 0 2.9556181857515185e-07
study O 0 9.51554795847187e-07
may O 0 1.57180693349801e-06
have O 0 8.77316281844287e-08
the O 0 8.965037068264792e-08
potential O 0 1.042472774770431e-07
to O 0 6.2620436835914e-08
determine O 0 1.5544506482001452e-07
the O 0 1.0728680877036822e-07
most O 0 3.0008365570211026e-07
appropriate O 0 1.3193638324082713e-06
surveillance O 0 8.042224180826452e-06
and O 0 2.122347950717085e-06
prophylactic O 0 0.002234033076092601
treatment O 0 0.058492306619882584
regimens O 0 0.000809833116363734
for O 0 1.6476682276334031e-06
those O 0 2.141440972991404e-06
patients O 0 7.036262104520574e-05
with O 0 2.0539687284326646e-06
mutations O 0 3.0438826797762886e-05
associated O 0 4.587373950926121e-06
with O 0 1.0189470458499272e-06
life O 0 4.208716927678324e-05
threatening O 0 0.0008186969789676368
conditions O 0 0.00214477744884789
. O 0 2.31083595281234e-05

This O 0 2.849325755960308e-05
study O 0 9.251465598936193e-06
also O 0 9.878735909296665e-07
provided O 0 6.885620678076521e-07
evidence O 0 6.623320700782642e-07
for O 0 2.031686250347775e-07
the O 0 9.429403462490882e-07
pathological O 0 3.295570058980957e-05
nature O 0 9.969213579097413e-07
of O 0 1.8704530191371305e-07
amino O 0 1.484080939917476e-06
acid O 0 2.1156890852580545e-06
changes O 0 7.659606922061357e-07
in O 0 1.4337914535644813e-06
APC O 0 3.288709922344424e-05
associated O 0 1.5552514014416374e-06
with O 0 3.1996088978303305e-07
both O 0 9.759055501490366e-07
FAP B-Disease 0 4.048578193760477e-05
and O 0 4.147780600760598e-06
non O 0 0.0003988338285125792
- O 1 0.9999035596847534
FAP O 1 0.9999892711639404
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 1 0.9284261465072632
. O 0 2.2033338609617203e-05
. O 0 3.904640470864251e-05

Inherited B-Disease 1 0.9999964237213135
colorectal I-Disease 1 1.0
polyposis I-Disease 1 0.9997337460517883
and O 0 0.0531386062502861
cancer B-Disease 1 0.9977691173553467
risk O 0 4.7331268433481455e-05
of O 0 2.702941856114194e-06
the O 0 2.095797572110314e-05
APC O 0 0.0032638313714414835
I1307K O 0 0.0008439344819635153
polymorphism O 0 0.00041972773033194244
. O 0 4.198334499960765e-05

Germ O 0 0.042089253664016724
- O 0 0.0008790799765847623
line O 0 8.834663458401337e-05
and O 0 6.5700942286639474e-06
somatic O 0 8.283044007839635e-05
truncating O 0 7.113245374057442e-05
mutations O 0 8.904783499019686e-06
of O 0 3.916057949027163e-07
the O 0 1.950868636413361e-06
APC B-Disease 0 0.00010188396117882803
gene O 0 4.5642027544090524e-06
are O 0 3.673915216495516e-07
thought O 0 2.2194060420588357e-06
to O 0 2.908230271714274e-06
initiate O 0 0.0014309032121673226
colorectal B-Disease 1 0.9999997615814209
tumor I-Disease 1 0.7679883241653442
formation O 0 8.816921035759151e-05
in O 0 0.0008803700329735875
familial B-Disease 1 0.9999996423721313
adenomatous I-Disease 1 0.9999994039535522
polyposis I-Disease 1 1.0
syndrome I-Disease 1 1.0
and O 0 0.0013400689931586385
sporadic O 1 0.9976187348365784
colorectal O 1 1.0
carcinogenesis O 1 0.9127299785614014
, O 0 4.7882953367661685e-05
respectively O 0 0.00010136338823940605
. O 0 5.4788390116300434e-05

Recently O 0 0.0003767910529859364
, O 0 1.550765045976732e-05
an O 0 8.280103429569863e-06
isoleucine O 0 0.0008449825108982623
- O 0 0.0010619597742334008
- O 0 0.0005213815020397305
> O 0 6.726328865624964e-05
lysine O 0 3.791534618358128e-05
polymorphism O 0 2.4305107217514887e-05
at O 0 3.5238695090811234e-06
codon O 0 2.4828710593283176e-05
1307 O 0 0.0001333411637460813
( O 0 1.7318272966804216e-06
I1307K O 0 6.570820914930664e-06
) O 0 1.9873496626132692e-07
of O 0 5.888135490295099e-08
the O 0 4.0695826442060934e-07
APC B-Disease 0 1.407453601132147e-05
gene O 0 1.2314958439674228e-06
has O 0 1.6794625423699472e-07
been O 0 1.9993258604245057e-07
identified O 0 4.2053889615090156e-07
in O 0 2.584414744433161e-07
6 O 0 9.515076158095326e-07
% O 0 8.170623573278135e-07
- O 0 4.812502993445378e-06
7 O 0 6.207584419826162e-07
% O 0 2.180109390792495e-07
of O 0 5.4606644539489935e-08
the O 0 7.127341064006032e-07
Ashkenazi O 0 0.0002140846336260438
Jewish O 0 5.67637971471413e-06
population O 0 4.5491624405258335e-06
. O 0 9.47775970416842e-06

To O 0 6.267648132052273e-05
assess O 0 0.0001320427400059998
the O 0 3.304928213765379e-06
risk O 0 2.5420679321541684e-06
of O 0 1.983244857228783e-07
this O 0 7.263903398779803e-07
common O 0 5.327388862497173e-06
APC B-Disease 0 0.00024785735877230763
allelic O 0 0.00014201455633156002
variant O 0 0.004092661663889885
in O 0 0.0012348360614851117
colorectal O 1 0.9999994039535522
carcinogenesis O 1 0.549467921257019
, O 0 7.648944119864609e-06
we O 0 8.034458574002201e-07
have O 0 4.257915975358628e-07
analyzed O 0 1.735890123200079e-06
a O 0 5.070461952527694e-07
large O 0 1.0269368431181647e-06
cohort O 0 2.51136370934546e-05
of O 0 1.502153395449568e-06
unselected O 0 0.0011272008996456861
Ashkenazi O 0 0.0004820341127924621
Jewish O 0 1.136526589107234e-05
subjects O 0 1.8910517610493116e-05
with O 0 8.506599442625884e-06
adenomatous B-Disease 0 0.010227550752460957
polyps I-Disease 0 0.0005118857370689511
and O 0 3.009256033692509e-06
. O 0 9.933757610269822e-06
or O 0 0.24714283645153046
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
, I-Disease 0 5.230594979366288e-06
for O 0 1.4659980251963134e-06
the O 0 9.491162927588448e-06
APC O 0 0.000706711201928556
I1307K O 0 0.0006082350155338645
polymorphism O 0 0.00035005295649170876
. O 0 5.949538535787724e-05

The O 0 0.000197764573385939
APC O 0 0.0010529888095334172
I1307K O 0 0.00031654612394049764
allele O 0 0.00012127873924328014
was O 0 1.2299839909246657e-05
identified O 0 2.771123035927303e-06
in O 0 5.13662939738424e-07
48 O 0 1.2832155107389553e-06
( O 0 3.5083235161437187e-07
10 O 0 1.5801738584286795e-07
. O 0 1.0224031399275191e-07
1 O 0 2.456243066717434e-07
% O 0 3.667071837298863e-07
) O 0 3.82716677904682e-07
of O 0 5.253844506114547e-07
476 O 0 0.0017839064821600914
patients O 0 0.009730408899486065
. O 0 5.025195423513651e-05

Compared O 0 0.00019316656107548624
with O 0 2.7473615773487836e-06
the O 0 8.364065706700785e-07
frequency O 0 2.201043116656365e-06
in O 0 4.4305059532234736e-07
two O 0 1.957167512500746e-07
separate O 0 2.798851426177862e-07
population O 0 2.4025843003983027e-07
control O 0 6.071616098779486e-07
groups O 0 1.5771779260376206e-07
, O 0 1.6472694142066757e-07
the O 0 5.780881906503055e-07
APC O 0 3.411468424019404e-05
I1307K O 0 3.982477937825024e-05
allele O 0 9.925955055223312e-06
is O 0 3.14644609034076e-07
associated O 0 4.0699202941141266e-07
with O 0 8.682255270286987e-08
an O 0 1.637776847474015e-07
estimated O 0 3.6685480608866783e-07
relative O 0 1.2475568382797064e-06
risk O 0 1.0162443686567713e-06
of O 0 3.1452157145395176e-07
1 O 0 4.4120642996858805e-06
. O 0 9.780123946256936e-06

5 O 0 0.0005432021571323276
- O 0 0.0009291264577768743
1 O 0 7.846983498893678e-05
. O 0 4.976486161467619e-05

7 O 0 0.0006723550031892955
for O 0 0.00026714205159805715
colorectal B-Disease 1 0.9999990463256836
neoplasia I-Disease 1 0.7374340891838074
( O 0 1.6941532521741465e-05
both O 0 6.671012670267373e-06
P O 0 0.005232975352555513
= O 0 6.40843209112063e-05
. O 0 3.277896666986635e-06
01 O 0 0.0001083099195966497
) O 0 5.01763861393556e-06
. O 0 6.942180334590375e-06

Furthermore O 0 0.00042073862277902663
, O 0 1.8922151866718195e-05
compared O 0 1.918181988003198e-05
with O 0 3.1501706416747766e-06
noncarriers O 0 0.0004340061859693378
, O 0 5.5316832003882155e-06
APC O 0 0.00015358171367552131
I1307K O 0 7.007020758464932e-05
carriers O 0 8.711350346857216e-06
had O 0 2.700705408642534e-06
increased O 0 1.2468693739720038e-06
numbers O 0 3.747795460640191e-07
of O 0 4.700550562120043e-07
adenomas B-Disease 0 0.01251466665416956
and O 0 0.009736104868352413
colorectal B-Disease 1 1.0
cancers I-Disease 1 0.8690851330757141
per O 0 3.3166466891998425e-05
patient O 0 0.005421099252998829
( O 0 8.452314432361163e-06
P O 0 0.0006985078216530383
= O 0 1.0808051229105331e-05
. O 0 4.120056189549359e-07
03 O 0 1.0601281246636063e-05
) O 0 1.7738608448780724e-07
, O 0 5.530938196329771e-08
as O 0 4.046782819955297e-08
well O 0 8.916708793549333e-08
as O 0 9.675562040456498e-08
a O 0 5.257704174255196e-07
younger O 0 2.51598066824954e-05
age O 0 1.5793793863849714e-05
at O 0 2.2986112526268698e-05
diagnosis O 1 0.6512205600738525
. O 0 3.0286057153716683e-05

We O 0 3.9333357563009486e-05
conclude O 0 5.3943855164106935e-05
that O 0 1.745846475387225e-06
the O 0 1.8434097910358105e-06
APC O 0 7.717694097664207e-05
I1307K O 0 7.66141529311426e-05
variant O 0 5.375073305913247e-05
leads O 0 3.1859967748459894e-06
to O 0 1.6559305322516593e-06
increased O 0 2.1546295101870783e-05
adenoma B-Disease 1 0.9991003274917603
formation O 0 2.861351731553441e-06
and O 0 3.084690547439095e-07
directly O 0 2.743683182870882e-07
contributes O 0 4.5679027493861213e-07
to O 0 1.1553127876595681e-07
3 O 0 3.9599072465534846e-07
% O 0 6.597656465601176e-07
- O 0 3.1724409836897394e-06
4 O 0 5.155833946446364e-07
% O 0 2.5911324996741314e-07
of O 0 8.406242812952769e-08
all O 0 9.454940936848288e-07
Ashkenazi O 1 0.9292309284210205
Jewish O 1 0.9937617182731628
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999990463256836
. O 0 0.0002679126337170601

The O 0 2.8589553039637394e-05
estimated O 0 1.3111894077155739e-05
relative O 0 1.1040259778383188e-05
risk O 0 3.96669111069059e-06
for O 0 4.7395641900038754e-07
carriers O 0 9.259551006834954e-06
may O 0 2.0358088477223646e-06
justify O 0 3.941256636608159e-06
specific O 0 1.7642337297729682e-06
clinical O 0 1.711966615403071e-05
screening O 0 5.914049779676134e-06
for O 0 3.3762134421522205e-07
the O 0 5.511003564606654e-07
360 O 0 3.529792365952744e-06
, O 0 2.1853070109045802e-07
000 O 0 7.637236194568686e-07
Americans O 0 4.4380965391610516e-07
expected O 0 6.175811222419725e-07
to O 0 1.4497558709081204e-07
harbor O 0 1.7691080529402825e-06
this O 0 2.4409268917224836e-07
allele O 0 2.74177068604331e-06
, O 0 2.1509572434297297e-07
and O 0 2.546653377066832e-07
genetic O 0 1.509157527834759e-06
testing O 0 1.6371628817068995e-06
in O 0 1.8997054951341852e-07
the O 0 1.1434821800548889e-07
setting O 0 3.088031519382639e-07
of O 0 9.015863611239183e-08
long O 0 1.9123290257994086e-06
- O 0 3.135502265649848e-05
term O 0 5.78196295464295e-06
- O 0 4.7457822802243754e-05
outcome O 0 3.8207190300454386e-06
studies O 0 2.1366754481277894e-06
may O 0 3.103965354966931e-06
impact O 0 3.448446477705147e-06
significantly O 0 0.00010568885772954673
on O 1 0.6133159399032593
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
prevention O 0 0.00045175981358624995
in O 0 4.467313374334481e-06
this O 0 2.1018408915551845e-06
population O 0 5.8809346228372306e-06
. O 0 1.3995968402014114e-05

Localization O 0 0.00034319463884457946
of O 0 5.311008862918243e-06
human O 0 1.1781630746554583e-05
BRCA1 O 0 0.00014088900934439152
and O 0 1.0657637403710396e-06
its O 0 7.904270660219481e-07
loss O 0 4.65925859316485e-06
in O 0 7.368954584308085e-07
high O 0 4.206915491522523e-06
- O 0 7.42718912078999e-05
grade O 0 7.857141099520959e-06
, O 0 1.1108220405731117e-06
non B-Disease 0 3.981418194598518e-05
- I-Disease 1 0.991104006767273
inherited I-Disease 1 0.999367892742157
breast I-Disease 1 0.9999692440032959
carcinomas I-Disease 1 0.9999933242797852
. O 0 0.00023877063358668238

Although O 0 5.3146592108532786e-05
the O 0 7.0944424805929884e-06
link O 0 1.6597961803199723e-05
between O 0 3.489647724563838e-06
the O 0 1.1479885870357975e-05
BRCA1 O 1 0.6047216653823853
tumour B-Disease 1 0.9999892711639404
- O 0 0.0004679391859099269
suppressor O 0 0.00011588673805817962
gene O 0 1.8607561287353747e-05
and O 0 6.246444627322489e-06
hereditary B-Disease 1 0.9798192381858826
breast I-Disease 1 0.9997223019599915
and I-Disease 1 0.9986515641212463
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.999998927116394
is O 0 9.236780442734016e-07
established O 0 6.59607053421496e-07
, O 0 9.320029903392424e-08
the O 0 7.333341045523412e-08
role O 0 2.3801163706593798e-07
, O 0 8.085221736564563e-08
if O 0 3.552739258338988e-08
any O 0 2.8551475850235875e-08
, O 0 4.709228562660428e-08
of O 0 6.051648426819156e-08
BRCA1 O 0 2.3434342438122258e-05
in O 0 1.7578669258000446e-06
non B-Disease 0 0.00011569316848181188
- I-Disease 1 0.938969075679779
familial I-Disease 0 0.1085866391658783
cancers I-Disease 1 0.56328946352005
is O 0 3.0313599381770473e-06
unclear O 0 3.528114393702708e-05
. O 0 1.7470872990088537e-05

BRCA1 O 1 0.9818546772003174
mutations O 0 0.0010773547692224383
are O 0 1.0735005162132438e-05
rare O 0 1.7800930436351337e-05
in O 0 7.516669484175509e-06
sporadic B-Disease 0 0.006285653915256262
cancers I-Disease 1 0.7871238589286804
, O 0 1.482963170928997e-06
but O 0 6.940968546587101e-07
loss O 0 1.8038560938293813e-06
of O 0 2.562088070590107e-07
BRCA1 O 0 8.680133032612503e-05
resulting O 0 1.1885599633387756e-06
from O 0 3.250714826208423e-07
reduced O 0 8.702976970198506e-07
expression O 0 9.353507266496308e-07
or O 0 3.4728580544651777e-07
incorrect O 0 6.023686637490755e-06
subcellular O 0 2.6320742108509876e-05
localization O 0 1.7371556168654934e-05
is O 0 2.3244110991527123e-07
postulated O 0 1.5157521602304769e-06
to O 0 7.964094095314067e-08
be O 0 5.0034905996199086e-08
important O 0 1.093961685683098e-07
in O 0 6.274178758758353e-07
non B-Disease 0 1.670381061558146e-05
- I-Disease 0 0.10358672589063644
familial I-Disease 0 0.00869734212756157
breast I-Disease 1 0.999444305896759
and I-Disease 1 0.9936475157737732
ovarian I-Disease 1 1.0
cancers I-Disease 1 0.9999986886978149
. O 0 0.00016555692127440125

Epigenetic O 0 0.003054387867450714
loss O 0 0.0005273683345876634
, O 0 3.935446329705883e-06
however O 0 1.3963259561933228e-06
, O 0 1.7883972702747997e-07
has O 0 8.205656598647693e-08
not O 0 7.179975369808744e-08
received O 0 2.380154882075658e-07
general O 0 3.8783710465395416e-07
acceptance O 0 4.136226834816625e-06
due O 0 1.1370124184395536e-06
to O 0 1.942323848425076e-07
controversy O 0 1.3465294159686891e-06
regarding O 0 6.625676860494423e-07
the O 0 3.934002563710237e-07
subcellular O 0 7.319810720218811e-06
localization O 0 4.304548383515794e-06
of O 0 2.126202076624395e-07
BRCA1 O 0 1.79896414920222e-05
proteins O 0 4.641969724161754e-07
, O 0 1.3155238320905482e-07
reports O 0 3.2688353712728713e-07
of O 0 3.015331628830609e-08
which O 0 7.188429407278818e-08
have O 0 8.122875527760698e-08
ranged O 0 6.241260166461871e-07
from O 0 1.211243585430566e-07
exclusively O 0 1.9542972040653694e-07
nuclear O 0 1.1064259979320923e-06
, O 0 1.134417999537618e-07
to O 0 1.5250552110046556e-07
conditionally O 0 3.434052359807538e-06
nuclear O 0 7.393507530650822e-07
, O 0 1.1261374055493434e-07
to O 0 1.0771348968319217e-07
the O 0 6.702244377265743e-07
ER O 0 0.005319133400917053
/ O 0 0.0007469403208233416
golgi O 0 0.001326254685409367
, O 0 9.01651446838514e-07
to O 0 6.159248187032063e-07
cytoplasmic O 0 9.512476026429795e-06
invaginations O 0 1.629491634957958e-05
into O 0 9.453507345824619e-07
the O 0 1.3026975693719578e-06
nucleus O 0 2.7384379791328683e-05
. O 0 1.2423432963259984e-05

In O 0 4.775563138537109e-05
an O 0 3.023434601345798e-06
attempt O 0 1.179725950350985e-05
to O 0 1.4801712495682295e-06
resolve O 0 5.08710263602552e-06
this O 0 3.972684510245017e-07
issue O 0 7.357648996730859e-07
, O 0 2.1144717265997315e-07
we O 0 2.326220567283599e-07
have O 0 2.7888543741028116e-07
comprehensively O 0 2.7637344828690402e-05
characterized O 0 1.3216495062806644e-05
19 O 0 7.035200724203605e-06
anti O 0 9.078282164409757e-05
- O 0 0.0077660237438976765
BRCA1 O 0 0.000632411043625325
antibodies O 0 8.397985220653936e-05
. O 0 2.3941494873724878e-05

These O 0 6.159066106192768e-05
reagents O 0 0.0002889963216148317
detect O 0 8.331207209266722e-05
a O 0 8.36292929307092e-06
220 O 0 2.0584340745699592e-05
- O 0 0.00014514611393678933
kD O 0 0.00021737604402005672
protein O 0 6.8290537456050515e-06
localized O 0 7.460009328497108e-06
in O 0 9.645763157095644e-07
discrete O 0 4.195185283606406e-06
nuclear O 0 1.1025193089153618e-05
foci O 0 2.6511568648857065e-05
in O 0 6.597398396479548e-07
all O 0 3.1927322652336443e-07
epithelial O 0 2.463784403516911e-05
cell O 0 1.4516429473587777e-05
lines O 0 1.7469290014560102e-06
, O 0 1.5989560608886677e-07
including O 0 1.6743641140237742e-07
those O 0 2.3987175268302963e-07
derived O 0 3.3760729820642155e-06
from O 0 1.115161012421595e-05
breast B-Disease 0 0.21602831780910492
malignancies I-Disease 0 0.010249278508126736
. O 0 0.0001012063366943039

Immunohistochemical O 0 0.021170230582356453
staining O 0 0.0036027145106345415
of O 0 4.818169691134244e-05
human O 0 0.00012122913176426664
breast O 1 0.7915841341018677
specimens O 0 8.996721589937806e-05
also O 0 1.5741885363240726e-05
revealed O 0 0.0002315040328539908
BRCA1 O 0 0.000316530728014186
nuclear O 0 5.3970201406627893e-05
foci O 0 0.00028540604398585856
in O 0 6.438078708015382e-05
benign O 1 0.9992918968200684
breast O 1 0.9985641837120056
, O 0 0.00028553372249007225
invasive B-Disease 1 0.9946056008338928
lobular I-Disease 1 0.999991774559021
cancers I-Disease 1 0.8454366326332092
and O 0 2.163660610676743e-05
low B-Disease 0 0.0005546881584450603
- I-Disease 1 0.8962559700012207
grade I-Disease 0 0.12857098877429962
ductal I-Disease 1 0.9998161196708679
carcinomas I-Disease 1 0.9999910593032837
. O 0 0.00014984568406362087

Conversely O 0 0.001037888927385211
, O 0 3.4833894460462034e-05
BRCA1 O 0 0.00017066093278117478
expression O 0 8.05065701570129e-06
was O 0 5.150337983650388e-06
reduced O 0 1.962978785741143e-06
or O 0 1.0043465863418533e-06
undetectable O 0 8.690016329637729e-06
in O 0 3.022968257937464e-07
the O 0 2.3974527607606433e-07
majority O 0 4.937003268423723e-07
of O 0 1.6798004764950747e-07
high O 0 4.499916030908935e-06
- O 0 0.0006044388865120709
grade O 0 3.972490958403796e-05
, O 0 1.2579670510604046e-05
ductal B-Disease 1 0.9822837710380554
carcinomas I-Disease 1 0.9999779462814331
, O 0 2.575017106209998e-06
suggesting O 0 5.132930709805805e-06
that O 0 3.165983741837408e-07
absence O 0 1.5481615491808043e-06
of O 0 5.168367920305172e-07
BRCA1 O 0 0.0009500068845227361
may O 0 3.650083954198635e-06
contribute O 0 4.95436495384638e-07
to O 0 2.3507139701450797e-07
the O 0 5.946326382400002e-07
pathogenesis O 0 1.1156313121318817e-05
of O 0 1.650064831437703e-07
a O 0 1.0681875437512645e-06
significant O 0 1.024667312776728e-06
percentage O 0 3.2857831229193835e-06
of O 0 1.0854313359232037e-06
sporadic B-Disease 0 0.21531210839748383
breast I-Disease 1 0.9999854564666748
cancers I-Disease 1 0.829017698764801
. O 0 1.8441976862959564e-05
. O 0 3.132958590867929e-05

